<SEC-DOCUMENT>0001193125-23-140697.txt : 20230510
<SEC-HEADER>0001193125-23-140697.hdr.sgml : 20230510
<ACCEPTANCE-DATETIME>20230510160410
ACCESSION NUMBER:		0001193125-23-140697
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230510
DATE AS OF CHANGE:		20230510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16174
		FILM NUMBER:		23906255

	BUSINESS ADDRESS:	
		STREET 1:		5 BAZEL ST
		STREET 2:		P O B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
		BUSINESS PHONE:		9729267267

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		5 BAZEL ST PO B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d464631d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:teva="http://www.tevapharm.com/20230331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>10-Q</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="">
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2023To03_31_2023">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2023To03_31_2023">Q1</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2023To03_31_2023">0000818686</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2023To03_31_2023">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="hidden78861945" contextRef="P01_01_2023To03_31_2023">00-0000000</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressCountry" id="hidden78861938" contextRef="P01_01_2023To03_31_2023">IL</ix:nonNumeric><ix:footnote id="FN_269435" xml:lang="en-US">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.</ix:footnote ><ix:footnote id="FN_269449" xml:lang="en-US">If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026. </ix:footnote ><ix:footnote id="FN_269453" xml:lang="en-US">Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. </ix:footnote ><ix:footnote id="FN_269452" xml:lang="en-US">In March 2023, Teva repaid $646 million of its 1.25% senior notes at maturity. </ix:footnote ><ix:footnote id="FN_269450" xml:lang="en-US">If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. </ix:footnote ><ix:footnote id="FN_269448" xml:lang="en-US">In March 2023, Teva consummated a cash tender offer and extinguished $630 million aggregate principal amount of its 1,000 million euro 6% senior notes due in 2025; $432 million aggregate principal amount of its 900 million euro 4.5% senior notes due in 2025; $573 million aggregate principal amount of its $1,000 million 7.13% senior notes due in 2025; $453 million aggregate principal amount of its $3,000 million 2.8% senior notes due in 2023; $293 million aggregate principal amount of its $1,250 million 6% senior notes due in 2024 and $122 million aggregate principal amount of its $3,500 million 3.15% senior notes due in 2026. </ix:footnote ><ix:footnote id="FN_269444" xml:lang="en-US">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 800 million euro bearing 7.38% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026. </ix:footnote ><ix:footnote id="FN_269445" xml:lang="en-US">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 500 million euro bearing 7.88% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026. </ix:footnote ><ix:footnote id="FN_269446" xml:lang="en-US">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $600 million bearing 7.88% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026. </ix:footnote ><ix:footnote id="FN_269447" xml:lang="en-US">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $500 million bearing 8.13% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026. </ix:footnote ><ix:footnote id="FN_269451" xml:lang="en-US">Debt issuance costs as of March 31, 2023 include $26 million in connection with the issuance of the sustainability-linked senior notes in March 2023, partially offset by $6 million acceleration of issuance costs related to the cash tender offer. </ix:footnote ><ix:footnote id="FN_269439" xml:lang="en-US">Including impairments related to exit and disposal activities.</ix:footnote ><ix:footnote id="FN_269440" xml:lang="en-US">Includes adjustments for foreign currency translation.</ix:footnote ><ix:footnote id="FN_269442" xml:lang="en-US">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. </ix:footnote ><ix:footnote id="FN_269443" xml:lang="en-US">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty and several other currencies to protect its projected operating results for 2023. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first quarter of 2023, the negative impact from these derivatives recognized under revenues was $6 million. In the first quarter of 2022, the positive impact from these derivatives recognized under revenues was $19 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. Cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </ix:footnote ><ix:footnote id="FN_269437" xml:lang="en-US">Amounts do not include a $53 million loss from foreign currency translation adjustments attributable to non-controlling interests.</ix:footnote ><ix:footnote id="FN_269436" xml:lang="en-US">Amounts do not include a $9 million loss from foreign currency translation adjustments attributable to non-controlling interests.</ix:footnote ><ix:footnote id="FN_269454" xml:lang="en-US">Amounts exclude attorneys&#8217; fees and costs, except New York.</ix:footnote ><ix:footnote id="FN_269457" xml:lang="en-US">Not including cash payment and attorneys&#8217; fees allocated under the nationwide settlement.</ix:footnote ><ix:footnote id="FN_269441" xml:lang="en-US">On March 31, 2023, Teva entered into a cross currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. </ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="teva-20230331.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2023To03_31_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_21_2018To08_21_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-08-21</xbrli:startDate> <xbrli:endDate>2022-08-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2005" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2005-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2008" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2008-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2013To04_30_2013" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-04-01</xbrli:startDate> <xbrli:endDate>2013-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2013To09_30_2013" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-09-01</xbrli:startDate> <xbrli:endDate>2013-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2010To12_31_2010" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2010-12-01</xbrli:startDate> <xbrli:endDate>2010-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2012To08_31_2012" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2012-08-01</xbrli:startDate> <xbrli:endDate>2012-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_30_2022To11_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-30</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_05_2021To08_05_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-05</xbrli:startDate> <xbrli:endDate>2021-08-05</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_08_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-31</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_09_2022To11_09_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-09</xbrli:startDate> <xbrli:endDate>2022-11-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:DemandDepositsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:DemandDepositsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:EquitySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:EquitySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >teva:OtherRestrictedCashMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >teva:OtherRestrictedCashMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >teva:OtherRestrictedCashMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >teva:SeniorNotesAndSustainabilityLinkedSeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >teva:SeniornotesandconvertibleseniordebenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TradeNamesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_InterestRateSwapMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:ShortCreditAgreement2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2030Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2027TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2029Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherDebentures2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:OtherDebentures2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmbeddedDerivativeFinancialInstrumentsMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccountsReceivableSecuritizationFacilityMemberusgaapDerivativeInstrumentRiskAxis_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022MemberusgaapPledgingPurposeAxis_PncBankMemberTEVAFactoringInstitutionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis" >teva:PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:AccountsReceivableSecuritizationFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:FactoringInstitutionAxis" >teva:PncBankMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:DemandDepositsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_DemandDepositsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:DemandDepositsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:EquitySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:EquitySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >teva:OtherRestrictedCashMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >teva:OtherRestrictedCashMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >teva:OtherRestrictedCashMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >teva:SeniorNotesAndSustainabilityLinkedSeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >teva:SeniornotesandconvertibleseniordebenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TradeNamesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_InterestRateSwapMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:ShortCreditAgreement2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2030Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2027TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2029Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_OtherDebentures2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:OtherDebentures2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >teva:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_EmbeddedDerivativeFinancialInstrumentsMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AccountsReceivableSecuritizationFacilityMemberusgaapDerivativeInstrumentRiskAxis_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022MemberusgaapPledgingPurposeAxis_PncBankMemberTEVAFactoringInstitutionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis" >teva:PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:AccountsReceivableSecuritizationFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:FactoringInstitutionAxis" >teva:PncBankMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AustedoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:BendekaAndTreandaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AndaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:RespiratoryProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:NoveTideAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CorporateMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:CorporateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:ActavisGenericsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EagleTransactionMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:EagleTransactionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:BendekaAndTreandaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AndaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:RespiratoryProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AustedoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:ShortCreditAgreement2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AlvotechMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:AlvotechMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_JPsrtStatementGeographicalAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_UpdatedMarketAssumptionsMemberTEVAEventBasisAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:JP</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:EventBasisAxis" >teva:UpdatedMarketAssumptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_RegulatoryPriceAndVolumeOfProductsMemberTEVAEventBasisAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:EventBasisAxis" >teva:RegulatoryPriceAndVolumeOfProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMemberTEVAEventBasisAxis_GenericPipelineProductsMembersrtProductOrServiceAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericPipelineProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:EventBasisAxis" >teva:DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_LenalidomideProductMembersrtProductOrServiceAxis_PriceAndVolumeOfProductsMemberTEVAEventBasisAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:LenalidomideProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:EventBasisAxis" >teva:PriceAndVolumeOfProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_CorporateMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:CorporateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2030Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2029Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2027TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilityLinkedSeniorNotesDue2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:ActavisGenericsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_EagleTransactionMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:EagleTransactionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_NovetideTransactionMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NovetideTransactionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_InternationalMarketsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OtherCountriesMembersrtStatementGeographicalAxis_TevasApiReportingUnitMemberusgaapReportingUnitAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis" >teva:TevasApiReportingUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:OtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_MedisReportingUnitMemberusgaapReportingUnitAxis_OtherCountriesMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis" >teva:MedisReportingUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:OtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_UnsecuredSyndicatedRevolvingCrediTfacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >teva:UnsecuredSyndicatedRevolvingCrediTfacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OKusgaapStatutoryAccountingPracticesByJurisdictionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis" >stpr:OK</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis" >teva:CuyahogaCountyOhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis" >teva:SummitCountyOhMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis" >stpr:LA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis" >stpr:TX</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis" >stpr:RI</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis" >stpr:FL</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis" >teva:SanFranciscoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis" >stpr:WV</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_NYusgaapStatutoryAccountingPracticesByJurisdictionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis" >stpr:NY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis" >teva:TribesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" >teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" >teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" >teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" >teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" >teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" >teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" >teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" >teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:InterestRateIncreaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:InterestRateIncreaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_MinimumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:OneTimePremiumPaymentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_MaximumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:OneTimePremiumPaymentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_InterestRateIncreaseMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:InterestRateIncreaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:OneTimePremiumPaymentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To10_31_2021_ModagMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ModagMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To10_31_2021_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_TaxYear2008To2011MemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >teva:TaxYear2008To2011Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To12_31_2021_ModagMemberusgaapBusinessAcquisitionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ModagMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:OtsukaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-05-12</xbrli:startDate> <xbrli:endDate>2017-05-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_OtsukaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:OtsukaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_OtsukaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:OtsukaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:TakedaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-12-01</xbrli:startDate> <xbrli:endDate>2016-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_TakedaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:TakedaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2021To08_31_2021_MedincellMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:MedincellMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-01</xbrli:startDate> <xbrli:endDate>2021-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_MedincellMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:MedincellMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis" >teva:EosinophilicEsophagitisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis" >teva:EosinophilicEsophagitisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2019_AndroGelRateAtOnePercentageMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AndroGelRateAtOnePercentageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:DefendantsAxis" >teva:FourOtherDefendantsOtherThanTevaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-21</xbrli:startDate> <xbrli:endDate>2021-07-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis_NationwideSettlementMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:NationwideSettlementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:DefendantsAxis" >teva:FourOtherDefendantsOtherThanTevaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-21</xbrli:startDate> <xbrli:endDate>2021-07-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:NoveTideAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_EuropeReportingUnitMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >teva:EuropeReportingUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2023To12_31_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2024To06_30_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-01</xbrli:startDate> <xbrli:endDate>2024-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2024To12_31_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_InternationalMarketsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherCountriesMembersrtStatementGeographicalAxis_TevasApiReportingUnitMemberusgaapReportingUnitAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:OtherCountriesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis" >teva:TevasApiReportingUnitMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MedisReportingUnitMemberusgaapReportingUnitAxis_OtherCountriesMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis" >teva:MedisReportingUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:OtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_InternationalMarketsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_OtherCountriesMembersrtStatementGeographicalAxis_TevasApiReportingUnitMemberusgaapReportingUnitAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis" >teva:TevasApiReportingUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:OtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_MedisReportingUnitMemberusgaapReportingUnitAxis_OtherCountriesMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis" >teva:MedisReportingUnitMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:OtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_EUR" > <xbrli:measure>iso4217:EUR</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_CHF" > <xbrli:measure>iso4217:CHF</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Segment" > <xbrli:measure>teva:Segment</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_ILS_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:ILS</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><ix:relationship fromRefs="Fact_78648272" toRefs="FN_269435"/><ix:relationship fromRefs="Fact_78648273" toRefs="FN_269435"/><ix:relationship fromRefs="Fact_78648274" toRefs="FN_269435"/><ix:relationship fromRefs="Fact_78648275" toRefs="FN_269435"/><ix:relationship fromRefs="Fact_78648314" toRefs="FN_269438"/><ix:relationship fromRefs="Fact_78648315" toRefs="FN_269438"/><ix:relationship fromRefs="Fact_78648316" toRefs="FN_269438"/><ix:relationship fromRefs="Fact_78648317" toRefs="FN_269438"/><ix:relationship fromRefs="Fact_78648318" toRefs="FN_269438"/><ix:relationship fromRefs="Fact_78648319" toRefs="FN_269438"/><ix:relationship fromRefs="Fact_78648326" toRefs="FN_269438"/><ix:relationship fromRefs="Fact_78648327" toRefs="FN_269438"/><ix:relationship fromRefs="Fact_78648328" toRefs="FN_269438"/><ix:relationship fromRefs="Fact_78648329" toRefs="FN_269438"/><ix:relationship fromRefs="Fact_78648330" toRefs="FN_269438"/><ix:relationship fromRefs="Fact_78648331" toRefs="FN_269438"/><ix:relationship fromRefs="Fact_78648578" toRefs="FN_269449"/><ix:relationship fromRefs="Fact_78648578" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648579" toRefs="FN_269452"/><ix:relationship fromRefs="Fact_78648580" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648580" toRefs="FN_269450"/><ix:relationship fromRefs="Fact_78648581" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648582" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648583" toRefs="FN_269444"/><ix:relationship fromRefs="Fact_78648583" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648586" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648586" toRefs="FN_269445"/><ix:relationship fromRefs="Fact_78648587" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648588" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648590" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648592" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648593" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648593" toRefs="FN_269450"/><ix:relationship fromRefs="Fact_78648594" toRefs="FN_269449"/><ix:relationship fromRefs="Fact_78648594" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648596" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648596" toRefs="FN_269446"/><ix:relationship fromRefs="Fact_78648597" toRefs="FN_269447"/><ix:relationship fromRefs="Fact_78648597" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648654" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648654" toRefs="FN_269449"/><ix:relationship fromRefs="Fact_78648656" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648656" toRefs="FN_269447"/><ix:relationship fromRefs="Fact_78648657" toRefs="FN_269446"/><ix:relationship fromRefs="Fact_78648657" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648659" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648659" toRefs="FN_269449"/><ix:relationship fromRefs="Fact_78648660" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648660" toRefs="FN_269450"/><ix:relationship fromRefs="Fact_78648661" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648663" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648665" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648666" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648667" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648667" toRefs="FN_269445"/><ix:relationship fromRefs="Fact_78648670" toRefs="FN_269444"/><ix:relationship fromRefs="Fact_78648670" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648671" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648672" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648673" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648673" toRefs="FN_269450"/><ix:relationship fromRefs="Fact_78648674" toRefs="FN_269452"/><ix:relationship fromRefs="Fact_78648791" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648791" toRefs="FN_269449"/><ix:relationship fromRefs="Fact_78648792" toRefs="FN_269449"/><ix:relationship fromRefs="Fact_78648792" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648793" toRefs="FN_269452"/><ix:relationship fromRefs="Fact_78648794" toRefs="FN_269452"/><ix:relationship fromRefs="Fact_78648795" toRefs="FN_269450"/><ix:relationship fromRefs="Fact_78648795" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648796" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648796" toRefs="FN_269450"/><ix:relationship fromRefs="Fact_78648797" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648798" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648799" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648800" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648801" toRefs="FN_269444"/><ix:relationship fromRefs="Fact_78648801" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648802" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648802" toRefs="FN_269444"/><ix:relationship fromRefs="Fact_78648807" toRefs="FN_269445"/><ix:relationship fromRefs="Fact_78648807" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648808" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648808" toRefs="FN_269445"/><ix:relationship fromRefs="Fact_78648809" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648810" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648811" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648812" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648815" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648816" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648819" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648820" toRefs="FN_269448"/><ix:relationship fromRefs="Fact_78648821" toRefs="FN_269450"/><ix:relationship fromRefs="Fact_78648821" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648822" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648822" toRefs="FN_269450"/><ix:relationship fromRefs="Fact_78648823" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648823" toRefs="FN_269449"/><ix:relationship fromRefs="Fact_78648824" toRefs="FN_269449"/><ix:relationship fromRefs="Fact_78648824" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648827" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648827" toRefs="FN_269446"/><ix:relationship fromRefs="Fact_78648828" toRefs="FN_269446"/><ix:relationship fromRefs="Fact_78648828" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648829" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648829" toRefs="FN_269447"/><ix:relationship fromRefs="Fact_78648830" toRefs="FN_269447"/><ix:relationship fromRefs="Fact_78648830" toRefs="FN_269453"/><ix:relationship fromRefs="Fact_78648843" toRefs="FN_269451"/><ix:relationship fromRefs="Fact_78648844" toRefs="FN_269451"/><ix:relationship fromRefs="Fact_78648932" toRefs="FN_269439"/><ix:relationship fromRefs="Fact_78648933" toRefs="FN_269439"/><ix:relationship fromRefs="Fact_78648964" toRefs="FN_269440"/><ix:relationship fromRefs="Fact_78648965" toRefs="FN_269440"/><ix:relationship fromRefs="Fact_78648966" toRefs="FN_269440"/><ix:relationship fromRefs="Fact_78648967" toRefs="FN_269440"/><ix:relationship fromRefs="Fact_78648968" toRefs="FN_269440"/><ix:relationship fromRefs="Fact_78648969" toRefs="FN_269440"/><ix:relationship fromRefs="Fact_78649125" toRefs="FN_269442"/><ix:relationship fromRefs="Fact_78649126" toRefs="FN_269442"/><ix:relationship fromRefs="Fact_78649127" toRefs="FN_269442"/><ix:relationship fromRefs="Fact_78649128" toRefs="FN_269442"/><ix:relationship fromRefs="Fact_78649129" toRefs="FN_269443"/><ix:relationship fromRefs="Fact_78649130" toRefs="FN_269443"/><ix:relationship fromRefs="Fact_78649131" toRefs="FN_269443"/><ix:relationship fromRefs="Fact_78649132" toRefs="FN_269443"/><ix:relationship fromRefs="Fact_78649194" toRefs="FN_269437"/><ix:relationship fromRefs="Fact_78649195" toRefs="FN_269437"/><ix:relationship fromRefs="Fact_78649196" toRefs="FN_269437"/><ix:relationship fromRefs="Fact_78649197" toRefs="FN_269436"/><ix:relationship fromRefs="Fact_78649198" toRefs="FN_269436"/><ix:relationship fromRefs="Fact_78649199" toRefs="FN_269436"/><ix:relationship fromRefs="Fact_78649200" toRefs="FN_269436"/><ix:relationship fromRefs="Fact_78649399" toRefs="FN_269454"/><ix:relationship fromRefs="Fact_78649400" toRefs="FN_269454"/><ix:relationship fromRefs="Fact_78649401" toRefs="FN_269454"/><ix:relationship fromRefs="Fact_78649402" toRefs="FN_269454"/><ix:relationship fromRefs="Fact_78649403" toRefs="FN_269454"/><ix:relationship fromRefs="Fact_78649404" toRefs="FN_269454"/><ix:relationship fromRefs="Fact_78649405" toRefs="FN_269454"/><ix:relationship fromRefs="Fact_78649406" toRefs="FN_269454"/><ix:relationship fromRefs="Fact_78649407" toRefs="FN_269454"/><ix:relationship fromRefs="Fact_78649408" toRefs="FN_269454"/><ix:relationship fromRefs="Fact_78649408" toRefs="FN_269457"/><ix:relationship fromRefs="Fact_78649409" toRefs="FN_269454"/><ix:relationship fromRefs="Fact_78649437" toRefs="FN_269441"/><ix:relationship fromRefs="Fact_78649438" toRefs="FN_269441"/><ix:relationship fromRefs="Fact_78649441" toRefs="FN_269441"/><ix:relationship fromRefs="Fact_78649442" toRefs="FN_269441"/><ix:relationship fromRefs="Fact_78649444" toRefs="FN_269441"/><ix:relationship fromRefs="Fact_78649445" toRefs="FN_269441"/></ix:resources></ix:header></div><div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto;text-indent: 0px;"><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="line-height: 3pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 4pt; margin-bottom: 0pt; font-size: 18pt; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">WASHINGTON, D.C. 20549</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 4pt; margin-bottom: 0pt; font-size: 18pt; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">FORM<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2023To03_31_2023">10-Q</ix:nonNumeric></div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 12pt; border: 0px; width: 816px; border-spacing: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 32.625px; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="P01_01_2023To03_31_2023" format="ixt:fixed-true">&#9746;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 4pt; margin-bottom: 0pt; font-size: 10pt; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2023To03_31_2023" format="ixt:date-monthname-day-year-en">March 31, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2023To03_31_2023">2023</ix:nonNumeric></ix:nonNumeric></div></div></div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 4pt; margin-bottom: 0pt; font-size: 10pt; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 12pt; border: 0px; width: 816px; border-spacing: 0px;">
<tr style="break-inside: avoid;">
<td style="width: 32.625px; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2023To03_31_2023" format="ixt:fixed-false">&#9744;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 4pt; margin-bottom: 0pt; font-size: 10pt; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Commission file number<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2023To03_31_2023">001-16174</ix:nonNumeric></div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 4pt; margin-bottom: 0pt; font-size: 22pt; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2023To03_31_2023">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</ix:nonNumeric></div></div></div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter)</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 8pt; width: 816px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 412.125px;"></td>
<td style="vertical-align: bottom; width: 8.23438px;"></td>
<td style="width: 395.641px;"></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2023To03_31_2023" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><span style="-sec-ix-hidden:hidden78861945">Not Applicable</span></div></div></div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: top;;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">incorporation or organization)</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(IRS Employer</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification Number)</div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 12pt;"><div style="display:inline;"></div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2023To03_31_2023">124 Dvora HaNevi&#8217;a St.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To03_31_2023">Tel Aviv</ix:nonNumeric>, <span style="-sec-ix-hidden:hidden78861938">ISRAEL</span></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2023To03_31_2023">6944020</ix:nonNumeric></div></div></div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Zip code)</div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2023To03_31_2023">+972 (3)</ix:nonNumeric><div style="white-space:nowrap;display:inline;">&#160;<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2023To03_31_2023">914-8213</ix:nonNumeric></div> </div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Registrant&#8217;s telephone number, including area code)</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 4pt; margin-bottom: 0pt; font-size: 10pt; text-align: center;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act:</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 8pt; width: 816px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 277.438px;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 261.109px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td style="width: 261.109px;"></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title of each class</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Symbol(s)</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom;;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of each exchange</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">on which registered</div></div></div></div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2023To03_31_2023">American Depositary Shares, each representing one Ordinary Share</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2023To03_31_2023">TEVA</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2023To03_31_2023" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 4pt; margin-bottom: 0pt; font-size: 10pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2023To03_31_2023">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 4pt; margin-bottom: 0pt; font-size: 10pt;"><div style="display:inline;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2023To03_31_2023">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 4pt; margin-bottom: 0pt; font-size: 10pt;"><div style="display:inline;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>of the Exchange Act.</div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; width: 816px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 163.188px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td style="width: 440.641px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td style="width: 171.359px;"></td>
<td style="vertical-align: bottom; width: 8.15625px;"></td>
<td style="width: 16.3438px;"></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: bottom;"><div style="display:inline;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2023To03_31_2023" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#9746;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">Accelerated&#160;filer</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#9744;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: bottom;"><div style="display:inline;">Non-accelerated filer</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#9744;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">Smaller&#160;reporting&#160;company</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2023To03_31_2023" format="ixt:fixed-false">&#9744;</ix:nonNumeric></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 10pt;">
<td style="vertical-align: bottom;"><div style="display:inline;">Emerging&#160;growth&#160;company</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2023To03_31_2023" format="ixt:fixed-false">&#9744;</ix:nonNumeric></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 4pt; margin-bottom: 0pt; font-size: 10pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 4pt; margin-bottom: 0pt; font-size: 10pt;"><div style="display:inline;">Indicate by check mark whether the registrant is a shell company (as defined in Rule<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2023To03_31_2023" format="ixt:fixed-false">&#9746;</ix:nonNumeric></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 4pt; margin-bottom: 0pt; font-size: 10pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2023, the registrant had <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,120,405,816</ix:nonFraction> ordinary shares outstanding.</div></div></div><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;<br/></div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For an accessible version of this Quarterly Report on Form&#160;10-Q, please visit www.tevapharm.com </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">INDEX </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:9%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:83%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">PART I.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold"><a href="#fin464631_1">Financial Statements (unaudited)</a></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_2">Financial Statements (unaudited)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_3">Consolidated Balance Sheets</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_4">Consolidated Statements of Income (loss)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_5">Consolidated Statements of Comprehensive Income (loss)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_6">Consolidated statements of changes in equity</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_7">Consolidated Statements of Cash Flows</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_8">Notes to Consolidated Financial Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 2.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_9">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 3.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_10">Quantitative and Qualitative Disclosures about Market Risk</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 4.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_11">Controls and Procedures</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">PART II.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold"><a href="#fin464631_12">OTHER INFORMATION</a></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_13">Legal Proceedings</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_14">Risk Factors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 2.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_15">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 3.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_16">Defaults Upon Senior Securities</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 4.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_17">Mine Safety Disclosures</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 5.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_18">Other Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 6.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_19">Exhibits</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#fin464631_20">Signatures</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">INTRODUCTION AND USE OF CERTAIN TERMS </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;Teva&#8221; refer to Teva Pharmaceutical Industries Limited and its subsidiaries, and references to &#8220;revenues&#8221; refer to net revenues. References to &#8220;U.S. dollars,&#8221; &#8220;dollars,&#8221; &#8220;U.S. $&#8221; and &#8220;$&#8221; are to the lawful currency of the United States of America, and references to &#8220;NIS&#8221; are to new Israeli shekels. References to &#8220;ADS(s)&#8221; are to Teva&#8217;s American Depositary Share(s). References to &#8220;MS&#8221; are to multiple sclerosis. Market data, including both sales and share data, is based on information provided by IQVIA, a provider of market research to the pharmaceutical industry (&#8220;IQVIA&#8221;), unless otherwise stated. References to &#8220;R&amp;D&#8221; are to Research and Development, references to &#8220;IPR&amp;D&#8221; are to <span style="white-space:nowrap">in-process</span> R&amp;D, references to &#8220;S&amp;M&#8221; are to Selling and Marketing and references to &#8220;G&amp;A&#8221; are to General and Administrative. Some amounts in this report may not add up due to rounding. All percentages have been calculated using unrounded amounts. This report on Form <span style="white-space:nowrap">10-Q</span> contains many of the trademarks and trade names used by Teva in the United States and internationally to distinguish its products and services. Any third-party trademarks mentioned in this report are the property of their respective owners. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to historical information, this Quarterly Report on Form <span style="white-space:nowrap">10-Q,</span> and the reports and documents incorporated by reference in this Quarterly Report on Form <span style="white-space:nowrap">10-Q,</span> may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management&#8217;s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;may,&#8221; &#8220;project,&#8221; &#8220;guidance,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe&#8221; and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.&#160;Important factors that could cause or contribute to such differences include risks relating to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and commercialize biopharmaceutical products; competition for our innovative medicines, including AUSTEDO<sup style="font-size:75%; vertical-align:top">&#174;</sup>, AJOVY<sup style="font-size:75%; vertical-align:top">&#174;</sup> and COPAXONE<sup style="font-size:75%; vertical-align:top">&#174;</sup>; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our business and operations in general, including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; the widespread outbreak of an illness or any other communicable disease, or any other public health crisis; effectiveness of our optimization efforts; our ability to attract, hire, integrate and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications and any delay in our ability to obtain sufficient participation of plaintiffs for the nationwide settlement of our opioid-related litigation in the United States; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice (&#8220;DOJ&#8221;) criminal charges of Sherman Act violations; potential liability for intellectual property right infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; compliance with anti-corruption, sanctions and trade control laws; environmental risks; and the impact of Environmental, Social and Governance (&#8220;ESG&#8221;) issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our long-lived assets; the impact of geopolitical conflicts including the ongoing conflict between Russia and Ukraine; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">and other factors discussed in this Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> and in our Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2022, including in the sections captioned &#8220;Risk Factors.&#8221; Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="hidden78649493" contextRef="P01_01_2023To03_31_2023">http://fasb.org/us-gaap/2022#IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</ix:nonNumeric><ix:nonFraction name="teva:BifurcatedEmbeddedDerivatives" id="hidden78649329" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6">0</ix:nonFraction><ix:nonFraction name="teva:BifurcatedEmbeddedDerivatives" id="hidden78649330" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6">0</ix:nonFraction><ix:nonNumeric name="us-gaap:DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="hidden78649497" contextRef="P01_01_2023To03_31_2023">http://fasb.org/us-gaap/2022#IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="hidden78649299" contextRef="P01_01_2023To03_31_2023_UnsecuredSyndicatedRevolvingCrediTfacilityMemberusgaapCreditFacilityAxis">2026-04-30</ix:nonNumeric><ix:nonFraction name="us-gaap:DerivativeLiabilities" id="hidden78648268" contextRef="PAsOn12_31_2022_EmbeddedDerivativeFinancialInstrumentsMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6">0</ix:nonFraction><ix:nonFraction name="us-gaap:DerivativeLiabilities" id="hidden78648269" contextRef="PAsOn03_31_2023_EmbeddedDerivativeFinancialInstrumentsMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6">0</ix:nonFraction><ix:nonNumeric name="us-gaap:EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration" id="hidden78649508" contextRef="PAsOn03_31_2023">http://fasb.org/us-gaap/2022#LiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="hidden78649487" contextRef="P01_01_2022To12_31_2022">http://fasb.org/us-gaap/2022#OperatingIncomeLoss</ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="hidden78649490" contextRef="PAsOn03_31_2023">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="hidden78649491" contextRef="PAsOn12_31_2022">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="hidden78649488" contextRef="PAsOn03_31_2023">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="hidden78649489" contextRef="PAsOn12_31_2022">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="teva-20230331.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="fin464631_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART I &#8212; FINANCIAL INFORMATION </div></div></div></div> <div id="fin464631_2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;1. FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div id="fin464631_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. dollars in millions, except for share data) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">ASSETS</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current assets:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivables, net of allowance for credit losses of $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">88</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">91</ix:nonFraction>&#160;million as of March&#160;31, 2023 and December&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,435</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,696</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventories</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,118</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,833</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,253</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,162</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other current assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">542</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assets held for sale</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,501</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,051</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Deferred income taxes</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,453</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">441</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Property, plant and equipment, net</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,751</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">420</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">419</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Identifiable intangible assets, net</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,964</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,270</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">17,633</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">43,456</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">44,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">LIABILITIES AND EQUITY</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current liabilities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term debt</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,023</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,109</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales reserves and allowances</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:SalesReservesAndAllowances" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,309</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:SalesReservesAndAllowances" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,887</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee-related obligations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">432</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">566</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:AccruedExpenses" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,267</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:AccruedExpenses" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,151</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other current liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,005</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,411</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,469</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Long-term liabilities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income taxes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">550</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">548</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other taxes and long-term liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,869</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,847</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes and loans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,668</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">349</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total long-term liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">24,433</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23,846</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commitments and contingencies</div></div>, see note 10</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">34,844</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">35,315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Equity:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Teva shareholders&#8217; equity:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ordinary shares of NIS <ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_ILS_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2023" unitRef="Unit_ILS_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction></ix:nonFraction> par value per share; March&#160;31, 2023 and December&#160;31, 2022: authorized <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">2,495</ix:nonFraction></ix:nonFraction>&#160;million shares; issued <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">1,226</ix:nonFraction>&#160;million shares and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">1,217</ix:nonFraction>&#160;million shares, respectively</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,719</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,688</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">13,086</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12,882</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,701</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Treasury shares as of March&#160;31, 2023 and December&#160;31, 2022: <ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="PAsOn03_31_2023" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">106</ix:nonFraction></ix:nonFraction>&#160;million ordinary shares</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,860</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,897</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-controlling</div> interests</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">751</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total equity</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,612</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,691</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities and equity</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">43,456</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">44,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Amounts may not add up due to rounding. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div id="fin464631_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF INCOME (LOSS) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. dollars in millions, except share and per share data) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net revenues</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,661</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,661</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of sales</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,079</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,921</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,740</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">234</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">225</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling and marketing expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">546</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">584</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">296</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">296</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets impairments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:IntangibleAssetsImpairments" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:IntangibleAssetsImpairments" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">149</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets impairments, restructuring and other items</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">96</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legal settlements and loss contingencies</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">233</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,124</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating income (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">713</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial expenses, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income (loss) before income taxes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">971</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income taxes (benefit)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share&#160;in (profits)&#160;losses of&#160;associated&#160;companies, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net income (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net income (loss) attributable to Teva</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">205</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">955</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Earnings (loss) per share attributable to ordinary shareholders:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares (in millions):</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,107</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,107</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#167;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Represents an amount less than $<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2023To03_31_2023_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million. </div> </td> </tr> </table> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Amounts may not add up due to rounding. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div id="fin464631_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. dollars in millions) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net income (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income (loss), net of tax:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Currency translation adjustment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gain (loss) from derivative financial instruments, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:UnrealizedGainLossOnDerivativeNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:UnrealizedGainLossOnDerivativeNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on defined benefit plans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other comprehensive income (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total comprehensive income (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1,009</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">42</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive income (loss) attributable to Teva</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">69</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">959</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Amounts may not add up due to rounding. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div id="fin464631_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY </div></div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:33%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="26" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Teva shareholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> shares (in<br/> millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stated<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><br/> capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retained<br/> earnings<br/> (accumulated<br/> deficit)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> other<br/> comprehensive<br/> (loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treasury<br/> shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Teva<br/> shareholders&#8217;<br/> equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">controlling</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">interests</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="34" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. dollars in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,217</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,688</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12,882</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,897</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,691</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net Income (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">205</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To03_31_2023_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">205</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To03_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2023To03_31_2023_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2023To03_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Shares</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To03_31_2023_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at March&#160;31, 2023</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,226</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,719</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">13,086</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,701</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7,860</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">751</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">8,612</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Represents an amount less than $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million. </div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="26" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Teva shareholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> shares (in<br/> millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stated<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><br/> capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retained<br/> earnings<br/> (accumulated<br/> deficit)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> other<br/> comprehensive<br/> (loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treasury<br/> shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Teva<br/> shareholders&#8217;<br/> equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">controlling</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">interests</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="34" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. dollars in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at December&#160;31, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,209</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,561</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10,529</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,278</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">966</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">11,244</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net Income (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">955</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">955</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of shares</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at March&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,216</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27,587</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11,484</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,687</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4,128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9,344</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">916</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10,260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Represents an amount less than $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million. </div> </td> </tr> </table> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Amounts may not add up due to rounding. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </div> </div> </div> </div> <div></div> </div> <div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div id="fin464631_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. dollars in millions) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating activities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net income (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net income (loss) to net cash provided by operations:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">304</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">323</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Impairment of long-lived assets and assets held for sale</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">189</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in operating assets and liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income taxes &#8211; net and uncertain tax positions</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:DeferredIncomeTaxesNetAndUncertainTaxPositions" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">106</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:DeferredIncomeTaxesNetAndUncertainTaxPositions" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other items</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss (gain) from investments and from sale of long lived assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ProfitFromSaleOfLongLivedAssetsAndInvestment" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ProfitFromSaleOfLongLivedAssetsAndInvestment" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash provided by (used in) operating activities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">145</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Investing activities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beneficial interest collected in exchange for securitized trade receivables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">323</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">305</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property, plant and equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">139</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from sale of business and long lived assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquisition of businesses, net of cash acquired</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of investments and other assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other investing activities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash provided by (used in) investing activities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">181</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financing activities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of senior notes and loans and other long term liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,152</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from senior notes, net of issuance costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,451</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other financing activities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash provided by (used in) financing activities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">706</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Translation adjustment on cash and cash equivalents</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">62</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net change in cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">658</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance of cash, cash equivalents and restricted cash at beginning of period</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,834</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,198</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance of cash, cash equivalents and restricted cash at end of period</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,176</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash included in other current assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,176</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> financing and investing activities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beneficial interest obtained in exchange for securitized accounts receivables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">334</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">299</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Amounts may not add up due to rounding </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin464631_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div><ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1 &#8211; Basis of presentation: </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">a. Basis of presentation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the financial statements reflect all normal and recurring adjustments necessary to fairly state the financial position and results of operations of Teva. The information included in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;). The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> balance sheet data was derived from the audited consolidated financial statements as of December&#160;31, 2022, but not all disclosures required by generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) are included. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing the Company&#8217;s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity and disclosure of contingent liabilities and assets at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing the Company&#8217;s consolidated financial statements, management also considered the economic implications of inflation expectations on its critical and significant accounting estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of IPR&amp;D assets, marketed product rights and goodwill, assessing sales reserves and allowances in the United States, uncertain tax positions, valuation allowances and contingencies. These estimates could <div style="display:inline;">be</div> impacted by higher costs and the ability to pass on such higher costs to customers, which is highly uncertain. Government actions taken to address macroeconomic developments, as well as their economic impact on Teva&#8217;s third-party manufacturers and suppliers, customers and markets, could also impact such estimates and may change in future periods. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2022, Russia launched an invasion of Ukraine. As of the date of this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q,</div> sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in Teva&#8217;s International Markets segment results. Teva has no manufacturing or R&amp;D facilities in these markets. During the three months ended March&#160;31, 2023, the impact of this conflict on Teva&#8217;s results <div style="display:inline;">of</div> operation and financial condition was immaterial. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">b. Significant accounting policies </div></div> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Recently adopted accounting pronouncements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2022, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-04</div> &#8220;Liabilities &#8212; Supplier Finance Programs: Disclosure of Supplier Finance Program Obligations (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">405-50)&#8221;.</div> This guidance is intended to address requests from stakeholders for information about an entity&#8217;s use of supplier finance programs and their effect on the entity&#8217;s working capital, liquidity and cash flows. The guidance is effective for the fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years, except for the amendment on roll-forward information requirement, which is effective for the fiscal years beginning after December&#160;15, 2023. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2021, the FASB issued ASU 2021-08 &#8220;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,&#8221; which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The Company adopted the new accounting standard effective January 1, 2023 and the guidance is applied prospectively to all business combinations with an acquisition date occurring on or after January 2023. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements.&#160;<br/></div> </div> </ix:nonNumeric><ix:nonNumeric name="teva:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Recently issued accounting pronouncements, not yet adopted </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;">10 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <ix:nonNumeric name="teva:CertainTransactionsDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649088"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">NOTE 2 &#8211; Certain transactions: </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company&#8217;s most significant agreements of this nature are summarized below. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">MODAG </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2021, Teva announced a license agreement with MODAG GmbH (&#8220;Modag&#8221;) that will provide Teva an exclusive global license to develop, manufacture and commercialize Modag&#8217;s lead compound <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-56286)</div> and a related compound <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-56287).</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TEV-56286</div> was initially developed for the treatment of Multiple System Atrophy (&#8220;MSA&#8221;) and Parkinson&#8217;s disease, and has the potential to be applied to other treatments for neurodegenerative disorders, such as Alzheimer&#8217;s disease. A phase 1b clinical trial for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TEV-56286</div> was completed and the results are being assessed. In the fourth quarter of 2021, Teva made an upfront payment of $<ix:nonFraction name="teva:MilestonePayment" contextRef="P10_01_2021To12_31_2021_ModagMemberusgaapBusinessAcquisitionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;million to Modag that was recorded as an R&amp;D expense. Modag may be eligible for future development milestone payments, totaling an aggregate amount of up to $<ix:nonFraction name="teva:LicenseAgreementPotentialAggregateMilestonePaymentsAmount" contextRef="P10_01_2021To10_31_2021_ModagMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction>&#160;million, as well as future commercial milestones and royalties. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Alvotech </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contains biosimilar candidates addressing multiple therapeutic areas, including proposed biosimilars to Humira<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"> </div>and Stelara<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>. Under the terms of the agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. Teva made an upfront payment in the third quarter of 2020 and additional upfront and milestone payments in the second quarter of 2021, which were recorded as R&amp;D expenses. Teva also made a milestone payment in January 2023, which was recorded as an R&amp;D expense in the fourth quarter of 2022. Additional development and commercial milestone payments of up to approximately $<ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P01_01_2023To03_31_2023_AlvotechMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">400</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="display:inline;">million, as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilars. Pursuant to a settlement agreement entered into in March 2022, regarding certain IP and trade secrets claims filed by Abbvie against Alvotech in relation to Alvotech&#8217;s proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (adalimumab), Alvotech and Teva may sell the proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in the United States beginning on July&#160;1, 2023, provided that U.S. regulatory approval is obtained by that date. Alvotech announced they received complete response letters (&#8220;CRL&#8221;) from the FDA with respect to Alvotech&#8217;s proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in September 2022, December 2022 and April 2023. The CRL from April 2023 stated that the application could not be approved at this time based on deficiencies associated with Alvotech&#8217;s manufacturing facility. The details following the most recent FDA&#8217;s inspection and CRL are being further assessed to determine next steps.<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>In January 2023, the FDA accepted for review the Biologics License Application (&#8220;BLA&#8221;) for Alvotech&#8217;s proposed biosimilar to Stelara<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"><ix:exclude>11</ix:exclude> </div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_78649088" continuedAt="TextSelectionAppend_78649088_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649088_1" continuedAt="TextSelectionAppend_78649088_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649088_2" continuedAt="TextSelectionAppend_78649088_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649088_3"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Otsuka </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;12, 2017, Teva entered into a license and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. (&#8220;Otsuka&#8221;) providing Otsuka with an exclusive license to develop and commercialize AJOVY in Japan. Otsuka paid Teva an upfront payment of $<ix:nonFraction name="teva:UpfrontPayments" contextRef="P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction>&#160;million in consideration for the transaction. In the third quarter of 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan and, as a result, paid Teva a milestone payment of $<ix:nonFraction name="teva:MilestonePayment" contextRef="P07_01_2020To09_30_2020_OtsukaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">15</ix:nonFraction>&#160;million, which was recognized as revenue in the third quarter of 2020. AJOVY was approved in Japan in June 2021 and launched on August&#160;30, 2021. As a result of the launch, Otsuka paid Teva a milestone payment of $<ix:nonFraction name="teva:MilestonePayment" contextRef="P07_01_2021To09_30_2021_OtsukaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction>&#160;million, which was recognized as revenue in the third quarter of 2021. Teva may receive additional milestone payments upon achievement of certain revenue targets. Otsuka also pays Teva royalties on AJOVY sales in Japan. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Takeda </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;), for the research, development, manufacture and commercialization of ATTENUKINE<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">TM</div> technology. Teva received a $<ix:nonFraction name="teva:UpfrontPayments" contextRef="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction>&#160;million upfront payment and a milestone payment of $<ix:nonFraction name="teva:MilestonePayment" contextRef="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction>&#160;million in 2017. During the second quarter of 2022, Takeda initiated its phase 2 study of modakafusp alfa (formerly TAK 573 or TEV 48573) and as a result paid Teva a milestone payment of $<ix:nonFraction name="teva:MilestonePayment" contextRef="P04_01_2022To06_30_2022_TakedaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction>&#160;million, which was recognized as revenue in the second quarter of 2022. The license agreement stipulates additional milestone payments to Teva of up to $<ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">519</ix:nonFraction>&#160;million with respect to this product candidate, as well as future <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">royalties. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">MedinCell </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable (&#8220;LAI&#8221;) products. Teva leads the clinical development and regulatory process and is responsible for commercialization of these products. The lead product <div style="display:inline;">is</div> risperidone LAI (formerly known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TV-46000).</div> On April&#160;28, 2023, the FDA approved UZEDY<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">TM </div>(risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults.&#160;UZEDY is expected to be available in the U.S. in the coming weeks. MedinCell may be eligible for future sales-based milestones of up to $<ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P08_01_2021To08_31_2021_MedincellMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">105</ix:nonFraction>&#160;million in respect of UZEDY. Teva will also pay MedinCell royalties on net sales. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The second selected product candidate is olanzapine LAI <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-44749)</div> for the treatment of schizophrenia. In the third quarter of 2022, Teva decided to progress development of the product to phase 3, and as a result a $<ix:nonFraction name="teva:MilestonePayment" contextRef="P07_01_2022To09_30_2022_MedincellMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction>&#160;million milestone payment was paid to MedinCell which was recognized as R&amp;D expenses. MedinCell may become eligible for further milestones and royalties on sales of olanzapine LAI <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-44749).</div> </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Assets Held for Sale: </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">General </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assets held for sale as of March&#160;31, 2023 and December&#160;31, 2022 included certain manufacturing assets that were sold in the second quarter of 2023. <ix:nonNumeric name="teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649089">The table below summarizes all of Teva&#8217;s assets included as held for sale as of March&#160;31, 2023 and December&#160;31, 2022: </ix:nonNumeric></div> <ix:continuation id="TextSelection_78649089"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:75%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventories</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property, plant and equipment, net and others</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments of assets held for sale to fair value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AssetsFairValueAdjustment" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AssetsFairValueAdjustment" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649103"> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 3 &#8211; Revenue from contracts with customers: </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Disaggregation of revenue </div></div> <ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table disaggregates Teva&#8217;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> activities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sale of goods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,319</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,176</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">131</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,090</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licensing arrangements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">434</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,766</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">492</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">219</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,661</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;">&#167;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> activities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sale of goods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,134</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">445</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licensing arrangements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">342</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">358</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">129</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,737</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,156</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">492</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">275</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,661</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;">&#167;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Variable consideration </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Variable consideration mainly includes sales reserves and allowances (&#8220;SR&amp;A&#8221;), comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against accounts receivables. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>13</ix:exclude> </div> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_78649103" continuedAt="TextSelectionAppend_78649103_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649103_1" continuedAt="TextSelectionAppend_78649103_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649103_2" continuedAt="TextSelectionAppend_78649103_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649103_3"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SR&amp;A to U.S. customers comprised approximately <ix:nonFraction name="teva:SalesReservesAndAllowancesToCustomersPercentage" contextRef="P01_01_2023To03_31_2023_USsrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">68</ix:nonFraction>% of the Company&#8217;s total SR&amp;A as of March&#160;31, 2023, with <div style="display:inline;">the</div> remaining balance primarily related to customers in Canada and Germany. The changes in SR&amp;A for third-party sales for the three months ended March&#160;31, 2023 and 2022 were as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div> <ix:nonNumeric name="teva:SalesReservesAndAllowancesCurrentTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:40%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/> included in<br/> Accounts<br/> Receivable,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/> other<br/> governmental<br/> allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total reserves<br/> included in<br/> Sales Reserves<br/> and&#160;Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="30" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">67</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">663</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">991</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">455</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">66</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,817</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions related to sales made in current year period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2023To03_31_2023_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2023To03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,003</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2023To03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">142</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2023To03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,855</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2023To03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2023To03_31_2023_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2023To03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,098</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions related to sales made in prior periods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2023To03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2023To03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2023To03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2023To03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2023To03_31_2023_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2023To03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Credits and payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2023To03_31_2023_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">84</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2023To03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2023To03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">289</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2023To03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,973</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2023To03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2023To03_31_2023_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2023To03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,505</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top;text-indent: 0px;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Translation differences</div></td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2023To03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2023To03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2023To03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2023To03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2023To03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2023_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,452</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">482</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">866</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">440</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2023_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">69</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,309</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,372</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:37%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/> included in<br/> Accounts<br/> Receivable,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/> other<br/> governmental<br/> allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total reserves<br/> included in<br/> Sales Reserves<br/> and&#160;Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="30" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at January&#160;1, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,655</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">854</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,085</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">535</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">112</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,241</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,309</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions related to sales made in current year period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">82</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">928</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">198</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,814</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,088</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,170</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions related to sales made in prior periods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Credits and payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,037</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">270</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,940</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,430</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Translation differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at March&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">62</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,453</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">807</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">951</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">469</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,807</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,869</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#167;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5 million.</div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-indent: 0px; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Pledged accounts receivables </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounts receivables, net of allowance for credit losses, include $<ix:nonFraction name="us-gaap:AccountsReceivableFromSecuritization" contextRef="PAsOn03_31_2023_AccountsReceivableSecuritizationFacilityMemberusgaapDerivativeInstrumentRiskAxis_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022MemberusgaapPledgingPurposeAxis_PncBankMemberTEVAFactoringInstitutionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">434</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AccountsReceivableFromSecuritization" contextRef="PAsOn12_31_2022_AccountsReceivableSecuritizationFacilityMemberusgaapDerivativeInstrumentRiskAxis_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022MemberusgaapPledgingPurposeAxis_PncBankMemberTEVAFactoringInstitutionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">436</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million as of March 31, 2023 and December 31, 2022, respectively, which are pledged to PNC Bank, National Association in connection with the U.S. securitization program entered into in November 2022. For further information on our securitization facilities, see note 10f to the consolidated financial statements for the year ended December 31, 2022, included in Teva&#8217;s Annual Report on Form 10-K.&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div> </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;">14 </div> </div></div> </div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 4 &#8211; Inventories: </div></div><ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventories, net of reserves, consisted of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finished products</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,987</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Raw and packaging materials</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,205</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,059</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Products in process</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">620</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">555</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Materials in transit and payments on account</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherInventoryInTransit" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">183</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherInventoryInTransit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,118</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,833</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649100"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 5 &#8211; Identifiable intangible assets: </div></div><ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifiable intangible assets consisted of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;carrying&#160;amount&#160;net&#160;of<br/> impairment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Product rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,094</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,067</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,934</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,437</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade names</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn03_31_2023_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">583</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">577</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn03_31_2023_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">241</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2023_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">342</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">346</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">In process research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">462</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">487</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">462</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">487</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,139</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,131</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">13,175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12,861</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5,964</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6,270</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product rights and trade names </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products in various therapeutic categories from various acquisitions with a weighted average life period of approximately <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2022To03_31_2022" format="ixt-sec:duryear">9</ix:nonNumeric> years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">165</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">200</ix:nonFraction>&#160;million in the three months ended March&#160;31, 2023 and 2022, respectively. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">IPR&amp;D </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s IPR&amp;D are assets that have not yet been approved in its major markets. IPR&amp;D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible assets impairments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Impairments of long-lived intangible assets for the three months ended March&#160;31, 2023 and 2022 were $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">178</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">149</ix:nonFraction>&#160;million, respectively. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Impairments in the first quarter of 2023 consisted of: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Identifiable product rights of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2023To03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">159</ix:nonFraction>&#160;million due to: (i) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2023To03_31_2023_JPsrtStatementGeographicalAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_UpdatedMarketAssumptionsMemberTEVAEventBasisAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">112</ix:nonFraction>&#160;million in Japan, mainly related to regulatory pricing reductions; and (ii) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2023To03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_RegulatoryPriceAndVolumeOfProductsMemberTEVAEventBasisAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">47</ix:nonFraction>&#160;million related to updated market assumptions regarding price and volume of products; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(b)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">IPR&amp;D assets of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2023To03_31_2023_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMemberTEVAEventBasisAxis_GenericPipelineProductsMembersrtProductOrServiceAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction>&#160;million, related to generic pipeline products resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape and launch date). </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>15</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_78649100" continuedAt="TextSelectionAppend_78649100_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649100_1" continuedAt="TextSelectionAppend_78649100_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649100_2" continuedAt="TextSelectionAppend_78649100_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649100_3"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div></ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Impairments in the first quarter of 2022 consisted primarily of identifiable product rights of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2023To03_31_2023_LenalidomideProductMembersrtProductOrServiceAxis_PriceAndVolumeOfProductsMemberTEVAEventBasisAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">129</ix:nonFraction>&#160;million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value measurement of the impaired intangible assets in the first quarter of 2023 is based on significant unobservable inputs in the market and thus represents a Level&#160;3 measurement within the fair value <div style="display:inline;">h</div>ierarchy. The discount rate applied ranged from <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">8.5</ix:nonFraction>% to <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">10</ix:nonFraction>%. A probability of success factor ranging from <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">20</ix:nonFraction>% to <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">90</ix:nonFraction>% was used in the fair value calculation to reflect inherent regulatory and commercial risk of IPR&amp;D. </div></ix:continuation><ix:nonNumeric name="us-gaap:GoodwillDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 6 &#8211; Goodwill: </div></div><ix:nonNumeric name="us-gaap:ScheduleOfGoodwillTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in the carrying amount of goodwill for the period ended March&#160;31, 2023 were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Teva&#8217;s<br/> API</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medis</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December&#160;31, 2022 (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2022_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648314">6,450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2022_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648315">8,302</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2022_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648316">1,339</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2022_OtherCountriesMembersrtStatementGeographicalAxis_TevasApiReportingUnitMemberusgaapReportingUnitAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648317">1,293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2022_MedisReportingUnitMemberusgaapReportingUnitAxis_OtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648319">249</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648318">17,633</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes during the period:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Translation differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2023To03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">82</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2023To03_31_2023_OtherCountriesMembersrtStatementGeographicalAxis_TevasApiReportingUnitMemberusgaapReportingUnitAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2023To03_31_2023_MedisReportingUnitMemberusgaapReportingUnitAxis_OtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March&#160;31, 2023 (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648326">6,451</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn03_31_2023_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648327">8,384</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn03_31_2023_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648328">1,400</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn03_31_2023_OtherCountriesMembersrtStatementGeographicalAxis_TevasApiReportingUnitMemberusgaapReportingUnitAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648329">1,305</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn03_31_2023_MedisReportingUnitMemberusgaapReportingUnitAxis_OtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648331">259</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648330">17,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><ix:footnote id="FN_269438" xml:lang="en-US">Accumulated goodwill impairment as of March&#160;31, 2023 and December&#160;31, 2022 was approximately $<ix:nonFraction name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">27.6</ix:nonFraction></ix:nonFraction>&#160;billion.</ix:footnote> </div></td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva operates its business through three reporting segments: North America, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Teva&#8217;s production and sale of APIs to third parties (&#8220;Teva API&#8221;) and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. Teva&#8217;s API and Medis reporting units are included under &#8220;Other&#8221; in the above table. See note 15 for additional segment information. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva begins with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva&#8217;s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (&#8220;WACC&#8221;), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva&#8217;s assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">First Quarter Deve<div style="display:inline;">lo</div>pments </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the first quarter of 2023, management evaluated whether there were any developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount as of March&#160;31, 2023. Management concluded that no triggering event had occurred and, therefore, no quantitative assessment was performed. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the goodwill impairment charges recorded in the fourth quarter of 2022 in relation to Teva&#8217;s International Markets and Teva&#8217;s API reporting units, the carrying values of those reporting units equaled their fair value as of December&#160;31, 2022. Additionally, as part of the quantitative analysis Teva conducted as part of its annual goodwill impairment test in the second quarter of 2022, it concluded that the estimated fair value of Teva&#8217;s Europe reporting unit exceeded its estimated carrying amount by <ix:nonFraction name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" contextRef="PAsOn06_30_2022_EuropeReportingUnitMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">9</ix:nonFraction>%. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to Teva&#8217;s International Markets, Teva&#8217;s Europe or Teva&#8217;s API reporting units in the future. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649106"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 7 &#8211; Debt obligations: </div></div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:ScheduleOfShortTermDebtTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Short-term debt: </div></div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:58%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest&#160;rate&#160;as&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible senior debentures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">2026</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="PAsOn03_31_2023_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="PAsOn12_31_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current maturities of long-term liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,086</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total short-term debt</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,023</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,109</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible senior debentures </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal amount of Teva&#8217;s <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.25</ix:nonFraction>% convertible senior debentures due 2026 was $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn03_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></ix:nonFraction>&#160;million as of March&#160;31, 2023 and December&#160;31, 2022. These convertible senior debentures include a &#8220;net share settlement&#8221; feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the &#8220;net share settlement&#8221; feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under short-term debt. </div> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="teva:LongTermDebtExcludingConvertibleDebtTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649108">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Long-term debt: </div></div> </td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest&#160;rate&#160;as&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,500</ix:nonFraction>&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">2024</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">683</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">670</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,500</ix:nonFraction>&#160;million (6)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648578">4.38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" id="Fact_78648654">2030</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648791">1,635</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648792">1,606</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,300</ix:nonFraction>&#160;million (9)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648579">1.25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" id="Fact_78648674">2023</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_78648793">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648794">633</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,100</ix:nonFraction>&#160;million (7)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648580">3.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" id="Fact_78648673">2027</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648795">1,199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648796">1,177</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction>&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648581">6.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" id="Fact_78648672">2025</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648797">449</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648798">1,070</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">900</ix:nonFraction>&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648582">4.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" id="Fact_78648671">2025</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648799">541</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648800">963</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">800</ix:nonFraction>&#160;million (1)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648583">7.38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" id="Fact_78648670">2029</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648801">872</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_78648802">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">750</ix:nonFraction>&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">2028</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">814</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">700</ix:nonFraction>&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis">2027</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">748</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:num-dot-decimal">500</ix:nonFraction>&#160;million (2)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648586">7.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" id="Fact_78648667">2031</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648807">545</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_78648808">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,500</ix:nonFraction>&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648587">3.15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" id="Fact_78648666">2026</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648809">3,374</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648810">3,496</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,000</ix:nonFraction>&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648588">2.80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" id="Fact_78648665">2023</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648811">1,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648812">1,453</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,000</ix:nonFraction>&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">2046</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,986</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,986</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,250</ix:nonFraction>&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648590">6.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" id="Fact_78648663">2024</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648815">957</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648816">1,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,250</ix:nonFraction>&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">2028</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction>&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648592">7.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" id="Fact_78648661">2025</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648819">427</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648820">1,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction>&#160;million (7)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648593">4.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" id="Fact_78648660">2027</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648821">1,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648822">1,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction>&#160;million (6)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648594">5.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" id="Fact_78648659">2029</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648823">1,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648824">1,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">789</ix:nonFraction>&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">2036</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">783</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">783</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">600</ix:nonFraction>&#160;million (3)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648596">7.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" id="Fact_78648657">2029</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648827">600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_78648828">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">500</ix:nonFraction>&#160;million (4)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Fact_78648597">8.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" id="Fact_78648656">2031</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648829">500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_78648830">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes CHF <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_CHF" decimals="-6" scale="6" format="ixt:num-dot-decimal">350</ix:nonFraction>&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">2025</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">384</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">382</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td colspan="8" style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total senior notes</div> </td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20,761</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21,266</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term debt</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn03_31_2023_OtherDebentures2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn12_31_2022_OtherDebentures2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less current maturities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,086</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less debt issuance costs (8)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNoncurrentNet" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648843">94</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNoncurrentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648844">78</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total senior notes and loans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,668</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>17</ix:exclude> </div> </ix:nonNumeric></ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_78649108" continuedAt="TextSelectionAppend_78649108_1"><ix:continuation id="TextSelection_78649106" continuedAt="TextSelectionAppend_78649106_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649106_1" continuedAt="TextSelectionAppend_78649106_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649106_2" continuedAt="TextSelectionAppend_78649106_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649106_3" continuedAt="TextSelectionAppend_78649106_4"><ix:continuation id="TextSelectionAppend_78649108_1"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="INF" scale="6" format="ixt:num-dot-decimal">800</ix:nonFraction>&#160;million euro bearing <ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">7.38</ix:nonFraction>% annual interest and due <ix:nonNumeric name="teva:DebtInstrumentMonthOfMaturity" contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-year-en">September 2029</ix:nonNumeric>. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">0.100</ix:nonFraction>%-<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">0.300</ix:nonFraction>%</div> per annum, from and including September&#160;15, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="INF" scale="6" format="ixt:num-dot-decimal">500</ix:nonFraction>&#160;million euro bearing <ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">7.88</ix:nonFraction>% annual interest and due <ix:nonNumeric name="teva:DebtInstrumentMonthOfMaturity" contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-year-en">September 2031</ix:nonNumeric>. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">0.100</ix:nonFraction>%-<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">0.300</ix:nonFraction>%</div> per annum, from and including September&#160;15, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal">600</ix:nonFraction>&#160;million bearing <ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">7.88</ix:nonFraction>% annual interest and due <ix:nonNumeric name="teva:DebtInstrumentMonthOfMaturity" contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-year-en">September 2029</ix:nonNumeric>. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">0.100</ix:nonFraction>%-<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">0.300</ix:nonFraction>%</div> per annum, from and including September&#160;15, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(4)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal">500</ix:nonFraction>&#160;million bearing <ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">8.13</ix:nonFraction>% annual interest and due <ix:nonNumeric name="teva:DebtInstrumentMonthOfMaturity" contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-year-en">September 2031</ix:nonNumeric>. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">0.100</ix:nonFraction>%-<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">0.300</ix:nonFraction>%</div> per annum, from and including September&#160;15, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(5)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva consummated a cash tender offer and extinguished $<ix:nonFraction name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">631</ix:nonFraction>&#160;million aggregate principal amount of its <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction>&#160;million euro 6% senior notes due in 2025; $<ix:nonFraction name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">432</ix:nonFraction>&#160;million aggregate principal amount of its <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">900</ix:nonFraction>&#160;million euro 4.5% senior notes due in 2025; $<ix:nonFraction name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">574</ix:nonFraction>&#160;million aggregate principal amount of its $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,000</ix:nonFraction>&#160;million 7.13% senior notes due in 2025; $<ix:nonFraction name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">454</ix:nonFraction>&#160;million aggregate principal amount of its $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,000</ix:nonFraction>&#160;million 2.8% senior notes due in 2023; $<ix:nonFraction name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">293</ix:nonFraction>&#160;million aggregate principal amount of its $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,250</ix:nonFraction>&#160;million 6% senior notes due in 2024 and $<ix:nonFraction name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">122</ix:nonFraction>&#160;million aggregate principal amount of its $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3,500</ix:nonFraction>&#160;million 3.15% senior notes due in 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(6)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">0.125</ix:nonFraction>%-<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:num-dot-decimal">0.375</ix:nonFraction>%</div> per annum, from and including <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_01_2023To03_31_2023_InterestRateIncreaseMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">May 9, 2026</ix:nonNumeric>. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(7)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">If Teva fails to achieve certain sustainability performance targets, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_MinimumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.15</ix:nonFraction>%-<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_MaximumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.45</ix:nonFraction>%</div> out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_01_2023To03_31_2023_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">May 9, 2026</ix:nonNumeric>. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(8)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Debt issuance costs as of March&#160;31, 2023 include $<ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="PAsOn03_31_2023_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">26</ix:nonFraction>&#160;million in connection with the issuance of the sustainability-linked senior notes in March 2023, partially offset by $<ix:nonFraction name="us-gaap:AccumulatedAmortizationDeferredFinanceCosts" contextRef="PAsOn03_31_2023_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction>&#160;million acceleration of issuance costs related to the cash tender offer. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(9)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva repaid $<ix:nonFraction name="teva:SeniorNotesRepaidAmount" contextRef="PAsOn03_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">646</ix:nonFraction>&#160;million of its <ix:nonFraction name="teva:SeniorNotesMaturityPercentage" contextRef="PAsOn03_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.25</ix:nonFraction>% senior notes at maturity. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(*)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Interest rate adjustments and a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. </div> </td> </tr> </table> </ix:continuation> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any. The long-term debt outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s debt as of March&#160;31, 2023 was effectively denominated in the following currencies: <ix:nonFraction name="teva:LongTermDebtCurrencyPortionUSD" contextRef="PAsOn03_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">62</ix:nonFraction>% in U.S. dollars, <ix:nonFraction name="teva:LongTermDebtCurrencyPortionEUR" contextRef="PAsOn03_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">36</ix:nonFraction>% in euro and <ix:nonFraction name="teva:LongTermDebtCurrencyPortionCHF" contextRef="PAsOn03_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>% in Swiss franc. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily its $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.8</ix:nonFraction>&#160;billion unsecured syndicated sustainability-linked revolving credit facility entered into in April 2022, which was amended in February 2023 (&#8220;RCF&#8221;). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RCF has a maturity date of <span style="-sec-ix-hidden:hidden78649299">April 2026</span>, with two <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="teva:LineOfCreditExtensionPeriod" contextRef="P01_01_2023To03_31_2023_UnsecuredSyndicatedRevolvingCrediTfacilityMemberusgaapCreditFacilityAxis">one-year</ix:nonNumeric></div> extension options. The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including a maximum leverage ratio, which becomes more restrictive over time. In addition, the RCF is linked to two sustainability performance targets: (i)&#160;the Company&#8217;s S&amp;P ESG Score and (ii)&#160;number of new regulatory submissions in low and middle-income countries. The RCF margin may increase or decrease depending on the Company&#8217;s sustainability performance. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;6, 2023, the terms of the RCF were amended to update the Company&#8217;s maximum leverage ratio under the RCF for certain periods. Under the terms of the RCF, as amended, the Company&#8217;s leverage ratio shall not exceed <ix:nonNumeric name="teva:LeverageRatio" contextRef="P01_01_2023To03_31_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"><ix:nonNumeric name="teva:LeverageRatio" contextRef="P04_01_2023To06_30_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"><ix:nonNumeric name="teva:LeverageRatio" contextRef="P07_01_2023To09_30_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.25</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>x in the first, second and third quarters of 2023, <ix:nonNumeric name="teva:LeverageRatio" contextRef="P10_01_2023To12_31_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.00</ix:nonNumeric>x in the fourth quarter of 2023, <ix:nonNumeric name="teva:LeverageRatio" contextRef="P01_01_2024To03_31_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"><ix:nonNumeric name="teva:LeverageRatio" contextRef="P04_01_2024To06_30_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"><ix:nonNumeric name="teva:LeverageRatio" contextRef="P07_01_2024To09_30_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.00</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>x in the first, second and third quarters of 2024, and <ix:nonNumeric name="teva:LeverageRatio" contextRef="P10_01_2024To12_31_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">3.50</ix:nonNumeric>x in the fourth quarter of 2024 and onwards. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>18</ix:exclude> </div> </ix:continuation></div> </div> </div> <ix:continuation id="TextSelectionAppend_78649106_4" continuedAt="TextSelectionAppend_78649106_5"><div></div></ix:continuation> </div> <ix:continuation id="TextSelectionAppend_78649106_5" continuedAt="TextSelectionAppend_78649106_6"><div> <div style="background-color:white;display: inline;"> <ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude> <ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></div> </div></ix:continuation> </div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649106_6"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:DebtInstrumentCovenantDescription" contextRef="P01_01_2023To03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">The RCF can be used for general corporate purposes, including repaying existing debt. As of March 31, 2023 and as of the date of this Quarterly Report on Form 10-Q, <ix:nonFraction name="us-gaap:LineOfCredit" contextRef="PAsOn03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued.</ix:nonNumeric> </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under specified circumstances, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF. Additionally, violations of the covenants, under the above-mentioned circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes and sustainability-linked senior notes is outstanding, could lead to an event of default under the Company&#8217;s senior notes and sustainability-linked senior notes due to cross-acceleration provisions. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that the financial statements are issued. </div> </ix:continuation><ix:nonNumeric name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649112"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 8 &#8211; Derivative instruments and hedging activities: </div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign exchange risk management:</div></div><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first <div style="display:inline;">quarter</div> of 2023, approximately <ix:nonFraction name="teva:RevenuesOtherThanUsd" contextRef="PAsOn03_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of Teva&#8217;s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency risks. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into forward exchange contracts and purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce its exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty, new Israeli shekel, Indian rupee and other currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (&#8220;net investment hedge&#8221;) and has in the past entered into cross-currency swaps and forward-contracts in order to hedge such an exposure. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. </div> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Interest risk management: </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company raises capital through various debt instruments, including senior notes, sustainability-linked senior notes, bank loans, convertible debentures and syndicated revolving credit facility that bear a fixed or variable interest rate. In some cases, the Company has swapped from a fixed to a variable interest rate (&#8220;fair value hedge&#8221;) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (&#8220;cash flow hedge&#8221;), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. </div> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Bifurcated embedded derivatives: </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the issuance of its sustainability-linked senior notes, Teva recognized embedded derivatives related to interest rate adjustments and a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment upon failure to achieve certain sustainability performance targets, such as access to medicines in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-to-middle-income</div></div> countries and reduction of absolute greenhouse gas emissions, which were bifurcated and are accounted for separately as derivative financial instruments. As of March&#160;31, 2023, the fair value of these derivative instruments is negligible. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>19</ix:exclude> </div> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_78649112" continuedAt="TextSelectionAppend_78649112_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649112_1" continuedAt="TextSelectionAppend_78649112_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649112_2" continuedAt="TextSelectionAppend_78649112_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649112_3" continuedAt="TextSelectionAppend_78649112_4"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </ix:exclude>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Derivative instruments outstanding: </div></div></td></tr></table> <ix:nonNumeric name="teva:DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cross-currency swap - cash flow hedge (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssetNotionalAmount" contextRef="PAsOn03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78649444">169</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssetNotionalAmount" contextRef="PAsOn12_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_78649445">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the classification and fair values <div style="display:inline;">of</div> derivative instruments: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:59%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Designated as hedging</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Not designated as hedging</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Asset derivatives:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other current assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option and forward contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="PAsOn03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="PAsOn12_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="PAsOn03_31_2023_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="PAsOn12_31_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cross-currency swap-cash flow hedge (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="PAsOn12_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="PAsOn03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="PAsOn12_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liability derivatives:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other current liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option and forward contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="PAsOn03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="PAsOn12_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="PAsOn03_31_2023_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="PAsOn12_31_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;">&#167;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5 million. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </ix:nonNumeric> <ix:nonNumeric name="teva:DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt;;display:inline;">The table below provides information regarding the location and amount of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div><div style="font-size: 10pt;;display:inline;"> (gains) losses from derivatives designated in cash flow hedging relationships:</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other&#160;comprehensive&#160;income&#160;(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Line items in which effects of hedges are recorded</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments" contextRef="P01_01_2023To03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments" contextRef="P01_01_2022To03_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" contextRef="P01_01_2023To03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" contextRef="P01_01_2022To03_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cross-currency swaps - cash flow hedge (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments" contextRef="P01_01_2023To03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78649441">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments" contextRef="P01_01_2022To03_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_78649442">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" contextRef="P01_01_2023To03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_78649437">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" contextRef="P01_01_2022To03_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_78649438">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>20</ix:exclude> </div> </ix:continuation></div></div> <ix:continuation id="TextSelectionAppend_78649112_4" continuedAt="TextSelectionAppend_78649112_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649112_5" continuedAt="TextSelectionAppend_78649112_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649112_6" continuedAt="TextSelectionAppend_78649112_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649112_7"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <ix:nonNumeric name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> (gains) losses from derivatives not designated as hedging instruments: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net revenues</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Line items in which effects of hedges are recorded</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To03_31_2023_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To03_31_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,661</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To03_31_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">3,661</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option and forward contracts (2)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To03_31_2023_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_78649125">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To03_31_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_78649126">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_78649127">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To03_31_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_78649128">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option and forward contracts economic hedge (3)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To03_31_2023_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_78649129">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To03_31_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="Fact_78649130">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78649131">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To03_31_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_78649132">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> </ix:nonNumeric> <div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">On March&#160;31, 2023, Teva entered into a cross currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty and several other currencies to protect its projected operating results for 2023. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first quarter of 2023, the negative impact from these derivatives recognized under revenues was $<ix:nonFraction name="us-gaap:DerivativeGainOnDerivative" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction>&#160;million. In the first quarter of 2022, the positive impact from these derivatives recognized under <span style="-sec-ix-hidden:hidden78649497">revenues</span> was $<ix:nonFraction name="us-gaap:DerivativeGainOnDerivative" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19</ix:nonFraction>&#160;million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. Cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </div> </td> </tr> </table> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">e.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Amortizations due to terminated derivative instruments: </div></div> </td> </tr> </table> <div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Forward-starting interest rate swaps and treasury lock agreements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015, Teva entered into forward-starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward-starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. Termination of these transactions resulted in a loss <span style="-sec-ix-hidden:hidden78649493">position</span> of $<ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">493</ix:nonFraction>&#160;million, which was recorded as other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to these forward-starting interest rate swaps and treasury lock agreements, losses of $<ix:nonFraction name="teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction>&#160;million and $<ix:nonFraction name="teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction>&#160;million were recognized under financial expenses, net, for each of the three months ended March&#160;31, 2023 and 2022, respectively. </div> </ix:continuation><ix:nonNumeric name="us-gaap:LegalMattersAndContingenciesTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 9 &#8211; Legal settlements and loss contingencies: </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, Teva recorded expenses of $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">233</ix:nonFraction>&#160;million in legal settlements and loss contingencies, compared to $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,124</ix:nonFraction>&#160;million in the first quarter of 2022. Expenses in the first quarter of 2023 were mainly related to estimated provision<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div> recorded in connection with the DOJ patient assistance program litigation and the reverse-payment antitrust litigation over certain HIV medicines, as well as an update to the estimated settlement provision&#160;related to the remaining opioid cases (mainly related to the effect that the passage of time had on the net present value of the discounted payments). Expenses in the first quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases. See note 10. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2023 and December&#160;31, 2022, Teva&#8217;s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $<ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,299</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">4,186</ix:nonFraction>&#160;million, respectively. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649109"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 10 &#8211; Commitments and contingencies: </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">General </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>21</ix:exclude> </div> </ix:nonNumeric></div> <ix:continuation id="TextSelection_78649109" continuedAt="TextSelectionAppend_78649109_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649109_1" continuedAt="TextSelectionAppend_78649109_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_2" continuedAt="TextSelectionAppend_78649109_3"><ix:exclude> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649109_3" continuedAt="TextSelectionAppend_78649109_4"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is reasonably estimable. Based upon the status of the cases described below, management&#8217;s assessments of the likelihood of damages, and the advice of counsel, no provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and excessive verdicts can occur. Accordingly, management&#8217;s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters where the exposures were fully resolved in the prior year, or determined to no longer meet the materiality threshold for disclosure, or were substantially resolved. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva&#8217;s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third party sales figures given below are based on IQVIA data. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Intellectual Property Litigation </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, Teva seeks to develop generic and biosimilar versions of patent-protected pharmaceuticals and biopharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator&#8217;s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. For many biosimilar products that are covered by patents, Teva participates in the &#8220;patent dance&#8221; procedures of the Biologics Price Competition and Innovation Act (&#8220;BPCIA&#8221;), which allow for the challenge to originator patents prior to obtaining biosimilar product approval. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator&#8217;s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic or biosimilar version of the product even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act or BPCIA. For example, Teva could be sued for patent infringement after commencing sales of a product. This type of litigation can involve any of Teva&#8217;s pharmaceutical products, not just its generic and biosimilar products. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva&#8217;s product. The amount of lost profits would generally be based on the lost sales of the patentee&#8217;s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>22</ix:exclude></div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_78649109_4" continuedAt="TextSelectionAppend_78649109_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649109_5" continuedAt="TextSelectionAppend_78649109_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_6" continuedAt="TextSelectionAppend_78649109_7"><ix:exclude> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> </div> </div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649109_7" continuedAt="TextSelectionAppend_78649109_8"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">In July 2014, GlaxoSmithKline (&#8220;GSK&#8221;) filed claims against Teva in the U.S. District Court for the District of Delaware for infringement of a patent directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva and eight other generic producers began selling their carvedilol tablets (the generic version of GSK&#8217;s Coreg&#174;) in September 2007. A jury trial was held and the jury returned a verdict in GSK&#8217;s favor finding Teva liable for induced infringement, including willful infringement, and assessing damages of $</div><ix:nonFraction name="teva:DamagesAssessment" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">235.5</ix:nonFraction><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million, not including pre- or post-judgment interest or a multiplier for willfulness. Thereafter, the court overturned the jury verdict, finding no induced infringement by Teva and that Teva did not owe any damages. On August 5, 2021, the Court of Appeals for the Federal Circuit issued a two-to-one decision reinstating the $</div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div><ix:nonFraction name="us-gaap:LossContingencyAccrualProvision" contextRef="P08_05_2021To08_05_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">235.5</ix:nonFraction><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million verdict and finding Teva liable for patent infringement. On February&#160;11, 2022, the Court of Appeals for the Federal Circuit denied rehearing. Teva appealed this decision to the U.S. Supreme Court on July&#160;11, 2022. In response to Teva&#8217;s <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">certiorari </div></div>petition, on October&#160;3, 2022, the U.S. Supreme Court issued an order seeking the views of the U.S. Solicitor General as to whether to review this case. On March&#160;29, 2023, the U.S. Solicitor General filed a brief recommending that the U.S. Supreme Court grant Teva&#8217;s request and reverse the judgment of the Court of Appeals for the Federal Circuit. In addition to the pending U.S. Supreme Court proceedings, the case has been remanded to the district court for further proceedings on Teva&#8217;s other legal and equitable defenses that have not yet been considered by the district court. In the first quarter of 2021, Teva recognized a provision based on its offer to settle such matter. </div></div> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Product Liability Litigation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both types of insurance, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in certain or all of its markets. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan are allegedly found in the active pharmaceutical ingredient (&#8220;API&#8221;) supplied to Teva by multiple API manufacturers, including by Zhejiang Huahai Pharmaceuticals Co. Ltd. (&#8220;Huahai&#8221;). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. In December 2019, Teva reached a settlement with Huahai resolving Teva&#8217;s claims related to certain sartan API supplied by Huahai. Under the settlement agreement, Huahai agreed to compensate Teva for some of its direct losses and provide it with prospective cost reductions for API. The settlement does not release Huahai from liability for any losses Teva may incur as a result of third party personal injury or product liability claims relating to the sartan API at issue, as discussed below. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, multiple lawsuits have been filed in connection with this matter. Teva&#8217;s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (&#8220;MDL&#8221;) pending in the United States District Courts against Teva and numerous other manufacturers. One MDL is pending in the United States District Court for the District of New Jersey for valsartan, losartan and irbesartan. Teva is not named in complaints with respect to irbesartan. The second MDL is pending in the United States District Court for the Southern District of Florida for ranitidine. The lawsuits against Teva in the MDLs consist of individual personal injury and/or product liability claims and economic damages claims brought by consumers and end payors on behalf of purported classes of other consumers and end payors as well as medical monitoring class claims. The judge in the valsartan MDL ordered that the first trial, likely commencing in late 2023 or early 2024, will involve third-party payor economic loss claims via a class representative on behalf of several subclasses of payors against Teva and two other defendants. On February&#160;8, 2023, the district court in the valsartan MDL entered an order that certified a series of subclasses on plaintiffs&#8217; economic loss claims and granted in part and denied in part the certification of a medical monitoring class. Defendants sought permission for appellate review of that decision, which was denied. In the ranitidine MDL, the generic manufacturers&#8217; motions to dismiss have been granted, although certain plaintiffs have appeals pending. In addition, on December&#160;6, 2022, the court in the ranitidine MDL granted the brand defendants&#8217; motions to exclude all of plaintiffs&#8217; general causation experts and granted summary judgment to the brand defendants on that ground. Teva, as well as other </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>23</ix:exclude> </div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_78649109_8" continuedAt="TextSelectionAppend_78649109_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649109_9" continuedAt="TextSelectionAppend_78649109_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_10" continuedAt="TextSelectionAppend_78649109_11"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649109_11" continuedAt="TextSelectionAppend_78649109_12"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> </ix:exclude> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">generic manufacturers, is also named in several state court actions asserting allegations similar to those in the ranitidine MDL and the valsartan and losartan MDL. State court valsartan and losartan actions are pending in New Jersey and Delaware and are currently stayed. State court ranitidine cases naming Teva are pending in coordinated proceedings in California, Illinois, Pennsylvania and New York, with motions to dismiss pending in Illinois, Pennsylvania and New York on preemption and other grounds. In addition to the valsartan and ranitidine MDLs and coordinated state court proceedings, Teva has also been named in a consolidated proceeding pending in the United States District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva&#8217;s, as well as other generic manufacturers&#8217; metformin products. Defendants&#8217; motion to dismiss the plaintiffs&#8217; amended metformin complaint from June 2021 was granted without prejudice with respect to the consumer economic loss plaintiffs, and granted in part and denied in part with respect to the end payor plaintiffs. Plaintiffs were granted leave to file a second amended complaint. Defendants&#8217; motion to dismiss that complaint was granted in part and denied in part. Similar lawsuits are pending in Canada and Germany. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Competition Matters </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva&#8217;s patent challenges have resulted in litigation relating to Teva&#8217;s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva and its subsidiaries have been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases are usually direct and indirect purchasers of pharmaceutical products, some of whom assert claims on behalf of classes of all direct and indirect purchasers, and they typically allege that (i)&#160;Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (ii)&#160;significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These plaintiffs seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been and disgorgement of profits, which are often automatically tripled under the relevant statutes, plus attorneys&#8217; fees and costs. The alleged damages generally depend on the size of the branded market and the length of the alleged delay, and can be substantial&#8212;potentially measured in multiples of the annual brand sales&#8212;particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva&#8217;s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (&#8220;FTC&#8221;) v. Actavis, Inc., that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This test has resulted in increased scrutiny of Teva&#8217;s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva&#8217;s currently pending antitrust litigations. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2020, the European Commission issued a final decision in its proceedings against both Cephalon and Teva, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling euro <ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:num-dot-decimal">60.5</ix:nonFraction>&#160;million on Teva and Cephalon. Teva and Cephalon filed an appeal against the decision in February 2021. A provision for this matter was included in the financial statements. Teva has provided the European Commission with a bank guarantee in the amount of the imposed fines. The hearing for the appeal took place in December 2022 and a decision is pending. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2011, three groups of plaintiffs filed claims against Wyeth and Teva for alleged violations of the antitrust laws in connection with their November 2005 settlement of patent litigation involving extended release venlafaxine (generic Effexor XR<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>). The cases were filed by a purported class of direct purchasers, by a purported class of indirect purchasers and by certain chain pharmacies in the U.S. District Court for the District of New Jersey. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. In March 2020, the district court temporarily stayed discovery and referred the case to mediation, and discovery remains stayed. Annual sales of Effexor XR<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> were approximately $<ix:nonFraction name="teva:AnnualSalesOfEffexor" contextRef="P08_21_2018To08_21_2022" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.6</ix:nonFraction>&#160;billion at the time of settlement and at the time Teva launched its generic version of Effexor XR<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> in July 2010. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>24</ix:exclude> </div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_78649109_12" continuedAt="TextSelectionAppend_78649109_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649109_13" continuedAt="TextSelectionAppend_78649109_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_14" continuedAt="TextSelectionAppend_78649109_15"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649109_15" continuedAt="TextSelectionAppend_78649109_16"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2012, two purported classes of direct-purchaser plaintiffs filed claims against GSK and Teva in New Jersey federal court for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving lamotrigine (generic Lamictal<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>) entered into in February 2005. The plaintiffs claimed that the settlement agreement unlawfully delayed generic entry and sought unspecified damages. On April&#160;9, 2021, the district court, which had previously granted an initial motion for class certification by the direct purchaser plaintiffs but was reversed on that ruling by the Third Circuit in April 2020, denied the direct purchaser plaintiffs&#8217; renewed motion for class certification. Plaintiffs filed a further renewed motion for class certification on May&#160;20, 2022, which was denied on February&#160;1, 2023. On February&#160;2, 2023, February&#160;7, 2023, and February&#160;27, 2023, a number of direct purchasers, who would otherwise have been members of the proposed class had it been certified, filed suit as individual plaintiffs in Pennsylvania&#8217;s federal court. Annual sales of Lamictal<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> were approximately $<ix:nonFraction name="teva:AnnualSalesOfLamictal" contextRef="PAsOn02_28_2005" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">950</ix:nonFraction>&#160;million at the time of the settlement and approximately $<ix:nonFraction name="teva:AnnualSalesOfLamictal" contextRef="PAsOn07_31_2008" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.3</ix:nonFraction>&#160;billion at the time Teva launched its generic version of Lamictal<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> in July 2008. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan&#174; (extended release niacin) filed claims against Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005 to resolve patent litigation over the product. A multidistrict litigation has been established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser opt-out plaintiffs filed complaints with allegations nearly identical to those of the direct purchasers&#8217; class. The court denied the indirect purchasers&#8217; motion for class certification with prejudice, and on April 24, 2023, the denial was affirmed by the Court of Appeals for the Third Circuit. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, alleging violations of state law and seeking restitution and civil penalties. Annual sales of Niaspan&#174; were approximately&#160;</div>$<ix:nonFraction name="teva:AnnualSalesOfNiaspan" contextRef="P04_01_2013To04_30_2013" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">416</ix:nonFraction>&#160;million at the time of the settlement and approximately $<ix:nonFraction name="teva:AnnualSalesOfNiaspan" contextRef="P09_01_2013To09_30_2013" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.1</ix:nonFraction>&#160;billion at the time Teva launched its generic version of Niaspan<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> in September 2013. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January 2014, numerous lawsuits have been filed in the U.S. District Court for the Southern District of New York by purported classes of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers</div> for, and direct-purchasers of, Actos<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met (pioglitazone and pioglitazone plus metformin) against Takeda, the innovator, and several generic manufacturers, including Teva, Actavis and Watson. The lawsuits allege, among other things, that the settlement agreements between Takeda and the generic manufacturers violated the antitrust laws. The court dismissed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers&#8217;</div> lawsuits against all defendants in September 2015. On February&#160;8, 2017, the Court of Appeals for the Second Circuit affirmed the dismissal in part and vacated and remanded the dismissal in part with respect to the claims against Takeda. The direct purchasers&#8217; case had been stayed pending resolution of the appeal in the end payer matter and the direct purchasers amended their complaint for a second time following the Second Circuit&#8217;s decision, but on October&#160;8, 2019, the district court dismissed, with prejudice, the direct purchasers&#8217; claims against the generic manufacturers (including Teva, Actavis, and Watson). At the time of Teva&#8217;s settlement, annual sales of Actos<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met were approximately $<ix:nonFraction name="teva:AnnualSalesOfActos" contextRef="P12_01_2010To12_31_2010" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">3.7</ix:nonFraction>&#160;billion and approximately $<ix:nonFraction name="teva:AnnualSalesOfActoplus" contextRef="P12_01_2010To12_31_2010" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">500</ix:nonFraction>&#160;million, respectively. At the time Teva launched its authorized generic version of Actos<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met in August 2012, annual sales of Actos<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met were approximately $<ix:nonFraction name="teva:AnnualSalesOfActos" contextRef="P08_01_2012To08_31_2012" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.8</ix:nonFraction>&#160;billion and approximately $<ix:nonFraction name="teva:AnnualSalesOfActoplus" contextRef="P08_01_2012To08_31_2012" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">430</ix:nonFraction>&#160;million, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Putative classes of direct-purchaser and end-payer plaintiffs have filed antitrust lawsuits (which have since been coordinated in federal court in Delaware) against Amgen and Teva alleging that the January 2, 2019 settlement agreement between Amgen and Teva, resolving patent litigation over cinacalcet (generic Sensipar&#174;), violated the antitrust laws. In March 2023, Teva moved for re-argument of its motion to certify the district court&#8217;s rulings denying Teva&#8217;s motion to dismiss in part for review by the U.S. Court of Appeals for the Third Circuit, and is awaiting the court&#8217;s decision. Annual sales of Sensipar&#174; in the United States were approximately $</div><ix:nonFraction name="teva:AnnualSalesOfSensipar" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.4</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;billion at the time Teva launched its generic version of Sensipar&#174; in December 2018, and at the time of the January 2, 2019 settlement.&#160;</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2019, certain direct-purchaser plaintiffs filed claims in federal court in Philadelphia naming Teva and its affiliates as defendants alleging that certain patent litigation settlement agreements relating to AndroGel<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>% (testosterone gel) violate the antitrust laws, specifically the September 2006 patent litigation settlement between Watson Pharmaceuticals, Inc. (&#8220;Watson&#8221;), from which Teva later acquired certain assets and liabilities, and Solvay Pharmaceuticals, Inc. (&#8220;Solvay&#8221;), and a December 2011 settlement between Teva and AbbVie. Those claims remain pending. Annual sales of AndroGel<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>% were approximately $<ix:nonFraction name="teva:AnnualSalesAtTimeOfSettlement" contextRef="PAsOn08_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">350</ix:nonFraction>&#160;million at the time of the earlier Watson/Solvay settlement and approximately $<ix:nonFraction name="teva:AnnualSalesAtTimeOfSettlement" contextRef="PAsOn08_31_2019_AndroGelRateAtOnePercentageMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">140</ix:nonFraction>&#160;million at the time Actavis launched its generic version of AndroGel<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>% in November 2015. A provision for these matters and related litigations in Georgia that have since been settled was included in the financial statements. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"><ix:exclude>25</ix:exclude> </div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_78649109_16" continuedAt="TextSelectionAppend_78649109_17"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649109_17" continuedAt="TextSelectionAppend_78649109_18"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_18" continuedAt="TextSelectionAppend_78649109_19"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649109_19" continuedAt="TextSelectionAppend_78649109_20"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between September&#160;1, 2020 and December&#160;20, 2020, separate plaintiffs purporting to represent putative classes of direct and indirect purchasers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> retailer purchasers of Bystolic<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> (nebivolol hydrochloride) filed separate complaints in the U.S. District Court for the Southern District of New York against several generic manufacturers, including Teva, Actavis, and Watson, alleging, among other things, that the settlement agreements these generic manufacturers entered into with Forest Laboratories, Inc., the innovator, to resolve patent litigation over Bystolic<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> violated the antitrust laws. The cases were coordinated and on January&#160;24, 2022, the court dismissed plaintiffs&#8217; amended complaints without prejudice. Plaintiffs subsequently filed second amended complaints, and on February&#160;21, 2023, the court granted defendants&#8217; motion to dismiss and dismissed all claims with prejudice. Plaintiffs have filed notices of their intent to appeal. Annual sales of Bystolic<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $<ix:nonFraction name="teva:AnnualSalesAtTimeOfSettlement" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">700</ix:nonFraction>&#160;million at the time of Watson&#8217;s 2013 settlement with Forest. </div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">In February 2021, the State of New Mexico filed a lawsuit against Teva and certain other defendants related to various medicines used to treat HIV. Between September and December 2021, several private plaintiffs including retailers and health insurance providers filed similar claims in federal court in the Northern District of California and in the District of Minnesota. As they relate to Teva, the lawsuits challenge settlement agreements Teva entered into with Gilead in 2013 and/or 2014 to resolve patent litigation relating to Teva&#8217;s generic versions of Viread</div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10px; vertical-align: top;;display:inline;">&#174;</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and/or Truvada</div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10px; vertical-align: top;;display:inline;">&#174;</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and Atripla</div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10px; vertical-align: top;;display:inline;">&#174;</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">. Plaintiffs allege that the settlement agreements contain improper reverse payments that delayed the availability of generic products, in violation of the federal antitrust laws and state law. On February&#160;16, 2022, Teva moved to dismiss the claims by certain private plaintiffs but that motion was denied. However, Teva has successfully moved to limit the potential damages period as to certain private plaintiffs. Plaintiffs in the Northern District of California cases have abandoned any claim for damages relating to the Viread</div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10px; vertical-align: top;;display:inline;">&#174;</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>settlement. On January&#160;5, 2023, the court denied the parties&#8217; motions for summary judgment. Trial is currently scheduled to commence in late May 2023. In the first quarter of 2023, Teva recognized a provision based on its offer to settle this matter.</div> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> In October 2022, the New Mexico Supreme Court granted Teva&#8217;s petition for a writ of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">certiorari</div></div> and scheduled oral argument for late May 2023 for Teva&#8217;s motion to dismiss the complaint brought by the State of New Mexico, which motion was previously denied by the trial court. Annual sales in the United States at the time of the settlement of Viread<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, Truvada<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Atripla<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> were approximately $<ix:nonFraction name="teva:AnnualSalesOfTheTimeOfSettlementOfViread" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">582</ix:nonFraction>&#160;million, $<ix:nonFraction name="teva:AnnualSalesOfTheTimeOfSettlementOfTruvada" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.4</ix:nonFraction>&#160;billion, and $<ix:nonFraction name="teva:AnnualSalesOfTheTimeOfSettlementOfAtripla" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.9</ix:nonFraction>&#160;billion, respectively. Annual sales in the United States at the time Teva launched its generic version of Viread<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in 2017, Truvada<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in 2020 and Atripla<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in 2020 were approximately<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="teva:AnnualSalesOfTheTimeOfNewLaunchOfViread" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">728</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="teva:AnnualSalesOfTheTimeOfNewLaunchOfTruvada" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">2.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;billion and $</div><ix:nonFraction name="teva:AnnualSalesOfTheTimeOfNewLaunchOfAtripla" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">444</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, following the 2019 European Commission&#8217;s inspection of Teva and subsequent request for information, the European Commission opened a formal antitrust investigation to assess whether Teva may have abused a dominant position by delaying the market entry and uptake of medicines that compete with COPAXONE. On October&#160;10, 2022, the European Commission issued a Statement of Objections, which sets forth its preliminary allegations that Teva had engaged in anti-competitive practices. Teva now has the opportunity to formally respond to the European Commission&#8217;s allegations. Annual sales of COPAXONE in the European Economic Area for 2021 were approximately $<ix:nonFraction name="teva:AnnualSalesOfCopaxone" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">373</ix:nonFraction>&#160;million. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;15, 2021, the U.K. Competition and Markets Authority (&#8220;CMA&#8221;) issued a decision imposing fines for breaches of U.K. competition law by Allergan, Actavis UK and Auden Mckenzie and a number of other companies in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. The decision combines the CMA&#8217;s three prior investigations into the supply of hydrocortisone tablets in the U.K., as well as the CMA&#8217;s subsequent investigation relating to an anti-competitive agreement with Waymade. On January&#160;9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva will indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to two of the three statements of objection from the CMA (dated December&#160;16, 2016 and March&#160;3, 2017), and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. On October&#160;6, 2021, Accord UK and Auden Mckenzie appealed the CMA&#8217;s decision. A provision for the estimated exposure for Teva related to the fines and/or damages has been recorded in the financial statements. The hearing for the appeal concluded in the first quarter of 2023, and a decision remains pending. </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"><ix:exclude>26</ix:exclude> </div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_78649109_20" continuedAt="TextSelectionAppend_78649109_21"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649109_21" continuedAt="TextSelectionAppend_78649109_22"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_22" continuedAt="TextSelectionAppend_78649109_23"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div> </div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649109_23" continuedAt="TextSelectionAppend_78649109_24"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2021, a plaintiff filed a putative class action suit in the United States District Court for the Eastern District of Pennsylvania against Takeda and several generic manufacturers, including Watson and Teva, alleging violations of the antitrust laws in connection with their settlement of patent litigation involving colchicine tablets (generic Colcrys<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>), entered into in January 2016. Plaintiff claims that the settlement was part of a conspiracy among Takeda and the generic manufacturers to unlawfully restrict output of colchicine by delaying generic entry. On November&#160;23, 2022, the court denied plaintiffs&#8217; motion for class certification without prejudice and on March&#160;1, 2023, the Court denied plaintiff&#8217;s renewed motion for class certification. On April&#160;10, 2023, plaintiff filed a motion for leave to amend its complaint to add 18 previously absent class members as plaintiffs. Defendants&#8217; motion for summary judgment, and plaintiffs&#8217; motion for partial summary judgment remain pending. Trial is currently scheduled to commence in September 2023. Annual sales of Colcrys<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $<ix:nonFraction name="teva:AnnualSalesOfColcrys" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">187</ix:nonFraction>&#160;million at the time of the settlement. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2022, two complaints, one brought by Walgreen Co. and Kroger Specialty Pharmacy, Inc. and another by Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund and Jacksonville Police Officers and Fire Fighters Health Insurance Trust (collectively the &#8220;Walgreen and EPP complaints&#8221;), were filed in the United States District Court for the District of New Jersey against Teva and its marketing partner, Natco Pharma Limited (&#8220;Natco&#8221;), alleging violations of the antitrust laws in connection with their December 2015 settlement of patent litigation with Celgene Corporation (which was subsequently acquired by Bristol-Myers Squibb Company (&#8220;BMS&#8221;)) involving the drug Revlimid<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> (lenalidomide). The Walgreen and EPP complaints also name Celgene and BMS as defendants. On January&#160;24, 2023, the Walgreen and EPP complaints were consolidated for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-trial</div> purposes only with an earlier-filed, already consolidated Insurer <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Opt-Out</div> Action filed against BMS and Celgene, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In Re Revlimid</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;&amp; Thalomid Purchaser Antitrust Litigation</div></div>, Case No. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2:19-cv-7532-ES-MAH.</div></div></div></div> On February&#160;16, 2023, the Walgreen and EPP plaintiffs filed amended complaints adding additional plaintiffs. On March&#160;21, 2023, Teva and Natco moved to dismiss the complaints against them, and briefing remains ongoing. Annual sales of Revlimid<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $<ix:nonFraction name="teva:AnnualSalesOfRevlimid" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">3.5</ix:nonFraction>&#160;billion at the time of the settlement. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="null;text-indent: 0px;;display:inline;">On December 2, 2022, plaintiffs purporting to represent putative classes of indirect purchasers of EpiPen&#174; (epinephrine injection) and Nuvigil&#174; (armodafinil) filed a complaint in the United States District Court for the District of Kansas against Teva, Cephalon, and a former Teva executive. Teva owns the New Drug Application (&#8220;NDA&#8221;) for Nuvigil&#174; and sold the brand product, for which generic entry occurred in 2016. Teva filed an ANDA to sell generic EpiPen&#174;, which Teva launched in 2018, following receipt of FDA approval. The complaint alleges, among other things, that the defendants violated the federal antitrust laws, the Racketeer Influenced and Corrupt Organizations Act (&#8220;RICO Act&#8221;), and various state laws in connection with settlements resolving patent litigation relating to those products. Plaintiffs seek injunctive relief, compensatory and punitive damages, interest, attorneys&#8217; fees and costs. On March 8, 2023, Teva filed a motion to dismiss the complaint, which is pending. Annual sales of Nuvigil&#174; in the United States were approximately $</div><ix:nonFraction name="teva:AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler" contextRef="P12_31_2022To12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">300</ix:nonFraction>&#160;million at the time Teva entered into the first settlement with an ANDA filer in 2012; annual sales of EpiPen<div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $<ix:nonFraction name="teva:AnnualSalesOfEpipen" contextRef="P12_31_2022To12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">600</ix:nonFraction>&#160;million at the time Teva entered into its settlement agreement for that product in 2012. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Government Investigations and Litigation Relating to Pricing and Marketing </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (&#8220;DOJ&#8221;) Antitrust Division seeking documents and other information relating to the marketing and pricing of certain Teva USA generic products and communications with competitors about such products. On August&#160;25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three-count indictment charging Teva USA with criminal felony Sherman Act violations. See <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;20-cr-200</div></div> (E.D. Pa.). The indictment alleges Teva USA participated in three separate conspiracies with certain other generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs. The indictment identified the following generic drugs: Pravastatin, Carbamazepine, Clotrimazole, Etodolac (IR and ER), Fluocinonide (Cream <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-Cream,</div> Gel, and Ointment), Warfarin, Nadolol, Temozolomide, and Tobramycin. On September&#160;8, 2020, Teva USA pled not guilty to all counts. On December&#160;14, 2022, the Court entered a scheduling order against Teva and its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-defendant</div> Glenmark, which sets a May 2024 trial date. While the Company is unable to estimate a range of loss at this time, a conviction on these criminal charges could have a material adverse impact on the Company&#8217;s business, including monetary penalties and debarment from federally funded health care programs. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>27</ix:exclude> </div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_78649109_24" continuedAt="TextSelectionAppend_78649109_25"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649109_25" continuedAt="TextSelectionAppend_78649109_26"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_26" continuedAt="TextSelectionAppend_78649109_27"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649109_27" continuedAt="TextSelectionAppend_78649109_28"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2018, Teva received a civil investigative demand from the DOJ Civil Division, pursuant to the federal False Claims Act, seeking documents and information produced since January&#160;1, 2009 relevant to the Civil Division&#8217;s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. An adverse resolution of this matter may include fines, penalties, financial forfeiture and compliance conditions. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. Subsequently, on December&#160;15, 2016, a civil action was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States. That complaint was later amended to add new states as named plaintiffs, as well as new allegations and new state law claims, and on June&#160;18, 2018, the attorneys general of 49 states plus Puerto Rico and the District of Columbia filed a consolidated amended complaint against Actavis and Teva, as well as other companies and individuals. On May&#160;10, 2019, most (though not all) of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals, alleging price-fixing and market allocation with respect to additional generic products. On November&#160;1, 2019, the state attorneys general filed an amended complaint, bringing the total number of plaintiff states and territories to 54. The amended complaint alleges that Teva was at the center of a conspiracy in the generic pharmaceutical industry, and asserts that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain additional products. On June&#160;10, 2020, most, but not all, of the same states, with the addition of the U.S. Virgin Islands, filed a third complaint in the District of Connecticut naming, among other defendants, Actavis, but not Teva USA, in a similar complaint relating to dermatological generics products. On September&#160;9, 2021, the states&#8217; attorneys general amended their third complaint to, among other things, add California as a plaintiff. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the various complaints described above, the states seek a finding that the defendants&#8217; actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints have been transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (&#8220;Pennsylvania MDL&#8221;). On July&#160;13, 2020, the court overseeing the Pennsylvania MDL chose the attorneys&#8217; general November&#160;1, 2019 amended complaint, referenced above, along with certain complaints filed by private plaintiffs, to proceed first in the litigation as bellwether complaints. On February&#160;9, 2021, Teva&#8217;s motion to reconsider that ruling was granted, and on May&#160;7, 2021, the Court chose the attorneys&#8217; general third complaint filed on June&#160;10, 2020 and subsequently amended to serve as a bellwether complaint in the Pennsylvania MDL, along with certain complaints filed by private plaintiffs. On December&#160;9, 2021, the Court entered an order setting the schedule for the proceedings in the bellwether cases, which the Court later amended on October&#160;13, 2022. This amended schedule does not include trial dates, but provides for the parties to complete briefing on motions for summary judgment in the third quarter of 2024. On June&#160;7, 2022, the Court dismissed the attorneys&#8217; general claims for monetary relief under federal law, concluding that the federal statute under which the attorneys general brought suit authorizes injunctive relief only. However, the attorneys general have pending claims for monetary relief under state law. On February&#160;27, 2023, the Court largely denied defendants&#8217; motions to dismiss the federal claims asserted by the attorneys general in their bellwether complaint. Another motion to dismiss, directed at that same complaint, and related to the state law claims asserted by the attorneys general, remains pending. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva has settled with the states of Mississippi (in June 2021), Louisiana (in March 2022), Georgia (in September 2022), Arkansas (in October 2022) and Florida (in February 2023). Teva paid each state an amount proportional to its share of the national population (approximately $<ix:nonFraction name="teva:LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation" contextRef="P12_31_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction> for each <ix:nonFraction name="teva:PercentageOfShareOfTheNationalPopulation" contextRef="P12_31_2022To12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>% share of the national population), and the states have dismissed their claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA, pursuant to these settlements. On March&#160;30, 2022, the State of Alabama voluntarily dismissed all of its claims in the litigation, including its claims against Actavis and Teva USA, without prejudice. The territories of American Samoa and Guam have also voluntarily dismissed all of their claims in the litigation, including their claims against Actavis and Teva USA; American Samoa&#8217;s dismissal was without prejudice in July 2020, and Guam&#8217;s dismissal was with prejudice in February 2023. The most recent settlement with Florida follows the pattern reached in earlier settlements. Specifically, as mentioned above, Teva agreed to pay each state an amount proportional to its share of the national population. This, in addition to the status of ongoing negotiations with several other U.S. state attorneys general to settle on comparable terms, caused management to consider settlement of the claims filed by the remaining attorneys general to be probable, and management recorded an estimated provision in the third quarter of 2022, in accordance with Accounting Standards Codification 450 &#8220;Accounting for Contingencies.&#8221; </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>28</ix:exclude> </div> </ix:continuation></div> </div> </div> <ix:continuation id="TextSelectionAppend_78649109_28" continuedAt="TextSelectionAppend_78649109_29"><div></div></ix:continuation> </div> <ix:continuation id="TextSelectionAppend_78649109_29" continuedAt="TextSelectionAppend_78649109_30"><div> <div style="background-color:white;display: inline;"> <ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude> <ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></div> </div></ix:continuation> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649109_30" continuedAt="TextSelectionAppend_78649109_31"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div></ix:exclude><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Beginning on March&#160;2, 2016, and continuing through December 2020, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> plaintiffs. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva USA and Actavis. The plaintiffs generally seek injunctive relief and damages under federal antitrust law, and damages under various state laws. On October&#160;16, 2018, the court denied certain of the defendants&#8217; motions to dismiss as to certain federal claims, pending as of that date, and on February&#160;15, 2019, the court granted in part and denied in part defendants&#8217; motions to dismiss as to certain state law claims. On July&#160;18, 2019, May&#160;6, 2020 and October&#160;8, 2021, certain individual plaintiffs commenced civil actions in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, but no complaints have been filed in the actions and each of the three cases have been placed in deferred status. Certain counties in New&#160;York and Texas have also commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been transferred to the Pennsylvania MDL. There is also one similar complaint brought in Canada, which alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. The action is in its early stages. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2017, Teva received a subpoena from the U.S. Attorney&#8217;s office in Boston, Massachusetts requesting documents related to Teva&#8217;s donations to patient assistance programs. Subsequently, in August 2020, the U.S. Attorney&#8217;s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law (the &#8220;DOJ PAP Complaint&#8221;). It is alleged that Teva caused the submission of false claims to Medicare through Teva&#8217;s donations to bona fide independent charities that provide financial assistance to patients. An adverse judgment may involve damages, civil penalties and injunctive remedies. On September&#160;10, 2021, the Court granted Teva&#8217;s motion to dismiss the unjust enrichment claim and denied the remainder of the motion. On October&#160;15, 2021, Teva filed an answer to the DOJ PAP Complaint. Trial for this matter is currently scheduled for September 2023. On April&#160;24, 2023, both parties filed summary judgment motions, which are currently pending. In the first quarter of 2023, Teva recognized a provision based on its offer to settle this matter. Additionally, on January&#160;8, 2021, Humana, Inc. filed an action against Teva in the United States District Court for the Middle District of Florida based on the allegations raised in the DOJ PAP Complaint. On April&#160;2, 2021, Teva filed a motion to dismiss Humana&#8217;s claims on the grounds that the claims are time-barred and/or insufficiently pled, and that motion remains pending. On April&#160;11, 2023, the court granted Teva&#8217;s motion to stay the case pending the court&#8217;s decision on Teva&#8217;s motion to dismiss and/or Humana&#8217;s motion to amend the complaint. On November&#160;17, 2022, United Healthcare also filed an action against Teva in the United States District Court for the District of New Jersey based on the conduct alleged in the DOJ PAP Complaint. On March&#160;10, 2023, Teva moved to dismiss United Healthcare&#8217;s claims on the grounds that it is time-barred and lacks standing and sufficient particularity to assert RICO claims, and that motion remains pending. </div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, a city and county in Washington filed claims against Teva in the United States District Court for the Western District of Washington for alleged violations of the Racketeer Influenced and Corrupt Organizations Act, Washington&#8217;s Consumer Protection Act, and unjust enrichment concerning Teva&#8217;s sale of COPAXONE. Plaintiffs purport to represent a nationwide class of health plans and a subclass of Washington-based health plans that purchased and/or reimbursed health plan members for COPAXONE. Plaintiffs allege that Teva engaged in several fraudulent schemes that resulted in plaintiffs and the putative class members purchasing and/or reimbursing plan members for additional prescriptions of COPAXONE and/or at inflated COPAXONE prices. Plaintiffs seek treble damages for the excess reimbursements and inflated costs, as well as injunctive relief. On September&#160;28, 2021, plaintiffs filed an amended complaint. On November&#160;17, 2021, Teva moved to dismiss the suit, on the grounds that plaintiffs&#8217; claims are barred by the applicable statutes of limitations and the direct purchaser rule, suffer from jurisdictional defects, and fail to plausibly allege fraud or other elements of their claims. On March&#160;9, 2023, the court held a hearing on the motion to dismiss, and a decision remains pending. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;29, 2021, Mylan Pharmaceuticals (&#8220;Mylan&#8221;) filed claims against Teva in the District Court for the District of New&#160;Jersey. On March&#160;11, 2022 and March&#160;15, 2022, FWK Holdings, LLC, KPH Healthcare Servs., Inc. d/b/a&#160;Kinney Drugs, Inc., Meijer Inc., Meijer Distribution, Inc., Labor-Management Healthcare Fund, the Mayor and City Council of Baltimore, and the New York State Teamsters Council Health and Hospital Fund filed claims against Teva in the District Court for the District of New Jersey on behalf of themselves and other similarly situated direct and indirect purchasers of COPAXONE. On August&#160;22, 2022, Blue Cross Blue Shield of Vermont and the Vermont Health Plan sued Teva in the </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>29</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_78649109_31" continuedAt="TextSelectionAppend_78649109_32"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_32" continuedAt="TextSelectionAppend_78649109_33"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_33" continuedAt="TextSelectionAppend_78649109_34"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649109_34" continuedAt="TextSelectionAppend_78649109_35"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div></ix:exclude><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">District Court for the District of Vermont on behalf of themselves and other similarly situated indirect purchasers of COPAXONE. The complaints assert claims for alleged violations of the Lanham Act, state and federal unfair competition and monopolization laws, tortious interference, trade libel, and a violation of the RICO Act. Additionally, plaintiffs claim Teva was involved in an unlawful scheme to delay and hinder generic competition concerning COPAXONE sales. Plaintiffs seek damages for lost profits and expenses, disgorgement, restitution, treble damages, attorneys&#8217; fees and costs, and injunctive relief. Teva has moved to dismiss the complaints filed by Mylan and the class plaintiffs in the District of New Jersey on the grounds, among others, that none of its challenged conduct, violates the law. Those motions are fully briefed and a decision remains pending. On November&#160;21, 2022, the Vermont court denied Teva&#8217;s motion to transfer the complaint filed in Vermont. On December&#160;21, 2022, Teva moved to dismiss the Vermont complaint on grounds similar to those asserted in its motions to dismiss the complaints in New Jersey. Those motions are fully briefed, and a decision remains pending.&#160;&#160;&#160;&#160; </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;1, 2022, Teva received a civil subpoena from the U.S. Attorney&#8217;s office in Boston, Massachusetts requesting certain documents related to the sale and marketing of AUSTEDO and risperidone LAI. Teva is cooperating with the request for documents. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Opioids Litigation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since May 2014, more than 3,500 complaints have been filed with respect to opioid sales and distribution against various Teva affiliates, along with several other pharmaceutical companies, by a number of cities, counties, states, other governmental agencies, tribes and private plaintiffs (including various putative class actions of individuals) in both state and federal courts. Most of the federal cases have been consolidated into a multidistrict litigation in the Northern District of Ohio (&#8220;MDL Opioid Proceeding&#8221;) and many of the cases filed in state court have been removed to federal court and consolidated into the MDL Opioid Proceeding. Two cases that were included in the MDL Opioid Proceeding were transferred back to federal district court for additional discovery, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-trial</div> proceedings and trial. Those cases are: City of Chicago v. Purdue Pharma L.P. et al., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;14-cv-04361</div></div> (N.D. Ill.) and City and County of San Francisco v. Purdue Pharma L.P. et al., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;18-cv-07591-CRB</div></div></div> (N.D. Cal.). Other cases remain pending in various states. In some jurisdictions, such as Illinois, New York, Pennsylvania, South Carolina, Texas, Utah and West Virginia, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. Complaints asserting claims under similar provisions of different state law generally contend that the defendants allegedly engaged in improper marketing and distribution of opioids, including ACTIQ<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> and FENTORA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>. The complaints also assert claims related to Teva&#8217;s generic opioid products. In addition, over 950 personal injury plaintiffs, including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding.&#160;Furthermore, approximately 700 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-personal</div> injury complaints and approximately 100 personal injury complaints have named Anda, Inc. (and other distributors and manufacturers) alleging that Anda failed to develop and implement systems sufficient to identify suspicious orders of opioid products and prevent the abuse and diversion of such products to individuals who used them for other than legitimate medical purposes. Plaintiffs seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages,&#160;attorneys&#8217; fees and injunctive relief. Certain plaintiffs assert that the measure of damages is the entirety of the costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. The individual personal injury plaintiffs further seek <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-economic</div> damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;19, 2021, a bench trial in California (The People of the State of California, acting by and through Santa Clara County Counsel James R. Williams, et. al. v. Purdue Pharma L.P., et. al.) commenced against Teva and other defendants focused on the marketing of branded opioids. On December&#160;14, 2021, the court issued its final judgment in favor of the defendants on all claims. Plaintiffs filed a notice of appeal of this judgment in February 2022. On June&#160;29, 2021, a jury trial in New York (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In re Opioid Litigation</div></div>, Index No.&#160;400000/2017) commenced against Teva and other defendants, focused on the marketing and distribution of opioids. The case was bifurcated between liability and damages. On December&#160;30, 2021, the jury returned a liability verdict in favor of plaintiffs (the County of Suffolk, the County of Nassau and the State of New York) on the plaintiffs&#8217; public nuisance claim. On November&#160;3, 2022, Teva reached an agreement with the Attorney General of New York that settled the state&#8217;s and its subdivisions&#8217; opioid-related claims, the details of which are included in the table below. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>30</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_78649109_35" continuedAt="TextSelectionAppend_78649109_36"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_36" continuedAt="TextSelectionAppend_78649109_37"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_37" continuedAt="TextSelectionAppend_78649109_38"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649109_38" continuedAt="TextSelectionAppend_78649109_39"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;21, 2021, it was announced that four other defendants (not including Teva) reached nationwide settlements, subject to certain conditions, which include payment of up to approximately $<ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:num-dot-decimal">26</ix:nonFraction>&#160;billion spread over up to <ix:nonNumeric name="teva:LitigationSettlementAmountAwardedDistributionPeriod" contextRef="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis_NationwideSettlementMembersrtLitigationCaseAxis" format="ixt-sec:duryear">18</ix:nonNumeric> years. In July 2022, Teva, the working group of States&#8217; Attorneys General (the &#8220;Working Group&#8221;), the Multi-District Litigation Plaintiffs&#8217; Executive Committee (&#8220;PEC&#8221;), and counsel for Native American tribes (&#8220;Tribes&#8221;) reached an agreement in principle on the financial terms of nationwide settlements similar in structure to the nationwide settlements of other defendants. During the third quarter of 2022, Teva and Allergan resolved their dispute with respect to Teva&#8217;s indemnification obligations. In November 2022, Teva, Allergan, the Working Group and PEC, and representatives for the Tribes, finalized the terms of their respective proposed opioids nationwide settlement agreements. Under the financial terms of the proposed nationwide settlement agreement with the states and subdivisions, Teva will pay up to $<ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="P11_30_2022To11_30_2022" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:num-dot-decimal">4.25</ix:nonFraction>&#160;billion (including the already settled cases), spread over <ix:nonNumeric name="teva:LitigationSettlementAmountAwardedDistributionPeriod" contextRef="P11_30_2022To11_30_2022" format="ixt-sec:duryear">13</ix:nonNumeric> years. This total includes the supply of up to $<ix:nonFraction name="teva:LitigationSettlementAmountDistributableinKind" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.2</ix:nonFraction>&#160;billion of Teva&#8217;s generic version of Narcan<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> (naloxone hydrochloride nasal spray), valued at wholesale acquisition cost, over 10 years or cash at <ix:nonFraction name="teva:LitigationSettlementAmountPayableInCashPercentage" contextRef="PAsOn11_30_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the wholesale acquisition cost ($<ix:nonFraction name="teva:LitigationSettlementAmountDistributableInCash" contextRef="PAsOn11_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">240</ix:nonFraction> million) in lieu of product. In January of 2023,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;Teva confirmed participation from all states except Nevada, and decided to move forward with the participation process of the subdivisions, and that process is ongoing. In February 2023, Teva and the Tribes finalized their opioids settlement with participation from 100% of the Tribes, the details of which are included in the table below.&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s proposed nationwide settlement agreement with the states and subdivisions is contingent upon sufficient participation by the subdivisions in Teva&#8217;s and Allergan&#8217;s respective nationwide opioids settlement agreements. Currently, more than<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonFraction name="teva:PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">99</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">% of the litigating subdivisions have chosen to participate in Teva&#8217;s nationwide settlement, which represents </div><ix:nonFraction name="teva:PercentageOfThePopulationOfTheParticipatingStates" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">98</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">% <div style="letter-spacing: 0px; top: 0px;;display:inline;">of the population of the participating states. Teva has until June 8, 2023 to determine whether or not to move forward with its proposed nationwide settlement. If these nationwide settlement agreements are not finalized or if Nevada or subdivisions choose not to participate, additional trials are expected to proceed. Trials in two opioids cases currently are scheduled to commence in the second half of 2023; one brought by the Nevada Attorney General, currently scheduled to commence in August 2023, and the other brought by eight hospitals against Teva, other manufacturers, distributors, and pharmacies, currently scheduled to commence in July 2023.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to its pending nationwide opioids settlement, Teva previously reached settlements with individual states and subdivisions to settle opioids claims brought by those jurisdictions. The material details of those individual settlements and Teva&#8217;s settlement with the Tribes appear in the table below, which includes the cash payment to be made by Teva and the wholesale acquisition cost (&#8220;WAC&#8221;) of product to be provided by Teva, in each case to such states and subdivisions and the Tribes. If the nationwide settlement reaches sufficient participation by the subdivisions, Teva will finalize opioid settlements with a total of 49 of the 50 states.</div></div><br/></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"><br/></div> <ix:nonNumeric name="us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 23%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 13%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 13%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 7%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 18%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 17%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdiction</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement<br/>Payment<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px">*</div></div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment<br/>Term</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement Product</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product&#160;WAC</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Value&#160;and&#160;Term</div></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementDate" contextRef="P01_01_2023To03_31_2023_OKusgaapStatutoryAccountingPracticesByJurisdictionAxis">June 7, 2019</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencyDomicileOfLitigation" contextRef="P01_01_2023To03_31_2023_OKusgaapStatutoryAccountingPracticesByJurisdictionAxis">Oklahoma</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P01_01_2023To03_31_2023_OKusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="Fact_78649399">72.3</ix:nonFraction>&#160;million (paid)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementTerms" contextRef="P01_01_2023To03_31_2023_OKusgaapStatutoryAccountingPracticesByJurisdictionAxis">1 year</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">N/A</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementDate" contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">December 27, 2019</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencyDomicileOfLitigation" contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">Cuyahoga County, OH</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="Fact_78649400">12.4</ix:nonFraction>&#160;million (paid)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementTerms" contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">2.5 years</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <ix:nonNumeric name="teva:ContingencySettlementProduct" contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">buprenorphine naloxone</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(generic Suboxone<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>)</div></ix:nonNumeric> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="teva:ProductWeightedAverageCost" contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.5</ix:nonFraction>&#160;million (<ix:nonNumeric name="teva:ProductWeightedAverageCostTerm" contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" format="ixt-sec:duryear">3</ix:nonNumeric> years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementDate" contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">December 27, 2019</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencyDomicileOfLitigation" contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">Summit County, OH</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="Fact_78649401">7.6</ix:nonFraction>&#160;million (paid)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementTerms" contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">2.5 years</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <ix:nonNumeric name="teva:ContingencySettlementProduct" contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">buprenorphine naloxone</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(generic Suboxone<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>)</div></ix:nonNumeric> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="teva:ProductWeightedAverageCost" contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.5</ix:nonFraction>&#160;million (<ix:nonNumeric name="teva:ProductWeightedAverageCostTerm" contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" format="ixt-sec:duryear">3</ix:nonNumeric> years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementDate" contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis">January 18, 2022</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencyDomicileOfLitigation" contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis">Louisiana</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78649402">15</ix:nonFraction>&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementTerms" contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis">18 years</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <ix:nonNumeric name="teva:ContingencySettlementProduct" contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">buprenorphine naloxone</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(generic Suboxone<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>)</div></ix:nonNumeric> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="teva:ProductWeightedAverageCost" contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction>&#160;million (<ix:nonNumeric name="teva:ProductWeightedAverageCostTerm" contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis" format="ixt-sec:duryear">1</ix:nonNumeric> year)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementDate" contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis">February 4, 2022</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencyDomicileOfLitigation" contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis">Texas</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="Fact_78649403">131.5</ix:nonFraction>&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementTerms" contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis">15 years</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="teva:ContingencySettlementProduct" contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis">naloxone hydrochloride (generic Narcan&#174;)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="teva:ProductWeightedAverageCost" contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">75</ix:nonFraction>&#160;million (<ix:nonNumeric name="teva:ProductWeightedAverageCostTerm" contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementDate" contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis">March 21, 2022</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencyDomicileOfLitigation" contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis">Rhode Island</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78649404">21</ix:nonFraction>&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementTerms" contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis">13 years</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <ix:nonNumeric name="teva:ContingencySettlementProduct" contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">naloxone hydrochloride (generic Narcan<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>) and</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">buprenorphine naloxone (generic Suboxone<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>)</div></ix:nonNumeric> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="teva:ProductWeightedAverageCost" contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">78.5</ix:nonFraction>&#160;million (<ix:nonNumeric name="teva:ProductWeightedAverageCostTerm" contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementDate" contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis">March 30, 2022</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencyDomicileOfLitigation" contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis">Florida</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="Fact_78649405">177.1</ix:nonFraction>&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementTerms" contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis">15 years</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="teva:ContingencySettlementProduct" contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis">naloxone hydrochloride (generic Narcan&#174;)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="teva:ProductWeightedAverageCost" contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">84</ix:nonFraction>&#160;million (<ix:nonNumeric name="teva:ProductWeightedAverageCostTerm" contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementDate" contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">July 12, 2022</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencyDomicileOfLitigation" contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">San Francisco</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="Fact_78649406">19.5</ix:nonFraction>&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementTerms" contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">13 years</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="teva:ContingencySettlementProduct" contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">naloxone hydrochloride (generic Narcan&#174;)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="teva:ProductWeightedAverageCost" contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction>&#160;million (<ix:nonNumeric name="teva:ProductWeightedAverageCostTerm" contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementDate" contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis">September 19, 2022</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencyDomicileOfLitigation" contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis">West Virginia</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="Fact_78649407">75.4</ix:nonFraction>&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementTerms" contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis">15 years</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="teva:ContingencySettlementProduct" contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis">naloxone hydrochloride (generic Narcan&#174;)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="teva:ProductWeightedAverageCost" contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">27</ix:nonFraction>&#160;million (<ix:nonNumeric name="teva:ProductWeightedAverageCostTerm" contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementDate" contextRef="P01_01_2023To03_31_2023_NYusgaapStatutoryAccountingPracticesByJurisdictionAxis">November 3, 2022</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencyDomicileOfLitigation" contextRef="P01_01_2023To03_31_2023_NYusgaapStatutoryAccountingPracticesByJurisdictionAxis">New York</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P01_01_2023To03_31_2023_NYusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="Fact_78649408">313.3</ix:nonFraction> million<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">**</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementTerms" contextRef="P01_01_2023To03_31_2023_NYusgaapStatutoryAccountingPracticesByJurisdictionAxis">18 years</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="teva:ContingencySettlementProduct" contextRef="P01_01_2023To03_31_2023_NYusgaapStatutoryAccountingPracticesByJurisdictionAxis">N/A</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">N/A</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementDate" contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">February 24, 2023</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencyDomicileOfLitigation" contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">Tribes</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="us-gaap:LossContingencyAccrualPayments" contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="Fact_78649409">108.3</ix:nonFraction>&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:LossContingencySettlementAgreementTerms" contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">13 years</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="teva:ContingencySettlementProduct" contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">naloxone hydrochloride (generic Narcan&#174;)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$<ix:nonFraction name="teva:ProductWeightedAverageCost" contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">25</ix:nonFraction>&#160;million (<ix:nonNumeric name="teva:ProductWeightedAverageCostTerm" contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years)</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">*</div>&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts exclude attorneys&#8217; fees and costs, except New York. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">**</div>&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not including cash payment and attorneys&#8217; fees allocated under the nationwide settlement. </div></div></div></td></tr></table></ix:nonNumeric> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"><ix:exclude>31</ix:exclude> </div> </ix:continuation></div></div><ix:continuation id="TextSelectionAppend_78649109_39" continuedAt="TextSelectionAppend_78649109_40"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_40" continuedAt="TextSelectionAppend_78649109_41"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_41" continuedAt="TextSelectionAppend_78649109_42"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649109_42" continuedAt="TextSelectionAppend_78649109_43"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div> </ix:exclude> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">In light of the agreement on the proposed nationwide settlement between Teva and the States&#8217; Attorneys General and their subdivisions, Teva&#8217;s indemnification obligations arising from Teva&#8217;s acquisition of the Actavis Generics business for opioid-related claims, prior settlements with Louisiana, Texas, Rhode Island, Florida, San Francisco, West Virginia, New York, and the Tribes, as well as an estimate for a number of items including, but not limited to, costs associated with administering injunctive terms, and most favored nations clauses associated with prior settlements, the Company has recorded a provision for the potential settlement. The provision is a reasonable estimate of the ultimate costs in the likely event that the nationwide settlement is finalized under its current proposed terms and conditions, after discounting payments to states to their net present value. However, if the nationwide settlement is not finalized for the entirety of the remaining cases, a reasonable upper end of a range of loss cannot be determined. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-monetary</div> relief and could have a material and adverse effect on Teva&#8217;s reputation, business, results of operations and cash flows. </div></div> <div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2019, Teva received subpoenas from the New York State Department of Financial Services (&#8220;NYDFS&#8221;) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. This was followed by a Statement of Charges and Notice of Hearing filed by the NYDFS. This matter has been resolved by Teva&#8217;s November&#160;3, 2022 settlement with the Attorney General of New York that settled the state&#8217;s and its subdivisions&#8217; opioid-related claims. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Teva, certain of its subsidiaries and other defendants, are defending claims and putative class action lawsuits in Canada related to the manufacture, sale, marketing and distribution of opioid medications. The lawsuits include a claim by the Province of British Columbia on behalf of itself and a putative class of other federal and provincial governments, and claims of municipalities, First Nations, and persons who used opioids on behalf of themselves and putative classes. These cases are in early stages with the preliminary motions brought by the Province of British Columbia expected to be heard in late 2023. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Shareholder Litigation </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;6, 2016 and December&#160;27, 2016, two putative securities class actions were filed in the U.S. District Court for the Central District of California against Teva and certain of its current and former officers and directors. Those lawsuits subsequently were consolidated and transferred to the U.S. District Court for the District of Connecticut (the &#8220;Ontario Teachers Securities Litigation&#8221;). On December&#160;13, 2019, the lead plaintiff filed an amended complaint, purportedly on behalf of purchasers of Teva&#8217;s securities between February&#160;6, 2014 and May&#160;10, 2019, asserting that Teva and certain of its current and former officers and directors violated federal securities and common laws in connection with Teva&#8217;s alleged failure to disclose pricing strategies for various drugs in its generic drug portfolio and by making allegedly false or misleading statements in certain offering materials. From July 2017&#160;to June 2019, other putative securities class actions were filed in other federal courts based on similar allegations and claims, and were transferred to the U.S. District Court for the District of Connecticut. Between August 2017 and January 2022, twenty-three complaints were filed against Teva and certain of its current and former officers and directors on behalf of plaintiffs in various forums across the country, but many of those plaintiffs <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opted-out&#8221;</div> of the Ontario Teachers Securities Litigation. On March&#160;10, 2020, the Court consolidated the Ontario Teachers Securities Litigation with all of the above-referenced putative class actions for all purposes and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> cases for pretrial purposes. On January&#160;18, 2022, Teva entered into a settlement in the Ontario Teachers Securities Litigation for $420&#160;million, which received final approval from the court on June&#160;2, 2022. The vast majority of the total settlement amount was covered by the Company&#8217;s insurance carriers, with a small portion contributed by Teva. Additionally, as part of the settlement, Teva admitted no liability and denied all allegations of wrongdoing. On January&#160;22, 2021, the Court dismissed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> plaintiffs&#8217; claims arising from statements made prior to the five year statute of repose, but denied Teva&#8217;s motion to dismiss their claims under Israeli laws. On May&#160;24, 2021, Teva moved to dismiss a majority of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> complaints on various other grounds, and on May&#160;1, 2023, the Court granted in part and denied in part Teva&#8217;s motions. Teva has settled several <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> claims, but a number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> cases remain outstanding. In addition, Teva reached a settlement agreement of Israeli shareholder motions to certify class action on similar allegations to those raised in the Ontario Teachers Securities Litigation. The settlement agreement is awaiting court approval. </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>32</ix:exclude> </div> </ix:continuation></div></div> <ix:continuation id="TextSelectionAppend_78649109_43" continuedAt="TextSelectionAppend_78649109_44"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649109_44" continuedAt="TextSelectionAppend_78649109_45"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_45" continuedAt="TextSelectionAppend_78649109_46"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div></div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649109_46" continuedAt="TextSelectionAppend_78649109_47"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers. On August&#160;10, 2021, the lead plaintiff filed a corrected amended class action complaint, purportedly on behalf of persons who purchased or otherwise acquired Teva securities between October&#160;29, 2015 and August&#160;18, 2020. The corrected amended complaint alleges that Teva and certain of its current and former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had allegedly caused the submission of false claims to Medicare through Teva&#8217;s donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONE&#8217;s commercial success and the sustainability of its revenues and resulted in the DOJ PAP Complaint filed by the DOJ. The corrected amended complaint seeks unspecified damages and legal fees. On March&#160;25, 2022, the court granted in part and denied in part Teva&#8217;s and the individual defendants&#8217; motion to dismiss the corrected amended complaint, (i)&#160;holding that the plaintiffs&#8217; complaint failed to plead that certain public statements regarding Teva&#8217;s compliance with the law were misleading, (ii)&#160;holding that two alleged partial corrective disclosures did not establish loss causation and cannot serve as the basis for plaintiff&#8217;s claimed loss, (iii)&#160;dismissing all claims against one of the individual defendants, and (iv)&#160;otherwise denying the motion to dismiss. On August&#160;2, 2022, the court stayed all proceedings other than class certification proceedings pending the resolution of the DOJ PAP Complaint filed by the DOJ. On September&#160;13, 2022, the plaintiff moved for class certification, which remains pending. A motion to approve a securities class action was also filed in the Central District Court in Israel, which has been stayed pending the U.S. litigation, with similar allegations to those made in the above complaint filed in the U.S. District Court for the Eastern District of Pennsylvania. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Environmental Matters </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva or its subsidiaries are party to a number of environmental proceedings, or have received claims, including under the federal Superfund law or other federal, provincial or state and local laws, imposing liability for alleged noncompliance, or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third party-owned site, or the party responsible for a release of hazardous substances that impacted a site, to investigate and clean the site or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have received claims, or been made a party to these proceedings, along with others, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Teva&#8217;s facilities or former facilities. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Teva&#8217;s potential liability varies greatly at each of the sites; for some sites the costs of the investigation, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> and natural resource damages have not yet been determined, and for others Teva&#8217;s allocable share of liability has not been determined. At other sites, Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> costs from insurers, indemnitors, former site owners or operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Teva&#8217;s facilities may result in the imposition of significant penalties (in amounts not expected to materially adversely affect Teva&#8217;s results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implemented. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Item&#160;103 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> promulgated by the SEC requires disclosure of certain environmental matters when a governmental authority is a party to the proceedings and such proceedings involve potential monetary sanctions, unless the Company reasonably believes that the matter will result in no monetary sanctions, or in monetary sanctions, exclusive of interest and costs, of less <span style="-sec-ix-hidden:hidden78649508">than</span> $<ix:nonFraction name="us-gaap:AccrualForEnvironmentalLossContingencies" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction>. The following matter is disclosed in accordance with that requirement. On July&#160;8, 2021, the National Green Tribunal Principal Bench, New Delhi, issued an order against Teva&#8217;s subsidiary in India, Teva API India Private Limited, finding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with environmental laws and assessed a penalty of $<ix:nonFraction name="teva:LossContingenciesOnEnvironmentalLawsPenalty" contextRef="PAsOn07_08_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.4</ix:nonFraction>&#160;million. The Company disputed certain of the findings and the amount of the penalty and filed an appeal before the Supreme Court of India. On August&#160;5, 2021, the Supreme Court of India admitted the appeal for hearing and granted an interim unconditional stay on the National Green Tribunal&#8217;s order. The Company does not believe that the eventual outcome of such matter will have a material effect on its business. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>33</ix:exclude> </div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_78649109_47" continuedAt="TextSelectionAppend_78649109_48"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649109_48" continuedAt="TextSelectionAppend_78649109_49"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649109_49" continuedAt="TextSelectionAppend_78649109_50"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649109_50"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Other Matters </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;1, 2018, former shareholders of Ception Therapeutics, Inc., a company that was acquired by and merged into Cephalon in 2010, prior to Cephalon&#8217;s acquisition by Teva, filed breach of contract and other related claims against the Company, Teva USA and Cephalon in the Delaware Court of Chancery.&#160;Among other things, the plaintiffs allege that Cephalon breached the terms of the 2010 Ception-Cephalon merger agreement by failing to exercise commercially reasonable efforts to develop and commercialize CINQAIR<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> (reslizumab) for the treatment of eosinophilic esophagitis (&#8220;EE&#8221;). The plaintiffs claim damages of at least $<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="P01_01_2021To09_30_2021_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">200</ix:nonFraction>&#160;million, an amount they allege is equivalent to the milestones payable to the former shareholders of Ception in the event Cephalon were to obtain regulatory approval for EE in the United States ($<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="P01_01_2021To09_30_2021_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction> million) and Europe ($<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="P01_01_2021To09_30_2021_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction> million). On December&#160;28, 2018, following defendants&#8217; motion to dismiss the complaint, the court granted the motion in part and dismissed all of plaintiffs&#8217; claims, except for their claim against Cephalon for breach of contract. In November 2021, plaintiffs moved to amend their complaint to, among other things, reassert claims against the Company and Teva USA. However, on July&#160;12, 2022, plaintiffs filed a new amended complaint that includes claims against Teva USA but not the Company, in exchange for Teva USA&#8217;s agreement to guarantee any judgment entered against Cephalon in the litigation. A bench trial for this matter was held in September 2022, and a ruling is expected in 2023, following closing arguments.</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 15, 2022, The Scripps Research Institute (&#8220;Scripps&#8221;) filed claims against Teva&#8217;s subsidiary, Teva Pharmaceuticals International GmbH (&#8220;TPIG&#8221;) in the United States District Court for the Southern District of California for alleged breach of a sublicense agreement between Scripps and Ivax Corporation (&#8220;Ivax&#8221;) dated November 2000 (&#8220;Sublicense Agreement&#8221;). After Teva&#8217;s acquisition of Ivax, TPIG became the successor-in-interest to Ivax under the Sublicense Agreement, pursuant to which Scripps licensed to Ivax certain rights to the drug cladribine. Scripps alleges that TPIG breached the Sublicense Agreement by failing to pay royalties on sales of cladribine in certain countries, and is seeking breach of contract damages for royalties allegedly due but not paid, as well as a declaratory judgment related to royalties due in the future. On November 17, 2022, the Court dismissed Scripps&#8217; claim for breach of the implied covenant of good faith and fair dealing but denied TPIG&#8217;s motion to dismiss Scripps&#8217; breach of contract and declaratory judgment claims. TPIG answered the first amended complaint on December 16, 2022, and discovery is ongoing. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;">Gain Contingencies</div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Teva may directly or indirectly pursue claims against certain parties, including but not limited to patent infringement lawsuits against other pharmaceutical companies to protect its patent rights, as well as derivative actions brought on behalf of Teva. Teva recognizes gain contingencies from the defendants in such lawsuits when they are realized or when all related contingencies have been resolved. No gain has been recognized regarding the matters disclosed below, unless mentioned otherwise. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2017, Teva filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that Eli Lilly&#160;&amp; Co.&#8217;s (&#8220;Lilly&#8221;) marketing and sale of its galcanezumab product for the treatment of migraine infringes nine Teva patents, including three method of treatment patents and six composition of matter patents. Lilly then submitted inter partes review (&#8220;IPR&#8221;) petitions to the Patent Trial and Appeal Board (&#8220;PTAB&#8221;), challenging the validity of the nine Teva patents. The PTAB issued decisions upholding the three method of treatment patents but finding the six composition of matter patents invalid, which decisions were affirmed by the Court of Appeals for the Federal Circuit on August&#160;16, 2021. A jury trial regarding the three method of treatment patents began on October&#160;18, 2022, and on November&#160;9, 2022, the jury issued a verdict in Teva&#8217;s favor, finding the three method of treatment patents valid and infringed by Lilly and awarding Teva $<ix:nonFraction name="us-gaap:LossContingencyDamagesAwardedValue" contextRef="P11_09_2022To11_09_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">176.5</ix:nonFraction>&#160;million in damages. On January&#160;28, 2023, Lilly filed a motion requesting that the District Court overturn the jury&#8217;s verdict. Once the motion is decided, the losing party may appeal the decision to the Court of Appeals for the Federal Circuit. On June&#160;8, 2021, Teva filed another lawsuit in the U.S. District Court for the District of Massachusetts alleging that Lilly&#8217;s marketing and sale of galcanezumab product infringes two patents related to the treatment of refractory migraine. Lilly&#8217;s IPR petitions challenging the patentability of these two patents as well as a third patent also related to the treatment of refractory migraine were instituted by the PTAB. The litigation in the District of Massachusetts was stayed during the pendency of these IPR proceedings. Teva intends to continue to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Motions to approve derivative actions seeking monetary damages against certain past and present directors and officers have been filed in Israeli Courts alleging negligence and recklessness, as well as motions for document disclosure prior to initiating derivative actions. Motions were filed with respect to several U.S. and EU settlement agreements, opioids, allegations related to the DOJ&#8217;s complaint regarding COPAXONE patient assistance program in the U.S., and with respect to the COPAXONE European Commission&#8217;s inspection. </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </div> </div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">NOTE 11 &#8211; Income taxes: </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, Teva recognized a tax benefit of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction>&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">258</ix:nonFraction>&#160;million. In the first quarter of 2022, Teva recognized a tax expense of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction>&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">971</ix:nonFraction>&#160;million. Teva&#8217;s tax rate for the first quarter of 2023 was mainly affected by legal settlements, impairments, amortization and interest expense disallowances. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The statutory Israeli corporate tax rate is <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To03_31_2023_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">23</ix:nonFraction>%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;in 2023. Teva&#8217;s tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, interest expense disallowances, tax benefits in Israel and other countries, as well as infrequent or non-recurring items.&#160;</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="null;text-indent: 0px;;display:inline;">Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. A trial for this case is currently scheduled to begin in July 2023. A final and binding decision against Teva in this case may lead to a charge of $</div><ix:nonFraction name="teva:ExpectedImpairmentOfIncomeTaxBenefit" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">128</ix:nonFraction>&#160;million. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Israeli tax authorities (&#8220;ITA&#8221;) issued tax assessment decrees for 2008-2011, 2012 and 2013-2016, challenging the Company&#8217;s positions on several issues. Teva has protested the 2008-2011, 2012 and 2013-2016 decrees before the Central District Court in Israel. On April&#160;17, 2023, the ITA issued a tax assessment for 2017-2020, challenging the Company&#8217;s positions on several issues. The Company intends to challenge the tax assessment for 2017-2020, as well. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2021, the Central District Court in Israel held in favor of the ITA with respect to 2008-2011 decrees. The case with respect to 2012-2016 remains pending with similar legal and other claims. Teva appealed this decision to the Israeli Supreme Court and expects the appeal hearing to begin in the second half of 2023. The tax liability resulting from the October 2021 Central District Court decision, with respect to the decrees for 2008-2011 and with regard to the similar legal claims in the related following years, was approximately $<ix:nonFraction name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" contextRef="P10_01_2021To10_31_2021_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_TaxYear2008To2011MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">350</ix:nonFraction>&#160;million, of which a portion has been and will continue to be paid during 2022 and 2023. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company believes it has adequately provided for all of its uncertain tax positions, including those items currently under dispute, however, adverse results could be material. </div> </ix:nonNumeric><ix:nonNumeric name="teva:OtherExpensesTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649114"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%; text-indent: -2%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 12 &#8211; Other assets impairments, restructuring and other items: </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden78649487">Impairments</span> of long-lived tangible assets (1)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648932">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648933">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contingent consideration</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restructuring</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ImpairmentAndRestructuring" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">96</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ImpairmentAndRestructuring" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Including impairments related to exit and disposal activities. </div> </td> </tr> </table> </ix:nonNumeric> <div style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairments </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Impairments of tangible assets for the three months ended March&#160;31, 2023 and 2022 were $<ix:nonFraction name="us-gaap:TangibleAssetImpairmentCharges" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:TangibleAssetImpairmentCharges" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">16</ix:nonFraction>&#160;million, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its network consolidation activities. </div> <div style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent consideration </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the three months ended March&#160;31, 2023, Teva recorded an expense of $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction>&#160;million for contingent consideration, compared to an expense of $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction>&#160;million in the three months ended March&#160;31, 2022. The expense in the first three months of 2023 was mainly related to a change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales and a change in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>). The expense in the first three months of 2022 was mainly related to a change in the estimated future royalty payments in connection with lenalidomide (generic equivalent of Revlimid<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>). </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"><ix:exclude>35</ix:exclude></div> </ix:nonNumeric></div> <ix:continuation id="TextSelection_78649114" continuedAt="TextSelectionAppend_78649114_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649114_1" continuedAt="TextSelectionAppend_78649114_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649114_2" continuedAt="TextSelectionAppend_78649114_3"><ix:exclude> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649114_3"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restructuring </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the three months ended March&#160;31, 2023, Teva recorded $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction>&#160;million of restructuring expenses, compared to $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction>&#160;million in the three months ended March&#160;31, 2022. The expenses for the three months ended March&#160;31, 2023 and March&#160;31, 2022 were primarily related to network consolidation activities. </div> <ix:nonNumeric name="teva:ScheduleOfRestructuringChargesTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables provide the components of restructuring costs: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restructuring</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee termination</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2022To03_31_2022_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2022To03_31_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides the components of and changes in the Company&#8217;s restructuring accruals: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee&#160;termination<br/> costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of January&#160;1, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">112</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2023To03_31_2023_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2023To03_31_2023_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Utilization and other*</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2023To03_31_2023_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648968">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2023To03_31_2023_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648969">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648964">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn03_31_2023_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn03_31_2023_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:68%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee&#160;termination<br/> costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of January&#160;1, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">131</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">138</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2022To03_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2022To03_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Utilization and other*</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2022To03_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648965">59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2022To03_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648966">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648967">65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn03_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">124</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn03_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">130</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Includes adjustments for foreign currency translation. </div> </td> </tr> </table> </ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649233"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 13 &#8211; Earnings (Loss) per share: </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva&#8217;s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested restricted share units (&#8220;RSUs&#8221;) and performance share units (&#8220;PSUs&#8221;) during the period, net of treasury shares. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In computing diluted loss per share for the three months ended March&#160;31, 2023 and 2022, <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To03_31_2022_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To03_31_2023_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> account was taken of the potential dilution that could occur upon the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended March&#160;31, 2023 and 2022 were <ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,115</ix:nonFraction>&#160;million and <ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,107</ix:nonFraction>&#160;million shares, respectively. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>36</ix:exclude></div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_78649233" continuedAt="TextSelectionAppend_78649233_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649233_1" continuedAt="TextSelectionAppend_78649233_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649233_2" continuedAt="TextSelectionAppend_78649233_3"><ix:exclude> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> </div> </div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649233_3"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div></ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted loss per share was $<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.18</ix:nonFraction></ix:nonFraction> for the three months ended March&#160;31, 2023, compared to basic and diluted loss per share of $<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.86</ix:nonFraction></ix:nonFraction> for the three months ended March&#160;31, 2022. </div></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 14 &#8211; Accumulated other comprehensive income (loss): </div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:58%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Unrealized&#160;Gains&#160;(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial&#160;gains<br/> (losses) and<br/> prior service<br/> (costs) credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December&#160;31, 2022, net of taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,514</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">295</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income (loss) before reclassifications</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2023To03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amounts reclassified to the statements of income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2023To03_31_2023_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2023To03_31_2023_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net other comprehensive income (loss) before tax</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2023To03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2023To03_31_2023_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2023To03_31_2023_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">129</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corresponding income tax</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2023To03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net other comprehensive income (loss) after tax*</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2023To03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78649200">129</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2023To03_31_2023_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78649199">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2023To03_31_2023_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_78649198">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78649197">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March&#160;31, 2023, net of taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,385</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2023_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">287</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2023_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,701</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Amounts do not include a $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2023To03_31_2023_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction>&#160;million loss from foreign currency translation adjustments attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests. </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:58%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Unrealized&#160;Gains&#160;(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial&#160;gains<br/> (losses) and<br/> prior service<br/> (costs)&#160;credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">Balance as of December&#160;31, 2021, net of taxes</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,274</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">324</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,683</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2022To03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">Amounts reclassified to the statements of income</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2022To03_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Net other comprehensive income (loss) before tax</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2022To03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2022To03_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">Corresponding income tax</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2022To03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Net other comprehensive income (loss) after tax*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2022To03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_78649196">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2022To03_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78649195">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal" id="Fact_78649194">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">Balance as of March&#160;31, 2022, net of taxes</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,285</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2,687</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Amounts do not include a $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2022To03_31_2022_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">53</ix:nonFraction>&#160;million loss from foreign currency translation adjustments attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests. </div></td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649237"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 15 &#8211; Segments: </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Teva operates its business and reports its financial results in three segments: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">North America segment, which includes the United States and Canada. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(b)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Europe segment, which includes the European Union, the United Kingdom and certain other European countries. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(c)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">International Markets segment, which includes all countries other than those in the North America and Europe segments. </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>37</ix:exclude></div></ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_78649237" continuedAt="TextSelectionAppend_78649237_1"><div></div></ix:continuation></div><div><div style="background-color:white;display: inline;"><ix:continuation id="TextSelectionAppend_78649237_1" continuedAt="TextSelectionAppend_78649237_2"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649237_2" continuedAt="TextSelectionAppend_78649237_3"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649237_3" continuedAt="TextSelectionAppend_78649237_4"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649237_4" continuedAt="TextSelectionAppend_78649237_5"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div></ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who is the chief operating decision maker (&#8220;CODM&#8221;), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely North America, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Segment profit is comprised of gross profit for the segment less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva&#8217;s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s CEO may review its strategy and organizational structure from time to time. Currently, Teva&#8217;s newly appointed CEO is reviewing its strategy and organizational structure. Any changes in strategy may lead to a reevaluation of the Company&#8217;s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 3 and note 6. </div><ix:nonNumeric name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">a. Segment information: </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:61%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenues</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,766</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">492</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">812</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">655</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">262</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">R&amp;D expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">156</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">S&amp;M expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">223</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">187</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">98</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">G&amp;A expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">102</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">70</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Segment profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">332</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#167;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Represents an amount less than $0.5&#160;million. </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenues</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,737</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,156</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">492</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">890</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">694</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">R&amp;D expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">S&amp;M expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">97</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">G&amp;A expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">112</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Segment profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">402</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#167;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Represents an amount less than $0.5&#160;million. </div></td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>38</ix:exclude></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_78649237_5" continuedAt="TextSelectionAppend_78649237_6"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649237_6" continuedAt="TextSelectionAppend_78649237_7"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649237_7" continuedAt="TextSelectionAppend_78649237_8"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649237_8" continuedAt="TextSelectionAppend_78649237_9"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <ix:nonNumeric name="teva:ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a reconciliation of Teva&#8217;s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended March&#160;31, 2023 and 2022: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">North America profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">332</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">402</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Europe profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">International Markets profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total reportable segments profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023_CorporateMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">791</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022_CorporateMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">962</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Profit (loss) of other activities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total segments profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">785</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,013</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amounts not allocated to segments:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets impairments, restructuring and other items</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">96</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets impairments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">149</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legal settlements and loss contingencies</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">233</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,124</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other unallocated amounts</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:OtherUnallocatedAmounts" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">112</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="teva:OtherUnallocatedAmounts" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consolidated operating income (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">713</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial expenses, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consolidated income (loss) before income taxes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">971</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">b. Segment revenues by major products and activities: </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649234"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present revenues by major products and activities for the three months ended March&#160;31, 2023 and 2022: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;">North America</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Generic products</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">899</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AJOVY</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AUSTEDO</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">170</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">154</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">BENDEKA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> and TREANDA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">82</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">COPAXONE</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">76</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Anda</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">342</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">139</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,766</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,737</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="break-inside: avoid; background-color: rgb(204, 238, 255); font-size: 0px;">
<td colspan="8" style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>39</ix:exclude></div> </ix:nonNumeric></ix:continuation></div> </div> <ix:continuation id="TextSelection_78649234" continuedAt="TextSelectionAppend_78649234_1"><ix:continuation id="TextSelectionAppend_78649237_9" continuedAt="TextSelectionAppend_78649237_10"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649237_10" continuedAt="TextSelectionAppend_78649237_11"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649237_11" continuedAt="TextSelectionAppend_78649237_12"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_78649237_12"><ix:continuation id="TextSelectionAppend_78649234_1"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> </ix:exclude> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">Europe</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Generic products</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">932</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">876</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AJOVY</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">COPAXONE</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Respiratory products</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">107</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,156</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">International markets</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Generic products</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">400</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">388</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AJOVY</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">COPAXONE</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">70</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">492</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">492</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:continuation> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649091"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 16 &#8211; Fair value measurement: </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649092"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial items carried at fair value on a recurring basis as of March&#160;31, 2023 and December&#160;31, 2022 are classified in the tables below in one of the three categories of fair value levels: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money markets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">702</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2023_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">702</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, deposits and other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2023_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,441</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2023_DemandDepositsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,441</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investment in securities:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity securities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2023_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2023_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2023_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derivatives:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden78649490">Asset derivatives</span>:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options and forward contracts</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssets" contextRef="PAsOn03_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssets" contextRef="PAsOn03_31_2023_InterestRateSwapMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cross currency interest rate swaps</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#167;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden78649488">Liability derivatives</span>:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options and forward contracts</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2023_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2023_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bifurcated embedded derivatives</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><span style="-sec-ix-hidden:hidden78648269">&#167;</span></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contingent consideration*</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn03_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648272">148</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648273">148</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,192</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn03_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn03_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">147</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,027</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>40</ix:exclude></div> </ix:nonNumeric></ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_78649092" continuedAt="TextSelectionAppend_78649092_1"><ix:continuation id="TextSelection_78649091" continuedAt="TextSelectionAppend_78649091_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_78649091_1" continuedAt="TextSelectionAppend_78649091_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649091_2" continuedAt="TextSelectionAppend_78649091_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></ix:continuation></div> </div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_78649091_3" continuedAt="TextSelectionAppend_78649091_4"><ix:continuation id="TextSelectionAppend_78649092_1"><ix:exclude><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,222</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,222</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2022_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden78649491">Asset derivatives</span>&#8212;options and forward contracts</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssets" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssets" contextRef="PAsOn12_31_2022_InterestRateSwapMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden78649489">Liability derivatives</span>:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options and forward contracts</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2022_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><span style="-sec-ix-hidden:hidden78648268">&#167;</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648274">153</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Fact_78648275">153</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,848</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">152</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. </div></div></td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva determined the fair value of the liabilities for contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level&#160;3 measurement within the fair value hierarchy. The fair value of contingent consideration is based on several factors, such as cash flows projected from the success of unapproved product candidates; probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; time and resources required to complete the development and approval of product candidates; life of the potential commercialized products and associated risks with obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. A probability of success factor of <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn03_31_2023_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">100</ix:nonFraction>% was used in the fair value calculation to reflect inherent regulatory and commercial risks of the contingent payments and IPR&amp;D. The discount rate applied ranged from <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn03_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">8.5</ix:nonFraction>% to <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn03_31_2023_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">11</ix:nonFraction>%. The weighted average discount rate, calculated based on the relative fair value of Teva&#8217;s contingent consideration liabilities, was <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn03_31_2023_WeightedAverageMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">8.95</ix:nonFraction>%. Contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in the consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. </div></div><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true" continuedAt="TextSelection_78649093"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity for the financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months<br/> ended&#160;March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months<br/> ended&#160;March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the beginning of the period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">152</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><span style="-sec-ix-hidden:hidden78649329">&#167;</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><span style="-sec-ix-hidden:hidden78649330">&#167;</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to provisions for contingent consideration:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" contextRef="P01_01_2023To03_31_2023_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" contextRef="P01_01_2022To03_31_2022_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eagle transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_EagleTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" contextRef="P01_01_2022To03_31_2022_EagleTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Novetide transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" contextRef="P01_01_2023To03_31_2023_NovetideTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement of contingent consideration:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2023To03_31_2023_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eagle transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2023To03_31_2023_EagleTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2022To03_31_2022_EagleTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Novetide transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2023To03_31_2023_NovetideTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional contingent consideration resulting from Novetide acquisition*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="P01_01_2022To03_31_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the end of the period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>41</ix:exclude> </div></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_78649093" continuedAt="TextSelectionAppend_78649093_1"><ix:continuation id="TextSelectionAppend_78649091_4" continuedAt="TextSelectionAppend_78649091_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649091_5" continuedAt="TextSelectionAppend_78649091_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_78649091_6" continuedAt="TextSelectionAppend_78649091_7"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_78649091_7"><ix:continuation id="TextSelectionAppend_78649093_1"><ix:exclude><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2022, Teva acquired <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn01_01_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% ownership of Novetide Ltd. (&#8220;Novetide&#8221;), which was previously accounted for as &#8220;investment in associated companies&#8221;. This transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under &#8220;Share in (profits) losses of associated companies, net&#8221;, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition. </div></div></td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments not measured at fair value </div></div></div><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="P01_01_2023To03_31_2023" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated fair value*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and sustainability-linked senior notes included under senior notes and loans</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2023_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,007</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2022_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">16,694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and convertible senior debentures included under short-term debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2023_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2022_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">2,075</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">19,020</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">18,769</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value was estimated based on quoted market prices.</div></div></td></tr></table></ix:nonNumeric></ix:continuation><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p>

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="fin464631_9"><span style="font-weight:bold">ITEM&#160;2.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Business Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a global pharmaceutical company, committed to helping patients around the world to access affordable medicines and benefit from innovations to improve their health. Our mission is to be a global leader in generics, innovative medicines and biopharmaceuticals, improving the lives of patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Our key strengths include our world-leading generic medicines expertise and portfolio, focused innovative medicines portfolio and global infrastructure and scale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva was incorporated in Israel on February&#160;13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Business Segments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate our business through three segments: North America, Europe and International Markets. Each business segment manages our entire product portfolio in its region, including generics, which includes biosimilars and OTC products, as well as innovative medicines. This structure enables strong alignment and integration between operations, commercial regions, R&amp;D and our global marketing and portfolio function, optimizing our product lifecycle across therapeutic areas. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these three segments, we have other activities, primarily the sale of API to third parties, certain contract manufacturing services and an <span style="white-space:nowrap">out-licensing</span> platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Macroeconomic Environment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent months, the global economy has been impacted by fluctuating foreign exchange rates. Approximately 50% of our revenues are denominated in currencies other than the U.S. dollar. The strengthening of the U.S. dollar versus other currencies in which we operate, negatively impacts our revenues, results of operations, profits and cash flows. We also manufacture largely outside of the United States, which may to varying degrees result in lower expenses. Additionally, high levels of inflation have recently resulted in significant economic volatility and monetary tightening by central banks. The global economy has also been impacted by the ongoing conflict between Russia and Ukraine, which has spurred rising energy costs and caused disruptions to the global and the Company&#8217;s internal supply chain. Supply chain disruptions and rising energy costs could continue to result in delays in our production and distribution processes, R&amp;D initiatives and our ability to timely respond to consumer demand. See also discussion under &#8220;&#8212;International Markets segment&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have implemented certain measures in response to such macroeconomic pressures and are continually considering various initiatives, including price adjustments where we are not restricted contractually or regulatorily, enhanced inventory management and alternative sourcing strategies for our raw material supply, to allow us to partially mitigate and offset the impact of these macroeconomic factors. However, although inflationary and other macroeconomic pressures may ease, the higher costs we have experienced during the recent periods have already impacted our operations and will likely continue to have an effect on our financial results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Highlights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant highlights in the first quarter of 2023 included: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Revenues in the first quarter of 2023 were $3,661&#160;million, flat compared to the first quarter of 2022. In local currency terms, revenues increased by 4%, mainly due to higher revenues from generic products in our Europe and International Markets segments, certain innovative products primarily AUSTEDO and AJOVY, as well as from Anda in our North America segment, partially offset by lower revenues from generic products in our North America segment, API sales to third parties and BENDEKA and TREANDA in our North America segment. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our North America segment generated revenues of $1,766&#160;million and segment profit of $332&#160;million in the first quarter of 2023. Revenues increased by 2% compared to the first quarter of 2022. Segment profit decreased by 17% compared to the first quarter of 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our Europe segment generated revenues of $1,184&#160;million and segment profit of $345&#160;million in the first quarter of 2023. Revenues increased by 2% in U.S. dollars, or 9% in local currency terms, compared to the first quarter of 2022. Segment profit decreased by 9% compared to the first quarter of 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our International Markets segment generated revenues of $492&#160;million and segment profit of $114&#160;million in the first quarter of 2023. Revenues were flat in U.S. dollars compared to the first quarter of 2022. In local currency terms, revenues increased by 8% compared to the first quarter of 2022. Segment profit decreased by 36% compared to the first quarter of 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our revenues from other activities in the first quarter of 2023 were $219&#160;million, a decrease of 20% in U.S. dollars, or 19% in local currency terms, compared to the first quarter of 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Exchange rate movements during the first quarter of 2023, including hedging effects, negatively impacted revenues by $128&#160;million compared to the first quarter of 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Gross profit in the first quarter of 2023 was $1,582&#160;million, a decrease of 9% compared to the first quarter of 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Gross profit margin was 43.2% in the first quarter of 2023, compared to 47.5% in the first quarter of 2022. This decrease was mainly driven by rising costs due to inflationary and other macroeconomic pressures, and an unfavorable product mix. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Impairments of identifiable intangible assets were $178&#160;million in the first quarter of 2023, compared to $149&#160;million in the first quarter of 2022. See note 5 to our consolidated financial statements. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We recorded expenses of $96&#160;million for other asset impairments, restructuring and other items in the first quarter of 2023, compared to expenses of $128&#160;million in the first quarter of 2022. See note 12 to our consolidated financial statements. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legal settlements and loss contingencies expenses were $233&#160;million in the first quarter of 2023, compared to $1,124&#160;million in the first quarter of 2022. See note 9 to our consolidated financial statements. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Operating income was $2&#160;million in the first quarter of 2023, compared to an operating loss of $713&#160;million in the first quarter of 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Financial expenses were $260&#160;million in the first quarter of 2023, compared to $258&#160;million in the first quarter of 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In the first quarter of 2023, we recognized a tax benefit of $19&#160;million, on a <span style="white-space:nowrap">pre-tax</span> loss of $258&#160;million. In the first quarter of 2022, we recognized a tax expense of $2&#160;million, on a <span style="white-space:nowrap">pre-tax</span> loss of $971&#160;million. See note&#160;11 to our consolidated financial statements. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">As of March&#160;31, 2023, our debt was $20,691&#160;million, compared to $21,212&#160;million as of December&#160;31, 2022. This decrease was mainly due to $646&#160;million senior notes repaid at maturity, partially offset by $176&#160;million of exchange rate fluctuations. Additionally, during the first quarter of 2023, we repurchased $2,506&#160;million aggregate principal amount of notes upon consummation of a cash tender offer, and issued $2,445&#160;million of sustainability-linked senior notes, net of issuance costs. See note 7 to our consolidated financial statements. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cash flow used in operating activities during the first quarter of 2023 was $145&#160;million, compared to $49&#160;million in the first quarter of 2022. The higher cash flow used in the first quarter of 2023 resulted mainly from lower profit and changes in working capital items, including an increase in accounts receivables net of SR&amp;A, partially offset by an increase in accounts payables. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">During the first quarter of 2023, we generated free cash flow of $41&#160;million, which we define as comprising: $145&#160;million in cash flow used in operating activities, $323&#160;million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $2&#160;million in proceeds from divestitures of businesses and other assets, partially offset by $139&#160;million in cash used for capital investment. During the first quarter of 2022, we generated free cash flow of $117&#160;million. The decrease in the first quarter of 2023 resulted mainly from higher cash flow used in operating activities. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Comparison of Three Months Ended March&#160;31, 2023 to Three Months Ended March&#160;31, 2022 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Segment Information </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">North America Segment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents revenues, expenses and profit for our North America segment for the three months ended March&#160;31, 2023 and 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:76%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three months ended</span><br /><span style="font-weight:bold">March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="14" align="center"><span style="font-weight:bold">(U.S.&#160;$&#160;in&#160;millions&#160;/&#160;%&#160;of&#160;Segment&#160;Revenues)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,766</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:10pt">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-size:10pt">100</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:10pt">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:10pt">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-size:10pt">100</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:10pt">%&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S&amp;M expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G&amp;A expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Segment profit*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:10pt">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-size:10pt">18.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:10pt">%&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">402</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:10pt">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-size:10pt">23.1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-size:10pt">%&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Segment profit does not include amortization and certain other items. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#167;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents an amount less than 0.5%. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">North America Revenues </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our North America segment includes the United States and Canada. Revenues from our North America segment in the first quarter of 2023 were $1,766&#160;million, an increase of $29&#160;million, or 2%, compared to the first quarter of 2022. This increase was mainly due to higher revenues from certain innovative products, primarily AUSTEDO and AJOVY, as well as Anda, partially offset by lower revenues from generic products and BENDEKA and TREANDA. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenues by Major Products and Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents revenues for our North America segment by major products and activities for the three months ended March&#160;31, 2023 and 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:74%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three&#160;months&#160;ended</span><br /><span style="font-weight:bold">March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Percentage</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Change</p></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023-2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">(U.S.&#160;$&#160;in&#160;millions)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Generic products</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">899</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AJOVY</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AUSTEDO</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BENDEKA and TREANDA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COPAXONE</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anda</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,766</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Other revenues in the first quarter of 2023 increased mainly due to a reduction in estimated liabilities in connection with ProAir<sup style="font-size:75%; vertical-align:top">&#174;</sup> HFA following its discontinuation on October&#160;1, 2022. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Generic products</span> revenues in our North America segment (including biosimilars) in the first quarter of 2023 were $824&#160;million, a decrease of 8% compared to the first quarter of 2022, mainly due to increased competition to parts of our portfolio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the most significant generic products we sold in North America in the first quarter of 2023 were lenalidomide capsules (the generic version of Revlimid<sup style="font-size:75%; vertical-align:top">&#174;</sup>), Truxima<sup style="font-size:75%; vertical-align:top">&#174;</sup> (the biosimilar to Rituxan<sup style="font-size:75%; vertical-align:top">&#174;</sup>), epinephrine injectable solution (the generic equivalent of EpiPen<sup style="font-size:75%; vertical-align:top">&#174;</sup> and EpiPen Jr.<sup style="font-size:75%; vertical-align:top">&#174;</sup>), and albuterol sulfate inhalation aerosol (our ProAir authorized generic). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;9, 2023, Teva and Natco Pharma Ltd. announced the launch of additional strengths for lenalidomide capsules (the generic equivalent of Revlimid<sup style="font-size:75%; vertical-align:top">&#174;</sup>) in the U.S., in 2.5 mg and 20 mg strengths. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, our total prescriptions were approximately 81&#160;million (based on trailing twelve months), representing 8.3% of total U.S. generic prescriptions according to IQVIA data. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">AJOVY</span> revenues in our North America segment in the first quarter of 2023 increased by 36% to $49&#160;million, compared to the first quarter of 2022, mainly due to growth in volume. In the first quarter of 2023, AJOVY&#8217;s exit market share in the United States in terms of total number of prescriptions was 24.5% compared to 23.9% in the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AJOVY is indicated for the preventive treatment of migraine in adults. AJOVY was launched in the U.S. in 2018, and was approved in Canada in April 2020. Our auto-injector device for AJOVY became commercially available in the U.S. in April 2020 and in Canada in April 2021. AJOVY is the only anti-CGRP subcutaneous product indicated for quarterly treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AJOVY is protected worldwide by patents expiring in 2026 at the earliest; extensions have been granted in several countries, including the United States and Europe, until 2031. Additional patents relating to the use of AJOVY in the treatment of migraine have also been issued in the United States and will expire between 2035 and 2039. Such patents are also pending in other countries. AJOVY will also be protected by regulatory exclusivity for 12 years from marketing approval in the United States and 10 years from marketing approval in Europe. We filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that Eli Lilly&#160;&amp; Co.&#8217;s (&#8220;Lilly&#8221;) marketing and sale of its galcanezumab product for the treatment of migraine infringes nine Teva patents, including three method of treatment patents and six composition of matter patents. Lilly then submitted inter partes review (&#8220;IPR&#8221;) petitions to the Patent Trial and Appeal Board (&#8220;PTAB&#8221;), challenging the validity of the nine Teva patents. The PTAB issued decisions upholding the three method of treatment patents but finding the asserted claims of the six composition of matter patents invalid, which decisions were affirmed by the Court of Appeals for the Federal Circuit on August&#160;16, 2021. A jury trial regarding the three method of treatment patents began on October&#160;18, 2022, and on November&#160;9, 2022, the jury issued a verdict in Teva&#8217;s favor, finding the three method of treatment patents valid and infringed by Lilly and awarding Teva $176.5&#160;million in damages. On January&#160;28, 2023, Lilly filed a motion requesting that the District Court overturn the jury&#8217;s verdict. Once the motion is decided, the losing party may appeal the decision to the Court of Appeals for the Federal Circuit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;8, 2021, we filed another lawsuit against Lilly in the U.S. District Court for the District of Massachusetts alleging that Lilly&#8217;s marketing and sale of galcanezumab product infringes two patents related to the treatment of refractory migraine. Lilly&#8217;s IPR petitions challenging the patentability of these two patents as well as a third patent also related to the treatment of refractory migraine were instituted by the PTAB. The litigation in the District of Massachusetts was stayed during the pendency of these IPR proceedings. In addition, in 2018 we entered into separate agreements with Alder Biopharmaceuticals, Inc. and Lilly, resolving the European Patent Office oppositions that they filed against our AJOVY patents. The settlement agreement with Lilly also resolved Lilly&#8217;s action to revoke the patent protecting AJOVY in the United Kingdom. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">AUSTEDO </span>revenues in our North America segment in the first quarter of 2023 increased by 10%, to $170&#160;million, compared to $154&#160;million in the first quarter of 2022, mainly due to growth in volume. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AUSTEDO was launched in the U.S. in 2017. It is indicated for the treatment of chorea associated with Huntington&#8217;s disease and for the treatment of tardive dyskinesia in adults. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AUSTEDO is protected in the United States by ten Orange Book patents expiring between 2031 and 2038 and in Europe by two patents expiring in 2029. We received notice letters from two ANDA filers regarding the filing of their ANDAs with paragraph (IV)&#160;certifications for certain of the patents listed in the Orange Book for AUSTEDO. On July&#160;1, 2021, we filed claims against two generic ANDA filers, Aurobindo and Lupin, in the U.S. District Court for the District of New Jersey. In addition, Apotex filed a petition for IPR by the PTAB of the patent covering the deutetrabenazine compound that expires in 2031. On March&#160;9, 2022, the U.S. Patent and Trademark Office denied Apotex&#8217;s petition and declined to institute a review of the deutetrabenazine patent. On April&#160;29, 2022 and June&#160;8, 2022, we reached agreements with Lupin and Aurobindo, respectively, to sell their generic products beginning April 2033, or earlier under certain circumstances. There are no further patent litigations pending regarding AUSTEDO. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February&#160;17, 2023. AUSTEDO XR is a new once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington&#8217;s disease, additional to the currently marketed twice-daily AUSTEDO. AUSTEDO XR is protected by eight Orange Book patents expiring between 2031 and 2041. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;28, 2023, the FDA approved <span style="font-weight:bold">UZEDY</span><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">TM</sup></span><span style="font-weight:bold"> </span>(risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting formulation of risperidone that controls the steady release of risperidone. UZEDY is expected to be available in the U.S. in the coming weeks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">BENDEKA </span>and<span style="font-weight:bold"> TREANDA</span> combined revenues in our North America segment in the first quarter of 2023 decreased by 23% to $63&#160;million, compared to the first quarter of 2022, mainly due to generic bendamustine product entry into the market. The orphan drug exclusivity that had attached to bendamustine products expired in December 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2019, we signed an amendment to the license agreement with Eagle extending the royalty term applicable to the United States to the full period for which we sell BENDEKA and increased the royalty rate. In consideration, Eagle agreed to assume a portion of BENDEKA-related patent litigation expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are 16 patents listed in the U.S. Orange Book for BENDEKA with expiry dates in 2026 and 2031. In September 2019, a patent infringement action against four of six ANDA filers for generic versions of BENDEKA was tried in the U.S. District Court for the District of Delaware. On April&#160;27, 2020, the district court upheld the validity of all of the asserted patents and found that all four ANDA filers infringe at least one of the patents. Three of the four ANDA filers appealed the district court decision. Teva settled with one of the three ANDA filers, and on August&#160;13, 2021, the Federal Circuit issued a Rule 36 affirmance of the district court decision. On December&#160;14, 2021, Apotex filed a Petition for a Writ of Certiorari with the U.S. Supreme Court, which was denied. Litigation against the fifth ANDA filer was dismissed after the withdrawal of its patent challenge, and the case against a sixth ANDA filer was also settled. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in July 2018, Teva and Eagle filed suit against Hospira, Inc. (&#8220;Hospira&#8221;) related to its 505(b)(2) NDA referencing BENDEKA in the U.S. District Court for the District of Delaware. On December&#160;16, 2019, the district court dismissed the case against Hospira on all but one of the asserted patents, which expires in 2031. On April&#160;18, 2022, Teva and Eagle settled this matter with Hospira. Teva had also filed suit against two other 505(b)(2) NDA filers, Doctor Reddy&#8217;s Laboratories (&#8220;DRL&#8221;) and Accord Healthcare (&#8220;Accord&#8221;). On December&#160;10, 2022 and April&#160;4, 2023, Teva and Eagle settled with Accord and DRL, respectively. Based on the settlement agreements, the three 505(b)(2) filers, Hospira, Accord and DRL can launch their products on November&#160;17, 2027 or earlier under certain circumstances. On May&#160;4, 2023, Teva and Eagle also filed suit against BendaRx Corp. in the U.S. District Court for the District of Delaware, following its filing of a 505(b)(2) NDA for a bendamustine product.&#160; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the settlement with Eagle regarding its bendamustine 505(b)(2) NDA, between 2015 and 2020, we reached final settlements with 22 ANDA filers for generic versions of the lyophilized form of TREANDA and one 505(b)(2) NDA filer for a generic version of the liquid form of TREANDA, providing for the launch of generic versions of TREANDA prior to patent expiration. The orphan drug exclusivity that had attached to bendamustine products expired in December 2022. <span style="white-space:nowrap">To-date</span> we are aware of one generic TREANDA product on the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">COPAXONE</span> revenues in our North America segment in the first quarter of 2023 decreased by 12% to $76&#160;million, compared to the first quarter of 2022, mainly due to generic competition in the United States and a decrease in glatiramer acetate market share due to availability of alternative therapies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for MS treatments continues to develop, particularly with the approval of generic versions of COPAXONE. Oral treatments for MS, such as Tecfidera<sup style="font-size:75%; vertical-align:top">&#174;</sup>, Gilenya<sup style="font-size:75%; vertical-align:top">&#174;</sup> and Aubagio<sup style="font-size:75%; vertical-align:top">&#174;</sup>, continue to present significant and increasing competition. COPAXONE also continues to face competition from existing injectable products, as well as from monoclonal antibodies, such as Ocrevus<sup style="font-size:75%; vertical-align:top">&#174;</sup> and Kesimpta<sup style="font-size:75%; vertical-align:top">&#174;</sup>. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Anda</span> revenues from third-party products in our North America segment in the first quarter of 2023 increased by 24% to $424&#160;million, compared to $342&#160;million in the first quarter of 2022, mainly due to higher demand. Anda, our distribution business in the United States, distributes generic and innovative medicines and OTC pharmaceutical products from Teva and various third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda is able to compete in the secondary distribution market by maintaining a broad portfolio of products, competitive pricing and offering next day delivery throughout the United States. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Product Launches and Pipeline </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, we launched the generic version of the following branded products in North America: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:57%"></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>

<td style="vertical-align:bottom;width:9%"></td>
<td></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Product Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Brand Name</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Launch</span><br /><span style="font-weight:bold">Date</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;Annual&#160;U.S.</span><br /><span style="font-weight:bold">Branded&#160;Sales&#160;at&#160;Time</span><br /><span style="font-weight:bold">of Launch</span><br /><span style="font-weight:bold">(U.S. $ in millions<br />(IQVIA))<sup style="font-size:75%; vertical-align:top">*</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teriflunomide Tablets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Aubagio<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#160;Tablets</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">March</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lubiprostone Capsules</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Amitiza<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#160;capsules</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">January</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Topiramate Extended-release Capsules</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Trokendi&#160;XR<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#160;ER&#160;capsules</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">March</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lenalidomide Capsules 2.5mg&#160;&amp; 20mg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Revlimid<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#160;capsules</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">March</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sorafenib Tablets, USP</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Nexavar<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#160;tablets</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">January</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Theophylline Extended-Release Tablets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="white-space:nowrap">Theo-Dur</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">January</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Doxepin Hydrochloride Cream</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Zonalon<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#160;Cream</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">February</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">*</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The figures presented are for the twelve months ended in the calendar quarter immediately prior to our launch or <span style="white-space:nowrap">re-launch.</span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our generic products pipeline in the United States includes, as of March&#160;31, 2023, 160 product applications awaiting FDA approval, including 70 tentative approvals. This total reflects all pending ANDAs, supplements for product line extensions and tentatively approved applications and includes some instances where more than one application was submitted for the same reference product. Excluding overlaps, the branded products underlying these pending applications had U.S. sales for the twelve months ended December&#160;31, 2022 of approximately $112&#160;billion, according to IQVIA. Approximately 76% of pending applications include a paragraph IV patent challenge, and we believe we are first to file with respect to 70 of these products, or 97 products including final approvals where launch is pending a settlement agreement or court decision. Collectively, these first-to-file opportunities represent over $75&#160;billion in U.S. brand sales for the twelve months ended December&#160;31, 2022, according to IQVIA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IQVIA reported brand sales are one of the many indicators of future potential value of a launch, but equally important are the mix and timing of competition, as well as cost effectiveness. The potential advantages of being the first filer with respect to some of these products may be subject to forfeiture, shared exclusivity or competition from <span style="white-space:nowrap">so-called</span> &#8220;authorized generics,&#8221; which may ultimately affect the value derived. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, we received tentative approvals for generic equivalents of the products listed in the table below, excluding overlapping applications. A &#8220;tentative approval&#8221; indicates that the FDA has substantially completed its review of an application and final approval is expected once the relevant patent expires, a court decision is reached, a <span style="white-space:nowrap">30-month</span> regulatory stay lapses or a <span style="white-space:nowrap">180-day</span> exclusivity period awarded to another manufacturer either expires or is forfeited. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:76%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Generic Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Brand&#160;Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;Annual&#160;U.S.</span><br /><span style="font-weight:bold">Branded&#160;Sales&#160;at&#160;Time</span><br /><span style="font-weight:bold">of Launch</span><br /><span style="font-weight:bold">(U.S. $ in millions<br />(IQVIA))<sup style="font-size:75%; vertical-align:top">*</sup></span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Aspirin Delayed-Release and Omeprazole Tablets, 81 mg/40 mg and 325 mg and 40 mg<sup style="font-size:75%; vertical-align:top">**</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Yosprala<sup style="font-size:75%; vertical-align:top">&#174;</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">No&#160;Data</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">*</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The figures presented are for the twelve months ended in the calendar quarter immediately prior to our launch or <span style="white-space:nowrap">re-launch.</span> </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">**</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Branded product discontinued on FDA website. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For information regarding our innovative and biosimilar products pipeline, see &#8220;&#8212;Teva Consolidated Results&#8212;Research and Development (R&amp;D) Expenses&#8221; below. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">North America Gross Profit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gross profit from our North America segment in the first quarter of 2023 was $812&#160;million, a decrease of 9%, compared to $890&#160;million in the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gross profit margin for our North America segment in the first quarter of 2023 decreased to 46.0%, compared to 51.2% in the first quarter of 2022. This decrease was mainly due to higher cost of goods sold, mainly driven by rising costs due to inflationary and other macroeconomic pressures, as well as an increase in revenues with lower profitability from Anda. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">North America R&amp;D Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">R&amp;D expenses relating to our North America segment in the first quarter of 2023 were $156&#160;million, an increase of 9%, compared to $143&#160;million in the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of our R&amp;D expenses in the first quarter of 2023, see &#8220;&#8212;Teva Consolidated Results&#8212;Research and Development (R&amp;D) Expenses&#8221; below. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">North America S&amp;M Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">S&amp;M expenses relating to our North America segment in the first quarter of 2023 were $223&#160;million, a decrease of 9%, compared to $245&#160;million in the first quarter of 2022, mainly due to cost efficiencies. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">North America G&amp;A Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G&amp;A expenses relating to our North America segment in the first quarter of 2023 were $102&#160;million, a decrease of 9% compared to $112&#160;million in the first quarter of 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">North America Profit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Profit from our North America segment consists of gross profit less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Profit from our North America segment in the first quarter of 2023 was $332&#160;million, a decrease of 17% compared to $402&#160;million in the first quarter of 2022. This decrease was mainly due to lower gross profit. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Europe Segment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents revenues, expenses and profit for our Europe segment for the three months ended March&#160;31, 2023 and 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:75%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three months ended March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="14" align="center"><span style="font-weight:bold">(U.S.&#160;$&#160;in&#160;millions&#160;/&#160;%&#160;of&#160;Segment&#160;Revenues)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S&amp;M expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G&amp;A expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Segment profit*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Segment profit does not include amortization and certain other items. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#167;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents an amount less than $0.5&#160;million or 0.5%, as applicable. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Europe Revenues </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Europe segment includes the European Union, the United Kingdom and certain other European countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from our Europe segment in the first quarter of 2023 were $1,184&#160;million, an increase of 2%, or $28&#160;million, compared to the first quarter of 2022. In local currency terms, revenues increased by 9%, mainly due to higher revenues from generic products and generic product launches. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, revenues were negatively impacted by exchange rate fluctuations of $79&#160;million, net of hedging effects, compared to the first quarter of 2022. Revenues in the first quarter of 2023 included $6&#160;million from a negative hedging impact, which is included in &#8220;Other&#8221; in the table below. See note 8d to our consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenues by Major Products and Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents revenues for our Europe segment by major products and activities for the three months ended March&#160;31, 2023 and 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:74%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three&#160;months&#160;ended</span><br /><span style="font-weight:bold">March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Percentage</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Change</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023-2022</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">(U.S. $ in millions)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Generic products</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">932</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">6%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AJOVY</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">17%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COPAXONE</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(17%)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Respiratory products</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(4%)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(17%)</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2%</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Generic products</span> revenues (including OTC and biosimilar products) in our Europe segment in the first quarter of 2023, increased by 6% to $932&#160;million, compared to the first quarter of 2022. In local currency terms, revenues increased by 12%, mainly due to higher revenues from generic and OTC products and from generic product launches. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">AJOVY</span> revenues in our Europe segment in the first quarter of 2023 increased by 17% to $36&#160;million, compared to $30&#160;million in the first quarter of 2022. In local currency terms, revenues increased by 28%, mainly due to growth in European countries in which AJOVY had previously been launched. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For information about AJOVY patent protection, see &#8220;&#8212;North America Revenues&#8212;Revenues by Major Product&#8221; above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">COPAXONE</span> revenues in our Europe segment in the first quarter of 2023 decreased by 17% to $59&#160;million, compared to the first quarter of 2022. In local currency terms, revenues decreased by 12%, due to price reductions and a decline in volume resulting from competing glatiramer acetate products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One European patent protecting COPAXONE 40 mg/mL was found invalid by the Board of Appeal of the European Patent Office in September 2020 and two additional patents expiring in 2030 were found invalid in December 2021. In certain countries, Teva remains in litigation against generic companies on an additional COPAXONE 40 mg/mL patent that expires in 2030. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Respiratory products</span> revenues in our Europe segment in the first quarter of 2023 decreased by 4% to $68&#160;million compared to the first quarter of 2022. In local currency terms, revenues increased by 2%, mainly due to higher demand. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Product Launches and Pipeline </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2023, our generic products pipeline in Europe included 128 generic approvals relating to 27 compounds in 53 formulations, with no European Medicines Agency (&#8220;EMA&#8221;) approvals received. In addition, approximately 1,129 marketing authorization applications are pending approval in 37 European countries, relating to 102 compounds in 206 formulations. One application is pending with the EMA relating to three strengths in 30 markets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For information regarding our innovative medicines and biosimilar products pipeline, see &#8220;&#8212;Teva Consolidated Results&#8212;Research and Development (R&amp;D) Expenses&#8221; below. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Europe Gross Profit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gross profit from our Europe segment in the first quarter of 2023 was $655&#160;million, a decrease of 6% compared to $694&#160;million in the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gross profit margin for our Europe segment in the first quarter of 2023 decreased to 55.3%, compared to 60.0% in the first quarter of 2022. This decrease was mainly due to higher cost of goods sold, mainly driven by rising costs due to inflationary and other macroeconomic pressures. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Europe R&amp;D Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">R&amp;D expenses relating to our Europe segment in the first quarter of 2023 were $53&#160;million, a decrease of 8% compared to $58&#160;million in the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of our R&amp;D expenses in the first quarter of 2023, see &#8220;&#8212;Teva Consolidated Results&#8212;Research and Development (R&amp;D) Expenses&#8221; below. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Europe S&amp;M Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">S&amp;M expenses relating to our Europe segment in the first quarter of 2023 were $187&#160;million, a decrease of 5% compared to $196&#160;million in the first quarter of 2022. This decrease was mainly due to exchange rate fluctuations. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Europe G&amp;A Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G&amp;A expenses relating to our Europe segment in the first quarter of 2023 were $70&#160;million, an increase of 18% compared to $59&#160;million in the first quarter of 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Europe Profit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Profit from our Europe segment consists of gross profit less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Profit from our Europe segment in the first quarter of 2023 was $345&#160;million, a decrease of 9%, compared to $381&#160;million in the first quarter of 2022. This decrease was mainly due to lower gross profit as described above and exchange rate fluctuations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">International Markets Segment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents revenues, expenses and profit for our International Markets segment for the three months ended March&#160;31, 2023 and 2022: </p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:80%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three months ended March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="14" align="center"><span style="font-weight:bold">(U.S.&#160;$&#160;in&#160;millions&#160;/&#160;%&#160;of&#160;Segment&#160;Revenues)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S&amp;M expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G&amp;A expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">(1)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="center">(40)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Segment profit*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Segment profit does not include amortization and certain other items. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#167;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents an amount less than 0.5%. </p></td></tr></table> <p style="margin-top:16pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International Markets Revenues </span></p> <p style="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our International Markets segment includes all countries in which we operate other than those in our North America and Europe segments. The International Markets segment includes more than 35 countries, covering a substantial portion of the global pharmaceutical market. The countries in our International Markets segment include highly regulated, pure generic markets, such as Israel, branded generics oriented markets, such as Russia and certain Latin America markets and hybrid markets, such as Japan. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2022, Russia launched an invasion of Ukraine. As of the date of this Quarterly Report on Form <span style="white-space:nowrap">10-Q,</span> sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in our International Markets segment results. We have no manufacturing or R&amp;D facilities in these markets. During the three months ended March&#160;31, 2023, the impact of this conflict on our International Markets segment&#8217;s results of operations and financial condition was immaterial. Consistent with our foreign exchange risk management hedging programs, we entered into hedges to hedge our exposure to currency exchange rate fluctuations with respect to our balance sheet assets, revenues and expenses. However, as of the end of the first quarter of 2023, we were unable to renew certain of our expiring hedging positions due to the liquidity situation in the market for Russian rubles and we currently hedge a small part of our projected net revenues for 2023. Prior to and since the escalation of the conflict, we have been taking measures to reduce our operational cash balances in Russia and Ukraine. We have been monitoring the solvency of our customers in Russia and Ukraine and have taken measures, where practicable, to mitigate our exposure to risks related to the conflict in the region. However, the duration, severity and global implications (including potential inflation and devaluation consequences) of the conflict cannot be predicted at this time and could have an effect on our business, including on our exchange rate exposure, supply chain, operational costs and commercial presence in these markets. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from our International Markets segment in the first quarter of 2023 were $492&#160;million, flat compared to the first quarter of 2022. In local currency terms, revenues increased by 8% compared to the first quarter of 2022. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, revenues were negatively impacted by exchange rate fluctuations of $41&#160;million, net of hedging effects, compared to the first quarter of 2022. Revenues in the first quarter of 2023 included a minimal hedging impact, compared to a positive hedging impact of $12&#160;million in the first quarter of 2022, which is included in &#8220;Other&#8221; in the table below. See note 8d to our consolidated financial statements. </p> <p style="margin-top:16pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenues by Major Products and Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents revenues for our International Markets segment by major products and activities for the three months ended March&#160;31, 2023 and 2022: </p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:75%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three&#160;months&#160;ended</span><br /><span style="font-weight:bold">March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Percentage</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Change</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023-2022</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">(U.S.&#160;$&#160;in&#160;millions)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Generic products</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AJOVY</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">74%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COPAXONE</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">16%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">(20%)</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">&#167;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Generic products</span> revenues in our International Markets segment in the first quarter of 2023, which include OTC products, increased by 3% in U.S. dollars to $400&#160;million. In local currency terms, revenues increased by 9% compared to the first quarter of 2022, mainly due to higher revenues in certain markets, as well as price increases largely as a result of rising costs due to inflationary pressure, partially offset by regulatory price reductions and generic competition to <span style="white-space:nowrap">off-patented</span> products in Japan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">AJOVY</span> was launched in certain markets in our International Markets segment, including in Japan in August 2021. We are moving forward with plans to launch AJOVY in other markets. AJOVY revenues in our International Markets segment in the first quarter of 2023 were $10&#160;million, compared to $6&#160;million in the first quarter of 2022, mainly due to growth in volume. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">COPAXONE</span> revenues in our International Markets segment in the first quarter of 2023 were $12&#160;million compared to $10&#160;million in the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">AUSTEDO</span> was launched in early 2021 in China for the treatment of chorea associated with Huntington&#8217;s disease and for the treatment of tardive dyskinesia, and was also launched in Israel during 2021. During the third quarter of 2022, AUSTEDO was launched in Brazil. We continue with additional submissions in various other markets. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International Markets Gross Profit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gross profit from our International Markets segment in the first quarter of 2023 was $262&#160;million, a decrease of 8% compared to $286&#160;million in the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gross profit margin for our International Markets segment in the first quarter of 2023 decreased to 53.2%, compared to 58.1% in the first quarter of 2022. This decrease was mainly due to regulatory price reductions and generic competition to <span style="white-space:nowrap">off-patented</span> products in Japan, the positive hedging impact of $12&#160;million in the first quarter of 2022, as well as rising costs due to inflationary and other macroeconomic pressures, partially offset by price increases largely as a result of such rising costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International Markets R&amp;D Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">R&amp;D expenses relating to our International Markets segment in the first quarter of 2023 were $20&#160;million, flat compared to the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of our R&amp;D expenses in the first quarter of 2023, see &#8220;&#8212;Teva Consolidated Results&#8212;Research and Development (R&amp;D) Expenses&#8221; below. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International Markets S&amp;M Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">S&amp;M expenses relating to our International Markets segment in the first quarter of 2023 were $98&#160;million, flat compared to the first quarter of 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International Markets G&amp;A Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G&amp;A expenses relating to our International Markets segment in the first quarter of 2023 were $31&#160;million, an increase of 7% compared to $29&#160;million in the first quarter of 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International Markets Other Income </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income relating to our International Markets segment in the first quarter of 2023 was $1&#160;million, compared to $40&#160;million in the first quarter of 2022. Other income in the first quarter of 2022 was mainly the result of settlement proceeds. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International Markets Profit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Profit from our International Markets segment consists of gross profit less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Profit from our International Markets segment in the first quarter of 2023 was $114&#160;million, a decrease of 36%, compared to $179&#160;million in the first quarter of 2022. This decrease was mainly due to higher other income and higher gross profit in the first quarter of 2022 as compared to the first quarter of 2023. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Activities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an <span style="white-space:nowrap">out-licensing</span> platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not included in our North America, Europe or International Markets segments described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues from other activities in the first quarter of 2023 were $219&#160;million, a decrease of 20% in U.S. dollars compared to the first quarter of 2022. In local currency terms, revenues decreased by 19%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">API sales to third parties in the first quarter of 2023 were $132&#160;million, a decrease of 27% in both U.S. dollars and local currency terms, compared to the first quarter of 2022, as many pharmaceutical customers de-stocked inventory levels that had remained high through the COVID-19 pandemic. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Teva Consolidated Results </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revenues </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues in the first quarter of 2023 were $3,661&#160;million, flat compared to the first quarter of 2022. In local currency terms, revenues increased by 4%, mainly due to higher revenues from generic products in our Europe and International Markets segments, certain innovative products primarily AUSTEDO and AJOVY, as well as from Anda in our North America segment, partially offset by lower revenues from generic products in our North America segment, API sales to third parties and BENDEKA and TREANDA in our North America segment. See &#8220;&#8212;North America Revenues,&#8221; &#8220;&#8212;Europe Revenues,&#8221; &#8220;&#8212;International Markets Revenues&#8221; and &#8220;&#8212;Other Activities&#8221; above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exchange rate movements during the first quarter of 2023, including hedging effects, negatively impacted revenues by $128&#160;million, compared to the first quarter of 2022. See note 8d to our consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Gross Profit </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gross profit in the first quarter of 2023 was $1,582&#160;million, a decrease of 9% compared to the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gross profit margin was 43.2% in the first quarter of 2023, compared to 47.5% in the first quarter of 2022. This decrease was mainly driven by rising costs due to inflationary and other macroeconomic pressures, an increase in revenues with lower profitability from Anda in our North America segment, lower revenues from COPAXONE and BENDEKA and TREANDA, and an unfavorable impact of hedging activities, partially offset by higher revenues from AUSTEDO and AJOVY. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Research and Development (R&amp;D) Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our R&amp;D activities for generic products in each of our segments include both (i)&#160;direct expenses relating to product formulation, analytical method development, stability testing, management of bioequivalence and other clinical studies and regulatory filings; and (ii)&#160;indirect expenses, such as costs of internal administration, infrastructure and personnel. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our R&amp;D activities for innovative medicines and biosimilar products in each of our segments include costs of discovery research, preclinical development, drug formulation, early- and late-clinical development and product registration costs. These expenditures are reported net of contributions received from collaboration partners. Our spending takes place throughout the development process, including (i)&#160;early-stage projects in both discovery and preclinical phases; (ii)&#160;middle-stage projects in clinical programs up to phase 3; (iii) late-stage projects in phase 3 programs, including where a new drug application is currently pending approval; (iv)&#160;post-approval studies for marketed products; and (v)&#160;indirect expenses, such as costs of internal administration, infrastructure and personnel. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">R&amp;D expenses in the first quarter of 2023 were $234&#160;million, an increase of 4% compared to $225&#160;million in the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, our R&amp;D expenses related primarily to innovative product candidates in neuroscience (such as neuropsychiatry migraine and movement disorders/&#160;neurodegeneration, including post-approval commitments), immunology (such as respiratory medicines) and selected other areas, as well as generic products and biosimilars. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our higher R&amp;D expenses in the first quarter of 2023, compared to the first quarter of 2022, were mainly due to an increase in neuroscience (mainly neuropsychiatry) and immunology as well as various generics and biosimilar products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">R&amp;D expenses as a percentage of revenues were 6.4% in the first quarter of 2023, compared to 6.2% in the first quarter of 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Innovative Medicines Pipeline </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Below is a description of key products in our innovative medicines pipeline as of May&#160;1, 2023: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:23%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:19%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:19%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:17%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Phase 2</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Phase 3</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Pre-Submission</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Under&#160;Regulatory&#160;Review</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Neuroscience</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Olanzapine LAI</span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schizophrenia</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(September 2022)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Immunology</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">TEV-48574</span></span></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Inflammatory Bowel Disease</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ICS-SABA</span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">TEV-56248</span></span></span>)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Respiratory</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(February 2023)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Other</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Digihaler<sup style="font-size:75%; vertical-align:top">&#174;</sup></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(beclomethasone</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">dipropionate</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">HFA)(U.S.)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Digihaler<sup style="font-size:75%; vertical-align:top">&#174;</sup></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(budesonide and</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">formoterol</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">fumarate dihydrate)</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(EU)<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Digital component approved in the U.K. by the Medicines and Healthcare products Regulatory Agency (MHRA). </p></td></tr></table> <p style="margin-top:13pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Discontinued Project </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, development of deutetrabenazine for dyskinesia in&#160;cerebral palsy was discontinued. </p> <p style="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Biosimilar Products Pipeline </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have additional biosimilar products in development internally and with our partners that are in various stages of clinical trials and regulatory review worldwide, including phase 3 clinical trials for biosimilars to Prolia<sup style="font-size:75%; vertical-align:top">&#174;</sup> (denosumab), Xolair<sup style="font-size:75%; vertical-align:top">&#174;</sup> (omalizumab), Eylea<sup style="font-size:75%; vertical-align:top">&#174;</sup> (afilbercept) and Simponi<sup style="font-size:75%; vertical-align:top">&#174;</sup> (golimumab), a biosimilar to Lucentis<sup style="font-size:75%; vertical-align:top">&#174;</sup> (ranibizumab) that was submitted in Canada, and biosimilars to Stelara<sup style="font-size:75%; vertical-align:top">&#174;</sup> (ustekinumab) and to Humira<sup style="font-size:75%; vertical-align:top">&#174;</sup><sup style="font-size:75%; vertical-align:top"> </sup>(adalimumab), each of which are currently under U.S. regulatory review. </p> <p style="margin-top:13pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Selling and Marketing (S&amp;M) Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">S&amp;M expenses in the first quarter of 2023 were $546&#160;million, a decrease of 6% compared to the first quarter of 2022. This decrease was mainly a result of the factors discussed above under &#8220;&#8212;North America segment&#8212;S&amp;M Expenses&#8221; and &#8220;&#8212;Europe Segment&#8212;S&amp;M Expenses.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">S&amp;M expenses as a percentage of revenues were 14.9% in the first quarter of 2023, compared to 15.9% in the first quarter of 2022. </p> <p style="margin-top:13pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General and Administrative (G&amp;A) Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G&amp;A expenses in the first quarter of 2023 were $296&#160;million, flat compared to the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G&amp;A expenses as a percentage of revenues were 8.1% in the first quarter of 2023 and in the first quarter of 2022. </p> <p style="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intangible Asset Impairments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded expenses of $178&#160;million for identifiable intangible asset impairments in the first quarter of 2023, compared to expenses of $149&#160;million in the first quarter of 2022. See note 5 to our consolidated financial statements. </p> <p style="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Goodwill Impairment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No goodwill impairments were recorded in the first quarters of 2023 and 2022. </p> <p style="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Asset Impairments, Restructuring and Other Items </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded expenses of $96&#160;million for other asset impairments, restructuring and other items in the first quarter of 2023, compared to expenses of $128&#160;million in the first quarter of 2022. See note 12 to our consolidated financial statements. </p> <p style="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Settlements and Loss Contingencies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, we recorded expenses of $233&#160;million in legal settlements and loss contingencies, compared to an expense of $1,124&#160;million in the first quarter of 2022. See note 9 to our consolidated financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Income </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income in the first quarter of 2023 was $2&#160;million, compared to $52&#160;million in the first quarter of 2022. Other income in the first quarter of 2022 was mainly the result of settlement proceeds in our International Markets segment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Operating Income (Loss) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating income was $2&#160;million in the first quarter of 2023, compared to an operating loss of $713&#160;million in the first quarter of 2022. The increase in operating income in the first quarter of 2023 was mainly due to higher legal settlements and loss contingencies in the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating income as a percentage of revenues was 0.1% in the first quarter of 2023, compared to operating loss as a percentage of revenues of 19.5% in the first quarter of 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial Expenses, Net </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial expenses were $260&#160;million in the first quarter of 2023, compared to $258&#160;million in the first quarter of 2022. Financial expenses in the first quarter of 2023 were mainly comprised of interest expenses of $260&#160;million. Financial expenses in the first quarter of 2022 were mainly comprised of interest expenses of $238&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a reconciliation of our segment profits to our consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended March&#160;31, 2023 and 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:83%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Three&#160;months&#160;ended</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">(U.S. $ in millions)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">North America profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">402</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Europe profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">International Markets profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total reportable segments profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">791</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Profit (loss) of other activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total segments profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,013</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts not allocated to segments:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets impairments, restructuring and other items</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets impairments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlements and loss contingencies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other unallocated amounts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated operating income (loss)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(713</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated income (loss) before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(258</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(971</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Income Taxes </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, we recognized a tax benefit of $19&#160;million, on a <span style="white-space:nowrap">pre-tax</span> loss of $258&#160;million. In the first quarter of 2022, we recognized a tax expense of $2&#160;million, on a <span style="white-space:nowrap">pre-tax</span> loss of $971&#160;million. See note 11 to our consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Share in (Profits) Losses of Associated Companies, Net </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share in profits of associated companies, net in the first quarter of 2023 was immaterial, compared to share in profits of associated companies, net of $21&#160;million in the first quarter of 2022. Share in profits of associated companies, net in the first quarter of 2022 was mainly related to the difference between the book value of our investment in Novetide and its fair value as of the date we completed its acquisition in January 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net Income (Loss) Attributable to Teva </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net loss was $205&#160;million in the first quarter of 2023, compared to net loss of $955&#160;million in the first quarter of 2022. Net loss in the first quarter of 2022 was mainly impacted by legal settlements and loss contingencies, as discussed above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Diluted Shares Outstanding and Earnings (Loss) per Share </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended March&#160;31, 2023 and 2022 were 1,115&#160;million and 1,107&#160;million shares, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diluted loss per share was $0.18 in the first quarter of 2023, compared to diluted loss per share of $0.86 in the first quarter of 2022. See note 13 to our consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Share Count for Market Capitalization </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We calculate share amounts using the outstanding number of shares (i.e., excluding treasury shares) plus shares that would be outstanding upon the exercise of options and vesting of RSUs and PSUs, and the conversion of our convertible senior debentures, in each case, at period end. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2023 and 2022, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,158&#160;million and 1,145&#160;million, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Impact of Currency Fluctuations on Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, approximately 50% of our revenues were denominated in currencies other than the U.S. dollar. Because our results are reported in U.S. dollars, we are subject to significant foreign currency risks. Accordingly, changes in the rate of exchange between the U.S. dollar and the local currencies in the markets in which we operate (primarily the euro, British pound, Canadian dollar, Russian ruble, Japanese yen, Swiss franc and the new Israeli shekel) impact our results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the first quarter of 2023, the following main currencies relevant to our operations decreased in value against the U.S. dollar (each on a quarterly average compared to quarterly average basis): Argentinian peso by 44%, Turkish lira by 26%, Ukrainian hryvna by 22%, Japanese yen by 12%, Swedish krona by 11%, Hungarian forint by 10%, Israeli shekel by 10%, British pound by 10% and the euro by 4%. The following main currencies increased in value against the U.S. dollar: Russian ruble by 18%, Mexican peso by 10% and Brazilian real by 1%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, exchange rate movements during the first quarter of 2023, including hedging effects, negatively impacted overall revenues by $128&#160;million and operating income by $32&#160;million, compared to the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, a negative hedging impact of $6&#160;million was recognized under revenues, and a minimal positive impact was recognized under cost of sales. In the first quarter of 2022, a positive hedging impact of $19&#160;million was recognized under revenues and a minimal negative impact was recognized under cost of sales. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hedging transactions against future projected revenues and expenses are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. See note 8d to our consolidated financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing in the third quarter of 2018, the cumulative inflation in Argentina exceeded 100% or more over a three-year period. Although this triggered highly inflationary accounting treatment, it did not have a material impact on our results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing in the second quarter of 2022, the cumulative inflation in Turkey exceeded 100% or more over a three-year period. Although this triggered highly inflationary accounting treatment, it did not have a material impact on our results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total balance sheet assets were $43,456&#160;million as of March&#160;31, 2023, compared to $44,006&#160;million as of December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our working capital balance, which includes accounts receivables net of SR&amp;A, inventories, prepaid expenses and other current assets, accounts payables, employee-related obligations, accrued expenses and other current liabilities, was negative $41&#160;million as of March&#160;31, 2023, compared to negative $119&#160;million as of December&#160;31, 2022. This increase was mainly due to an increase in accounts receivables, net of SR&amp;A, as well as in inventory levels and prepaid expenses, and a decrease in employee-related obligations, partially offset by an increase in accounts payables and provisions for legal settlements and loss contingencies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employee-related obligations, as of March&#160;31, 2023 were $432&#160;million, compared to $566&#160;million as of December&#160;31, 2022. The decrease in the first quarter of 2023 was mainly due to performance incentive payments to employees for 2022, partially offset by an accrual for performance incentive payments to employees for 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash investment in property, plant and equipment in the first quarter of 2023 was $139&#160;million, compared to $157&#160;million in the first quarter of 2022. Depreciation in the first quarter of 2023 was $139&#160;million, compared to $123&#160;million in the first quarter of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents and short-term and long-term investments as of March&#160;31, 2023 were $2,161&#160;million, compared to $2,817&#160;million as of December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our cash on hand that is not used for ongoing operations is generally invested in bank deposits as well as liquid securities that bear fixed and floating rates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily our $1.8&#160;billion unsecured syndicated sustainability-linked revolving credit facility, entered into in April 2022, which was amended in February 2023 (&#8220;RCF&#8221;). See note 7 to our consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Debt Balance and Movements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2023, our debt was $20,691&#160;million, compared to $21,212&#160;million as of December&#160;31, 2022. This decrease was mainly due to $646&#160;million senior notes repaid at maturity, partially offset by $176&#160;million of exchange rate fluctuations. Additionally, during the first quarter of 2023, we repurchased $2,506&#160;million aggregate principal amount of notes upon consummation of a cash tender offer, and issued $2,445&#160;million of sustainability-linked senior notes, net of issuance costs. For further information, see note 7 to our consolidated financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our debt as of March&#160;31, 2023 was effectively denominated in the following currencies: 62% in U.S. dollars, 36% in euros and 2% in Swiss francs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The portion of total debt classified as short-term as of March&#160;31, 2023 was 5%, compared to 10% as of December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial leverage, which is the ratio between our debt and the sum of our debt and equity, was 71% as of March&#160;31, 2023 and as of December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our average debt maturity was approximately 6.4 years as of March&#160;31, 2023, compared to 5.8 years as of December&#160;31, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total Equity </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total equity was $8,612&#160;million as of March&#160;31, 2023, compared to $8,691&#160;million as of December&#160;31, 2022. This decrease was mainly due to a net loss of $238&#160;million, partially offset by a positive impact of $120&#160;million from exchange rate fluctuations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exchange rate fluctuations affected our balance sheet, as approximately 82% of our net assets as of March&#160;31, 2023 (including both <span style="white-space:nowrap">non-monetary</span> and monetary assets) were in currencies other than the U.S. dollar. When compared to December&#160;31, 2022, changes in currency rates had a positive impact of $120&#160;million on our equity as of March&#160;31, 2023. The following main currencies increased in value against the U.S. dollar: Mexican peso by 7%, Chilean peso by 7%, Polish zloty by 2%, British pound by 2%, Bulgarian lev by 2% and euro by 2%. The Russian ruble decreased in value against the U.S. dollar by 5%. All comparisons are on a year-to-date basis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cash Flow </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to continually improve the efficiency of our working capital management. From time to time, as part of our cash and commercial relationship management activities, we may make decisions in our commercial and supply chain activities which may drive an acceleration of receivable payments from customers or deceleration of payments to vendors, having the effect of increasing or decreasing cash from operations during an individual period. Such decisions may have an impact on our annual operating cash flow measurement, as well as on our quarterly results. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash flow used in operating activities during the first quarter of 2023 was $145&#160;million, compared to $49&#160;million in the first quarter of 2022. The higher cash flow used in the first quarter of 2023 resulted mainly from lower profit and changes in working capital items, including an increase in accounts receivables, net of SR&amp;A, partially offset by an increase in accounts payables. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the first quarter of 2023, we generated free cash flow of $41&#160;million, which we define as comprising $145&#160;million in cash flow used in operating activities, $323&#160;million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $2&#160;million in proceeds from divestitures of businesses and other assets, partially offset by $139&#160;million in cash used for capital investment. During the first quarter of 2022, we generated free cash flow of $117&#160;million, which we define as comprising $49&#160;million in cash flow used in operating activities, $305&#160;million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $25&#160;million in proceeds from divestitures of businesses and other assets, partially offset by $157&#160;million in cash used for capital investment and $7&#160;million in cash used for acquisition of businesses, net of cash acquired. The decrease in the first quarter of 2023, resulted mainly from higher cash flow used in operating activities, as discussed above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividends </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid dividends on our ordinary shares or ADSs since December 2017. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Commitments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to financing obligations under short-term debt and long-term senior notes and loans, debentures and convertible debentures, our major contractual obligations and commercial commitments include leases, royalty payments, contingent payments pursuant to acquisition agreements and participation in joint ventures associated with R&amp;D activities. For further information on our agreements with Modag, Alvotech, Otsuka, Takeda and MedinCell, see note 2 to our consolidated financial statements.&#160;&#160;&#160;&#160; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to paying royalties to owners of <span style="white-space:nowrap">know-how,</span> partners in alliances and certain other arrangements, and to parties that financed R&amp;D at a wide range of rates as a percentage of sales of certain products, as defined in the agreements. In some cases, the royalty period is not defined; in other cases, royalties will be paid over various periods not exceeding 20 years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with certain development, supply and marketing, and research and collaboration or services agreements, we are required to indemnify, in unspecified amounts, the parties to such agreements against third-party claims relating to (i)&#160;infringement or violation of intellectual property or other rights of such third party; or (ii)&#160;damages to users of the related products. Except as described in our financial statements, we are not aware of any material pending action that may result in the counterparties to these agreements claiming such indemnification. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2023 Aggregated Contractual Obligations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have not been any material changes in our assessment of material contractual obligations and commitments as set forth in Item 7 of our Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-GAAP</span> Net Income and <span style="white-space:nowrap">Non-GAAP</span> EPS Data </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We present <span style="white-space:nowrap">non-GAAP</span> net income and <span style="white-space:nowrap">non-GAAP</span> earnings per share (&#8220;EPS&#8221;) as management believes that such data provide useful information to investors because they are used by management and our Board of Directors, in conjunction with other performance metrics, to evaluate our operational performance, to prepare and evaluate our work plans and annual budgets and ultimately to evaluate the performance of management, including annual compensation. While other qualitative factors and judgment also affect annual compensation, the principal quantitative element in the determination of such compensation are performance targets tied to the work plan, which are based on these <span style="white-space:nowrap">non-GAAP</span> measures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-GAAP</span> financial measures have no standardized meaning and accordingly have limitations in their usefulness to investors. Investors are cautioned that, unlike financial measures prepared in accordance with U.S. GAAP, <span style="white-space:nowrap">non-GAAP</span> measures may not be comparable with the calculation of similar measures for other companies. These <span style="white-space:nowrap">non-GAAP</span> financial measures are presented solely to permit investors to more fully understand how management assesses our performance. The limitations of using <span style="white-space:nowrap">non-GAAP</span> financial measures as performance measures are that they provide a view of our results of operations without including all events during a period and may not provide a comparable view of our performance to other companies in the pharmaceutical industry. Investors should consider <span style="white-space:nowrap">non-GAAP</span> net income and <span style="white-space:nowrap">non-GAAP</span> EPS in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing our <span style="white-space:nowrap">non-GAAP</span> net income and <span style="white-space:nowrap">non-GAAP</span> EPS data, we exclude items that either have a <span style="white-space:nowrap">non-recurring</span> impact on our financial performance or which, in the judgment of our management, are items that, either as a result of their nature or size, could, were they not excluded, potentially cause investors to extrapolate future performance from an improper base that is not reflective of our underlying business performance. Certain of these items are also excluded because of the difficulty in predicting their timing and scope. The items excluded from our <span style="white-space:nowrap">non-GAAP</span> net income and <span style="white-space:nowrap">non-GAAP</span> EPS include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">amortization of purchased intangible assets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">legal settlements and material litigation fees and/or loss contingencies, due to the difficulty in predicting their timing and scope; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">impairments of long-lived assets, including intangibles, property, plant and equipment and goodwill; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restructuring expenses, including severance, retention costs, contract cancellation costs and certain accelerated depreciation expenses primarily related to the rationalization of our plants or to certain other strategic activities, such as the realignment of R&amp;D focus or other similar activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acquisition- or divestment- related items, including changes in contingent consideration, integration costs, banker and other professional fees and inventory <span style="white-space:nowrap">step-up;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expenses related to our equity compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant <span style="white-space:nowrap">one-time</span> financing costs, amortization of issuance costs and terminated derivative instruments, and marketable securities investment valuation gains/losses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unusual tax items; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other awards or settlement amounts, either paid or received; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as impacts due to changes in accounting, significant costs for remediation of plants, or other unusual events; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">corresponding tax effects of the foregoing items. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present our <span style="white-space:nowrap">non-GAAP</span> net income and <span style="white-space:nowrap">non-GAAP</span> EPS for the three months ended March&#160;31, 2023 and 2022, as well as reconciliations of each measure to their nearest GAAP equivalents: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:83%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center">Three&#160;months&#160;ended</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center">March&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-style:italic">($ in millions except per share amounts)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to Teva</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;(205</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(955</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) for excluded items:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of purchased intangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlements and loss contingencies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment of long-lived assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs related to regulatory actions taken in facilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accelerated depreciation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share in profits (losses) of associated companies &#8211; net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Items attributable to <span style="white-space:nowrap">non-controlling</span> interests</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(40</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <span style="white-space:nowrap">non-GAAP</span> items<sup style="font-size:75%; vertical-align:top">*</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corresponding tax effects and unusual tax items</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(104</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(140</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-GAAP</span> net income attributable to Teva</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">609</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted earnings (loss) per share attributable to Teva</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.18</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.86</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EPS difference<sup style="font-size:75%; vertical-align:top">**</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted <span style="white-space:nowrap">Non-GAAP</span> EPS attributable to Teva<sup style="font-size:75%; vertical-align:top">**</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-GAAP</span> weighted average number of shares (in millions)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">*</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Other <span style="white-space:nowrap">non-GAAP</span> items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as inventory write-offs, primarily related to the rationalization of our plants, material litigation fees and other unusual events. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">**</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">EPS difference and diluted <span style="white-space:nowrap">non-GAAP</span> EPS are calculated by dividing our <span style="white-space:nowrap">non-GAAP</span> net income attributable to Teva by our <span style="white-space:nowrap">non-GAAP</span> diluted weighted average number of shares. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Off-Balance</span> Sheet Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for securitization transactions, which are disclosed in note 10f to our consolidated financial statements included in our Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2022, we do not have any material <span style="white-space:nowrap">off-balance</span> sheet arrangements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a summary of our significant accounting policies, see note 1 to our consolidated financial statements and &#8220;Critical Accounting Policies&#8221; included in our Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recently Issued Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See note 1 to our consolidated financial statements. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="fin464631_10"><span style="font-weight:bold">ITEM&#160;3.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has not been any material change in our assessment of market risk as set forth in Item 7A to our Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2022. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="fin464631_11"><span style="font-weight:bold">ITEM&#160;4.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">CONTROLS AND PROCEDURES </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Disclosure Controls and Procedures </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva maintains &#8220;disclosure controls and procedures&#8221; (as defined in <span style="white-space:nowrap"><span style="white-space:nowrap">Rules&#160;13a-15(e)&#160;and&#160;15d-15(e)&#160;under</span></span> the Securities Exchange Act of 1934, as amended) that are designed to provide reasonable assurance that information required to be disclosed in Teva&#8217;s reports filed or submitted under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to Teva&#8217;s management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After evaluating the effectiveness of our disclosure controls and procedures as of March&#160;31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, Teva&#8217;s disclosure controls and procedures were effective at the reasonable assurance level. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Changes in Internal Control over Financial Reporting </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three months ended March&#160;31, 2023, there were no changes in internal control over financial reporting that materially affected or are reasonably likely to materially affect Teva&#8217;s internal control over financial reporting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="fin464631_12">PART II &#8212; OTHER INFORMATION </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="fin464631_13"><span style="font-weight:bold">ITEM&#160;1.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">LEGAL PROCEEDINGS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to various litigation and other legal proceedings. For a discussion of these matters, see &#8220;Commitments and Contingencies&#8221; included in note 10 to the consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form <span style="white-space:nowrap">10-Q.</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="fin464631_14"><span style="font-weight:bold">ITEM&#160;1A.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">RISK FACTORS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no material changes to the risk factors previously disclosed in our Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2022. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="fin464631_15"><span style="font-weight:bold">ITEM&#160;2.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Unregistered Sales of Equity Securities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no sales of unregistered equity securities during the three months ended March&#160;31, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Repurchase of Shares </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not repurchase any of our shares during the three months ended March&#160;31, 2023 and currently cannot conduct share repurchases or pay dividends due to our accumulated deficit. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="fin464631_16"><span style="font-weight:bold">ITEM&#160;3.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">DEFAULTS UPON SENIOR SECURITIES </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="fin464631_17"><span style="font-weight:bold">ITEM&#160;4.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">MINE SAFETY DISCLOSURES </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="fin464631_18"><span style="font-weight:bold">ITEM&#160;5.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">OTHER INFORMATION </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left" id="fin464631_19"><span style="font-weight:bold">ITEM&#160;6.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">EXHIBITS </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:90%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312523066281/d475718dex42.htm">Fourth Supplemental Senior Indenture, dated as of March&#160;9, 2023, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent (incorporated by reference to Exhibit 4.2 to Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on March&#160;9, 2023) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312523066281/d475718dex42.htm">Form of 2029 Euro Notes (included in Exhibit 4.1)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312523066281/d475718dex42.htm">Form of 2031 Euro Notes (included in Exhibit 4.1)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312523066281/d475718dex46.htm">Fourth Supplemental Senior Indenture, dated as of March&#160;9, 2023, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee (incorporated by reference to Exhibit 4.6 to Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on March&#160;9, 2023) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312523066281/d475718dex46.htm">Form of 2029 USD Notes (included in Exhibit 4.4)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312523066281/d475718dex46.htm">Form of 2031 USD Notes (included in Exhibit 4.4)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d464631dex101.htm">Letter Agreement, dated as of February&#160;8, 2023, between Teva Pharmaceutical Industries Ltd. and Eric Drap&#233; * </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">31.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d464631dex311.htm">Certification of the Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002&#160;* </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">31.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d464631dex312.htm">Certification of the Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002&#160;* </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">32</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d464631dex32.htm">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 * </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Instance Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Labels Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="fin464631_20">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3">TEVA&#160;PHARMACEUTICAL&#160;INDUSTRIES&#160;LIMITED</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: May&#160;10, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/&#160;Eli Kalif</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Eli Kalif</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Executive Vice President,</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Chief Financial Officer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Duly Authorized Officer)</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d464631dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g464631g66p75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">February&nbsp;8, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To: Eric Drape </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Eric, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I am pleased to inform you that in recognition of your importance and criticality to the success of the Teva Group, the Board of Directors and its
Compensation Committee approved granting you with the following additional terms. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#9726;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Certain continued vesting benefits</U>: In the event you are terminated by the Company without cause (as
defined in Section&nbsp;7.4 of your employment agreement with the Company), or if you retire from the Company on or after December&nbsp;31, 2024, you will receive full continued vesting of equity awards that were and/or will be granted to you by the
end of your employee-employer relationship, and all vested options shall continue to be exercisable in accordance with their original terms, including expiration terms. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All other terms of your Employment Agreement will remain without change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are confident that you will continue to make a significant contribution to our future growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Richard Francis</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard Francis </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer </P>
<P STYLE="font-size:330pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g464631teva2.jpg" ALT="LOGO">
 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>d464631dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Richard D. Francis, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Teva
Pharmaceutical Industries Limited; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The company&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the company and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluated the effectiveness of the company&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosed in this report any change in the company&#146;s internal control over financial reporting that
occurred during the company&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The company&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the company&#146;s auditors and the audit committee of the company&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the company&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any fraud, whether or not material, that involves management or other employees who have a significant role in
the company&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;10, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard D. Francis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Richard D. Francis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>d464631dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Eli Kalif, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Teva
Pharmaceutical Industries Limited; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The company&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the company and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluated the effectiveness of the company&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosed in this report any change in the company&#146;s internal control over financial reporting that
occurred during the company&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The company&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the company&#146;s auditors and the audit committee of the company&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the company&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any fraud, whether or not material, that involves management or other employees who have a significant role in
the company&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;10, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eli Kalif</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Eli Kalif</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Vice President, Chief Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>d464631dex32.htm
<DESCRIPTION>EX-32
<TEXT>
<HTML><HEAD>
<TITLE>EX-32</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report of Teva Pharmaceutical Industries Limited (the &#147;Company&#148;) on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended March&nbsp;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), we, Richard D. Francis, President and Chief Executive Officer of
the Company, and Eli Kalif, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of
1934; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May&nbsp;10, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard D. Francis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Richard D. Francis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eli Kalif</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Eli Kalif</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Vice President, Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>teva-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 10-May-2023 [04:37:29] {PM}-->
<schema targetNamespace="http://www.tevapharm.com/20230331" elementFormDefault="qualified" xmlns:teva="http://www.tevapharm.com/20230331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.tevapharm.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" id="ConsolidatedStatementsOfIncomeLoss">
<link:definition>1004 - Statement - Consolidated Statements of Income (Loss)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical" id="ConsolidatedStatementsOfIncomeLossParenthetical">
<link:definition>1005 - Statement - Consolidated Statements of Income (Loss) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" id="ConsolidatedStatementsOfComprehensiveIncomeLoss">
<link:definition>1006 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" id="ConsolidatedStatementsOfChangesInEquity">
<link:definition>1007 - Statement - Consolidated Statements of Changes in Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" id="ConsolidatedStatementsOfChangesInEquityParenthetical">
<link:definition>1008 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1009 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/BasisOfPresentation" id="BasisOfPresentation">
<link:definition>1010 - Disclosure - Basis of presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactions" id="CertainTransactions">
<link:definition>1011 - Disclosure - Certain transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers" id="RevenueFromContractsWithCustomers">
<link:definition>1012 - Disclosure - Revenue from contracts with customers</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/Inventories" id="Inventories">
<link:definition>1013 - Disclosure - Inventories</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssets" id="IdentifiableIntangibleAssets">
<link:definition>1014 - Disclosure - Identifiable Intangible Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/Goodwill" id="Goodwill">
<link:definition>1015 - Disclosure - Goodwill</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligations" id="DebtObligations">
<link:definition>1016 - Disclosure - Debt obligations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities" id="DerivativeInstrumentsAndHedgingActivities">
<link:definition>1017 - Disclosure - Derivative instruments and hedging activities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies" id="LegalSettlementsAndLossContingencies">
<link:definition>1018 - Disclosure - Legal Settlements and Loss Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1019 - Disclosure - Commitments and contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1020 - Disclosure - Income taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems" id="OtherAssetsImpairmentsRestructuringAndOtherItems">
<link:definition>1021 - Disclosure - Other assets impairments, restructuring and other items</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EarningsLossPerShare" id="EarningsLossPerShare">
<link:definition>1022 - Disclosure - Earnings (Loss) per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss" id="AccumulatedOtherComprehensiveIncomeLoss">
<link:definition>1023 - Disclosure - Accumulated other comprehensive income (loss)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/Segments" id="Segments">
<link:definition>1024 - Disclosure - Segments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurement" id="FairValueMeasurement">
<link:definition>1025 - Disclosure - Fair value measurement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
<link:definition>1026 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactionsTables" id="CertainTransactionsTables">
<link:definition>1027 - Disclosure - Certain transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" id="RevenueFromContractsWithCustomersTables">
<link:definition>1028 - Disclosure - Revenue from contracts with customers (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/InventoriesTables" id="InventoriesTables">
<link:definition>1029 - Disclosure - Inventories (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables" id="IdentifiableIntangibleAssetsTables">
<link:definition>1030 - Disclosure - Identifiable Intangible Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/GoodwillTables" id="GoodwillTables">
<link:definition>1031 - Disclosure - Goodwill (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsTables" id="DebtObligationsTables">
<link:definition>1032 - Disclosure - Debt obligations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" id="DerivativeInstrumentsAndHedgingActivitiesTables">
<link:definition>1033 - Disclosure - Derivative instruments and hedging activities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
<link:definition>1034 - Disclosure - Commitments and contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" id="OtherAssetsImpairmentsRestructuringAndOtherItemsTables">
<link:definition>1035 - Disclosure - Other assets impairments, restructuring and other items (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables" id="AccumulatedOtherComprehensiveIncomeLossTables">
<link:definition>1036 - Disclosure - Accumulated other comprehensive income (loss) (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsTables" id="SegmentsTables">
<link:definition>1037 - Disclosure - Segments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
<link:definition>1038 - Disclosure - Fair Value Measurement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" id="CertainTransactionsOtherTransactionsAdditionalInformationDetail">
<link:definition>1039 - Disclosure - Certain Transactions - Other Transactions - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" id="CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail">
<link:definition>1040 - Disclosure - Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" id="RevenueFromContractsWithCustomersAdditionalInformationDetail">
<link:definition>1041 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" id="RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail">
<link:definition>1042 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" id="RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail">
<link:definition>1043 - Disclosure - Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" id="InventoriesSummaryOfInventoriesDetail">
<link:definition>1044 - Disclosure - Inventories - Summary of Inventories (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" id="IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail">
<link:definition>1045 - Disclosure - Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" id="IdentifiableIntangibleAssetsAdditionalInformationDetail">
<link:definition>1046 - Disclosure - Identifiable Intangible Assets - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" id="GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail">
<link:definition>1047 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" id="GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail">
<link:definition>1048 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail" id="GoodwillAdditionalInformationDetail">
<link:definition>1049 - Disclosure - Goodwill - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" id="DebtObligationsScheduleOfShortTermDebtDetail">
<link:definition>1050 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" id="DebtObligationsScheduleOfSeniorNotesAndLoansDetail">
<link:definition>1051 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" id="DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail">
<link:definition>1052 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" id="DebtObligationsAdditionalInformationDetail">
<link:definition>1053 - Disclosure - Debt Obligations - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail" id="DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail">
<link:definition>1054 - Disclosure - Derivative instruments and hedging activities - Summary of Notional Amounts for Hedged Items (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" id="DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail">
<link:definition>1055 - Disclosure - Derivative instruments and hedging activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" id="DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail">
<link:definition>1056 - Disclosure - Derivative instruments and hedging activities - Summary Of Pre-tax (gains) losses from Derivatives Designated in Cash Flow Hedging Relationships (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail" id="DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail">
<link:definition>1057 - Disclosure - Derivative instruments and hedging activities - Schedule of Other Derivatives Not Designated As Hedging Instruments Statements of Financial Performance And Financial Position Location (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" id="DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail">
<link:definition>1058 - Disclosure - Derivative instruments and hedging activities - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" id="LegalSettlementsAndLossContingenciesAdditionalInformationDetail">
<link:definition>1059 - Disclosure - Legal Settlements and Loss Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesContingenciesAdditionalInformationDetail">
<link:definition>1060 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail" id="CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail">
<link:definition>1061 - Disclosure - Commitments and contingencies - Schedule Of Material Details Of Individual Settlements (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1062 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" id="OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail">
<link:definition>1063 - Disclosure - Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" id="OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail">
<link:definition>1064 - Disclosure - Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" id="OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail">
<link:definition>1065 - Disclosure - Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" id="OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail">
<link:definition>1066 - Disclosure - Other assets impairments, restructuring and other items - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" id="EarningsLossPerShareAdditionalInformationDetail">
<link:definition>1067 - Disclosure - Earnings (Loss) per Share - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" id="AccumulatedOtherComprehensiveIncomeLossDetail">
<link:definition>1068 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" id="AccumulatedOtherComprehensiveIncomeLossParentheticalDetail">
<link:definition>1069 - Disclosure - Accumulated Other Comprehensive Income (Loss)  (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" id="SegmentsSummaryOfSegmentProfitDetail">
<link:definition>1070 - Disclosure - Segments - Summary of Segment Profit (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" id="SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail">
<link:definition>1071 - Disclosure - Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" id="SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail">
<link:definition>1072 - Disclosure - Segments - Schedule of Revenues by Major Products and Activities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" id="SegmentsAdditionalInformationDetail">
<link:definition>1073 - Disclosure - Segments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" id="FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail">
<link:definition>1074 - Disclosure - Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" id="FairValueMeasurementAdditionalInformationDetail">
<link:definition>1075 - Disclosure - Fair value measurement - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" id="FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail">
<link:definition>1076 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" id="FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail">
<link:definition>1077 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" id="FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail">
<link:definition>1078 - Disclosure - Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="teva-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="teva-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="teva-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="teva-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
<import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
<import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
<import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
<element name="AccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_AccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SalesReservesAndAllowances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_SalesReservesAndAllowances" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ImpairmentsRestructuringAndOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ImpairmentsRestructuringAndOthers" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IntangibleAssetsImpairments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_IntangibleAssetsImpairments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LegalSettlementsAndLossContingencies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LegalSettlementsAndLossContingencies" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnrealizedGainLossOnDerivativeNetOfTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_UnrealizedGainLossOnDerivativeNetOfTax" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProfitFromSaleOfLongLivedAssetsAndInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredIncomeTaxesNetAndUncertainTaxPositions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentToAcquireMarketableSecuritiesAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BasisOfPresentationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_BasisOfPresentationAbstract" substitutionGroup="xbrli:item" />
<element name="CertainTransactionsDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_CertainTransactionsDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="OtherExpensesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OtherExpensesTextBlock" substitutionGroup="xbrli:item" />
<element name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SalesReservesAndAllowancesCurrentTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_SalesReservesAndAllowancesCurrentTableTextBlock" substitutionGroup="xbrli:item" />
<element name="LongTermDebtExcludingConvertibleDebtTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfRestructuringChargesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfRestructuringChargesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" substitutionGroup="xbrli:item" />
<element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_MilestonePayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UpfrontPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_UpfrontPayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CollaborativeAgreementMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_CollaborativeAgreementMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LicenseAgreementPotentialAggregateMilestonePaymentsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AlvotechMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AlvotechMember" substitutionGroup="xbrli:item" />
<element name="OtsukaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtsukaMember" substitutionGroup="xbrli:item" />
<element name="ModagMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ModagMember" substitutionGroup="xbrli:item" />
<element name="MedincellMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_MedincellMember" substitutionGroup="xbrli:item" />
<element name="TakedaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TakedaMember" substitutionGroup="xbrli:item" />
<element name="RevenueRecognitionTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RevenueRecognitionTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RevenueRecognitionLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RevenueRecognitionLineItems" substitutionGroup="xbrli:item" />
<element name="SalesReservesAndAllowancesToCustomersPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_SalesReservesAndAllowancesToCustomersPercentage" substitutionGroup="xbrli:item" />
<element name="PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member" substitutionGroup="xbrli:item" />
<element name="FactoringInstitutionAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_FactoringInstitutionAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="FactoringInstitutionDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_FactoringInstitutionDomain" substitutionGroup="xbrli:item" />
<element name="PncBankMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_PncBankMember" substitutionGroup="xbrli:item" />
<element name="AccountsReceivableSecuritizationFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AccountsReceivableSecuritizationFacilityMember" substitutionGroup="xbrli:item" />
<element name="InternationalMarketsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_InternationalMarketsMember" substitutionGroup="xbrli:item" />
<element name="OtherActivitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherActivitiesMember" substitutionGroup="xbrli:item" />
<element name="ValuationAllowancesAndReservesForeignCurrencyTranslation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ValuationAllowancesAndReservesRelatedToPriorPeriodSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RebatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RebatesMember" substitutionGroup="xbrli:item" />
<element name="ReturnsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ReturnsMember" substitutionGroup="xbrli:item" />
<element name="MedicaidAndOtherGovernmentalAllowancesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_MedicaidAndOtherGovernmentalAllowancesMember" substitutionGroup="xbrli:item" />
<element name="ReservesIncludedInAccountsReceivableNetMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ReservesIncludedInAccountsReceivableNetMember" substitutionGroup="xbrli:item" />
<element name="ChargebacksMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ChargebacksMember" substitutionGroup="xbrli:item" />
<element name="TotalReservesIncludedInSalesReservesAndAllowancesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" substitutionGroup="xbrli:item" />
<element name="OtherSalesReservesAndAllowancesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherSalesReservesAndAllowancesMember" substitutionGroup="xbrli:item" />
<element name="InventoriesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_InventoriesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="InventoriesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_InventoriesLineItems" substitutionGroup="xbrli:item" />
<element name="ProductRightsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ProductRightsMember" substitutionGroup="xbrli:item" />
<element name="DiscontinuationOfBusinessAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DiscontinuationOfBusinessAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DiscontinuationOfBusinessDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DiscontinuationOfBusinessDomain" substitutionGroup="xbrli:item" />
<element name="GenericPipelineProductsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_GenericPipelineProductsMember" substitutionGroup="xbrli:item" />
<element name="LenalidomideProductMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_LenalidomideProductMember" substitutionGroup="xbrli:item" />
<element name="ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" substitutionGroup="xbrli:item" />
<element name="EventBasisAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EventBasisAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventBasisDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EventBasisDomain" substitutionGroup="xbrli:item" />
<element name="UpdatedMarketAssumptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_UpdatedMarketAssumptionsMember" substitutionGroup="xbrli:item" />
<element name="PriceAndVolumeOfProductsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_PriceAndVolumeOfProductsMember" substitutionGroup="xbrli:item" />
<element name="RegulatoryPriceAndVolumeOfProductsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RegulatoryPriceAndVolumeOfProductsMember" substitutionGroup="xbrli:item" />
<element name="DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember" substitutionGroup="xbrli:item" />
<element name="TevasApiReportingUnitMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TevasApiReportingUnitMember" substitutionGroup="xbrli:item" />
<element name="MedisReportingUnitMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_MedisReportingUnitMember" substitutionGroup="xbrli:item" />
<element name="OtherCountriesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherCountriesMember" substitutionGroup="xbrli:item" />
<element name="EuropeReportingUnitMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EuropeReportingUnitMember" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentMaturityYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_DebtInstrumentMaturityYear" substitutionGroup="xbrli:item" />
<element name="ShortCreditAgreement2026Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ShortCreditAgreement2026Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2036Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2036Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2028Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2028Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2028OneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2028OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2025OneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2025OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2026OneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2026OneMember" substitutionGroup="xbrli:item" />
<element name="SustainabilityLinkedSeniorNotesDue2029Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SustainabilityLinkedSeniorNotesDue2029Member" substitutionGroup="xbrli:item" />
<element name="SustainabilityLinkedSeniorNotesDue2027Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SustainabilityLinkedSeniorNotesDue2027Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2024Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2024Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2022ThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2022ThreeMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2023OneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2023OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2022OneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2022OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2023TwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2023TwoMember" substitutionGroup="xbrli:item" />
<element name="SustainabilityLinkedSeniorNotesDue2030Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SustainabilityLinkedSeniorNotesDue2030Member" substitutionGroup="xbrli:item" />
<element name="OtherDebentures2026Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherDebentures2026Member" substitutionGroup="xbrli:item" />
<element name="SustainabilityLinkedSeniorNotesDue2027TwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2046Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2046Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2025TwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2025TwoMember" substitutionGroup="xbrli:item" />
<element name="SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember" substitutionGroup="xbrli:item" />
<element name="SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember" substitutionGroup="xbrli:item" />
<element name="SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember" substitutionGroup="xbrli:item" />
<element name="SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2024OneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2024OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2025Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2025Member" substitutionGroup="xbrli:item" />
<element name="SeniorNotesMaturityPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_SeniorNotesMaturityPercentage" substitutionGroup="xbrli:item" />
<element name="SeniorNotesRepaidAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_SeniorNotesRepaidAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentMonthOfMaturity" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_DebtInstrumentMonthOfMaturity" substitutionGroup="xbrli:item" />
<element name="InterestRateIncreaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_InterestRateIncreaseMember" substitutionGroup="xbrli:item" />
<element name="OneTimePremiumPaymentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OneTimePremiumPaymentMember" substitutionGroup="xbrli:item" />
<element name="SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember" substitutionGroup="xbrli:item" />
<element name="PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain" substitutionGroup="xbrli:item" />
<element name="FromSeptemberFifteenthTwoThousandAndTwentySixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember" substitutionGroup="xbrli:item" />
<element name="UnsecuredSyndicatedRevolvingCrediTfacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember" substitutionGroup="xbrli:item" />
<element name="AmendedRevolvingCreditFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AmendedRevolvingCreditFacilityMember" substitutionGroup="xbrli:item" />
<element name="LongTermDebtCurrencyPortionUSD" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LongTermDebtCurrencyPortionUSD" substitutionGroup="xbrli:item" />
<element name="LongTermDebtCurrencyPortionCHF" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LongTermDebtCurrencyPortionCHF" substitutionGroup="xbrli:item" />
<element name="LongTermDebtCurrencyPortionEUR" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LongTermDebtCurrencyPortionEUR" substitutionGroup="xbrli:item" />
<element name="LeverageRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LeverageRatio" substitutionGroup="xbrli:item" />
<element name="LineOfCreditExtensionPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LineOfCreditExtensionPeriod" substitutionGroup="xbrli:item" />
<element name="PeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_PeriodAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PeriodDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_PeriodDomain" substitutionGroup="xbrli:item" />
<element name="TrancheAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TrancheAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TrancheDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TrancheDomain" substitutionGroup="xbrli:item" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems" substitutionGroup="xbrli:item" />
<element name="CrossCurrencySwapCashFlowHedgeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_CrossCurrencySwapCashFlowHedgeMember" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FinancialExpensesNetMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_FinancialExpensesNetMember" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems" substitutionGroup="xbrli:item" />
<element name="NetRevenuesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_NetRevenuesMember" substitutionGroup="xbrli:item" />
<element name="FinancialExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_FinancialExpensesMember" substitutionGroup="xbrli:item" />
<element name="ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RevenuesOtherThanUsd" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_RevenuesOtherThanUsd" substitutionGroup="xbrli:item" />
<element name="CommitmentAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_CommitmentAndContingenciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommitmentAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_CommitmentAndContingenciesLineItems" substitutionGroup="xbrli:item" />
<element name="AnnualSalesOfNiaspan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfNiaspan" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnnualSalesOfActoplus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfActoplus" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DamagesAssessment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_DamagesAssessment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfTheTimeOfNewLaunchOfAtripla" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LossContingenciesOnEnvironmentalLawsPenalty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LossContingenciesOnEnvironmentalLawsPenalty" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LitigationSettlementAmountAwardedDistributionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LitigationSettlementAmountAwardedDistributionPeriod" substitutionGroup="xbrli:item" />
<element name="AnnualSalesOfLamictal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_AnnualSalesOfLamictal" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LitigationSettlementAmountDistributableinKind" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LitigationSettlementAmountDistributableinKind" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfTheTimeOfNewLaunchOfTruvada" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfRevlimid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfRevlimid" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfTheTimeOfSettlementOfTruvada" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfTheTimeOfSettlementOfTruvada" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfTheTimeOfSettlementOfViread" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfTheTimeOfSettlementOfViread" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfActos" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfActos" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnnualSalesAtTimeOfSettlement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_AnnualSalesAtTimeOfSettlement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfEffexor" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfEffexor" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LitigationSettlementAmountDistributableInCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LitigationSettlementAmountDistributableInCash" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfColcrys" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfColcrys" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfTheTimeOfNewLaunchOfViread" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfTheTimeOfNewLaunchOfViread" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LitigationSettlementAmountPayableInCashPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LitigationSettlementAmountPayableInCashPercentage" substitutionGroup="xbrli:item" />
<element name="PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement" substitutionGroup="xbrli:item" />
<element name="PercentageOfThePopulationOfTheParticipatingStates" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_PercentageOfThePopulationOfTheParticipatingStates" substitutionGroup="xbrli:item" />
<element name="PercentageOfShareOfTheNationalPopulation" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_PercentageOfShareOfTheNationalPopulation" substitutionGroup="xbrli:item" />
<element name="AnnualSalesOfSensipar" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfSensipar" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnnualSalesOfEpipen" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfEpipen" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfCopaxone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfCopaxone" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfTheTimeOfSettlementOfAtripla" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfTheTimeOfSettlementOfAtripla" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EosinophilicEsophagitisMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EosinophilicEsophagitisMember" substitutionGroup="xbrli:item" />
<element name="NationwideSettlementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_NationwideSettlementMember" substitutionGroup="xbrli:item" />
<element name="AndroGelRateAtOnePercentageMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AndroGelRateAtOnePercentageMember" substitutionGroup="xbrli:item" />
<element name="DefendantsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DefendantsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DefendantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DefendantsMember" substitutionGroup="xbrli:item" />
<element name="FourOtherDefendantsOtherThanTevaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_FourOtherDefendantsOtherThanTevaMember" substitutionGroup="xbrli:item" />
<element name="CuyahogaCountyOhMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_CuyahogaCountyOhMember" substitutionGroup="xbrli:item" />
<element name="TribesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TribesMember" substitutionGroup="xbrli:item" />
<element name="SanFranciscoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SanFranciscoMember" substitutionGroup="xbrli:item" />
<element name="SummitCountyOhMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SummitCountyOhMember" substitutionGroup="xbrli:item" />
<element name="ContingencySettlementProduct" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ContingencySettlementProduct" substitutionGroup="xbrli:item" />
<element name="ProductWeightedAverageCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ProductWeightedAverageCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProductWeightedAverageCostTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ProductWeightedAverageCostTerm" substitutionGroup="xbrli:item" />
<element name="IncomeTaxTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_IncomeTaxTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_IncomeTaxLineItems" substitutionGroup="xbrli:item" />
<element name="ExpectedImpairmentOfIncomeTaxBenefit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ExpectedImpairmentOfIncomeTaxBenefit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxYear2008To2011Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TaxYear2008To2011Member" substitutionGroup="xbrli:item" />
<element name="YearOfSettlementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_YearOfSettlementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="YearOfSettlementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_YearOfSettlementDomain" substitutionGroup="xbrli:item" />
<element name="RestructuringAndImpairmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RestructuringAndImpairmentAbstract" substitutionGroup="xbrli:item" />
<element name="RestructuringAndImpairmentCostsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RestructuringAndImpairmentCostsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RestructuringAndImpairmentCostsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RestructuringAndImpairmentCostsLineItems" substitutionGroup="xbrli:item" />
<element name="ImpairmentAndRestructuring" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ImpairmentAndRestructuring" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LegalSettlementsLossContingenciesImpairmentsOtherExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ExitAndDisposalAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExitAndDisposalAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ExitAndDisposalDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExitAndDisposalDomain" substitutionGroup="xbrli:item" />
<element name="EmployeeTerminationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EmployeeTerminationMember" substitutionGroup="xbrli:item" />
<element name="OtherExitAndDisposalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherExitAndDisposalMember" substitutionGroup="xbrli:item" />
<element name="UtilizationAndOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_UtilizationAndOther" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RestructuringAccrualProvision" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_RestructuringAccrualProvision" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherOperatingIncomeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OtherOperatingIncomeExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NorthAmericaSegmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_NorthAmericaSegmentMember" substitutionGroup="xbrli:item" />
<element name="EuropeSegmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EuropeSegmentMember" substitutionGroup="xbrli:item" />
<element name="SegmentsAndOtherActivitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SegmentsAndOtherActivitiesMember" substitutionGroup="xbrli:item" />
<element name="AmountsNotAllocatedToSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AmountsNotAllocatedToSegmentsAbstract" substitutionGroup="xbrli:item" />
<element name="OtherUnallocatedAmounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OtherUnallocatedAmounts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AmountsAllocatedToSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AmountsAllocatedToSegmentsAbstract" substitutionGroup="xbrli:item" />
<element name="RevenueTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RevenueTypeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="RevenueTypeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RevenueTypeDomain" substitutionGroup="xbrli:item" />
<element name="RespiratoryProductMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RespiratoryProductMember" substitutionGroup="xbrli:item" />
<element name="AustedoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AustedoMember" substitutionGroup="xbrli:item" />
<element name="AndaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AndaMember" substitutionGroup="xbrli:item" />
<element name="BendekaAndTreandaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_BendekaAndTreandaMember" substitutionGroup="xbrli:item" />
<element name="OtherProductsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherProductsMember" substitutionGroup="xbrli:item" />
<element name="AjovyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AjovyMember" substitutionGroup="xbrli:item" />
<element name="GenericsMediciansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_GenericsMediciansMember" substitutionGroup="xbrli:item" />
<element name="COPAXONEMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_COPAXONEMember" substitutionGroup="xbrli:item" />
<element name="OptionsAndForwardContractsDerivativeLiabilitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" substitutionGroup="xbrli:item" />
<element name="OtherRestrictedCashMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherRestrictedCashMember" substitutionGroup="xbrli:item" />
<element name="MeasurementInputProbabilityOfSuccessMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_MeasurementInputProbabilityOfSuccessMember" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BifurcatedEmbeddedDerivatives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_BifurcatedEmbeddedDerivatives" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EagleTransactionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EagleTransactionMember" substitutionGroup="xbrli:item" />
<element name="ActavisGenericsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ActavisGenericsMember" substitutionGroup="xbrli:item" />
<element name="NovetideTransactionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_NovetideTransactionMember" substitutionGroup="xbrli:item" />
<element name="NoveTideAcquisitionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_NoveTideAcquisitionMember" substitutionGroup="xbrli:item" />
<element name="SeniorNotesAndSustainabilityLinkedSeniorNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" substitutionGroup="xbrli:item" />
<element name="SeniornotesandconvertibleseniordebenturesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniornotesandconvertibleseniordebenturesMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>teva-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 10-May-2023 [04:37:29] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#InventoriesSummaryOfInventoriesDetail" roleURI="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DebtObligationsScheduleOfShortTermDebtDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DebtCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SalesReservesAndAllowances" xlink:label="loc_TEVA_SalesReservesAndAllowances" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_TEVA_SalesReservesAndAllowances" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AccruedExpenses" xlink:label="loc_TEVA_AccruedExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_TEVA_AccruedExpenses" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesNoncurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_LongTermNotesAndLoans" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TreasuryStockValue" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" use="optional" order="21" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="34" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GrossProfit" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SellingAndMarketingExpense" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_IntangibleAssetsImpairments" xlink:label="loc_TEVA_IntangibleAssetsImpairments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_TEVA_IntangibleAssetsImpairments" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_TEVA_ImpairmentsRestructuringAndOthers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_TEVA_ImpairmentsRestructuringAndOthers" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_TEVA_LegalSettlementsAndLossContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_TEVA_LegalSettlementsAndLossContingencies" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="17" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UnrealizedGainLossOnDerivativeNetOfTax" xlink:label="loc_TEVA_UnrealizedGainLossOnDerivativeNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_TEVA_UnrealizedGainLossOnDerivativeNetOfTax" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" use="optional" order="7" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AssetImpairmentCharges" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationAndAmortization" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:label="loc_TEVA_DeferredIncomeTaxesNetAndUncertainTaxPositions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TEVA_DeferredIncomeTaxesNetAndUncertainTaxPositions" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_TEVA_ProfitFromSaleOfLongLivedAssetsAndInvestment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TEVA_ProfitFromSaleOfLongLivedAssetsAndInvestment" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:label="loc_TEVA_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_TEVA_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:label="loc_TEVA_PaymentToAcquireMarketableSecuritiesAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_TEVA_PaymentToAcquireMarketableSecuritiesAndOtherAssets" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" use="optional" order="21" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" use="optional" order="23" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryInTransit" xlink:label="loc_us-gaap_OtherInventoryInTransit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_OtherInventoryInTransit" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="loc_us-gaap_ShortTermBorrowings" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="loc_us-gaap_LongTermDebtCurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail">
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentAndRestructuring" xlink:label="loc_TEVA_ImpairmentAndRestructuring" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_ImpairmentAndRestructuring" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_ImpairmentAndRestructuring" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_ImpairmentAndRestructuring" xlink:to="loc_us-gaap_RestructuringCharges" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:label="loc_TEVA_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_ImpairmentAndRestructuring" xlink:to="loc_TEVA_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" use="optional" order="4" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>teva-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 10-May-2023 [04:37:29] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfIncomeLossParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfChangesInEquity" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfChangesInEquityParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#BasisOfPresentation" roleURI="http://www.tevapharm.com/role/BasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CertainTransactions" roleURI="http://www.tevapharm.com/role/CertainTransactions" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#RevenueFromContractsWithCustomers" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#Inventories" roleURI="http://www.tevapharm.com/role/Inventories" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#IdentifiableIntangibleAssets" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#Goodwill" roleURI="http://www.tevapharm.com/role/Goodwill" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DebtObligations" roleURI="http://www.tevapharm.com/role/DebtObligations" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivities" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#LegalSettlementsAndLossContingencies" roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CommitmentsAndContingencies" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#IncomeTaxes" roleURI="http://www.tevapharm.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#OtherAssetsImpairmentsRestructuringAndOtherItems" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#EarningsLossPerShare" roleURI="http://www.tevapharm.com/role/EarningsLossPerShare" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#Segments" roleURI="http://www.tevapharm.com/role/Segments" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurement" roleURI="http://www.tevapharm.com/role/FairValueMeasurement" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CertainTransactionsTables" roleURI="http://www.tevapharm.com/role/CertainTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#RevenueFromContractsWithCustomersTables" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#InventoriesTables" roleURI="http://www.tevapharm.com/role/InventoriesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#IdentifiableIntangibleAssetsTables" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#GoodwillTables" roleURI="http://www.tevapharm.com/role/GoodwillTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DebtObligationsTables" roleURI="http://www.tevapharm.com/role/DebtObligationsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivitiesTables" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsTables" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#SegmentsTables" roleURI="http://www.tevapharm.com/role/SegmentsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurementTables" roleURI="http://www.tevapharm.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CertainTransactionsOtherTransactionsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#RevenueFromContractsWithCustomersAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#InventoriesSummaryOfInventoriesDetail" roleURI="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#IdentifiableIntangibleAssetsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#GoodwillAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DebtObligationsScheduleOfShortTermDebtDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DebtObligationsScheduleOfSeniorNotesAndLoansDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DebtObligationsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#LegalSettlementsAndLossContingenciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#EarningsLossPerShareAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#AccumulatedOtherComprehensiveIncomeLossDetail" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#SegmentsSummaryOfSegmentProfitDetail" roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#SegmentsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurementAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CoverPage" roleURI="http://www.tevapharm.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_31" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AccruedExpenses" xlink:label="loc_teva_AccruedExpenses_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_teva_AccruedExpenses_59" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_LiabilitiesCurrent_62" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_60" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_DebtCurrent_55" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_57" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SalesReservesAndAllowances" xlink:label="loc_teva_SalesReservesAndAllowances_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_teva_SalesReservesAndAllowances_56" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_MinorityInterest_52" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquityAbstract_35" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_CommonStockValue_68" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_StockholdersEquity_73" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_72" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_TreasuryStockValue_72" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AdditionalPaidInCapital_69" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_Liabilities_51" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_389981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_389981" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_63" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_64" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_66" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_LongTermNotesAndLoans_65" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_CommitmentsAndContingencies_50" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_AssetsAbstract_27" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_36" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_37" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_Assets_41" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_Goodwill_40" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_AssetsCurrentAbstract_28" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_47" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AssetsCurrent_48" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_InventoryNet_44" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_45" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_OtherAssetsCurrent_46" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_43" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_389976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_389976" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_38" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_39" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_StatementTable_34" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_34" xlink:to="loc_dei_LegalEntityAxis_29" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_29" xlink:to="loc_dei_EntityDomain_49" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_49_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_29" xlink:to="loc_dei_EntityDomain_49_default" use="optional" order="47" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_84" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_84" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_83" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_83" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_85" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockSharesIssued_85" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_688255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_688255" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_86" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_TreasuryStockShares_86" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_StatementTable_78" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_78" xlink:to="loc_dei_LegalEntityAxis_76" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_76" xlink:to="loc_dei_EntityDomain_79" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_76" xlink:to="loc_dei_EntityDomain_79_default" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_91" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_408527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_408527" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_109" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_ProfitLoss_113" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GrossProfit_99" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_OperatingIncomeLoss_108" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_IntangibleAssetsImpairments" xlink:label="loc_teva_IntangibleAssetsImpairments_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_IntangibleAssetsImpairments_103" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_92" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_StatementTable_92" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_90" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_92" xlink:to="loc_dei_LegalEntityAxis_90" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_90" xlink:to="loc_dei_EntityDomain_96" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_96_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_90" xlink:to="loc_dei_EntityDomain_96_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_98" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_98" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_89" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_EarningsPerShareAbstract_89" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_95" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_95" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_94" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareBasic_94" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLoss_115" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_SellingAndMarketingExpense_101" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_102" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_119" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_111" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_110" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_107" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_114" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_112" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_100" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies_412170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_LegalSettlementsAndLossContingencies_412170" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2147448878" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2147448891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2147448878" xlink:to="loc_us-gaap_StatementTable_2147448891" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2147448877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2147448891" xlink:to="loc_srt_RangeAxis_2147448877" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2147448876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2147448877" xlink:to="loc_srt_RangeMember_2147448876" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2147448876_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2147448877" xlink:to="loc_srt_RangeMember_2147448876_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2147448875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2147448876" xlink:to="loc_srt_MaximumMember_2147448875" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2147448873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2147448878" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2147448873" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_124" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_131" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UnrealizedGainLossOnDerivativeNetOfTax" xlink:label="loc_teva_UnrealizedGainLossOnDerivativeNetOfTax_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_teva_UnrealizedGainLossOnDerivativeNetOfTax_128" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_720057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_720057" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_127" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_StatementTable_125" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_dei_LegalEntityAxis_122" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_122" xlink:to="loc_dei_EntityDomain_126" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_126_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_122" xlink:to="loc_dei_EntityDomain_126_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ProfitLoss_132" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_133" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_135" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_134" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_141" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_158" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_155" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_SharesIssued_154" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_720066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_ProfitLoss_720066" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_760310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_760310" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_152" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StatementTable_142" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_142" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_140" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_140" xlink:to="loc_us-gaap_EquityComponentDomain_138" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_138_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_140" xlink:to="loc_us-gaap_EquityComponentDomain_138_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_NoncontrollingInterestMember_150" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_145" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_ParentMember_149" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_CommonStockMember_143" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_TreasuryStockMember_148" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_147" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_RetainedEarningsMember_146" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_176" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_181" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_StatementTable_177" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_175" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175" xlink:to="loc_us-gaap_EquityComponentDomain_171" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_171_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175" xlink:to="loc_us-gaap_EquityComponentDomain_171_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_171" xlink:to="loc_us-gaap_CommonStockMember_178" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_472727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" xlink:to="loc_us-gaap_TypeOfAdoptionMember_472727" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_472727_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" xlink:to="loc_us-gaap_TypeOfAdoptionMember_472727_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_srt_RangeAxis_173" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_173" xlink:to="loc_srt_RangeMember_174" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_174_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_173" xlink:to="loc_srt_RangeMember_174_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_174" xlink:to="loc_srt_MaximumMember_180" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_190" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" xlink:to="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables_235" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_ProfitLoss_229" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_AssetImpairmentCharges_193" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_195" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_200" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_DepreciationAndAmortization_194" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:label="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions_196" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_412174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_ShareBasedCompensation_412174" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_515089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_515089" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_230" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_226" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:label="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets_225" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_224" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_228" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables_222" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_555980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_555980" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1260619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1260619" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1260700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1260700" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1260699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1260699" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_221" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2147448882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2147448882" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_211" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_StatementTable_191" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_191" xlink:to="loc_dei_LegalEntityAxis_186" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_186" xlink:to="loc_dei_EntityDomain_210" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_210_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_186" xlink:to="loc_dei_EntityDomain_210_default" use="optional" order="36" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/BasisOfPresentation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_673774" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_673771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_673774" xlink:to="loc_us-gaap_StatementTable_673771" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_671372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_673774" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_671372" use="optional" order="2" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1696" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1696" xlink:to="loc_us-gaap_StatementTable_1697" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1697" xlink:to="loc_dei_LegalEntityAxis_1695" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1695" xlink:to="loc_dei_EntityDomain_1698" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1698_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1695" xlink:to="loc_dei_EntityDomain_1698_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CertainTransactionsDisclosureTextBlock" xlink:label="loc_teva_CertainTransactionsDisclosureTextBlock_1699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1696" xlink:to="loc_teva_CertainTransactionsDisclosureTextBlock_1699" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1797" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1797" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1800" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1797" xlink:to="loc_us-gaap_StatementTable_1798" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1798" xlink:to="loc_dei_LegalEntityAxis_1796" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1796" xlink:to="loc_dei_EntityDomain_1799" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1799_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1796" xlink:to="loc_dei_EntityDomain_1799_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Inventories">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1741" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1741" xlink:to="loc_us-gaap_StatementTable_1742" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1742" xlink:to="loc_dei_LegalEntityAxis_1740" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1740" xlink:to="loc_dei_EntityDomain_1743" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1743_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1740" xlink:to="loc_dei_EntityDomain_1743_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1741" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1744" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1783" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1783" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1786" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1783" xlink:to="loc_us-gaap_StatementTable_1784" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1784" xlink:to="loc_dei_LegalEntityAxis_1782" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1782" xlink:to="loc_dei_EntityDomain_1785" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1785_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1782" xlink:to="loc_dei_EntityDomain_1785_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Goodwill">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1769" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_1772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1769" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_1772" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1769" xlink:to="loc_us-gaap_StatementTable_1770" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1770" xlink:to="loc_dei_LegalEntityAxis_1768" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1768" xlink:to="loc_dei_EntityDomain_1771" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1771_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1768" xlink:to="loc_dei_EntityDomain_1771_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1826" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1826" xlink:to="loc_us-gaap_StatementTable_1827" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1827" xlink:to="loc_dei_LegalEntityAxis_1825" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1825" xlink:to="loc_dei_EntityDomain_1828" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1828_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1825" xlink:to="loc_dei_EntityDomain_1828_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1826" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1829" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1903" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1903" xlink:to="loc_us-gaap_StatementTable_1904" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1904" xlink:to="loc_dei_LegalEntityAxis_1902" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1902" xlink:to="loc_dei_EntityDomain_1905" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1905_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1902" xlink:to="loc_dei_EntityDomain_1905_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1903" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1906" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1949" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1949" xlink:to="loc_us-gaap_StatementTable_1950" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1950" xlink:to="loc_dei_LegalEntityAxis_1948" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1948" xlink:to="loc_dei_EntityDomain_1951" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1951_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1948" xlink:to="loc_dei_EntityDomain_1951_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1949" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1952" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1856" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1856" xlink:to="loc_us-gaap_StatementTable_1857" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1857" xlink:to="loc_dei_LegalEntityAxis_1855" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1855" xlink:to="loc_dei_EntityDomain_1858" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1858_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1855" xlink:to="loc_dei_EntityDomain_1858_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1856" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1859" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1884" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1884" xlink:to="loc_us-gaap_StatementTable_1885" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1885" xlink:to="loc_dei_LegalEntityAxis_1883" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1883" xlink:to="loc_dei_EntityDomain_1886" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1886_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1883" xlink:to="loc_dei_EntityDomain_1886_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1884" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1887" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1933" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherExpensesTextBlock" xlink:label="loc_teva_OtherExpensesTextBlock_1936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1933" xlink:to="loc_teva_OtherExpensesTextBlock_1936" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1933" xlink:to="loc_us-gaap_StatementTable_1934" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1934" xlink:to="loc_dei_LegalEntityAxis_1932" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1932" xlink:to="loc_dei_EntityDomain_1935" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1935_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1932" xlink:to="loc_dei_EntityDomain_1935_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1974" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1974" xlink:to="loc_us-gaap_StatementTable_1975" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1975" xlink:to="loc_dei_LegalEntityAxis_1973" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1973" xlink:to="loc_dei_EntityDomain_1976" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1976_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1973" xlink:to="loc_dei_EntityDomain_1976_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1974" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1977" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390015" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_390015" xlink:to="loc_us-gaap_StatementTable_390014" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390014" xlink:to="loc_dei_LegalEntityAxis_390018" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_390018" xlink:to="loc_dei_EntityDomain_390019" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390019_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_390018" xlink:to="loc_dei_EntityDomain_390019_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_390022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390015" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_390022" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Segments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1956" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1956" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1959" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1956" xlink:to="loc_us-gaap_StatementTable_1957" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1957" xlink:to="loc_dei_LegalEntityAxis_1955" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1955" xlink:to="loc_dei_EntityDomain_1958" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1958_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1955" xlink:to="loc_dei_EntityDomain_1958_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1710" xlink:to="loc_us-gaap_StatementTable_1711" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1711" xlink:to="loc_dei_LegalEntityAxis_1709" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1709" xlink:to="loc_dei_EntityDomain_1712" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1712_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1709" xlink:to="loc_dei_EntityDomain_1712_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1713" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1661" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1665" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_514943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_514943" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_StatementTable_1662" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1662" xlink:to="loc_dei_LegalEntityAxis_1660" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1660" xlink:to="loc_dei_EntityDomain_1663" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1663_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1660" xlink:to="loc_dei_EntityDomain_1663_default" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1703" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1703" xlink:to="loc_us-gaap_StatementTable_1704" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1704" xlink:to="loc_dei_LegalEntityAxis_1702" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1702" xlink:to="loc_dei_EntityDomain_1705" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1705_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1702" xlink:to="loc_dei_EntityDomain_1705_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:label="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1703" xlink:to="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1706" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1804" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SalesReservesAndAllowancesCurrentTableTextBlock" xlink:label="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock_1808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock_1808" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_us-gaap_StatementTable_1805" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1805" xlink:to="loc_dei_LegalEntityAxis_1803" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1803" xlink:to="loc_dei_EntityDomain_1806" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1806_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1803" xlink:to="loc_dei_EntityDomain_1806_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1807" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1748" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1748" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1751" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1748" xlink:to="loc_us-gaap_StatementTable_1749" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1749" xlink:to="loc_dei_LegalEntityAxis_1747" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1747" xlink:to="loc_dei_EntityDomain_1750" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1750_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1747" xlink:to="loc_dei_EntityDomain_1750_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1790" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1790" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1793" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1790" xlink:to="loc_us-gaap_StatementTable_1791" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1791" xlink:to="loc_dei_LegalEntityAxis_1789" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1789" xlink:to="loc_dei_EntityDomain_1792" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1792_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1789" xlink:to="loc_dei_EntityDomain_1792_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1776" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_1779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1776" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_1779" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1776" xlink:to="loc_us-gaap_StatementTable_1777" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1777" xlink:to="loc_dei_LegalEntityAxis_1775" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1775" xlink:to="loc_dei_EntityDomain_1778" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1778_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1775" xlink:to="loc_dei_EntityDomain_1778_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1833" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xlink:label="loc_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock_1837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock_1837" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_1836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_1836" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_us-gaap_StatementTable_1834" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1834" xlink:to="loc_dei_LegalEntityAxis_1832" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1832" xlink:to="loc_dei_EntityDomain_1835" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1835_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1832" xlink:to="loc_dei_EntityDomain_1835_default" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1910" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_406869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_406869" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_StatementTable_1911" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1911" xlink:to="loc_dei_LegalEntityAxis_1909" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1909" xlink:to="loc_dei_EntityDomain_1912" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1912_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1909" xlink:to="loc_dei_EntityDomain_1912_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock" xlink:label="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock_2147448865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock_2147448865" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock" xlink:label="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock_2147448849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock_2147448849" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1914" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1940" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ScheduleOfRestructuringChargesTableTextBlock" xlink:label="loc_teva_ScheduleOfRestructuringChargesTableTextBlock_1944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_teva_ScheduleOfRestructuringChargesTableTextBlock_1944" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_StatementTable_1941" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1941" xlink:to="loc_dei_LegalEntityAxis_1939" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1939" xlink:to="loc_dei_EntityDomain_1942" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1942_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1939" xlink:to="loc_dei_EntityDomain_1942_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1943" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1945" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390179" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390179" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390181" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_390179" xlink:to="loc_us-gaap_StatementTable_390175" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390175" xlink:to="loc_dei_LegalEntityAxis_390177" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_390177" xlink:to="loc_dei_EntityDomain_390178" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390178_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_390177" xlink:to="loc_dei_EntityDomain_390178_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1963" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_1968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_1968" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1966" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xlink:label="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock_1967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock_1967" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_StatementTable_1964" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1964" xlink:to="loc_dei_LegalEntityAxis_1962" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1962" xlink:to="loc_dei_EntityDomain_1965" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1965_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1962" xlink:to="loc_dei_EntityDomain_1965_default" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1717" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1722" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1721" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_StatementTable_1718" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1718" xlink:to="loc_dei_LegalEntityAxis_1716" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1716" xlink:to="loc_dei_EntityDomain_1719" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1719_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1716" xlink:to="loc_dei_EntityDomain_1719_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1720" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MilestonePayment" xlink:label="loc_teva_MilestonePayment_572506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_MilestonePayment_572506" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UpfrontPayments" xlink:label="loc_teva_UpfrontPayments_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_UpfrontPayments_326" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CollaborativeAgreementMilestonePayments" xlink:label="loc_teva_CollaborativeAgreementMilestonePayments_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_CollaborativeAgreementMilestonePayments_327" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsTable" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_dei_LegalEntityAxis_304" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_304" xlink:to="loc_dei_EntityDomain_319" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_319_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_304" xlink:to="loc_dei_EntityDomain_319_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_CounterpartyNameAxis_303" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_303" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_303" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_ProductOrServiceAxis_307" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_307" xlink:to="loc_srt_ProductsAndServicesDomain_308" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_308_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_307" xlink:to="loc_srt_ProductsAndServicesDomain_308_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" xlink:to="loc_us-gaap_RelatedPartyDomain_309" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_309_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" xlink:to="loc_us-gaap_RelatedPartyDomain_309_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_RangeAxis_765341" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_765341" xlink:to="loc_srt_RangeMember_765342" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765342_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_765341" xlink:to="loc_srt_RangeMember_765342_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_758266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_758266" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_758267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_758266" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_758267" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_758267_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_758266" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_758267_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_758268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_758267" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_758268" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_758271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_LeaseContractualTermAxis_758271" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_758272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_758271" xlink:to="loc_us-gaap_LeaseContractualTermDomain_758272" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_758272_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_758271" xlink:to="loc_us-gaap_LeaseContractualTermDomain_758272_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_302" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_302" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_302" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AlvotechMember" xlink:label="loc_teva_AlvotechMember_758265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_AlvotechMember_758265" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtsukaMember" xlink:label="loc_teva_OtsukaMember_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_OtsukaMember_314" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ModagMember" xlink:label="loc_teva_ModagMember_1241734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_ModagMember_1241734" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MedincellMember" xlink:label="loc_teva_MedincellMember_1241907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_MedincellMember_1241907" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TakedaMember" xlink:label="loc_teva_TakedaMember_2147449570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_TakedaMember_2147449570" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1241737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1241737" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1241738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1241737" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1241738" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1241738_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1241737" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1241738_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xlink:label="loc_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount_1241741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount_1241741" use="optional" order="38" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems_607" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableFromSecuritization" xlink:label="loc_us-gaap_AccountsReceivableFromSecuritization_2147468965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_607" xlink:to="loc_us-gaap_AccountsReceivableFromSecuritization_2147468965" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SalesReservesAndAllowancesToCustomersPercentage" xlink:label="loc_teva_SalesReservesAndAllowancesToCustomersPercentage_616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_607" xlink:to="loc_teva_SalesReservesAndAllowancesToCustomersPercentage_616" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_RevenueRecognitionLineItems_607" xlink:to="loc_teva_RevenueRecognitionTable_608" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_dei_LegalEntityAxis_604" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_604" xlink:to="loc_dei_EntityDomain_611" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_611_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_604" xlink:to="loc_dei_EntityDomain_611_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis" xlink:label="loc_us-gaap_PledgingPurposeAxis_2147468956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_us-gaap_PledgingPurposeAxis_2147468956" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="loc_us-gaap_PledgingPurposeDomain_2147468957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PledgingPurposeAxis_2147468956" xlink:to="loc_us-gaap_PledgingPurposeDomain_2147468957" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="loc_us-gaap_PledgingPurposeDomain_2147468957_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PledgingPurposeAxis_2147468956" xlink:to="loc_us-gaap_PledgingPurposeDomain_2147468957_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member" xlink:label="loc_teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member_2147468962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PledgingPurposeDomain_2147468957" xlink:to="loc_teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member_2147468962" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FactoringInstitutionAxis" xlink:label="loc_teva_FactoringInstitutionAxis_2147448888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_teva_FactoringInstitutionAxis_2147448888" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FactoringInstitutionDomain" xlink:label="loc_teva_FactoringInstitutionDomain_2147448887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_FactoringInstitutionAxis_2147448888" xlink:to="loc_teva_FactoringInstitutionDomain_2147448887" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FactoringInstitutionDomain" xlink:label="loc_teva_FactoringInstitutionDomain_2147448887_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_FactoringInstitutionAxis_2147448888" xlink:to="loc_teva_FactoringInstitutionDomain_2147448887_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PncBankMember" xlink:label="loc_teva_PncBankMember_2147448886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_FactoringInstitutionDomain_2147448887" xlink:to="loc_teva_PncBankMember_2147448886" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_srt_StatementGeographicalAxis_610" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_610" xlink:to="loc_srt_SegmentGeographicalDomain_609" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_609_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_610" xlink:to="loc_srt_SegmentGeographicalDomain_609_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_609" xlink:to="loc_country_US_617" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448885" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2147448884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448885" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2147448884" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2147448884_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448885" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2147448884_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AccountsReceivableSecuritizationFacilityMember" xlink:label="loc_teva_AccountsReceivableSecuritizationFacilityMember_2147448883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2147448884" xlink:to="loc_teva_AccountsReceivableSecuritizationFacilityMember_2147448883" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_620" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_620" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_621" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_srt_StatementGeographicalAxis_628" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_628" xlink:to="loc_srt_SegmentGeographicalDomain_626" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_626_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_628" xlink:to="loc_srt_SegmentGeographicalDomain_626_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_626" xlink:to="loc_srt_NorthAmericaMember_637" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_626" xlink:to="loc_srt_EuropeMember_638" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_dei_LegalEntityAxis_622" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_622" xlink:to="loc_dei_EntityDomain_630" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_630_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_622" xlink:to="loc_dei_EntityDomain_630_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_627" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_627" xlink:to="loc_us-gaap_SegmentDomain_625" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_625_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_627" xlink:to="loc_us-gaap_SegmentDomain_625_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_625" xlink:to="loc_teva_InternationalMarketsMember_635" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherActivitiesMember" xlink:label="loc_teva_OtherActivitiesMember_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_625" xlink:to="loc_teva_OtherActivitiesMember_636" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_srt_ProductOrServiceAxis_623" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_623" xlink:to="loc_srt_ProductsAndServicesDomain_624" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_624_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_623" xlink:to="loc_srt_ProductsAndServicesDomain_624_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_634" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionServiceMember" xlink:label="loc_us-gaap_DistributionServiceMember_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_DistributionServiceMember_633" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_ProductMember_631" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_LicenseMember_632" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_620" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_629" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail">
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems_642" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xlink:label="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation_651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation_651" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_647" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_RevenueRecognitionTable_643" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_dei_LegalEntityAxis_641" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_641" xlink:to="loc_dei_EntityDomain_646" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_646_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_641" xlink:to="loc_dei_EntityDomain_646_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_644_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_644_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RebatesMember" xlink:label="loc_teva_RebatesMember_654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_RebatesMember_654" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ReturnsMember" xlink:label="loc_teva_ReturnsMember_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ReturnsMember_657" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MedicaidAndOtherGovernmentalAllowancesMember" xlink:label="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember_655" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ReservesIncludedInAccountsReceivableNetMember" xlink:label="loc_teva_ReservesIncludedInAccountsReceivableNetMember_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ReservesIncludedInAccountsReceivableNetMember_653" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ChargebacksMember" xlink:label="loc_teva_ChargebacksMember_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ChargebacksMember_656" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xlink:label="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember_659" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherSalesReservesAndAllowancesMember" xlink:label="loc_teva_OtherSalesReservesAndAllowancesMember_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_OtherSalesReservesAndAllowancesMember_658" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_650" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales_648" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales_649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales_649" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail">
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InventoriesLineItems" xlink:label="loc_teva_InventoriesLineItems_452" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_457" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_456" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InventoriesTable" xlink:label="loc_teva_InventoriesTable_453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_teva_InventoriesTable_453" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_InventoriesTable_453" xlink:to="loc_dei_LegalEntityAxis_454" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_454" xlink:to="loc_dei_EntityDomain_460" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_460_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_454" xlink:to="loc_dei_EntityDomain_460_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryInTransit" xlink:label="loc_us-gaap_OtherInventoryInTransit_458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_OtherInventoryInTransit_458" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryNet_459" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_455" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_565" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_564" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_566" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_teva_ProductRightsMember_567" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_us-gaap_TradeNamesMember_568" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_569" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_587" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_588" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DiscontinuationOfBusinessAxis" xlink:label="loc_teva_DiscontinuationOfBusinessAxis_581599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_DiscontinuationOfBusinessAxis_581599" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DiscontinuationOfBusinessDomain" xlink:label="loc_teva_DiscontinuationOfBusinessDomain_581600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_DiscontinuationOfBusinessAxis_581599" xlink:to="loc_teva_DiscontinuationOfBusinessDomain_581600" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DiscontinuationOfBusinessDomain" xlink:label="loc_teva_DiscontinuationOfBusinessDomain_581600_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_DiscontinuationOfBusinessAxis_581599" xlink:to="loc_teva_DiscontinuationOfBusinessDomain_581600_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_764554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_764554" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_764555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_764554" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_764555" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_764555_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_764554" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_764555_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_764556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_764555" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_764556" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_574" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_574" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_574" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_408202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_ProductOrServiceAxis_408202" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_408203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_408202" xlink:to="loc_srt_ProductsAndServicesDomain_408203" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_408203_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_408202" xlink:to="loc_srt_ProductsAndServicesDomain_408203_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_GenericPipelineProductsMember" xlink:label="loc_teva_GenericPipelineProductsMember_473346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_408203" xlink:to="loc_teva_GenericPipelineProductsMember_473346" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LenalidomideProductMember" xlink:label="loc_teva_LenalidomideProductMember_408205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_408203" xlink:to="loc_teva_LenalidomideProductMember_408205" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_StatementGeographicalAxis_581" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_581" xlink:to="loc_srt_SegmentGeographicalDomain_580" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_580_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_581" xlink:to="loc_srt_SegmentGeographicalDomain_580_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="loc_country_JP_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_580" xlink:to="loc_country_JP_601" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_764548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_RangeAxis_764548" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_764549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_764548" xlink:to="loc_srt_RangeMember_764549" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_764549_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_764548" xlink:to="loc_srt_RangeMember_764549_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_764551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_764549" xlink:to="loc_srt_MaximumMember_764551" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_764550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_764549" xlink:to="loc_srt_MinimumMember_764550" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_597" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" xlink:to="loc_teva_ProductRightsMember_598" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_dei_LegalEntityAxis_578" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_578" xlink:to="loc_dei_EntityDomain_599" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_599_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_578" xlink:to="loc_dei_EntityDomain_599_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis" xlink:label="loc_us-gaap_ReclassificationTypeAxis_1261963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_ReclassificationTypeAxis_1261963" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain" xlink:label="loc_us-gaap_ReclassificationTypeDomain_1261964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationTypeAxis_1261963" xlink:to="loc_us-gaap_ReclassificationTypeDomain_1261964" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain" xlink:label="loc_us-gaap_ReclassificationTypeDomain_1261964_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationTypeAxis_1261963" xlink:to="loc_us-gaap_ReclassificationTypeDomain_1261964_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EventBasisAxis" xlink:label="loc_teva_EventBasisAxis_2147473654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_EventBasisAxis_2147473654" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EventBasisDomain" xlink:label="loc_teva_EventBasisDomain_2147473655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_EventBasisAxis_2147473654" xlink:to="loc_teva_EventBasisDomain_2147473655" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EventBasisDomain" xlink:label="loc_teva_EventBasisDomain_2147473655_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_EventBasisAxis_2147473654" xlink:to="loc_teva_EventBasisDomain_2147473655_default" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UpdatedMarketAssumptionsMember" xlink:label="loc_teva_UpdatedMarketAssumptionsMember_2147473656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_EventBasisDomain_2147473655" xlink:to="loc_teva_UpdatedMarketAssumptionsMember_2147473656" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PriceAndVolumeOfProductsMember" xlink:label="loc_teva_PriceAndVolumeOfProductsMember_2147448879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_EventBasisDomain_2147473655" xlink:to="loc_teva_PriceAndVolumeOfProductsMember_2147448879" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RegulatoryPriceAndVolumeOfProductsMember" xlink:label="loc_teva_RegulatoryPriceAndVolumeOfProductsMember_2147448881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_EventBasisDomain_2147473655" xlink:to="loc_teva_RegulatoryPriceAndVolumeOfProductsMember_2147448881" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember" xlink:label="loc_teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember_2147448880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_EventBasisDomain_2147473655" xlink:to="loc_teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember_2147448880" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_596" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_764546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_764546" use="optional" order="50" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_499" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_501" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_391588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_srt_ConsolidationItemsAxis_391588" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_391589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_391588" xlink:to="loc_srt_ConsolidationItemsDomain_391589" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_391589_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_391588" xlink:to="loc_srt_ConsolidationItemsDomain_391589_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_dei_LegalEntityAxis_500" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_500" xlink:to="loc_dei_EntityDomain_514" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_514_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_500" xlink:to="loc_dei_EntityDomain_514_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_2147448872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_us-gaap_ReportingUnitAxis_2147448872" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_2147448871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_2147448872" xlink:to="loc_us-gaap_ReportingUnitDomain_2147448871" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_2147448871_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_2147448872" xlink:to="loc_us-gaap_ReportingUnitDomain_2147448871_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TevasApiReportingUnitMember" xlink:label="loc_teva_TevasApiReportingUnitMember_2147448870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_2147448871" xlink:to="loc_teva_TevasApiReportingUnitMember_2147448870" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MedisReportingUnitMember" xlink:label="loc_teva_MedisReportingUnitMember_2147448869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_2147448871" xlink:to="loc_teva_MedisReportingUnitMember_2147448869" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_504" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_504" xlink:to="loc_us-gaap_SegmentDomain_502" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_502_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_504" xlink:to="loc_us-gaap_SegmentDomain_502_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_srt_StatementGeographicalAxis_505" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_505" xlink:to="loc_srt_SegmentGeographicalDomain_503" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_503_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_505" xlink:to="loc_srt_SegmentGeographicalDomain_503_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_srt_EuropeMember_519" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_teva_InternationalMarketsMember_520" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherCountriesMember" xlink:label="loc_teva_OtherCountriesMember_521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_teva_OtherCountriesMember_521" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_srt_NorthAmericaMember_518" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_Goodwill_506" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_511" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_524" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_524" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_527" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_524" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_526" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_526" xlink:to="loc_dei_LegalEntityAxis_525" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_525" xlink:to="loc_dei_EntityDomain_528" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_528_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_525" xlink:to="loc_dei_EntityDomain_528_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_2147471385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_526" xlink:to="loc_us-gaap_ReportingUnitAxis_2147471385" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_2147471386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_2147471385" xlink:to="loc_us-gaap_ReportingUnitDomain_2147471386" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_2147471386_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_2147471385" xlink:to="loc_us-gaap_ReportingUnitDomain_2147471386_default" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_531" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_536" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_RangeAxis_533" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_533" xlink:to="loc_srt_RangeMember_534" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_534_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_533" xlink:to="loc_srt_RangeMember_534_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_539" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_539" xlink:to="loc_us-gaap_SegmentDomain_537" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_537_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_539" xlink:to="loc_us-gaap_SegmentDomain_537_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_StatementGeographicalAxis_540" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_540" xlink:to="loc_srt_SegmentGeographicalDomain_538" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_538_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_540" xlink:to="loc_srt_SegmentGeographicalDomain_538_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_2147450324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_ReportingUnitAxis_2147450324" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_2147450325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_2147450324" xlink:to="loc_us-gaap_ReportingUnitDomain_2147450325" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_2147450325_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_2147450324" xlink:to="loc_us-gaap_ReportingUnitDomain_2147450325_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_dei_LegalEntityAxis_532" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_532" xlink:to="loc_dei_EntityDomain_545" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_545_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_532" xlink:to="loc_dei_EntityDomain_545_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_556283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_StatementScenarioAxis_556283" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_556284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_556283" xlink:to="loc_srt_ScenarioUnspecifiedDomain_556284" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_556284_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_556283" xlink:to="loc_srt_ScenarioUnspecifiedDomain_556284_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_2147449567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_2147449567" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2147449568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2147449567" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2147449568" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2147449568_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2147449567" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2147449568_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EuropeReportingUnitMember" xlink:label="loc_teva_EuropeReportingUnitMember_2147449633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2147449568" xlink:to="loc_teva_EuropeReportingUnitMember_2147449633" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_412047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_412047" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_688" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_695" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtInstrumentTable_690" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_srt_CurrencyAxis_686" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_686" xlink:to="loc_currency_AllCurrenciesDomain_685" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_685_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_686" xlink:to="loc_currency_AllCurrenciesDomain_685_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_dei_LegalEntityAxis_691" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_691" xlink:to="loc_dei_EntityDomain_705" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_705_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_691" xlink:to="loc_dei_EntityDomain_705_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_504448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_CreditFacilityAxis_504448" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_504449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_504448" xlink:to="loc_us-gaap_CreditFacilityDomain_504449" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_504449_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_504448" xlink:to="loc_us-gaap_CreditFacilityDomain_504449_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_VariableRateAxis_692" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_692" xlink:to="loc_us-gaap_VariableRateDomain_693" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_693_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_692" xlink:to="loc_us-gaap_VariableRateDomain_693_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_DebtInstrumentAxis_687" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_687" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_687" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ShortCreditAgreement2026Member" xlink:label="loc_teva_ShortCreditAgreement2026Member_704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689" xlink:to="loc_teva_ShortCreditAgreement2026Member_704" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_LongTermDebtCurrent_700" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_teva_DebtInstrumentMaturityYear_698" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_ShortTermBorrowings_699" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtCurrent_701" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_762" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongTermNotesAndLoans_781" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_769" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_teva_DebtInstrumentMaturityYear_772" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_DebtInstrumentTable_764" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_DebtInstrumentAxis_761" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_761" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_763" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_763_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_761" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_763_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2036Member_799" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member_787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028Member_787" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028OneMember_797" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572204" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2026OneMember_790" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2029Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260379" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2027Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260377" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024Member_783" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_804" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023OneMember_784" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022OneMember_788" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_673253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_673253" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2030Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member_1260375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member_1260375" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherDebentures2026Member" xlink:label="loc_teva_OtherDebentures2026Member_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_OtherDebentures2026Member_814" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260378" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2046Member_794" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572603" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember_2147448833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember_2147448833" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember_2147448831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember_2147448831" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember_2147448830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember_2147448830" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember_2147448829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember_2147448829" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024OneMember_796" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025Member_786" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_VariableRateAxis_766" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_766" xlink:to="loc_us-gaap_VariableRateDomain_767" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_767_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_766" xlink:to="loc_us-gaap_VariableRateDomain_767_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_dei_LegalEntityAxis_765" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_765" xlink:to="loc_dei_EntityDomain_815" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_815_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_765" xlink:to="loc_dei_EntityDomain_815_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_srt_CurrencyAxis_760" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_760" xlink:to="loc_currency_AllCurrenciesDomain_759" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_759_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_760" xlink:to="loc_currency_AllCurrenciesDomain_759_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongTermDebtCurrent_778" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_780" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_SeniorNotes_775" use="optional" order="42" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_820" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SeniorNotesMaturityPercentage" xlink:label="loc_teva_SeniorNotesMaturityPercentage_2147450882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_teva_SeniorNotesMaturityPercentage_2147450882" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentTable_822" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2147450841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_srt_RangeAxis_2147450841" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2147450842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2147450841" xlink:to="loc_srt_RangeMember_2147450842" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2147450842_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2147450841" xlink:to="loc_srt_RangeMember_2147450842_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2147450843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2147450842" xlink:to="loc_srt_MaximumMember_2147450843" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2147450844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2147450842" xlink:to="loc_srt_MinimumMember_2147450844" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2147450878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2147450878" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2147450880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2147450878" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2147450880" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2147450880_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2147450878" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2147450880_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_2147450881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2147450880" xlink:to="loc_us-gaap_SeniorNotesMember_2147450881" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_DebtInstrumentAxis_819" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_819" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_821" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_821_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_819" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_821_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember_833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2026OneMember_833" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_847" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member_826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024Member_826" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member_829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025Member_829" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member_842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2036Member_842" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2029Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260400" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2027Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260398" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InterestRateIncreaseMember" xlink:label="loc_teva_InterestRateIncreaseMember_2147450851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_InterestRateIncreaseMember_2147450851" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember_839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024OneMember_839" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member_830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028Member_830" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028OneMember_840" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember_827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023OneMember_827" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572210" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260399" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2030Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member_1260397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member_1260397" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember_831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022OneMember_831" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_835" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember_2147448802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember_2147448802" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember_2147448801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember_2147448801" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember_2147448800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember_2147448800" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember_2147448799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember_2147448799" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OneTimePremiumPaymentMember" xlink:label="loc_teva_OneTimePremiumPaymentMember_2147450854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_OneTimePremiumPaymentMember_2147450854" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572208" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2046Member_837" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember" xlink:label="loc_teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember_2147448789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember_2147448789" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" xlink:label="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_2147448795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_2147448795" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain" xlink:label="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain_2147448794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_2147448795" xlink:to="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain_2147448794" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain" xlink:label="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain_2147448794_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_2147448795" xlink:to="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain_2147448794_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember" xlink:label="loc_teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember_2147448793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain_2147448794" xlink:to="loc_teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember_2147448793" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2147450840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2147450840" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_824" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SeniorNotesRepaidAmount" xlink:label="loc_teva_SeniorNotesRepaidAmount_2147450867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_teva_SeniorNotesRepaidAmount_2147450867" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_2147448797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_2147448797" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DebtInstrumentMonthOfMaturity" xlink:label="loc_teva_DebtInstrumentMonthOfMaturity_2147448796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_teva_DebtInstrumentMonthOfMaturity_2147448796" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_2147450853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_2147450853" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_2147448792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_2147448792" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_2147448791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_2147448791" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_2147448790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_2147448790" use="optional" order="52" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_722" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_732" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription_466634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentCovenantDescription_466634" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LongTermDebtCurrencyPortionUSD" xlink:label="loc_teva_LongTermDebtCurrencyPortionUSD_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionUSD_739" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentTable_724" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_CreditFacilityAxis_719" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_719" xlink:to="loc_us-gaap_CreditFacilityDomain_720" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_720_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_719" xlink:to="loc_us-gaap_CreditFacilityDomain_720_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_720" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_728" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember" xlink:label="loc_teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember_2147450329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_720" xlink:to="loc_teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember_2147450329" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_DebtInstrumentAxis_721" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_721" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_723" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_723_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_721" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_723_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AmendedRevolvingCreditFacilityMember" xlink:label="loc_teva_AmendedRevolvingCreditFacilityMember_2147468973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_723" xlink:to="loc_teva_AmendedRevolvingCreditFacilityMember_2147468973" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_dei_LegalEntityAxis_725" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_725" xlink:to="loc_dei_EntityDomain_755" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_755_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_725" xlink:to="loc_dei_EntityDomain_755_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_726" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_726" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_727" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_727_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_726" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_727_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_727" xlink:to="loc_us-gaap_ConvertibleDebtMember_756" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_408262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_408262" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_408264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_408262" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_408264" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_408264_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_408262" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_408264_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_srt_RangeAxis_765345" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_765345" xlink:to="loc_srt_RangeMember_765346" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765346_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_765345" xlink:to="loc_srt_RangeMember_765346_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodAxis" xlink:label="loc_teva_PeriodAxis_2147450317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_teva_PeriodAxis_2147450317" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodDomain" xlink:label="loc_teva_PeriodDomain_2147450318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_PeriodAxis_2147450317" xlink:to="loc_teva_PeriodDomain_2147450318" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodDomain" xlink:label="loc_teva_PeriodDomain_2147450318_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_PeriodAxis_2147450317" xlink:to="loc_teva_PeriodDomain_2147450318_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_682892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_682892" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_682892" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_682892" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_466637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_466637" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_466638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_466637" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_466638" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_466638_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_466637" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_466638_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_466640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_466638" xlink:to="loc_us-gaap_SubsequentEventMember_466640" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TrancheAxis" xlink:label="loc_teva_TrancheAxis_682383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_teva_TrancheAxis_682383" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TrancheDomain" xlink:label="loc_teva_TrancheDomain_682384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_TrancheAxis_682383" xlink:to="loc_teva_TrancheDomain_682384" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TrancheDomain" xlink:label="loc_teva_TrancheDomain_682384_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_TrancheAxis_682383" xlink:to="loc_teva_TrancheDomain_682384_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AgreementAxis" xlink:label="loc_teva_AgreementAxis_1280331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_teva_AgreementAxis_1280331" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain_1280332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_AgreementAxis_1280331" xlink:to="loc_teva_AgreementDomain_1280332" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain_1280332_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_AgreementAxis_1280331" xlink:to="loc_teva_AgreementDomain_1280332_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LongTermDebtCurrencyPortionCHF" xlink:label="loc_teva_LongTermDebtCurrencyPortionCHF_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionCHF_741" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_735" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LongTermDebtCurrencyPortionEUR" xlink:label="loc_teva_LongTermDebtCurrencyPortionEUR_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionEUR_740" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_466635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LineOfCredit_466635" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1241835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1241835" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LeverageRatio" xlink:label="loc_teva_LeverageRatio_2147450347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LeverageRatio_2147450347" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_682881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_682881" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LineOfCreditExtensionPeriod" xlink:label="loc_teva_LineOfCreditExtensionPeriod_2147450333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LineOfCreditExtensionPeriod_2147450333" use="optional" order="50" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail">
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems" xlink:label="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems_2147448855" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_2147448854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems_2147448855" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_2147448854" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable" xlink:label="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable_2147448862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems_2147448855" xlink:to="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable_2147448862" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_2147448858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable_2147448862" xlink:to="loc_us-gaap_HedgingDesignationAxis_2147448858" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_2147448857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_2147448858" xlink:to="loc_us-gaap_HedgingDesignationDomain_2147448857" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_2147448857_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_2147448858" xlink:to="loc_us-gaap_HedgingDesignationDomain_2147448857_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2147448856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2147448857" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2147448856" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable_2147448862" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448861" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2147448860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448861" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2147448860" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2147448860_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448861" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2147448860_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CrossCurrencySwapCashFlowHedgeMember" xlink:label="loc_teva_CrossCurrencySwapCashFlowHedgeMember_2147448859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2147448860" xlink:to="loc_teva_CrossCurrencySwapCashFlowHedgeMember_2147448859" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1339" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeTable_1340" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1336" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1336_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1336_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1336" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1348" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CrossCurrencySwapCashFlowHedgeMember" xlink:label="loc_teva_CrossCurrencySwapCashFlowHedgeMember_2147448851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1336" xlink:to="loc_teva_CrossCurrencySwapCashFlowHedgeMember_2147448851" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1334" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1334" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1335" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1335_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1334" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1335_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1347" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1345" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_390198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_390198" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1343" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1343_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1343_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_dei_LegalEntityAxis_1344" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1344" xlink:to="loc_dei_EntityDomain_1357" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1357_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1344" xlink:to="loc_dei_EntityDomain_1357_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_1341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_HedgingDesignationAxis_1341" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_1341" xlink:to="loc_us-gaap_HedgingDesignationDomain_1342" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1342_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_1341" xlink:to="loc_us-gaap_HedgingDesignationDomain_1342_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1342" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1353" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_1354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1342" xlink:to="loc_us-gaap_NondesignatedMember_1354" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1352" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1351" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail">
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems" xlink:label="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems_2147448836" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments" xlink:label="loc_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments_2147448835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems_2147448836" xlink:to="loc_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments_2147448835" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_2147448834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems_2147448836" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_2147448834" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable" xlink:label="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable_2147448846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems_2147448836" xlink:to="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable_2147448846" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2147448839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable_2147448846" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2147448839" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2147448838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2147448839" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2147448838" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2147448838_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2147448839" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2147448838_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FinancialExpensesNetMember" xlink:label="loc_teva_FinancialExpensesNetMember_2147448837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2147448838" xlink:to="loc_teva_FinancialExpensesNetMember_2147448837" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable_2147448846" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448845" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2147448844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448845" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2147448844" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2147448844_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448845" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2147448844_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CrossCurrencySwapCashFlowHedgeMember" xlink:label="loc_teva_CrossCurrencySwapCashFlowHedgeMember_2147448843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2147448844" xlink:to="loc_teva_CrossCurrencySwapCashFlowHedgeMember_2147448843" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_2147448842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable_2147448846" xlink:to="loc_us-gaap_HedgingDesignationAxis_2147448842" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_2147448841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_2147448842" xlink:to="loc_us-gaap_HedgingDesignationDomain_2147448841" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_2147448841_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_2147448842" xlink:to="loc_us-gaap_HedgingDesignationDomain_2147448841_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2147448840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2147448841" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2147448840" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_390516" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_390515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_390516" xlink:to="loc_us-gaap_DerivativeTable_390515" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_682287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" xlink:to="loc_us-gaap_HedgingRelationshipDomain_682287" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_682287_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" xlink:to="loc_us-gaap_HedgingRelationshipDomain_682287_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_406887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_HedgingDesignationAxis_406887" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_406888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_406887" xlink:to="loc_us-gaap_HedgingDesignationDomain_406888" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_406888_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_406887" xlink:to="loc_us-gaap_HedgingDesignationDomain_406888_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_466838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_466838" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_406890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NondesignatedMember_406890" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember_406891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember_406891" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390519" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390519" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390520" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390520_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390519" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390520_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NetRevenuesMember" xlink:label="loc_teva_NetRevenuesMember_406886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390520" xlink:to="loc_teva_NetRevenuesMember_406886" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FinancialExpensesMember" xlink:label="loc_teva_FinancialExpensesMember_406916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390520" xlink:to="loc_teva_FinancialExpensesMember_406916" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_406900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_390516" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_406900" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1285" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeTable_1286" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1282" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1282_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1282_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1287" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1287_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1287_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1288" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1288" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1289" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1289_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1288" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1289_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FactoringInstitutionAxis" xlink:label="loc_teva_FactoringInstitutionAxis_2147449602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_teva_FactoringInstitutionAxis_2147449602" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FactoringInstitutionDomain" xlink:label="loc_teva_FactoringInstitutionDomain_2147449605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_FactoringInstitutionAxis_2147449602" xlink:to="loc_teva_FactoringInstitutionDomain_2147449605" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FactoringInstitutionDomain" xlink:label="loc_teva_FactoringInstitutionDomain_2147449605_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_FactoringInstitutionAxis_2147449602" xlink:to="loc_teva_FactoringInstitutionDomain_2147449605_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_dei_LegalEntityAxis_1290" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1290" xlink:to="loc_dei_EntityDomain_1312" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1312_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1290" xlink:to="loc_dei_EntityDomain_1312_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_817877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_srt_RangeAxis_817877" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_817878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_817877" xlink:to="loc_srt_RangeMember_817878" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_817878_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_817877" xlink:to="loc_srt_RangeMember_817878_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodAxis" xlink:label="loc_teva_PeriodAxis_2147457593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_teva_PeriodAxis_2147457593" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodDomain" xlink:label="loc_teva_PeriodDomain_2147457594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_PeriodAxis_2147457593" xlink:to="loc_teva_PeriodDomain_2147457594" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodDomain" xlink:label="loc_teva_PeriodDomain_2147457594_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_PeriodAxis_2147457593" xlink:to="loc_teva_PeriodDomain_2147457594_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_558657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_HedgingDesignationAxis_558657" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_558658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_558657" xlink:to="loc_us-gaap_HedgingDesignationDomain_558658" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_558658_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_558657" xlink:to="loc_us-gaap_HedgingDesignationDomain_558658_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_688630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_688630" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xlink:label="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses_1303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses_1303" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenuesOtherThanUsd" xlink:label="loc_teva_RevenuesOtherThanUsd_1298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_RevenuesOtherThanUsd_1298" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2147451284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2147451284" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_1301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_1301" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2147451288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2147451288" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1458" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1462" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LossContingenciesTable_1459" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_dei_LegalEntityAxis_1457" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1457" xlink:to="loc_dei_EntityDomain_1460" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1460_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1457" xlink:to="loc_dei_EntityDomain_1460_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_720032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_srt_StatementGeographicalAxis_720032" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_720033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_720032" xlink:to="loc_srt_SegmentGeographicalDomain_720033" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_720033_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_720032" xlink:to="loc_srt_SegmentGeographicalDomain_720033_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_471102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_srt_LitigationCaseAxis_471102" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_471102" xlink:to="loc_srt_LitigationCaseTypeDomain_471103" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471103_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_471102" xlink:to="loc_srt_LitigationCaseTypeDomain_471103_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LitigationSettlementExpense_1461" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CommitmentAndContingenciesLineItems" xlink:label="loc_teva_CommitmentAndContingenciesLineItems_900" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfNiaspan" xlink:label="loc_teva_AnnualSalesOfNiaspan_922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfNiaspan_922" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfActoplus" xlink:label="loc_teva_AnnualSalesOfActoplus_926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfActoplus_926" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CommitmentAndContingenciesTable" xlink:label="loc_teva_CommitmentAndContingenciesTable_901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_CommitmentAndContingenciesTable_901" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" xlink:to="loc_us-gaap_LossContingencyNatureDomain_905" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_905_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" xlink:to="loc_us-gaap_LossContingencyNatureDomain_905_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EosinophilicEsophagitisMember" xlink:label="loc_teva_EosinophilicEsophagitisMember_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_905" xlink:to="loc_teva_EosinophilicEsophagitisMember_936" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_471076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_LitigationCaseAxis_471076" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_471076" xlink:to="loc_srt_LitigationCaseTypeDomain_471078" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471078_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_471076" xlink:to="loc_srt_LitigationCaseTypeDomain_471078_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NationwideSettlementMember" xlink:label="loc_teva_NationwideSettlementMember_515110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_NationwideSettlementMember_515110" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AgreementAxis" xlink:label="loc_teva_AgreementAxis_1280188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_teva_AgreementAxis_1280188" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain_1281018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_AgreementAxis_1280188" xlink:to="loc_teva_AgreementDomain_1281018" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain_1281018_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_AgreementAxis_1280188" xlink:to="loc_teva_AgreementDomain_1281018_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_CounterpartyNameAxis_902" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_902" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_902" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_StatementGeographicalAxis_910" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_910" xlink:to="loc_srt_SegmentGeographicalDomain_909" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_909_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_910" xlink:to="loc_srt_SegmentGeographicalDomain_909_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_srt_EuropeMember_941" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_country_US_940" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_515106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_515106" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_515107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515106" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_515107" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_515107_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515106" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_515107_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_ProductOrServiceAxis_906" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_906" xlink:to="loc_srt_ProductsAndServicesDomain_907" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_907_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_906" xlink:to="loc_srt_ProductsAndServicesDomain_907_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AndroGelRateAtOnePercentageMember" xlink:label="loc_teva_AndroGelRateAtOnePercentageMember_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_AndroGelRateAtOnePercentageMember_937" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DefendantsAxis" xlink:label="loc_teva_DefendantsAxis_1280170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_teva_DefendantsAxis_1280170" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DefendantsMember" xlink:label="loc_teva_DefendantsMember_1280172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_DefendantsAxis_1280170" xlink:to="loc_teva_DefendantsMember_1280172" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DefendantsMember" xlink:label="loc_teva_DefendantsMember_1280172_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_DefendantsAxis_1280170" xlink:to="loc_teva_DefendantsMember_1280172_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FourOtherDefendantsOtherThanTevaMember" xlink:label="loc_teva_FourOtherDefendantsOtherThanTevaMember_1280174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DefendantsMember_1280172" xlink:to="loc_teva_FourOtherDefendantsOtherThanTevaMember_1280174" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DamagesAssessment" xlink:label="loc_teva_DamagesAssessment_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_DamagesAssessment_911" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla" xlink:label="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla_1280138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla_1280138" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LossContingenciesOnEnvironmentalLawsPenalty" xlink:label="loc_teva_LossContingenciesOnEnvironmentalLawsPenalty_1280223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LossContingenciesOnEnvironmentalLawsPenalty_1280223" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LitigationSettlementAmountAwardedDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod_515103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod_515103" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_818712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_818712" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_932" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfLamictal" xlink:label="loc_teva_AnnualSalesOfLamictal_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfLamictal_921" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LitigationSettlementAmountDistributableinKind" xlink:label="loc_teva_LitigationSettlementAmountDistributableinKind_1280198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountDistributableinKind_1280198" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_934" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada" xlink:label="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada_1280137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada_1280137" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfRevlimid" xlink:label="loc_teva_AnnualSalesOfRevlimid_2147469263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfRevlimid_2147469263" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler" xlink:label="loc_teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler_2147469264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler_2147469264" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfSettlementOfTruvada" xlink:label="loc_teva_AnnualSalesOfTheTimeOfSettlementOfTruvada_1280128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfTheTimeOfSettlementOfTruvada_1280128" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfSettlementOfViread" xlink:label="loc_teva_AnnualSalesOfTheTimeOfSettlementOfViread_1280127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfTheTimeOfSettlementOfViread_1280127" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfActos" xlink:label="loc_teva_AnnualSalesOfActos_925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfActos_925" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesAtTimeOfSettlement" xlink:label="loc_teva_AnnualSalesAtTimeOfSettlement_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesAtTimeOfSettlement_919" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_933" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfEffexor" xlink:label="loc_teva_AnnualSalesOfEffexor_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfEffexor_920" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_2147471392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_2147471392" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LitigationSettlementAmountDistributableInCash" xlink:label="loc_teva_LitigationSettlementAmountDistributableInCash_2147469337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountDistributableInCash_2147469337" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation" xlink:label="loc_teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation_2147469266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation_2147469266" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_1279981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_1279981" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfColcrys" xlink:label="loc_teva_AnnualSalesOfColcrys_1280142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfColcrys_1280142" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfNewLaunchOfViread" xlink:label="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfViread_1280135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfViread_1280135" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LitigationSettlementAmountPayableInCashPercentage" xlink:label="loc_teva_LitigationSettlementAmountPayableInCashPercentage_2147469336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountPayableInCashPercentage_2147469336" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement" xlink:label="loc_teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement_2147448867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement_2147448867" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PercentageOfThePopulationOfTheParticipatingStates" xlink:label="loc_teva_PercentageOfThePopulationOfTheParticipatingStates_2147448866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_PercentageOfThePopulationOfTheParticipatingStates_2147448866" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PercentageOfShareOfTheNationalPopulation" xlink:label="loc_teva_PercentageOfShareOfTheNationalPopulation_2147469267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_PercentageOfShareOfTheNationalPopulation_2147469267" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfSensipar" xlink:label="loc_teva_AnnualSalesOfSensipar_471045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfSensipar_471045" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration_2147470183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration_2147470183" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfEpipen" xlink:label="loc_teva_AnnualSalesOfEpipen_2147469265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfEpipen_2147469265" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfCopaxone" xlink:label="loc_teva_AnnualSalesOfCopaxone_720069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfCopaxone_720069" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForEnvironmentalLossContingencies" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies_1280219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_AccrualForEnvironmentalLossContingencies_1280219" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfSettlementOfAtripla" xlink:label="loc_teva_AnnualSalesOfTheTimeOfSettlementOfAtripla_1280132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfTheTimeOfSettlementOfAtripla_1280132" use="optional" order="67" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_2147448809" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencySettlementAgreementDate" xlink:label="loc_us-gaap_LossContingencySettlementAgreementDate_2147448808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_us-gaap_LossContingencySettlementAgreementDate_2147448808" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDomicileOfLitigation" xlink:label="loc_us-gaap_LossContingencyDomicileOfLitigation_2147448807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_us-gaap_LossContingencyDomicileOfLitigation_2147448807" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_2147448806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_2147448806" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_2147448823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_us-gaap_LossContingenciesTable_2147448823" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesByJurisdictionAxis" xlink:label="loc_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis_2147448822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2147448823" xlink:to="loc_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis_2147448822" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesJurisdictionDomain" xlink:label="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis_2147448822" xlink:to="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesJurisdictionDomain" xlink:label="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis_2147448822" xlink:to="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CuyahogaCountyOhMember" xlink:label="loc_teva_CuyahogaCountyOhMember_2147448819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_teva_CuyahogaCountyOhMember_2147448819" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TribesMember" xlink:label="loc_teva_TribesMember_2147448810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_teva_TribesMember_2147448810" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SanFranciscoMember" xlink:label="loc_teva_SanFranciscoMember_2147448813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_teva_SanFranciscoMember_2147448813" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SummitCountyOhMember" xlink:label="loc_teva_SummitCountyOhMember_2147448818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_teva_SummitCountyOhMember_2147448818" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV" xlink:label="loc_stpr_WV_2147448785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_WV_2147448785" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TX" xlink:label="loc_stpr_TX_2147448784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_TX_2147448784" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OK" xlink:label="loc_stpr_OK_2147448783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_OK_2147448783" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_LA" xlink:label="loc_stpr_LA_2147448782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_LA_2147448782" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_RI" xlink:label="loc_stpr_RI_2147448788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_RI_2147448788" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL" xlink:label="loc_stpr_FL_2147448787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_FL_2147448787" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY" xlink:label="loc_stpr_NY_2147448786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_NY_2147448786" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencySettlementAgreementTerms" xlink:label="loc_us-gaap_LossContingencySettlementAgreementTerms_2147448805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_us-gaap_LossContingencySettlementAgreementTerms_2147448805" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ContingencySettlementProduct" xlink:label="loc_teva_ContingencySettlementProduct_2147448804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_teva_ContingencySettlementProduct_2147448804" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProductWeightedAverageCost" xlink:label="loc_teva_ProductWeightedAverageCost_2147448803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_teva_ProductWeightedAverageCost_2147448803" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProductWeightedAverageCostTerm" xlink:label="loc_teva_ProductWeightedAverageCostTerm_2147448798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_teva_ProductWeightedAverageCostTerm_2147448798" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_IncomeTaxLineItems" xlink:label="loc_teva_IncomeTaxLineItems_1209" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_IncomeTaxTable" xlink:label="loc_teva_IncomeTaxTable_1210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_IncomeTaxTable_1210" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_dei_LegalEntityAxis_1211" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1211" xlink:to="loc_dei_EntityDomain_1242" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1242_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1211" xlink:to="loc_dei_EntityDomain_1242_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_TaxPeriodAxis_1218" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_1218" xlink:to="loc_us-gaap_TaxPeriodDomain_1219" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1219_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_1218" xlink:to="loc_us-gaap_TaxPeriodDomain_1219_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TaxYear2008To2011Member" xlink:label="loc_teva_TaxYear2008To2011Member_1280227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1219" xlink:to="loc_teva_TaxYear2008To2011Member_1280227" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1216" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1216" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1216" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_srt_RangeAxis_1214" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1214" xlink:to="loc_srt_RangeMember_1215" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1215_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1214" xlink:to="loc_srt_RangeMember_1215_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaap_IsraelTaxAuthorityMember_1220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" xlink:to="loc_us-gaap_IsraelTaxAuthorityMember_1220" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_YearOfSettlementAxis" xlink:label="loc_teva_YearOfSettlementAxis_2147449861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_teva_YearOfSettlementAxis_2147449861" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_YearOfSettlementDomain" xlink:label="loc_teva_YearOfSettlementDomain_2147449920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_YearOfSettlementAxis_2147449861" xlink:to="loc_teva_YearOfSettlementDomain_2147449920" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_YearOfSettlementDomain" xlink:label="loc_teva_YearOfSettlementDomain_2147449920_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_YearOfSettlementAxis_2147449861" xlink:to="loc_teva_YearOfSettlementDomain_2147449920_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_581719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_581719" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_581720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_581719" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_581720" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_581720_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_581719" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_581720_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_673833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_srt_StatementScenarioAxis_673833" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_673834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_673833" xlink:to="loc_srt_ScenarioUnspecifiedDomain_673834" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_673834_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_673833" xlink:to="loc_srt_ScenarioUnspecifiedDomain_673834_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1229" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ExpectedImpairmentOfIncomeTaxBenefit" xlink:label="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit_581718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit_581718" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_672012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_672012" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_671996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_671996" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_1280226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_1280226" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail">
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_RestructuringCharges_1398" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentAndRestructuring" xlink:label="loc_teva_ImpairmentAndRestructuring_1401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_ImpairmentAndRestructuring_1401" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:label="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses_1400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses_1400" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable_1393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_RestructuringAndImpairmentCostsTable_1393" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1393" xlink:to="loc_dei_LegalEntityAxis_1391" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1391" xlink:to="loc_dei_EntityDomain_1394" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1394_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1391" xlink:to="loc_dei_EntityDomain_1394_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1396" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1395" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2147451045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2147451045" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390248" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390248" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390250" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390250_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390248" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390250_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_dei_LegalEntityAxis_1432" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1432" xlink:to="loc_dei_EntityDomain_1437" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1437_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1432" xlink:to="loc_dei_EntityDomain_1437_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1433" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1433" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1436" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1436_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1433" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1436_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_1440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1436" xlink:to="loc_us-gaap_OtherRestructuringMember_1440" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_1439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1436" xlink:to="loc_us-gaap_EmployeeSeveranceMember_1439" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" xlink:to="loc_us-gaap_RestructuringCharges_1438" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UtilizationAndOther" xlink:label="loc_teva_UtilizationAndOther_1453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_teva_UtilizationAndOther_1453" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_1451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_us-gaap_RestructuringReserve_1451" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAccrualProvision" xlink:label="loc_teva_RestructuringAccrualProvision_1452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_teva_RestructuringAccrualProvision_1452" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ExitAndDisposalAxis" xlink:label="loc_teva_ExitAndDisposalAxis_1443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_teva_ExitAndDisposalAxis_1443" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ExitAndDisposalDomain" xlink:label="loc_teva_ExitAndDisposalDomain_1444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_ExitAndDisposalAxis_1443" xlink:to="loc_teva_ExitAndDisposalDomain_1444" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ExitAndDisposalDomain" xlink:label="loc_teva_ExitAndDisposalDomain_1444_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_ExitAndDisposalAxis_1443" xlink:to="loc_teva_ExitAndDisposalDomain_1444_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EmployeeTerminationMember" xlink:label="loc_teva_EmployeeTerminationMember_1448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ExitAndDisposalDomain_1444" xlink:to="loc_teva_EmployeeTerminationMember_1448" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherExitAndDisposalMember" xlink:label="loc_teva_OtherExitAndDisposalMember_1449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ExitAndDisposalDomain_1444" xlink:to="loc_teva_OtherExitAndDisposalMember_1449" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_dei_LegalEntityAxis_1445" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1445" xlink:to="loc_dei_EntityDomain_1450" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1450_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1445" xlink:to="loc_dei_EntityDomain_1450_default" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable_1412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_teva_RestructuringAndImpairmentCostsTable_1412" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_515346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_StatementScenarioAxis_515346" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_515347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_515346" xlink:to="loc_srt_ScenarioUnspecifiedDomain_515347" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_515347_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_515346" xlink:to="loc_srt_ScenarioUnspecifiedDomain_515347_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_dei_LegalEntityAxis_1406" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1406" xlink:to="loc_dei_EntityDomain_1416" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1416_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1406" xlink:to="loc_dei_EntityDomain_1416_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1404" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1404" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1405" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1405_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1404" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1405_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_ProductOrServiceAxis_1407" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1407" xlink:to="loc_srt_ProductsAndServicesDomain_1408" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1408_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1407" xlink:to="loc_srt_ProductsAndServicesDomain_1408_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_StatementGeographicalAxis_1414" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1414" xlink:to="loc_srt_SegmentGeographicalDomain_1413" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1413_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1414" xlink:to="loc_srt_SegmentGeographicalDomain_1413_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_1419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_1419" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_758336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_758336" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_RestructuringCharges_1421" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2147448894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2147448894" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1601" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_dei_LegalEntityAxis_1595" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1595" xlink:to="loc_dei_EntityDomain_1603" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1603_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1595" xlink:to="loc_dei_EntityDomain_1603_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_718514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_EarningsPerShareDiluted_718514" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1597" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_718513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_EarningsPerShareBasic_718513" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_390034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_390034" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_390033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_390033" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_390031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_390031" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_StatementTable_390027" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_390055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390027" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_390055" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_390057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_390055" xlink:to="loc_us-gaap_EquityComponentDomain_390057" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_390057_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_390055" xlink:to="loc_us-gaap_EquityComponentDomain_390057_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_390090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_390090" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_390087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_390087" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_390089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_390089" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_390091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_390091" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390027" xlink:to="loc_dei_LegalEntityAxis_390028" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_390028" xlink:to="loc_dei_EntityDomain_390029" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390029_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_390028" xlink:to="loc_dei_EntityDomain_390029_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_390049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_390049" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_466595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_466595" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_390032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_390032" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390135" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390135" xlink:to="loc_us-gaap_StatementTable_390130" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_dei_LegalEntityAxis_390133" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_390133" xlink:to="loc_dei_EntityDomain_390134" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390134_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_390133" xlink:to="loc_dei_EntityDomain_390134_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_390148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" xlink:to="loc_us-gaap_TypeOfAdoptionMember_390148" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_390148_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" xlink:to="loc_us-gaap_TypeOfAdoptionMember_390148_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_390149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_390148" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_390149" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_720088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_srt_RangeAxis_720088" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_720089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_720088" xlink:to="loc_srt_RangeMember_720089" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_720089_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_720088" xlink:to="loc_srt_RangeMember_720089_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_390142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_390142" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_390143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_390142" xlink:to="loc_us-gaap_EquityComponentDomain_390143" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_390143_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_390142" xlink:to="loc_us-gaap_EquityComponentDomain_390143_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_390137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390135" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_390137" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherOperatingIncomeExpense" xlink:label="loc_teva_OtherOperatingIncomeExpense_1496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_teva_OtherOperatingIncomeExpense_1496" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_1494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_SellingAndMarketingExpense_1494" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1493" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1486" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1486" xlink:to="loc_us-gaap_SegmentDomain_1484" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1484_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1486" xlink:to="loc_us-gaap_SegmentDomain_1484_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_InternationalMarketsMember_1490" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_NorthAmericaSegmentMember_1488" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_EuropeSegmentMember_1489" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_dei_LegalEntityAxis_1482" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1482" xlink:to="loc_dei_EntityDomain_1487" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1487_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1482" xlink:to="loc_dei_EntityDomain_1487_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_OperatingIncomeLoss_1497" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1495" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_GrossProfit_1492" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1491" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AmountsNotAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1511" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_1508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_AdjustmentForAmortization_1508" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherUnallocatedAmounts" xlink:label="loc_teva_OtherUnallocatedAmounts_1517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_OtherUnallocatedAmounts_1517" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies_1516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_LegalSettlementsAndLossContingencies_1516" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_1509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_1509" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1506" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1506" xlink:to="loc_us-gaap_SegmentDomain_1504" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1504_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1506" xlink:to="loc_us-gaap_SegmentDomain_1504_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1523" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_EuropeSegmentMember_1520" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_InternationalMarketsMember_1521" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_NorthAmericaSegmentMember_1519" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaap_CorporateMember_1522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_us-gaap_CorporateMember_1522" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SegmentsAndOtherActivitiesMember" xlink:label="loc_teva_SegmentsAndOtherActivitiesMember_1524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_SegmentsAndOtherActivitiesMember_1524" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_dei_LegalEntityAxis_1502" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1502" xlink:to="loc_dei_EntityDomain_1518" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1518_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1502" xlink:to="loc_dei_EntityDomain_1518_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1526" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" xlink:to="loc_us-gaap_OperatingIncomeLoss_1507" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AmountsAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1525" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems_1530" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_1533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_1530" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_1533" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1535" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1535" xlink:to="loc_us-gaap_SegmentDomain_1534" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1534_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1535" xlink:to="loc_us-gaap_SegmentDomain_1534_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_NorthAmericaSegmentMember_1548" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_InternationalMarketsMember_1550" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_EuropeSegmentMember_1549" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_dei_LegalEntityAxis_1529" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1529" xlink:to="loc_dei_EntityDomain_1536" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1536_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1529" xlink:to="loc_dei_EntityDomain_1536_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueTypeAxis" xlink:label="loc_teva_RevenueTypeAxis_558204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_teva_RevenueTypeAxis_558204" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueTypeDomain" xlink:label="loc_teva_RevenueTypeDomain_558211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_RevenueTypeAxis_558204" xlink:to="loc_teva_RevenueTypeDomain_558211" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueTypeDomain" xlink:label="loc_teva_RevenueTypeDomain_558211_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_RevenueTypeAxis_558204" xlink:to="loc_teva_RevenueTypeDomain_558211_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_srt_ProductOrServiceAxis_1531" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1531" xlink:to="loc_srt_ProductsAndServicesDomain_1532" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1532_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1531" xlink:to="loc_srt_ProductsAndServicesDomain_1532_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RespiratoryProductMember" xlink:label="loc_teva_RespiratoryProductMember_1545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_RespiratoryProductMember_1545" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AustedoMember" xlink:label="loc_teva_AustedoMember_1543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AustedoMember_1543" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AndaMember" xlink:label="loc_teva_AndaMember_1546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AndaMember_1546" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_BendekaAndTreandaMember" xlink:label="loc_teva_BendekaAndTreandaMember_1540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_BendekaAndTreandaMember_1540" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherProductsMember" xlink:label="loc_teva_OtherProductsMember_1547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_OtherProductsMember_1547" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AjovyMember" xlink:label="loc_teva_AjovyMember_408213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AjovyMember_408213" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_GenericsMediciansMember" xlink:label="loc_teva_GenericsMediciansMember_1538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_GenericsMediciansMember_1538" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_COPAXONEMember" xlink:label="loc_teva_COPAXONEMember_1539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_COPAXONEMember_1539" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_1530" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1537" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1472" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1472" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1468" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1468_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1468_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1260430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" xlink:to="loc_us-gaap_SegmentDomain_1260430" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1260430_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" xlink:to="loc_us-gaap_SegmentDomain_1260430_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_dei_LegalEntityAxis_1469" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1469" xlink:to="loc_dei_EntityDomain_1476" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1476_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1469" xlink:to="loc_dei_EntityDomain_1476_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_srt_StatementGeographicalAxis_1473" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1473" xlink:to="loc_srt_SegmentGeographicalDomain_1471" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1471_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1473" xlink:to="loc_srt_SegmentGeographicalDomain_1471_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_1478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1472" xlink:to="loc_us-gaap_NumberOfReportableSegments_1478" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeLiabilities_371" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_372" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_FairValueNetAssetLiability_373" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeAssets_370" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_362" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_362" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_362" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xlink:label="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember_379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" xlink:to="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember_379" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_380" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_382" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_381" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FinancialInstrumentAxis_365" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_365" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_365" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" xlink:to="loc_us-gaap_InterestRateSwapMember_384" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_2147448890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_2147448890" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_dei_LegalEntityAxis_366" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_366" xlink:to="loc_dei_EntityDomain_383" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_383_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_366" xlink:to="loc_dei_EntityDomain_383_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_360" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_360" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_360" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_MoneyMarketFundsMember_374" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherRestrictedCashMember" xlink:label="loc_teva_OtherRestrictedCashMember_1260419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_teva_OtherRestrictedCashMember_1260419" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemandDepositsMember" xlink:label="loc_us-gaap_DemandDepositsMember_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_DemandDepositsMember_375" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_EquitySecuritiesMember_376" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_2147451276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_2147451276" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_1280201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_RestrictedCash_1280201" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_369" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_2147451277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_2147451277" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_682381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_682381" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_682378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_682378" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_682379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_682378" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_682379" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_682379_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_682378" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_682379_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MeasurementInputProbabilityOfSuccessMember" xlink:label="loc_teva_MeasurementInputProbabilityOfSuccessMember_682380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_682379" xlink:to="loc_teva_MeasurementInputProbabilityOfSuccessMember_682380" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_682382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_682379" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_682382" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:label="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:label="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" xlink:to="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:label="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" xlink:to="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_682372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_srt_RangeAxis_682372" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_682373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_682372" xlink:to="loc_srt_RangeMember_682373" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_682373_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_682372" xlink:to="loc_srt_RangeMember_682373_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_688250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_WeightedAverageMember_688250" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_682375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_MinimumMember_682375" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_682374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_MaximumMember_682374" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease_401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease_401" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_397" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod_400" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_BifurcatedEmbeddedDerivatives" xlink:label="loc_teva_BifurcatedEmbeddedDerivatives_1280215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_BifurcatedEmbeddedDerivatives_1280215" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_402" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_1280210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_1280210" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_dei_LegalEntityAxis_394" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_394" xlink:to="loc_dei_EntityDomain_407" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_407_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_394" xlink:to="loc_dei_EntityDomain_407_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_392" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_392" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_393" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_393_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_392" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_393_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EagleTransactionMember" xlink:label="loc_teva_EagleTransactionMember_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_EagleTransactionMember_406" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ActavisGenericsMember" xlink:label="loc_teva_ActavisGenericsMember_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_ActavisGenericsMember_404" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NovetideTransactionMember" xlink:label="loc_teva_NovetideTransactionMember_2147448889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_NovetideTransactionMember_2147448889" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_389" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_389" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_389" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NoveTideAcquisitionMember" xlink:label="loc_teva_NoveTideAcquisitionMember_2147450147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" xlink:to="loc_teva_NoveTideAcquisitionMember_2147450147" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2147450629" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2147450630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2147450629" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2147450630" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2147450622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2147450629" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2147450622" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2147450624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2147450622" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2147450624" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2147450625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2147450624" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2147450625" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2147450625_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2147450624" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2147450625_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NoveTideAcquisitionMember" xlink:label="loc_teva_NoveTideAcquisitionMember_2147450627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2147450625" xlink:to="loc_teva_NoveTideAcquisitionMember_2147450627" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_dei_LegalEntityAxis_412" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_412" xlink:to="loc_dei_EntityDomain_416" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_416_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_412" xlink:to="loc_dei_EntityDomain_416_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_413" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_413" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_414" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_414_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_413" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_414_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xlink:label="loc_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember_1260415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_414" xlink:to="loc_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember_1260415" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SeniornotesandconvertibleseniordebenturesMember" xlink:label="loc_teva_SeniornotesandconvertibleseniordebenturesMember_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_414" xlink:to="loc_teva_SeniornotesandconvertibleseniordebenturesMember_418" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" xlink:to="loc_us-gaap_DebtInstrumentFairValue_415" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsCurrent" order="1.0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="2.0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="1.0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" order="2.0" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>teva-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 10-May-2023 [04:37:29] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Smaller Reporting Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport" xml:lang="en-US">Document Quarterly Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AccruedExpenses" xlink:label="loc_teva_AccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AccruedExpenses" xml:lang="en-US">Accrued Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AccruedExpenses" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AccruedExpenses" xlink:to="lab_teva_AccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AccruedExpenses" xml:lang="en-US">Accrued expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Debt, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Short-term debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Total short-term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SalesReservesAndAllowances" xlink:label="loc_teva_SalesReservesAndAllowances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SalesReservesAndAllowances" xml:lang="en-US">Sales Reserves And Allowances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SalesReservesAndAllowances" xml:lang="en-US">Sales reserves and allowances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SalesReservesAndAllowances" xlink:to="lab_teva_SalesReservesAndAllowances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SalesReservesAndAllowances" xml:lang="en-US">The sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Teva shareholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Ordinary shares of NIS 0.10 par value per share; March 31, 2023 and December 31, 2022: authorized 2,495 million shares; issued 1,226 million shares and 1,217 million shares, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' equity attributable to Teva shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury shares as of March 31, 2023 and December 31, 2022: 106 million ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional&#160;paid-in&#160;capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Long-term liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other taxes and long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermNotesAndLoans" xml:lang="en-US">Notes and Loans, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermNotesAndLoans" xml:lang="en-US">Senior notes and loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermNotesAndLoans" xml:lang="en-US">Total senior notes and loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesAndLoans" xlink:to="lab_us-gaap_LongTermNotesAndLoans" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies, see note 10</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other&#160;non-current&#160;assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets held for sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivables, net of allowance for credit losses of $88 million and $91 million as of March 31, 2023 and December 31, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, plant and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Identifiable intangible assets, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Net carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Ordinary shares, authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par or stated value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Ordinary shares, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for credit losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury Stock, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ImpairmentsRestructuringAndOthers" xml:lang="en-US">Impairments Restructuring And Others</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_teva_ImpairmentsRestructuringAndOthers" xml:lang="en-US">Other assets impairments, restructuring and other items</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_ImpairmentsRestructuringAndOthers" xml:lang="en-US">Other asset impairments, restructuring and other items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ImpairmentsRestructuringAndOthers" xlink:to="lab_teva_ImpairmentsRestructuringAndOthers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ImpairmentsRestructuringAndOthers" xml:lang="en-US">Impairments restructuring and others.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Financial expenses, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Financial expenses, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Segment profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Consolidated operating income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Segments profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_IntangibleAssetsImpairments" xlink:label="loc_teva_IntangibleAssetsImpairments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IntangibleAssetsImpairments" xml:lang="en-US">Intangible Assets Impairments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IntangibleAssetsImpairments" xml:lang="en-US">Intangible assets impairments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IntangibleAssetsImpairments" xlink:to="lab_teva_IntangibleAssetsImpairments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IntangibleAssetsImpairments" xml:lang="en-US">Intangible Assets Impairments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of Goods and Services Sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings (loss) per share attributable to ordinary shareholders:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings per share, Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings per share, Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss) attributable to Teva</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Selling and Marketing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Selling and marketing expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">S&amp;M expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">G&amp;A expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted average number of shares (in millions):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income taxes (benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Tax Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (loss) before income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Pre tax income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Net revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Total revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Other Operating Income (Expense), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net income (loss) attributable to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Share in (profits) losses of associated companies, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income loss from equity method investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and development expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">R&amp;D expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LegalSettlementsAndLossContingencies" xml:lang="en-US">Legal Settlements And Loss Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LegalSettlementsAndLossContingencies" xml:lang="en-US">Legal settlements and loss contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LegalSettlementsAndLossContingencies" xlink:to="lab_teva_LegalSettlementsAndLossContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LegalSettlementsAndLossContingencies" xml:lang="en-US">The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Total other comprehensive income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other comprehensive income (loss), net of tax:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UnrealizedGainLossOnDerivativeNetOfTax" xlink:label="loc_teva_UnrealizedGainLossOnDerivativeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UnrealizedGainLossOnDerivativeNetOfTax" xml:lang="en-US">Unrealized gain (loss) on derivative net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_UnrealizedGainLossOnDerivativeNetOfTax" xml:lang="en-US">Unrealized gain (loss) from derivative financial instruments, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UnrealizedGainLossOnDerivativeNetOfTax" xlink:to="lab_teva_UnrealizedGainLossOnDerivativeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UnrealizedGainLossOnDerivativeNetOfTax" xml:lang="en-US">Unrealized gain (loss) on derivative net of tax.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xml:lang="en-US">Unrealized loss on defined benefit plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive income (loss) attributable to Teva</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive income (loss) attributable to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Shares, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Ending balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Beginning balance, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of Shares, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Non-controlling Interests [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ParentMember" xml:lang="en-US">Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ParentMember" xml:lang="en-US">Total Teva Shareholders' Equity [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Ordinary Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of options by employees and vested RSUs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Balance of cash, cash equivalents and restricted cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Balance of cash, cash equivalents and restricted cash at end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Translation adjustment on cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Non-cash&#160;financing and investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Beneficial Interest Obtained in Exchange for Securitized Trade Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Beneficial interest obtained in exchange for securitized accounts receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xlink:to="lab_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Beneficial Interest Obtained in Exchange for Securitized Trade Receivables</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Impairment of long-lived assets and assets held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xml:lang="en-US">Increase (Decrease) in Operating Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xml:lang="en-US">Net change in operating assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapital" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xml:lang="en-US">Profit From Sale Of Long Lived Assets And Investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xml:lang="en-US">Net loss (gain) from investments and from sale of long lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:to="lab_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xml:lang="en-US">Profit from sale of long lived assets and investment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:label="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xml:lang="en-US">Deferred Income Taxes Net And Uncertain Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xml:lang="en-US">Deferred income taxes &#8211; net and uncertain tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:to="lab_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xml:lang="en-US">Deferred income taxes net and uncertain tax positions.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xml:lang="en-US">Other items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Other investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:label="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xml:lang="en-US">Payment To Acquire Marketable Securities And Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xml:lang="en-US">Purchases of investments and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:to="lab_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xml:lang="en-US">The cash outflow from purchase of available for sales securities and other assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Proceeds from beneficial interest in exchange for securitized trade receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Beneficial interest collected in exchange for securitized trade receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:to="lab_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Proceeds from beneficial interest in exchange for securitized trade receivables</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Acquisition of businesses, net of cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from sale of business and long lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted cash included in other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xml:lang="en-US">Other financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xml:lang="en-US">Proceeds from senior notes, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Repayments of Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Repayment of senior notes and loans and other long term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_BasisOfPresentationAbstract" xlink:label="loc_teva_BasisOfPresentationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_BasisOfPresentationAbstract" xml:lang="en-US">Basis of Presentation [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_BasisOfPresentationAbstract" xlink:to="lab_teva_BasisOfPresentationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TextBlockAbstract" xml:lang="en-US">Text Block [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CertainTransactionsDisclosureTextBlock" xlink:label="loc_teva_CertainTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CertainTransactionsDisclosureTextBlock" xml:lang="en-US">Certain Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CertainTransactionsDisclosureTextBlock" xml:lang="en-US">Certain transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CertainTransactionsDisclosureTextBlock" xlink:to="lab_teva_CertainTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CertainTransactionsDisclosureTextBlock" xml:lang="en-US">This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from contracts with customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Identifiable Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xml:lang="en-US">Goodwill Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xml:lang="en-US">Legal Settlements and Loss Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherExpensesTextBlock" xlink:label="loc_teva_OtherExpensesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherExpensesTextBlock" xml:lang="en-US">Other Expenses [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherExpensesTextBlock" xml:lang="en-US">Other assets impairments, restructuring and other items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherExpensesTextBlock" xlink:to="lab_teva_OtherExpensesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherExpensesTextBlock" xml:lang="en-US">Other Expenses [Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings (Loss) per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Reporting [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair value measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently adopted and issued accounting pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">Recently issued accounting pronouncements, not yet adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="lab_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">Recently issued accounting pronouncements not yet adopted.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:label="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xml:lang="en-US">Schedule Of Assets And Liabilities Held For Sale [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xml:lang="en-US">Summary of Major Classes of Assets and Liabilities Included as Held for Sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:to="lab_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xml:lang="en-US">Schedule Of Assets And Liabilities Held For Sale [Table Text Block]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SalesReservesAndAllowancesCurrentTableTextBlock" xlink:label="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SalesReservesAndAllowancesCurrentTableTextBlock" xml:lang="en-US">Sales Reserves And Allowances Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SalesReservesAndAllowancesCurrentTableTextBlock" xml:lang="en-US">Summary of Sales Reserves and Allowances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock" xlink:to="lab_teva_SalesReservesAndAllowancesCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SalesReservesAndAllowancesCurrentTableTextBlock" xml:lang="en-US">Tabular disclosure of sales reserves and allowances current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Summary of disaggregates revenues by major revenue streams</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Summary of Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Summary of Identifiable Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xml:lang="en-US">Summary of Changes in the Carrying Amount of Goodwill by Segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xlink:label="loc_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xml:lang="en-US">Long Term Debt Excluding Convertible Debt Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xml:lang="en-US">Schedule of Senior Notes and Loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xlink:to="lab_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xml:lang="en-US">A schedule of data and information pertaining to long-debt instruments or arrangements, excluding convertible debt, that includes identification, terms, features, collateral requirements and other information necessary to a fair presentation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xml:lang="en-US">Schedule of Short-term Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xml:lang="en-US">Schedule of Short-term Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock" xlink:label="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock" xml:lang="en-US">Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock" xml:lang="en-US">Summary of Notional Amounts for Hedged Items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock" xlink:to="lab_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock" xml:lang="en-US">Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock" xlink:label="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock" xml:lang="en-US">Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock" xml:lang="en-US">Summary Of Pre-tax (gains) losses from Derivatives Designated in Cash Flow Hedging Relationships</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock" xlink:to="lab_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock" xml:lang="en-US">Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xml:lang="en-US">Summary of Classification and Fair Values of Derivative Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xml:lang="en-US">Schedule of Loss Contingencies by Contingency [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xml:lang="en-US">Schedule Of Material Details Of Individual Settlements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:to="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ScheduleOfRestructuringChargesTableTextBlock" xlink:label="loc_teva_ScheduleOfRestructuringChargesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfRestructuringChargesTableTextBlock" xml:lang="en-US">Schedule of Restructuring Charges [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfRestructuringChargesTableTextBlock" xml:lang="en-US">Summary of Restructuring Plan Including Costs Related to Exit and Disposal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfRestructuringChargesTableTextBlock" xlink:to="lab_teva_ScheduleOfRestructuringChargesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfRestructuringChargesTableTextBlock" xml:lang="en-US">Schedule of Restructuring Charges [Table Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xml:lang="en-US">Schedule of Other Assets Impairments, Restructuring and Other Items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xml:lang="en-US">Summary of Restructuring Accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss) (Net of Tax)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xml:lang="en-US">Schedule of Net Sales by Product Line</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xml:lang="en-US">Summary of Segment Profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xlink:label="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xml:lang="en-US">Schedule Of Consolidated Income Before Income Tax [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xml:lang="en-US">Schedule Of Consolidated Income Before Income Tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xlink:to="lab_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xml:lang="en-US">Schedule of consolidated income before income tax.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Summary of Financial Instrument Measured on a Basis Other Than Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Summary of Financial Items Carried at Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xml:lang="en-US">Business Combination, Consideration Transferred [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsTable" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionsTable" xml:lang="en-US">Noncash or Part Noncash Acquisitions [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionsTable" xml:lang="en-US">Noncash or Part Noncash Acquisitions [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xml:lang="en-US">Noncash or Part Noncash Acquisitions [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xml:lang="en-US">Noncash or Part Noncash Acquisitions [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MilestonePayment" xlink:label="loc_teva_MilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MilestonePayment" xml:lang="en-US">Milestone Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MilestonePayment" xml:lang="en-US">Milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MilestonePayment" xlink:to="lab_teva_MilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MilestonePayment" xml:lang="en-US">Milestone payment.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UpfrontPayments" xlink:label="loc_teva_UpfrontPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UpfrontPayments" xml:lang="en-US">Upfront Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_UpfrontPayments" xml:lang="en-US">Upfront payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UpfrontPayments" xlink:to="lab_teva_UpfrontPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UpfrontPayments" xml:lang="en-US">Upfront payments</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CollaborativeAgreementMilestonePayments" xlink:label="loc_teva_CollaborativeAgreementMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CollaborativeAgreementMilestonePayments" xml:lang="en-US">Collaborative Agreement Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CollaborativeAgreementMilestonePayments" xml:lang="en-US">Collaborative agreement milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CollaborativeAgreementMilestonePayments" xlink:to="lab_teva_CollaborativeAgreementMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CollaborativeAgreementMilestonePayments" xml:lang="en-US">Collaborative Agreement Milestone Payments</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xlink:label="loc_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xml:lang="en-US">License Agreement Potential Aggregate Milestone Payments Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xml:lang="en-US">License agreement potential aggregate milestone payments amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xlink:to="lab_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xml:lang="en-US">License agreement potential aggregate milestone payments amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AlvotechMember" xlink:label="loc_teva_AlvotechMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AlvotechMember" xml:lang="en-US">Alvotech [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AlvotechMember" xml:lang="en-US">Alvotech [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AlvotechMember" xlink:to="lab_teva_AlvotechMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AlvotechMember" xml:lang="en-US">Alvotech.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtsukaMember" xlink:label="loc_teva_OtsukaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtsukaMember" xml:lang="en-US">Otsuka [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtsukaMember" xml:lang="en-US">Otsuka [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtsukaMember" xlink:to="lab_teva_OtsukaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtsukaMember" xml:lang="en-US">Otsuka [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ModagMember" xlink:label="loc_teva_ModagMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ModagMember" xml:lang="en-US">Modag [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ModagMember" xml:lang="en-US">MODAG [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ModagMember" xlink:to="lab_teva_ModagMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ModagMember" xml:lang="en-US">Modag .</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MedincellMember" xlink:label="loc_teva_MedincellMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MedincellMember" xml:lang="en-US">MedinCell [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MedincellMember" xlink:to="lab_teva_MedincellMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MedincellMember" xml:lang="en-US">MedinCell [ Member].</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TakedaMember" xlink:label="loc_teva_TakedaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TakedaMember" xml:lang="en-US">Takeda [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TakedaMember" xlink:to="lab_teva_TakedaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TakedaMember" xml:lang="en-US">Takeda.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="loc_us-gaap_AssetsFairValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueAdjustment" xml:lang="en-US">Assets, Fair Value Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueAdjustment" xml:lang="en-US">Adjustments of assets held for sale to fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueAdjustment" xlink:to="lab_us-gaap_AssetsFairValueAdjustment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xml:lang="en-US">Property, plant and equipment, net and others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xml:lang="en-US">Revenue Recognition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAbstract" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenueRecognitionTable" xml:lang="en-US">Revenue Recognition [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RevenueRecognitionTable" xml:lang="en-US">Revenue Recognition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenueRecognitionTable" xlink:to="lab_teva_RevenueRecognitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RevenueRecognitionTable" xml:lang="en-US">Revenue Recognition [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenueRecognitionLineItems" xml:lang="en-US">Revenue Recognition [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RevenueRecognitionLineItems" xml:lang="en-US">Revenue Recognition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenueRecognitionLineItems" xlink:to="lab_teva_RevenueRecognitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RevenueRecognitionLineItems" xml:lang="en-US">Revenue Recognition [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableFromSecuritization" xlink:label="loc_us-gaap_AccountsReceivableFromSecuritization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableFromSecuritization" xml:lang="en-US">Accounts Receivable from Securitization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableFromSecuritization" xml:lang="en-US">Accounts receivable from securitization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableFromSecuritization" xlink:to="lab_us-gaap_AccountsReceivableFromSecuritization" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SalesReservesAndAllowancesToCustomersPercentage" xlink:label="loc_teva_SalesReservesAndAllowancesToCustomersPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SalesReservesAndAllowancesToCustomersPercentage" xml:lang="en-US">Sales Reserves and Allowances to Customers Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SalesReservesAndAllowancesToCustomersPercentage" xml:lang="en-US">Percentage sales reserves and allowances to U.S. customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SalesReservesAndAllowancesToCustomersPercentage" xlink:to="lab_teva_SalesReservesAndAllowancesToCustomersPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SalesReservesAndAllowancesToCustomersPercentage" xml:lang="en-US">Sales reserves and allowances to customers percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis" xlink:label="loc_us-gaap_PledgingPurposeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PledgingPurposeAxis" xml:lang="en-US">Pledging Purpose [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgingPurposeAxis" xlink:to="lab_us-gaap_PledgingPurposeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="loc_us-gaap_PledgingPurposeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PledgingPurposeDomain" xml:lang="en-US">Pledging Purpose [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgingPurposeDomain" xlink:to="lab_us-gaap_PledgingPurposeDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member" xlink:label="loc_teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member" xml:lang="en-US">Pledged to PNC Bank, National Association in connection with the U.S. securitization program entered into in November 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member" xlink:to="lab_teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member" xml:lang="en-US">Pledged to PNC Bank, national association in connection with the U.S. securitization program entered into in November 2022.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FactoringInstitutionAxis" xlink:label="loc_teva_FactoringInstitutionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FactoringInstitutionAxis" xml:lang="en-US">Factoring Institution [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FactoringInstitutionAxis" xlink:to="lab_teva_FactoringInstitutionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FactoringInstitutionAxis" xml:lang="en-US">Factoring institution.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FactoringInstitutionDomain" xlink:label="loc_teva_FactoringInstitutionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FactoringInstitutionDomain" xml:lang="en-US">Factoring Institution [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FactoringInstitutionDomain" xlink:to="lab_teva_FactoringInstitutionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FactoringInstitutionDomain" xml:lang="en-US">Factoring institution.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PncBankMember" xlink:label="loc_teva_PncBankMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PncBankMember" xml:lang="en-US">PNC Bank [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PncBankMember" xml:lang="en-US">PNC Bank [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PncBankMember" xlink:to="lab_teva_PncBankMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PncBankMember" xml:lang="en-US">PNC bank.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US" xml:lang="en-US">United States [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AccountsReceivableSecuritizationFacilityMember" xlink:label="loc_teva_AccountsReceivableSecuritizationFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AccountsReceivableSecuritizationFacilityMember" xml:lang="en-US">Accounts Receivable Securitization Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AccountsReceivableSecuritizationFacilityMember" xml:lang="en-US">Accounts Receivable Securitization Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AccountsReceivableSecuritizationFacilityMember" xlink:to="lab_teva_AccountsReceivableSecuritizationFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AccountsReceivableSecuritizationFacilityMember" xml:lang="en-US">Accounts receivable securitization facility.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NorthAmericaMember" xml:lang="en-US">North America [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_NorthAmericaMember" xml:lang="en-US">North America [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NorthAmericaMember" xlink:to="lab_srt_NorthAmericaMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EuropeMember" xml:lang="en-US">Europe [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_EuropeMember" xml:lang="en-US">Europe [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InternationalMarketsMember" xml:lang="en-US">International Markets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_InternationalMarketsMember" xml:lang="en-US">International Markets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InternationalMarketsMember" xlink:to="lab_teva_InternationalMarketsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InternationalMarketsMember" xml:lang="en-US">International markets.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherActivitiesMember" xlink:label="loc_teva_OtherActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherActivitiesMember" xml:lang="en-US">Other Activities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherActivitiesMember" xml:lang="en-US">Other activities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherActivitiesMember" xlink:to="lab_teva_OtherActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherActivitiesMember" xml:lang="en-US">Other Activities [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Product and Service, Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionServiceMember" xlink:label="loc_us-gaap_DistributionServiceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DistributionServiceMember" xml:lang="en-US">Distribution Service [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DistributionServiceMember" xml:lang="en-US">Distribution [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionServiceMember" xlink:to="lab_us-gaap_DistributionServiceMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Sale of Goods [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">License [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">Licensing Arrangements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xlink:label="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xml:lang="en-US">Valuation Allowances And Reserves Foreign Currency Translation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xml:lang="en-US">Translation differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xlink:to="lab_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xml:lang="en-US">Valuation allowances and reserves foreign currency translation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xml:lang="en-US">Balance at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xml:lang="en-US">Balance at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xml:lang="en-US">Credits and payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xml:lang="en-US">Valuation Allowances And Reserves Related To Current Period Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xml:lang="en-US">Provisions related to sales made in current year period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xlink:to="lab_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xml:lang="en-US">Valuation allowances and reserves related to current period sales.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xml:lang="en-US">Valuation Allowances And Reserves Related To Prior Period Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xml:lang="en-US">Provisions related to sales made in prior periods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xlink:to="lab_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xml:lang="en-US">Valuation allowances and reserves related to prior period sales.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RebatesMember" xlink:label="loc_teva_RebatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RebatesMember" xml:lang="en-US">Rebates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RebatesMember" xml:lang="en-US">Rebates [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RebatesMember" xlink:to="lab_teva_RebatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RebatesMember" xml:lang="en-US">Rebates.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ReturnsMember" xlink:label="loc_teva_ReturnsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ReturnsMember" xml:lang="en-US">Returns [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ReturnsMember" xml:lang="en-US">Returns [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ReturnsMember" xlink:to="lab_teva_ReturnsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ReturnsMember" xml:lang="en-US">Returns.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MedicaidAndOtherGovernmentalAllowancesMember" xlink:label="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MedicaidAndOtherGovernmentalAllowancesMember" xml:lang="en-US">Medicaid And Other Governmental Allowances [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MedicaidAndOtherGovernmentalAllowancesMember" xml:lang="en-US">Medicaid and other governmental allowances [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember" xlink:to="lab_teva_MedicaidAndOtherGovernmentalAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MedicaidAndOtherGovernmentalAllowancesMember" xml:lang="en-US">Medicaid and other governmental allowances.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ReservesIncludedInAccountsReceivableNetMember" xlink:label="loc_teva_ReservesIncludedInAccountsReceivableNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ReservesIncludedInAccountsReceivableNetMember" xml:lang="en-US">Reserves Included In Accounts Receivable Net [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ReservesIncludedInAccountsReceivableNetMember" xml:lang="en-US">Reserves Included in Accounts Receivable, net [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ReservesIncludedInAccountsReceivableNetMember" xlink:to="lab_teva_ReservesIncludedInAccountsReceivableNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ReservesIncludedInAccountsReceivableNetMember" xml:lang="en-US">Reserves included in accounts receivable net.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ChargebacksMember" xlink:label="loc_teva_ChargebacksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ChargebacksMember" xml:lang="en-US">Chargebacks [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ChargebacksMember" xml:lang="en-US">Chargebacks [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ChargebacksMember" xlink:to="lab_teva_ChargebacksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ChargebacksMember" xml:lang="en-US">Chargebacks.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xlink:label="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xml:lang="en-US">Total Reserves Included In Sales Reserves And Allowances [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xml:lang="en-US">Total reserves included in sales reserves and allowances [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xlink:to="lab_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xml:lang="en-US">Total reserves included in sales reserves and allowances.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherSalesReservesAndAllowancesMember" xlink:label="loc_teva_OtherSalesReservesAndAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherSalesReservesAndAllowancesMember" xml:lang="en-US">Other Sales Reserves And Allowances [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherSalesReservesAndAllowancesMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherSalesReservesAndAllowancesMember" xlink:to="lab_teva_OtherSalesReservesAndAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherSalesReservesAndAllowancesMember" xml:lang="en-US">Other sales reserves and allowances.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InventoriesTable" xlink:label="loc_teva_InventoriesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InventoriesTable" xml:lang="en-US">Inventories [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_InventoriesTable" xml:lang="en-US">Inventories [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InventoriesTable" xlink:to="lab_teva_InventoriesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InventoriesTable" xml:lang="en-US">Inventories [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InventoriesLineItems" xlink:label="loc_teva_InventoriesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InventoriesLineItems" xml:lang="en-US">Inventories [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_InventoriesLineItems" xml:lang="en-US">Inventories [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InventoriesLineItems" xlink:to="lab_teva_InventoriesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InventoriesLineItems" xml:lang="en-US">Inventories [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Products in process</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Raw and packaging materials</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryInTransit" xlink:label="loc_us-gaap_OtherInventoryInTransit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherInventoryInTransit" xml:lang="en-US">Other Inventory, in Transit, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherInventoryInTransit" xml:lang="en-US">Materials in transit and payments on account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryInTransit" xlink:to="lab_us-gaap_OtherInventoryInTransit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Finished products</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProductRightsMember" xml:lang="en-US">Product Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_ProductRightsMember" xml:lang="en-US">Product rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ProductRightsMember" xml:lang="en-US">Identifiable product rights [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProductRightsMember" xlink:to="lab_teva_ProductRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProductRightsMember" xml:lang="en-US">Product Rights [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeNamesMember" xml:lang="en-US">Trade Names [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TradeNamesMember" xml:lang="en-US">Trade names [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xml:lang="en-US">In Process Research and Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xml:lang="en-US">In process research and development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Gross carrying amount net of impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DiscontinuationOfBusinessAxis" xlink:label="loc_teva_DiscontinuationOfBusinessAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DiscontinuationOfBusinessAxis" xml:lang="en-US">Discontinuation Of Business [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DiscontinuationOfBusinessAxis" xlink:to="lab_teva_DiscontinuationOfBusinessAxis" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DiscontinuationOfBusinessDomain" xlink:label="loc_teva_DiscontinuationOfBusinessDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DiscontinuationOfBusinessDomain" xml:lang="en-US">Discontinuation Of Business [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DiscontinuationOfBusinessDomain" xlink:to="lab_teva_DiscontinuationOfBusinessDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement input, discount rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_GenericPipelineProductsMember" xlink:label="loc_teva_GenericPipelineProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_GenericPipelineProductsMember" xml:lang="en-US">Generic Pipeline Products [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_GenericPipelineProductsMember" xlink:to="lab_teva_GenericPipelineProductsMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LenalidomideProductMember" xlink:label="loc_teva_LenalidomideProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LenalidomideProductMember" xml:lang="en-US">Lenalidomide Product [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LenalidomideProductMember" xlink:to="lab_teva_LenalidomideProductMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="loc_country_JP" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_JP" xml:lang="en-US">JAPAN</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_JP" xml:lang="en-US">Japan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xml:lang="en-US">Impairment Of Intangible Assets Reasons For Impairment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xlink:to="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xml:lang="en-US">Impairment Of Intangible Assets Reasons For Impairment.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xml:lang="en-US">Impairment Of Intangible Assets Reasons For Impairment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:to="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xml:lang="en-US">Impairment Of Intangible Assets Reasons For Impairment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Amortization of intangible assets useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Impairment of intangible assets excluding goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Intangible asset impairments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xml:lang="en-US">Business combination, contingent consideration, liability, measurement input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis" xlink:label="loc_us-gaap_ReclassificationTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReclassificationTypeAxis" xml:lang="en-US">Reclassification, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTypeAxis" xlink:to="lab_us-gaap_ReclassificationTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain" xlink:label="loc_us-gaap_ReclassificationTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReclassificationTypeDomain" xml:lang="en-US">Reclassification, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTypeDomain" xlink:to="lab_us-gaap_ReclassificationTypeDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EventBasisAxis" xlink:label="loc_teva_EventBasisAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EventBasisAxis" xml:lang="en-US">Event Basis [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EventBasisAxis" xlink:to="lab_teva_EventBasisAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EventBasisAxis" xml:lang="en-US">Event basis .</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EventBasisDomain" xlink:label="loc_teva_EventBasisDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EventBasisDomain" xml:lang="en-US">Event Basis [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EventBasisDomain" xlink:to="lab_teva_EventBasisDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EventBasisDomain" xml:lang="en-US">Event basis .</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UpdatedMarketAssumptionsMember" xlink:label="loc_teva_UpdatedMarketAssumptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UpdatedMarketAssumptionsMember" xml:lang="en-US">Updated Market Assumptions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_UpdatedMarketAssumptionsMember" xml:lang="en-US">Updated Market Assumptions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UpdatedMarketAssumptionsMember" xlink:to="lab_teva_UpdatedMarketAssumptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UpdatedMarketAssumptionsMember" xml:lang="en-US">Updated market assumptions .</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PriceAndVolumeOfProductsMember" xlink:label="loc_teva_PriceAndVolumeOfProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PriceAndVolumeOfProductsMember" xml:lang="en-US">Price And Volume Of Products [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_PriceAndVolumeOfProductsMember" xml:lang="en-US">Price And Volume Of Products [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PriceAndVolumeOfProductsMember" xlink:to="lab_teva_PriceAndVolumeOfProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PriceAndVolumeOfProductsMember" xml:lang="en-US">Price and volume of products.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RegulatoryPriceAndVolumeOfProductsMember" xlink:label="loc_teva_RegulatoryPriceAndVolumeOfProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RegulatoryPriceAndVolumeOfProductsMember" xml:lang="en-US">Regulatory Price And Volume Of Products [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RegulatoryPriceAndVolumeOfProductsMember" xml:lang="en-US">Regulatory Price And Volume Of Products [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RegulatoryPriceAndVolumeOfProductsMember" xlink:to="lab_teva_RegulatoryPriceAndVolumeOfProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RegulatoryPriceAndVolumeOfProductsMember" xml:lang="en-US">Regulatory price and volume of products.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember" xlink:label="loc_teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember" xml:lang="en-US">Development Progress And Changes In Other Key Valuation Assumptions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember" xml:lang="en-US">Development Progress And Changes In Other Key Valuation Assumptions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember" xlink:to="lab_teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember" xml:lang="en-US">Development progress and changes in other key valuation assumptions.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillRollForward" xml:lang="en-US">Goodwill [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xml:lang="en-US">Schedule of Goodwill [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xml:lang="en-US">Schedule of Goodwill [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsAxis" xml:lang="en-US">Consolidation Items [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsDomain" xml:lang="en-US">Consolidation Items [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReportingUnitAxis" xml:lang="en-US">Reporting Unit [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReportingUnitDomain" xml:lang="en-US">Reporting Unit [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TevasApiReportingUnitMember" xlink:label="loc_teva_TevasApiReportingUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TevasApiReportingUnitMember" xml:lang="en-US">Tevas API Reporting Unit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TevasApiReportingUnitMember" xml:lang="en-US">Tevas API Reporting Unit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TevasApiReportingUnitMember" xlink:to="lab_teva_TevasApiReportingUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TevasApiReportingUnitMember" xml:lang="en-US">Teva's API reporting unit.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MedisReportingUnitMember" xlink:label="loc_teva_MedisReportingUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MedisReportingUnitMember" xml:lang="en-US">Medis Reporting Unit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MedisReportingUnitMember" xml:lang="en-US">Medis Reporting Unit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MedisReportingUnitMember" xlink:to="lab_teva_MedisReportingUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MedisReportingUnitMember" xml:lang="en-US">Medis reporting unit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillLineItems" xml:lang="en-US">Goodwill [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillLineItems" xml:lang="en-US">Goodwill [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xml:lang="en-US">Translation differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherCountriesMember" xlink:label="loc_teva_OtherCountriesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherCountriesMember" xml:lang="en-US">Other Countries [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherCountriesMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherCountriesMember" xlink:to="lab_teva_OtherCountriesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherCountriesMember" xml:lang="en-US">Other countries.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xml:lang="en-US">Accumulated goodwill impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xml:lang="en-US">Reporting unit percentage of fair value in excess of carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EuropeReportingUnitMember" xlink:label="loc_teva_EuropeReportingUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EuropeReportingUnitMember" xml:lang="en-US">Europe Reporting Unit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EuropeReportingUnitMember" xml:lang="en-US">Europe Reporting Unit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EuropeReportingUnitMember" xlink:to="lab_teva_EuropeReportingUnitMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EuropeReportingUnitMember" xml:lang="en-US">Europe reporting unit member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Weighted average interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Current maturities of long-term liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Less current maturities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DebtInstrumentMaturityYear" xml:lang="en-US">Debt Instrument Maturity Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DebtInstrumentMaturityYear" xml:lang="en-US">Maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DebtInstrumentMaturityYear" xlink:to="lab_teva_DebtInstrumentMaturityYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DebtInstrumentMaturityYear" xml:lang="en-US">Debt Instrument Maturity Year</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermBorrowings" xml:lang="en-US">Convertible senior debentures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ShortCreditAgreement2026Member" xlink:label="loc_teva_ShortCreditAgreement2026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ShortCreditAgreement2026Member" xml:lang="en-US">Short Credit Agreement 2026 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ShortCreditAgreement2026Member" xml:lang="en-US">Convertible senior debentures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ShortCreditAgreement2026Member" xlink:to="lab_teva_ShortCreditAgreement2026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ShortCreditAgreement2026Member" xml:lang="en-US">Short credit agreement 2026.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2036Member" xml:lang="en-US">Subsidiary Senior Notes Due 2036 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2036Member" xml:lang="en-US">Senior notes USD 789 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2036Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2036Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2036Member" xml:lang="en-US">Subsidiary senior notes due 2036.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028Member" xml:lang="en-US">Subsidiary Senior Notes Due 2028 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028Member" xml:lang="en-US">Senior notes EUR 750 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2028Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2028Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028Member" xml:lang="en-US">Subsidiary senior notes due 2028.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2028 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028OneMember" xml:lang="en-US">Senior notes USD 1,250 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2028OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2028OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2028 One [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2025 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025OneMember" xml:lang="en-US">Senior notes EUR 1,000 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2025OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2025OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2025 One [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2026OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2026 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2026OneMember" xml:lang="en-US">Senior notes USD 3,500 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2026OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2026OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2026OneMember" xml:lang="en-US">Subsidiary senior notes due 2026 one.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2029Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2029Member" xml:lang="en-US">Sustainability Linked Senior Notes Due 2029 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2029Member" xml:lang="en-US">Sustainability-linked senior notes USD 1,000&#160;million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member" xlink:to="lab_teva_SustainabilityLinkedSeniorNotesDue2029Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2029Member" xml:lang="en-US">Sustainability linked senior notes due 2029.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2027Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2027Member" xml:lang="en-US">Sustainability Linked Senior Notes Due 2027 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2027Member" xml:lang="en-US">Sustainability-linked senior notes EUR 1,100&#160;million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member" xlink:to="lab_teva_SustainabilityLinkedSeniorNotesDue2027Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2027Member" xml:lang="en-US">Sustainability linked senior notes due 2027.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024Member" xml:lang="en-US">Subsidiary Senior Notes Due 2024 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024Member" xml:lang="en-US">Senior notes EUR 1,500 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2024Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024Member" xml:lang="en-US">Subsidiary senior notes due 2024.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022ThreeMember" xml:lang="en-US">Subsidiary Senior Notes Due 2022 Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022ThreeMember" xml:lang="en-US">Senior notes CHF 350 Million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2022ThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022ThreeMember" xml:lang="en-US">Subsidiary Senior Notes Due 2022 Three [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2023 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023OneMember" xml:lang="en-US">Senior notes EUR 1,300 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2023OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2023OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023OneMember" xml:lang="en-US">Subsidiary senior notes due 2023 one.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2022 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022OneMember" xml:lang="en-US">Senior notes EUR 700 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2022OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2022OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022OneMember" xml:lang="en-US">Subsidiary senior notes due 2022 one.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023TwoMember" xml:lang="en-US">Subsidiary Senior Notes Due 2023 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023TwoMember" xml:lang="en-US">Senior notes USD 3,000 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2023TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023TwoMember" xml:lang="en-US">Subsidiary senior notes due 2023 two.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2030Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2030Member" xml:lang="en-US">Sustainability Linked Senior Notes Due 2030 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2030Member" xml:lang="en-US">Sustainability-linked senior notes EUR 1,500&#160;million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member" xlink:to="lab_teva_SustainabilityLinkedSeniorNotesDue2030Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2030Member" xml:lang="en-US">Sustainability linked senior notes due 2030.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherDebentures2026Member" xlink:label="loc_teva_OtherDebentures2026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherDebentures2026Member" xml:lang="en-US">Other Debentures 2026 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherDebentures2026Member" xml:lang="en-US">Other Debentures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherDebentures2026Member" xlink:to="lab_teva_OtherDebentures2026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherDebentures2026Member" xml:lang="en-US">Other debentures 2026.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xml:lang="en-US">Sustainability Linked Senior Notes Due 2027 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xml:lang="en-US">Sustainability-linked senior notes USD 1,000&#160;million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xlink:to="lab_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xml:lang="en-US">Sustainability linked senior notes due 2027 two.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2046Member" xml:lang="en-US">Subsidiary Senior Notes Due 2046 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2046Member" xml:lang="en-US">Senior notes USD 2,000 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2046Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2046Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2046Member" xml:lang="en-US">Subsidiary senior notes due 2046.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" xml:lang="en-US">Subsidiary Senior Notes Due 2025 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" xml:lang="en-US">Senior notes USD 1,000 million [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" xml:lang="en-US">Senior notes USD 1,000 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" xml:lang="en-US">Subsidiary senior notes due 2025 two.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember" xml:lang="en-US">Sustainability Senior Linked Loans Due Two Thousand And Twenty Nine One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember" xml:lang="en-US">Sustainability-linked senior notes EUR 800&#160;million</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember" xlink:to="lab_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember" xml:lang="en-US">Sustainability Senior Linked Loans Due Two Thousand And Thirty One One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember" xml:lang="en-US">Sustainability-linked senior notes EUR 500&#160;million</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember" xlink:to="lab_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember" xml:lang="en-US">Sustainability Senior Linked Loans Due Two Thousand And Twenty Nine Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember" xml:lang="en-US">Sustainability-linked senior notes USD 600&#160;million</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember" xlink:to="lab_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember" xml:lang="en-US">Sustainability Senior Linked Loans Due Two Thousand And Thirty One Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember" xml:lang="en-US">Sustainability-linked senior notes USD 500&#160;million</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember" xlink:to="lab_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2024 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024OneMember" xml:lang="en-US">Senior notes USD 1,250 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2024OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2024OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2024 One [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025Member" xml:lang="en-US">Subsidiary Senior Notes Due 2025 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025Member" xml:lang="en-US">Senior notes EUR 900 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2025Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2025Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025Member" xml:lang="en-US">Subsidiary Senior Notes Due 2025 Member</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xml:lang="en-US">Less debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeniorNotes" xml:lang="en-US">Senior Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeniorNotes" xml:lang="en-US">Total senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes" xlink:to="lab_us-gaap_SeniorNotes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeniorNotesMember" xml:lang="en-US">Senior Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeniorNotesMember" xml:lang="en-US">Senior Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SeniorNotesMaturityPercentage" xlink:label="loc_teva_SeniorNotesMaturityPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesMaturityPercentage" xml:lang="en-US">Senior Notes Maturity Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_SeniorNotesMaturityPercentage" xml:lang="en-US">Senior notes maturity percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesMaturityPercentage" xlink:to="lab_teva_SeniorNotesMaturityPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesMaturityPercentage" xml:lang="en-US">Senior notes maturity percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt instrument face amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SeniorNotesRepaidAmount" xlink:label="loc_teva_SeniorNotesRepaidAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesRepaidAmount" xml:lang="en-US">Senior Notes Repaid Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_SeniorNotesRepaidAmount" xml:lang="en-US">Senior notes repaid amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesRepaidAmount" xlink:to="lab_teva_SeniorNotesRepaidAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesRepaidAmount" xml:lang="en-US">Senior notes repaid amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xml:lang="en-US">Long term debt bearing fixed interest rate percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DebtInstrumentMonthOfMaturity" xlink:label="loc_teva_DebtInstrumentMonthOfMaturity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DebtInstrumentMonthOfMaturity" xml:lang="en-US">Debt Instrument Month Of Maturity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DebtInstrumentMonthOfMaturity" xml:lang="en-US">Debt instrument month of maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DebtInstrumentMonthOfMaturity" xlink:to="lab_teva_DebtInstrumentMonthOfMaturity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DebtInstrumentMonthOfMaturity" xml:lang="en-US">Debt instrument month of maturity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xml:lang="en-US">Extinguishment of Debt, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xml:lang="en-US">Debt instrument principal amount of debt extinguished</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xml:lang="en-US">Debt Issuance Costs, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xml:lang="en-US">Debt issuance costs gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xml:lang="en-US">Accumulated Amortization, Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xml:lang="en-US">Debt instrument accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:to="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InterestRateIncreaseMember" xlink:label="loc_teva_InterestRateIncreaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InterestRateIncreaseMember" xml:lang="en-US">Interest Rate Increase [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_InterestRateIncreaseMember" xml:lang="en-US">Interest Rate Increase [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InterestRateIncreaseMember" xlink:to="lab_teva_InterestRateIncreaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InterestRateIncreaseMember" xml:lang="en-US">Interest rate increase.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OneTimePremiumPaymentMember" xlink:label="loc_teva_OneTimePremiumPaymentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OneTimePremiumPaymentMember" xml:lang="en-US">One Time Premium Payment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OneTimePremiumPaymentMember" xml:lang="en-US">One Time Premium Payment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OneTimePremiumPaymentMember" xlink:to="lab_teva_OneTimePremiumPaymentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OneTimePremiumPaymentMember" xml:lang="en-US">One time&#160;premium payment.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember" xlink:label="loc_teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember" xml:lang="en-US">Sustainiability Senior Linked Notes Two Thousand Twenty Nine And Two Thousand And Thirty One One And Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember" xlink:to="lab_teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" xlink:label="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" xml:lang="en-US">Period From Which Interest Rate Increase Could Be Applicable [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" xlink:to="lab_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain" xlink:label="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain" xml:lang="en-US">Period From Which Interest Rate Increase Could Be Applicable [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain" xlink:to="lab_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember" xlink:label="loc_teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember" xml:lang="en-US">From September Fifteenth Two Thousand And Twenty Six [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember" xlink:to="lab_teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember" xlink:label="loc_teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember" xml:lang="en-US">Unsecured Syndicated Revolving Credi tFacility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember" xlink:to="lab_teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember" xml:lang="en-US">Unsecured syndicated revolving credit facility member.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AmendedRevolvingCreditFacilityMember" xlink:label="loc_teva_AmendedRevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AmendedRevolvingCreditFacilityMember" xml:lang="en-US">Amended Revolving Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AmendedRevolvingCreditFacilityMember" xlink:to="lab_teva_AmendedRevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AmendedRevolvingCreditFacilityMember" xml:lang="en-US">Amended revolving credit facility member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-term Debt, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Principal amount currently outstanding on the debt instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCovenantDescription" xml:lang="en-US">Debt Instrument, Covenant Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCovenantDescription" xlink:to="lab_us-gaap_DebtInstrumentCovenantDescription" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LongTermDebtCurrencyPortionUSD" xlink:label="loc_teva_LongTermDebtCurrencyPortionUSD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtCurrencyPortionUSD" xml:lang="en-US">Long Term Debt Currency Portion U S D</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtCurrencyPortionUSD" xml:lang="en-US">Long term debt currency portion USD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtCurrencyPortionUSD" xlink:to="lab_teva_LongTermDebtCurrencyPortionUSD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtCurrencyPortionUSD" xml:lang="en-US">Long term debt currency portion U S D.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LongTermDebtCurrencyPortionCHF" xlink:label="loc_teva_LongTermDebtCurrencyPortionCHF" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtCurrencyPortionCHF" xml:lang="en-US">Long Term Debt Currency Portion C H F</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtCurrencyPortionCHF" xml:lang="en-US">Long term debt currency portion CHF</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtCurrencyPortionCHF" xlink:to="lab_teva_LongTermDebtCurrencyPortionCHF" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtCurrencyPortionCHF" xml:lang="en-US">Long term debt currency portion C H F.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LongTermDebtCurrencyPortionEUR" xlink:label="loc_teva_LongTermDebtCurrencyPortionEUR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtCurrencyPortionEUR" xml:lang="en-US">Long Term Debt Currency Portion E U R</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtCurrencyPortionEUR" xml:lang="en-US">Long term debt currency portion EUR</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtCurrencyPortionEUR" xlink:to="lab_teva_LongTermDebtCurrencyPortionEUR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtCurrencyPortionEUR" xml:lang="en-US">Long term debt currency portion E U R.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Long-term Line of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Long Term Debt Payable Under Revolving Credit Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LeverageRatio" xlink:label="loc_teva_LeverageRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LeverageRatio" xml:lang="en-US">Leverage Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LeverageRatio" xml:lang="en-US">Leverage Ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LeverageRatio" xlink:to="lab_teva_LeverageRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LeverageRatio" xml:lang="en-US">Leverage ratio.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LineOfCreditExtensionPeriod" xlink:label="loc_teva_LineOfCreditExtensionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LineOfCreditExtensionPeriod" xml:lang="en-US">Line Of Credit Extension Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LineOfCreditExtensionPeriod" xml:lang="en-US">Line of credit extension period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LineOfCreditExtensionPeriod" xlink:to="lab_teva_LineOfCreditExtensionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LineOfCreditExtensionPeriod" xml:lang="en-US">Line of credit extension period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodAxis" xlink:label="loc_teva_PeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PeriodAxis" xml:lang="en-US">Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PeriodAxis" xlink:to="lab_teva_PeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PeriodAxis" xml:lang="en-US">Period axsis.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodDomain" xlink:label="loc_teva_PeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PeriodDomain" xml:lang="en-US">Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PeriodDomain" xlink:to="lab_teva_PeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PeriodDomain" xml:lang="en-US">Period domain.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xml:lang="en-US">Lender Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TrancheAxis" xlink:label="loc_teva_TrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TrancheAxis" xml:lang="en-US">Tranche [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TrancheAxis" xlink:to="lab_teva_TrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TrancheAxis" xml:lang="en-US">Tranche.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TrancheDomain" xlink:label="loc_teva_TrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TrancheDomain" xml:lang="en-US">Tranche [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TrancheDomain" xlink:to="lab_teva_TrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TrancheDomain" xml:lang="en-US">Tranche.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AgreementAxis" xlink:label="loc_teva_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AgreementAxis" xlink:to="lab_teva_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AgreementAxis" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AgreementDomain" xlink:to="lab_teva_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AgreementDomain" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable" xlink:label="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable" xml:lang="en-US">Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable" xlink:to="lab_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable" xml:lang="en-US">Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HedgingDesignationAxis" xml:lang="en-US">Hedging Designation [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HedgingDesignationAxis" xml:lang="en-US">Hedging Designation [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HedgingDesignationDomain" xml:lang="en-US">Hedging Designation [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HedgingDesignationDomain" xml:lang="en-US">Hedging Designation [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xml:lang="en-US">Designated as Hedging Instrument [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xml:lang="en-US">Designated as Hedging Instrument [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems" xlink:label="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems" xml:lang="en-US">Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems" xlink:to="lab_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems" xml:lang="en-US">Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xml:lang="en-US">Derivative Asset, Notional Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xml:lang="en-US">Cross-currency swap - cash flow hedge</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CrossCurrencySwapCashFlowHedgeMember" xlink:label="loc_teva_CrossCurrencySwapCashFlowHedgeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CrossCurrencySwapCashFlowHedgeMember" xml:lang="en-US">Cross Currency Swap Cash Flow Hedge [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CrossCurrencySwapCashFlowHedgeMember" xlink:to="lab_teva_CrossCurrencySwapCashFlowHedgeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CrossCurrencySwapCashFlowHedgeMember" xml:lang="en-US">Cross Currency Swap Cash Flow Hedge</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xml:lang="en-US">Derivative Instrument Detail [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentDetailAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xml:lang="en-US">Liability derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xml:lang="en-US">Asset derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xml:lang="en-US">Foreign Exchange Contract [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xml:lang="en-US">Foreign Exchange Contract [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xml:lang="en-US">Other Current Liabilities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xml:lang="en-US">Other Current Liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xml:lang="en-US">Other Noncurrent Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xml:lang="en-US">Other Non-current Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xml:lang="en-US">Other Current Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xml:lang="en-US">Hedging Relationship [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xml:lang="en-US">Hedging Relationship [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xml:lang="en-US">Hedging Relationship [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xml:lang="en-US">Hedging Relationship [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NondesignatedMember" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NondesignatedMember" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable" xlink:label="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable" xml:lang="en-US">Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable" xlink:to="lab_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable" xml:lang="en-US">Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FinancialExpensesNetMember" xlink:label="loc_teva_FinancialExpensesNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FinancialExpensesNetMember" xml:lang="en-US">Financial Expenses Net [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FinancialExpensesNetMember" xlink:to="lab_teva_FinancialExpensesNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FinancialExpensesNetMember" xml:lang="en-US">Financial expenses net.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems" xlink:label="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems" xml:lang="en-US">Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems" xlink:to="lab_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems" xml:lang="en-US">Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments" xlink:label="loc_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments" xml:lang="en-US">Unrealized Gain (Loss) on Cash Flow Hedging Instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments" xml:lang="en-US">Financial expenses, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments" xlink:to="lab_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax, Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xml:lang="en-US">Other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xml:lang="en-US">Not Designated as Hedging Instrument, Economic Hedge [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xml:lang="en-US">Not Designated as Hedging Instrument, Economic Hedge [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:to="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xml:lang="en-US">Not Designated as Hedging Instrument, Trading [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xml:lang="en-US">Not Designated as Hedging Instrument, Trading [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xlink:to="lab_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NetRevenuesMember" xlink:label="loc_teva_NetRevenuesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NetRevenuesMember" xml:lang="en-US">Net Revenues [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_NetRevenuesMember" xml:lang="en-US">Net Revenues [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NetRevenuesMember" xlink:to="lab_teva_NetRevenuesMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FinancialExpensesMember" xlink:label="loc_teva_FinancialExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FinancialExpensesMember" xml:lang="en-US">Financial expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FinancialExpensesMember" xml:lang="en-US">Financial expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FinancialExpensesMember" xlink:to="lab_teva_FinancialExpensesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainOnDerivative" xml:lang="en-US">Derivative, Gain on Derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainOnDerivative" xlink:to="lab_us-gaap_DerivativeGainOnDerivative" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xlink:label="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xml:lang="en-US">Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xml:lang="en-US">Forward starting interest rate swaps and treasury lock agreements losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xlink:to="lab_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xml:lang="en-US">Forward starting interest rate swaps and treasury lock agreements losses.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenuesOtherThanUsd" xlink:label="loc_teva_RevenuesOtherThanUsd" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenuesOtherThanUsd" xml:lang="en-US">Revenues Other Than Usd</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RevenuesOtherThanUsd" xml:lang="en-US">Revenues other than USD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenuesOtherThanUsd" xlink:to="lab_teva_RevenuesOtherThanUsd" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RevenuesOtherThanUsd" xml:lang="en-US">Revenues other than US Dollar.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xml:lang="en-US">Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xml:lang="en-US">Derivative, Loss on Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xml:lang="en-US">Teva other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLossOnDerivative" xlink:to="lab_us-gaap_DerivativeLossOnDerivative" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xml:lang="en-US">Derivative, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Loss Contingency Accrual</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Accrued amount for legal settlements and loss contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Generic modafinil, and imposed fines amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Litigation Settlement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Legal settlements and loss contingencies, expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_LitigationCaseAxis" xml:lang="en-US">Litigation Case [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_LitigationCaseTypeDomain" xml:lang="en-US">Litigation Case [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CommitmentAndContingenciesTable" xlink:label="loc_teva_CommitmentAndContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CommitmentAndContingenciesTable" xml:lang="en-US">Commitment And Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CommitmentAndContingenciesTable" xml:lang="en-US">Commitment And Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CommitmentAndContingenciesTable" xlink:to="lab_teva_CommitmentAndContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CommitmentAndContingenciesTable" xml:lang="en-US">Commitment And Contingencies [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CommitmentAndContingenciesLineItems" xlink:label="loc_teva_CommitmentAndContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CommitmentAndContingenciesLineItems" xml:lang="en-US">Commitment And Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CommitmentAndContingenciesLineItems" xml:lang="en-US">Commitment And Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CommitmentAndContingenciesLineItems" xlink:to="lab_teva_CommitmentAndContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CommitmentAndContingenciesLineItems" xml:lang="en-US">Commitment And Contingencies [Line Items]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfNiaspan" xlink:label="loc_teva_AnnualSalesOfNiaspan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfNiaspan" xml:lang="en-US">Annual Sales Of Niaspan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfNiaspan" xml:lang="en-US">Annual sales of Niaspan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfNiaspan" xlink:to="lab_teva_AnnualSalesOfNiaspan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfNiaspan" xml:lang="en-US">Annual sales of Niaspan.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfActoplus" xlink:label="loc_teva_AnnualSalesOfActoplus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfActoplus" xml:lang="en-US">Annual Sales Of Actoplus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfActoplus" xml:lang="en-US">Annual sales of Acto plus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfActoplus" xlink:to="lab_teva_AnnualSalesOfActoplus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfActoplus" xml:lang="en-US">Annual sales of Acto plus.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DamagesAssessment" xlink:label="loc_teva_DamagesAssessment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DamagesAssessment" xml:lang="en-US">Damages Assessment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DamagesAssessment" xml:lang="en-US">Damages assessment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DamagesAssessment" xlink:to="lab_teva_DamagesAssessment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DamagesAssessment" xml:lang="en-US">Damages assessment.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla" xlink:label="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla" xml:lang="en-US">Annual Sales Of The Time Of New Launch Of Atripla</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla" xml:lang="en-US">Annual sales of the time of New launch of Atripla</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla" xlink:to="lab_teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla" xml:lang="en-US">Annual sales of the time of new launch of Atripla.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LossContingenciesOnEnvironmentalLawsPenalty" xlink:label="loc_teva_LossContingenciesOnEnvironmentalLawsPenalty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LossContingenciesOnEnvironmentalLawsPenalty" xml:lang="en-US">Loss Contingencies On Environmental Laws Penalty</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LossContingenciesOnEnvironmentalLawsPenalty" xml:lang="en-US">Loss Contingencies On Environmental Laws Penalty</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LossContingenciesOnEnvironmentalLawsPenalty" xlink:to="lab_teva_LossContingenciesOnEnvironmentalLawsPenalty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LossContingenciesOnEnvironmentalLawsPenalty" xml:lang="en-US">Loss contingencies on environmental laws penalty.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LitigationSettlementAmountAwardedDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationSettlementAmountAwardedDistributionPeriod" xml:lang="en-US">Litigation Settlement Amount Awarded Distribution Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationSettlementAmountAwardedDistributionPeriod" xml:lang="en-US">Litigation settlement amount awarded distribution period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod" xlink:to="lab_teva_LitigationSettlementAmountAwardedDistributionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationSettlementAmountAwardedDistributionPeriod" xml:lang="en-US">Litigation settlement amount awarded distribution period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xml:lang="en-US">Litigation settlement amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfLamictal" xlink:label="loc_teva_AnnualSalesOfLamictal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfLamictal" xml:lang="en-US">Annual Sales Of Lamictal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfLamictal" xml:lang="en-US">Annual sales of Lamictal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfLamictal" xlink:to="lab_teva_AnnualSalesOfLamictal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfLamictal" xml:lang="en-US">Annual sales of Lamictal.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LitigationSettlementAmountDistributableinKind" xlink:label="loc_teva_LitigationSettlementAmountDistributableinKind" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationSettlementAmountDistributableinKind" xml:lang="en-US">Litigation Settlement Amount DistributableIn Kind</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationSettlementAmountDistributableinKind" xml:lang="en-US">Litigation Settlement Amount Distributable In Kind</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationSettlementAmountDistributableinKind" xlink:to="lab_teva_LitigationSettlementAmountDistributableinKind" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationSettlementAmountDistributableinKind" xml:lang="en-US">Litigation settlement amount distributableIn kind.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xml:lang="en-US">Loss Contingency, Damages Sought, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xml:lang="en-US">Damage claimed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada" xlink:label="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada" xml:lang="en-US">Annual Sales Of The Time Of New Launch Of Truvada</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada" xml:lang="en-US">Annual sales of the time of New launch of Truvada</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada" xlink:to="lab_teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada" xml:lang="en-US">Annual sales of the time of New launch of truvada.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfRevlimid" xlink:label="loc_teva_AnnualSalesOfRevlimid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfRevlimid" xml:lang="en-US">Annual Sales Of Revlimid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfRevlimid" xml:lang="en-US">Annual Sales Of Revlimid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfRevlimid" xlink:to="lab_teva_AnnualSalesOfRevlimid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfRevlimid" xml:lang="en-US">Annual sales of revlimid.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler" xlink:label="loc_teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler" xml:lang="en-US">Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler" xml:lang="en-US">Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler" xlink:to="lab_teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler" xml:lang="en-US">Annual sales at The time of nuvigil entered into first settlement of with AN ANDA hiler.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfSettlementOfTruvada" xlink:label="loc_teva_AnnualSalesOfTheTimeOfSettlementOfTruvada" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfTheTimeOfSettlementOfTruvada" xml:lang="en-US">Annual Sales Of The Time Of Settlement Of Truvada</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfTheTimeOfSettlementOfTruvada" xml:lang="en-US">Annual sales of the time of settlement of Truvada</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfTheTimeOfSettlementOfTruvada" xlink:to="lab_teva_AnnualSalesOfTheTimeOfSettlementOfTruvada" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfTheTimeOfSettlementOfTruvada" xml:lang="en-US">Annual sales of the time of settlement of truvada.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfSettlementOfViread" xlink:label="loc_teva_AnnualSalesOfTheTimeOfSettlementOfViread" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfTheTimeOfSettlementOfViread" xml:lang="en-US">Annual Sales Of The Time Of Settlement Of Viread</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfTheTimeOfSettlementOfViread" xml:lang="en-US">Annual sales of the time of settlement of viread</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfTheTimeOfSettlementOfViread" xlink:to="lab_teva_AnnualSalesOfTheTimeOfSettlementOfViread" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfTheTimeOfSettlementOfViread" xml:lang="en-US">Annual sales of the time of settlement of viread.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfActos" xlink:label="loc_teva_AnnualSalesOfActos" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfActos" xml:lang="en-US">Annual Sales Of Actos</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfActos" xml:lang="en-US">Annual sales of Actos</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfActos" xlink:to="lab_teva_AnnualSalesOfActos" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfActos" xml:lang="en-US">Annual sales of Actos.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesAtTimeOfSettlement" xlink:label="loc_teva_AnnualSalesAtTimeOfSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesAtTimeOfSettlement" xml:lang="en-US">Annual Sales At Time Of Settlement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesAtTimeOfSettlement" xml:lang="en-US">Annual sales at the time of settlement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesAtTimeOfSettlement" xlink:to="lab_teva_AnnualSalesAtTimeOfSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesAtTimeOfSettlement" xml:lang="en-US">Annual sales at time of settlement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xml:lang="en-US">Loss Contingency, Damages Paid, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xml:lang="en-US">Loss contingency payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:to="lab_us-gaap_LossContingencyDamagesPaidValue" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfEffexor" xlink:label="loc_teva_AnnualSalesOfEffexor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfEffexor" xml:lang="en-US">Annual Sales Of Effexor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfEffexor" xml:lang="en-US">Annual sales of Effexor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfEffexor" xlink:to="lab_teva_AnnualSalesOfEffexor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfEffexor" xml:lang="en-US">Annual sales of effexor.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LitigationSettlementAmountDistributableInCash" xlink:label="loc_teva_LitigationSettlementAmountDistributableInCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationSettlementAmountDistributableInCash" xml:lang="en-US">Litigation Settlement Amount Distributable in Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationSettlementAmountDistributableInCash" xml:lang="en-US">Litigation Settlement Amount Distributable in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationSettlementAmountDistributableInCash" xlink:to="lab_teva_LitigationSettlementAmountDistributableInCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationSettlementAmountDistributableInCash" xml:lang="en-US">Litigation settlement amount distributable in cash.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation" xlink:label="loc_teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation" xml:lang="en-US">Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation" xml:lang="en-US">Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation" xlink:to="lab_teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation" xml:lang="en-US">Loss contingency claims dismissed value paid to each state proportional to its share of national population</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xml:lang="en-US">Loss Contingency Accrual, Provision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xml:lang="en-US">Loss Contingency Accrual, Provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision" xlink:to="lab_us-gaap_LossContingencyAccrualProvision" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfColcrys" xlink:label="loc_teva_AnnualSalesOfColcrys" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfColcrys" xml:lang="en-US">Annual sales of Colcrys</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfColcrys" xml:lang="en-US">Annual sales of Colcrys</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfColcrys" xlink:to="lab_teva_AnnualSalesOfColcrys" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfColcrys" xml:lang="en-US">Annual sales of colcrys.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfNewLaunchOfViread" xlink:label="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfViread" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfTheTimeOfNewLaunchOfViread" xml:lang="en-US">Annual Sales Of The Time Of New Launch Of Viread</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfTheTimeOfNewLaunchOfViread" xml:lang="en-US">Annual sales of the time of New launch of viread</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfViread" xlink:to="lab_teva_AnnualSalesOfTheTimeOfNewLaunchOfViread" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfTheTimeOfNewLaunchOfViread" xml:lang="en-US">Annual sales of the time of new launch of viread.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LitigationSettlementAmountPayableInCashPercentage" xlink:label="loc_teva_LitigationSettlementAmountPayableInCashPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationSettlementAmountPayableInCashPercentage" xml:lang="en-US">Litigation settlement amount payable in cash percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationSettlementAmountPayableInCashPercentage" xml:lang="en-US">Percentgae of amount in cash settlement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationSettlementAmountPayableInCashPercentage" xlink:to="lab_teva_LitigationSettlementAmountPayableInCashPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationSettlementAmountPayableInCashPercentage" xml:lang="en-US">Litigation settlement amount payable in cash percentage</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement" xlink:label="loc_teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement" xml:lang="en-US">Percentage Of The Litigating Subdivisions Have Chosen To Participate In Tevas Nationwide Settlement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement" xml:lang="en-US">Percentage of the litigating subdivisions have chosen to participate in Teva's nationwide settlement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement" xlink:to="lab_teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement" xml:lang="en-US">Percentage of the litigating subdivisions have chosen to participate in teva's nationwide settlement.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PercentageOfThePopulationOfTheParticipatingStates" xlink:label="loc_teva_PercentageOfThePopulationOfTheParticipatingStates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PercentageOfThePopulationOfTheParticipatingStates" xml:lang="en-US">Percentage Of The Population Of The Participating States</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PercentageOfThePopulationOfTheParticipatingStates" xml:lang="en-US">Percentage of the population of the participating states</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PercentageOfThePopulationOfTheParticipatingStates" xlink:to="lab_teva_PercentageOfThePopulationOfTheParticipatingStates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PercentageOfThePopulationOfTheParticipatingStates" xml:lang="en-US">Percentage of the population of the participating states.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PercentageOfShareOfTheNationalPopulation" xlink:label="loc_teva_PercentageOfShareOfTheNationalPopulation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PercentageOfShareOfTheNationalPopulation" xml:lang="en-US">Percentage Of Share Of The National Population</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PercentageOfShareOfTheNationalPopulation" xml:lang="en-US">Percentage Of Share Of The National Population</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PercentageOfShareOfTheNationalPopulation" xlink:to="lab_teva_PercentageOfShareOfTheNationalPopulation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PercentageOfShareOfTheNationalPopulation" xml:lang="en-US">Percentage of share of the national population.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfSensipar" xlink:label="loc_teva_AnnualSalesOfSensipar" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfSensipar" xml:lang="en-US">Annual Sales Of Sensipar</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfSensipar" xml:lang="en-US">Annual Sales Of Sensipar</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfSensipar" xlink:to="lab_teva_AnnualSalesOfSensipar" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfSensipar" xml:lang="en-US">Represents Annual Sales Of Sensipar.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration" xml:lang="en-US">Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfEpipen" xlink:label="loc_teva_AnnualSalesOfEpipen" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfEpipen" xml:lang="en-US">Annual Sales Of EpiPen</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfEpipen" xml:lang="en-US">Annual Sales Of EpiPen</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfEpipen" xlink:to="lab_teva_AnnualSalesOfEpipen" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfEpipen" xml:lang="en-US">Annual sales of EpiPen.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfCopaxone" xlink:label="loc_teva_AnnualSalesOfCopaxone" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfCopaxone" xml:lang="en-US">Annual Sales Of Copaxone</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfCopaxone" xml:lang="en-US">Annual sales of Copaxone</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfCopaxone" xlink:to="lab_teva_AnnualSalesOfCopaxone" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfCopaxone" xml:lang="en-US">Annual Sales Of Copaxone.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForEnvironmentalLossContingencies" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccrualForEnvironmentalLossContingencies" xml:lang="en-US">Accrual for Environmental Loss Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccrualForEnvironmentalLossContingencies" xml:lang="en-US">Accrual for Environmental Loss Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccrualForEnvironmentalLossContingencies" xlink:to="lab_us-gaap_AccrualForEnvironmentalLossContingencies" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfSettlementOfAtripla" xlink:label="loc_teva_AnnualSalesOfTheTimeOfSettlementOfAtripla" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfTheTimeOfSettlementOfAtripla" xml:lang="en-US">Annual Sales Of The Time Of Settlement Of Atripla</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfTheTimeOfSettlementOfAtripla" xml:lang="en-US">Annual sales of the time of settlement of Atripla</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfTheTimeOfSettlementOfAtripla" xlink:to="lab_teva_AnnualSalesOfTheTimeOfSettlementOfAtripla" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfTheTimeOfSettlementOfAtripla" xml:lang="en-US">Annual sales of the time of settlement of atripla.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EosinophilicEsophagitisMember" xlink:label="loc_teva_EosinophilicEsophagitisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EosinophilicEsophagitisMember" xml:lang="en-US">Eosinophilic Esophagitis [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EosinophilicEsophagitisMember" xml:lang="en-US">Eosinophilic Esophagitis [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EosinophilicEsophagitisMember" xlink:to="lab_teva_EosinophilicEsophagitisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EosinophilicEsophagitisMember" xml:lang="en-US">Eosinophilic Esophagitis [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NationwideSettlementMember" xlink:label="loc_teva_NationwideSettlementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NationwideSettlementMember" xml:lang="en-US">Nationwide Settlement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NationwideSettlementMember" xlink:to="lab_teva_NationwideSettlementMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AndroGelRateAtOnePercentageMember" xlink:label="loc_teva_AndroGelRateAtOnePercentageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AndroGelRateAtOnePercentageMember" xml:lang="en-US">Andro Gel Rate At One Percentage [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AndroGelRateAtOnePercentageMember" xml:lang="en-US">AndroGel Rate at 1% [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AndroGelRateAtOnePercentageMember" xlink:to="lab_teva_AndroGelRateAtOnePercentageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AndroGelRateAtOnePercentageMember" xml:lang="en-US">Andro gel rate at one percentage.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DefendantsAxis" xlink:label="loc_teva_DefendantsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DefendantsAxis" xml:lang="en-US">Defendants [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DefendantsAxis" xlink:to="lab_teva_DefendantsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DefendantsAxis" xml:lang="en-US">Defendants.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DefendantsMember" xlink:label="loc_teva_DefendantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DefendantsMember" xml:lang="en-US">Defendants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DefendantsMember" xlink:to="lab_teva_DefendantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DefendantsMember" xml:lang="en-US">Defendants.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FourOtherDefendantsOtherThanTevaMember" xlink:label="loc_teva_FourOtherDefendantsOtherThanTevaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FourOtherDefendantsOtherThanTevaMember" xml:lang="en-US">Four Other Defendants Other Than Teva [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FourOtherDefendantsOtherThanTevaMember" xml:lang="en-US">Four Other Defendants Other Than Teva [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FourOtherDefendantsOtherThanTevaMember" xlink:to="lab_teva_FourOtherDefendantsOtherThanTevaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FourOtherDefendantsOtherThanTevaMember" xml:lang="en-US">Four other defendants other than teva.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesByJurisdictionAxis" xlink:label="loc_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis" xml:lang="en-US">Jurisdiction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis" xlink:to="lab_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesJurisdictionDomain" xlink:label="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatutoryAccountingPracticesJurisdictionDomain" xml:lang="en-US">Statutory Accounting Practices, Jurisdiction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain" xlink:to="lab_us-gaap_StatutoryAccountingPracticesJurisdictionDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CuyahogaCountyOhMember" xlink:label="loc_teva_CuyahogaCountyOhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CuyahogaCountyOhMember" xml:lang="en-US">Cuyahoga County, OH [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CuyahogaCountyOhMember" xlink:to="lab_teva_CuyahogaCountyOhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CuyahogaCountyOhMember" xml:lang="en-US">Cuyahoga County, OH</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TribesMember" xlink:label="loc_teva_TribesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TribesMember" xml:lang="en-US">Tribes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TribesMember" xlink:to="lab_teva_TribesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TribesMember" xml:lang="en-US">Tribes</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SanFranciscoMember" xlink:label="loc_teva_SanFranciscoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SanFranciscoMember" xml:lang="en-US">San Francisco [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SanFranciscoMember" xlink:to="lab_teva_SanFranciscoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SanFranciscoMember" xml:lang="en-US">San Francisco</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SummitCountyOhMember" xlink:label="loc_teva_SummitCountyOhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SummitCountyOhMember" xml:lang="en-US">Summit County, OH [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SummitCountyOhMember" xlink:to="lab_teva_SummitCountyOhMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SummitCountyOhMember" xml:lang="en-US">Summit County, OH</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV" xlink:label="loc_stpr_WV" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_stpr_WV" xml:lang="en-US">WEST VIRGINIA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WV" xlink:to="lab_stpr_WV" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TX" xlink:label="loc_stpr_TX" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_stpr_TX" xml:lang="en-US">TEXAS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TX" xlink:to="lab_stpr_TX" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OK" xlink:label="loc_stpr_OK" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_stpr_OK" xml:lang="en-US">OKLAHOMA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_OK" xlink:to="lab_stpr_OK" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_LA" xlink:label="loc_stpr_LA" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_stpr_LA" xml:lang="en-US">LOUISIANA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_LA" xlink:to="lab_stpr_LA" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_RI" xlink:label="loc_stpr_RI" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_stpr_RI" xml:lang="en-US">RHODE ISLAND</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_RI" xlink:to="lab_stpr_RI" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL" xlink:label="loc_stpr_FL" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_stpr_FL" xml:lang="en-US">FLORIDA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_FL" xlink:to="lab_stpr_FL" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY" xlink:label="loc_stpr_NY" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_stpr_NY" xml:lang="en-US">NEW YORK</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencySettlementAgreementDate" xlink:label="loc_us-gaap_LossContingencySettlementAgreementDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencySettlementAgreementDate" xml:lang="en-US">Loss Contingency, Settlement Agreement, Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencySettlementAgreementDate" xml:lang="en-US">Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencySettlementAgreementDate" xlink:to="lab_us-gaap_LossContingencySettlementAgreementDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDomicileOfLitigation" xlink:label="loc_us-gaap_LossContingencyDomicileOfLitigation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDomicileOfLitigation" xml:lang="en-US">Loss Contingency, Domicile of Litigation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyDomicileOfLitigation" xml:lang="en-US">Jurisdiction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDomicileOfLitigation" xlink:to="lab_us-gaap_LossContingencyDomicileOfLitigation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xml:lang="en-US">Loss Contingency Accrual, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xml:lang="en-US">Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencySettlementAgreementTerms" xlink:label="loc_us-gaap_LossContingencySettlementAgreementTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencySettlementAgreementTerms" xml:lang="en-US">Loss Contingency, Settlement Agreement, Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LossContingencySettlementAgreementTerms" xml:lang="en-US">Payment Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencySettlementAgreementTerms" xlink:to="lab_us-gaap_LossContingencySettlementAgreementTerms" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ContingencySettlementProduct" xlink:label="loc_teva_ContingencySettlementProduct" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ContingencySettlementProduct" xml:lang="en-US">Contingency Settlement Product</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_ContingencySettlementProduct" xml:lang="en-US">Settlement Product</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ContingencySettlementProduct" xlink:to="lab_teva_ContingencySettlementProduct" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ContingencySettlementProduct" xml:lang="en-US">Contingency Settlement Product</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProductWeightedAverageCost" xlink:label="loc_teva_ProductWeightedAverageCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProductWeightedAverageCost" xml:lang="en-US">Product Weighted Average Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_ProductWeightedAverageCost" xml:lang="en-US">Product WAC Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProductWeightedAverageCost" xlink:to="lab_teva_ProductWeightedAverageCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProductWeightedAverageCost" xml:lang="en-US">Product&#160; Weighted Average Cost</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProductWeightedAverageCostTerm" xlink:label="loc_teva_ProductWeightedAverageCostTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProductWeightedAverageCostTerm" xml:lang="en-US">Product Weighted Average Cost term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ProductWeightedAverageCostTerm" xml:lang="en-US">Product WAC Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProductWeightedAverageCostTerm" xlink:to="lab_teva_ProductWeightedAverageCostTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProductWeightedAverageCostTerm" xml:lang="en-US">Product Weighted Average Cost term</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_IncomeTaxTable" xlink:label="loc_teva_IncomeTaxTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IncomeTaxTable" xlink:to="lab_teva_IncomeTaxTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_IncomeTaxLineItems" xlink:label="loc_teva_IncomeTaxLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IncomeTaxLineItems" xlink:to="lab_teva_IncomeTaxLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory tax rate in Israel</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ExpectedImpairmentOfIncomeTaxBenefit" xlink:label="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExpectedImpairmentOfIncomeTaxBenefit" xml:lang="en-US">Expected Impairment OF Income Tax Benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExpectedImpairmentOfIncomeTaxBenefit" xml:lang="en-US">Expected impairment of income tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit" xlink:to="lab_teva_ExpectedImpairmentOfIncomeTaxBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExpectedImpairmentOfIncomeTaxBenefit" xml:lang="en-US">Expected impairment of income tax benefit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xml:lang="en-US">Income Tax Examination, Estimate of Possible Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xml:lang="en-US">Income Tax Examination, Estimate of Possible Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:to="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TaxYear2008To2011Member" xlink:label="loc_teva_TaxYear2008To2011Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TaxYear2008To2011Member" xml:lang="en-US">Tax Year 2008 To 2011 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TaxYear2008To2011Member" xlink:to="lab_teva_TaxYear2008To2011Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaap_IsraelTaxAuthorityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IsraelTaxAuthorityMember" xml:lang="en-US">Israel Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IsraelTaxAuthorityMember" xml:lang="en-US">Israel Tax Authority [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IsraelTaxAuthorityMember" xlink:to="lab_us-gaap_IsraelTaxAuthorityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category of Item Purchased [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category of Item Purchased [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_YearOfSettlementAxis" xlink:label="loc_teva_YearOfSettlementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_YearOfSettlementAxis" xml:lang="en-US">Year Of Settlement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_YearOfSettlementAxis" xml:lang="en-US">Year of settlement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_YearOfSettlementAxis" xlink:to="lab_teva_YearOfSettlementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_YearOfSettlementAxis" xml:lang="en-US">Year of settlement.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_YearOfSettlementDomain" xlink:label="loc_teva_YearOfSettlementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_YearOfSettlementDomain" xml:lang="en-US">Year Of Settlement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_YearOfSettlementDomain" xlink:to="lab_teva_YearOfSettlementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_YearOfSettlementDomain" xml:lang="en-US">Year of settlement.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAndImpairmentAbstract" xlink:label="loc_teva_RestructuringAndImpairmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringAndImpairmentAbstract" xml:lang="en-US">Restructuring And Impairment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringAndImpairmentAbstract" xlink:to="lab_teva_RestructuringAndImpairmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringAndImpairmentAbstract" xml:lang="en-US">Restructuring and impairment.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringAndImpairmentCostsTable" xml:lang="en-US">Restructuring And Impairment Costs [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RestructuringAndImpairmentCostsTable" xml:lang="en-US">Restructuring And Impairment Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable" xlink:to="lab_teva_RestructuringAndImpairmentCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringAndImpairmentCostsTable" xml:lang="en-US">Restructuring And Impairment Costs [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringAndImpairmentCostsLineItems" xml:lang="en-US">Restructuring And Impairment Costs [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RestructuringAndImpairmentCostsLineItems" xml:lang="en-US">Restructuring and Impairment Costs [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems" xlink:to="lab_teva_RestructuringAndImpairmentCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringAndImpairmentCostsLineItems" xml:lang="en-US">Restructuring and impairment costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentAndRestructuring" xlink:label="loc_teva_ImpairmentAndRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ImpairmentAndRestructuring" xml:lang="en-US">Impairment And Restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_teva_ImpairmentAndRestructuring" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ImpairmentAndRestructuring" xlink:to="lab_teva_ImpairmentAndRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ImpairmentAndRestructuring" xml:lang="en-US">Impairment and restructuring.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:label="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xml:lang="en-US">Legal Settlements Loss Contingencies Impairments Other Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:to="lab_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xml:lang="en-US">Legal settlements loss contingencies impairments other expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Contingent consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Business combination contingent consideration arrangements change in amount of contingent consideration liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairments of long-lived tangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xml:lang="en-US">Restructuring and Related Activities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherRestructuringMember" xml:lang="en-US">Other Restructuring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherRestructuringMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xml:lang="en-US">Employee Severance [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xml:lang="en-US">Employee termination [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ExitAndDisposalAxis" xlink:label="loc_teva_ExitAndDisposalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExitAndDisposalAxis" xml:lang="en-US">Exit And Disposal [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExitAndDisposalAxis" xml:lang="en-US">Exit And Disposal [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExitAndDisposalAxis" xlink:to="lab_teva_ExitAndDisposalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExitAndDisposalAxis" xml:lang="en-US">Exit And Disposal [Axis]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ExitAndDisposalDomain" xlink:label="loc_teva_ExitAndDisposalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExitAndDisposalDomain" xml:lang="en-US">Exit And Disposal [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExitAndDisposalDomain" xml:lang="en-US">Exit And Disposal [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExitAndDisposalDomain" xlink:to="lab_teva_ExitAndDisposalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExitAndDisposalDomain" xml:lang="en-US">Exit And Disposal [Domain]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EmployeeTerminationMember" xlink:label="loc_teva_EmployeeTerminationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EmployeeTerminationMember" xml:lang="en-US">Employee Termination [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EmployeeTerminationMember" xml:lang="en-US">Employee termination costs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EmployeeTerminationMember" xlink:to="lab_teva_EmployeeTerminationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EmployeeTerminationMember" xml:lang="en-US">Employee termination.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherExitAndDisposalMember" xlink:label="loc_teva_OtherExitAndDisposalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherExitAndDisposalMember" xml:lang="en-US">Other Exit And Disposal [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherExitAndDisposalMember" xml:lang="en-US">Other Exit and Disposal [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherExitAndDisposalMember" xlink:to="lab_teva_OtherExitAndDisposalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherExitAndDisposalMember" xml:lang="en-US">Other exit and disposal.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UtilizationAndOther" xlink:label="loc_teva_UtilizationAndOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UtilizationAndOther" xml:lang="en-US">Utilization And Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_UtilizationAndOther" xml:lang="en-US">Utilization and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UtilizationAndOther" xlink:to="lab_teva_UtilizationAndOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UtilizationAndOther" xml:lang="en-US">Utilization and other.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Restructuring Reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAccrualProvision" xlink:label="loc_teva_RestructuringAccrualProvision" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringAccrualProvision" xml:lang="en-US">Restructuring Accrual Provision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_teva_RestructuringAccrualProvision" xml:lang="en-US">Provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringAccrualProvision" xlink:to="lab_teva_RestructuringAccrualProvision" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringAccrualProvision" xml:lang="en-US">Restructuring Accrual Provision</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xml:lang="en-US">Tangible Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xml:lang="en-US">Impairments of property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xml:lang="en-US">Weighted average number of shares outstanding, diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Weighted average shares with anti-dilutive effect on earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xml:lang="en-US">Benefit Plans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xml:lang="en-US">Foreign Currency Translation Adjustments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xml:lang="en-US">Derivative Financial Instruments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xml:lang="en-US">Net other comprehensive income (loss) before tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xml:lang="en-US">Amounts reclassified to the statements of income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Net other comprehensive income (loss) after tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xml:lang="en-US">Corresponding income tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Foreign currency translation attributable to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherOperatingIncomeExpense" xlink:label="loc_teva_OtherOperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherOperatingIncomeExpense" xml:lang="en-US">Other Operating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_OtherOperatingIncomeExpense" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherOperatingIncomeExpense" xlink:to="lab_teva_OtherOperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherOperatingIncomeExpense" xml:lang="en-US">Other Operating Income (Expense)</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NorthAmericaSegmentMember" xml:lang="en-US">North America Segment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_NorthAmericaSegmentMember" xml:lang="en-US">North America [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NorthAmericaSegmentMember" xlink:to="lab_teva_NorthAmericaSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_NorthAmericaSegmentMember" xml:lang="en-US">North America segment.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EuropeSegmentMember" xml:lang="en-US">Europe Segment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EuropeSegmentMember" xml:lang="en-US">Europe [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EuropeSegmentMember" xlink:to="lab_teva_EuropeSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EuropeSegmentMember" xml:lang="en-US">Europe segment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xml:lang="en-US">Other Segments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xml:lang="en-US">Other Segments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaap_CorporateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CorporateMember" xml:lang="en-US">Corporate Segment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CorporateMember" xml:lang="en-US">Corporate Segment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateMember" xlink:to="lab_us-gaap_CorporateMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SegmentsAndOtherActivitiesMember" xlink:label="loc_teva_SegmentsAndOtherActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SegmentsAndOtherActivitiesMember" xml:lang="en-US">Segments And Other Activities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SegmentsAndOtherActivitiesMember" xml:lang="en-US">Segments and Other Activities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SegmentsAndOtherActivitiesMember" xlink:to="lab_teva_SegmentsAndOtherActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SegmentsAndOtherActivitiesMember" xml:lang="en-US">Segments and other activities.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AmountsNotAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsNotAllocatedToSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AmountsNotAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts Not Allocated To Segments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AmountsNotAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts not allocated to segments:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract" xlink:to="lab_teva_AmountsNotAllocatedToSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AmountsNotAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts not allocated to segments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherUnallocatedAmounts" xlink:label="loc_teva_OtherUnallocatedAmounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherUnallocatedAmounts" xml:lang="en-US">Other Unallocated Amounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherUnallocatedAmounts" xml:lang="en-US">Other unallocated amounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherUnallocatedAmounts" xlink:to="lab_teva_OtherUnallocatedAmounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherUnallocatedAmounts" xml:lang="en-US">Other unallocated amounts.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AmountsAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsAllocatedToSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AmountsAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts Allocated To Segments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AmountsAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts allocated to segments:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AmountsAllocatedToSegmentsAbstract" xlink:to="lab_teva_AmountsAllocatedToSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AmountsAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts allocated to segments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xml:lang="en-US">Schedule of Product Information [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xml:lang="en-US">Schedule of Product Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable" xlink:to="lab_us-gaap_ScheduleOfProductInformationTable" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueTypeAxis" xlink:label="loc_teva_RevenueTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenueTypeAxis" xml:lang="en-US">Revenue Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenueTypeAxis" xlink:to="lab_teva_RevenueTypeAxis" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueTypeDomain" xlink:label="loc_teva_RevenueTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenueTypeDomain" xml:lang="en-US">Revenue Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenueTypeDomain" xlink:to="lab_teva_RevenueTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductInformationLineItems" xml:lang="en-US">Product Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductInformationLineItems" xml:lang="en-US">Product Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems" xlink:to="lab_us-gaap_ProductInformationLineItems" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RespiratoryProductMember" xlink:label="loc_teva_RespiratoryProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RespiratoryProductMember" xml:lang="en-US">Respiratory Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RespiratoryProductMember" xml:lang="en-US">Respiratory Product [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RespiratoryProductMember" xlink:to="lab_teva_RespiratoryProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RespiratoryProductMember" xml:lang="en-US">Respiratory product.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AustedoMember" xlink:label="loc_teva_AustedoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AustedoMember" xml:lang="en-US">Austedo [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AustedoMember" xml:lang="en-US">AUSTEDO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AustedoMember" xlink:to="lab_teva_AustedoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AustedoMember" xml:lang="en-US">Austedo [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AndaMember" xlink:label="loc_teva_AndaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AndaMember" xml:lang="en-US">Anda [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AndaMember" xml:lang="en-US">Anda [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AndaMember" xlink:to="lab_teva_AndaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AndaMember" xml:lang="en-US">Anda [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_BendekaAndTreandaMember" xlink:label="loc_teva_BendekaAndTreandaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_BendekaAndTreandaMember" xml:lang="en-US">BENDEKA and TREANDA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_BendekaAndTreandaMember" xml:lang="en-US">BENDEKA&#174; and TREANDA&#174; [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_BendekaAndTreandaMember" xlink:to="lab_teva_BendekaAndTreandaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_BendekaAndTreandaMember" xml:lang="en-US">BENDEKA and TREANDA.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherProductsMember" xlink:label="loc_teva_OtherProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherProductsMember" xml:lang="en-US">Other Products [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherProductsMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherProductsMember" xlink:to="lab_teva_OtherProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherProductsMember" xml:lang="en-US">Other Products [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AjovyMember" xlink:label="loc_teva_AjovyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AjovyMember" xml:lang="en-US">AJOVY [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AjovyMember" xlink:to="lab_teva_AjovyMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_GenericsMediciansMember" xlink:label="loc_teva_GenericsMediciansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_GenericsMediciansMember" xml:lang="en-US">Generics Medicians [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_GenericsMediciansMember" xml:lang="en-US">Generic products [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_GenericsMediciansMember" xlink:to="lab_teva_GenericsMediciansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_GenericsMediciansMember" xml:lang="en-US">Generics Medicians.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_COPAXONEMember" xlink:label="loc_teva_COPAXONEMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_COPAXONEMember" xml:lang="en-US">COPAXONE [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_COPAXONEMember" xml:lang="en-US">COPAXONE [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_COPAXONEMember" xlink:to="lab_teva_COPAXONEMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_COPAXONEMember" xml:lang="en-US">COPAXONE.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of Reportable Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of reportable segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xlink:label="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xml:lang="en-US">Options And Forward Contracts Derivative Liabilities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xml:lang="en-US">Liabilities Derivatives Options and Forward Contracts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xlink:to="lab_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xml:lang="en-US">Options and forward contracts derivative liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestRateSwapMember" xml:lang="en-US">Interest Rate Swap [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestRateSwapMember" xml:lang="en-US">Asset Derivatives - Options and Forward Contracts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xml:lang="en-US">Embedded Derivative Financial Instruments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xml:lang="en-US">Bifurcated embedded derivatives [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:to="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xml:lang="en-US">Fair Value, Net Asset (Liability)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeAssets" xml:lang="en-US">Derivative Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeAssets" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investment in securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Markets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherRestrictedCashMember" xlink:label="loc_teva_OtherRestrictedCashMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherRestrictedCashMember" xml:lang="en-US">Other Restricted Cash [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherRestrictedCashMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherRestrictedCashMember" xlink:to="lab_teva_OtherRestrictedCashMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherRestrictedCashMember" xml:lang="en-US">Other restricted cash.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemandDepositsMember" xlink:label="loc_us-gaap_DemandDepositsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DemandDepositsMember" xml:lang="en-US">Demand Deposits [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DemandDepositsMember" xml:lang="en-US">Cash, Deposits and Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DemandDepositsMember" xlink:to="lab_us-gaap_DemandDepositsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquitySecuritiesMember" xml:lang="en-US">Equity Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquitySecuritiesMember" xml:lang="en-US">Equity Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MeasurementInputProbabilityOfSuccessMember" xlink:label="loc_teva_MeasurementInputProbabilityOfSuccessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MeasurementInputProbabilityOfSuccessMember" xml:lang="en-US">Measurement Input Probability Of Success [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MeasurementInputProbabilityOfSuccessMember" xml:lang="en-US">Measurement input probability of success [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MeasurementInputProbabilityOfSuccessMember" xlink:to="lab_teva_MeasurementInputProbabilityOfSuccessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MeasurementInputProbabilityOfSuccessMember" xml:lang="en-US">Measurement input probability of success.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:label="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xml:lang="en-US">Fresh-Start Adjustments [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xml:lang="en-US">Fresh-Start Adjustments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="lab_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:label="loc_us-gaap_TypeOfFreshStartAdjustmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfFreshStartAdjustmentDomain" xml:lang="en-US">Type of Fresh-Start Adjustment [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfFreshStartAdjustmentDomain" xml:lang="en-US">Type of Fresh-Start Adjustment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:to="lab_us-gaap_TypeOfFreshStartAdjustmentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_WeightedAverageMember" xml:lang="en-US">Weighted Average [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_WeightedAverageMember" xml:lang="en-US">Weighted Average [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Increase Decrease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xml:lang="en-US">Adjustments to provisions for contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xlink:to="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair value at the beginning of the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair value at the end of the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Arising During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xml:lang="en-US">Actavis Generics transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xlink:to="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration arising during period.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_BifurcatedEmbeddedDerivatives" xlink:label="loc_teva_BifurcatedEmbeddedDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_BifurcatedEmbeddedDerivatives" xml:lang="en-US">Bifurcated Embedded Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_BifurcatedEmbeddedDerivatives" xml:lang="en-US">Bifurcated embedded derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_BifurcatedEmbeddedDerivatives" xlink:to="lab_teva_BifurcatedEmbeddedDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_BifurcatedEmbeddedDerivatives" xml:lang="en-US">Bifurcated embedded derivatives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Settlement of contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Redemption of debt securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EagleTransactionMember" xlink:label="loc_teva_EagleTransactionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EagleTransactionMember" xml:lang="en-US">Eagle Transaction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EagleTransactionMember" xml:lang="en-US">Eagle Transaction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EagleTransactionMember" xlink:to="lab_teva_EagleTransactionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EagleTransactionMember" xml:lang="en-US">Eagle transaction.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ActavisGenericsMember" xlink:label="loc_teva_ActavisGenericsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ActavisGenericsMember" xml:lang="en-US">Actavis Generics [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ActavisGenericsMember" xml:lang="en-US">Actavis Generics [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ActavisGenericsMember" xlink:to="lab_teva_ActavisGenericsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ActavisGenericsMember" xml:lang="en-US">Actavis Generics [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NovetideTransactionMember" xlink:label="loc_teva_NovetideTransactionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NovetideTransactionMember" xml:lang="en-US">Novetide Transaction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_NovetideTransactionMember" xml:lang="en-US">Novetide Transaction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NovetideTransactionMember" xlink:to="lab_teva_NovetideTransactionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_NovetideTransactionMember" xml:lang="en-US">Novetide transaction.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NoveTideAcquisitionMember" xlink:label="loc_teva_NoveTideAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NoveTideAcquisitionMember" xml:lang="en-US">Nove Tide Acquisition [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_NoveTideAcquisitionMember" xml:lang="en-US">Nove tide Acquisition [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NoveTideAcquisitionMember" xlink:to="lab_teva_NoveTideAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_NoveTideAcquisitionMember" xml:lang="en-US">Nove tide acquisition.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business acquisition, Percentage of voting interests acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xlink:label="loc_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xml:lang="en-US">Senior Notes And Sustainability Linked Senior Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xml:lang="en-US">Senior Notes And Sustainability Linked Senior Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xlink:to="lab_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xml:lang="en-US">Senior notes and sustainability linked senior notes.</label>
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SeniornotesandconvertibleseniordebenturesMember" xlink:label="loc_teva_SeniornotesandconvertibleseniordebenturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniornotesandconvertibleseniordebenturesMember" xml:lang="en-US">Seniornotesandconvertibleseniordebentures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniornotesandconvertibleseniordebenturesMember" xml:lang="en-US">Senior Notes and Convertible Senior Debentures Included Under Short-Term Debt [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniornotesandconvertibleseniordebenturesMember" xlink:to="lab_teva_SeniornotesandconvertibleseniordebenturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniornotesandconvertibleseniordebenturesMember" xml:lang="en-US">Senior notes and convertible senior debentures.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>teva-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 10-May-2023 [04:37:29] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CoverPage" roleURI="http://www.tevapharm.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfIncomeLossParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfChangesInEquity" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfChangesInEquityParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#BasisOfPresentation" roleURI="http://www.tevapharm.com/role/BasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CertainTransactions" roleURI="http://www.tevapharm.com/role/CertainTransactions" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#RevenueFromContractsWithCustomers" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#Inventories" roleURI="http://www.tevapharm.com/role/Inventories" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#IdentifiableIntangibleAssets" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#Goodwill" roleURI="http://www.tevapharm.com/role/Goodwill" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DebtObligations" roleURI="http://www.tevapharm.com/role/DebtObligations" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivities" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#LegalSettlementsAndLossContingencies" roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CommitmentsAndContingencies" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#IncomeTaxes" roleURI="http://www.tevapharm.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#OtherAssetsImpairmentsRestructuringAndOtherItems" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#EarningsLossPerShare" roleURI="http://www.tevapharm.com/role/EarningsLossPerShare" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#Segments" roleURI="http://www.tevapharm.com/role/Segments" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurement" roleURI="http://www.tevapharm.com/role/FairValueMeasurement" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CertainTransactionsTables" roleURI="http://www.tevapharm.com/role/CertainTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#RevenueFromContractsWithCustomersTables" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#InventoriesTables" roleURI="http://www.tevapharm.com/role/InventoriesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#IdentifiableIntangibleAssetsTables" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#GoodwillTables" roleURI="http://www.tevapharm.com/role/GoodwillTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DebtObligationsTables" roleURI="http://www.tevapharm.com/role/DebtObligationsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivitiesTables" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsTables" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#SegmentsTables" roleURI="http://www.tevapharm.com/role/SegmentsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurementTables" roleURI="http://www.tevapharm.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CertainTransactionsOtherTransactionsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#RevenueFromContractsWithCustomersAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#InventoriesSummaryOfInventoriesDetail" roleURI="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#IdentifiableIntangibleAssetsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#GoodwillAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DebtObligationsScheduleOfShortTermDebtDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DebtObligationsScheduleOfSeniorNotesAndLoansDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DebtObligationsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#LegalSettlementsAndLossContingenciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#EarningsLossPerShareAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#AccumulatedOtherComprehensiveIncomeLossDetail" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" roleURI="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#SegmentsSummaryOfSegmentProfitDetail" roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#SegmentsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurementAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20230331.xsd#FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_187796" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_486714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentType_486714" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_507077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_AmendmentFlag_507077" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_507079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentFiscalYearFocus_507079" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_486701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentTransitionReport_486701" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_486682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentPeriodEndDate_486682" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_507080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentFiscalPeriodFocus_507080" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_673334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentQuarterlyReport_673334" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_486687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityRegistrantName_486687" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_507081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityCentralIndexKey_507081" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_507082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_CurrentFiscalYearEndDate_507082" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_486685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityCurrentReportingStatus_486685" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_486688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityInteractiveDataCurrent_486688" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_486689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_486689" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_486709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_Security12bTitle_486709" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_486710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_TradingSymbol_486710" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_486711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_SecurityExchangeName_486711" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_486690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityFileNumber_486690" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_486691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityIncorporationStateCountryCode_486691" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_486692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityTaxIdentificationNumber_486692" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_486693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressAddressLine1_486693" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_486694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressCityOrTown_486694" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_486695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressPostalZipCode_486695" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_486708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressCountry_486708" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_486698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_CityAreaCode_486698" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_486699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_LocalPhoneNumber_486699" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_486715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityFilerCategory_486715" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_555878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntitySmallBusiness_555878" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_486704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityEmergingGrowthCompany_486704" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_486702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityShellCompany_486702" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26" xlink:to="loc_us-gaap_StatementTable_34" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_34" xlink:to="loc_dei_LegalEntityAxis_29" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_29" xlink:to="loc_dei_EntityDomain_49" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_34" xlink:to="loc_us-gaap_StatementLineItems_33" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_AssetsAbstract_27" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_AssetsCurrentAbstract_28" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_43" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_InventoryNet_44" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_45" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_OtherAssetsCurrent_46" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_47" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AssetsCurrent_48" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_36" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_37" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_38" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_389976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_389976" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_39" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_Goodwill_40" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_Assets_41" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_31" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_DebtCurrent_55" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SalesReservesAndAllowances" xlink:label="loc_teva_SalesReservesAndAllowances_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_teva_SalesReservesAndAllowances_56" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_57" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AccruedExpenses" xlink:label="loc_teva_AccruedExpenses_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_teva_AccruedExpenses_59" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_60" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_LiabilitiesCurrent_62" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_63" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_64" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_LongTermNotesAndLoans_65" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_389981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_389981" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_66" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_CommitmentsAndContingencies_50" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_Liabilities_51" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquityAbstract_35" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_CommonStockValue_68" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AdditionalPaidInCapital_69" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_TreasuryStockValue_72" use="optional" order="43" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_StockholdersEquity_73" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_MinorityInterest_52" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75" xlink:to="loc_us-gaap_StatementTable_78" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_78" xlink:to="loc_dei_LegalEntityAxis_76" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_76" xlink:to="loc_dei_EntityDomain_79" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_78" xlink:to="loc_us-gaap_StatementLineItems_77" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_688255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_688255" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_83" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_84" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockSharesIssued_85" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_86" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_TreasuryStockShares_86" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_88" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88" xlink:to="loc_us-gaap_StatementTable_92" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92" xlink:to="loc_dei_LegalEntityAxis_90" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_90" xlink:to="loc_dei_EntityDomain_96" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92" xlink:to="loc_us-gaap_StatementLineItems_91" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_98" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GrossProfit_99" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_100" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_SellingAndMarketingExpense_101" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_102" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_IntangibleAssetsImpairments" xlink:label="loc_teva_IntangibleAssetsImpairments_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_IntangibleAssetsImpairments_103" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_408527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_408527" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies_412170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_LegalSettlementsAndLossContingencies_412170" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_107" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_OperatingIncomeLoss_108" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_109" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_110" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_111" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_112" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_ProfitLoss_113" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_114" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLoss_115" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_EarningsPerShareAbstract_89" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_94" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareBasic_94" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_95" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_95" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_119" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_2147448892" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2147448891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2147448892" xlink:to="loc_us-gaap_StatementTable_2147448891" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2147448877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2147448891" xlink:to="loc_srt_RangeAxis_2147448877" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2147448876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2147448877" xlink:to="loc_srt_RangeMember_2147448876" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2147448875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2147448876" xlink:to="loc_srt_MaximumMember_2147448875" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2147448878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2147448891" xlink:to="loc_us-gaap_StatementLineItems_2147448878" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2147448873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2147448878" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2147448873" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_121" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_121" xlink:to="loc_us-gaap_StatementTable_125" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_dei_LegalEntityAxis_122" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_122" xlink:to="loc_dei_EntityDomain_126" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_StatementLineItems_124" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ProfitLoss_132" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_127" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UnrealizedGainLossOnDerivativeNetOfTax" xlink:label="loc_teva_UnrealizedGainLossOnDerivativeNetOfTax_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_teva_UnrealizedGainLossOnDerivativeNetOfTax_128" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_720057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_720057" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_131" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_133" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_134" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_135" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_137" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_137" xlink:to="loc_us-gaap_StatementTable_142" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_142" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_140" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_140" xlink:to="loc_us-gaap_EquityComponentDomain_138" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_CommonStockMember_143" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_145" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_RetainedEarningsMember_146" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_147" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_TreasuryStockMember_148" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_ParentMember_149" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_NoncontrollingInterestMember_150" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_142" xlink:to="loc_us-gaap_StatementLineItems_141" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_152" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_SharesIssued_154" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_720066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_ProfitLoss_720066" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_155" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_760310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_760310" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_158" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_167" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_SharesIssued_168" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_170" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_170" xlink:to="loc_us-gaap_StatementTable_177" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_srt_RangeAxis_173" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_173" xlink:to="loc_srt_RangeMember_174" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_174" xlink:to="loc_srt_MaximumMember_180" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_175" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175" xlink:to="loc_us-gaap_EquityComponentDomain_171" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_171" xlink:to="loc_us-gaap_CommonStockMember_178" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_472727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" xlink:to="loc_us-gaap_TypeOfAdoptionMember_472727" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_StatementLineItems_176" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_181" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_183" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_183" xlink:to="loc_us-gaap_StatementTable_191" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_191" xlink:to="loc_dei_LegalEntityAxis_186" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_186" xlink:to="loc_dei_EntityDomain_210" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_191" xlink:to="loc_us-gaap_StatementLineItems_190" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_ProfitLoss_229" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_DepreciationAndAmortization_194" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_AssetImpairmentCharges_193" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_195" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:label="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions_196" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_412174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_ShareBasedCompensation_412174" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_515089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_515089" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_200" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_230" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables_222" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_224" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1260619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1260619" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_555980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_555980" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:label="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets_225" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_226" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_228" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_211" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2147448882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2147448882" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_221" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_234" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1260699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1260699" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1260700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1260700" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1260701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1260697" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1260701" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" xlink:to="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables_235" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/BasisOfPresentation">
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_BasisOfPresentationAbstract" xlink:label="loc_teva_BasisOfPresentationAbstract_389321" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_673771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_BasisOfPresentationAbstract_389321" xlink:to="loc_us-gaap_StatementTable_673771" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_673774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_673771" xlink:to="loc_us-gaap_StatementLineItems_673774" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_671372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_673774" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_671372" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1694" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1694" xlink:to="loc_us-gaap_StatementTable_1697" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1697" xlink:to="loc_dei_LegalEntityAxis_1695" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1695" xlink:to="loc_dei_EntityDomain_1698" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1697" xlink:to="loc_us-gaap_StatementLineItems_1696" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CertainTransactionsDisclosureTextBlock" xlink:label="loc_teva_CertainTransactionsDisclosureTextBlock_1699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1696" xlink:to="loc_teva_CertainTransactionsDisclosureTextBlock_1699" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1795" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1795" xlink:to="loc_us-gaap_StatementTable_1798" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1798" xlink:to="loc_dei_LegalEntityAxis_1796" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1796" xlink:to="loc_dei_EntityDomain_1799" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1798" xlink:to="loc_us-gaap_StatementLineItems_1797" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1797" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1800" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Inventories">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1739" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1739" xlink:to="loc_us-gaap_StatementTable_1742" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1742" xlink:to="loc_dei_LegalEntityAxis_1740" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1740" xlink:to="loc_dei_EntityDomain_1743" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1742" xlink:to="loc_us-gaap_StatementLineItems_1741" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1741" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1744" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1781" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1781" xlink:to="loc_us-gaap_StatementTable_1784" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1784" xlink:to="loc_dei_LegalEntityAxis_1782" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1782" xlink:to="loc_dei_EntityDomain_1785" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1784" xlink:to="loc_us-gaap_StatementLineItems_1783" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1783" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1786" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Goodwill">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1767" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1767" xlink:to="loc_us-gaap_StatementTable_1770" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1770" xlink:to="loc_dei_LegalEntityAxis_1768" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1768" xlink:to="loc_dei_EntityDomain_1771" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1770" xlink:to="loc_us-gaap_StatementLineItems_1769" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_1772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1769" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_1772" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1824" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1824" xlink:to="loc_us-gaap_StatementTable_1827" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1827" xlink:to="loc_dei_LegalEntityAxis_1825" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1825" xlink:to="loc_dei_EntityDomain_1828" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1827" xlink:to="loc_us-gaap_StatementLineItems_1826" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1826" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1829" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1901" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1901" xlink:to="loc_us-gaap_StatementTable_1904" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1904" xlink:to="loc_dei_LegalEntityAxis_1902" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1902" xlink:to="loc_dei_EntityDomain_1905" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1904" xlink:to="loc_us-gaap_StatementLineItems_1903" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1903" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1906" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1947" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1947" xlink:to="loc_us-gaap_StatementTable_1950" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1950" xlink:to="loc_dei_LegalEntityAxis_1948" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1948" xlink:to="loc_dei_EntityDomain_1951" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1950" xlink:to="loc_us-gaap_StatementLineItems_1949" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1949" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1952" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1854" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1854" xlink:to="loc_us-gaap_StatementTable_1857" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1857" xlink:to="loc_dei_LegalEntityAxis_1855" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1855" xlink:to="loc_dei_EntityDomain_1858" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1857" xlink:to="loc_us-gaap_StatementLineItems_1856" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1856" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1859" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1882" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1882" xlink:to="loc_us-gaap_StatementTable_1885" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1885" xlink:to="loc_dei_LegalEntityAxis_1883" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1883" xlink:to="loc_dei_EntityDomain_1886" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1885" xlink:to="loc_us-gaap_StatementLineItems_1884" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1884" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1887" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1931" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1931" xlink:to="loc_us-gaap_StatementTable_1934" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1934" xlink:to="loc_dei_LegalEntityAxis_1932" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1932" xlink:to="loc_dei_EntityDomain_1935" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1934" xlink:to="loc_us-gaap_StatementLineItems_1933" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherExpensesTextBlock" xlink:label="loc_teva_OtherExpensesTextBlock_1936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1933" xlink:to="loc_teva_OtherExpensesTextBlock_1936" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1972" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1972" xlink:to="loc_us-gaap_StatementTable_1975" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1975" xlink:to="loc_dei_LegalEntityAxis_1973" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1973" xlink:to="loc_dei_EntityDomain_1976" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1975" xlink:to="loc_us-gaap_StatementLineItems_1974" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1974" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1977" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_390011" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_390011" xlink:to="loc_us-gaap_StatementTable_390014" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390014" xlink:to="loc_dei_LegalEntityAxis_390018" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_390018" xlink:to="loc_dei_EntityDomain_390019" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390014" xlink:to="loc_us-gaap_StatementLineItems_390015" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_390022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390015" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_390022" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Segments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1954" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1954" xlink:to="loc_us-gaap_StatementTable_1957" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1957" xlink:to="loc_dei_LegalEntityAxis_1955" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1955" xlink:to="loc_dei_EntityDomain_1958" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1957" xlink:to="loc_us-gaap_StatementLineItems_1956" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1956" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1959" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1708" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1708" xlink:to="loc_us-gaap_StatementTable_1711" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1711" xlink:to="loc_dei_LegalEntityAxis_1709" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1709" xlink:to="loc_dei_EntityDomain_1712" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1711" xlink:to="loc_us-gaap_StatementLineItems_1710" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1713" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1659" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1659" xlink:to="loc_us-gaap_StatementTable_1662" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1662" xlink:to="loc_dei_LegalEntityAxis_1660" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1660" xlink:to="loc_dei_EntityDomain_1663" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1662" xlink:to="loc_us-gaap_StatementLineItems_1661" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1665" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_514943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_514943" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1701" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1701" xlink:to="loc_us-gaap_StatementTable_1704" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1704" xlink:to="loc_dei_LegalEntityAxis_1702" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1702" xlink:to="loc_dei_EntityDomain_1705" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1704" xlink:to="loc_us-gaap_StatementLineItems_1703" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:label="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1703" xlink:to="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1706" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1802" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1802" xlink:to="loc_us-gaap_StatementTable_1805" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1805" xlink:to="loc_dei_LegalEntityAxis_1803" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1803" xlink:to="loc_dei_EntityDomain_1806" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1805" xlink:to="loc_us-gaap_StatementLineItems_1804" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1807" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SalesReservesAndAllowancesCurrentTableTextBlock" xlink:label="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock_1808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock_1808" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1746" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1746" xlink:to="loc_us-gaap_StatementTable_1749" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1749" xlink:to="loc_dei_LegalEntityAxis_1747" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1747" xlink:to="loc_dei_EntityDomain_1750" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1749" xlink:to="loc_us-gaap_StatementLineItems_1748" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1748" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1751" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1788" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1788" xlink:to="loc_us-gaap_StatementTable_1791" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1791" xlink:to="loc_dei_LegalEntityAxis_1789" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1789" xlink:to="loc_dei_EntityDomain_1792" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1791" xlink:to="loc_us-gaap_StatementLineItems_1790" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1790" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1793" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1774" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1774" xlink:to="loc_us-gaap_StatementTable_1777" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1777" xlink:to="loc_dei_LegalEntityAxis_1775" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1775" xlink:to="loc_dei_EntityDomain_1778" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1777" xlink:to="loc_us-gaap_StatementLineItems_1776" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_1779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1776" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_1779" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1831" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1831" xlink:to="loc_us-gaap_StatementTable_1834" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1834" xlink:to="loc_dei_LegalEntityAxis_1832" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1832" xlink:to="loc_dei_EntityDomain_1835" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1834" xlink:to="loc_us-gaap_StatementLineItems_1833" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_1836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_1836" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xlink:label="loc_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock_1837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock_1837" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1908" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1908" xlink:to="loc_us-gaap_StatementTable_1911" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1911" xlink:to="loc_dei_LegalEntityAxis_1909" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1909" xlink:to="loc_dei_EntityDomain_1912" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1911" xlink:to="loc_us-gaap_StatementLineItems_1910" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock" xlink:label="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock_2147448865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock_2147448865" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1914" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_406869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_406869" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock" xlink:label="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock_2147448849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock_2147448849" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2147448827" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_2147448826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2147448827" xlink:to="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_2147448826" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1938" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1938" xlink:to="loc_us-gaap_StatementTable_1941" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1941" xlink:to="loc_dei_LegalEntityAxis_1939" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1939" xlink:to="loc_dei_EntityDomain_1942" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1941" xlink:to="loc_us-gaap_StatementLineItems_1940" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1943" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ScheduleOfRestructuringChargesTableTextBlock" xlink:label="loc_teva_ScheduleOfRestructuringChargesTableTextBlock_1944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_teva_ScheduleOfRestructuringChargesTableTextBlock_1944" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1945" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_390174" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_390174" xlink:to="loc_us-gaap_StatementTable_390175" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390175" xlink:to="loc_dei_LegalEntityAxis_390177" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_390177" xlink:to="loc_dei_EntityDomain_390178" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390175" xlink:to="loc_us-gaap_StatementLineItems_390179" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390179" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390181" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1961" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1961" xlink:to="loc_us-gaap_StatementTable_1964" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1964" xlink:to="loc_dei_LegalEntityAxis_1962" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1962" xlink:to="loc_dei_EntityDomain_1965" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1964" xlink:to="loc_us-gaap_StatementLineItems_1963" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1966" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xlink:label="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock_1967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock_1967" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_1968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_1968" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1715" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1715" xlink:to="loc_us-gaap_StatementTable_1718" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1718" xlink:to="loc_dei_LegalEntityAxis_1716" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1716" xlink:to="loc_dei_EntityDomain_1719" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1718" xlink:to="loc_us-gaap_StatementLineItems_1717" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1720" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1721" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1722" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_300" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsTable" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_300" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_dei_LegalEntityAxis_304" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_304" xlink:to="loc_dei_EntityDomain_319" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1241737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1241737" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1241738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1241737" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1241738" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_302" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_302" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtsukaMember" xlink:label="loc_teva_OtsukaMember_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_OtsukaMember_314" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TakedaMember" xlink:label="loc_teva_TakedaMember_2147449570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_TakedaMember_2147449570" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AlvotechMember" xlink:label="loc_teva_AlvotechMember_758265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_AlvotechMember_758265" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MedincellMember" xlink:label="loc_teva_MedincellMember_1241907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_MedincellMember_1241907" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ModagMember" xlink:label="loc_teva_ModagMember_1241734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_ModagMember_1241734" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_ProductOrServiceAxis_307" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_307" xlink:to="loc_srt_ProductsAndServicesDomain_308" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_CounterpartyNameAxis_303" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_303" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" xlink:to="loc_us-gaap_RelatedPartyDomain_309" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_758266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_758266" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_758267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_758266" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_758267" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_758268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_758267" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_758268" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_758271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_LeaseContractualTermAxis_758271" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_758272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_758271" xlink:to="loc_us-gaap_LeaseContractualTermDomain_758272" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_RangeAxis_765341" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_765341" xlink:to="loc_srt_RangeMember_765342" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UpfrontPayments" xlink:label="loc_teva_UpfrontPayments_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_UpfrontPayments_326" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MilestonePayment" xlink:label="loc_teva_MilestonePayment_572506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_MilestonePayment_572506" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CollaborativeAgreementMilestonePayments" xlink:label="loc_teva_CollaborativeAgreementMilestonePayments_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_CollaborativeAgreementMilestonePayments_327" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount" xlink:label="loc_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount_1241741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount_1241741" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_340" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_347" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_348" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="loc_us-gaap_AssetsFairValueAdjustment_718560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_AssetsFairValueAdjustment_718560" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_351" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_603" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_603" xlink:to="loc_teva_RevenueRecognitionTable_608" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_dei_LegalEntityAxis_604" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_604" xlink:to="loc_dei_EntityDomain_611" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_srt_StatementGeographicalAxis_610" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_610" xlink:to="loc_srt_SegmentGeographicalDomain_609" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_609" xlink:to="loc_country_US_617" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis" xlink:label="loc_us-gaap_PledgingPurposeAxis_2147468956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_us-gaap_PledgingPurposeAxis_2147468956" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain" xlink:label="loc_us-gaap_PledgingPurposeDomain_2147468957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgingPurposeAxis_2147468956" xlink:to="loc_us-gaap_PledgingPurposeDomain_2147468957" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member" xlink:label="loc_teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member_2147468962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgingPurposeDomain_2147468957" xlink:to="loc_teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member_2147468962" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448885" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2147448884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448885" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2147448884" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AccountsReceivableSecuritizationFacilityMember" xlink:label="loc_teva_AccountsReceivableSecuritizationFacilityMember_2147448883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2147448884" xlink:to="loc_teva_AccountsReceivableSecuritizationFacilityMember_2147448883" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FactoringInstitutionAxis" xlink:label="loc_teva_FactoringInstitutionAxis_2147448888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_teva_FactoringInstitutionAxis_2147448888" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FactoringInstitutionDomain" xlink:label="loc_teva_FactoringInstitutionDomain_2147448887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_FactoringInstitutionAxis_2147448888" xlink:to="loc_teva_FactoringInstitutionDomain_2147448887" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PncBankMember" xlink:label="loc_teva_PncBankMember_2147448886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_FactoringInstitutionDomain_2147448887" xlink:to="loc_teva_PncBankMember_2147448886" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_teva_RevenueRecognitionLineItems_607" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SalesReservesAndAllowancesToCustomersPercentage" xlink:label="loc_teva_SalesReservesAndAllowancesToCustomersPercentage_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_607" xlink:to="loc_teva_SalesReservesAndAllowancesToCustomersPercentage_616" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableFromSecuritization" xlink:label="loc_us-gaap_AccountsReceivableFromSecuritization_2147468965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_607" xlink:to="loc_us-gaap_AccountsReceivableFromSecuritization_2147468965" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_619" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_619" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_621" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_dei_LegalEntityAxis_622" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_622" xlink:to="loc_dei_EntityDomain_630" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_srt_StatementGeographicalAxis_628" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_628" xlink:to="loc_srt_SegmentGeographicalDomain_626" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_626" xlink:to="loc_srt_NorthAmericaMember_637" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_626" xlink:to="loc_srt_EuropeMember_638" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_627" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_627" xlink:to="loc_us-gaap_SegmentDomain_625" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_625" xlink:to="loc_teva_InternationalMarketsMember_635" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherActivitiesMember" xlink:label="loc_teva_OtherActivitiesMember_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_625" xlink:to="loc_teva_OtherActivitiesMember_636" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_srt_ProductOrServiceAxis_623" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_623" xlink:to="loc_srt_ProductsAndServicesDomain_624" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_ProductMember_631" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_LicenseMember_632" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionServiceMember" xlink:label="loc_us-gaap_DistributionServiceMember_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_DistributionServiceMember_633" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_634" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_620" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_620" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_629" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_640" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_640" xlink:to="loc_teva_RevenueRecognitionTable_643" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_dei_LegalEntityAxis_641" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_641" xlink:to="loc_dei_EntityDomain_646" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ReservesIncludedInAccountsReceivableNetMember" xlink:label="loc_teva_ReservesIncludedInAccountsReceivableNetMember_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ReservesIncludedInAccountsReceivableNetMember_653" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RebatesMember" xlink:label="loc_teva_RebatesMember_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_RebatesMember_654" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MedicaidAndOtherGovernmentalAllowancesMember" xlink:label="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember_655" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ChargebacksMember" xlink:label="loc_teva_ChargebacksMember_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ChargebacksMember_656" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ReturnsMember" xlink:label="loc_teva_ReturnsMember_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ReturnsMember_657" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherSalesReservesAndAllowancesMember" xlink:label="loc_teva_OtherSalesReservesAndAllowancesMember_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_OtherSalesReservesAndAllowancesMember_658" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xlink:label="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember_659" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_teva_RevenueRecognitionLineItems_642" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_647" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales_648" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales_649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales_649" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_650" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xlink:label="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation_651" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_652" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_451" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InventoriesTable" xlink:label="loc_teva_InventoriesTable_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_451" xlink:to="loc_teva_InventoriesTable_453" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesTable_453" xlink:to="loc_dei_LegalEntityAxis_454" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_454" xlink:to="loc_dei_EntityDomain_460" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InventoriesLineItems" xlink:label="loc_teva_InventoriesLineItems_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesTable_453" xlink:to="loc_teva_InventoriesLineItems_452" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_455" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_456" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_457" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryInTransit" xlink:label="loc_us-gaap_OtherInventoryInTransit_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_OtherInventoryInTransit_458" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryNet_459" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_558" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_558" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_teva_ProductRightsMember_567" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_us-gaap_TradeNamesMember_568" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_569" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_564" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_565" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_566" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_572" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_572" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_dei_LegalEntityAxis_578" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_578" xlink:to="loc_dei_EntityDomain_599" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_StatementGeographicalAxis_581" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_581" xlink:to="loc_srt_SegmentGeographicalDomain_580" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="loc_country_JP_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_580" xlink:to="loc_country_JP_601" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_574" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_574" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_597" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" xlink:to="loc_teva_ProductRightsMember_598" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_408202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_ProductOrServiceAxis_408202" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_408203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_408202" xlink:to="loc_srt_ProductsAndServicesDomain_408203" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LenalidomideProductMember" xlink:label="loc_teva_LenalidomideProductMember_408205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_408203" xlink:to="loc_teva_LenalidomideProductMember_408205" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_GenericPipelineProductsMember" xlink:label="loc_teva_GenericPipelineProductsMember_473346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_408203" xlink:to="loc_teva_GenericPipelineProductsMember_473346" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DiscontinuationOfBusinessAxis" xlink:label="loc_teva_DiscontinuationOfBusinessAxis_581599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_DiscontinuationOfBusinessAxis_581599" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DiscontinuationOfBusinessDomain" xlink:label="loc_teva_DiscontinuationOfBusinessDomain_581600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DiscontinuationOfBusinessAxis_581599" xlink:to="loc_teva_DiscontinuationOfBusinessDomain_581600" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_764548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_RangeAxis_764548" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_764549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_764548" xlink:to="loc_srt_RangeMember_764549" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_764550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_764549" xlink:to="loc_srt_MinimumMember_764550" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_764551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_764549" xlink:to="loc_srt_MaximumMember_764551" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_764554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_764554" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_764555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_764554" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_764555" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_764556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_764555" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_764556" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis" xlink:label="loc_us-gaap_ReclassificationTypeAxis_1261963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_ReclassificationTypeAxis_1261963" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain" xlink:label="loc_us-gaap_ReclassificationTypeDomain_1261964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeAxis_1261963" xlink:to="loc_us-gaap_ReclassificationTypeDomain_1261964" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EventBasisAxis" xlink:label="loc_teva_EventBasisAxis_2147473654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_EventBasisAxis_2147473654" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EventBasisDomain" xlink:label="loc_teva_EventBasisDomain_2147473655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_EventBasisAxis_2147473654" xlink:to="loc_teva_EventBasisDomain_2147473655" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PriceAndVolumeOfProductsMember" xlink:label="loc_teva_PriceAndVolumeOfProductsMember_2147448879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_EventBasisDomain_2147473655" xlink:to="loc_teva_PriceAndVolumeOfProductsMember_2147448879" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember" xlink:label="loc_teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember_2147448880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_EventBasisDomain_2147473655" xlink:to="loc_teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember_2147448880" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RegulatoryPriceAndVolumeOfProductsMember" xlink:label="loc_teva_RegulatoryPriceAndVolumeOfProductsMember_2147448881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_EventBasisDomain_2147473655" xlink:to="loc_teva_RegulatoryPriceAndVolumeOfProductsMember_2147448881" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UpdatedMarketAssumptionsMember" xlink:label="loc_teva_UpdatedMarketAssumptionsMember_2147473656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_EventBasisDomain_2147473655" xlink:to="loc_teva_UpdatedMarketAssumptionsMember_2147473656" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_587" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_588" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_596" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_764546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_764546" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_498" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_498" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_501" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_dei_LegalEntityAxis_500" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_500" xlink:to="loc_dei_EntityDomain_514" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_391588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_srt_ConsolidationItemsAxis_391588" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_391589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_391588" xlink:to="loc_srt_ConsolidationItemsDomain_391589" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_srt_StatementGeographicalAxis_505" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_505" xlink:to="loc_srt_SegmentGeographicalDomain_503" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_srt_NorthAmericaMember_518" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_srt_EuropeMember_519" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_teva_InternationalMarketsMember_520" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherCountriesMember" xlink:label="loc_teva_OtherCountriesMember_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_teva_OtherCountriesMember_521" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_504" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_504" xlink:to="loc_us-gaap_SegmentDomain_502" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_2147448872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_us-gaap_ReportingUnitAxis_2147448872" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_2147448871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_2147448872" xlink:to="loc_us-gaap_ReportingUnitDomain_2147448871" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MedisReportingUnitMember" xlink:label="loc_teva_MedisReportingUnitMember_2147448869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_2147448871" xlink:to="loc_teva_MedisReportingUnitMember_2147448869" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TevasApiReportingUnitMember" xlink:label="loc_teva_TevasApiReportingUnitMember_2147448870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_2147448871" xlink:to="loc_teva_TevasApiReportingUnitMember_2147448870" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_us-gaap_GoodwillLineItems_499" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_Goodwill_506" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_511" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_Goodwill_512" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_523" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_523" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_526" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_526" xlink:to="loc_dei_LegalEntityAxis_525" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_525" xlink:to="loc_dei_EntityDomain_528" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_2147471385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_526" xlink:to="loc_us-gaap_ReportingUnitAxis_2147471385" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_2147471386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_2147471385" xlink:to="loc_us-gaap_ReportingUnitDomain_2147471386" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_526" xlink:to="loc_us-gaap_GoodwillLineItems_524" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_524" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_527" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_530" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_530" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_536" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_dei_LegalEntityAxis_532" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_532" xlink:to="loc_dei_EntityDomain_545" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_539" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_539" xlink:to="loc_us-gaap_SegmentDomain_537" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_StatementGeographicalAxis_540" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_540" xlink:to="loc_srt_SegmentGeographicalDomain_538" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_RangeAxis_533" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_533" xlink:to="loc_srt_RangeMember_534" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_556283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_StatementScenarioAxis_556283" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_556284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_556283" xlink:to="loc_srt_ScenarioUnspecifiedDomain_556284" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_2147450324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_ReportingUnitAxis_2147450324" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_2147450325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_2147450324" xlink:to="loc_us-gaap_ReportingUnitDomain_2147450325" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_2147449567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_2147449567" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2147449568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2147449567" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2147449568" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EuropeReportingUnitMember" xlink:label="loc_teva_EuropeReportingUnitMember_2147449633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2147449568" xlink:to="loc_teva_EuropeReportingUnitMember_2147449633" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_GoodwillLineItems_531" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_412047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_412047" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_684" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_684" xlink:to="loc_us-gaap_DebtInstrumentTable_690" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_dei_LegalEntityAxis_691" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_691" xlink:to="loc_dei_EntityDomain_705" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_DebtInstrumentAxis_687" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_687" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ShortCreditAgreement2026Member" xlink:label="loc_teva_ShortCreditAgreement2026Member_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689" xlink:to="loc_teva_ShortCreditAgreement2026Member_704" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_VariableRateAxis_692" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_692" xlink:to="loc_us-gaap_VariableRateDomain_693" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_srt_CurrencyAxis_686" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_686" xlink:to="loc_currency_AllCurrenciesDomain_685" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_504448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_CreditFacilityAxis_504448" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_504449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_504448" xlink:to="loc_us-gaap_CreditFacilityDomain_504449" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_DebtInstrumentLineItems_688" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_695" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_teva_DebtInstrumentMaturityYear_698" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_ShortTermBorrowings_699" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_LongTermDebtCurrent_700" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtCurrent_701" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_758" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_758" xlink:to="loc_us-gaap_DebtInstrumentTable_764" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_dei_LegalEntityAxis_765" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_765" xlink:to="loc_dei_EntityDomain_815" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_DebtInstrumentAxis_761" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_761" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_763" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherDebentures2026Member" xlink:label="loc_teva_OtherDebentures2026Member_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_OtherDebentures2026Member_814" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024Member_783" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2030Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member_1260375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member_1260375" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023OneMember_784" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2027Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260377" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572204" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025Member_786" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member_787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028Member_787" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022OneMember_788" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2026OneMember_790" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_673253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_673253" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2046Member_794" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024OneMember_796" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028OneMember_797" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572603" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260378" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2029Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260379" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2036Member_799" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_804" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember_2147448829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember_2147448829" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember_2147448830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember_2147448830" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember_2147448831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember_2147448831" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember_2147448833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember_2147448833" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_VariableRateAxis_766" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_766" xlink:to="loc_us-gaap_VariableRateDomain_767" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_srt_CurrencyAxis_760" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_760" xlink:to="loc_currency_AllCurrenciesDomain_759" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_DebtInstrumentLineItems_762" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_769" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_teva_DebtInstrumentMaturityYear_772" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_SeniorNotes_775" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongTermDebtCurrent_778" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_780" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongTermNotesAndLoans_781" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_818" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_818" xlink:to="loc_us-gaap_DebtInstrumentTable_822" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_DebtInstrumentAxis_819" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_819" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_821" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024Member_826" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2030Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member_1260397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2030Member_1260397" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023OneMember_827" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025Member_829" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member_830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028Member_830" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022OneMember_831" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572208" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572210" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember_833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2026OneMember_833" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_835" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2046Member_837" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember_839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024OneMember_839" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028OneMember_840" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member_842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2036Member_842" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_847" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2027Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027Member_1260398" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2027TwoMember" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2027TwoMember_1260399" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilityLinkedSeniorNotesDue2029Member" xlink:label="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilityLinkedSeniorNotesDue2029Member_1260400" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember" xlink:label="loc_teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember_2147448789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember_2147448789" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember_2147448799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember_2147448799" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember_2147448800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember_2147448800" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember_2147448801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember_2147448801" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember" xlink:label="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember_2147448802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember_2147448802" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InterestRateIncreaseMember" xlink:label="loc_teva_InterestRateIncreaseMember_2147450851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_InterestRateIncreaseMember_2147450851" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OneTimePremiumPaymentMember" xlink:label="loc_teva_OneTimePremiumPaymentMember_2147450854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_OneTimePremiumPaymentMember_2147450854" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2147450841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_srt_RangeAxis_2147450841" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2147450842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2147450841" xlink:to="loc_srt_RangeMember_2147450842" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2147450843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2147450842" xlink:to="loc_srt_MaximumMember_2147450843" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2147450844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2147450842" xlink:to="loc_srt_MinimumMember_2147450844" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis" xlink:label="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_2147448795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_2147448795" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain" xlink:label="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain_2147448794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_2147448795" xlink:to="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain_2147448794" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember" xlink:label="loc_teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember_2147448793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain_2147448794" xlink:to="loc_teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember_2147448793" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2147450878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2147450878" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2147450880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2147450878" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2147450880" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_2147450881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2147450880" xlink:to="loc_us-gaap_SeniorNotesMember_2147450881" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_DebtInstrumentLineItems_820" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_824" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_2147448790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_2147448790" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_2147448791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_2147448791" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_2147448792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_2147448792" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DebtInstrumentMonthOfMaturity" xlink:label="loc_teva_DebtInstrumentMonthOfMaturity_2147448796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_teva_DebtInstrumentMonthOfMaturity_2147448796" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_2147448797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_2147448797" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2147450840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_2147450840" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_2147450853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_2147450853" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SeniorNotesRepaidAmount" xlink:label="loc_teva_SeniorNotesRepaidAmount_2147450867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_teva_SeniorNotesRepaidAmount_2147450867" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SeniorNotesMaturityPercentage" xlink:label="loc_teva_SeniorNotesMaturityPercentage_2147450882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_teva_SeniorNotesMaturityPercentage_2147450882" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_718" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_718" xlink:to="loc_us-gaap_DebtInstrumentTable_724" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_dei_LegalEntityAxis_725" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_725" xlink:to="loc_dei_EntityDomain_755" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_CreditFacilityAxis_719" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_719" xlink:to="loc_us-gaap_CreditFacilityDomain_720" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_720" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_728" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember" xlink:label="loc_teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember_2147450329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_720" xlink:to="loc_teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember_2147450329" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_726" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_726" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_727" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_727" xlink:to="loc_us-gaap_ConvertibleDebtMember_756" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_DebtInstrumentAxis_721" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_721" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_723" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AmendedRevolvingCreditFacilityMember" xlink:label="loc_teva_AmendedRevolvingCreditFacilityMember_2147468973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_723" xlink:to="loc_teva_AmendedRevolvingCreditFacilityMember_2147468973" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_408262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_408262" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_408264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_408262" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_408264" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_466637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_466637" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_466638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_466637" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_466638" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_466640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_466638" xlink:to="loc_us-gaap_SubsequentEventMember_466640" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TrancheAxis" xlink:label="loc_teva_TrancheAxis_682383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_teva_TrancheAxis_682383" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TrancheDomain" xlink:label="loc_teva_TrancheDomain_682384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_TrancheAxis_682383" xlink:to="loc_teva_TrancheDomain_682384" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_682892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_682892" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_682892" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_srt_RangeAxis_765345" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_765345" xlink:to="loc_srt_RangeMember_765346" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AgreementAxis" xlink:label="loc_teva_AgreementAxis_1280331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_teva_AgreementAxis_1280331" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain_1280332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AgreementAxis_1280331" xlink:to="loc_teva_AgreementDomain_1280332" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodAxis" xlink:label="loc_teva_PeriodAxis_2147450317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_teva_PeriodAxis_2147450317" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodDomain" xlink:label="loc_teva_PeriodDomain_2147450318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_PeriodAxis_2147450317" xlink:to="loc_teva_PeriodDomain_2147450318" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_DebtInstrumentLineItems_722" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_732" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_735" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LongTermDebtCurrencyPortionUSD" xlink:label="loc_teva_LongTermDebtCurrencyPortionUSD_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionUSD_739" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LongTermDebtCurrencyPortionEUR" xlink:label="loc_teva_LongTermDebtCurrencyPortionEUR_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionEUR_740" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LongTermDebtCurrencyPortionCHF" xlink:label="loc_teva_LongTermDebtCurrencyPortionCHF_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionCHF_741" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription_466634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentCovenantDescription_466634" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_466635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LineOfCredit_466635" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_682881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_682881" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1241835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1241835" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LineOfCreditExtensionPeriod" xlink:label="loc_teva_LineOfCreditExtensionPeriod_2147450333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LineOfCreditExtensionPeriod_2147450333" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LeverageRatio" xlink:label="loc_teva_LeverageRatio_2147450347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LeverageRatio_2147450347" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2147448863" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable" xlink:label="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable_2147448862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2147448863" xlink:to="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable_2147448862" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_2147448858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable_2147448862" xlink:to="loc_us-gaap_HedgingDesignationAxis_2147448858" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_2147448857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_2147448858" xlink:to="loc_us-gaap_HedgingDesignationDomain_2147448857" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2147448856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2147448857" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2147448856" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable_2147448862" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448861" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2147448860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448861" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2147448860" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CrossCurrencySwapCashFlowHedgeMember" xlink:label="loc_teva_CrossCurrencySwapCashFlowHedgeMember_2147448859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2147448860" xlink:to="loc_teva_CrossCurrencySwapCashFlowHedgeMember_2147448859" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems" xlink:label="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems_2147448855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable_2147448862" xlink:to="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems_2147448855" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotionalAmount" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_2147448854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems_2147448855" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_2147448854" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_1333" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1333" xlink:to="loc_us-gaap_DerivativeTable_1340" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_dei_LegalEntityAxis_1344" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1344" xlink:to="loc_dei_EntityDomain_1357" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_1341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_HedgingDesignationAxis_1341" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_1341" xlink:to="loc_us-gaap_HedgingDesignationDomain_1342" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1342" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1353" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_1354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1342" xlink:to="loc_us-gaap_NondesignatedMember_1354" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1336" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1336" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1348" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CrossCurrencySwapCashFlowHedgeMember" xlink:label="loc_teva_CrossCurrencySwapCashFlowHedgeMember_2147448851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1336" xlink:to="loc_teva_CrossCurrencySwapCashFlowHedgeMember_2147448851" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1334" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1334" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1335" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1345" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1347" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_390198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_390198" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1343" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeLineItems_1339" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1351" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1352" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2147448847" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable" xlink:label="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable_2147448846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2147448847" xlink:to="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable_2147448846" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2147448839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable_2147448846" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2147448839" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2147448838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2147448839" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2147448838" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FinancialExpensesNetMember" xlink:label="loc_teva_FinancialExpensesNetMember_2147448837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2147448838" xlink:to="loc_teva_FinancialExpensesNetMember_2147448837" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_2147448842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable_2147448846" xlink:to="loc_us-gaap_HedgingDesignationAxis_2147448842" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_2147448841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_2147448842" xlink:to="loc_us-gaap_HedgingDesignationDomain_2147448841" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2147448840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2147448841" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2147448840" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable_2147448846" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448845" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2147448844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2147448845" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2147448844" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CrossCurrencySwapCashFlowHedgeMember" xlink:label="loc_teva_CrossCurrencySwapCashFlowHedgeMember_2147448843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2147448844" xlink:to="loc_teva_CrossCurrencySwapCashFlowHedgeMember_2147448843" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems" xlink:label="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems_2147448836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable_2147448846" xlink:to="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems_2147448836" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments" xlink:label="loc_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments_2147448835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems_2147448836" xlink:to="loc_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments_2147448835" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_2147448834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems_2147448836" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_2147448834" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_390514" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_390515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_390514" xlink:to="loc_us-gaap_DerivativeTable_390515" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390519" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390519" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390520" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NetRevenuesMember" xlink:label="loc_teva_NetRevenuesMember_406886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390520" xlink:to="loc_teva_NetRevenuesMember_406886" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FinancialExpensesMember" xlink:label="loc_teva_FinancialExpensesMember_406916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390520" xlink:to="loc_teva_FinancialExpensesMember_406916" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_406887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_HedgingDesignationAxis_406887" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_406888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_406887" xlink:to="loc_us-gaap_HedgingDesignationDomain_406888" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_406890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NondesignatedMember_406890" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember_406891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember_406891" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_466838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_466838" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_682287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" xlink:to="loc_us-gaap_HedgingRelationshipDomain_682287" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_390516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_DerivativeLineItems_390516" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_406900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_390516" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_406900" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1281" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1281" xlink:to="loc_us-gaap_DerivativeTable_1286" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_dei_LegalEntityAxis_1290" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1290" xlink:to="loc_dei_EntityDomain_1312" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1282" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1288" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1288" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1289" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1287" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_558657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_HedgingDesignationAxis_558657" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_558658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_558657" xlink:to="loc_us-gaap_HedgingDesignationDomain_558658" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_817877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_srt_RangeAxis_817877" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_817878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_817877" xlink:to="loc_srt_RangeMember_817878" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FactoringInstitutionAxis" xlink:label="loc_teva_FactoringInstitutionAxis_2147449602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_teva_FactoringInstitutionAxis_2147449602" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FactoringInstitutionDomain" xlink:label="loc_teva_FactoringInstitutionDomain_2147449605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_FactoringInstitutionAxis_2147449602" xlink:to="loc_teva_FactoringInstitutionDomain_2147449605" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodAxis" xlink:label="loc_teva_PeriodAxis_2147457593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_teva_PeriodAxis_2147457593" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PeriodDomain" xlink:label="loc_teva_PeriodDomain_2147457594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_PeriodAxis_2147457593" xlink:to="loc_teva_PeriodDomain_2147457594" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeLineItems_1285" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenuesOtherThanUsd" xlink:label="loc_teva_RevenuesOtherThanUsd_1298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_RevenuesOtherThanUsd_1298" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_1301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_1301" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2147451284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2147451284" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xlink:label="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses_1303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses_1303" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_688630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_688630" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2147451288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2147451288" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" xlink:to="loc_us-gaap_LossContingenciesTable_1459" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_dei_LegalEntityAxis_1457" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1457" xlink:to="loc_dei_EntityDomain_1460" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_471102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_srt_LitigationCaseAxis_471102" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_471102" xlink:to="loc_srt_LitigationCaseTypeDomain_471103" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_720032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_srt_StatementGeographicalAxis_720032" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_720033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_720032" xlink:to="loc_srt_SegmentGeographicalDomain_720033" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_us-gaap_LossContingenciesLineItems_1458" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LitigationSettlementExpense_1461" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1462" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_899" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CommitmentAndContingenciesTable" xlink:label="loc_teva_CommitmentAndContingenciesTable_901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_899" xlink:to="loc_teva_CommitmentAndContingenciesTable_901" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_ProductOrServiceAxis_906" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_906" xlink:to="loc_srt_ProductsAndServicesDomain_907" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AndroGelRateAtOnePercentageMember" xlink:label="loc_teva_AndroGelRateAtOnePercentageMember_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_AndroGelRateAtOnePercentageMember_937" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_CounterpartyNameAxis_902" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_902" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" xlink:to="loc_us-gaap_LossContingencyNatureDomain_905" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EosinophilicEsophagitisMember" xlink:label="loc_teva_EosinophilicEsophagitisMember_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_905" xlink:to="loc_teva_EosinophilicEsophagitisMember_936" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_StatementGeographicalAxis_910" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_910" xlink:to="loc_srt_SegmentGeographicalDomain_909" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_country_US_940" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_srt_EuropeMember_941" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_471076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_LitigationCaseAxis_471076" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_471076" xlink:to="loc_srt_LitigationCaseTypeDomain_471078" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NationwideSettlementMember" xlink:label="loc_teva_NationwideSettlementMember_515110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_NationwideSettlementMember_515110" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_515106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_515106" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_515107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515106" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_515107" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DefendantsAxis" xlink:label="loc_teva_DefendantsAxis_1280170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_teva_DefendantsAxis_1280170" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DefendantsMember" xlink:label="loc_teva_DefendantsMember_1280172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DefendantsAxis_1280170" xlink:to="loc_teva_DefendantsMember_1280172" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FourOtherDefendantsOtherThanTevaMember" xlink:label="loc_teva_FourOtherDefendantsOtherThanTevaMember_1280174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DefendantsMember_1280172" xlink:to="loc_teva_FourOtherDefendantsOtherThanTevaMember_1280174" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AgreementAxis" xlink:label="loc_teva_AgreementAxis_1280188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_teva_AgreementAxis_1280188" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AgreementDomain" xlink:label="loc_teva_AgreementDomain_1281018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AgreementAxis_1280188" xlink:to="loc_teva_AgreementDomain_1281018" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CommitmentAndContingenciesLineItems" xlink:label="loc_teva_CommitmentAndContingenciesLineItems_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_teva_CommitmentAndContingenciesLineItems_900" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_DamagesAssessment" xlink:label="loc_teva_DamagesAssessment_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_DamagesAssessment_911" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesAtTimeOfSettlement" xlink:label="loc_teva_AnnualSalesAtTimeOfSettlement_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesAtTimeOfSettlement_919" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfEffexor" xlink:label="loc_teva_AnnualSalesOfEffexor_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfEffexor_920" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfLamictal" xlink:label="loc_teva_AnnualSalesOfLamictal_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfLamictal_921" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfNiaspan" xlink:label="loc_teva_AnnualSalesOfNiaspan_922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfNiaspan_922" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfActos" xlink:label="loc_teva_AnnualSalesOfActos_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfActos_925" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfActoplus" xlink:label="loc_teva_AnnualSalesOfActoplus_926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfActoplus_926" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_932" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_933" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_934" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfSensipar" xlink:label="loc_teva_AnnualSalesOfSensipar_471045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfSensipar_471045" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LitigationSettlementAmountAwardedDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod_515103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod_515103" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfCopaxone" xlink:label="loc_teva_AnnualSalesOfCopaxone_720069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfCopaxone_720069" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_818712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_818712" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_1279981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_1279981" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfSettlementOfViread" xlink:label="loc_teva_AnnualSalesOfTheTimeOfSettlementOfViread_1280127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfTheTimeOfSettlementOfViread_1280127" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfSettlementOfTruvada" xlink:label="loc_teva_AnnualSalesOfTheTimeOfSettlementOfTruvada_1280128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfTheTimeOfSettlementOfTruvada_1280128" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfSettlementOfAtripla" xlink:label="loc_teva_AnnualSalesOfTheTimeOfSettlementOfAtripla_1280132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfTheTimeOfSettlementOfAtripla_1280132" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfNewLaunchOfViread" xlink:label="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfViread_1280135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfViread_1280135" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada" xlink:label="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada_1280137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada_1280137" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla" xlink:label="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla_1280138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla_1280138" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfColcrys" xlink:label="loc_teva_AnnualSalesOfColcrys_1280142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfColcrys_1280142" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LitigationSettlementAmountDistributableinKind" xlink:label="loc_teva_LitigationSettlementAmountDistributableinKind_1280198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountDistributableinKind_1280198" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccrualForEnvironmentalLossContingencies" xlink:label="loc_us-gaap_AccrualForEnvironmentalLossContingencies_1280219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_AccrualForEnvironmentalLossContingencies_1280219" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration_2147470183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration_2147470183" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LossContingenciesOnEnvironmentalLawsPenalty" xlink:label="loc_teva_LossContingenciesOnEnvironmentalLawsPenalty_1280223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LossContingenciesOnEnvironmentalLawsPenalty_1280223" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PercentageOfThePopulationOfTheParticipatingStates" xlink:label="loc_teva_PercentageOfThePopulationOfTheParticipatingStates_2147448866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_PercentageOfThePopulationOfTheParticipatingStates_2147448866" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement" xlink:label="loc_teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement_2147448867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement_2147448867" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfRevlimid" xlink:label="loc_teva_AnnualSalesOfRevlimid_2147469263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfRevlimid_2147469263" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler" xlink:label="loc_teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler_2147469264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler_2147469264" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AnnualSalesOfEpipen" xlink:label="loc_teva_AnnualSalesOfEpipen_2147469265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfEpipen_2147469265" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation" xlink:label="loc_teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation_2147469266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation_2147469266" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_PercentageOfShareOfTheNationalPopulation" xlink:label="loc_teva_PercentageOfShareOfTheNationalPopulation_2147469267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_PercentageOfShareOfTheNationalPopulation_2147469267" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LitigationSettlementAmountPayableInCashPercentage" xlink:label="loc_teva_LitigationSettlementAmountPayableInCashPercentage_2147469336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountPayableInCashPercentage_2147469336" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LitigationSettlementAmountDistributableInCash" xlink:label="loc_teva_LitigationSettlementAmountDistributableInCash_2147469337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountDistributableInCash_2147469337" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_2147471392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_2147471392" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2147448824" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_2147448823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2147448824" xlink:to="loc_us-gaap_LossContingenciesTable_2147448823" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesByJurisdictionAxis" xlink:label="loc_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis_2147448822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2147448823" xlink:to="loc_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis_2147448822" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesJurisdictionDomain" xlink:label="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis_2147448822" xlink:to="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_LA" xlink:label="loc_stpr_LA_2147448782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_LA_2147448782" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OK" xlink:label="loc_stpr_OK_2147448783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_OK_2147448783" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TX" xlink:label="loc_stpr_TX_2147448784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_TX_2147448784" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WV" xlink:label="loc_stpr_WV_2147448785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_WV_2147448785" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY" xlink:label="loc_stpr_NY_2147448786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_NY_2147448786" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL" xlink:label="loc_stpr_FL_2147448787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_FL_2147448787" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_RI" xlink:label="loc_stpr_RI_2147448788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_stpr_RI_2147448788" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_CuyahogaCountyOhMember" xlink:label="loc_teva_CuyahogaCountyOhMember_2147448819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_teva_CuyahogaCountyOhMember_2147448819" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SummitCountyOhMember" xlink:label="loc_teva_SummitCountyOhMember_2147448818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_teva_SummitCountyOhMember_2147448818" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SanFranciscoMember" xlink:label="loc_teva_SanFranciscoMember_2147448813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_teva_SanFranciscoMember_2147448813" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TribesMember" xlink:label="loc_teva_TribesMember_2147448810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesJurisdictionDomain_2147448821" xlink:to="loc_teva_TribesMember_2147448810" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_2147448809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2147448823" xlink:to="loc_us-gaap_LossContingenciesLineItems_2147448809" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencySettlementAgreementDate" xlink:label="loc_us-gaap_LossContingencySettlementAgreementDate_2147448808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_us-gaap_LossContingencySettlementAgreementDate_2147448808" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDomicileOfLitigation" xlink:label="loc_us-gaap_LossContingencyDomicileOfLitigation_2147448807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_us-gaap_LossContingencyDomicileOfLitigation_2147448807" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_2147448806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_2147448806" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencySettlementAgreementTerms" xlink:label="loc_us-gaap_LossContingencySettlementAgreementTerms_2147448805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_us-gaap_LossContingencySettlementAgreementTerms_2147448805" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ContingencySettlementProduct" xlink:label="loc_teva_ContingencySettlementProduct_2147448804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_teva_ContingencySettlementProduct_2147448804" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProductWeightedAverageCost" xlink:label="loc_teva_ProductWeightedAverageCost_2147448803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_teva_ProductWeightedAverageCost_2147448803" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ProductWeightedAverageCostTerm" xlink:label="loc_teva_ProductWeightedAverageCostTerm_2147448798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2147448809" xlink:to="loc_teva_ProductWeightedAverageCostTerm_2147448798" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1206" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_IncomeTaxTable" xlink:label="loc_teva_IncomeTaxTable_1210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1206" xlink:to="loc_teva_IncomeTaxTable_1210" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_dei_LegalEntityAxis_1211" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1211" xlink:to="loc_dei_EntityDomain_1242" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_srt_RangeAxis_1214" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1214" xlink:to="loc_srt_RangeMember_1215" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1216" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1216" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaap_IsraelTaxAuthorityMember_1220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" xlink:to="loc_us-gaap_IsraelTaxAuthorityMember_1220" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_TaxPeriodAxis_1218" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_1218" xlink:to="loc_us-gaap_TaxPeriodDomain_1219" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_TaxYear2008To2011Member" xlink:label="loc_teva_TaxYear2008To2011Member_1280227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1219" xlink:to="loc_teva_TaxYear2008To2011Member_1280227" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_581719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_581719" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_581720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_581719" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_581720" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_673833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_srt_StatementScenarioAxis_673833" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_673834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_673833" xlink:to="loc_srt_ScenarioUnspecifiedDomain_673834" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_YearOfSettlementAxis" xlink:label="loc_teva_YearOfSettlementAxis_2147449861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_teva_YearOfSettlementAxis_2147449861" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_YearOfSettlementDomain" xlink:label="loc_teva_YearOfSettlementDomain_2147449920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_YearOfSettlementAxis_2147449861" xlink:to="loc_teva_YearOfSettlementDomain_2147449920" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_IncomeTaxLineItems" xlink:label="loc_teva_IncomeTaxLineItems_1209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_teva_IncomeTaxLineItems_1209" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1229" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ExpectedImpairmentOfIncomeTaxBenefit" xlink:label="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit_581718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit_581718" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_671996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_671996" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_672012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_672012" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_1280226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_1280226" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail">
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAndImpairmentAbstract" xlink:label="loc_teva_RestructuringAndImpairmentAbstract_1390" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable_1393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentAbstract_1390" xlink:to="loc_teva_RestructuringAndImpairmentCostsTable_1393" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1393" xlink:to="loc_dei_LegalEntityAxis_1391" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1391" xlink:to="loc_dei_EntityDomain_1394" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1393" xlink:to="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1395" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1396" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_RestructuringCharges_1398" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:label="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses_1400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses_1400" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentAndRestructuring" xlink:label="loc_teva_ImpairmentAndRestructuring_1401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_ImpairmentAndRestructuring_1401" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2147451045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2147451045" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1431" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1431" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_dei_LegalEntityAxis_1432" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1432" xlink:to="loc_dei_EntityDomain_1437" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1433" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1433" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1436" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_1439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1436" xlink:to="loc_us-gaap_EmployeeSeveranceMember_1439" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_1440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1436" xlink:to="loc_us-gaap_OtherRestructuringMember_1440" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390248" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390248" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390250" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" xlink:to="loc_us-gaap_RestructuringCharges_1438" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1442" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1442" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_dei_LegalEntityAxis_1445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1445" xlink:to="loc_dei_EntityDomain_1450" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ExitAndDisposalAxis" xlink:label="loc_teva_ExitAndDisposalAxis_1443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_teva_ExitAndDisposalAxis_1443" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ExitAndDisposalDomain" xlink:label="loc_teva_ExitAndDisposalDomain_1444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExitAndDisposalAxis_1443" xlink:to="loc_teva_ExitAndDisposalDomain_1444" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EmployeeTerminationMember" xlink:label="loc_teva_EmployeeTerminationMember_1448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExitAndDisposalDomain_1444" xlink:to="loc_teva_EmployeeTerminationMember_1448" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherExitAndDisposalMember" xlink:label="loc_teva_OtherExitAndDisposalMember_1449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExitAndDisposalDomain_1444" xlink:to="loc_teva_OtherExitAndDisposalMember_1449" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_1451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_us-gaap_RestructuringReserve_1451" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAccrualProvision" xlink:label="loc_teva_RestructuringAccrualProvision_1452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_teva_RestructuringAccrualProvision_1452" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_UtilizationAndOther" xlink:label="loc_teva_UtilizationAndOther_1453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_teva_UtilizationAndOther_1453" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_1454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_us-gaap_RestructuringReserve_1454" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAndImpairmentAbstract" xlink:label="loc_teva_RestructuringAndImpairmentAbstract_1403" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable_1412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentAbstract_1403" xlink:to="loc_teva_RestructuringAndImpairmentCostsTable_1412" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_dei_LegalEntityAxis_1406" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1406" xlink:to="loc_dei_EntityDomain_1416" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_ProductOrServiceAxis_1407" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1407" xlink:to="loc_srt_ProductsAndServicesDomain_1408" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1404" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1404" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1405" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_StatementGeographicalAxis_1414" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1414" xlink:to="loc_srt_SegmentGeographicalDomain_1413" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_515346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_StatementScenarioAxis_515346" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_515347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_515346" xlink:to="loc_srt_ScenarioUnspecifiedDomain_515347" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_1419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_1419" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_758336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_758336" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_RestructuringCharges_1421" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1591" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1591" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_dei_LegalEntityAxis_1595" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1595" xlink:to="loc_dei_EntityDomain_1603" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1601" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1597" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_718513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_EarningsPerShareBasic_718513" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_718514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_EarningsPerShareDiluted_718514" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2147448894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2147448894" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_390025" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_390025" xlink:to="loc_us-gaap_StatementTable_390027" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390027" xlink:to="loc_dei_LegalEntityAxis_390028" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_390028" xlink:to="loc_dei_EntityDomain_390029" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_390055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390027" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_390055" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_390057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_390055" xlink:to="loc_us-gaap_EquityComponentDomain_390057" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_390087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_390087" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_390089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_390089" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_390090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_390090" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_390091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_390057" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_390091" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390027" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_390031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_390031" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_390032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_390032" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_390033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_390033" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_390034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_390034" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_466595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_466595" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_390049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_390049" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_390052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390030" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_390052" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_390129" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_390129" xlink:to="loc_us-gaap_StatementTable_390130" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_dei_LegalEntityAxis_390133" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_390133" xlink:to="loc_dei_EntityDomain_390134" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_390142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_390142" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_390143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_390142" xlink:to="loc_us-gaap_EquityComponentDomain_390143" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_390148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_390146" xlink:to="loc_us-gaap_TypeOfAdoptionMember_390148" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_390149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_390148" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_390149" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_720088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_srt_RangeAxis_720088" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_720089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_720088" xlink:to="loc_srt_RangeMember_720089" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390130" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390135" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_390137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_390135" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_390137" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_1481" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_1481" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_dei_LegalEntityAxis_1482" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1482" xlink:to="loc_dei_EntityDomain_1487" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1486" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1486" xlink:to="loc_us-gaap_SegmentDomain_1484" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_NorthAmericaSegmentMember_1488" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_EuropeSegmentMember_1489" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_InternationalMarketsMember_1490" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1491" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_GrossProfit_1492" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1493" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_1494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_SellingAndMarketingExpense_1494" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1495" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherOperatingIncomeExpense" xlink:label="loc_teva_OtherOperatingIncomeExpense_1496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_teva_OtherOperatingIncomeExpense_1496" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_OperatingIncomeLoss_1497" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_1499" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_1499" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_dei_LegalEntityAxis_1502" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1502" xlink:to="loc_dei_EntityDomain_1518" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1506" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1506" xlink:to="loc_us-gaap_SegmentDomain_1504" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_NorthAmericaSegmentMember_1519" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_EuropeSegmentMember_1520" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_InternationalMarketsMember_1521" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaap_CorporateMember_1522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_us-gaap_CorporateMember_1522" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1523" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SegmentsAndOtherActivitiesMember" xlink:label="loc_teva_SegmentsAndOtherActivitiesMember_1524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_SegmentsAndOtherActivitiesMember_1524" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AmountsAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" xlink:to="loc_us-gaap_OperatingIncomeLoss_1507" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AmountsNotAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_1508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_AdjustmentForAmortization_1508" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_1509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_1509" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1511" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies_1516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_LegalSettlementsAndLossContingencies_1516" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherUnallocatedAmounts" xlink:label="loc_teva_OtherUnallocatedAmounts_1517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_OtherUnallocatedAmounts_1517" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_390232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_OperatingIncomeLoss_390232" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1525" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1526" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1528" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_1533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1528" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_1533" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_dei_LegalEntityAxis_1529" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1529" xlink:to="loc_dei_EntityDomain_1536" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_srt_ProductOrServiceAxis_1531" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1531" xlink:to="loc_srt_ProductsAndServicesDomain_1532" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_GenericsMediciansMember" xlink:label="loc_teva_GenericsMediciansMember_1538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_GenericsMediciansMember_1538" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AjovyMember" xlink:label="loc_teva_AjovyMember_408213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AjovyMember_408213" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AustedoMember" xlink:label="loc_teva_AustedoMember_1543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AustedoMember_1543" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_BendekaAndTreandaMember" xlink:label="loc_teva_BendekaAndTreandaMember_1540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_BendekaAndTreandaMember_1540" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_COPAXONEMember" xlink:label="loc_teva_COPAXONEMember_1539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_COPAXONEMember_1539" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_AndaMember" xlink:label="loc_teva_AndaMember_1546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AndaMember_1546" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RespiratoryProductMember" xlink:label="loc_teva_RespiratoryProductMember_1545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_RespiratoryProductMember_1545" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherProductsMember" xlink:label="loc_teva_OtherProductsMember_1547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_OtherProductsMember_1547" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1535" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1535" xlink:to="loc_us-gaap_SegmentDomain_1534" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_NorthAmericaSegmentMember_1548" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_EuropeSegmentMember_1549" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_InternationalMarketsMember_1550" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueTypeAxis" xlink:label="loc_teva_RevenueTypeAxis_558204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_teva_RevenueTypeAxis_558204" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_RevenueTypeDomain" xlink:label="loc_teva_RevenueTypeDomain_558211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueTypeAxis_558204" xlink:to="loc_teva_RevenueTypeDomain_558211" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems_1530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_us-gaap_ProductInformationLineItems_1530" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_1530" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1537" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1464" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1464" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_dei_LegalEntityAxis_1469" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1469" xlink:to="loc_dei_EntityDomain_1476" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_srt_StatementGeographicalAxis_1473" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1473" xlink:to="loc_srt_SegmentGeographicalDomain_1471" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1468" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1260430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1260429" xlink:to="loc_us-gaap_SegmentDomain_1260430" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_1472" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_1478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1472" xlink:to="loc_us-gaap_NumberOfReportableSegments_1478" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_356" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_356" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_dei_LegalEntityAxis_366" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_366" xlink:to="loc_dei_EntityDomain_383" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_380" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_381" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_382" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_360" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_360" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_MoneyMarketFundsMember_374" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemandDepositsMember" xlink:label="loc_us-gaap_DemandDepositsMember_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_DemandDepositsMember_375" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_EquitySecuritiesMember_376" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OtherRestrictedCashMember" xlink:label="loc_teva_OtherRestrictedCashMember_1260419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_teva_OtherRestrictedCashMember_1260419" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_362" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_362" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xlink:label="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" xlink:to="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember_379" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FinancialInstrumentAxis_365" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_365" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" xlink:to="loc_us-gaap_InterestRateSwapMember_384" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_2147448890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_2147448890" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_369" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_1280201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_RestrictedCash_1280201" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeAssets_370" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeLiabilities_371" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_372" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_FairValueNetAssetLiability_373" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_2147451277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_2147451277" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_2147451276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_2147451276" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_682369" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_682369" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_682372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_srt_RangeAxis_682372" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_682373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_682372" xlink:to="loc_srt_RangeMember_682373" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_682374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_MaximumMember_682374" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_682375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_MinimumMember_682375" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_688250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_WeightedAverageMember_688250" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_682378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_682378" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_682379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_682378" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_682379" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_MeasurementInputProbabilityOfSuccessMember" xlink:label="loc_teva_MeasurementInputProbabilityOfSuccessMember_682380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_682379" xlink:to="loc_teva_MeasurementInputProbabilityOfSuccessMember_682380" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_682382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_682379" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_682382" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:label="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:label="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" xlink:to="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_682381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_682381" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_387" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_387" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_dei_LegalEntityAxis_394" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_394" xlink:to="loc_dei_EntityDomain_407" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_392" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_392" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_393" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_ActavisGenericsMember" xlink:label="loc_teva_ActavisGenericsMember_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_ActavisGenericsMember_404" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_EagleTransactionMember" xlink:label="loc_teva_EagleTransactionMember_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_EagleTransactionMember_406" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NovetideTransactionMember" xlink:label="loc_teva_NovetideTransactionMember_2147448889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_NovetideTransactionMember_2147448889" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_389" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_389" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NoveTideAcquisitionMember" xlink:label="loc_teva_NoveTideAcquisitionMember_2147450147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" xlink:to="loc_teva_NoveTideAcquisitionMember_2147450147" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_397" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_1280210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_1280210" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_BifurcatedEmbeddedDerivatives" xlink:label="loc_teva_BifurcatedEmbeddedDerivatives_1280215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_BifurcatedEmbeddedDerivatives_1280215" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod_400" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease_401" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_402" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_403" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_2147450621" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2147450622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_2147450621" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2147450622" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2147450624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2147450622" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2147450624" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2147450625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2147450624" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2147450625" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_NoveTideAcquisitionMember" xlink:label="loc_teva_NoveTideAcquisitionMember_2147450627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2147450625" xlink:to="loc_teva_NoveTideAcquisitionMember_2147450627" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2147450629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2147450622" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2147450629" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2147450630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2147450629" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2147450630" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_409" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_409" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_dei_LegalEntityAxis_412" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_412" xlink:to="loc_dei_EntityDomain_416" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_413" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_413" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_414" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember" xlink:label="loc_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember_1260415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_414" xlink:to="loc_teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember_1260415" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20230331.xsd#teva_SeniornotesandconvertibleseniordebenturesMember" xlink:label="loc_teva_SeniornotesandconvertibleseniordebenturesMember_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_414" xlink:to="loc_teva_SeniornotesandconvertibleseniordebenturesMember_418" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" xlink:to="loc_us-gaap_DebtInstrumentFairValue_415" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g464631g66p75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g464631g66p75.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2= 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )R2^$ (#A"24T$!       (1P!6@ #&R5'' (   (  !P"!0 -5&5V85
M],;V=O7U)'0@ X0DE-!"4      !#*SFLL9@!BWHZCINKI2IL;.$))300Z
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M--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M      3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F
M-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M    !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G
M)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M  4G-L=%5N=$8C4'AL0'P@           *=F5C=&]R1&%T86)O;VP!     %
M!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
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M^    X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M  "0           0 X0DE-)Q        H  0         !.$))30/U
M!( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %
MH    &       ! #4    ! "T    &       !.$))30/X      !P  #___
M__________________________ ^@     __________________________
M___P/H     /____________________________\#Z     #___________
M__________________ ^@  #A"24T$"       $     $   )    "0
M X0DE-!!X       0     .$))300:      ,U    !@              L0
M   <L          0                         !              '+
M  L0                     !                         !     !
M      ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M    !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M  L0    !29VAT;&]N9P   <L    &<VQI8V5S5FQ,<P    %/8FIC     0
M      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&
MQO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&
M]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M  !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M       $QE9G1L;VYG          !"=&]M;&]N9P   +$     4F=H=&QO;F
M<   '+     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37
M-G951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$
MES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9V
MYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&
MEG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;V
MQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&
M]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='
M1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))30
M0H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M0    #.$))300,     !RL     0   *     ^   !X   =$   !R0 !@  ?
M_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\
MX  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $  /
M;6  $     TRU(4" @
M                     18W!R=    5     S9&5S8P   80   !L=W1P=
M   ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48E
MA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M"&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M    !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;G
MD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U
M)'0B!)14,V,3DV-BTR+C$
M                           %A96B        #S40 !     1;,6%E:(
M                    !865H@        ;Z(  #CU   #D%A96B
M!BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14
M,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=R
MYI96,N8V@
M          9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B
M!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2
M!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&
MEO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=V
MEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M            !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M%865H@      !,"58 4    %<?YVUE87,          0
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M*6HP:C=J/FI%:DQZ4XI:FF&J:+H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%A<B.#E!475XM[C_Q  = 0 " @,! 0$            '" 4&  ($ 0D#_\0
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M;7A222+D-@GD,8W+<!M.;;.[N_+>FNK9J7;.N>:%UUU>(W$1:JO)<-)$<26
M22.:VTLF-T@#(BN,&"C%C% F"EBE#LOCOM.MI7BN4L=VSQUN"]2M8"O:K/Y(
M9DSRED;8J2 ^096!5BI5E*L"000>KID\MWMS%"UC,ECM4VJ-V(PV:[Z7=5EC
M)#;%DQ:NI#*K*R,K*P#*00#UDOIJXC\SJ1R]FXNW<;^06KJ3L[CIR"U;;;;L
M+4&PZ+5AA+/KX\B %-G;178J)P\5=XJJH$%62IYXC"%--*PTM2(WN-F,#>TV
MRU\MC+EF#(4+%>&K>JV9BZ3<)&6.&5WV6O),6;;8#T3[ ,CVETOJVAJBPEO
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MH6))/2 ]W<91Q7<#.UL>D<5=VJ6V@B4+'#/<IP6;"(J_94--(\H4 !/)Q
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?$4:0QQPQKQCB1(XUW)XHBA57<DD[* -R23]23U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g464631teva2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g464631teva2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MODA3\K$#IR#R/2JY'I\_P5_ZL0J\'MY?BTOUZV'-XH#:G%9P:=<2([3(TVY
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M.,_RP#SB5:TF^EOQO_E_PQ4I.,HQ2O?^OZ_4CTO7I=3UB2V^QRV\ M4G3SE
M=MS$9X8C& /?UJN6R=]T[$1J\SC9:--_E_F;E2;!0 4 % !0 4 % !0 4 %
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M,;5 ' ]*4_?BXOS_ !'2A[)W3[+[ADWAJRGM+6UD>8QV]L]JOS#)1E"G/'7
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2:^]W+<$VWW:?W?\ #&I2+/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177554859904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TEVA PHARMACEUTICAL INDUSTRIES LIMITED<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000818686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">1,120,405,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one Ordinary Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TEVA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-16174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">124 Dvora HaNevi&#8217;a St.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6944020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972 (3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">914-8213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Smaller Reporting Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177554950368">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,143<span></span>
</td>
<td class="nump">$ 2,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables, net of allowance for credit losses of $88 million and $91 million as of March 31, 2023 and December 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,435<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,118<span></span>
</td>
<td class="nump">3,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,253<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">542<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,501<span></span>
</td>
<td class="nump">12,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,572<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other&#160;non-current&#160;assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">450<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,751<span></span>
</td>
<td class="nump">5,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">420<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Identifiable intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,964<span></span>
</td>
<td class="nump">6,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,799<span></span>
</td>
<td class="nump">17,633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,456<span></span>
</td>
<td class="nump">44,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">2,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_SalesReservesAndAllowances', window );">Sales reserves and allowances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,381<span></span>
</td>
<td class="nump">1,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee-related obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">432<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AccruedExpenses', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,267<span></span>
</td>
<td class="nump">2,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,411<span></span>
</td>
<td class="nump">11,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">550<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other taxes and long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,869<span></span>
</td>
<td class="nump">3,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesAndLoans', window );">Senior notes and loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,668<span></span>
</td>
<td class="nump">19,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">345<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,433<span></span>
</td>
<td class="nump">23,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies, see note 10</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,844<span></span>
</td>
<td class="nump">35,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Teva shareholders' equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares of NIS 0.10 par value per share; March 31, 2023 and December 31, 2022: authorized 2,495 million shares; issued 1,226 million shares and 1,217 million shares, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional&#160;paid-in&#160;capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,719<span></span>
</td>
<td class="nump">27,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,086)<span></span>
</td>
<td class="num">(12,882)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,701)<span></span>
</td>
<td class="num">(2,838)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury shares as of March 31, 2023 and December 31, 2022: 106 million ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,128)<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to Teva shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,860<span></span>
</td>
<td class="nump">7,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">751<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,612<span></span>
</td>
<td class="nump">8,691<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 43,456<span></span>
</td>
<td class="nump">$ 44,006<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accumulated goodwill impairment as of March&#160;31, 2023 and December&#160;31, 2022 was approximately $27.6&#160;billion.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SalesReservesAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SalesReservesAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesAndLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesAndLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177554842384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8362; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for credit losses | $</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized</a></td>
<td class="nump">2,495,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,495,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">1,226,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,217,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury shares</a></td>
<td class="nump">106,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177557976416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income (Loss) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 3,661<span></span>
</td>
<td class="nump">$ 3,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">2,079<span></span>
</td>
<td class="nump">1,921<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,582<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing expenses</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_IntangibleAssetsImpairments', window );">Intangible assets impairments</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ImpairmentsRestructuringAndOthers', window );">Other assets impairments, restructuring and other items</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LegalSettlementsAndLossContingencies', window );">Legal settlements and loss contingencies</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial expenses, net</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="num">(258)<span></span>
</td>
<td class="num">(971)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (benefit)</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in (profits) losses of associated companies, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(238)<span></span>
</td>
<td class="num">(952)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to non-controlling interests</a></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Teva</a></td>
<td class="num">$ (205)<span></span>
</td>
<td class="num">$ (955)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to ordinary shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares (in millions):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ImpairmentsRestructuringAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairments restructuring and others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ImpairmentsRestructuringAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_IntangibleAssetsImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Impairments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_IntangibleAssetsImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LegalSettlementsAndLossContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LegalSettlementsAndLossContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555794816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income (Loss) (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income loss from equity method investments</a></td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177559490016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (238)<span></span>
</td>
<td class="num">$ (952)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">120<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_UnrealizedGainLossOnDerivativeNetOfTax', window );">Unrealized gain (loss) from derivative financial instruments, net</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax', window );">Unrealized loss on defined benefit plans</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">127<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income (loss)</a></td>
<td class="num">(111)<span></span>
</td>
<td class="num">(1,009)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to non-controlling interests</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Teva</a></td>
<td class="num">$ (69)<span></span>
</td>
<td class="num">$ (959)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_UnrealizedGainLossOnDerivativeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized gain (loss) on derivative net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_UnrealizedGainLossOnDerivativeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177554870560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Ordinary Shares [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Treasury Shares [Member]</div></th>
<th class="th"><div>Total Teva Shareholders' Equity [Member]</div></th>
<th class="th"><div>Non-controlling Interests [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 11,244<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 27,561<span></span>
</td>
<td class="num">$ (10,529)<span></span>
</td>
<td class="num">$ (2,683)<span></span>
</td>
<td class="num">$ (4,128)<span></span>
</td>
<td class="nump">$ 10,278<span></span>
</td>
<td class="nump">$ 966<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(952)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(955)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(955)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Shares, value</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">10,260<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">27,587<span></span>
</td>
<td class="num">(11,484)<span></span>
</td>
<td class="num">(2,687)<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
<td class="nump">9,344<span></span>
</td>
<td class="nump">916<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">8,691<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">27,688<span></span>
</td>
<td class="num">(12,882)<span></span>
</td>
<td class="num">(2,838)<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
<td class="nump">7,897<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 8,612<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 27,719<span></span>
</td>
<td class="num">$ (13,086)<span></span>
</td>
<td class="num">$ (2,701)<span></span>
</td>
<td class="num">$ (4,128)<span></span>
</td>
<td class="nump">$ 7,860<span></span>
</td>
<td class="nump">$ 751<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177554866768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options by employees and vested RSUs</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177554456240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (238)<span></span>
</td>
<td class="num">$ (952)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets and assets held for sale</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Net change in operating assets and liabilities</a></td>
<td class="num">(364)<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions', window );">Deferred income taxes &#8211; net and uncertain tax positions</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other items</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment', window );">Net loss (gain) from investments and from sale of long lived assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(145)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables', window );">Beneficial interest collected in exchange for securitized trade receivables</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from sale of business and long lived assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of businesses, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets', window );">Purchases of investments and other assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of senior notes and loans and other long term liabilities</a></td>
<td class="num">(3,152)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from senior notes, net of issuance costs</a></td>
<td class="nump">2,451<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(706)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Translation adjustment on cash and cash equivalents</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(658)<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Balance of cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">2,834<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Balance of cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">2,176<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">2,143<span></span>
</td>
<td class="nump">2,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash included in other current assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">2,176<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Non-cash&#160;financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables', window );">Beneficial interest obtained in exchange for securitized accounts receivables</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Beneficial Interest Obtained in Exchange for Securitized Trade Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred income taxes net and uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DeferredIncomeTaxesNetAndUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from purchase of available for sales securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from beneficial interest in exchange for securitized trade receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit from sale of long lived assets and investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ProfitFromSaleOfLongLivedAssetsAndInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555980944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of presentation</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1 &#8211; Basis of presentation: </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">a. Basis of presentation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the financial statements reflect all normal and recurring adjustments necessary to fairly state the financial position and results of operations of Teva. The information included in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;). The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> balance sheet data was derived from the audited consolidated financial statements as of December&#160;31, 2022, but not all disclosures required by generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) are included. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing the Company&#8217;s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity and disclosure of contingent liabilities and assets at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing the Company&#8217;s consolidated financial statements, management also considered the economic implications of inflation expectations on its critical and significant accounting estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of IPR&amp;D assets, marketed product rights and goodwill, assessing sales reserves and allowances in the United States, uncertain tax positions, valuation allowances and contingencies. These estimates could <div style="display:inline;">be</div> impacted by higher costs and the ability to pass on such higher costs to customers, which is highly uncertain. Government actions taken to address macroeconomic developments, as well as their economic impact on Teva&#8217;s third-party manufacturers and suppliers, customers and markets, could also impact such estimates and may change in future periods. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2022, Russia launched an invasion of Ukraine. As of the date of this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q,</div> sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in Teva&#8217;s International Markets segment results. Teva has no manufacturing or R&amp;D facilities in these markets. During the three months ended March&#160;31, 2023, the impact of this conflict on Teva&#8217;s results <div style="display:inline;">of</div> operation and financial condition was immaterial. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">b. Significant accounting policies </div></div>  <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Recently adopted accounting pronouncements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2022, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-04</div> &#8220;Liabilities &#8212; Supplier Finance Programs: Disclosure of Supplier Finance Program Obligations (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">405-50)&#8221;.</div> This guidance is intended to address requests from stakeholders for information about an entity&#8217;s use of supplier finance programs and their effect on the entity&#8217;s working capital, liquidity and cash flows. The guidance is effective for the fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years, except for the amendment on roll-forward information requirement, which is effective for the fiscal years beginning after December&#160;15, 2023. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2021, the FASB issued ASU 2021-08 &#8220;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,&#8221; which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The Company adopted the new accounting standard effective January 1, 2023 and the guidance is applied prospectively to all business combinations with an acquisition date occurring on or after January 2023. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements.&#160;<br/></div> </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Recently issued accounting pronouncements, not yet adopted </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555942784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_CertainTransactionsDisclosureTextBlock', window );">Certain transactions</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">NOTE 2 &#8211; Certain transactions: </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company&#8217;s most significant agreements of this nature are summarized below. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">MODAG </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2021, Teva announced a license agreement with MODAG GmbH (&#8220;Modag&#8221;) that will provide Teva an exclusive global license to develop, manufacture and commercialize Modag&#8217;s lead compound <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-56286)</div> and a related compound <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-56287).</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TEV-56286</div> was initially developed for the treatment of Multiple System Atrophy (&#8220;MSA&#8221;) and Parkinson&#8217;s disease, and has the potential to be applied to other treatments for neurodegenerative disorders, such as Alzheimer&#8217;s disease. A phase 1b clinical trial for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TEV-56286</div> was completed and the results are being assessed. In the fourth quarter of 2021, Teva made an upfront payment of $10&#160;million to Modag that was recorded as an R&amp;D expense. Modag may be eligible for future development milestone payments, totaling an aggregate amount of up to $30&#160;million, as well as future commercial milestones and royalties. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Alvotech </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contains biosimilar candidates addressing multiple therapeutic areas, including proposed biosimilars to Humira<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"> </div>and Stelara<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>. Under the terms of the agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. Teva made an upfront payment in the third quarter of 2020 and additional upfront and milestone payments in the second quarter of 2021, which were recorded as R&amp;D expenses. Teva also made a milestone payment in January 2023, which was recorded as an R&amp;D expense in the fourth quarter of 2022. Additional development and commercial milestone payments of up to approximately $400<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="display:inline;">million, as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilars. Pursuant to a settlement agreement entered into in March 2022, regarding certain IP and trade secrets claims filed by Abbvie against Alvotech in relation to Alvotech&#8217;s proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> (adalimumab), Alvotech and Teva may sell the proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in the United States beginning on July&#160;1, 2023, provided that U.S. regulatory approval is obtained by that date. Alvotech announced they received complete response letters (&#8220;CRL&#8221;) from the FDA with respect to Alvotech&#8217;s proposed biosimilar to Humira<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in September 2022, December 2022 and April 2023. The CRL from April 2023 stated that the application could not be approved at this time based on deficiencies associated with Alvotech&#8217;s manufacturing facility. The details following the most recent FDA&#8217;s inspection and CRL are being further assessed to determine next steps.<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>In January 2023, the FDA accepted for review the Biologics License Application (&#8220;BLA&#8221;) for Alvotech&#8217;s proposed biosimilar to Stelara<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"> </div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Otsuka </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;12, 2017, Teva entered into a license and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. (&#8220;Otsuka&#8221;) providing Otsuka with an exclusive license to develop and commercialize AJOVY in Japan. Otsuka paid Teva an upfront payment of $50&#160;million in consideration for the transaction. In the third quarter of 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan and, as a result, paid Teva a milestone payment of $15&#160;million, which was recognized as revenue in the third quarter of 2020. AJOVY was approved in Japan in June 2021 and launched on August&#160;30, 2021. As a result of the launch, Otsuka paid Teva a milestone payment of $35&#160;million, which was recognized as revenue in the third quarter of 2021. Teva may receive additional milestone payments upon achievement of certain revenue targets. Otsuka also pays Teva royalties on AJOVY sales in Japan. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Takeda </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;), for the research, development, manufacture and commercialization of ATTENUKINE<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">TM</div> technology. Teva received a $30&#160;million upfront payment and a milestone payment of $20&#160;million in 2017. During the second quarter of 2022, Takeda initiated its phase 2 study of modakafusp alfa (formerly TAK 573 or TEV 48573) and as a result paid Teva a milestone payment of $25&#160;million, which was recognized as revenue in the second quarter of 2022. The license agreement stipulates additional milestone payments to Teva of up to $519&#160;million with respect to this product candidate, as well as future <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">royalties. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">MedinCell </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable (&#8220;LAI&#8221;) products. Teva leads the clinical development and regulatory process and is responsible for commercialization of these products. The lead product <div style="display:inline;">is</div> risperidone LAI (formerly known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TV-46000).</div> On April&#160;28, 2023, the FDA approved UZEDY<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">TM </div>(risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults.&#160;UZEDY is expected to be available in the U.S. in the coming weeks. MedinCell may be eligible for future sales-based milestones of up to $105&#160;million in respect of UZEDY. Teva will also pay MedinCell royalties on net sales. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The second selected product candidate is olanzapine LAI <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-44749)</div> for the treatment of schizophrenia. In the third quarter of 2022, Teva decided to progress development of the product to phase 3, and as a result a $3&#160;million milestone payment was paid to MedinCell which was recognized as R&amp;D expenses. MedinCell may become eligible for further milestones and royalties on sales of olanzapine LAI <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TEV-44749).</div> </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Assets Held for Sale: </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">General </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assets held for sale as of March&#160;31, 2023 and December&#160;31, 2022 included certain manufacturing assets that were sold in the second quarter of 2023. The table below summarizes all of Teva&#8217;s assets included as held for sale as of March&#160;31, 2023 and December&#160;31, 2022: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:75%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventories</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property, plant and equipment, net and others</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments of assets held for sale to fair value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CertainTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CertainTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555980944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from contracts with customers<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from contracts with customers</a></td>
<td class="text"> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 3 &#8211; Revenue from contracts with customers: </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Disaggregation of revenue </div></div>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table disaggregates Teva&#8217;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> activities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sale of goods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,319</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">464</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licensing arrangements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">434</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,766</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;">&#167;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> activities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sale of goods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,134</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licensing arrangements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;">&#167;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Variable consideration </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Variable consideration mainly includes sales reserves and allowances (&#8220;SR&amp;A&#8221;), comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against accounts receivables. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SR&amp;A to U.S. customers comprised approximately 68% of the Company&#8217;s total SR&amp;A as of March&#160;31, 2023, with <div style="display:inline;">the</div> remaining balance primarily related to customers in Canada and Germany. The changes in SR&amp;A for third-party sales for the three months ended March&#160;31, 2023 and 2022 were as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:40%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/> included in<br/> Accounts<br/> Receivable,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/> other<br/> governmental<br/> allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total reserves<br/> included in<br/> Sales Reserves<br/> and&#160;Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="30" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">663</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,817</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions related to sales made in current year period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,855</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,098</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions related to sales made in prior periods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Credits and payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,127</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(289</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,973</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(95</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,505</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,589</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top;text-indent: 0px;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Translation differences</div></td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">440</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,372</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:37%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/> included in<br/> Accounts<br/> Receivable,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/> other<br/> governmental<br/> allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total reserves<br/> included in<br/> Sales Reserves<br/> and&#160;Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="30" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at January&#160;1, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">854</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">535</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions related to sales made in current year period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,814</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions related to sales made in prior periods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(90</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(87</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(87</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Credits and payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(88</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,037</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(270</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,940</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(110</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(73</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,430</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,518</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Translation differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at March&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">807</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">469</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,807</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,869</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#167;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5 million.</div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-indent: 0px; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Pledged accounts receivables </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounts receivables, net of allowance for credit losses, include $434&#160;million and $436<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million as of March 31, 2023 and December 31, 2022, respectively, which are pledged to PNC Bank, National Association in connection with the U.S. securitization program entered into in November 2022. For further information on our securitization facilities, see note 10f to the consolidated financial statements for the year ended December 31, 2022, included in Teva&#8217;s Annual Report on Form 10-K.&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"/> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555968688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 4 &#8211; Inventories: </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventories, net of reserves, consisted of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finished products</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Raw and packaging materials</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,059</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Products in process</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">620</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">555</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Materials in transit and payments on account</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177556008960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Identifiable Intangible Assets</a></td>
<td class="text"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 5 &#8211; Identifiable intangible assets: </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifiable intangible assets consisted of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:48%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;carrying&#160;amount&#160;net&#160;of<br/> impairment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Product rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,067</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,934</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade names</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">In process research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">487</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">487</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,861</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product rights and trade names </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products in various therapeutic categories from various acquisitions with a weighted average life period of approximately 9 years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets was $165&#160;million and $200&#160;million in the three months ended March&#160;31, 2023 and 2022, respectively. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">IPR&amp;D </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s IPR&amp;D are assets that have not yet been approved in its major markets. IPR&amp;D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible assets impairments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Impairments of long-lived intangible assets for the three months ended March&#160;31, 2023 and 2022 were $178&#160;million and $149&#160;million, respectively. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Impairments in the first quarter of 2023 consisted of: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Identifiable product rights of $159&#160;million due to: (i) $112&#160;million in Japan, mainly related to regulatory pricing reductions; and (ii) $47&#160;million related to updated market assumptions regarding price and volume of products; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(b)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">IPR&amp;D assets of $19&#160;million, related to generic pipeline products resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape and launch date). </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Impairments in the first quarter of 2022 consisted primarily of identifiable product rights of $129&#160;million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value measurement of the impaired intangible assets in the first quarter of 2023 is based on significant unobservable inputs in the market and thus represents a Level&#160;3 measurement within the fair value <div style="display:inline;">h</div>ierarchy. The discount rate applied ranged from 8.5% to 10%. A probability of success factor ranging from 20% to 90% was used in the fair value calculation to reflect inherent regulatory and commercial risk of IPR&amp;D. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177556001856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 6 &#8211; Goodwill: </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in the carrying amount of goodwill for the period ended March&#160;31, 2023 were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Teva&#8217;s<br/> API</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medis</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December&#160;31, 2022 (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,302</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,633</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes during the period:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Translation differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March&#160;31, 2023 (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,305</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,799</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Accumulated goodwill impairment as of March&#160;31, 2023 and December&#160;31, 2022 was approximately $27.6&#160;billion. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva operates its business through three reporting segments: North America, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Teva&#8217;s production and sale of APIs to third parties (&#8220;Teva API&#8221;) and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. Teva&#8217;s API and Medis reporting units are included under &#8220;Other&#8221; in the above table. See note 15 for additional segment information. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva begins with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva&#8217;s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (&#8220;WACC&#8221;), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva&#8217;s assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">First Quarter Deve<div style="display:inline;">lo</div>pments </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the first quarter of 2023, management evaluated whether there were any developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount as of March&#160;31, 2023. Management concluded that no triggering event had occurred and, therefore, no quantitative assessment was performed. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the goodwill impairment charges recorded in the fourth quarter of 2022 in relation to Teva&#8217;s International Markets and Teva&#8217;s API reporting units, the carrying values of those reporting units equaled their fair value as of December&#160;31, 2022. Additionally, as part of the quantitative analysis Teva conducted as part of its annual goodwill impairment test in the second quarter of 2022, it concluded that the estimated fair value of Teva&#8217;s Europe reporting unit exceeded its estimated carrying amount by 9%. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to Teva&#8217;s International Markets, Teva&#8217;s Europe or Teva&#8217;s API reporting units in the future. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555959024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt obligations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt obligations</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 7 &#8211; Debt obligations: </div></div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Short-term debt: </div></div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:58%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest&#160;rate&#160;as&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible senior debentures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current maturities of long-term liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,086</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total short-term debt</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible senior debentures </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal amount of Teva&#8217;s 0.25% convertible senior debentures due 2026 was $23&#160;million as of March&#160;31, 2023 and December&#160;31, 2022. These convertible senior debentures include a &#8220;net share settlement&#8221; feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the &#8220;net share settlement&#8221; feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under short-term debt. </div> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Long-term debt: </div></div> </td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest&#160;rate&#160;as&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR 1,500&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes EUR 1,500&#160;million (6)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.38</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR 1,300&#160;million (9)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">633</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes EUR 1,100&#160;million (7)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR 1,000&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,070</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR 900&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">541</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">963</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes EUR 800&#160;million (1)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.38</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">872</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR 750&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">814</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR 700&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">748</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes EUR 500&#160;million (2)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">545</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 3,500&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,374</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 3,000&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.80</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 2,000&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2046</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 1,250&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">957</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 1,250&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 1,000&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes USD 1,000&#160;million (7)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes USD 1,000&#160;million (6)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 789&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2036</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">783</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">783</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes USD 600&#160;million (3)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes USD 500&#160;million (4)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes CHF 350&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">382</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td colspan="8" style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total senior notes</div> </td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,761</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term debt</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less current maturities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,086</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less debt issuance costs (8)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(94</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total senior notes and loans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,668</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 800&#160;million euro bearing 7.38% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.100%-0.300%</div> per annum, from and including September&#160;15, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 500&#160;million euro bearing 7.88% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.100%-0.300%</div> per annum, from and including September&#160;15, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $600&#160;million bearing 7.88% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.100%-0.300%</div> per annum, from and including September&#160;15, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(4)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $500&#160;million bearing 8.13% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.100%-0.300%</div> per annum, from and including September&#160;15, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(5)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva consummated a cash tender offer and extinguished $631&#160;million aggregate principal amount of its 1,000&#160;million euro 6% senior notes due in 2025; $432&#160;million aggregate principal amount of its 900&#160;million euro 4.5% senior notes due in 2025; $574&#160;million aggregate principal amount of its $1,000&#160;million 7.13% senior notes due in 2025; $454&#160;million aggregate principal amount of its $3,000&#160;million 2.8% senior notes due in 2023; $293&#160;million aggregate principal amount of its $1,250&#160;million 6% senior notes due in 2024 and $122&#160;million aggregate principal amount of its $3,500&#160;million 3.15% senior notes due in 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(6)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.125%-0.375%</div> per annum, from and including May 9, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(7)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">If Teva fails to achieve certain sustainability performance targets, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.15%-0.45%</div> out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(8)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Debt issuance costs as of March&#160;31, 2023 include $26&#160;million in connection with the issuance of the sustainability-linked senior notes in March 2023, partially offset by $6&#160;million acceleration of issuance costs related to the cash tender offer. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(9)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva repaid $646&#160;million of its 1.25% senior notes at maturity. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(*)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Interest rate adjustments and a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. </div> </td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any. The long-term debt outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s debt as of March&#160;31, 2023 was effectively denominated in the following currencies: 62% in U.S. dollars, 36% in euro and 2% in Swiss franc. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily its $1.8&#160;billion unsecured syndicated sustainability-linked revolving credit facility entered into in April 2022, which was amended in February 2023 (&#8220;RCF&#8221;). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RCF has a maturity date of <span style="-sec-ix-hidden:hidden78649299">April 2026</span>, with two <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> extension options. The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including a maximum leverage ratio, which becomes more restrictive over time. In addition, the RCF is linked to two sustainability performance targets: (i)&#160;the Company&#8217;s S&amp;P ESG Score and (ii)&#160;number of new regulatory submissions in low and middle-income countries. The RCF margin may increase or decrease depending on the Company&#8217;s sustainability performance. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;6, 2023, the terms of the RCF were amended to update the Company&#8217;s maximum leverage ratio under the RCF for certain periods. Under the terms of the RCF, as amended, the Company&#8217;s leverage ratio shall not exceed 4.25x in the first, second and third quarters of 2023, 4.00x in the fourth quarter of 2023, 4.00x in the first, second and third quarters of 2024, and 3.50x in the fourth quarter of 2024 and onwards. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div/><div> <div style="background-color:white;display: inline;">  </div> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RCF can be used for general corporate purposes, including repaying existing debt. As of March 31, 2023 and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under specified circumstances, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF. Additionally, violations of the covenants, under the above-mentioned circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes and sustainability-linked senior notes is outstanding, could lead to an event of default under the Company&#8217;s senior notes and sustainability-linked senior notes due to cross-acceleration provisions. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that the financial statements are issued. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177646224176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 8 &#8211; Derivative instruments and hedging activities: </div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign exchange risk management:</div></div><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first <div style="display:inline;">quarter</div> of 2023, approximately 50% of Teva&#8217;s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency risks. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into forward exchange contracts and purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce its exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty, new Israeli shekel, Indian rupee and other currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (&#8220;net investment hedge&#8221;) and has in the past entered into cross-currency swaps and forward-contracts in order to hedge such an exposure. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. </div> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Interest risk management: </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company raises capital through various debt instruments, including senior notes, sustainability-linked senior notes, bank loans, convertible debentures and syndicated revolving credit facility that bear a fixed or variable interest rate. In some cases, the Company has swapped from a fixed to a variable interest rate (&#8220;fair value hedge&#8221;) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (&#8220;cash flow hedge&#8221;), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. </div> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Bifurcated embedded derivatives: </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the issuance of its sustainability-linked senior notes, Teva recognized embedded derivatives related to interest rate adjustments and a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment upon failure to achieve certain sustainability performance targets, such as access to medicines in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-to-middle-income</div></div> countries and reduction of absolute greenhouse gas emissions, which were bifurcated and are accounted for separately as derivative financial instruments. As of March&#160;31, 2023, the fair value of these derivative instruments is negligible. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Derivative instruments outstanding: </div></div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cross-currency swap - cash flow hedge (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>   <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the classification and fair values <div style="display:inline;">of</div> derivative instruments: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:59%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Designated as hedging</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Not designated as hedging</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Asset derivatives:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other current assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option and forward contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cross-currency swap-cash flow hedge (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liability derivatives:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other current liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option and forward contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(101</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;">&#167;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5 million. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>   <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt;;display:inline;">The table below provides information regarding the location and amount of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div><div style="font-size: 10pt;;display:inline;"> (gains) losses from derivatives designated in cash flow hedging relationships:</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other&#160;comprehensive&#160;income&#160;(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Line items in which effects of hedges are recorded</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cross-currency swaps - cash flow hedge (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div>  <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> (gains) losses from derivatives not designated as hedging instruments: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net revenues</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Line items in which effects of hedges are recorded</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,661</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,661</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option and forward contracts (2)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option and forward contracts economic hedge (3)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table>  <div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">On March&#160;31, 2023, Teva entered into a cross currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty and several other currencies to protect its projected operating results for 2023. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first quarter of 2023, the negative impact from these derivatives recognized under revenues was $6&#160;million. In the first quarter of 2022, the positive impact from these derivatives recognized under <span style="-sec-ix-hidden:hidden78649497">revenues</span> was $19&#160;million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. Cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </div> </td> </tr> </table> <div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">e.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Amortizations due to terminated derivative instruments: </div></div> </td> </tr> </table> <div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Forward-starting interest rate swaps and treasury lock agreements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015, Teva entered into forward-starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward-starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. Termination of these transactions resulted in a loss <span style="-sec-ix-hidden:hidden78649493">position</span> of $493&#160;million, which was recorded as other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to these forward-starting interest rate swaps and treasury lock agreements, losses of $11&#160;million and $7&#160;million were recognized under financial expenses, net, for each of the three months ended March&#160;31, 2023 and 2022, respectively. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555923888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Settlements and Loss Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Settlements and Loss Contingencies</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 9 &#8211; Legal settlements and loss contingencies: </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, Teva recorded expenses of $233&#160;million in legal settlements and loss contingencies, compared to $1,124&#160;million in the first quarter of 2022. Expenses in the first quarter of 2023 were mainly related to estimated provision<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div> recorded in connection with the DOJ patient assistance program litigation and the reverse-payment antitrust litigation over certain HIV medicines, as well as an update to the estimated settlement provision&#160;related to the remaining opioid cases (mainly related to the effect that the passage of time had on the net present value of the discounted payments). Expenses in the first quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases. See note 10. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2023 and December&#160;31, 2022, Teva&#8217;s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,299&#160;million and $4,186&#160;million, respectively. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177556063040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 10 &#8211; Commitments and contingencies: </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">General </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is reasonably estimable. Based upon the status of the cases described below, management&#8217;s assessments of the likelihood of damages, and the advice of counsel, no provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and excessive verdicts can occur. Accordingly, management&#8217;s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters where the exposures were fully resolved in the prior year, or determined to no longer meet the materiality threshold for disclosure, or were substantially resolved. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva&#8217;s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third party sales figures given below are based on IQVIA data. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Intellectual Property Litigation </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, Teva seeks to develop generic and biosimilar versions of patent-protected pharmaceuticals and biopharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator&#8217;s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. For many biosimilar products that are covered by patents, Teva participates in the &#8220;patent dance&#8221; procedures of the Biologics Price Competition and Innovation Act (&#8220;BPCIA&#8221;), which allow for the challenge to originator patents prior to obtaining biosimilar product approval. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator&#8217;s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic or biosimilar version of the product even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act or BPCIA. For example, Teva could be sued for patent infringement after commencing sales of a product. This type of litigation can involve any of Teva&#8217;s pharmaceutical products, not just its generic and biosimilar products. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva&#8217;s product. The amount of lost profits would generally be based on the lost sales of the patentee&#8217;s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">In July 2014, GlaxoSmithKline (&#8220;GSK&#8221;) filed claims against Teva in the U.S. District Court for the District of Delaware for infringement of a patent directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva and eight other generic producers began selling their carvedilol tablets (the generic version of GSK&#8217;s Coreg&#174;) in September 2007. A jury trial was held and the jury returned a verdict in GSK&#8217;s favor finding Teva liable for induced infringement, including willful infringement, and assessing damages of $</div>235.5<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million, not including pre- or post-judgment interest or a multiplier for willfulness. Thereafter, the court overturned the jury verdict, finding no induced infringement by Teva and that Teva did not owe any damages. On August 5, 2021, the Court of Appeals for the Federal Circuit issued a two-to-one decision reinstating the $</div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/></div>235.5<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million verdict and finding Teva liable for patent infringement. On February&#160;11, 2022, the Court of Appeals for the Federal Circuit denied rehearing. Teva appealed this decision to the U.S. Supreme Court on July&#160;11, 2022. In response to Teva&#8217;s <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">certiorari </div></div>petition, on October&#160;3, 2022, the U.S. Supreme Court issued an order seeking the views of the U.S. Solicitor General as to whether to review this case. On March&#160;29, 2023, the U.S. Solicitor General filed a brief recommending that the U.S. Supreme Court grant Teva&#8217;s request and reverse the judgment of the Court of Appeals for the Federal Circuit. In addition to the pending U.S. Supreme Court proceedings, the case has been remanded to the district court for further proceedings on Teva&#8217;s other legal and equitable defenses that have not yet been considered by the district court. In the first quarter of 2021, Teva recognized a provision based on its offer to settle such matter. </div></div> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Product Liability Litigation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both types of insurance, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in certain or all of its markets. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan are allegedly found in the active pharmaceutical ingredient (&#8220;API&#8221;) supplied to Teva by multiple API manufacturers, including by Zhejiang Huahai Pharmaceuticals Co. Ltd. (&#8220;Huahai&#8221;). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. In December 2019, Teva reached a settlement with Huahai resolving Teva&#8217;s claims related to certain sartan API supplied by Huahai. Under the settlement agreement, Huahai agreed to compensate Teva for some of its direct losses and provide it with prospective cost reductions for API. The settlement does not release Huahai from liability for any losses Teva may incur as a result of third party personal injury or product liability claims relating to the sartan API at issue, as discussed below. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, multiple lawsuits have been filed in connection with this matter. Teva&#8217;s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (&#8220;MDL&#8221;) pending in the United States District Courts against Teva and numerous other manufacturers. One MDL is pending in the United States District Court for the District of New Jersey for valsartan, losartan and irbesartan. Teva is not named in complaints with respect to irbesartan. The second MDL is pending in the United States District Court for the Southern District of Florida for ranitidine. The lawsuits against Teva in the MDLs consist of individual personal injury and/or product liability claims and economic damages claims brought by consumers and end payors on behalf of purported classes of other consumers and end payors as well as medical monitoring class claims. The judge in the valsartan MDL ordered that the first trial, likely commencing in late 2023 or early 2024, will involve third-party payor economic loss claims via a class representative on behalf of several subclasses of payors against Teva and two other defendants. On February&#160;8, 2023, the district court in the valsartan MDL entered an order that certified a series of subclasses on plaintiffs&#8217; economic loss claims and granted in part and denied in part the certification of a medical monitoring class. Defendants sought permission for appellate review of that decision, which was denied. In the ranitidine MDL, the generic manufacturers&#8217; motions to dismiss have been granted, although certain plaintiffs have appeals pending. In addition, on December&#160;6, 2022, the court in the ranitidine MDL granted the brand defendants&#8217; motions to exclude all of plaintiffs&#8217; general causation experts and granted summary judgment to the brand defendants on that ground. Teva, as well as other </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">generic manufacturers, is also named in several state court actions asserting allegations similar to those in the ranitidine MDL and the valsartan and losartan MDL. State court valsartan and losartan actions are pending in New Jersey and Delaware and are currently stayed. State court ranitidine cases naming Teva are pending in coordinated proceedings in California, Illinois, Pennsylvania and New York, with motions to dismiss pending in Illinois, Pennsylvania and New York on preemption and other grounds. In addition to the valsartan and ranitidine MDLs and coordinated state court proceedings, Teva has also been named in a consolidated proceeding pending in the United States District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva&#8217;s, as well as other generic manufacturers&#8217; metformin products. Defendants&#8217; motion to dismiss the plaintiffs&#8217; amended metformin complaint from June 2021 was granted without prejudice with respect to the consumer economic loss plaintiffs, and granted in part and denied in part with respect to the end payor plaintiffs. Plaintiffs were granted leave to file a second amended complaint. Defendants&#8217; motion to dismiss that complaint was granted in part and denied in part. Similar lawsuits are pending in Canada and Germany. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Competition Matters </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva&#8217;s patent challenges have resulted in litigation relating to Teva&#8217;s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva and its subsidiaries have been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases are usually direct and indirect purchasers of pharmaceutical products, some of whom assert claims on behalf of classes of all direct and indirect purchasers, and they typically allege that (i)&#160;Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (ii)&#160;significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These plaintiffs seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been and disgorgement of profits, which are often automatically tripled under the relevant statutes, plus attorneys&#8217; fees and costs. The alleged damages generally depend on the size of the branded market and the length of the alleged delay, and can be substantial&#8212;potentially measured in multiples of the annual brand sales&#8212;particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva&#8217;s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (&#8220;FTC&#8221;) v. Actavis, Inc., that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This test has resulted in increased scrutiny of Teva&#8217;s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva&#8217;s currently pending antitrust litigations. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2020, the European Commission issued a final decision in its proceedings against both Cephalon and Teva, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling euro 60.5&#160;million on Teva and Cephalon. Teva and Cephalon filed an appeal against the decision in February 2021. A provision for this matter was included in the financial statements. Teva has provided the European Commission with a bank guarantee in the amount of the imposed fines. The hearing for the appeal took place in December 2022 and a decision is pending. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2011, three groups of plaintiffs filed claims against Wyeth and Teva for alleged violations of the antitrust laws in connection with their November 2005 settlement of patent litigation involving extended release venlafaxine (generic Effexor XR<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>). The cases were filed by a purported class of direct purchasers, by a purported class of indirect purchasers and by certain chain pharmacies in the U.S. District Court for the District of New Jersey. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. In March 2020, the district court temporarily stayed discovery and referred the case to mediation, and discovery remains stayed. Annual sales of Effexor XR<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> were approximately $2.6&#160;billion at the time of settlement and at the time Teva launched its generic version of Effexor XR<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> in July 2010. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2012, two purported classes of direct-purchaser plaintiffs filed claims against GSK and Teva in New Jersey federal court for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving lamotrigine (generic Lamictal<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>) entered into in February 2005. The plaintiffs claimed that the settlement agreement unlawfully delayed generic entry and sought unspecified damages. On April&#160;9, 2021, the district court, which had previously granted an initial motion for class certification by the direct purchaser plaintiffs but was reversed on that ruling by the Third Circuit in April 2020, denied the direct purchaser plaintiffs&#8217; renewed motion for class certification. Plaintiffs filed a further renewed motion for class certification on May&#160;20, 2022, which was denied on February&#160;1, 2023. On February&#160;2, 2023, February&#160;7, 2023, and February&#160;27, 2023, a number of direct purchasers, who would otherwise have been members of the proposed class had it been certified, filed suit as individual plaintiffs in Pennsylvania&#8217;s federal court. Annual sales of Lamictal<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> were approximately $950&#160;million at the time of the settlement and approximately $2.3&#160;billion at the time Teva launched its generic version of Lamictal<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> in July 2008. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan&#174; (extended release niacin) filed claims against Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005 to resolve patent litigation over the product. A multidistrict litigation has been established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser opt-out plaintiffs filed complaints with allegations nearly identical to those of the direct purchasers&#8217; class. The court denied the indirect purchasers&#8217; motion for class certification with prejudice, and on April 24, 2023, the denial was affirmed by the Court of Appeals for the Third Circuit. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, alleging violations of state law and seeking restitution and civil penalties. Annual sales of Niaspan&#174; were approximately&#160;</div>$416&#160;million at the time of the settlement and approximately $1.1&#160;billion at the time Teva launched its generic version of Niaspan<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> in September 2013. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January 2014, numerous lawsuits have been filed in the U.S. District Court for the Southern District of New York by purported classes of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers</div> for, and direct-purchasers of, Actos<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met (pioglitazone and pioglitazone plus metformin) against Takeda, the innovator, and several generic manufacturers, including Teva, Actavis and Watson. The lawsuits allege, among other things, that the settlement agreements between Takeda and the generic manufacturers violated the antitrust laws. The court dismissed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers&#8217;</div> lawsuits against all defendants in September 2015. On February&#160;8, 2017, the Court of Appeals for the Second Circuit affirmed the dismissal in part and vacated and remanded the dismissal in part with respect to the claims against Takeda. The direct purchasers&#8217; case had been stayed pending resolution of the appeal in the end payer matter and the direct purchasers amended their complaint for a second time following the Second Circuit&#8217;s decision, but on October&#160;8, 2019, the district court dismissed, with prejudice, the direct purchasers&#8217; claims against the generic manufacturers (including Teva, Actavis, and Watson). At the time of Teva&#8217;s settlement, annual sales of Actos<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met were approximately $3.7&#160;billion and approximately $500&#160;million, respectively. At the time Teva launched its authorized generic version of Actos<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met in August 2012, annual sales of Actos<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> and Actoplus Met were approximately $2.8&#160;billion and approximately $430&#160;million, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Putative classes of direct-purchaser and end-payer plaintiffs have filed antitrust lawsuits (which have since been coordinated in federal court in Delaware) against Amgen and Teva alleging that the January 2, 2019 settlement agreement between Amgen and Teva, resolving patent litigation over cinacalcet (generic Sensipar&#174;), violated the antitrust laws. In March 2023, Teva moved for re-argument of its motion to certify the district court&#8217;s rulings denying Teva&#8217;s motion to dismiss in part for review by the U.S. Court of Appeals for the Third Circuit, and is awaiting the court&#8217;s decision. Annual sales of Sensipar&#174; in the United States were approximately $</div>1.4<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;billion at the time Teva launched its generic version of Sensipar&#174; in December 2018, and at the time of the January 2, 2019 settlement.&#160;</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2019, certain direct-purchaser plaintiffs filed claims in federal court in Philadelphia naming Teva and its affiliates as defendants alleging that certain patent litigation settlement agreements relating to AndroGel<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>% (testosterone gel) violate the antitrust laws, specifically the September 2006 patent litigation settlement between Watson Pharmaceuticals, Inc. (&#8220;Watson&#8221;), from which Teva later acquired certain assets and liabilities, and Solvay Pharmaceuticals, Inc. (&#8220;Solvay&#8221;), and a December 2011 settlement between Teva and AbbVie. Those claims remain pending. Annual sales of AndroGel<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>% were approximately $350&#160;million at the time of the earlier Watson/Solvay settlement and approximately $140&#160;million at the time Actavis launched its generic version of AndroGel<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>% in November 2015. A provision for these matters and related litigations in Georgia that have since been settled was included in the financial statements. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"> </div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between September&#160;1, 2020 and December&#160;20, 2020, separate plaintiffs purporting to represent putative classes of direct and indirect purchasers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> retailer purchasers of Bystolic<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> (nebivolol hydrochloride) filed separate complaints in the U.S. District Court for the Southern District of New York against several generic manufacturers, including Teva, Actavis, and Watson, alleging, among other things, that the settlement agreements these generic manufacturers entered into with Forest Laboratories, Inc., the innovator, to resolve patent litigation over Bystolic<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> violated the antitrust laws. The cases were coordinated and on January&#160;24, 2022, the court dismissed plaintiffs&#8217; amended complaints without prejudice. Plaintiffs subsequently filed second amended complaints, and on February&#160;21, 2023, the court granted defendants&#8217; motion to dismiss and dismissed all claims with prejudice. Plaintiffs have filed notices of their intent to appeal. Annual sales of Bystolic<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $700&#160;million at the time of Watson&#8217;s 2013 settlement with Forest. </div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">In February 2021, the State of New Mexico filed a lawsuit against Teva and certain other defendants related to various medicines used to treat HIV. Between September and December 2021, several private plaintiffs including retailers and health insurance providers filed similar claims in federal court in the Northern District of California and in the District of Minnesota. As they relate to Teva, the lawsuits challenge settlement agreements Teva entered into with Gilead in 2013 and/or 2014 to resolve patent litigation relating to Teva&#8217;s generic versions of Viread</div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10px; vertical-align: top;;display:inline;">&#174;</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and/or Truvada</div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10px; vertical-align: top;;display:inline;">&#174;</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and Atripla</div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10px; vertical-align: top;;display:inline;">&#174;</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">. Plaintiffs allege that the settlement agreements contain improper reverse payments that delayed the availability of generic products, in violation of the federal antitrust laws and state law. On February&#160;16, 2022, Teva moved to dismiss the claims by certain private plaintiffs but that motion was denied. However, Teva has successfully moved to limit the potential damages period as to certain private plaintiffs. Plaintiffs in the Northern District of California cases have abandoned any claim for damages relating to the Viread</div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10px; vertical-align: top;;display:inline;">&#174;</div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>settlement. On January&#160;5, 2023, the court denied the parties&#8217; motions for summary judgment. Trial is currently scheduled to commence in late May 2023. In the first quarter of 2023, Teva recognized a provision based on its offer to settle this matter.</div> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> In October 2022, the New Mexico Supreme Court granted Teva&#8217;s petition for a writ of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">certiorari</div></div> and scheduled oral argument for late May 2023 for Teva&#8217;s motion to dismiss the complaint brought by the State of New Mexico, which motion was previously denied by the trial court. Annual sales in the United States at the time of the settlement of Viread<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div>, Truvada<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Atripla<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> were approximately $582&#160;million, $2.4&#160;billion, and $2.9&#160;billion, respectively. Annual sales in the United States at the time Teva launched its generic version of Viread<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in 2017, Truvada<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in 2020 and Atripla<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> in 2020 were approximately<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>728<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>2.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;billion and $</div>444<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, following the 2019 European Commission&#8217;s inspection of Teva and subsequent request for information, the European Commission opened a formal antitrust investigation to assess whether Teva may have abused a dominant position by delaying the market entry and uptake of medicines that compete with COPAXONE. On October&#160;10, 2022, the European Commission issued a Statement of Objections, which sets forth its preliminary allegations that Teva had engaged in anti-competitive practices. Teva now has the opportunity to formally respond to the European Commission&#8217;s allegations. Annual sales of COPAXONE in the European Economic Area for 2021 were approximately $373&#160;million. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;15, 2021, the U.K. Competition and Markets Authority (&#8220;CMA&#8221;) issued a decision imposing fines for breaches of U.K. competition law by Allergan, Actavis UK and Auden Mckenzie and a number of other companies in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. The decision combines the CMA&#8217;s three prior investigations into the supply of hydrocortisone tablets in the U.K., as well as the CMA&#8217;s subsequent investigation relating to an anti-competitive agreement with Waymade. On January&#160;9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva will indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to two of the three statements of objection from the CMA (dated December&#160;16, 2016 and March&#160;3, 2017), and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. On October&#160;6, 2021, Accord UK and Auden Mckenzie appealed the CMA&#8217;s decision. A provision for the estimated exposure for Teva related to the fines and/or damages has been recorded in the financial statements. The hearing for the appeal concluded in the first quarter of 2023, and a decision remains pending. </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"> </div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2021, a plaintiff filed a putative class action suit in the United States District Court for the Eastern District of Pennsylvania against Takeda and several generic manufacturers, including Watson and Teva, alleging violations of the antitrust laws in connection with their settlement of patent litigation involving colchicine tablets (generic Colcrys<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>), entered into in January 2016. Plaintiff claims that the settlement was part of a conspiracy among Takeda and the generic manufacturers to unlawfully restrict output of colchicine by delaying generic entry. On November&#160;23, 2022, the court denied plaintiffs&#8217; motion for class certification without prejudice and on March&#160;1, 2023, the Court denied plaintiff&#8217;s renewed motion for class certification. On April&#160;10, 2023, plaintiff filed a motion for leave to amend its complaint to add 18 previously absent class members as plaintiffs. Defendants&#8217; motion for summary judgment, and plaintiffs&#8217; motion for partial summary judgment remain pending. Trial is currently scheduled to commence in September 2023. Annual sales of Colcrys<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $187&#160;million at the time of the settlement. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2022, two complaints, one brought by Walgreen Co. and Kroger Specialty Pharmacy, Inc. and another by Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund and Jacksonville Police Officers and Fire Fighters Health Insurance Trust (collectively the &#8220;Walgreen and EPP complaints&#8221;), were filed in the United States District Court for the District of New Jersey against Teva and its marketing partner, Natco Pharma Limited (&#8220;Natco&#8221;), alleging violations of the antitrust laws in connection with their December 2015 settlement of patent litigation with Celgene Corporation (which was subsequently acquired by Bristol-Myers Squibb Company (&#8220;BMS&#8221;)) involving the drug Revlimid<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> (lenalidomide). The Walgreen and EPP complaints also name Celgene and BMS as defendants. On January&#160;24, 2023, the Walgreen and EPP complaints were consolidated for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-trial</div> purposes only with an earlier-filed, already consolidated Insurer <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Opt-Out</div> Action filed against BMS and Celgene, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In Re Revlimid</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;&amp; Thalomid Purchaser Antitrust Litigation</div></div>, Case No. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2:19-cv-7532-ES-MAH.</div></div></div></div> On February&#160;16, 2023, the Walgreen and EPP plaintiffs filed amended complaints adding additional plaintiffs. On March&#160;21, 2023, Teva and Natco moved to dismiss the complaints against them, and briefing remains ongoing. Annual sales of Revlimid<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $3.5&#160;billion at the time of the settlement. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="null;text-indent: 0px;;display:inline;">On December 2, 2022, plaintiffs purporting to represent putative classes of indirect purchasers of EpiPen&#174; (epinephrine injection) and Nuvigil&#174; (armodafinil) filed a complaint in the United States District Court for the District of Kansas against Teva, Cephalon, and a former Teva executive. Teva owns the New Drug Application (&#8220;NDA&#8221;) for Nuvigil&#174; and sold the brand product, for which generic entry occurred in 2016. Teva filed an ANDA to sell generic EpiPen&#174;, which Teva launched in 2018, following receipt of FDA approval. The complaint alleges, among other things, that the defendants violated the federal antitrust laws, the Racketeer Influenced and Corrupt Organizations Act (&#8220;RICO Act&#8221;), and various state laws in connection with settlements resolving patent litigation relating to those products. Plaintiffs seek injunctive relief, compensatory and punitive damages, interest, attorneys&#8217; fees and costs. On March 8, 2023, Teva filed a motion to dismiss the complaint, which is pending. Annual sales of Nuvigil&#174; in the United States were approximately $</div>300&#160;million at the time Teva entered into the first settlement with an ANDA filer in 2012; annual sales of EpiPen<div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:8.3px">&#174;</div> in the United States were approximately $600&#160;million at the time Teva entered into its settlement agreement for that product in 2012. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Government Investigations and Litigation Relating to Pricing and Marketing </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (&#8220;DOJ&#8221;) Antitrust Division seeking documents and other information relating to the marketing and pricing of certain Teva USA generic products and communications with competitors about such products. On August&#160;25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three-count indictment charging Teva USA with criminal felony Sherman Act violations. See <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;20-cr-200</div></div> (E.D. Pa.). The indictment alleges Teva USA participated in three separate conspiracies with certain other generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs. The indictment identified the following generic drugs: Pravastatin, Carbamazepine, Clotrimazole, Etodolac (IR and ER), Fluocinonide (Cream <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-Cream,</div> Gel, and Ointment), Warfarin, Nadolol, Temozolomide, and Tobramycin. On September&#160;8, 2020, Teva USA pled not guilty to all counts. On December&#160;14, 2022, the Court entered a scheduling order against Teva and its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-defendant</div> Glenmark, which sets a May 2024 trial date. While the Company is unable to estimate a range of loss at this time, a conviction on these criminal charges could have a material adverse impact on the Company&#8217;s business, including monetary penalties and debarment from federally funded health care programs. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2018, Teva received a civil investigative demand from the DOJ Civil Division, pursuant to the federal False Claims Act, seeking documents and information produced since January&#160;1, 2009 relevant to the Civil Division&#8217;s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. An adverse resolution of this matter may include fines, penalties, financial forfeiture and compliance conditions. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. Subsequently, on December&#160;15, 2016, a civil action was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States. That complaint was later amended to add new states as named plaintiffs, as well as new allegations and new state law claims, and on June&#160;18, 2018, the attorneys general of 49 states plus Puerto Rico and the District of Columbia filed a consolidated amended complaint against Actavis and Teva, as well as other companies and individuals. On May&#160;10, 2019, most (though not all) of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals, alleging price-fixing and market allocation with respect to additional generic products. On November&#160;1, 2019, the state attorneys general filed an amended complaint, bringing the total number of plaintiff states and territories to 54. The amended complaint alleges that Teva was at the center of a conspiracy in the generic pharmaceutical industry, and asserts that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain additional products. On June&#160;10, 2020, most, but not all, of the same states, with the addition of the U.S. Virgin Islands, filed a third complaint in the District of Connecticut naming, among other defendants, Actavis, but not Teva USA, in a similar complaint relating to dermatological generics products. On September&#160;9, 2021, the states&#8217; attorneys general amended their third complaint to, among other things, add California as a plaintiff. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the various complaints described above, the states seek a finding that the defendants&#8217; actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints have been transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (&#8220;Pennsylvania MDL&#8221;). On July&#160;13, 2020, the court overseeing the Pennsylvania MDL chose the attorneys&#8217; general November&#160;1, 2019 amended complaint, referenced above, along with certain complaints filed by private plaintiffs, to proceed first in the litigation as bellwether complaints. On February&#160;9, 2021, Teva&#8217;s motion to reconsider that ruling was granted, and on May&#160;7, 2021, the Court chose the attorneys&#8217; general third complaint filed on June&#160;10, 2020 and subsequently amended to serve as a bellwether complaint in the Pennsylvania MDL, along with certain complaints filed by private plaintiffs. On December&#160;9, 2021, the Court entered an order setting the schedule for the proceedings in the bellwether cases, which the Court later amended on October&#160;13, 2022. This amended schedule does not include trial dates, but provides for the parties to complete briefing on motions for summary judgment in the third quarter of 2024. On June&#160;7, 2022, the Court dismissed the attorneys&#8217; general claims for monetary relief under federal law, concluding that the federal statute under which the attorneys general brought suit authorizes injunctive relief only. However, the attorneys general have pending claims for monetary relief under state law. On February&#160;27, 2023, the Court largely denied defendants&#8217; motions to dismiss the federal claims asserted by the attorneys general in their bellwether complaint. Another motion to dismiss, directed at that same complaint, and related to the state law claims asserted by the attorneys general, remains pending. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva has settled with the states of Mississippi (in June 2021), Louisiana (in March 2022), Georgia (in September 2022), Arkansas (in October 2022) and Florida (in February 2023). Teva paid each state an amount proportional to its share of the national population (approximately $1,000,000 for each 1% share of the national population), and the states have dismissed their claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA, pursuant to these settlements. On March&#160;30, 2022, the State of Alabama voluntarily dismissed all of its claims in the litigation, including its claims against Actavis and Teva USA, without prejudice. The territories of American Samoa and Guam have also voluntarily dismissed all of their claims in the litigation, including their claims against Actavis and Teva USA; American Samoa&#8217;s dismissal was without prejudice in July 2020, and Guam&#8217;s dismissal was with prejudice in February 2023. The most recent settlement with Florida follows the pattern reached in earlier settlements. Specifically, as mentioned above, Teva agreed to pay each state an amount proportional to its share of the national population. This, in addition to the status of ongoing negotiations with several other U.S. state attorneys general to settle on comparable terms, caused management to consider settlement of the claims filed by the remaining attorneys general to be probable, and management recorded an estimated provision in the third quarter of 2022, in accordance with Accounting Standards Codification 450 &#8220;Accounting for Contingencies.&#8221; </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div/><div> <div style="background-color:white;display: inline;">  </div> </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Beginning on March&#160;2, 2016, and continuing through December 2020, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> plaintiffs. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva USA and Actavis. The plaintiffs generally seek injunctive relief and damages under federal antitrust law, and damages under various state laws. On October&#160;16, 2018, the court denied certain of the defendants&#8217; motions to dismiss as to certain federal claims, pending as of that date, and on February&#160;15, 2019, the court granted in part and denied in part defendants&#8217; motions to dismiss as to certain state law claims. On July&#160;18, 2019, May&#160;6, 2020 and October&#160;8, 2021, certain individual plaintiffs commenced civil actions in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, but no complaints have been filed in the actions and each of the three cases have been placed in deferred status. Certain counties in New&#160;York and Texas have also commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been transferred to the Pennsylvania MDL. There is also one similar complaint brought in Canada, which alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. The action is in its early stages. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2017, Teva received a subpoena from the U.S. Attorney&#8217;s office in Boston, Massachusetts requesting documents related to Teva&#8217;s donations to patient assistance programs. Subsequently, in August 2020, the U.S. Attorney&#8217;s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law (the &#8220;DOJ PAP Complaint&#8221;). It is alleged that Teva caused the submission of false claims to Medicare through Teva&#8217;s donations to bona fide independent charities that provide financial assistance to patients. An adverse judgment may involve damages, civil penalties and injunctive remedies. On September&#160;10, 2021, the Court granted Teva&#8217;s motion to dismiss the unjust enrichment claim and denied the remainder of the motion. On October&#160;15, 2021, Teva filed an answer to the DOJ PAP Complaint. Trial for this matter is currently scheduled for September 2023. On April&#160;24, 2023, both parties filed summary judgment motions, which are currently pending. In the first quarter of 2023, Teva recognized a provision based on its offer to settle this matter. Additionally, on January&#160;8, 2021, Humana, Inc. filed an action against Teva in the United States District Court for the Middle District of Florida based on the allegations raised in the DOJ PAP Complaint. On April&#160;2, 2021, Teva filed a motion to dismiss Humana&#8217;s claims on the grounds that the claims are time-barred and/or insufficiently pled, and that motion remains pending. On April&#160;11, 2023, the court granted Teva&#8217;s motion to stay the case pending the court&#8217;s decision on Teva&#8217;s motion to dismiss and/or Humana&#8217;s motion to amend the complaint. On November&#160;17, 2022, United Healthcare also filed an action against Teva in the United States District Court for the District of New Jersey based on the conduct alleged in the DOJ PAP Complaint. On March&#160;10, 2023, Teva moved to dismiss United Healthcare&#8217;s claims on the grounds that it is time-barred and lacks standing and sufficient particularity to assert RICO claims, and that motion remains pending. </div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, a city and county in Washington filed claims against Teva in the United States District Court for the Western District of Washington for alleged violations of the Racketeer Influenced and Corrupt Organizations Act, Washington&#8217;s Consumer Protection Act, and unjust enrichment concerning Teva&#8217;s sale of COPAXONE. Plaintiffs purport to represent a nationwide class of health plans and a subclass of Washington-based health plans that purchased and/or reimbursed health plan members for COPAXONE. Plaintiffs allege that Teva engaged in several fraudulent schemes that resulted in plaintiffs and the putative class members purchasing and/or reimbursing plan members for additional prescriptions of COPAXONE and/or at inflated COPAXONE prices. Plaintiffs seek treble damages for the excess reimbursements and inflated costs, as well as injunctive relief. On September&#160;28, 2021, plaintiffs filed an amended complaint. On November&#160;17, 2021, Teva moved to dismiss the suit, on the grounds that plaintiffs&#8217; claims are barred by the applicable statutes of limitations and the direct purchaser rule, suffer from jurisdictional defects, and fail to plausibly allege fraud or other elements of their claims. On March&#160;9, 2023, the court held a hearing on the motion to dismiss, and a decision remains pending. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;29, 2021, Mylan Pharmaceuticals (&#8220;Mylan&#8221;) filed claims against Teva in the District Court for the District of New&#160;Jersey. On March&#160;11, 2022 and March&#160;15, 2022, FWK Holdings, LLC, KPH Healthcare Servs., Inc. d/b/a&#160;Kinney Drugs, Inc., Meijer Inc., Meijer Distribution, Inc., Labor-Management Healthcare Fund, the Mayor and City Council of Baltimore, and the New York State Teamsters Council Health and Hospital Fund filed claims against Teva in the District Court for the District of New Jersey on behalf of themselves and other similarly situated direct and indirect purchasers of COPAXONE. On August&#160;22, 2022, Blue Cross Blue Shield of Vermont and the Vermont Health Plan sued Teva in the </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">District Court for the District of Vermont on behalf of themselves and other similarly situated indirect purchasers of COPAXONE. The complaints assert claims for alleged violations of the Lanham Act, state and federal unfair competition and monopolization laws, tortious interference, trade libel, and a violation of the RICO Act. Additionally, plaintiffs claim Teva was involved in an unlawful scheme to delay and hinder generic competition concerning COPAXONE sales. Plaintiffs seek damages for lost profits and expenses, disgorgement, restitution, treble damages, attorneys&#8217; fees and costs, and injunctive relief. Teva has moved to dismiss the complaints filed by Mylan and the class plaintiffs in the District of New Jersey on the grounds, among others, that none of its challenged conduct, violates the law. Those motions are fully briefed and a decision remains pending. On November&#160;21, 2022, the Vermont court denied Teva&#8217;s motion to transfer the complaint filed in Vermont. On December&#160;21, 2022, Teva moved to dismiss the Vermont complaint on grounds similar to those asserted in its motions to dismiss the complaints in New Jersey. Those motions are fully briefed, and a decision remains pending.&#160;&#160;&#160;&#160; </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;1, 2022, Teva received a civil subpoena from the U.S. Attorney&#8217;s office in Boston, Massachusetts requesting certain documents related to the sale and marketing of AUSTEDO and risperidone LAI. Teva is cooperating with the request for documents. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Opioids Litigation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since May 2014, more than 3,500 complaints have been filed with respect to opioid sales and distribution against various Teva affiliates, along with several other pharmaceutical companies, by a number of cities, counties, states, other governmental agencies, tribes and private plaintiffs (including various putative class actions of individuals) in both state and federal courts. Most of the federal cases have been consolidated into a multidistrict litigation in the Northern District of Ohio (&#8220;MDL Opioid Proceeding&#8221;) and many of the cases filed in state court have been removed to federal court and consolidated into the MDL Opioid Proceeding. Two cases that were included in the MDL Opioid Proceeding were transferred back to federal district court for additional discovery, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-trial</div> proceedings and trial. Those cases are: City of Chicago v. Purdue Pharma L.P. et al., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;14-cv-04361</div></div> (N.D. Ill.) and City and County of San Francisco v. Purdue Pharma L.P. et al., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;18-cv-07591-CRB</div></div></div> (N.D. Cal.). Other cases remain pending in various states. In some jurisdictions, such as Illinois, New York, Pennsylvania, South Carolina, Texas, Utah and West Virginia, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. Complaints asserting claims under similar provisions of different state law generally contend that the defendants allegedly engaged in improper marketing and distribution of opioids, including ACTIQ<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> and FENTORA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>. The complaints also assert claims related to Teva&#8217;s generic opioid products. In addition, over 950 personal injury plaintiffs, including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding.&#160;Furthermore, approximately 700 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-personal</div> injury complaints and approximately 100 personal injury complaints have named Anda, Inc. (and other distributors and manufacturers) alleging that Anda failed to develop and implement systems sufficient to identify suspicious orders of opioid products and prevent the abuse and diversion of such products to individuals who used them for other than legitimate medical purposes. Plaintiffs seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages,&#160;attorneys&#8217; fees and injunctive relief. Certain plaintiffs assert that the measure of damages is the entirety of the costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. The individual personal injury plaintiffs further seek <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-economic</div> damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;19, 2021, a bench trial in California (The People of the State of California, acting by and through Santa Clara County Counsel James R. Williams, et. al. v. Purdue Pharma L.P., et. al.) commenced against Teva and other defendants focused on the marketing of branded opioids. On December&#160;14, 2021, the court issued its final judgment in favor of the defendants on all claims. Plaintiffs filed a notice of appeal of this judgment in February 2022. On June&#160;29, 2021, a jury trial in New York (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In re Opioid Litigation</div></div>, Index No.&#160;400000/2017) commenced against Teva and other defendants, focused on the marketing and distribution of opioids. The case was bifurcated between liability and damages. On December&#160;30, 2021, the jury returned a liability verdict in favor of plaintiffs (the County of Suffolk, the County of Nassau and the State of New York) on the plaintiffs&#8217; public nuisance claim. On November&#160;3, 2022, Teva reached an agreement with the Attorney General of New York that settled the state&#8217;s and its subdivisions&#8217; opioid-related claims, the details of which are included in the table below. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;21, 2021, it was announced that four other defendants (not including Teva) reached nationwide settlements, subject to certain conditions, which include payment of up to approximately $26&#160;billion spread over up to 18 years. In July 2022, Teva, the working group of States&#8217; Attorneys General (the &#8220;Working Group&#8221;), the Multi-District Litigation Plaintiffs&#8217; Executive Committee (&#8220;PEC&#8221;), and counsel for Native American tribes (&#8220;Tribes&#8221;) reached an agreement in principle on the financial terms of nationwide settlements similar in structure to the nationwide settlements of other defendants. During the third quarter of 2022, Teva and Allergan resolved their dispute with respect to Teva&#8217;s indemnification obligations. In November 2022, Teva, Allergan, the Working Group and PEC, and representatives for the Tribes, finalized the terms of their respective proposed opioids nationwide settlement agreements. Under the financial terms of the proposed nationwide settlement agreement with the states and subdivisions, Teva will pay up to $4.25&#160;billion (including the already settled cases), spread over 13 years. This total includes the supply of up to $1.2&#160;billion of Teva&#8217;s generic version of Narcan<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> (naloxone hydrochloride nasal spray), valued at wholesale acquisition cost, over 10 years or cash at 20% of the wholesale acquisition cost ($240 million) in lieu of product. In January of 2023,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;Teva confirmed participation from all states except Nevada, and decided to move forward with the participation process of the subdivisions, and that process is ongoing. In February 2023, Teva and the Tribes finalized their opioids settlement with participation from 100% of the Tribes, the details of which are included in the table below.&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s proposed nationwide settlement agreement with the states and subdivisions is contingent upon sufficient participation by the subdivisions in Teva&#8217;s and Allergan&#8217;s respective nationwide opioids settlement agreements. Currently, more than<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>99<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">% of the litigating subdivisions have chosen to participate in Teva&#8217;s nationwide settlement, which represents </div>98<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">% <div style="letter-spacing: 0px; top: 0px;;display:inline;">of the population of the participating states. Teva has until June 8, 2023 to determine whether or not to move forward with its proposed nationwide settlement. If these nationwide settlement agreements are not finalized or if Nevada or subdivisions choose not to participate, additional trials are expected to proceed. Trials in two opioids cases currently are scheduled to commence in the second half of 2023; one brought by the Nevada Attorney General, currently scheduled to commence in August 2023, and the other brought by eight hospitals against Teva, other manufacturers, distributors, and pharmacies, currently scheduled to commence in July 2023.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to its pending nationwide opioids settlement, Teva previously reached settlements with individual states and subdivisions to settle opioids claims brought by those jurisdictions. The material details of those individual settlements and Teva&#8217;s settlement with the Tribes appear in the table below, which includes the cash payment to be made by Teva and the wholesale acquisition cost (&#8220;WAC&#8221;) of product to be provided by Teva, in each case to such states and subdivisions and the Tribes. If the nationwide settlement reaches sufficient participation by the subdivisions, Teva will finalize opioid settlements with a total of 49 of the 50 states.</div></div><br/></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 23%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 13%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 13%;"/>
<td style="vertical-align: bottom;"/>
<td style="width: 7%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 18%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 17%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdiction</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement<br/>Payment<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px">*</div></div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment<br/>Term</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement Product</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product&#160;WAC</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Value&#160;and&#160;Term</div></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">June 7, 2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Oklahoma</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$72.3&#160;million (paid)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">1 year</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">N/A</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">December 27, 2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cuyahoga County, OH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$12.4&#160;million (paid)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">buprenorphine naloxone</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(generic Suboxone<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$15.5&#160;million (3 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">December 27, 2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Summit County, OH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$7.6&#160;million (paid)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">buprenorphine naloxone</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(generic Suboxone<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$9.5&#160;million (3 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">January 18, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Louisiana</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$15&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">18 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">buprenorphine naloxone</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(generic Suboxone<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$3&#160;million (1 year)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">February 4, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Texas</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$131.5&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">15 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">naloxone hydrochloride (generic Narcan&#174;)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$75&#160;million (10 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">March 21, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Rhode Island</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$21&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">13 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">naloxone hydrochloride (generic Narcan<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>) and</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">buprenorphine naloxone (generic Suboxone<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$78.5&#160;million (10 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">March 30, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Florida</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$177.1&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">15 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">naloxone hydrochloride (generic Narcan&#174;)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$84&#160;million (10 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">July 12, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">San Francisco</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$19.5&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">13 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">naloxone hydrochloride (generic Narcan&#174;)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$20&#160;million (10 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">September 19, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">West Virginia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$75.4&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">15 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">naloxone hydrochloride (generic Narcan&#174;)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$27&#160;million (10 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">November 3, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">New York</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$313.3 million<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">**</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">18 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">N/A</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">February 24, 2023</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Tribes</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$108.3&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">13 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">naloxone hydrochloride (generic Narcan&#174;)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$25&#160;million (10 years)</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">*</div>&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts exclude attorneys&#8217; fees and costs, except New York. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">**</div>&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not including cash payment and attorneys&#8217; fees allocated under the nationwide settlement. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"> </div>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div> <div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">In light of the agreement on the proposed nationwide settlement between Teva and the States&#8217; Attorneys General and their subdivisions, Teva&#8217;s indemnification obligations arising from Teva&#8217;s acquisition of the Actavis Generics business for opioid-related claims, prior settlements with Louisiana, Texas, Rhode Island, Florida, San Francisco, West Virginia, New York, and the Tribes, as well as an estimate for a number of items including, but not limited to, costs associated with administering injunctive terms, and most favored nations clauses associated with prior settlements, the Company has recorded a provision for the potential settlement. The provision is a reasonable estimate of the ultimate costs in the likely event that the nationwide settlement is finalized under its current proposed terms and conditions, after discounting payments to states to their net present value. However, if the nationwide settlement is not finalized for the entirety of the remaining cases, a reasonable upper end of a range of loss cannot be determined. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-monetary</div> relief and could have a material and adverse effect on Teva&#8217;s reputation, business, results of operations and cash flows. </div></div> <div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"/> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2019, Teva received subpoenas from the New York State Department of Financial Services (&#8220;NYDFS&#8221;) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. This was followed by a Statement of Charges and Notice of Hearing filed by the NYDFS. This matter has been resolved by Teva&#8217;s November&#160;3, 2022 settlement with the Attorney General of New York that settled the state&#8217;s and its subdivisions&#8217; opioid-related claims. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Teva, certain of its subsidiaries and other defendants, are defending claims and putative class action lawsuits in Canada related to the manufacture, sale, marketing and distribution of opioid medications. The lawsuits include a claim by the Province of British Columbia on behalf of itself and a putative class of other federal and provincial governments, and claims of municipalities, First Nations, and persons who used opioids on behalf of themselves and putative classes. These cases are in early stages with the preliminary motions brought by the Province of British Columbia expected to be heard in late 2023. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Shareholder Litigation </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;6, 2016 and December&#160;27, 2016, two putative securities class actions were filed in the U.S. District Court for the Central District of California against Teva and certain of its current and former officers and directors. Those lawsuits subsequently were consolidated and transferred to the U.S. District Court for the District of Connecticut (the &#8220;Ontario Teachers Securities Litigation&#8221;). On December&#160;13, 2019, the lead plaintiff filed an amended complaint, purportedly on behalf of purchasers of Teva&#8217;s securities between February&#160;6, 2014 and May&#160;10, 2019, asserting that Teva and certain of its current and former officers and directors violated federal securities and common laws in connection with Teva&#8217;s alleged failure to disclose pricing strategies for various drugs in its generic drug portfolio and by making allegedly false or misleading statements in certain offering materials. From July 2017&#160;to June 2019, other putative securities class actions were filed in other federal courts based on similar allegations and claims, and were transferred to the U.S. District Court for the District of Connecticut. Between August 2017 and January 2022, twenty-three complaints were filed against Teva and certain of its current and former officers and directors on behalf of plaintiffs in various forums across the country, but many of those plaintiffs <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opted-out&#8221;</div> of the Ontario Teachers Securities Litigation. On March&#160;10, 2020, the Court consolidated the Ontario Teachers Securities Litigation with all of the above-referenced putative class actions for all purposes and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> cases for pretrial purposes. On January&#160;18, 2022, Teva entered into a settlement in the Ontario Teachers Securities Litigation for $420&#160;million, which received final approval from the court on June&#160;2, 2022. The vast majority of the total settlement amount was covered by the Company&#8217;s insurance carriers, with a small portion contributed by Teva. Additionally, as part of the settlement, Teva admitted no liability and denied all allegations of wrongdoing. On January&#160;22, 2021, the Court dismissed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> plaintiffs&#8217; claims arising from statements made prior to the five year statute of repose, but denied Teva&#8217;s motion to dismiss their claims under Israeli laws. On May&#160;24, 2021, Teva moved to dismiss a majority of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> complaints on various other grounds, and on May&#160;1, 2023, the Court granted in part and denied in part Teva&#8217;s motions. Teva has settled several <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> claims, but a number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> cases remain outstanding. In addition, Teva reached a settlement agreement of Israeli shareholder motions to certify class action on similar allegations to those raised in the Ontario Teachers Securities Litigation. The settlement agreement is awaiting court approval. </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers. On August&#160;10, 2021, the lead plaintiff filed a corrected amended class action complaint, purportedly on behalf of persons who purchased or otherwise acquired Teva securities between October&#160;29, 2015 and August&#160;18, 2020. The corrected amended complaint alleges that Teva and certain of its current and former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had allegedly caused the submission of false claims to Medicare through Teva&#8217;s donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONE&#8217;s commercial success and the sustainability of its revenues and resulted in the DOJ PAP Complaint filed by the DOJ. The corrected amended complaint seeks unspecified damages and legal fees. On March&#160;25, 2022, the court granted in part and denied in part Teva&#8217;s and the individual defendants&#8217; motion to dismiss the corrected amended complaint, (i)&#160;holding that the plaintiffs&#8217; complaint failed to plead that certain public statements regarding Teva&#8217;s compliance with the law were misleading, (ii)&#160;holding that two alleged partial corrective disclosures did not establish loss causation and cannot serve as the basis for plaintiff&#8217;s claimed loss, (iii)&#160;dismissing all claims against one of the individual defendants, and (iv)&#160;otherwise denying the motion to dismiss. On August&#160;2, 2022, the court stayed all proceedings other than class certification proceedings pending the resolution of the DOJ PAP Complaint filed by the DOJ. On September&#160;13, 2022, the plaintiff moved for class certification, which remains pending. A motion to approve a securities class action was also filed in the Central District Court in Israel, which has been stayed pending the U.S. litigation, with similar allegations to those made in the above complaint filed in the U.S. District Court for the Eastern District of Pennsylvania. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Environmental Matters </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva or its subsidiaries are party to a number of environmental proceedings, or have received claims, including under the federal Superfund law or other federal, provincial or state and local laws, imposing liability for alleged noncompliance, or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third party-owned site, or the party responsible for a release of hazardous substances that impacted a site, to investigate and clean the site or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have received claims, or been made a party to these proceedings, along with others, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Teva&#8217;s facilities or former facilities. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Teva&#8217;s potential liability varies greatly at each of the sites; for some sites the costs of the investigation, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> and natural resource damages have not yet been determined, and for others Teva&#8217;s allocable share of liability has not been determined. At other sites, Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> costs from insurers, indemnitors, former site owners or operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Teva&#8217;s facilities may result in the imposition of significant penalties (in amounts not expected to materially adversely affect Teva&#8217;s results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implemented. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Item&#160;103 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> promulgated by the SEC requires disclosure of certain environmental matters when a governmental authority is a party to the proceedings and such proceedings involve potential monetary sanctions, unless the Company reasonably believes that the matter will result in no monetary sanctions, or in monetary sanctions, exclusive of interest and costs, of less <span style="-sec-ix-hidden:hidden78649508">than</span> $300,000. The following matter is disclosed in accordance with that requirement. On July&#160;8, 2021, the National Green Tribunal Principal Bench, New Delhi, issued an order against Teva&#8217;s subsidiary in India, Teva API India Private Limited, finding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with environmental laws and assessed a penalty of $1.4&#160;million. The Company disputed certain of the findings and the amount of the penalty and filed an appeal before the Supreme Court of India. On August&#160;5, 2021, the Supreme Court of India admitted the appeal for hearing and granted an interim unconditional stay on the National Green Tribunal&#8217;s order. The Company does not believe that the eventual outcome of such matter will have a material effect on its business. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Other Matters </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;1, 2018, former shareholders of Ception Therapeutics, Inc., a company that was acquired by and merged into Cephalon in 2010, prior to Cephalon&#8217;s acquisition by Teva, filed breach of contract and other related claims against the Company, Teva USA and Cephalon in the Delaware Court of Chancery.&#160;Among other things, the plaintiffs allege that Cephalon breached the terms of the 2010 Ception-Cephalon merger agreement by failing to exercise commercially reasonable efforts to develop and commercialize CINQAIR<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> (reslizumab) for the treatment of eosinophilic esophagitis (&#8220;EE&#8221;). The plaintiffs claim damages of at least $200&#160;million, an amount they allege is equivalent to the milestones payable to the former shareholders of Ception in the event Cephalon were to obtain regulatory approval for EE in the United States ($150 million) and Europe ($50 million). On December&#160;28, 2018, following defendants&#8217; motion to dismiss the complaint, the court granted the motion in part and dismissed all of plaintiffs&#8217; claims, except for their claim against Cephalon for breach of contract. In November 2021, plaintiffs moved to amend their complaint to, among other things, reassert claims against the Company and Teva USA. However, on July&#160;12, 2022, plaintiffs filed a new amended complaint that includes claims against Teva USA but not the Company, in exchange for Teva USA&#8217;s agreement to guarantee any judgment entered against Cephalon in the litigation. A bench trial for this matter was held in September 2022, and a ruling is expected in 2023, following closing arguments.</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 15, 2022, The Scripps Research Institute (&#8220;Scripps&#8221;) filed claims against Teva&#8217;s subsidiary, Teva Pharmaceuticals International GmbH (&#8220;TPIG&#8221;) in the United States District Court for the Southern District of California for alleged breach of a sublicense agreement between Scripps and Ivax Corporation (&#8220;Ivax&#8221;) dated November 2000 (&#8220;Sublicense Agreement&#8221;). After Teva&#8217;s acquisition of Ivax, TPIG became the successor-in-interest to Ivax under the Sublicense Agreement, pursuant to which Scripps licensed to Ivax certain rights to the drug cladribine. Scripps alleges that TPIG breached the Sublicense Agreement by failing to pay royalties on sales of cladribine in certain countries, and is seeking breach of contract damages for royalties allegedly due but not paid, as well as a declaratory judgment related to royalties due in the future. On November 17, 2022, the Court dismissed Scripps&#8217; claim for breach of the implied covenant of good faith and fair dealing but denied TPIG&#8217;s motion to dismiss Scripps&#8217; breach of contract and declaratory judgment claims. TPIG answered the first amended complaint on December 16, 2022, and discovery is ongoing. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;">Gain Contingencies</div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Teva may directly or indirectly pursue claims against certain parties, including but not limited to patent infringement lawsuits against other pharmaceutical companies to protect its patent rights, as well as derivative actions brought on behalf of Teva. Teva recognizes gain contingencies from the defendants in such lawsuits when they are realized or when all related contingencies have been resolved. No gain has been recognized regarding the matters disclosed below, unless mentioned otherwise. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2017, Teva filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that Eli Lilly&#160;&amp; Co.&#8217;s (&#8220;Lilly&#8221;) marketing and sale of its galcanezumab product for the treatment of migraine infringes nine Teva patents, including three method of treatment patents and six composition of matter patents. Lilly then submitted inter partes review (&#8220;IPR&#8221;) petitions to the Patent Trial and Appeal Board (&#8220;PTAB&#8221;), challenging the validity of the nine Teva patents. The PTAB issued decisions upholding the three method of treatment patents but finding the six composition of matter patents invalid, which decisions were affirmed by the Court of Appeals for the Federal Circuit on August&#160;16, 2021. A jury trial regarding the three method of treatment patents began on October&#160;18, 2022, and on November&#160;9, 2022, the jury issued a verdict in Teva&#8217;s favor, finding the three method of treatment patents valid and infringed by Lilly and awarding Teva $176.5&#160;million in damages. On January&#160;28, 2023, Lilly filed a motion requesting that the District Court overturn the jury&#8217;s verdict. Once the motion is decided, the losing party may appeal the decision to the Court of Appeals for the Federal Circuit. On June&#160;8, 2021, Teva filed another lawsuit in the U.S. District Court for the District of Massachusetts alleging that Lilly&#8217;s marketing and sale of galcanezumab product infringes two patents related to the treatment of refractory migraine. Lilly&#8217;s IPR petitions challenging the patentability of these two patents as well as a third patent also related to the treatment of refractory migraine were instituted by the PTAB. The litigation in the District of Massachusetts was stayed during the pendency of these IPR proceedings. Teva intends to continue to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Motions to approve derivative actions seeking monetary damages against certain past and present directors and officers have been filed in Israeli Courts alleging negligence and recklessness, as well as motions for document disclosure prior to initiating derivative actions. Motions were filed with respect to several U.S. and EU settlement agreements, opioids, allegations related to the DOJ&#8217;s complaint regarding COPAXONE patient assistance program in the U.S., and with respect to the COPAXONE European Commission&#8217;s inspection. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177557024000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">NOTE 11 &#8211; Income taxes: </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, Teva recognized a tax benefit of $19&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $258&#160;million. In the first quarter of 2022, Teva recognized a tax expense of $2&#160;million, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $971&#160;million. Teva&#8217;s tax rate for the first quarter of 2023 was mainly affected by legal settlements, impairments, amortization and interest expense disallowances. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The statutory Israeli corporate tax rate is 23%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;in 2023. Teva&#8217;s tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, interest expense disallowances, tax benefits in Israel and other countries, as well as infrequent or non-recurring items.&#160;</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="null;text-indent: 0px;;display:inline;">Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. A trial for this case is currently scheduled to begin in July 2023. A final and binding decision against Teva in this case may lead to a charge of $</div>128&#160;million. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Israeli tax authorities (&#8220;ITA&#8221;) issued tax assessment decrees for 2008-2011, 2012 and 2013-2016, challenging the Company&#8217;s positions on several issues. Teva has protested the 2008-2011, 2012 and 2013-2016 decrees before the Central District Court in Israel. On April&#160;17, 2023, the ITA issued a tax assessment for 2017-2020, challenging the Company&#8217;s positions on several issues. The Company intends to challenge the tax assessment for 2017-2020, as well. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2021, the Central District Court in Israel held in favor of the ITA with respect to 2008-2011 decrees. The case with respect to 2012-2016 remains pending with similar legal and other claims. Teva appealed this decision to the Israeli Supreme Court and expects the appeal hearing to begin in the second half of 2023. The tax liability resulting from the October 2021 Central District Court decision, with respect to the decrees for 2008-2011 and with regard to the similar legal claims in the related following years, was approximately $350&#160;million, of which a portion has been and will continue to be paid during 2022 and 2023. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company believes it has adequately provided for all of its uncertain tax positions, including those items currently under dispute, however, adverse results could be material. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177556019568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_OtherExpensesTextBlock', window );">Other assets impairments, restructuring and other items</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%; text-indent: -2%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 12 &#8211; Other assets impairments, restructuring and other items: </div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:81%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden78649487">Impairments</span> of long-lived tangible assets (1)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contingent consideration</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restructuring</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Including impairments related to exit and disposal activities. </div> </td> </tr> </table>  <div style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairments </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Impairments of tangible assets for the three months ended March&#160;31, 2023 and 2022 were $10&#160;million and $16&#160;million, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its network consolidation activities. </div> <div style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent consideration </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the three months ended March&#160;31, 2023, Teva recorded an expense of $20&#160;million for contingent consideration, compared to an expense of $33&#160;million in the three months ended March&#160;31, 2022. The expense in the first three months of 2023 was mainly related to a change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales and a change in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>). The expense in the first three months of 2022 was mainly related to a change in the estimated future royalty payments in connection with lenalidomide (generic equivalent of Revlimid<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>). </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"/>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restructuring </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the three months ended March&#160;31, 2023, Teva recorded $56&#160;million of restructuring expenses, compared to $57&#160;million in the three months ended March&#160;31, 2022. The expenses for the three months ended March&#160;31, 2023 and March&#160;31, 2022 were primarily related to network consolidation activities. </div>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables provide the components of restructuring costs: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restructuring</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee termination</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>   <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides the components of and changes in the Company&#8217;s restructuring accruals: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee&#160;termination<br/> costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of January&#160;1, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(112</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(119</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(56</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Utilization and other*</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(110</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(123</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:68%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee&#160;termination<br/> costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of January&#160;1, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(138</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Utilization and other*</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(124</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(130</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Includes adjustments for foreign currency translation. </div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OtherExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Expenses [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OtherExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177556054064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 13 &#8211; Earnings (Loss) per share: </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva&#8217;s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested restricted share units (&#8220;RSUs&#8221;) and performance share units (&#8220;PSUs&#8221;) during the period, net of treasury shares. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In computing diluted loss per share for the three months ended March&#160;31, 2023 and 2022, no account was taken of the potential dilution that could occur upon the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended March&#160;31, 2023 and 2022 were 1,115&#160;million and 1,107&#160;million shares, respectively. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"/> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted loss per share was $0.18 for the three months ended March&#160;31, 2023, compared to basic and diluted loss per share of $0.86 for the three months ended March&#160;31, 2022. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555956032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated other comprehensive income (loss)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 14 &#8211; Accumulated other comprehensive income (loss): </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:58%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Unrealized&#160;Gains&#160;(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial&#160;gains<br/> (losses) and<br/> prior service<br/> (costs) credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December&#160;31, 2022, net of taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,514</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(295</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,838</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income (loss) before reclassifications</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amounts reclassified to the statements of income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net other comprehensive income (loss) before tax</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corresponding income tax</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net other comprehensive income (loss) after tax*</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March&#160;31, 2023, net of taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,385</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(287</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,701</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Amounts do not include a $9&#160;million loss from foreign currency translation adjustments attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests. </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:58%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Unrealized&#160;Gains&#160;(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial&#160;gains<br/> (losses) and<br/> prior service<br/> (costs)&#160;credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">Balance as of December&#160;31, 2021, net of taxes</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,274</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(324</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(85</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,683</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">Amounts reclassified to the statements of income</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Net other comprehensive income (loss) before tax</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">Corresponding income tax</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Net other comprehensive income (loss) after tax*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">Balance as of March&#160;31, 2022, net of taxes</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,285</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(85</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,687</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Amounts do not include a $53&#160;million loss from foreign currency translation adjustments attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests. </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555978976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 15 &#8211; Segments: </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Teva operates its business and reports its financial results in three segments: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(a)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">North America segment, which includes the United States and Canada. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(b)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Europe segment, which includes the European Union, the United Kingdom and certain other European countries. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(c)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">International Markets segment, which includes all countries other than those in the North America and Europe segments. </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div/><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who is the chief operating decision maker (&#8220;CODM&#8221;), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely North America, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Segment profit is comprised of gross profit for the segment less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva&#8217;s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#8217;s CEO may review its strategy and organizational structure from time to time. Currently, Teva&#8217;s newly appointed CEO is reviewing its strategy and organizational structure. Any changes in strategy may lead to a reevaluation of the Company&#8217;s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 3 and note 6. </div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">a. Segment information: </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:61%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenues</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,766</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">R&amp;D expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">S&amp;M expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">G&amp;A expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Segment profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#167;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Represents an amount less than $0.5&#160;million. </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenues</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">R&amp;D expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">S&amp;M expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">G&amp;A expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Segment profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">402</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#167;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Represents an amount less than $0.5&#160;million. </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>  <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a reconciliation of Teva&#8217;s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended March&#160;31, 2023 and 2022: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">North America profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">402</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Europe profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">International Markets profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total reportable segments profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">791</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Profit (loss) of other activities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total segments profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,013</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amounts not allocated to segments:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets impairments, restructuring and other items</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets impairments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legal settlements and loss contingencies</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other unallocated amounts</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consolidated operating income (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(713</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial expenses, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consolidated income (loss) before income taxes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(258</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(971</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">b. Segment revenues by major products and activities: </div></div>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present revenues by major products and activities for the three months ended March&#160;31, 2023 and 2022: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;">North America</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Generic products</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">899</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AJOVY</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AUSTEDO</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">BENDEKA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> and TREANDA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">COPAXONE</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Anda</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,766</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="break-inside: avoid; background-color: rgb(204, 238, 255); font-size: 0px;">
<td colspan="8" style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/>  <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">Europe</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Generic products</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">932</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AJOVY</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">COPAXONE</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Respiratory products</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">International markets</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Generic products</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AJOVY</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">COPAXONE</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177556109712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurement</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 16 &#8211; Fair value measurement: </div></div>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial items carried at fair value on a recurring basis as of March&#160;31, 2023 and December&#160;31, 2022 are classified in the tables below in one of the three categories of fair value levels: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money markets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">702</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">702</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, deposits and other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investment in securities:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity securities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derivatives:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden78649490">Asset derivatives</span>:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options and forward contracts</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cross currency interest rate swaps</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#167;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden78649488">Liability derivatives</span>:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options and forward contracts</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bifurcated embedded derivatives</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><span style="-sec-ix-hidden:hidden78648269">&#167;</span></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contingent consideration*</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(148</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(148</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">2,192</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(18</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(147</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">2,027</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,579</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,579</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden78649491">Asset derivatives</span>&#8212;options and forward contracts</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden78649489">Liability derivatives</span>:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options and forward contracts</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(101</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(101</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><span style="-sec-ix-hidden:hidden78648268">&#167;</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(153</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(153</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,848</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(73</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(152</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva determined the fair value of the liabilities for contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level&#160;3 measurement within the fair value hierarchy. The fair value of contingent consideration is based on several factors, such as cash flows projected from the success of unapproved product candidates; probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; time and resources required to complete the development and approval of product candidates; life of the potential commercialized products and associated risks with obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. A probability of success factor of 100% was used in the fair value calculation to reflect inherent regulatory and commercial risks of the contingent payments and IPR&amp;D. The discount rate applied ranged from 8.5% to 11%. The weighted average discount rate, calculated based on the relative fair value of Teva&#8217;s contingent consideration liabilities, was 8.95%. Contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in the consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity for the financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months<br/> ended&#160;March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months<br/> ended&#160;March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the beginning of the period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(152</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(175</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><span style="-sec-ix-hidden:hidden78649329">&#167;</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><span style="-sec-ix-hidden:hidden78649330">&#167;</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to provisions for contingent consideration:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eagle transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Novetide transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement of contingent consideration:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eagle transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Novetide transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional contingent consideration resulting from Novetide acquisition*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the end of the period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(148</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(196</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2022, Teva acquired 100% ownership of Novetide Ltd. (&#8220;Novetide&#8221;), which was previously accounted for as &#8220;investment in associated companies&#8221;. This transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under &#8220;Share in (profits) losses of associated companies, net&#8221;, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition. </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments not measured at fair value </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated fair value*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and sustainability-linked senior notes included under senior notes and loans</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,007</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and convertible senior debentures included under short-term debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,075</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value was estimated based on quoted market prices.</div></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555784624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted and issued accounting pronouncements</a></td>
<td class="text"> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Recently adopted accounting pronouncements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2022, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-04</div> &#8220;Liabilities &#8212; Supplier Finance Programs: Disclosure of Supplier Finance Program Obligations (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">405-50)&#8221;.</div> This guidance is intended to address requests from stakeholders for information about an entity&#8217;s use of supplier finance programs and their effect on the entity&#8217;s working capital, liquidity and cash flows. The guidance is effective for the fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years, except for the amendment on roll-forward information requirement, which is effective for the fiscal years beginning after December&#160;15, 2023. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2021, the FASB issued ASU 2021-08 &#8220;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,&#8221; which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The Company adopted the new accounting standard effective January 1, 2023 and the guidance is applied prospectively to all business combinations with an acquisition date occurring on or after January 2023. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements.&#160;<br/></div> </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recently issued accounting pronouncements, not yet adopted</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Recently issued accounting pronouncements, not yet adopted </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555960592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock', window );">Summary of Major Classes of Assets and Liabilities Included as Held for Sale</a></td>
<td class="text">The table below summarizes all of Teva&#8217;s assets included as held for sale as of March&#160;31, 2023 and December&#160;31, 2022: <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:75%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventories</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property, plant and equipment, net and others</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments of assets held for sale to fair value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Assets And Liabilities Held For Sale [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177556058592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from contracts with customers (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of disaggregates revenues by major revenue streams</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table disaggregates Teva&#8217;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15. </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> activities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sale of goods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,319</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">464</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licensing arrangements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">434</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,766</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;">&#167;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other<br/> activities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sale of goods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,134</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licensing arrangements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distribution</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;">&#167;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_SalesReservesAndAllowancesCurrentTableTextBlock', window );">Summary of Sales Reserves and Allowances</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:40%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/> included in<br/> Accounts<br/> Receivable,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/> other<br/> governmental<br/> allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total reserves<br/> included in<br/> Sales Reserves<br/> and&#160;Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="30" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">663</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,817</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions related to sales made in current year period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,855</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,098</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions related to sales made in prior periods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(47</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Credits and payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,127</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(289</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,973</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(95</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,505</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,589</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top;text-indent: 0px;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Translation differences</div></td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at March&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">440</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,372</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:37%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/> included in<br/> Accounts<br/> Receivable,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/> other<br/> governmental<br/> allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total reserves<br/> included in<br/> Sales Reserves<br/> and&#160;Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="30" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at January&#160;1, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">854</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">535</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions related to sales made in current year period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,814</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions related to sales made in prior periods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(90</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(87</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(87</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Credits and payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(88</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,037</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(270</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,940</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(110</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(73</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,430</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,518</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Translation differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at March&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">807</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">469</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,807</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,869</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#167;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5 million.</div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-indent: 0px; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SalesReservesAndAllowancesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of sales reserves and allowances current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SalesReservesAndAllowancesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555989088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventories, net of reserves, consisted of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finished products</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Raw and packaging materials</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,059</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Products in process</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">620</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">555</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Materials in transit and payments on account</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555952288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Identifiable Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifiable intangible assets consisted of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:48%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;carrying&#160;amount&#160;net&#160;of<br/> impairment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Product rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,067</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,934</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade names</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">In process research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">487</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">487</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,861</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177557412976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of Changes in the Carrying Amount of Goodwill by Segment</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in the carrying amount of goodwill for the period ended March&#160;31, 2023 were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Teva&#8217;s<br/> API</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medis</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December&#160;31, 2022 (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,302</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,633</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes during the period:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Translation differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March&#160;31, 2023 (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,305</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,799</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Accumulated goodwill impairment as of March&#160;31, 2023 and December&#160;31, 2022 was approximately $27.6&#160;billion. </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555903056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of Short-term Debt</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Short-term debt: </div></div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:58%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest&#160;rate&#160;as&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible senior debentures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current maturities of long-term liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,086</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total short-term debt</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock', window );">Schedule of Senior Notes and Loans</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Long-term debt: </div></div> </td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest&#160;rate&#160;as&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR 1,500&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes EUR 1,500&#160;million (6)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.38</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR 1,300&#160;million (9)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">633</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes EUR 1,100&#160;million (7)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR 1,000&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,070</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR 900&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">541</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">963</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes EUR 800&#160;million (1)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.38</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">872</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR 750&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">814</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes EUR 700&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">748</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes EUR 500&#160;million (2)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">545</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 3,500&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,374</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 3,000&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.80</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 2,000&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2046</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 1,250&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">957</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 1,250&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 1,000&#160;million (5)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes USD 1,000&#160;million (7)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes USD 1,000&#160;million (6)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes USD 789&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2036</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">783</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">783</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes USD 600&#160;million (3)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sustainability-linked senior notes USD 500&#160;million (4)(*)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior notes CHF 350&#160;million</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">382</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td colspan="8" style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total senior notes</div> </td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,761</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term debt</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less current maturities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,086</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less debt issuance costs (8)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(94</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total senior notes and loans</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,668</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>    <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 800&#160;million euro bearing 7.38% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.100%-0.300%</div> per annum, from and including September&#160;15, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 500&#160;million euro bearing 7.88% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.100%-0.300%</div> per annum, from and including September&#160;15, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $600&#160;million bearing 7.88% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.100%-0.300%</div> per annum, from and including September&#160;15, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(4)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $500&#160;million bearing 8.13% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.100%-0.300%</div> per annum, from and including September&#160;15, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(5)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva consummated a cash tender offer and extinguished $631&#160;million aggregate principal amount of its 1,000&#160;million euro 6% senior notes due in 2025; $432&#160;million aggregate principal amount of its 900&#160;million euro 4.5% senior notes due in 2025; $574&#160;million aggregate principal amount of its $1,000&#160;million 7.13% senior notes due in 2025; $454&#160;million aggregate principal amount of its $3,000&#160;million 2.8% senior notes due in 2023; $293&#160;million aggregate principal amount of its $1,250&#160;million 6% senior notes due in 2024 and $122&#160;million aggregate principal amount of its $3,500&#160;million 3.15% senior notes due in 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(6)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.125%-0.375%</div> per annum, from and including May 9, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(7)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">If Teva fails to achieve certain sustainability performance targets, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.15%-0.45%</div> out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(8)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Debt issuance costs as of March&#160;31, 2023 include $26&#160;million in connection with the issuance of the sustainability-linked senior notes in March 2023, partially offset by $6&#160;million acceleration of issuance costs related to the cash tender offer. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(9)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In March 2023, Teva repaid $646&#160;million of its 1.25% senior notes at maturity. </div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(*)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Interest rate adjustments and a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. </div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A schedule of data and information pertaining to long-debt instruments or arrangements, excluding convertible debt, that includes identification, terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtExcludingConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177554487984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock', window );">Summary of Notional Amounts for Hedged Items</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cross-currency swap - cash flow hedge (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of Classification and Fair Values of Derivative Instruments</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the classification and fair values <div style="display:inline;">of</div> derivative instruments: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:59%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Designated as hedging</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Not designated as hedging</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Asset derivatives:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other current assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option and forward contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cross-currency swap-cash flow hedge (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liability derivatives:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other current liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option and forward contracts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(101</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;">&#167;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5 million. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> (gains) losses from derivatives not designated as hedging instruments: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net revenues</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Line items in which effects of hedges are recorded</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,661</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,661</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option and forward contracts (2)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Option and forward contracts economic hedge (3)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock', window );">Summary Of Pre-tax (gains) losses from Derivatives Designated in Cash Flow Hedging Relationships</a></td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt;;display:inline;">The table below provides information regarding the location and amount of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div><div style="font-size: 10pt;;display:inline;"> (gains) losses from derivatives designated in cash flow hedging relationships:</div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other&#160;comprehensive&#160;income&#160;(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Line items in which effects of hedges are recorded</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cross-currency swaps - cash flow hedge (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555911152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock', window );">Schedule Of Material Details Of Individual Settlements</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 23%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 13%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 13%;"/>
<td style="vertical-align: bottom;"/>
<td style="width: 7%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 18%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 17%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdiction</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement<br/>Payment<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px">*</div></div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment<br/>Term</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement Product</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product&#160;WAC</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Value&#160;and&#160;Term</div></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">June 7, 2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Oklahoma</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$72.3&#160;million (paid)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">1 year</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">N/A</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">December 27, 2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cuyahoga County, OH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$12.4&#160;million (paid)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">buprenorphine naloxone</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(generic Suboxone<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$15.5&#160;million (3 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">December 27, 2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Summit County, OH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$7.6&#160;million (paid)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">buprenorphine naloxone</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(generic Suboxone<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$9.5&#160;million (3 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">January 18, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Louisiana</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$15&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">18 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">buprenorphine naloxone</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(generic Suboxone<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$3&#160;million (1 year)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">February 4, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Texas</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$131.5&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">15 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">naloxone hydrochloride (generic Narcan&#174;)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$75&#160;million (10 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">March 21, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Rhode Island</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$21&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">13 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">naloxone hydrochloride (generic Narcan<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>) and</div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">buprenorphine naloxone (generic Suboxone<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div>)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$78.5&#160;million (10 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">March 30, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Florida</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$177.1&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">15 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">naloxone hydrochloride (generic Narcan&#174;)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$84&#160;million (10 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">July 12, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">San Francisco</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$19.5&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">13 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">naloxone hydrochloride (generic Narcan&#174;)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$20&#160;million (10 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">September 19, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">West Virginia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$75.4&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">15 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">naloxone hydrochloride (generic Narcan&#174;)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$27&#160;million (10 years)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">November 3, 2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">New York</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$313.3 million<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">**</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">18 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">N/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">N/A</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">February 24, 2023</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Tribes</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$108.3&#160;million</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">13 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">naloxone hydrochloride (generic Narcan&#174;)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">$25&#160;million (10 years)</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">*</div>&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts exclude attorneys&#8217; fees and costs, except New York. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">**</div>&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not including cash payment and attorneys&#8217; fees allocated under the nationwide settlement. </div></div></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12053-110248<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177559486960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Other Assets Impairments, Restructuring and Other Items</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:81%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden78649487">Impairments</span> of long-lived tangible assets (1)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contingent consideration</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restructuring</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Including impairments related to exit and disposal activities. </div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ScheduleOfRestructuringChargesTableTextBlock', window );">Summary of Restructuring Plan Including Costs Related to Exit and Disposal</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables provide the components of restructuring costs: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restructuring</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee termination</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring Accruals</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides the components of and changes in the Company&#8217;s restructuring accruals: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:67%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee&#160;termination<br/> costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of January&#160;1, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(112</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(119</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(56</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Utilization and other*</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(110</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(123</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:68%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee&#160;termination<br/> costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of January&#160;1, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(138</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(57</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Utilization and other*</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March&#160;31, 2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(124</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(130</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Includes adjustments for foreign currency translation. </div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ScheduleOfRestructuringChargesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Restructuring Charges [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ScheduleOfRestructuringChargesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555931232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated other comprehensive income (loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Accumulated Other Comprehensive Income/(Loss) (Net of Tax)</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:58%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Unrealized&#160;Gains&#160;(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial&#160;gains<br/> (losses) and<br/> prior service<br/> (costs) credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December&#160;31, 2022, net of taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,514</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(295</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,838</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income (loss) before reclassifications</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amounts reclassified to the statements of income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net other comprehensive income (loss) before tax</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corresponding income tax</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net other comprehensive income (loss) after tax*</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March&#160;31, 2023, net of taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,385</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(287</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,701</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Amounts do not include a $9&#160;million loss from foreign currency translation adjustments attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests. </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:58%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Unrealized&#160;Gains&#160;(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial&#160;gains<br/> (losses) and<br/> prior service<br/> (costs)&#160;credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">Balance as of December&#160;31, 2021, net of taxes</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,274</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(324</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(85</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,683</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">Amounts reclassified to the statements of income</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Net other comprehensive income (loss) before tax</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">Corresponding income tax</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Net other comprehensive income (loss) after tax*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">Balance as of March&#160;31, 2022, net of taxes</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,285</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(317</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(85</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,687</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">*</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Amounts do not include a $53&#160;million loss from foreign currency translation adjustments attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests. </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555141248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Summary of Segment Profit</a></td>
<td class="text"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">a. Segment information: </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:61%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenues</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,766</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">R&amp;D expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">S&amp;M expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">G&amp;A expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Segment profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#167;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Represents an amount less than $0.5&#160;million. </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenues</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">R&amp;D expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">S&amp;M expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">G&amp;A expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#167;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Segment profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">402</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#167;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Represents an amount less than $0.5&#160;million. </div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock', window );">Schedule Of Consolidated Income Before Income Tax</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a reconciliation of Teva&#8217;s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended March&#160;31, 2023 and 2022: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">North America profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">402</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Europe profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">International Markets profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total reportable segments profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">791</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Profit (loss) of other activities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total segments profit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,013</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amounts not allocated to segments:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets impairments, restructuring and other items</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets impairments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legal settlements and loss contingencies</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other unallocated amounts</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consolidated operating income (loss)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(713</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial expenses, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consolidated income (loss) before income taxes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(258</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(971</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Net Sales by Product Line</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present revenues by major products and activities for the three months ended March&#160;31, 2023 and 2022: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;">North America</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Generic products</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">899</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AJOVY</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AUSTEDO</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">BENDEKA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div> and TREANDA<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">COPAXONE</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Anda</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,766</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="break-inside: avoid; background-color: rgb(204, 238, 255); font-size: 0px;">
<td colspan="8" style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/>    <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">Europe</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Generic products</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">932</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AJOVY</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">COPAXONE</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Respiratory products</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">International markets</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months&#160;ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Generic products</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">AJOVY</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">COPAXONE</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of consolidated income before income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177554900464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Items Carried at Fair Value</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial items carried at fair value on a recurring basis as of March&#160;31, 2023 and December&#160;31, 2022 are classified in the tables below in one of the three categories of fair value levels: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money markets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">702</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">702</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, deposits and other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investment in securities:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity securities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derivatives:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden78649490">Asset derivatives</span>:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options and forward contracts</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cross currency interest rate swaps</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#167;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><span style="-sec-ix-hidden:hidden78649488">Liability derivatives</span>:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options and forward contracts</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bifurcated embedded derivatives</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><span style="-sec-ix-hidden:hidden78648269">&#167;</span></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contingent consideration*</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(148</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(148</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">2,192</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(18</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(147</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">2,027</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,579</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,579</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden78649491">Asset derivatives</span>&#8212;options and forward contracts</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden78649489">Liability derivatives</span>:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options and forward contracts</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(101</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(101</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><span style="-sec-ix-hidden:hidden78648268">&#167;</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(153</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(153</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,848</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(73</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(152</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. </div></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity for the financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months<br/> ended&#160;March&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;months<br/> ended&#160;March&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the beginning of the period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(152</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(175</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bifurcated embedded derivatives</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><span style="-sec-ix-hidden:hidden78649329">&#167;</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><span style="-sec-ix-hidden:hidden78649330">&#167;</span></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to provisions for contingent consideration:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eagle transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Novetide transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement of contingent consideration:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eagle transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Novetide transaction</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional contingent consideration resulting from Novetide acquisition*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the end of the period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(148</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(196</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2022, Teva acquired 100% ownership of Novetide Ltd. (&#8220;Novetide&#8221;), which was previously accounted for as &#8220;investment in associated companies&#8221;. This transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under &#8220;Share in (profits) losses of associated companies, net&#8221;, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition. </div></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Financial Instrument Measured on a Basis Other Than Fair Value</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated fair value*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and sustainability-linked senior notes included under senior notes and loans</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,007</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and convertible senior debentures included under short-term debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,075</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value was estimated based on quoted market prices.</div></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177550154848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Transactions - Other Transactions - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 12, 2017</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_OtsukaMember', window );">Otsuka [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_UpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_TakedaMember', window );">Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_UpfrontPayments', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_CollaborativeAgreementMilestonePayments', window );">Collaborative agreement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember', window );">Alvotech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_CollaborativeAgreementMilestonePayments', window );">Collaborative agreement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_MedincellMember', window );">MedinCell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_CollaborativeAgreementMilestonePayments', window );">Collaborative agreement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_ModagMember', window );">MODAG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount', window );">License agreement potential aggregate milestone payments amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_ModagMember', window );">MODAG [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CollaborativeAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CollaborativeAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement potential aggregate milestone payments amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_OtsukaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_OtsukaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_MedincellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_MedincellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_ModagMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_ModagMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177557614560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventories</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent', window );">Property, plant and equipment, net and others</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Adjustments of assets held for sale to fair value</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177554443568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PledgingPurposeAxis=teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member', window );">Pledged to PNC Bank, National Association in connection with the U.S. securitization program entered into in November 2022 [Member] | Accounts Receivable Securitization Facility [Member] | PNC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableFromSecuritization', window );">Accounts receivable from securitization</a></td>
<td class="nump">$ 434<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_SalesReservesAndAllowancesToCustomersPercentage', window );">Percentage sales reserves and allowances to U.S. customers</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RevenueRecognitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RevenueRecognitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SalesReservesAndAllowancesToCustomersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales reserves and allowances to customers percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SalesReservesAndAllowancesToCustomersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableFromSecuritization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount owed to the reporting entity by counterparties in securitized loan transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableFromSecuritization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgingPurposeAxis=teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgingPurposeAxis=teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=teva_AccountsReceivableSecuritizationFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=teva_AccountsReceivableSecuritizationFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FactoringInstitutionAxis=teva_PncBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FactoringInstitutionAxis=teva_PncBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177557785680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 3,661<span></span>
</td>
<td class="nump">$ 3,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">3,090<span></span>
</td>
<td class="nump">3,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_DistributionServiceMember', window );">Distribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">434<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Distribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member] | Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member] | Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member] | Distribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">1,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member] | Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member] | Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member] | Distribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">1,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_DistributionServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_DistributionServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177549818224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 3,817<span></span>
</td>
<td class="nump">$ 4,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">3,178<span></span>
</td>
<td class="nump">3,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(3,589)<span></span>
</td>
<td class="num">(3,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">3,372<span></span>
</td>
<td class="nump">3,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReservesIncludedInAccountsReceivableNetMember', window );">Reserves Included in Accounts Receivable, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_RebatesMember', window );">Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">1,575<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(1,127)<span></span>
</td>
<td class="num">(1,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_MedicaidAndOtherGovernmentalAllowancesMember', window );">Medicaid and other governmental allowances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(289)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ChargebacksMember', window );">Chargebacks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">991<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">1,855<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(1,973)<span></span>
</td>
<td class="num">(1,940)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReturnsMember', window );">Returns [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">455<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_OtherSalesReservesAndAllowancesMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_TotalReservesIncludedInSalesReservesAndAllowancesMember', window );">Total reserves included in sales reserves and allowances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">4,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">3,098<span></span>
</td>
<td class="nump">3,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(3,505)<span></span>
</td>
<td class="num">(3,430)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 3,309<span></span>
</td>
<td class="nump">$ 3,807<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RevenueRecognitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RevenueRecognitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation allowances and reserves foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ValuationAllowancesAndReservesForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation allowances and reserves related to current period sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation allowances and reserves related to prior period sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReservesIncludedInAccountsReceivableNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReservesIncludedInAccountsReceivableNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_RebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_RebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_MedicaidAndOtherGovernmentalAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_MedicaidAndOtherGovernmentalAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_OtherSalesReservesAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_OtherSalesReservesAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_TotalReservesIncludedInSalesReservesAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_TotalReservesIncludedInSalesReservesAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177557264816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Summary of Inventories (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_InventoriesLineItems', window );"><strong>Inventories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished products</a></td>
<td class="nump">$ 2,110<span></span>
</td>
<td class="nump">$ 1,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw and packaging materials</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Products in process</a></td>
<td class="nump">620<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryInTransit', window );">Materials in transit and payments on account</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 4,118<span></span>
</td>
<td class="nump">$ 3,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_InventoriesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_InventoriesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryInTransit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryInTransit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177559306992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount net of impairment</a></td>
<td class="nump">$ 19,139<span></span>
</td>
<td class="nump">$ 19,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">13,175<span></span>
</td>
<td class="nump">12,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">5,964<span></span>
</td>
<td class="nump">6,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember', window );">Product rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount net of impairment</a></td>
<td class="nump">18,094<span></span>
</td>
<td class="nump">18,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">12,934<span></span>
</td>
<td class="nump">12,630<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">5,160<span></span>
</td>
<td class="nump">5,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount net of impairment</a></td>
<td class="nump">583<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In process research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount net of impairment</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">$ 462<span></span>
</td>
<td class="nump">$ 487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177550121888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization of intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In process research and development [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In process research and development [Member] | Minimum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In process research and development [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In process research and development [Member] | Maximum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In process research and development [Member] | Generic Pipeline Products [Member] | Development Progress And Changes In Other Key Valuation Assumptions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember', window );">Identifiable product rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember', window );">Identifiable product rights [Member] | Regulatory Price And Volume Of Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember', window );">Identifiable product rights [Member] | Lenalidomide Product [Member] | Price And Volume Of Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan [Member] | Identifiable product rights [Member] | Updated Market Assumptions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">$ 112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_GenericPipelineProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_GenericPipelineProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_EventBasisAxis=teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_EventBasisAxis=teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_EventBasisAxis=teva_RegulatoryPriceAndVolumeOfProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_EventBasisAxis=teva_RegulatoryPriceAndVolumeOfProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_LenalidomideProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_LenalidomideProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_EventBasisAxis=teva_PriceAndVolumeOfProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_EventBasisAxis=teva_PriceAndVolumeOfProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_EventBasisAxis=teva_UpdatedMarketAssumptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_EventBasisAxis=teva_UpdatedMarketAssumptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177557980896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 17,633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="nump">166<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">17,799<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">6,450<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">6,451<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">8,302<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="nump">82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">8,384<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="nump">61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=teva_OtherCountriesMember', window );">Other [Member] | Medis Reporting Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">249<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">259<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=teva_OtherCountriesMember', window );">Other [Member] | Tevas API Reporting Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">1,293<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="nump">12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 1,305<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accumulated goodwill impairment as of March&#160;31, 2023 and December&#160;31, 2022 was approximately $27.6&#160;billion.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=teva_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=teva_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=teva_MedisReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=teva_MedisReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=teva_TevasApiReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=teva_TevasApiReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177556910432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment</a></td>
<td class="nump">$ 27.6<span></span>
</td>
<td class="nump">$ 27.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177552008368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=teva_EuropeReportingUnitMember', window );">Europe Reporting Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Reporting unit percentage of fair value in excess of carrying amount</a></td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=teva_EuropeReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=teva_EuropeReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177549969744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Schedule of Short-term Debt (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities of long-term liabilities</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,086<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total short-term debt</a></td>
<td class="nump">$ 1,023<span></span>
</td>
<td class="nump">2,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_ShortCreditAgreement2026Member', window );">Convertible senior debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Convertible senior debentures</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DebtInstrumentMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Maturity Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DebtInstrumentMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_ShortCreditAgreement2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_ShortCreditAgreement2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177550787120">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Schedule of Senior Notes and Loans (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20,761<span></span>
</td>
<td class="nump">$ 21,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(2,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Less debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesAndLoans', window );">Total senior notes and loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,668<span></span>
</td>
<td class="nump">19,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_OtherDebentures2026Member', window );">Other Debentures [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesAndLoans', window );">Total senior notes and loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member', window );">Senior notes EUR 1,500 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 683<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2030Member', window );">Sustainability-linked senior notes EUR 1,500&#160;million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">4.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">$ 1,635<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember', window );">Senior notes EUR 1,300 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member', window );">Sustainability-linked senior notes EUR 1,100&#160;million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[5]</sup></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[5]</sup></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[5]</sup></td>
<td class="nump">$ 1,199<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember', window );">Senior notes EUR 1,000 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 449<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member', window );">Senior notes EUR 900 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 541<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member', window );">Senior notes EUR 750 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 814<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember', window );">Senior notes EUR 700 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 762<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember', window );">Senior notes USD 3,500 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 3,374<span></span>
</td>
<td class="nump">3,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember', window );">Senior notes USD 3,000 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member', window );">Senior notes USD 2,000 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="nump">1,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember', window );">Senior notes USD 1,250 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 957<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember', window );">Senior notes USD 1,250 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember', window );">Senior notes USD 1,000 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">7.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 427<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027TwoMember', window );">Sustainability-linked senior notes USD 1,000&#160;million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[5]</sup></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[5]</sup></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[5]</sup></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member', window );">Sustainability-linked senior notes USD 1,000&#160;million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">5.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member', window );">Senior notes USD 789 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 783<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember', window );">Senior notes CHF 350 Million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 384<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember', window );">Sustainability-linked senior notes USD 500&#160;million</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[7]</sup></td>
<td class="nump">8.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[7]</sup></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[7]</sup></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember', window );">Sustainability-linked senior notes USD 600&#160;million</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[8]</sup></td>
<td class="nump">7.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[8]</sup></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[8]</sup></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember', window );">Sustainability-linked senior notes EUR 500&#160;million</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[9]</sup></td>
<td class="nump">7.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[9]</sup></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[9]</sup></td>
<td class="nump">$ 545<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember', window );">Sustainability-linked senior notes EUR 800&#160;million</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[10]</sup></td>
<td class="nump">7.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[10]</sup></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[10]</sup></td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Debt issuance costs as of March 31, 2023 include $26 million in connection with the issuance of the sustainability-linked senior notes in March 2023, partially offset by $6 million acceleration of issuance costs related to the cash tender offer.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">In March 2023, Teva repaid $646 million of its 1.25% senior notes at maturity.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">In March 2023, Teva consummated a cash tender offer and extinguished $630 million aggregate principal amount of its 1,000 million euro 6% senior notes due in 2025; $432 million aggregate principal amount of its 900 million euro 4.5% senior notes due in 2025; $573 million aggregate principal amount of its $1,000 million 7.13% senior notes due in 2025; $453 million aggregate principal amount of its $3,000 million 2.8% senior notes due in 2023; $293 million aggregate principal amount of its $1,250 million 6% senior notes due in 2024 and $122 million aggregate principal amount of its $3,500 million 3.15% senior notes due in 2026.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $500 million bearing 8.13% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $600 million bearing 7.88% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 500 million euro bearing 7.88% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[10]</td>
<td style="vertical-align: top;" valign="top">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 800 million euro bearing 7.38% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DebtInstrumentMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Maturity Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DebtInstrumentMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesAndLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesAndLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_OtherDebentures2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_OtherDebentures2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177548487872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail) - 3 months ended Mar. 31, 2023<br> SFr in Millions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>EUR (&#8364;)</div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>CHF (SFr)</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_SeniorNotesRepaidAmount', window );">Senior notes repaid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 646,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_SeniorNotesMaturityPercentage', window );">Senior notes maturity percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member', window );">Senior notes EUR 1,500 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2030Member', window );">Sustainability-linked senior notes EUR 1,500&#160;million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember', window );">Senior notes EUR 1,300 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member', window );">Senior notes EUR 900 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt instrument principal amount of debt extinguished</a></td>
<td class="nump">$ 432,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member', window );">Senior notes EUR 750 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember', window );">Senior notes EUR 700 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember', window );">Senior notes EUR 1,000 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt instrument principal amount of debt extinguished</a></td>
<td class="nump">631,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember', window );">Senior notes USD 1,000 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt instrument principal amount of debt extinguished</a></td>
<td class="nump">574,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember', window );">Senior notes USD 3,500 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt instrument principal amount of debt extinguished</a></td>
<td class="nump">122,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember', window );">Senior notes USD 3,000 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt instrument principal amount of debt extinguished</a></td>
<td class="nump">454,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member', window );">Senior notes USD 2,000 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember', window );">Senior notes USD 1,250 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember', window );">Senior notes USD 1,250 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt instrument principal amount of debt extinguished</a></td>
<td class="nump">$ 293,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member', window );">Senior notes USD 789 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">789,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember', window );">Senior notes CHF 350 Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member', window );">Sustainability-linked senior notes EUR 1,100&#160;million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027TwoMember', window );">Sustainability-linked senior notes USD 1,000&#160;million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member', window );">Sustainability-linked senior notes USD 1,000&#160;million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember', window );">Sustainiability Senior Linked Notes Two Thousand Twenty Nine And Two Thousand And Thirty One One And Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts', window );">Debt instrument accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember', window );">Sustainability-linked senior notes EUR 800&#160;million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMonthOfMaturity', window );">Debt instrument month of maturity</a></td>
<td class="text">2029-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long term debt bearing fixed interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.38%<span></span>
</td>
<td class="nump">7.38%<span></span>
</td>
<td class="nump">7.38%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember', window );">Sustainability-linked senior notes EUR 800&#160;million | Maximum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember', window );">Sustainability-linked senior notes EUR 800&#160;million | Minimum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember', window );">Sustainability-linked senior notes EUR 500&#160;million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMonthOfMaturity', window );">Debt instrument month of maturity</a></td>
<td class="text">2031-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long term debt bearing fixed interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.88%<span></span>
</td>
<td class="nump">7.88%<span></span>
</td>
<td class="nump">7.88%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember', window );">Sustainability-linked senior notes EUR 500&#160;million | Maximum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember', window );">Sustainability-linked senior notes EUR 500&#160;million | Minimum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember', window );">Sustainability-linked senior notes USD 600&#160;million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMonthOfMaturity', window );">Debt instrument month of maturity</a></td>
<td class="text">2029-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long term debt bearing fixed interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.88%<span></span>
</td>
<td class="nump">7.88%<span></span>
</td>
<td class="nump">7.88%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember', window );">Sustainability-linked senior notes USD 600&#160;million | Maximum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember', window );">Sustainability-linked senior notes USD 600&#160;million | Minimum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember', window );">Sustainability-linked senior notes USD 500&#160;million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DebtInstrumentMonthOfMaturity', window );">Debt instrument month of maturity</a></td>
<td class="text">2031-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long term debt bearing fixed interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.13%<span></span>
</td>
<td class="nump">8.13%<span></span>
</td>
<td class="nump">8.13%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember', window );">Sustainability-linked senior notes USD 500&#160;million | Maximum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember', window );">Sustainability-linked senior notes USD 500&#160;million | Minimum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_InterestRateIncreaseMember', window );">Interest Rate Increase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">May  09,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_InterestRateIncreaseMember', window );">Interest Rate Increase [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_InterestRateIncreaseMember', window );">Interest Rate Increase [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_OneTimePremiumPaymentMember', window );">One Time Premium Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">May  09,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_OneTimePremiumPaymentMember', window );">One Time Premium Payment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_OneTimePremiumPaymentMember', window );">One Time Premium Payment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DebtInstrumentMonthOfMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument month of maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DebtInstrumentMonthOfMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SeniorNotesMaturityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Senior notes maturity percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SeniorNotesMaturityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SeniorNotesRepaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Senior notes repaid amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SeniorNotesRepaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedAmortizationDeferredFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2027TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilityLinkedSeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis=teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis=teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_InterestRateIncreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_InterestRateIncreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_OneTimePremiumPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_OneTimePremiumPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177550724016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LongTermDebtCurrencyPortionUSD', window );">Long term debt currency portion USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LongTermDebtCurrencyPortionEUR', window );">Long term debt currency portion EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LongTermDebtCurrencyPortionCHF', window );">Long term debt currency portion CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount currently outstanding on the debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantDescription', window );">Debt Instrument, Covenant Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The RCF can be used for general corporate purposes, including repaying existing debt. As of March 31, 2023 and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long Term Debt Payable Under Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Amended Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LeverageRatio', window );">Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Amended Revolving Credit Facility [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LeverageRatio', window );">Leverage Ratio</a></td>
<td class="text">3.50<span></span>
</td>
<td class="text">4.00<span></span>
</td>
<td class="text">4.00<span></span>
</td>
<td class="text">4.00<span></span>
</td>
<td class="text">4.00<span></span>
</td>
<td class="text">4.25<span></span>
</td>
<td class="text">4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember', window );">Unsecured Syndicated Revolving Credi tFacility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LineOfCreditExtensionPeriod', window );">Line of credit extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leverage ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LineOfCreditExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit extension period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LineOfCreditExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtCurrencyPortionCHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt currency portion C H F.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtCurrencyPortionCHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtCurrencyPortionEUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt currency portion E U R.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtCurrencyPortionEUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtCurrencyPortionUSD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt currency portion U S D.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtCurrencyPortionUSD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_AmendedRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_AmendedRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177556088704">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Summary of Notional Amounts for Hedged Items (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Cross Currency Swap Cash Flow Hedge [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Cross-currency swap - cash flow hedge</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On March 31, 2023, Teva entered into a cross currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=teva_CrossCurrencySwapCashFlowHedgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=teva_CrossCurrencySwapCashFlowHedgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177559448192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Summary of Classification and Fair Values of Derivative Instruments (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Cross Currency Swap Cash Flow Hedge [Member] | Other Non-current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument [Member] | Cross Currency Swap Cash Flow Hedge [Member] | Other Non-current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=teva_CrossCurrencySwapCashFlowHedgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=teva_CrossCurrencySwapCashFlowHedgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177556826064">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Summary Of Pre-tax (gains) losses from Derivatives Designated in Cash Flow Hedging Relationships (Detail) - Designated as Hedging Instrument [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 127<span></span>
</td>
<td class="num">$ (57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Cross Currency Swap Cash Flow Hedge [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesNetMember', window );">Financial Expenses Net [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments', window );">Financial expenses, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">260<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesNetMember', window );">Financial Expenses Net [Member] | Cross Currency Swap Cash Flow Hedge [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems', window );"><strong>Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments', window );">Financial expenses, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On March 31, 2023, Teva entered into a cross currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) related to derivatives designated as cash flow hedging instruments, recorded in results of operations to the extent that the cash flow hedge is determined to be ineffective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=teva_CrossCurrencySwapCashFlowHedgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=teva_CrossCurrencySwapCashFlowHedgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177559268816">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Schedule of Other Derivatives Not Designated As Hedging Instruments Statements of Financial Performance And Financial Position Location (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember', window );">Net Revenues [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (3,661)<span></span>
</td>
<td class="num">$ (3,661)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember', window );">Net Revenues [Member] | Not Designated as Hedging Instrument, Trading [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember', window );">Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">6<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember', window );">Financial expenses [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">260<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember', window );">Financial expenses [Member] | Not Designated as Hedging Instrument, Trading [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember', window );">Financial expenses [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty and several other currencies to protect its projected operating results for 2023. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first quarter of 2023, the negative impact from these derivatives recognized under revenues was $6 million. In the first quarter of 2022, the positive impact from these derivatives recognized under revenues was $19 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. Cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentTradingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentTradingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177550486304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RevenuesOtherThanUsd', window );">Revenues other than USD</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Teva other comprehensive loss</a></td>
<td class="nump">$ 493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses', window );">Forward starting interest rate swaps and treasury lock agreements losses</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forward starting interest rate swaps and treasury lock agreements losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RevenuesOtherThanUsd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues other than US Dollar.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RevenuesOtherThanUsd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain from derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes loss from derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177559548096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Settlements and Loss Contingencies - Additional Information (Detail)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Legal settlements and loss contingencies, expense</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 1,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrued amount for legal settlements and loss contingencies</a></td>
<td class="nump">$ 4,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,186<span></span>
</td>
<td class="nump">&#8364; 60.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177546566544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Contingencies - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1">48 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 09, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 21, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 21, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2008 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2005 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DamagesAssessment', window );">Damages assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesAtTimeOfSettlement', window );">Annual sales at the time of settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfEffexor', window );">Annual sales of Effexor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfLamictal', window );">Annual sales of Lamictal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 950,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfNiaspan', window );">Annual sales of Niaspan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="nump">$ 416,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfActos', window );">Annual sales of Actos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="nump">$ 3,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfActoplus', window );">Annual sales of Acto plus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,000,000<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfSensipar', window );">Annual Sales Of Sensipar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LitigationSettlementAmountAwardedDistributionPeriod', window );">Litigation settlement amount awarded distribution period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfCopaxone', window );">Annual sales of Copaxone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Generic modafinil, and imposed fines amount</a></td>
<td class="nump">$ 4,186,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,299,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,186,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 60.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss Contingency Accrual, Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfTheTimeOfSettlementOfViread', window );">Annual sales of the time of settlement of viread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfTheTimeOfSettlementOfTruvada', window );">Annual sales of the time of settlement of Truvada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfTheTimeOfSettlementOfAtripla', window );">Annual sales of the time of settlement of Atripla</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfTheTimeOfNewLaunchOfViread', window );">Annual sales of the time of New launch of viread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 728,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada', window );">Annual sales of the time of New launch of Truvada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla', window );">Annual sales of the time of New launch of Atripla</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfColcrys', window );">Annual sales of Colcrys</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LitigationSettlementAmountDistributableinKind', window );">Litigation Settlement Amount Distributable In Kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForEnvironmentalLossContingencies', window );">Accrual for Environmental Loss Contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration', window );">Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Liabilities, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LossContingenciesOnEnvironmentalLawsPenalty', window );">Loss Contingencies On Environmental Laws Penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_PercentageOfThePopulationOfTheParticipatingStates', window );">Percentage of the population of the participating states</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement', window );">Percentage of the litigating subdivisions have chosen to participate in Teva's nationwide settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfRevlimid', window );">Annual Sales Of Revlimid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler', window );">Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesOfEpipen', window );">Annual Sales Of EpiPen</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation', window );">Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_PercentageOfShareOfTheNationalPopulation', window );">Percentage Of Share Of The National Population</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LitigationSettlementAmountPayableInCashPercentage', window );">Percentgae of amount in cash settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LitigationSettlementAmountDistributableInCash', window );">Litigation Settlement Amount Distributable in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss Contingency, Damages Awarded, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_DefendantsAxis=teva_FourOtherDefendantsOtherThanTevaMember', window );">Four Other Defendants Other Than Teva [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Loss contingency payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=teva_NationwideSettlementMember', window );">Nationwide Settlement [Member] | Four Other Defendants Other Than Teva [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LitigationSettlementAmountAwardedDistributionPeriod', window );">Litigation settlement amount awarded distribution period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damage claimed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember', window );">Eosinophilic Esophagitis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damage claimed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember', window );">Eosinophilic Esophagitis [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damage claimed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember', window );">AndroGel Rate at 1% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AnnualSalesAtTimeOfSettlement', window );">Annual sales at the time of settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales at The time of nuvigil entered into first settlement of with AN ANDA hiler.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesAtTimeOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales at time of settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesAtTimeOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfActoplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of Acto plus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfActoplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfActos">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of Actos.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfActos</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfColcrys">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of colcrys.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfColcrys</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfCopaxone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Sales Of Copaxone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfCopaxone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfEffexor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of effexor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfEffexor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfEpipen">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of EpiPen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfEpipen</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfLamictal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of Lamictal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfLamictal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfNiaspan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of Niaspan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfNiaspan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfRevlimid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of revlimid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfRevlimid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfSensipar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Annual Sales Of Sensipar.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfSensipar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of the time of new launch of Atripla.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of the time of New launch of truvada.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfTheTimeOfNewLaunchOfViread">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of the time of new launch of viread.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfTheTimeOfNewLaunchOfViread</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfTheTimeOfSettlementOfAtripla">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of the time of settlement of atripla.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfTheTimeOfSettlementOfAtripla</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfTheTimeOfSettlementOfTruvada">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of the time of settlement of truvada.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfTheTimeOfSettlementOfTruvada</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfTheTimeOfSettlementOfViread">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual sales of the time of settlement of viread.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfTheTimeOfSettlementOfViread</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DamagesAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Damages assessment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DamagesAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationSettlementAmountAwardedDistributionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount awarded distribution period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationSettlementAmountAwardedDistributionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationSettlementAmountDistributableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount distributable in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationSettlementAmountDistributableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationSettlementAmountDistributableinKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount distributableIn kind.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationSettlementAmountDistributableinKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationSettlementAmountPayableInCashPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount payable in cash percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationSettlementAmountPayableInCashPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LossContingenciesOnEnvironmentalLawsPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss contingencies on environmental laws penalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LossContingenciesOnEnvironmentalLawsPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss contingency claims dismissed value paid to each state proportional to its share of national population</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PercentageOfShareOfTheNationalPopulation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of share of the national population.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PercentageOfShareOfTheNationalPopulation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the litigating subdivisions have chosen to participate in teva's nationwide settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PercentageOfThePopulationOfTheParticipatingStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the population of the participating states.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PercentageOfThePopulationOfTheParticipatingStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForEnvironmentalLossContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs accrued as of the balance sheet date for environmental loss contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13237-110859<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13207-110859<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13237-110859<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 55<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=6571209&amp;loc=d3e13703-110860<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForEnvironmentalLossContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes accrual for environmental loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.Y.Q4)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DefendantsAxis=teva_FourOtherDefendantsOtherThanTevaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DefendantsAxis=teva_FourOtherDefendantsOtherThanTevaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=teva_NationwideSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=teva_NationwideSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177551198752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies - Schedule Of Material Details Of Individual Settlements (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_LA', window );">LOUISIANA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementDate', window );">Date</a></td>
<td class="text">January 18, 2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDomicileOfLitigation', window );">Jurisdiction</a></td>
<td class="text">Louisiana<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payment</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementTerms', window );">Payment Term</a></td>
<td class="text">18 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ContingencySettlementProduct', window );">Settlement Product</a></td>
<td class="text">buprenorphine naloxone (generic Suboxone&#174;)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCost', window );">Product WAC Value</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCostTerm', window );">Product WAC Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_OK', window );">OKLAHOMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementDate', window );">Date</a></td>
<td class="text">June 7, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDomicileOfLitigation', window );">Jurisdiction</a></td>
<td class="text">Oklahoma<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payment</a></td>
<td class="nump">$ 72.3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementTerms', window );">Payment Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_TX', window );">TEXAS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementDate', window );">Date</a></td>
<td class="text">February 4, 2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDomicileOfLitigation', window );">Jurisdiction</a></td>
<td class="text">Texas<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payment</a></td>
<td class="nump">$ 131.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementTerms', window );">Payment Term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ContingencySettlementProduct', window );">Settlement Product</a></td>
<td class="text">naloxone hydrochloride (generic Narcan&#174;)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCost', window );">Product WAC Value</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCostTerm', window );">Product WAC Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_WV', window );">WEST VIRGINIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementDate', window );">Date</a></td>
<td class="text">September 19, 2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDomicileOfLitigation', window );">Jurisdiction</a></td>
<td class="text">West Virginia<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payment</a></td>
<td class="nump">$ 75.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementTerms', window );">Payment Term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ContingencySettlementProduct', window );">Settlement Product</a></td>
<td class="text">naloxone hydrochloride (generic Narcan&#174;)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCost', window );">Product WAC Value</a></td>
<td class="nump">$ 27.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCostTerm', window );">Product WAC Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_NY', window );">NEW YORK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementDate', window );">Date</a></td>
<td class="text">November 3, 2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDomicileOfLitigation', window );">Jurisdiction</a></td>
<td class="text">New York<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payment</a></td>
<td class="nump">$ 313.3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementTerms', window );">Payment Term</a></td>
<td class="text">18 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ContingencySettlementProduct', window );">Settlement Product</a></td>
<td class="text">N/A<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_FL', window );">FLORIDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementDate', window );">Date</a></td>
<td class="text">March 30, 2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDomicileOfLitigation', window );">Jurisdiction</a></td>
<td class="text">Florida<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payment</a></td>
<td class="nump">$ 177.1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementTerms', window );">Payment Term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ContingencySettlementProduct', window );">Settlement Product</a></td>
<td class="text">naloxone hydrochloride (generic Narcan&#174;)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCost', window );">Product WAC Value</a></td>
<td class="nump">$ 84.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCostTerm', window );">Product WAC Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_RI', window );">RHODE ISLAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementDate', window );">Date</a></td>
<td class="text">March 21, 2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDomicileOfLitigation', window );">Jurisdiction</a></td>
<td class="text">Rhode Island<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payment</a></td>
<td class="nump">$ 21.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementTerms', window );">Payment Term</a></td>
<td class="text">13 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ContingencySettlementProduct', window );">Settlement Product</a></td>
<td class="text">naloxone hydrochloride (generic Narcan&#174;) and buprenorphine naloxone (generic Suboxone&#174;)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCost', window );">Product WAC Value</a></td>
<td class="nump">$ 78.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCostTerm', window );">Product WAC Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=teva_CuyahogaCountyOhMember', window );">Cuyahoga County, OH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementDate', window );">Date</a></td>
<td class="text">December 27, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDomicileOfLitigation', window );">Jurisdiction</a></td>
<td class="text">Cuyahoga County, OH<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payment</a></td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementTerms', window );">Payment Term</a></td>
<td class="text">2.5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ContingencySettlementProduct', window );">Settlement Product</a></td>
<td class="text">buprenorphine naloxone (generic Suboxone&#174;)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCost', window );">Product WAC Value</a></td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCostTerm', window );">Product WAC Term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=teva_SummitCountyOhMember', window );">Summit County, OH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementDate', window );">Date</a></td>
<td class="text">December 27, 2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDomicileOfLitigation', window );">Jurisdiction</a></td>
<td class="text">Summit County, OH<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payment</a></td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementTerms', window );">Payment Term</a></td>
<td class="text">2.5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ContingencySettlementProduct', window );">Settlement Product</a></td>
<td class="text">buprenorphine naloxone (generic Suboxone&#174;)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCost', window );">Product WAC Value</a></td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCostTerm', window );">Product WAC Term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=teva_SanFranciscoMember', window );">San Francisco [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementDate', window );">Date</a></td>
<td class="text">July 12, 2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDomicileOfLitigation', window );">Jurisdiction</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payment</a></td>
<td class="nump">$ 19.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementTerms', window );">Payment Term</a></td>
<td class="text">13 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ContingencySettlementProduct', window );">Settlement Product</a></td>
<td class="text">naloxone hydrochloride (generic Narcan&#174;)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCost', window );">Product WAC Value</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCostTerm', window );">Product WAC Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=teva_TribesMember', window );">Tribes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementDate', window );">Date</a></td>
<td class="text">February 24, 2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDomicileOfLitigation', window );">Jurisdiction</a></td>
<td class="text">Tribes<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Payment</a></td>
<td class="nump">$ 108.3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementTerms', window );">Payment Term</a></td>
<td class="text">13 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ContingencySettlementProduct', window );">Settlement Product</a></td>
<td class="text">naloxone hydrochloride (generic Narcan&#174;)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCost', window );">Product WAC Value</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ProductWeightedAverageCostTerm', window );">Product WAC Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts exclude attorneys&#8217; fees and costs, except New York.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Not including cash payment and attorneys&#8217; fees allocated under the nationwide settlement.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ContingencySettlementProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingency Settlement Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ContingencySettlementProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ProductWeightedAverageCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product&#160; Weighted Average Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ProductWeightedAverageCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ProductWeightedAverageCostTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Weighted Average Cost term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ProductWeightedAverageCostTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDomicileOfLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identifies the domicile or jurisdiction of the court of law, arbitration or mediation proceeding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDomicileOfLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencySettlementAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective date of a duly executed litigation settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencySettlementAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencySettlementAgreementTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the terms of a settlement agreement which resolved the legal matter, including the nature of the consideration, timing of payment, and the nature of rights obtained or lost (for example, but not limited to, patent, trademark, copyright, license and franchise rights).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencySettlementAgreementTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_LA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_LA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_OK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_OK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_WV">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_WV</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_RI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=stpr_RI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=teva_CuyahogaCountyOhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=teva_CuyahogaCountyOhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=teva_SummitCountyOhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=teva_SummitCountyOhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=teva_SanFranciscoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=teva_SanFranciscoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=teva_TribesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesByJurisdictionAxis=teva_TribesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177550110336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ExpectedImpairmentOfIncomeTaxBenefit', window );">Expected impairment of income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Pre tax income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (258)<span></span>
</td>
<td class="num">$ (971)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate in Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member] | Tax Year 2008 To 2011 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Income Tax Examination, Estimate of Possible Loss</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ExpectedImpairmentOfIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected impairment of income tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ExpectedImpairmentOfIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of loss resulting from an adverse tax position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=teva_TaxYear2008To2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=teva_TaxYear2008To2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177548283152">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RestructuringAndImpairmentCostsLineItems', window );"><strong>Restructuring and Impairment Costs [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairments of long-lived tangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ImpairmentAndRestructuring', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Consolidated operating income (loss)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Including impairments related to exit and disposal activities.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ImpairmentAndRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment and restructuring.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ImpairmentAndRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal settlements loss contingencies impairments other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RestructuringAndImpairmentCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and impairment costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RestructuringAndImpairmentCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177559291056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177559354144">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (119)<span></span>
</td>
<td class="num">$ (138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RestructuringAccrualProvision', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_UtilizationAndOther', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">52<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ExitAndDisposalAxis=teva_EmployeeTerminationMember', window );">Employee termination costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(112)<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RestructuringAccrualProvision', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_UtilizationAndOther', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">25<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ExitAndDisposalAxis=teva_OtherExitAndDisposalMember', window );">Other Exit and Disposal [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RestructuringAccrualProvision', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_UtilizationAndOther', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (13)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes adjustments for foreign currency translation.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RestructuringAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Accrual Provision</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RestructuringAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_UtilizationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Utilization and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_UtilizationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ExitAndDisposalAxis=teva_EmployeeTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ExitAndDisposalAxis=teva_EmployeeTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ExitAndDisposalAxis=teva_OtherExitAndDisposalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ExitAndDisposalAxis=teva_OtherExitAndDisposalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177551920256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_RestructuringAndImpairmentCostsLineItems', window );"><strong>Restructuring and Impairment Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairments of property, plant and equipment</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business combination contingent consideration arrangements change in amount of contingent consideration liability</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RestructuringAndImpairmentCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and impairment costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RestructuringAndImpairmentCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177556885376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, Basic</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, Diluted</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted average number of shares outstanding, diluted</a></td>
<td class="nump">1,115,000,000<span></span>
</td>
<td class="nump">1,107,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average shares with anti-dilutive effect on earnings per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177546429296">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2023</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,838)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,701)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,514)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (2,274)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">122<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">122<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Corresponding income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) after tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">129<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(11)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,385)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,285)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Financial Instruments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(295)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(324)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Amounts reclassified to the statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) after tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(287)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(317)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Benefit Plans [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(28)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(85)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Amounts reclassified to the statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) after tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(85)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,838)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,683)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">122<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Amounts reclassified to the statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">129<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Corresponding income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) after tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">136<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,701)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (2,687)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts do not include a $9 million loss from foreign currency translation adjustments attributable to non-controlling interests.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts do not include a $53 million loss from foreign currency translation adjustments attributable to non-controlling interests.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177559486832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss)  (Parenthetical) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign currency translation attributable to non-controlling interests</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177546448672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Summary of Segment Profit (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,661<span></span>
</td>
<td class="nump">$ 3,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,582<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">R&amp;D expenses</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">S&amp;M expenses</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A expenses</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment profit</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(713)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">1,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">R&amp;D expenses</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">S&amp;M expenses</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A expenses</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_OtherOperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment profit</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">R&amp;D expenses</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">S&amp;M expenses</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A expenses</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment profit</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">R&amp;D expenses</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">S&amp;M expenses</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A expenses</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_OtherOperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment profit</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177559325792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (713)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_ImpairmentsRestructuringAndOthers', window );">Other asset impairments, restructuring and other items</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_LegalSettlementsAndLossContingencies', window );">Legal settlements and loss contingencies</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_OtherUnallocatedAmounts', window );">Other unallocated amounts</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial expenses, net</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="num">(258)<span></span>
</td>
<td class="num">(971)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Corporate Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_SegmentsAndOtherActivitiesMember', window );">Segments and Other Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">$ 785<span></span>
</td>
<td class="nump">$ 1,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AmountsAllocatedToSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AmountsAllocatedToSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AmountsNotAllocatedToSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts not allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AmountsNotAllocatedToSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ImpairmentsRestructuringAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairments restructuring and others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ImpairmentsRestructuringAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LegalSettlementsAndLossContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LegalSettlementsAndLossContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OtherUnallocatedAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other unallocated amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OtherUnallocatedAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_SegmentsAndOtherActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_SegmentsAndOtherActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177548994352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Schedule of Revenues by Major Products and Activities (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,661<span></span>
</td>
<td class="nump">$ 3,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">1,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_GenericsMediciansMember', window );">Generic products [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">824<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_GenericsMediciansMember', window );">Generic products [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">932<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_GenericsMediciansMember', window );">Generic products [Member] | International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AjovyMember', window );">AJOVY [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AjovyMember', window );">AJOVY [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AjovyMember', window );">AJOVY [Member] | International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AustedoMember', window );">AUSTEDO [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_BendekaAndTreandaMember', window );">BENDEKA&#174; and TREANDA&#174; [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_COPAXONEMember', window );">COPAXONE [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_COPAXONEMember', window );">COPAXONE [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_COPAXONEMember', window );">COPAXONE [Member] | International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AndaMember', window );">Anda [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_RespiratoryProductMember', window );">Respiratory Product [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_OtherProductsMember', window );">Other [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_OtherProductsMember', window );">Other [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_OtherProductsMember', window );">Other [Member] | International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_GenericsMediciansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_GenericsMediciansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_AjovyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_AjovyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_AustedoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_AustedoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_BendekaAndTreandaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_BendekaAndTreandaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_COPAXONEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_COPAXONEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_AndaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_AndaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_RespiratoryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_RespiratoryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177556001328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177551476672">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,027<span></span>
</td>
<td class="nump">$ 2,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Other Assets, Current<span></span>
</td>
<td class="text">Other Assets, Current<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Other Liabilities, Current<span></span>
</td>
<td class="text">Other Liabilities, Current<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember', window );">Asset Derivatives - Options and Forward Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=teva_OptionsAndForwardContractsDerivativeLiabilitiesMember', window );">Liabilities Derivatives Options and Forward Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Markets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">702<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DemandDepositsMember', window );">Cash, Deposits and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,441<span></span>
</td>
<td class="nump">1,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=teva_OtherRestrictedCashMember', window );">Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,192<span></span>
</td>
<td class="nump">2,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Money Markets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">702<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Cash, Deposits and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,441<span></span>
</td>
<td class="nump">1,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Equity Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Asset Derivatives - Options and Forward Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Liabilities Derivatives Options and Forward Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Bifurcated embedded derivatives [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=teva_OptionsAndForwardContractsDerivativeLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=teva_OptionsAndForwardContractsDerivativeLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=teva_OtherRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=teva_OtherRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177550486720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurement - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=teva_MeasurementInputProbabilityOfSuccessMember', window );">Measurement input probability of success [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">8.95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=teva_MeasurementInputProbabilityOfSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=teva_MeasurementInputProbabilityOfSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177559423344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at the beginning of the period</a></td>
<td class="num">$ (152)<span></span>
</td>
<td class="num">$ (175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_BifurcatedEmbeddedDerivatives', window );">Bifurcated embedded derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at the end of the period</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_NoveTideAcquisitionMember', window );">Nove Tide Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Redemption of debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_ActavisGenericsMember', window );">Actavis Generics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod', window );">Actavis Generics transaction</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlement of contingent consideration</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_EagleTransactionMember', window );">Eagle Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease', window );">Adjustments to provisions for contingent consideration</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlement of contingent consideration</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_NovetideTransactionMember', window );">Novetide Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease', window );">Adjustments to provisions for contingent consideration</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlement of contingent consideration</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_BifurcatedEmbeddedDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bifurcated embedded derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_BifurcatedEmbeddedDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration arising during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_NoveTideAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_NoveTideAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_ActavisGenericsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_ActavisGenericsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_EagleTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_EagleTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_NovetideTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_NovetideTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177555964288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)<br></strong></div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_NoveTideAcquisitionMember', window );">Nove tide Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, Percentage of voting interests acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_NoveTideAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_NoveTideAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140177551247360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total</a></td>
<td class="nump">$ 19,020<span></span>
</td>
<td class="nump">$ 18,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember', window );">Senior Notes And Sustainability Linked Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total</a></td>
<td class="nump">18,007<span></span>
</td>
<td class="nump">16,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=teva_SeniornotesandconvertibleseniordebenturesMember', window );">Senior Notes and Convertible Senior Debentures Included Under Short-Term Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total</a></td>
<td class="nump">$ 1,013<span></span>
</td>
<td class="nump">$ 2,075<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=teva_SeniornotesandconvertibleseniordebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=teva_SeniornotesandconvertibleseniordebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>d464631d10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:teva="http://www.tevapharm.com/20230331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="teva-20230331.xsd" xlink:type="simple"/>
    <context id="P01_01_2023To03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="P08_21_2018To08_21_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2018-08-21</startDate>
            <endDate>2022-08-21</endDate>
        </period>
    </context>
    <context id="PAsOn02_28_2005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2005-02-28</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2008-07-31</instant>
        </period>
    </context>
    <context id="P04_01_2013To04_30_2013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2013-04-01</startDate>
            <endDate>2013-04-30</endDate>
        </period>
    </context>
    <context id="P09_01_2013To09_30_2013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2013-09-01</startDate>
            <endDate>2013-09-30</endDate>
        </period>
    </context>
    <context id="P12_01_2010To12_31_2010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2010-12-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="P08_01_2012To08_31_2012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2012-08-01</startDate>
            <endDate>2012-08-31</endDate>
        </period>
    </context>
    <context id="P11_30_2022To11_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2022-11-30</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P08_05_2021To08_05_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn11_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="PAsOn07_08_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2021-07-08</instant>
        </period>
    </context>
    <context id="P12_31_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P11_09_2022To11_09_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2022-11-09</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">teva:OtherRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">teva:OtherRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">teva:OtherRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">teva:SeniorNotesAndSustainabilityLinkedSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">teva:SeniornotesandconvertibleseniordebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_InterestRateSwapMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:ShortCreditAgreement2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2027TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherDebentures2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:OtherDebentures2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmbeddedDerivativeFinancialInstrumentsMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccountsReceivableSecuritizationFacilityMemberusgaapDerivativeInstrumentRiskAxis_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022MemberusgaapPledgingPurposeAxis_PncBankMemberTEVAFactoringInstitutionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:AccountsReceivableSecuritizationFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">teva:PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:FactoringInstitutionAxis">teva:PncBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_DemandDepositsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">teva:OtherRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">teva:OtherRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">teva:OtherRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">teva:SeniorNotesAndSustainabilityLinkedSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">teva:SeniornotesandconvertibleseniordebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_InterestRateSwapMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:ShortCreditAgreement2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2027TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_OtherDebentures2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:OtherDebentures2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">teva:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_EmbeddedDerivativeFinancialInstrumentsMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AccountsReceivableSecuritizationFacilityMemberusgaapDerivativeInstrumentRiskAxis_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022MemberusgaapPledgingPurposeAxis_PncBankMemberTEVAFactoringInstitutionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:AccountsReceivableSecuritizationFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">teva:PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:FactoringInstitutionAxis">teva:PncBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AustedoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:BendekaAndTreandaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AndaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:RespiratoryProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:NoveTideAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CorporateMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ActavisGenericsMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:ActavisGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EagleTransactionMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:EagleTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:BendekaAndTreandaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AndaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:RespiratoryProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AustedoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:ShortCreditAgreement2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AlvotechMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:AlvotechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_JPsrtStatementGeographicalAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_UpdatedMarketAssumptionsMemberTEVAEventBasisAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:EventBasisAxis">teva:UpdatedMarketAssumptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_RegulatoryPriceAndVolumeOfProductsMemberTEVAEventBasisAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:EventBasisAxis">teva:RegulatoryPriceAndVolumeOfProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMemberTEVAEventBasisAxis_GenericPipelineProductsMembersrtProductOrServiceAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericPipelineProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:EventBasisAxis">teva:DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_LenalidomideProductMembersrtProductOrServiceAxis_PriceAndVolumeOfProductsMemberTEVAEventBasisAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:LenalidomideProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:EventBasisAxis">teva:PriceAndVolumeOfProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_CorporateMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2027TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilityLinkedSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ActavisGenericsMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:ActavisGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_EagleTransactionMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:EagleTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_NovetideTransactionMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NovetideTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_InternationalMarketsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OtherCountriesMembersrtStatementGeographicalAxis_TevasApiReportingUnitMemberusgaapReportingUnitAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">teva:TevasApiReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_MedisReportingUnitMemberusgaapReportingUnitAxis_OtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">teva:MedisReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_UnsecuredSyndicatedRevolvingCrediTfacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">teva:UnsecuredSyndicatedRevolvingCrediTfacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OKusgaapStatutoryAccountingPracticesByJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis">stpr:OK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis">teva:CuyahogaCountyOhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis">teva:SummitCountyOhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis">stpr:LA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis">stpr:RI</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis">teva:SanFranciscoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis">stpr:WV</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_NYusgaapStatutoryAccountingPracticesByJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatutoryAccountingPracticesByJurisdictionAxis">teva:TribesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:CrossCurrencySwapCashFlowHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis">teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis">teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis">teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis">teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis">teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis">teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis">teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis">teva:FromSeptemberFifteenthTwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:InterestRateIncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:InterestRateIncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_MinimumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:OneTimePremiumPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_MaximumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:OneTimePremiumPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_InterestRateIncreaseMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:InterestRateIncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:OneTimePremiumPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P10_01_2021To10_31_2021_ModagMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ModagMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="P10_01_2021To10_31_2021_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_TaxYear2008To2011MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">teva:TaxYear2008To2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="P10_01_2021To12_31_2021_ModagMemberusgaapBusinessAcquisitionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ModagMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:OtsukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-12</startDate>
            <endDate>2017-05-12</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_OtsukaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:OtsukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_OtsukaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:OtsukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:TakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_TakedaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:TakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P08_01_2021To08_31_2021_MedincellMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:MedincellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_MedincellMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:MedincellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">teva:EosinophilicEsophagitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">teva:EosinophilicEsophagitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn08_31_2019_AndroGelRateAtOnePercentageMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AndroGelRateAtOnePercentageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:DefendantsAxis">teva:FourOtherDefendantsOtherThanTevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-21</startDate>
            <endDate>2021-07-21</endDate>
        </period>
    </context>
    <context id="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis_NationwideSettlementMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:NationwideSettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:DefendantsAxis">teva:FourOtherDefendantsOtherThanTevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-21</startDate>
            <endDate>2021-07-21</endDate>
        </period>
    </context>
    <context id="PAsOn01_01_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:NoveTideAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_EuropeReportingUnitMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">teva:EuropeReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="P10_01_2023To12_31_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2024To06_30_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2024To12_31_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:AmendedRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_InternationalMarketsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherCountriesMembersrtStatementGeographicalAxis_TevasApiReportingUnitMemberusgaapReportingUnitAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">teva:TevasApiReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MedisReportingUnitMemberusgaapReportingUnitAxis_OtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">teva:MedisReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_InternationalMarketsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_OtherCountriesMembersrtStatementGeographicalAxis_TevasApiReportingUnitMemberusgaapReportingUnitAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">teva:TevasApiReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_MedisReportingUnitMemberusgaapReportingUnitAxis_OtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">teva:MedisReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_CHF">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Segment">
        <measure>teva:Segment</measure>
    </unit>
    <unit id="Unit_ILS_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2023To03_31_2023">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2023To03_31_2023">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P01_01_2023To03_31_2023">0000818686</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2023To03_31_2023">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2023To03_31_2023" id="hidden78861945">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressCountry contextRef="P01_01_2023To03_31_2023" id="hidden78861938">IL</dei:EntityAddressCountry>
    <dei:DocumentType contextRef="P01_01_2023To03_31_2023">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="P01_01_2023To03_31_2023">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2023To03_31_2023">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2023To03_31_2023">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P01_01_2023To03_31_2023">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P01_01_2023To03_31_2023">001-16174</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2023To03_31_2023">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2023To03_31_2023">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2023To03_31_2023">124 Dvora HaNevi&#x2019;a St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2023To03_31_2023">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2023To03_31_2023">6944020</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2023To03_31_2023">+972 (3)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2023To03_31_2023">914-8213</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P01_01_2023To03_31_2023">American Depositary Shares, each representing one Ordinary Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2023To03_31_2023">TEVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2023To03_31_2023">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2023To03_31_2023">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2023To03_31_2023">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2023To03_31_2023">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2023To03_31_2023">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2023To03_31_2023">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="P01_01_2023To03_31_2023">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">1120405816</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="P01_01_2023To03_31_2023" id="hidden78649493">http://fasb.org/us-gaap/2022#IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</us-gaap:DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <teva:BifurcatedEmbeddedDerivatives
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      id="hidden78649329"
      unitRef="Unit_USD">0</teva:BifurcatedEmbeddedDerivatives>
    <teva:BifurcatedEmbeddedDerivatives
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      id="hidden78649330"
      unitRef="Unit_USD">0</teva:BifurcatedEmbeddedDerivatives>
    <us-gaap:DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="P01_01_2023To03_31_2023" id="hidden78649497">http://fasb.org/us-gaap/2022#IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</us-gaap:DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P01_01_2023To03_31_2023_UnsecuredSyndicatedRevolvingCrediTfacilityMemberusgaapCreditFacilityAxis"
      id="hidden78649299">2026-04-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2022_EmbeddedDerivativeFinancialInstrumentsMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      id="hidden78648268"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2023_EmbeddedDerivativeFinancialInstrumentsMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      id="hidden78648269"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration contextRef="PAsOn03_31_2023" id="hidden78649508">http://fasb.org/us-gaap/2022#LiabilitiesCurrent</us-gaap:EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="P01_01_2022To12_31_2022" id="hidden78649487">http://fasb.org/us-gaap/2022#OperatingIncomeLoss</us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration contextRef="PAsOn03_31_2023" id="hidden78649490">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration contextRef="PAsOn12_31_2022" id="hidden78649491">http://fasb.org/us-gaap/2022#OtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="PAsOn03_31_2023" id="hidden78649488">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="PAsOn12_31_2022" id="hidden78649489">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2143000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2801000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">88000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">91000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">3435000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3696000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">4118000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3833000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">1253000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1162000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">542000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">549000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">11501000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">12051000000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">1572000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1453000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">450000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">441000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">5751000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">5739000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">420000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">419000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">5964000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">6270000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">17799000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">17633000000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">43456000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">44006000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">1023000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2109000000</us-gaap:DebtCurrent>
    <teva:SalesReservesAndAllowances
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">3309000000</teva:SalesReservesAndAllowances>
    <teva:SalesReservesAndAllowances
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3750000000</teva:SalesReservesAndAllowances>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2381000000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1887000000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">432000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">566000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <teva:AccruedExpenses
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2267000000</teva:AccruedExpenses>
    <teva:AccruedExpenses
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2151000000</teva:AccruedExpenses>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1005000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">10411000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">11469000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">550000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">548000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">3869000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3847000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">19668000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">19103000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">345000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">349000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">24433000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">23846000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn03_31_2023"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">34844000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">35315000000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_ILS_per_Share">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_ILS_per_Share">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">2495000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">2495000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">1226000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">1217000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">27719000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">27688000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-13086000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-12882000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-2701000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-2838000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">106000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="PAsOn03_31_2023"
      decimals="INF"
      unitRef="Unit_shares">106000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">4128000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">4128000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">7860000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">7897000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">751000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">794000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">8612000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">8691000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">43456000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">44006000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">3661000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3661000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2079000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1921000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">1582000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1740000000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">234000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">225000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">546000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">584000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">296000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">296000000</us-gaap:GeneralAndAdministrativeExpense>
    <teva:IntangibleAssetsImpairments
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">178000000</teva:IntangibleAssetsImpairments>
    <teva:IntangibleAssetsImpairments
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">149000000</teva:IntangibleAssetsImpairments>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">96000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">128000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">233000000</teva:LegalSettlementsAndLossContingencies>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1124000000</teva:LegalSettlementsAndLossContingencies>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">52000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-713000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-260000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-258000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-258000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-971000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-19000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">21000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-238000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-952000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-33000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-205000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-955000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_shares">1115000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_shares">1107000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_shares">1115000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_shares">1107000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2023To03_31_2023_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-238000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-952000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">120000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-64000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <teva:UnrealizedGainLossOnDerivativeNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">8000000</teva:UnrealizedGainLossOnDerivativeNetOfTax>
    <teva:UnrealizedGainLossOnDerivativeNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">7000000</teva:UnrealizedGainLossOnDerivativeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-1000000</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">127000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-57000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-111000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-1009000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-42000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-50000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-69000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-959000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1217000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27688000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-12882000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2838000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">7897000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">8691000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-205000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To03_31_2023_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-205000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To03_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-33000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-238000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">136000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2023To03_31_2023_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">136000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2023To03_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-9000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">127000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">9000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">32000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To03_31_2023_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">32000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">32000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1226000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27719000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-13086000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2701000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">7860000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">751000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">8612000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1209000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27561000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-10529000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2683000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">966000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">11244000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-955000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-955000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-952000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-53000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-57000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">7000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">24000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">24000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">24000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1216000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27587000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-11484000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2687000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">9344000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">916000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">10260000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-238000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-952000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">304000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">323000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">189000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">165000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">364000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-559000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <teva:DeferredIncomeTaxesNetAndUncertainTaxPositions
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-106000000</teva:DeferredIncomeTaxesNetAndUncertainTaxPositions>
    <teva:DeferredIncomeTaxesNetAndUncertainTaxPositions
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-175000000</teva:DeferredIncomeTaxesNetAndUncertainTaxPositions>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">32000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">24000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">34000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">30000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <teva:ProfitFromSaleOfLongLivedAssetsAndInvestment
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-4000000</teva:ProfitFromSaleOfLongLivedAssetsAndInvestment>
    <teva:ProfitFromSaleOfLongLivedAssetsAndInvestment
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">23000000</teva:ProfitFromSaleOfLongLivedAssetsAndInvestment>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-145000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-49000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">323000000</teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables>
    <teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">305000000</teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">139000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">157000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">25000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">4000000</teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets>
    <teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">4000000</teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">181000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">161000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">3152000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2451000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-5000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-706000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">12000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-62000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-658000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">52000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2834000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">2198000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2176000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2250000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2143000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2175000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">75000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2176000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2250000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">334000000</teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables>
    <teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">299000000</teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 1 &#x2013; Basis of presentation: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a. Basis of presentation &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the financial statements reflect all normal and recurring adjustments necessary to fairly state the financial position and results of operations of Teva. The information included in this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-end&lt;/div&gt; balance sheet data was derived from the audited consolidated financial statements as of December&#160;31, 2022, but not all disclosures required by generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) are included. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In preparing the Company&#x2019;s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity and disclosure of contingent liabilities and assets at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In preparing the Company&#x2019;s consolidated financial statements, management also considered the economic implications of inflation expectations on its critical and significant accounting estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of IPR&amp;amp;D assets, marketed product rights and goodwill, assessing sales reserves and allowances in the United States, uncertain tax positions, valuation allowances and contingencies. These estimates could &lt;div style="display:inline;"&gt;be&lt;/div&gt; impacted by higher costs and the ability to pass on such higher costs to customers, which is highly uncertain. Government actions taken to address macroeconomic developments, as well as their economic impact on Teva&#x2019;s third-party manufacturers and suppliers, customers and markets, could also impact such estimates and may change in future periods. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2022, Russia launched an invasion of Ukraine. As of the date of this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q,&lt;/div&gt; sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in Teva&#x2019;s International Markets segment results. Teva has no manufacturing or R&amp;amp;D facilities in these markets. During the three months ended March&#160;31, 2023, the impact of this conflict on Teva&#x2019;s results &lt;div style="display:inline;"&gt;of&lt;/div&gt; operation and financial condition was immaterial. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva&#x2019;s results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b. Significant accounting policies &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recently adopted accounting pronouncements &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In September 2022, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022-04&lt;/div&gt; &#x201c;Liabilities &#x2014; Supplier Finance Programs: Disclosure of Supplier Finance Program Obligations (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;405-50)&#x201d;.&lt;/div&gt; This guidance is intended to address requests from stakeholders for information about an entity&#x2019;s use of supplier finance programs and their effect on the entity&#x2019;s working capital, liquidity and cash flows. The guidance is effective for the fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years, except for the amendment on roll-forward information requirement, which is effective for the fiscal years beginning after December&#160;15, 2023. The adoption of this guidance did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2021, the FASB issued ASU 2021-08 &#x201c;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,&#x201d; which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The Company adopted the new accounting standard effective January 1, 2023 and the guidance is applied prospectively to all business combinations with an acquisition date occurring on or after January 2023. The adoption of this guidance did not have a material impact on the Company&#x2019;s consolidated financial statements.&#160;&lt;br/&gt;&lt;/div&gt; &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recently issued accounting pronouncements, not yet adopted &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;None. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; </us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recently adopted accounting pronouncements &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In September 2022, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022-04&lt;/div&gt; &#x201c;Liabilities &#x2014; Supplier Finance Programs: Disclosure of Supplier Finance Program Obligations (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;405-50)&#x201d;.&lt;/div&gt; This guidance is intended to address requests from stakeholders for information about an entity&#x2019;s use of supplier finance programs and their effect on the entity&#x2019;s working capital, liquidity and cash flows. The guidance is effective for the fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years, except for the amendment on roll-forward information requirement, which is effective for the fiscal years beginning after December&#160;15, 2023. The adoption of this guidance did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2021, the FASB issued ASU 2021-08 &#x201c;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,&#x201d; which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The Company adopted the new accounting standard effective January 1, 2023 and the guidance is applied prospectively to all business combinations with an acquisition date occurring on or after January 2023. The adoption of this guidance did not have a material impact on the Company&#x2019;s consolidated financial statements.&#160;&lt;br/&gt;&lt;/div&gt; &lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <teva:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recently issued accounting pronouncements, not yet adopted &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;None. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; </teva:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <teva:CertainTransactionsDisclosureTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 2 &#x2013; Certain transactions: &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company&#x2019;s most significant agreements of this nature are summarized below. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;MODAG &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In October 2021, Teva announced a license agreement with MODAG GmbH (&#x201c;Modag&#x201d;) that will provide Teva an exclusive global license to develop, manufacture and commercialize Modag&#x2019;s lead compound &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(TEV-56286)&lt;/div&gt; and a related compound &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(TEV-56287).&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;TEV-56286&lt;/div&gt; was initially developed for the treatment of Multiple System Atrophy (&#x201c;MSA&#x201d;) and Parkinson&#x2019;s disease, and has the potential to be applied to other treatments for neurodegenerative disorders, such as Alzheimer&#x2019;s disease. A phase 1b clinical trial for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;TEV-56286&lt;/div&gt; was completed and the results are being assessed. In the fourth quarter of 2021, Teva made an upfront payment of $10&#160;million to Modag that was recorded as an R&amp;amp;D expense. Modag may be eligible for future development milestone payments, totaling an aggregate amount of up to $30&#160;million, as well as future commercial milestones and royalties. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Alvotech &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contains biosimilar candidates addressing multiple therapeutic areas, including proposed biosimilars to Humira&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt; &lt;/div&gt;and Stelara&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;. Under the terms of the agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. Teva made an upfront payment in the third quarter of 2020 and additional upfront and milestone payments in the second quarter of 2021, which were recorded as R&amp;amp;D expenses. Teva also made a milestone payment in January 2023, which was recorded as an R&amp;amp;D expense in the fourth quarter of 2022. Additional development and commercial milestone payments of up to approximately $400&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;million, as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilars. Pursuant to a settlement agreement entered into in March 2022, regarding certain IP and trade secrets claims filed by Abbvie against Alvotech in relation to Alvotech&#x2019;s proposed biosimilar to Humira&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; (adalimumab), Alvotech and Teva may sell the proposed biosimilar to Humira&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in the United States beginning on July&#160;1, 2023, provided that U.S. regulatory approval is obtained by that date. Alvotech announced they received complete response letters (&#x201c;CRL&#x201d;) from the FDA with respect to Alvotech&#x2019;s proposed biosimilar to Humira&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in September 2022, December 2022 and April 2023. The CRL from April 2023 stated that the application could not be approved at this time based on deficiencies associated with Alvotech&#x2019;s manufacturing facility. The details following the most recent FDA&#x2019;s inspection and CRL are being further assessed to determine next steps.&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;In January 2023, the FDA accepted for review the Biologics License Application (&#x201c;BLA&#x201d;) for Alvotech&#x2019;s proposed biosimilar to Stelara&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"&gt; &lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Otsuka &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;12, 2017, Teva entered into a license and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. (&#x201c;Otsuka&#x201d;) providing Otsuka with an exclusive license to develop and commercialize AJOVY in Japan. Otsuka paid Teva an upfront payment of $50&#160;million in consideration for the transaction. In the third quarter of 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan and, as a result, paid Teva a milestone payment of $15&#160;million, which was recognized as revenue in the third quarter of 2020. AJOVY was approved in Japan in June 2021 and launched on August&#160;30, 2021. As a result of the launch, Otsuka paid Teva a milestone payment of $35&#160;million, which was recognized as revenue in the third quarter of 2021. Teva may receive additional milestone payments upon achievement of certain revenue targets. Otsuka also pays Teva royalties on AJOVY sales in Japan. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Takeda &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2016, Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. (&#x201c;Takeda&#x201d;), for the research, development, manufacture and commercialization of ATTENUKINE&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;TM&lt;/div&gt; technology. Teva received a $30&#160;million upfront payment and a milestone payment of $20&#160;million in 2017. During the second quarter of 2022, Takeda initiated its phase 2 study of modakafusp alfa (formerly TAK 573 or TEV 48573) and as a result paid Teva a milestone payment of $25&#160;million, which was recognized as revenue in the second quarter of 2022. The license agreement stipulates additional milestone payments to Teva of up to $519&#160;million with respect to this product candidate, as well as future &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;royalties. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;MedinCell &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable (&#x201c;LAI&#x201d;) products. Teva leads the clinical development and regulatory process and is responsible for commercialization of these products. The lead product &lt;div style="display:inline;"&gt;is&lt;/div&gt; risperidone LAI (formerly known as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;TV-46000).&lt;/div&gt; On April&#160;28, 2023, the FDA approved UZEDY&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;TM &lt;/div&gt;(risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults.&#160;UZEDY is expected to be available in the U.S. in the coming weeks. MedinCell may be eligible for future sales-based milestones of up to $105&#160;million in respect of UZEDY. Teva will also pay MedinCell royalties on net sales. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The second selected product candidate is olanzapine LAI &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(TEV-44749)&lt;/div&gt; for the treatment of schizophrenia. In the third quarter of 2022, Teva decided to progress development of the product to phase 3, and as a result a $3&#160;million milestone payment was paid to MedinCell which was recognized as R&amp;amp;D expenses. MedinCell may become eligible for further milestones and royalties on sales of olanzapine LAI &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(TEV-44749).&lt;/div&gt; &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets Held for Sale: &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;General &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Assets held for sale as of March&#160;31, 2023 and December&#160;31, 2022 included certain manufacturing assets that were sold in the second quarter of 2023. The table below summarizes all of Teva&#x2019;s assets included as held for sale as of March&#160;31, 2023 and December&#160;31, 2022: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:75%"/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Inventories&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property, plant and equipment, net and others&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Adjustments of assets held for sale to fair value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total assets of the disposal group classified as held for sale in the consolidated balance sheets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:CertainTransactionsDisclosureTextBlock>
    <teva:MilestonePayment
      contextRef="P10_01_2021To12_31_2021_ModagMemberusgaapBusinessAcquisitionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</teva:MilestonePayment>
    <teva:LicenseAgreementPotentialAggregateMilestonePaymentsAmount
      contextRef="P10_01_2021To10_31_2021_ModagMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</teva:LicenseAgreementPotentialAggregateMilestonePaymentsAmount>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P01_01_2023To03_31_2023_AlvotechMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">400000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:UpfrontPayments
      contextRef="P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">50000000</teva:UpfrontPayments>
    <teva:MilestonePayment
      contextRef="P07_01_2020To09_30_2020_OtsukaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">15000000</teva:MilestonePayment>
    <teva:MilestonePayment
      contextRef="P07_01_2021To09_30_2021_OtsukaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">35000000</teva:MilestonePayment>
    <teva:UpfrontPayments
      contextRef="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</teva:UpfrontPayments>
    <teva:MilestonePayment
      contextRef="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</teva:MilestonePayment>
    <teva:MilestonePayment
      contextRef="P04_01_2022To06_30_2022_TakedaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">25000000</teva:MilestonePayment>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P12_01_2016To12_31_2016_TakedaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">519000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P08_01_2021To08_31_2021_MedincellMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">105000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:MilestonePayment
      contextRef="P07_01_2022To09_30_2022_MedincellMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</teva:MilestonePayment>
    <teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock contextRef="P01_01_2023To03_31_2023">The table below summarizes all of Teva&#x2019;s assets included as held for sale as of March&#160;31, 2023 and December&#160;31, 2022: &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:75%"/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Inventories&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property, plant and equipment, net and others&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Adjustments of assets held for sale to fair value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total assets of the disposal group classified as held for sale in the consolidated balance sheets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">18000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">18000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-10000000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-10000000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 3 &#x2013; Revenue from contracts with customers: &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Disaggregation of revenue &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table disaggregates Teva&#x2019;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:71%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended March&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt; America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt; activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sale of goods&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,319&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Licensing arrangements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;434&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,766&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;219&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,661&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt; America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt; activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sale of goods&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,134&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;445&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Licensing arrangements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;342&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;358&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,737&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,156&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;275&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,661&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Variable consideration &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Variable consideration mainly includes sales reserves and allowances (&#x201c;SR&amp;amp;A&#x201d;), comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against accounts receivables. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;SR&amp;amp;A to U.S. customers comprised approximately 68% of the Company&#x2019;s total SR&amp;amp;A as of March&#160;31, 2023, with &lt;div style="display:inline;"&gt;the&lt;/div&gt; remaining balance primarily related to customers in Canada and Germany. The changes in SR&amp;amp;A for third-party sales for the three months ended March&#160;31, 2023 and 2022 were as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:40%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sales Reserves and Allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reserves&lt;br/&gt; included in&lt;br/&gt; Accounts&lt;br/&gt; Receivable,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rebates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medicaid and&lt;br/&gt; other&lt;br/&gt; governmental&lt;br/&gt; allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Returns&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total reserves&lt;br/&gt; included in&lt;br/&gt; Sales Reserves&lt;br/&gt; and&#160;Allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="30" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at January&#160;1, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;663&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;455&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,817&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions related to sales made in current year period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,003&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;142&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,855&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,098&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions related to sales made in prior periods&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Credits and payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(289&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,973&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,505&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top;text-indent: 0px;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Translation differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,452&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;482&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;866&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;440&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,309&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,372&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:37%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sales Reserves and Allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reserves&lt;br/&gt; included in&lt;br/&gt; Accounts&lt;br/&gt; Receivable,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rebates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medicaid and&lt;br/&gt; other&lt;br/&gt; governmental&lt;br/&gt; allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Returns&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total reserves&lt;br/&gt; included in&lt;br/&gt; Sales Reserves&lt;br/&gt; and&#160;Allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="30" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at January&#160;1, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;854&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,085&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;535&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,241&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,309&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions related to sales made in current year period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;928&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,814&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,170&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions related to sales made in prior periods&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Credits and payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,037&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(270&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,430&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Translation differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at March&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;807&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;469&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,807&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,869&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5 million.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-indent: 0px; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Pledged accounts receivables &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accounts receivables, net of allowance for credit losses, include $434&#160;million and $436&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million as of March 31, 2023 and December 31, 2022, respectively, which are pledged to PNC Bank, National Association in connection with the U.S. securitization program entered into in November 2022. For further information on our securitization facilities, see note 10f to the consolidated financial statements for the year ended December 31, 2022, included in Teva&#x2019;s Annual Report on Form 10-K.&#160;&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;/div&gt; </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table disaggregates Teva&#x2019;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:71%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended March&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt; America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt; activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sale of goods&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,319&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Licensing arrangements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;434&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,766&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;219&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,661&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt; America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;br/&gt; activities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sale of goods&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,134&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;445&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Licensing arrangements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Distribution&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;342&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;358&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,737&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,156&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;275&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,661&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1319000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">3090000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">424000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_DistributionServiceMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">-6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">87000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">95000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1766000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">492000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">3661000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1377000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">445000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">180000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">3136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">342000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_DistributionServiceMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">358000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">-2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">95000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1737000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">492000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3661000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <teva:SalesReservesAndAllowancesToCustomersPercentage
      contextRef="P01_01_2023To03_31_2023_USsrtStatementGeographicalAxis"
      decimals="2"
      unitRef="Unit_pure">0.68</teva:SalesReservesAndAllowancesToCustomersPercentage>
    <teva:SalesReservesAndAllowancesCurrentTableTextBlock contextRef="P01_01_2023To03_31_2023">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:40%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sales Reserves and Allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reserves&lt;br/&gt; included in&lt;br/&gt; Accounts&lt;br/&gt; Receivable,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rebates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medicaid and&lt;br/&gt; other&lt;br/&gt; governmental&lt;br/&gt; allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Returns&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total reserves&lt;br/&gt; included in&lt;br/&gt; Sales Reserves&lt;br/&gt; and&#160;Allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="30" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at January&#160;1, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;663&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;455&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,817&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions related to sales made in current year period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,003&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;142&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,855&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,098&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions related to sales made in prior periods&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Credits and payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(289&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,973&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,505&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top;text-indent: 0px;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Translation differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at March&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,452&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;482&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;866&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;440&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,309&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,372&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:37%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="30" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sales Reserves and Allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reserves&lt;br/&gt; included in&lt;br/&gt; Accounts&lt;br/&gt; Receivable,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rebates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medicaid and&lt;br/&gt; other&lt;br/&gt; governmental&lt;br/&gt; allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Returns&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total reserves&lt;br/&gt; included in&lt;br/&gt; Sales Reserves&lt;br/&gt; and&#160;Allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="30" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at January&#160;1, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;854&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,085&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;535&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,241&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,309&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions related to sales made in current year period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;928&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,814&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,088&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,170&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions related to sales made in prior periods&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Credits and payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,037&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(270&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,430&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Translation differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at March&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;807&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;469&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,807&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,869&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5 million.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-indent: 0px; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; </teva:SalesReservesAndAllowancesCurrentTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">67000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1575000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">663000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">991000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">455000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">66000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3750000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3817000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2023To03_31_2023_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">80000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2023To03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1003000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2023To03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">142000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2023To03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1855000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2023To03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">73000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2023To03_31_2023_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">25000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2023To03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3098000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">3178000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2023To03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-7000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2023To03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-36000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2023To03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-9000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2023To03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">6000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2023To03_31_2023_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2023To03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-47000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-47000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2023To03_31_2023_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">84000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2023To03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1127000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2023To03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">289000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2023To03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1973000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2023To03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">95000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2023To03_31_2023_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">21000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2023To03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3505000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">3589000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2023To03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">8000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2023To03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2023To03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2023To03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2023To03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">13000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">13000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2023_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">63000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2023_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1452000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2023_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">482000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2023_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">866000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2023_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">440000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2023_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">69000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2023_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3309000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">3372000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">68000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1655000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">854000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1085000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">535000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">112000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">4241000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">4309000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">82000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">928000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">198000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1814000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">58000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">90000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3088000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3170000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-90000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">26000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-8000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-14000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-87000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-87000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">88000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1037000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">270000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1940000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">110000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">73000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3430000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3518000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-3000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-5000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-5000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2022_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">62000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2022_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1453000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2022_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">807000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2022_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">951000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2022_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">469000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2022_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">127000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2022_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3807000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3869000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:AccountsReceivableFromSecuritization
      contextRef="PAsOn03_31_2023_AccountsReceivableSecuritizationFacilityMemberusgaapDerivativeInstrumentRiskAxis_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022MemberusgaapPledgingPurposeAxis_PncBankMemberTEVAFactoringInstitutionAxis"
      decimals="-6"
      unitRef="Unit_USD">434000000</us-gaap:AccountsReceivableFromSecuritization>
    <us-gaap:AccountsReceivableFromSecuritization
      contextRef="PAsOn12_31_2022_AccountsReceivableSecuritizationFacilityMemberusgaapDerivativeInstrumentRiskAxis_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022MemberusgaapPledgingPurposeAxis_PncBankMemberTEVAFactoringInstitutionAxis"
      decimals="-6"
      unitRef="Unit_USD">436000000</us-gaap:AccountsReceivableFromSecuritization>
    <us-gaap:InventoryDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 4 &#x2013; Inventories: &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Inventories, net of reserves, consisted of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finished products&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Raw and packaging materials&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,205&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,059&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Products in process&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;620&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;555&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Materials in transit and payments on account&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;183&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,118&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,833&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Inventories, net of reserves, consisted of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finished products&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Raw and packaging materials&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,205&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,059&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Products in process&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;620&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;555&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Materials in transit and payments on account&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;183&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,118&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,833&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2110000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1987000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">1205000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1059000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">620000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">555000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:OtherInventoryInTransit
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">183000000</us-gaap:OtherInventoryInTransit>
    <us-gaap:OtherInventoryInTransit
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">232000000</us-gaap:OtherInventoryInTransit>
    <us-gaap:InventoryNet
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">4118000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3833000000</us-gaap:InventoryNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 5 &#x2013; Identifiable intangible assets: &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Identifiable intangible assets consisted of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:48%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;carrying&#160;amount&#160;net&#160;of&lt;br/&gt; impairment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Product rights&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,094&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,067&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,934&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Trade names&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;583&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;577&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;241&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;342&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;In process research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;462&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;487&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;462&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;487&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,139&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,861&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,964&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,270&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product rights and trade names &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products in various therapeutic categories from various acquisitions with a weighted average life period of approximately 9 years. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Amortization of intangible assets was $165&#160;million and $200&#160;million in the three months ended March&#160;31, 2023 and 2022, respectively. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;IPR&amp;amp;D &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva&#x2019;s IPR&amp;amp;D are assets that have not yet been approved in its major markets. IPR&amp;amp;D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Intangible assets impairments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Impairments of long-lived intangible assets for the three months ended March&#160;31, 2023 and 2022 were $178&#160;million and $149&#160;million, respectively. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;Impairments in the first quarter of 2023 consisted of: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Identifiable product rights of $159&#160;million due to: (i) $112&#160;million in Japan, mainly related to regulatory pricing reductions; and (ii) $47&#160;million related to updated market assumptions regarding price and volume of products; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;IPR&amp;amp;D assets of $19&#160;million, related to generic pipeline products resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape and launch date). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Impairments in the first quarter of 2022 consisted primarily of identifiable product rights of $129&#160;million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value measurement of the impaired intangible assets in the first quarter of 2023 is based on significant unobservable inputs in the market and thus represents a Level&#160;3 measurement within the fair value &lt;div style="display:inline;"&gt;h&lt;/div&gt;ierarchy. The discount rate applied ranged from 8.5% to 10%. A probability of success factor ranging from 20% to 90% was used in the fair value calculation to reflect inherent regulatory and commercial risk of IPR&amp;amp;D. &lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Identifiable intangible assets consisted of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:48%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;carrying&#160;amount&#160;net&#160;of&lt;br/&gt; impairment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Product rights&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,094&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,067&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,934&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Trade names&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;583&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;577&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;241&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;342&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;In process research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;462&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;487&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;462&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;487&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,139&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,861&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,964&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,270&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">18094000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">18067000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">12934000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">12630000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">5160000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2022_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">5437000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn03_31_2023_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">583000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">577000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn03_31_2023_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">241000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">231000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2023_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">342000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2022_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">346000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">462000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">487000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">462000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2022_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">487000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">19139000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">19131000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">13175000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">12861000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">5964000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">6270000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2022To03_31_2022">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">165000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">200000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">178000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">149000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2023To03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">159000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2023To03_31_2023_JPsrtStatementGeographicalAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_UpdatedMarketAssumptionsMemberTEVAEventBasisAxis"
      decimals="-6"
      unitRef="Unit_USD">112000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2023To03_31_2023_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_RegulatoryPriceAndVolumeOfProductsMemberTEVAEventBasisAxis"
      decimals="-6"
      unitRef="Unit_USD">47000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2023To03_31_2023_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMemberTEVAEventBasisAxis_GenericPipelineProductsMembersrtProductOrServiceAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2023To03_31_2023_LenalidomideProductMembersrtProductOrServiceAxis_PriceAndVolumeOfProductsMemberTEVAEventBasisAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">129000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MinimumMembersrtRangeAxis"
      decimals="1"
      unitRef="Unit_pure">8.5</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis"
      decimals="0"
      unitRef="Unit_pure">10</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="0"
      unitRef="Unit_pure">20</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn03_31_2023_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">90</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 6 &#x2013; Goodwill: &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Changes in the carrying amount of goodwill for the period ended March&#160;31, 2023 were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt; America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Teva&#x2019;s&lt;br/&gt; API&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medis&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of December&#160;31, 2022 (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,302&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,339&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;249&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,633&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes during the period:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Translation differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of March&#160;31, 2023 (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,305&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Accumulated goodwill impairment as of March&#160;31, 2023 and December&#160;31, 2022 was approximately $27.6&#160;billion. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva operates its business through three reporting segments: North America, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Teva&#x2019;s production and sale of APIs to third parties (&#x201c;Teva API&#x201d;) and an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licensing&lt;/div&gt; platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. Teva&#x2019;s API and Medis reporting units are included under &#x201c;Other&#x201d; in the above table. See note 15 for additional segment information. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva begins with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva&#x2019;s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (&#x201c;WACC&#x201d;), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva&#x2019;s assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;First Quarter Deve&lt;div style="display:inline;"&gt;lo&lt;/div&gt;pments &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;During the first quarter of 2023, management evaluated whether there were any developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount as of March&#160;31, 2023. Management concluded that no triggering event had occurred and, therefore, no quantitative assessment was performed. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Following the goodwill impairment charges recorded in the fourth quarter of 2022 in relation to Teva&#x2019;s International Markets and Teva&#x2019;s API reporting units, the carrying values of those reporting units equaled their fair value as of December&#160;31, 2022. Additionally, as part of the quantitative analysis Teva conducted as part of its annual goodwill impairment test in the second quarter of 2022, it concluded that the estimated fair value of Teva&#x2019;s Europe reporting unit exceeded its estimated carrying amount by 9%. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to Teva&#x2019;s International Markets, Teva&#x2019;s Europe or Teva&#x2019;s API reporting units in the future. &lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Changes in the carrying amount of goodwill for the period ended March&#160;31, 2023 were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt; America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Teva&#x2019;s&lt;br/&gt; API&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medis&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of December&#160;31, 2022 (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,302&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,339&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;249&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,633&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes during the period:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Translation differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of March&#160;31, 2023 (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,451&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,305&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Accumulated goodwill impairment as of March&#160;31, 2023 and December&#160;31, 2022 was approximately $27.6&#160;billion. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2022_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_78648314"
      unitRef="Unit_USD">6450000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2022_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_78648315"
      unitRef="Unit_USD">8302000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2022_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_78648316"
      unitRef="Unit_USD">1339000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2022_OtherCountriesMembersrtStatementGeographicalAxis_TevasApiReportingUnitMemberusgaapReportingUnitAxis"
      decimals="-6"
      id="Fact_78648317"
      unitRef="Unit_USD">1293000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2022_MedisReportingUnitMemberusgaapReportingUnitAxis_OtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_78648319"
      unitRef="Unit_USD">249000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      id="Fact_78648318"
      unitRef="Unit_USD">17633000000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2023To03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2023To03_31_2023_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">-82000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">-61000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2023To03_31_2023_OtherCountriesMembersrtStatementGeographicalAxis_TevasApiReportingUnitMemberusgaapReportingUnitAxis"
      decimals="-6"
      unitRef="Unit_USD">-12000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2023To03_31_2023_MedisReportingUnitMemberusgaapReportingUnitAxis_OtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">-10000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-166000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="PAsOn03_31_2023_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_78648326"
      unitRef="Unit_USD">6451000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn03_31_2023_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_78648327"
      unitRef="Unit_USD">8384000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn03_31_2023_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_78648328"
      unitRef="Unit_USD">1400000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn03_31_2023_OtherCountriesMembersrtStatementGeographicalAxis_TevasApiReportingUnitMemberusgaapReportingUnitAxis"
      decimals="-6"
      id="Fact_78648329"
      unitRef="Unit_USD">1305000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn03_31_2023_MedisReportingUnitMemberusgaapReportingUnitAxis_OtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_78648331"
      unitRef="Unit_USD">259000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      id="Fact_78648330"
      unitRef="Unit_USD">17799000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="PAsOn03_31_2023"
      decimals="-8"
      unitRef="Unit_USD">27600000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="PAsOn12_31_2022"
      decimals="-8"
      unitRef="Unit_USD">27600000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="PAsOn06_30_2022_EuropeReportingUnitMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.09</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 7 &#x2013; Debt obligations: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Short-term debt: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:58%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&#160;rate&#160;as&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible senior debentures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2026&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current maturities of long-term liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,086&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total short-term debt&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,109&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible senior debentures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The principal amount of Teva&#x2019;s 0.25% convertible senior debentures due 2026 was $23&#160;million as of March&#160;31, 2023 and December&#160;31, 2022. These convertible senior debentures include a &#x201c;net share settlement&#x201d; feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the &#x201c;net share settlement&#x201d; feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under short-term debt. &lt;/div&gt; &lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Long-term debt: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&#160;rate&#160;as&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes EUR 1,500&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;683&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;670&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes EUR 1,500&#160;million (6)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2030&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,606&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes EUR 1,300&#160;million (9)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;633&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes EUR 1,100&#160;million (7)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,177&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes EUR 1,000&#160;million (5)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,070&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes EUR 900&#160;million (5)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;541&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;963&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes EUR 800&#160;million (1)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2029&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes EUR 750&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;814&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes EUR 700&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;748&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes EUR 500&#160;million (2)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;545&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 3,500&#160;million (5)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2026&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,374&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 3,000&#160;million (5)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 2,000&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2046&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 1,250&#160;million (5)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;957&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 1,250&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 1,000&#160;million (5)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;427&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes USD 1,000&#160;million (7)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes USD 1,000&#160;million (6)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2029&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 789&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2036&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;783&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;783&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes USD 600&#160;million (3)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2029&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes USD 500&#160;million (4)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes CHF 350&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;382&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td colspan="8" style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total senior notes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,761&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,266&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other long-term debt&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less current maturities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,086&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less debt issuance costs (8)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total senior notes and loans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,668&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 800&#160;million euro bearing 7.38% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.100%-0.300%&lt;/div&gt; per annum, from and including September&#160;15, 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 500&#160;million euro bearing 7.88% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.100%-0.300%&lt;/div&gt; per annum, from and including September&#160;15, 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(3)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $600&#160;million bearing 7.88% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.100%-0.300%&lt;/div&gt; per annum, from and including September&#160;15, 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(4)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $500&#160;million bearing 8.13% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.100%-0.300%&lt;/div&gt; per annum, from and including September&#160;15, 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(5)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;In March 2023, Teva consummated a cash tender offer and extinguished $631&#160;million aggregate principal amount of its 1,000&#160;million euro 6% senior notes due in 2025; $432&#160;million aggregate principal amount of its 900&#160;million euro 4.5% senior notes due in 2025; $574&#160;million aggregate principal amount of its $1,000&#160;million 7.13% senior notes due in 2025; $454&#160;million aggregate principal amount of its $3,000&#160;million 2.8% senior notes due in 2023; $293&#160;million aggregate principal amount of its $1,250&#160;million 6% senior notes due in 2024 and $122&#160;million aggregate principal amount of its $3,500&#160;million 3.15% senior notes due in 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(6)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.125%-0.375%&lt;/div&gt; per annum, from and including May 9, 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(7)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;If Teva fails to achieve certain sustainability performance targets, a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; premium payment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.15%-0.45%&lt;/div&gt; out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(8)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Debt issuance costs as of March&#160;31, 2023 include $26&#160;million in connection with the issuance of the sustainability-linked senior notes in March 2023, partially offset by $6&#160;million acceleration of issuance costs related to the cash tender offer. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(9)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;In March 2023, Teva repaid $646&#160;million of its 1.25% senior notes at maturity. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(*)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Interest rate adjustments and a potential &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Long-term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any. The long-term debt outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva&#x2019;s debt as of March&#160;31, 2023 was effectively denominated in the following currencies: 62% in U.S. dollars, 36% in euro and 2% in Swiss franc. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva&#x2019;s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily its $1.8&#160;billion unsecured syndicated sustainability-linked revolving credit facility entered into in April 2022, which was amended in February 2023 (&#x201c;RCF&#x201d;). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The RCF has a maturity date of &lt;span style="-sec-ix-hidden:hidden78649299"&gt;April 2026&lt;/span&gt;, with two &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; extension options. The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including a maximum leverage ratio, which becomes more restrictive over time. In addition, the RCF is linked to two sustainability performance targets: (i)&#160;the Company&#x2019;s S&amp;amp;P ESG Score and (ii)&#160;number of new regulatory submissions in low and middle-income countries. The RCF margin may increase or decrease depending on the Company&#x2019;s sustainability performance. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;6, 2023, the terms of the RCF were amended to update the Company&#x2019;s maximum leverage ratio under the RCF for certain periods. Under the terms of the RCF, as amended, the Company&#x2019;s leverage ratio shall not exceed 4.25x in the first, second and third quarters of 2023, 4.00x in the fourth quarter of 2023, 4.00x in the first, second and third quarters of 2024, and 3.50x in the fourth quarter of 2024 and onwards. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div/&gt;&lt;div&gt; &lt;div style="background-color:white;display: inline;"&gt;  &lt;/div&gt; &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The RCF can be used for general corporate purposes, including repaying existing debt. As of March 31, 2023 and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Under specified circumstances, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compliance&lt;/div&gt; with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF. Additionally, violations of the covenants, under the above-mentioned circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes and sustainability-linked senior notes is outstanding, could lead to an event of default under the Company&#x2019;s senior notes and sustainability-linked senior notes due to cross-acceleration provisions. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that the financial statements are issued. &lt;/div&gt; </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="P01_01_2023To03_31_2023">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Short-term debt: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:58%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&#160;rate&#160;as&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible senior debentures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2026&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current maturities of long-term liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,086&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total short-term debt&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,109&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0025</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2023To03_31_2023_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">2026</teva:DebtInstrumentMaturityYear>
    <us-gaap:ShortTermBorrowings
      contextRef="PAsOn03_31_2023_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="PAsOn12_31_2022_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:ShortTermBorrowings>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2086000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">1023000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2109000000</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0025</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn03_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:DebtInstrumentCarryingAmount>
    <teva:LongTermDebtExcludingConvertibleDebtTableTextBlock contextRef="P01_01_2023To03_31_2023">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Long-term debt: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&#160;rate&#160;as&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes EUR 1,500&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;683&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;670&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes EUR 1,500&#160;million (6)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2030&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,606&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes EUR 1,300&#160;million (9)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;633&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes EUR 1,100&#160;million (7)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,177&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes EUR 1,000&#160;million (5)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;449&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,070&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes EUR 900&#160;million (5)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;541&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;963&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes EUR 800&#160;million (1)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2029&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes EUR 750&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;814&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes EUR 700&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;748&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes EUR 500&#160;million (2)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;545&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 3,500&#160;million (5)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2026&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,374&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 3,000&#160;million (5)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 2,000&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2046&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 1,250&#160;million (5)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;957&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 1,250&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 1,000&#160;million (5)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;427&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes USD 1,000&#160;million (7)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes USD 1,000&#160;million (6)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2029&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes USD 789&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2036&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;783&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;783&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes USD 600&#160;million (3)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2029&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sustainability-linked senior notes USD 500&#160;million (4)(*)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Senior notes CHF 350&#160;million&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;382&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td colspan="8" style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total senior notes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,761&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,266&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other long-term debt&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less current maturities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,086&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less debt issuance costs (8)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total senior notes and loans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,668&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;    &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 800&#160;million euro bearing 7.38% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.100%-0.300%&lt;/div&gt; per annum, from and including September&#160;15, 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 500&#160;million euro bearing 7.88% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.100%-0.300%&lt;/div&gt; per annum, from and including September&#160;15, 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(3)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $600&#160;million bearing 7.88% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.100%-0.300%&lt;/div&gt; per annum, from and including September&#160;15, 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(4)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $500&#160;million bearing 8.13% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.100%-0.300%&lt;/div&gt; per annum, from and including September&#160;15, 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(5)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;In March 2023, Teva consummated a cash tender offer and extinguished $631&#160;million aggregate principal amount of its 1,000&#160;million euro 6% senior notes due in 2025; $432&#160;million aggregate principal amount of its 900&#160;million euro 4.5% senior notes due in 2025; $574&#160;million aggregate principal amount of its $1,000&#160;million 7.13% senior notes due in 2025; $454&#160;million aggregate principal amount of its $3,000&#160;million 2.8% senior notes due in 2023; $293&#160;million aggregate principal amount of its $1,250&#160;million 6% senior notes due in 2024 and $122&#160;million aggregate principal amount of its $3,500&#160;million 3.15% senior notes due in 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(6)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.125%-0.375%&lt;/div&gt; per annum, from and including May 9, 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(7)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;If Teva fails to achieve certain sustainability performance targets, a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; premium payment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.15%-0.45%&lt;/div&gt; out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(8)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Debt issuance costs as of March&#160;31, 2023 include $26&#160;million in connection with the issuance of the sustainability-linked senior notes in March 2023, partially offset by $6&#160;million acceleration of issuance costs related to the cash tender offer. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(9)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;In March 2023, Teva repaid $646&#160;million of its 1.25% senior notes at maturity. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(*)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Interest rate adjustments and a potential &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:LongTermDebtExcludingConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0113</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">2024</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">683000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">670000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648578"
      unitRef="Unit_pure">0.0438</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis"
      id="Fact_78648654">2030</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648791"
      unitRef="Unit_USD">1635000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2030MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648792"
      unitRef="Unit_USD">1606000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648579"
      unitRef="Unit_pure">0.0125</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis"
      id="Fact_78648674">2023</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648793"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648794"
      unitRef="Unit_USD">633000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648580"
      unitRef="Unit_pure">0.0375</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      id="Fact_78648673">2027</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648795"
      unitRef="Unit_USD">1199000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648796"
      unitRef="Unit_USD">1177000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648581"
      unitRef="Unit_pure">0.06</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      id="Fact_78648672">2025</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648797"
      unitRef="Unit_USD">449000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648798"
      unitRef="Unit_USD">1070000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648582"
      unitRef="Unit_pure">0.045</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      id="Fact_78648671">2025</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648799"
      unitRef="Unit_USD">541000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648800"
      unitRef="Unit_USD">963000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">800000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648583"
      unitRef="Unit_pure">0.0738</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis"
      id="Fact_78648670">2029</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648801"
      unitRef="Unit_USD">872000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648802"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0163</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">2028</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">814000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">800000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0188</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis">2027</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">762000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">748000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648586"
      unitRef="Unit_pure">0.0788</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis"
      id="Fact_78648667">2031</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648807"
      unitRef="Unit_USD">545000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648808"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">3500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648587"
      unitRef="Unit_pure">0.0315</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      id="Fact_78648666">2026</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648809"
      unitRef="Unit_USD">3374000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648810"
      unitRef="Unit_USD">3496000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648588"
      unitRef="Unit_pure">0.028</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      id="Fact_78648665">2023</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648811"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648812"
      unitRef="Unit_USD">1453000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.041</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">2046</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1986000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1986000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648590"
      unitRef="Unit_pure">0.06</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis"
      id="Fact_78648663">2024</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648815"
      unitRef="Unit_USD">957000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648816"
      unitRef="Unit_USD">1250000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0675</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">2028</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648592"
      unitRef="Unit_pure">0.0713</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      id="Fact_78648661">2025</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648819"
      unitRef="Unit_USD">427000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648820"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648593"
      unitRef="Unit_pure">0.0475</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis"
      id="Fact_78648660">2027</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648821"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2027TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648822"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648594"
      unitRef="Unit_pure">0.0513</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis"
      id="Fact_78648659">2029</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648823"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SustainabilityLinkedSeniorNotesDue2029MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648824"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">789000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0615</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">2036</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">783000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">783000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648596"
      unitRef="Unit_pure">0.0788</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis"
      id="Fact_78648657">2029</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648827"
      unitRef="Unit_USD">600000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648828"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_78648597"
      unitRef="Unit_pure">0.0813</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis"
      id="Fact_78648656">2031</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648829"
      unitRef="Unit_USD">500000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_78648830"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_CHF">350000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.01</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">2025</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">384000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">382000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">20761000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">21266000000</us-gaap:SeniorNotes>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn03_31_2023_OtherDebentures2026MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn12_31_2022_OtherDebentures2026MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2086000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      id="Fact_78648843"
      unitRef="Unit_USD">94000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      id="Fact_78648844"
      unitRef="Unit_USD">78000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">19668000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">19103000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_EUR">800000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0738</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <teva:DebtInstrumentMonthOfMaturity contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis">2029-09</teva:DebtInstrumentMonthOfMaturity>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis"
      decimals="5"
      unitRef="Unit_pure">0.001</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMemberusgaapDebtInstrumentAxis"
      decimals="5"
      unitRef="Unit_pure">0.003</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_EUR">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0788</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <teva:DebtInstrumentMonthOfMaturity contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis">2031-09</teva:DebtInstrumentMonthOfMaturity>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis"
      decimals="5"
      unitRef="Unit_pure">0.001</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMemberusgaapDebtInstrumentAxis"
      decimals="5"
      unitRef="Unit_pure">0.003</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_USD">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0788</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <teva:DebtInstrumentMonthOfMaturity contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis">2029-09</teva:DebtInstrumentMonthOfMaturity>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis"
      decimals="5"
      unitRef="Unit_pure">0.001</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMemberusgaapDebtInstrumentAxis"
      decimals="5"
      unitRef="Unit_pure">0.003</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_USD">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="PAsOn03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0813</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <teva:DebtInstrumentMonthOfMaturity contextRef="P01_01_2023To03_31_2023_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis">2031-09</teva:DebtInstrumentMonthOfMaturity>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MinimumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis"
      decimals="5"
      unitRef="Unit_pure">0.001</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_FromSeptemberFifteenthTwoThousandAndTwentySixMemberTEVAPeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis_MaximumMembersrtRangeAxis_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMemberusgaapDebtInstrumentAxis"
      decimals="5"
      unitRef="Unit_pure">0.003</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">631000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">432000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">574000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">454000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">293000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="P01_01_2023To03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">122000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2023_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">3500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MinimumMembersrtRangeAxis"
      decimals="5"
      unitRef="Unit_pure">0.00125</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_InterestRateIncreaseMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis"
      decimals="5"
      unitRef="Unit_pure">0.00375</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P01_01_2023To03_31_2023_InterestRateIncreaseMemberusgaapDebtInstrumentAxis">2026-05-09</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_MinimumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0015</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_MaximumMembersrtRangeAxis_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0045</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P01_01_2023To03_31_2023_OneTimePremiumPaymentMemberusgaapDebtInstrumentAxis">2026-05-09</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="PAsOn03_31_2023_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">26000000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:AccumulatedAmortizationDeferredFinanceCosts
      contextRef="PAsOn03_31_2023_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
    <teva:SeniorNotesRepaidAmount
      contextRef="PAsOn03_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">646000000</teva:SeniorNotesRepaidAmount>
    <teva:SeniorNotesMaturityPercentage
      contextRef="PAsOn03_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0125</teva:SeniorNotesMaturityPercentage>
    <teva:LongTermDebtCurrencyPortionUSD
      contextRef="PAsOn03_31_2023"
      decimals="2"
      unitRef="Unit_pure">0.62</teva:LongTermDebtCurrencyPortionUSD>
    <teva:LongTermDebtCurrencyPortionEUR
      contextRef="PAsOn03_31_2023"
      decimals="2"
      unitRef="Unit_pure">0.36</teva:LongTermDebtCurrencyPortionEUR>
    <teva:LongTermDebtCurrencyPortionCHF
      contextRef="PAsOn03_31_2023"
      decimals="2"
      unitRef="Unit_pure">0.02</teva:LongTermDebtCurrencyPortionCHF>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-8"
      unitRef="Unit_USD">1800000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <teva:LineOfCreditExtensionPeriod contextRef="P01_01_2023To03_31_2023_UnsecuredSyndicatedRevolvingCrediTfacilityMemberusgaapCreditFacilityAxis">one-year</teva:LineOfCreditExtensionPeriod>
    <teva:LeverageRatio contextRef="P01_01_2023To03_31_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">4.25</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P04_01_2023To06_30_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.25</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P07_01_2023To09_30_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.25</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P10_01_2023To12_31_2023_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.00</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P01_01_2024To03_31_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.00</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P04_01_2024To06_30_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.00</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P07_01_2024To09_30_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">4.00</teva:LeverageRatio>
    <teva:LeverageRatio contextRef="P10_01_2024To12_31_2024_AmendedRevolvingCreditFacilityMemberusgaapDebtInstrumentAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">3.50</teva:LeverageRatio>
    <us-gaap:DebtInstrumentCovenantDescription contextRef="P01_01_2023To03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">The RCF can be used for general corporate purposes, including repaying existing debt. As of March 31, 2023 and as of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued.</us-gaap:DebtInstrumentCovenantDescription>
    <us-gaap:LineOfCredit
      contextRef="PAsOn03_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:LineOfCredit>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 8 &#x2013; Derivative instruments and hedging activities: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign exchange risk management:&lt;/div&gt;&lt;/div&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the first &lt;div style="display:inline;"&gt;quarter&lt;/div&gt; of 2023, approximately 50% of Teva&#x2019;s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency risks. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company enters into forward exchange contracts and purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce its exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty, new Israeli shekel, Indian rupee and other currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (&#x201c;net investment hedge&#x201d;) and has in the past entered into cross-currency swaps and forward-contracts in order to hedge such an exposure. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest risk management: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company raises capital through various debt instruments, including senior notes, sustainability-linked senior notes, bank loans, convertible debentures and syndicated revolving credit facility that bear a fixed or variable interest rate. In some cases, the Company has swapped from a fixed to a variable interest rate (&#x201c;fair value hedge&#x201d;) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (&#x201c;cash flow hedge&#x201d;), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;c.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Bifurcated embedded derivatives: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon the issuance of its sustainability-linked senior notes, Teva recognized embedded derivatives related to interest rate adjustments and a potential &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; premium payment upon failure to achieve certain sustainability performance targets, such as access to medicines in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-to-middle-income&lt;/div&gt;&lt;/div&gt; countries and reduction of absolute greenhouse gas emissions, which were bifurcated and are accounted for separately as derivative financial instruments. As of March&#160;31, 2023, the fair value of these derivative instruments is negligible. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;d.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative instruments outstanding: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cross-currency swap - cash flow hedge (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the classification and fair values &lt;div style="display:inline;"&gt;of&lt;/div&gt; derivative instruments: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:59%"/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Designated as hedging&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Not designated as hedging&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Asset derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other current assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Option and forward contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Cross-currency swap-cash flow hedge (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liability derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other current liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Option and forward contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5 million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;   &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;;display:inline;"&gt;The table below provides information regarding the location and amount of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt;&lt;div style="font-size: 10pt;;display:inline;"&gt; (gains) losses from derivatives designated in cash flow hedging relationships:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial expenses, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&#160;comprehensive&#160;income&#160;(loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Line items in which effects of hedges are recorded&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cross-currency swaps - cash flow hedge (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The table below provides information regarding the location and amount of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; (gains) losses from derivatives not designated as hedging instruments: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:67%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial expenses, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net revenues&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Line items in which effects of hedges are recorded&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,661&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,661&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Option and forward contracts (2)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Option and forward contracts economic hedge (3)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;On March&#160;31, 2023, Teva entered into a cross currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(3)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty and several other currencies to protect its projected operating results for 2023. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first quarter of 2023, the negative impact from these derivatives recognized under revenues was $6&#160;million. In the first quarter of 2022, the positive impact from these derivatives recognized under &lt;span style="-sec-ix-hidden:hidden78649497"&gt;revenues&lt;/span&gt; was $19&#160;million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. Cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 18pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;e.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortizations due to terminated derivative instruments: &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Forward-starting interest rate swaps and treasury lock agreements &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In 2015, Teva entered into forward-starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward-starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. Termination of these transactions resulted in a loss &lt;span style="-sec-ix-hidden:hidden78649493"&gt;position&lt;/span&gt; of $493&#160;million, which was recorded as other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;With respect to these forward-starting interest rate swaps and treasury lock agreements, losses of $11&#160;million and $7&#160;million were recognized under financial expenses, net, for each of the three months ended March&#160;31, 2023 and 2022, respectively. &lt;/div&gt; </us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <teva:RevenuesOtherThanUsd
      contextRef="PAsOn03_31_2023"
      decimals="2"
      unitRef="Unit_pure">0.50</teva:RevenuesOtherThanUsd>
    <teva:DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cross-currency swap - cash flow hedge (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </teva:DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="PAsOn03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_78649444"
      unitRef="Unit_USD">169000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="PAsOn12_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_78649445"
      unitRef="Unit_USD">0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the classification and fair values &lt;div style="display:inline;"&gt;of&lt;/div&gt; derivative instruments: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:59%"/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Designated as hedging&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Not designated as hedging&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Asset derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other current assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Option and forward contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;Cross-currency swap-cash flow hedge (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liability derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other current liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Option and forward contracts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5 million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; </us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="PAsOn03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="PAsOn12_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="PAsOn03_31_2023_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">45000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="PAsOn12_31_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">29000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="PAsOn12_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="PAsOn03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="PAsOn12_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="PAsOn03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="PAsOn12_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="PAsOn03_31_2023_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">63000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="PAsOn12_31_2022_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">101000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <teva:DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;;display:inline;"&gt;The table below provides information regarding the location and amount of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt;&lt;div style="font-size: 10pt;;display:inline;"&gt; (gains) losses from derivatives designated in cash flow hedging relationships:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial expenses, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&#160;comprehensive&#160;income&#160;(loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Line items in which effects of hedges are recorded&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cross-currency swaps - cash flow hedge (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </teva:DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock>
    <us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments
      contextRef="P01_01_2023To03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">260000000</us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments>
    <us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments
      contextRef="P01_01_2022To03_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">258000000</us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
      contextRef="P01_01_2023To03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">127000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
      contextRef="P01_01_2022To03_31_2022_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">-57000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent>
    <us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments
      contextRef="P01_01_2023To03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      id="Fact_78649441"
      unitRef="Unit_USD">1000000</us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments>
    <us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments
      contextRef="P01_01_2022To03_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesNetMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      id="Fact_78649442"
      unitRef="Unit_USD">0</us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
      contextRef="P01_01_2023To03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_78649437"
      unitRef="Unit_USD">-2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent
      contextRef="P01_01_2022To03_31_2022_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_78649438"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The table below provides information regarding the location and amount of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; (gains) losses from derivatives not designated as hedging instruments: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:67%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial expenses, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net revenues&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Line items in which effects of hedges are recorded&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,661&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,661&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Option and forward contracts (2)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Option and forward contracts economic hedge (3)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To03_31_2023_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">260000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To03_31_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">258000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">-3661000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To03_31_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">-3661000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To03_31_2023_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_78649125"
      unitRef="Unit_USD">-13000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To03_31_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_78649126"
      unitRef="Unit_USD">-5000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_78649127"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To03_31_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_78649128"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To03_31_2023_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_78649129"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To03_31_2022_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_78649130"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_78649131"
      unitRef="Unit_USD">6000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To03_31_2022_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_78649132"
      unitRef="Unit_USD">-19000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">493000000</us-gaap:DerivativeLossOnDerivative>
    <teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">11000000</teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses>
    <teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">7000000</teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 9 &#x2013; Legal settlements and loss contingencies: &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the first quarter of 2023, Teva recorded expenses of $233&#160;million in legal settlements and loss contingencies, compared to $1,124&#160;million in the first quarter of 2022. Expenses in the first quarter of 2023 were mainly related to estimated provision&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt; recorded in connection with the DOJ patient assistance program litigation and the reverse-payment antitrust litigation over certain HIV medicines, as well as an update to the estimated settlement provision&#160;related to the remaining opioid cases (mainly related to the effect that the passage of time had on the net present value of the discounted payments). Expenses in the first quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases. See note 10. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, Teva&#x2019;s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,299&#160;million and $4,186&#160;million, respectively. &lt;/div&gt; </us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LitigationSettlementExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">233000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1124000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">4299000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">4186000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 10 &#x2013; Commitments and contingencies: &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;General &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is reasonably estimable. Based upon the status of the cases described below, management&#x2019;s assessments of the likelihood of damages, and the advice of counsel, no provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and excessive verdicts can occur. Accordingly, management&#x2019;s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters where the exposures were fully resolved in the prior year, or determined to no longer meet the materiality threshold for disclosure, or were substantially resolved. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the financial statements. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva&#x2019;s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third party sales figures given below are based on IQVIA data. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intellectual Property Litigation &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, Teva seeks to develop generic and biosimilar versions of patent-protected pharmaceuticals and biopharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator&#x2019;s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. For many biosimilar products that are covered by patents, Teva participates in the &#x201c;patent dance&#x201d; procedures of the Biologics Price Competition and Innovation Act (&#x201c;BPCIA&#x201d;), which allow for the challenge to originator patents prior to obtaining biosimilar product approval. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator&#x2019;s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic or biosimilar version of the product even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act or BPCIA. For example, Teva could be sued for patent infringement after commencing sales of a product. This type of litigation can involve any of Teva&#x2019;s pharmaceutical products, not just its generic and biosimilar products. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva&#x2019;s product. The amount of lost profits would generally be based on the lost sales of the patentee&#x2019;s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2014, GlaxoSmithKline (&#x201c;GSK&#x201d;) filed claims against Teva in the U.S. District Court for the District of Delaware for infringement of a patent directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva and eight other generic producers began selling their carvedilol tablets (the generic version of GSK&#x2019;s Coreg&#xae;) in September 2007. A jury trial was held and the jury returned a verdict in GSK&#x2019;s favor finding Teva liable for induced infringement, including willful infringement, and assessing damages of $&lt;/div&gt;235.5&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, not including pre- or post-judgment interest or a multiplier for willfulness. Thereafter, the court overturned the jury verdict, finding no induced infringement by Teva and that Teva did not owe any damages. On August 5, 2021, the Court of Appeals for the Federal Circuit issued a two-to-one decision reinstating the $&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt;235.5&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million verdict and finding Teva liable for patent infringement. On February&#160;11, 2022, the Court of Appeals for the Federal Circuit denied rehearing. Teva appealed this decision to the U.S. Supreme Court on July&#160;11, 2022. In response to Teva&#x2019;s &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;certiorari &lt;/div&gt;&lt;/div&gt;petition, on October&#160;3, 2022, the U.S. Supreme Court issued an order seeking the views of the U.S. Solicitor General as to whether to review this case. On March&#160;29, 2023, the U.S. Solicitor General filed a brief recommending that the U.S. Supreme Court grant Teva&#x2019;s request and reverse the judgment of the Court of Appeals for the Federal Circuit. In addition to the pending U.S. Supreme Court proceedings, the case has been remanded to the district court for further proceedings on Teva&#x2019;s other legal and equitable defenses that have not yet been considered by the district court. In the first quarter of 2021, Teva recognized a provision based on its offer to settle such matter. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Product Liability Litigation &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva&#x2019;s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both types of insurance, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in certain or all of its markets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan are allegedly found in the active pharmaceutical ingredient (&#x201c;API&#x201d;) supplied to Teva by multiple API manufacturers, including by Zhejiang Huahai Pharmaceuticals Co. Ltd. (&#x201c;Huahai&#x201d;). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. In December 2019, Teva reached a settlement with Huahai resolving Teva&#x2019;s claims related to certain sartan API supplied by Huahai. Under the settlement agreement, Huahai agreed to compensate Teva for some of its direct losses and provide it with prospective cost reductions for API. The settlement does not release Huahai from liability for any losses Teva may incur as a result of third party personal injury or product liability claims relating to the sartan API at issue, as discussed below. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, multiple lawsuits have been filed in connection with this matter. Teva&#x2019;s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (&#x201c;MDL&#x201d;) pending in the United States District Courts against Teva and numerous other manufacturers. One MDL is pending in the United States District Court for the District of New Jersey for valsartan, losartan and irbesartan. Teva is not named in complaints with respect to irbesartan. The second MDL is pending in the United States District Court for the Southern District of Florida for ranitidine. The lawsuits against Teva in the MDLs consist of individual personal injury and/or product liability claims and economic damages claims brought by consumers and end payors on behalf of purported classes of other consumers and end payors as well as medical monitoring class claims. The judge in the valsartan MDL ordered that the first trial, likely commencing in late 2023 or early 2024, will involve third-party payor economic loss claims via a class representative on behalf of several subclasses of payors against Teva and two other defendants. On February&#160;8, 2023, the district court in the valsartan MDL entered an order that certified a series of subclasses on plaintiffs&#x2019; economic loss claims and granted in part and denied in part the certification of a medical monitoring class. Defendants sought permission for appellate review of that decision, which was denied. In the ranitidine MDL, the generic manufacturers&#x2019; motions to dismiss have been granted, although certain plaintiffs have appeals pending. In addition, on December&#160;6, 2022, the court in the ranitidine MDL granted the brand defendants&#x2019; motions to exclude all of plaintiffs&#x2019; general causation experts and granted summary judgment to the brand defendants on that ground. Teva, as well as other &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;generic manufacturers, is also named in several state court actions asserting allegations similar to those in the ranitidine MDL and the valsartan and losartan MDL. State court valsartan and losartan actions are pending in New Jersey and Delaware and are currently stayed. State court ranitidine cases naming Teva are pending in coordinated proceedings in California, Illinois, Pennsylvania and New York, with motions to dismiss pending in Illinois, Pennsylvania and New York on preemption and other grounds. In addition to the valsartan and ranitidine MDLs and coordinated state court proceedings, Teva has also been named in a consolidated proceeding pending in the United States District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva&#x2019;s, as well as other generic manufacturers&#x2019; metformin products. Defendants&#x2019; motion to dismiss the plaintiffs&#x2019; amended metformin complaint from June 2021 was granted without prejudice with respect to the consumer economic loss plaintiffs, and granted in part and denied in part with respect to the end payor plaintiffs. Plaintiffs were granted leave to file a second amended complaint. Defendants&#x2019; motion to dismiss that complaint was granted in part and denied in part. Similar lawsuits are pending in Canada and Germany. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Competition Matters &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva&#x2019;s patent challenges have resulted in litigation relating to Teva&#x2019;s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva and its subsidiaries have been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases are usually direct and indirect purchasers of pharmaceutical products, some of whom assert claims on behalf of classes of all direct and indirect purchasers, and they typically allege that (i)&#160;Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (ii)&#160;significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These plaintiffs seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been and disgorgement of profits, which are often automatically tripled under the relevant statutes, plus attorneys&#x2019; fees and costs. The alleged damages generally depend on the size of the branded market and the length of the alleged delay, and can be substantial&#x2014;potentially measured in multiples of the annual brand sales&#x2014;particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva&#x2019;s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (&#x201c;FTC&#x201d;) v. Actavis, Inc., that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This test has resulted in increased scrutiny of Teva&#x2019;s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva&#x2019;s currently pending antitrust litigations. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2020, the European Commission issued a final decision in its proceedings against both Cephalon and Teva, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling euro 60.5&#160;million on Teva and Cephalon. Teva and Cephalon filed an appeal against the decision in February 2021. A provision for this matter was included in the financial statements. Teva has provided the European Commission with a bank guarantee in the amount of the imposed fines. The hearing for the appeal took place in December 2022 and a decision is pending. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2011, three groups of plaintiffs filed claims against Wyeth and Teva for alleged violations of the antitrust laws in connection with their November 2005 settlement of patent litigation involving extended release venlafaxine (generic Effexor XR&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;). The cases were filed by a purported class of direct purchasers, by a purported class of indirect purchasers and by certain chain pharmacies in the U.S. District Court for the District of New Jersey. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. In March 2020, the district court temporarily stayed discovery and referred the case to mediation, and discovery remains stayed. Annual sales of Effexor XR&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; were approximately $2.6&#160;billion at the time of settlement and at the time Teva launched its generic version of Effexor XR&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in July 2010. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2012, two purported classes of direct-purchaser plaintiffs filed claims against GSK and Teva in New Jersey federal court for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving lamotrigine (generic Lamictal&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;) entered into in February 2005. The plaintiffs claimed that the settlement agreement unlawfully delayed generic entry and sought unspecified damages. On April&#160;9, 2021, the district court, which had previously granted an initial motion for class certification by the direct purchaser plaintiffs but was reversed on that ruling by the Third Circuit in April 2020, denied the direct purchaser plaintiffs&#x2019; renewed motion for class certification. Plaintiffs filed a further renewed motion for class certification on May&#160;20, 2022, which was denied on February&#160;1, 2023. On February&#160;2, 2023, February&#160;7, 2023, and February&#160;27, 2023, a number of direct purchasers, who would otherwise have been members of the proposed class had it been certified, filed suit as individual plaintiffs in Pennsylvania&#x2019;s federal court. Annual sales of Lamictal&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; were approximately $950&#160;million at the time of the settlement and approximately $2.3&#160;billion at the time Teva launched its generic version of Lamictal&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in July 2008. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan&#xae; (extended release niacin) filed claims against Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005 to resolve patent litigation over the product. A multidistrict litigation has been established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser opt-out plaintiffs filed complaints with allegations nearly identical to those of the direct purchasers&#x2019; class. The court denied the indirect purchasers&#x2019; motion for class certification with prejudice, and on April 24, 2023, the denial was affirmed by the Court of Appeals for the Third Circuit. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, alleging violations of state law and seeking restitution and civil penalties. Annual sales of Niaspan&#xae; were approximately&#160;&lt;/div&gt;$416&#160;million at the time of the settlement and approximately $1.1&#160;billion at the time Teva launched its generic version of Niaspan&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in September 2013. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Since January 2014, numerous lawsuits have been filed in the U.S. District Court for the Southern District of New York by purported classes of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;end-payers&lt;/div&gt; for, and direct-purchasers of, Actos&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and Actoplus Met (pioglitazone and pioglitazone plus metformin) against Takeda, the innovator, and several generic manufacturers, including Teva, Actavis and Watson. The lawsuits allege, among other things, that the settlement agreements between Takeda and the generic manufacturers violated the antitrust laws. The court dismissed the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;end-payers&#x2019;&lt;/div&gt; lawsuits against all defendants in September 2015. On February&#160;8, 2017, the Court of Appeals for the Second Circuit affirmed the dismissal in part and vacated and remanded the dismissal in part with respect to the claims against Takeda. The direct purchasers&#x2019; case had been stayed pending resolution of the appeal in the end payer matter and the direct purchasers amended their complaint for a second time following the Second Circuit&#x2019;s decision, but on October&#160;8, 2019, the district court dismissed, with prejudice, the direct purchasers&#x2019; claims against the generic manufacturers (including Teva, Actavis, and Watson). At the time of Teva&#x2019;s settlement, annual sales of Actos&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and Actoplus Met were approximately $3.7&#160;billion and approximately $500&#160;million, respectively. At the time Teva launched its authorized generic version of Actos&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and Actoplus Met in August 2012, annual sales of Actos&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and Actoplus Met were approximately $2.8&#160;billion and approximately $430&#160;million, respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Putative classes of direct-purchaser and end-payer plaintiffs have filed antitrust lawsuits (which have since been coordinated in federal court in Delaware) against Amgen and Teva alleging that the January 2, 2019 settlement agreement between Amgen and Teva, resolving patent litigation over cinacalcet (generic Sensipar&#xae;), violated the antitrust laws. In March 2023, Teva moved for re-argument of its motion to certify the district court&#x2019;s rulings denying Teva&#x2019;s motion to dismiss in part for review by the U.S. Court of Appeals for the Third Circuit, and is awaiting the court&#x2019;s decision. Annual sales of Sensipar&#xae; in the United States were approximately $&lt;/div&gt;1.4&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;billion at the time Teva launched its generic version of Sensipar&#xae; in December 2018, and at the time of the January 2, 2019 settlement.&#160;&lt;/div&gt; &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In August 2019, certain direct-purchaser plaintiffs filed claims in federal court in Philadelphia naming Teva and its affiliates as defendants alleging that certain patent litigation settlement agreements relating to AndroGel&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;% (testosterone gel) violate the antitrust laws, specifically the September 2006 patent litigation settlement between Watson Pharmaceuticals, Inc. (&#x201c;Watson&#x201d;), from which Teva later acquired certain assets and liabilities, and Solvay Pharmaceuticals, Inc. (&#x201c;Solvay&#x201d;), and a December 2011 settlement between Teva and AbbVie. Those claims remain pending. Annual sales of AndroGel&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;% were approximately $350&#160;million at the time of the earlier Watson/Solvay settlement and approximately $140&#160;million at the time Actavis launched its generic version of AndroGel&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;% in November 2015. A provision for these matters and related litigations in Georgia that have since been settled was included in the financial statements. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"&gt; &lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Between September&#160;1, 2020 and December&#160;20, 2020, separate plaintiffs purporting to represent putative classes of direct and indirect purchasers and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;opt-out&lt;/div&gt; retailer purchasers of Bystolic&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; (nebivolol hydrochloride) filed separate complaints in the U.S. District Court for the Southern District of New York against several generic manufacturers, including Teva, Actavis, and Watson, alleging, among other things, that the settlement agreements these generic manufacturers entered into with Forest Laboratories, Inc., the innovator, to resolve patent litigation over Bystolic&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; violated the antitrust laws. The cases were coordinated and on January&#160;24, 2022, the court dismissed plaintiffs&#x2019; amended complaints without prejudice. Plaintiffs subsequently filed second amended complaints, and on February&#160;21, 2023, the court granted defendants&#x2019; motion to dismiss and dismissed all claims with prejudice. Plaintiffs have filed notices of their intent to appeal. Annual sales of Bystolic&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in the United States were approximately $700&#160;million at the time of Watson&#x2019;s 2013 settlement with Forest. &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;In February 2021, the State of New Mexico filed a lawsuit against Teva and certain other defendants related to various medicines used to treat HIV. Between September and December 2021, several private plaintiffs including retailers and health insurance providers filed similar claims in federal court in the Northern District of California and in the District of Minnesota. As they relate to Teva, the lawsuits challenge settlement agreements Teva entered into with Gilead in 2013 and/or 2014 to resolve patent litigation relating to Teva&#x2019;s generic versions of Viread&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10px; vertical-align: top;;display:inline;"&gt;&#xae;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;and/or Truvada&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10px; vertical-align: top;;display:inline;"&gt;&#xae;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;and Atripla&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10px; vertical-align: top;;display:inline;"&gt;&#xae;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;. Plaintiffs allege that the settlement agreements contain improper reverse payments that delayed the availability of generic products, in violation of the federal antitrust laws and state law. On February&#160;16, 2022, Teva moved to dismiss the claims by certain private plaintiffs but that motion was denied. However, Teva has successfully moved to limit the potential damages period as to certain private plaintiffs. Plaintiffs in the Northern District of California cases have abandoned any claim for damages relating to the Viread&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10px; vertical-align: top;;display:inline;"&gt;&#xae;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;settlement. On January&#160;5, 2023, the court denied the parties&#x2019; motions for summary judgment. Trial is currently scheduled to commence in late May 2023. In the first quarter of 2023, Teva recognized a provision based on its offer to settle this matter.&lt;/div&gt; &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt; In October 2022, the New Mexico Supreme Court granted Teva&#x2019;s petition for a writ of &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;certiorari&lt;/div&gt;&lt;/div&gt; and scheduled oral argument for late May 2023 for Teva&#x2019;s motion to dismiss the complaint brought by the State of New Mexico, which motion was previously denied by the trial court. Annual sales in the United States at the time of the settlement of Viread&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;, Truvada&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and Atripla&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; were approximately $582&#160;million, $2.4&#160;billion, and $2.9&#160;billion, respectively. Annual sales in the United States at the time Teva launched its generic version of Viread&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in 2017, Truvada&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in 2020 and Atripla&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in 2020 were approximately&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;728&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;2.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;billion and $&lt;/div&gt;444&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In March 2021, following the 2019 European Commission&#x2019;s inspection of Teva and subsequent request for information, the European Commission opened a formal antitrust investigation to assess whether Teva may have abused a dominant position by delaying the market entry and uptake of medicines that compete with COPAXONE. On October&#160;10, 2022, the European Commission issued a Statement of Objections, which sets forth its preliminary allegations that Teva had engaged in anti-competitive practices. Teva now has the opportunity to formally respond to the European Commission&#x2019;s allegations. Annual sales of COPAXONE in the European Economic Area for 2021 were approximately $373&#160;million. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;15, 2021, the U.K. Competition and Markets Authority (&#x201c;CMA&#x201d;) issued a decision imposing fines for breaches of U.K. competition law by Allergan, Actavis UK and Auden Mckenzie and a number of other companies in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. The decision combines the CMA&#x2019;s three prior investigations into the supply of hydrocortisone tablets in the U.K., as well as the CMA&#x2019;s subsequent investigation relating to an anti-competitive agreement with Waymade. On January&#160;9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva will indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to two of the three statements of objection from the CMA (dated December&#160;16, 2016 and March&#160;3, 2017), and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. On October&#160;6, 2021, Accord UK and Auden Mckenzie appealed the CMA&#x2019;s decision. A provision for the estimated exposure for Teva related to the fines and/or damages has been recorded in the financial statements. The hearing for the appeal concluded in the first quarter of 2023, and a decision remains pending. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"&gt; &lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In August 2021, a plaintiff filed a putative class action suit in the United States District Court for the Eastern District of Pennsylvania against Takeda and several generic manufacturers, including Watson and Teva, alleging violations of the antitrust laws in connection with their settlement of patent litigation involving colchicine tablets (generic Colcrys&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;), entered into in January 2016. Plaintiff claims that the settlement was part of a conspiracy among Takeda and the generic manufacturers to unlawfully restrict output of colchicine by delaying generic entry. On November&#160;23, 2022, the court denied plaintiffs&#x2019; motion for class certification without prejudice and on March&#160;1, 2023, the Court denied plaintiff&#x2019;s renewed motion for class certification. On April&#160;10, 2023, plaintiff filed a motion for leave to amend its complaint to add 18 previously absent class members as plaintiffs. Defendants&#x2019; motion for summary judgment, and plaintiffs&#x2019; motion for partial summary judgment remain pending. Trial is currently scheduled to commence in September 2023. Annual sales of Colcrys&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in the United States were approximately $187&#160;million at the time of the settlement. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2022, two complaints, one brought by Walgreen Co. and Kroger Specialty Pharmacy, Inc. and another by Fraternal Order of Police, Miami Lodge 20, Insurance Trust Fund and Jacksonville Police Officers and Fire Fighters Health Insurance Trust (collectively the &#x201c;Walgreen and EPP complaints&#x201d;), were filed in the United States District Court for the District of New Jersey against Teva and its marketing partner, Natco Pharma Limited (&#x201c;Natco&#x201d;), alleging violations of the antitrust laws in connection with their December 2015 settlement of patent litigation with Celgene Corporation (which was subsequently acquired by Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;)) involving the drug Revlimid&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; (lenalidomide). The Walgreen and EPP complaints also name Celgene and BMS as defendants. On January&#160;24, 2023, the Walgreen and EPP complaints were consolidated for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-trial&lt;/div&gt; purposes only with an earlier-filed, already consolidated Insurer &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Opt-Out&lt;/div&gt; Action filed against BMS and Celgene, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;In Re Revlimid&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&amp;amp; Thalomid Purchaser Antitrust Litigation&lt;/div&gt;&lt;/div&gt;, Case No. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2:19-cv-7532-ES-MAH.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; On February&#160;16, 2023, the Walgreen and EPP plaintiffs filed amended complaints adding additional plaintiffs. On March&#160;21, 2023, Teva and Natco moved to dismiss the complaints against them, and briefing remains ongoing. Annual sales of Revlimid&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in the United States were approximately $3.5&#160;billion at the time of the settlement. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="null;text-indent: 0px;;display:inline;"&gt;On December 2, 2022, plaintiffs purporting to represent putative classes of indirect purchasers of EpiPen&#xae; (epinephrine injection) and Nuvigil&#xae; (armodafinil) filed a complaint in the United States District Court for the District of Kansas against Teva, Cephalon, and a former Teva executive. Teva owns the New Drug Application (&#x201c;NDA&#x201d;) for Nuvigil&#xae; and sold the brand product, for which generic entry occurred in 2016. Teva filed an ANDA to sell generic EpiPen&#xae;, which Teva launched in 2018, following receipt of FDA approval. The complaint alleges, among other things, that the defendants violated the federal antitrust laws, the Racketeer Influenced and Corrupt Organizations Act (&#x201c;RICO Act&#x201d;), and various state laws in connection with settlements resolving patent litigation relating to those products. Plaintiffs seek injunctive relief, compensatory and punitive damages, interest, attorneys&#x2019; fees and costs. On March 8, 2023, Teva filed a motion to dismiss the complaint, which is pending. Annual sales of Nuvigil&#xae; in the United States were approximately $&lt;/div&gt;300&#160;million at the time Teva entered into the first settlement with an ANDA filer in 2012; annual sales of EpiPen&lt;div style="font-size:75%; vertical-align:top;text-indent: 0px;;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; in the United States were approximately $600&#160;million at the time Teva entered into its settlement agreement for that product in 2012. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Government Investigations and Litigation Relating to Pricing and Marketing &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (&#x201c;DOJ&#x201d;) Antitrust Division seeking documents and other information relating to the marketing and pricing of certain Teva USA generic products and communications with competitors about such products. On August&#160;25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three-count indictment charging Teva USA with criminal felony Sherman Act violations. See &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;20-cr-200&lt;/div&gt;&lt;/div&gt; (E.D. Pa.). The indictment alleges Teva USA participated in three separate conspiracies with certain other generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs. The indictment identified the following generic drugs: Pravastatin, Carbamazepine, Clotrimazole, Etodolac (IR and ER), Fluocinonide (Cream &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;E-Cream,&lt;/div&gt; Gel, and Ointment), Warfarin, Nadolol, Temozolomide, and Tobramycin. On September&#160;8, 2020, Teva USA pled not guilty to all counts. On December&#160;14, 2022, the Court entered a scheduling order against Teva and its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-defendant&lt;/div&gt; Glenmark, which sets a May 2024 trial date. While the Company is unable to estimate a range of loss at this time, a conviction on these criminal charges could have a material adverse impact on the Company&#x2019;s business, including monetary penalties and debarment from federally funded health care programs. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In May 2018, Teva received a civil investigative demand from the DOJ Civil Division, pursuant to the federal False Claims Act, seeking documents and information produced since January&#160;1, 2009 relevant to the Civil Division&#x2019;s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. An adverse resolution of this matter may include fines, penalties, financial forfeiture and compliance conditions. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. Subsequently, on December&#160;15, 2016, a civil action was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States. That complaint was later amended to add new states as named plaintiffs, as well as new allegations and new state law claims, and on June&#160;18, 2018, the attorneys general of 49 states plus Puerto Rico and the District of Columbia filed a consolidated amended complaint against Actavis and Teva, as well as other companies and individuals. On May&#160;10, 2019, most (though not all) of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals, alleging price-fixing and market allocation with respect to additional generic products. On November&#160;1, 2019, the state attorneys general filed an amended complaint, bringing the total number of plaintiff states and territories to 54. The amended complaint alleges that Teva was at the center of a conspiracy in the generic pharmaceutical industry, and asserts that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain additional products. On June&#160;10, 2020, most, but not all, of the same states, with the addition of the U.S. Virgin Islands, filed a third complaint in the District of Connecticut naming, among other defendants, Actavis, but not Teva USA, in a similar complaint relating to dermatological generics products. On September&#160;9, 2021, the states&#x2019; attorneys general amended their third complaint to, among other things, add California as a plaintiff. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the various complaints described above, the states seek a finding that the defendants&#x2019; actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints have been transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (&#x201c;Pennsylvania MDL&#x201d;). On July&#160;13, 2020, the court overseeing the Pennsylvania MDL chose the attorneys&#x2019; general November&#160;1, 2019 amended complaint, referenced above, along with certain complaints filed by private plaintiffs, to proceed first in the litigation as bellwether complaints. On February&#160;9, 2021, Teva&#x2019;s motion to reconsider that ruling was granted, and on May&#160;7, 2021, the Court chose the attorneys&#x2019; general third complaint filed on June&#160;10, 2020 and subsequently amended to serve as a bellwether complaint in the Pennsylvania MDL, along with certain complaints filed by private plaintiffs. On December&#160;9, 2021, the Court entered an order setting the schedule for the proceedings in the bellwether cases, which the Court later amended on October&#160;13, 2022. This amended schedule does not include trial dates, but provides for the parties to complete briefing on motions for summary judgment in the third quarter of 2024. On June&#160;7, 2022, the Court dismissed the attorneys&#x2019; general claims for monetary relief under federal law, concluding that the federal statute under which the attorneys general brought suit authorizes injunctive relief only. However, the attorneys general have pending claims for monetary relief under state law. On February&#160;27, 2023, the Court largely denied defendants&#x2019; motions to dismiss the federal claims asserted by the attorneys general in their bellwether complaint. Another motion to dismiss, directed at that same complaint, and related to the state law claims asserted by the attorneys general, remains pending. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva has settled with the states of Mississippi (in June 2021), Louisiana (in March 2022), Georgia (in September 2022), Arkansas (in October 2022) and Florida (in February 2023). Teva paid each state an amount proportional to its share of the national population (approximately $1,000,000 for each 1% share of the national population), and the states have dismissed their claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA, pursuant to these settlements. On March&#160;30, 2022, the State of Alabama voluntarily dismissed all of its claims in the litigation, including its claims against Actavis and Teva USA, without prejudice. The territories of American Samoa and Guam have also voluntarily dismissed all of their claims in the litigation, including their claims against Actavis and Teva USA; American Samoa&#x2019;s dismissal was without prejudice in July 2020, and Guam&#x2019;s dismissal was with prejudice in February 2023. The most recent settlement with Florida follows the pattern reached in earlier settlements. Specifically, as mentioned above, Teva agreed to pay each state an amount proportional to its share of the national population. This, in addition to the status of ongoing negotiations with several other U.S. state attorneys general to settle on comparable terms, caused management to consider settlement of the claims filed by the remaining attorneys general to be probable, and management recorded an estimated provision in the third quarter of 2022, in accordance with Accounting Standards Codification 450 &#x201c;Accounting for Contingencies.&#x201d; &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div/&gt;&lt;div&gt; &lt;div style="background-color:white;display: inline;"&gt;  &lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Beginning on March&#160;2, 2016, and continuing through December 2020, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;opt-out&lt;/div&gt; plaintiffs. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva USA and Actavis. The plaintiffs generally seek injunctive relief and damages under federal antitrust law, and damages under various state laws. On October&#160;16, 2018, the court denied certain of the defendants&#x2019; motions to dismiss as to certain federal claims, pending as of that date, and on February&#160;15, 2019, the court granted in part and denied in part defendants&#x2019; motions to dismiss as to certain state law claims. On July&#160;18, 2019, May&#160;6, 2020 and October&#160;8, 2021, certain individual plaintiffs commenced civil actions in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, but no complaints have been filed in the actions and each of the three cases have been placed in deferred status. Certain counties in New&#160;York and Texas have also commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been transferred to the Pennsylvania MDL. There is also one similar complaint brought in Canada, which alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. The action is in its early stages. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2017, Teva received a subpoena from the U.S. Attorney&#x2019;s office in Boston, Massachusetts requesting documents related to Teva&#x2019;s donations to patient assistance programs. Subsequently, in August 2020, the U.S. Attorney&#x2019;s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law (the &#x201c;DOJ PAP Complaint&#x201d;). It is alleged that Teva caused the submission of false claims to Medicare through Teva&#x2019;s donations to bona fide independent charities that provide financial assistance to patients. An adverse judgment may involve damages, civil penalties and injunctive remedies. On September&#160;10, 2021, the Court granted Teva&#x2019;s motion to dismiss the unjust enrichment claim and denied the remainder of the motion. On October&#160;15, 2021, Teva filed an answer to the DOJ PAP Complaint. Trial for this matter is currently scheduled for September 2023. On April&#160;24, 2023, both parties filed summary judgment motions, which are currently pending. In the first quarter of 2023, Teva recognized a provision based on its offer to settle this matter. Additionally, on January&#160;8, 2021, Humana, Inc. filed an action against Teva in the United States District Court for the Middle District of Florida based on the allegations raised in the DOJ PAP Complaint. On April&#160;2, 2021, Teva filed a motion to dismiss Humana&#x2019;s claims on the grounds that the claims are time-barred and/or insufficiently pled, and that motion remains pending. On April&#160;11, 2023, the court granted Teva&#x2019;s motion to stay the case pending the court&#x2019;s decision on Teva&#x2019;s motion to dismiss and/or Humana&#x2019;s motion to amend the complaint. On November&#160;17, 2022, United Healthcare also filed an action against Teva in the United States District Court for the District of New Jersey based on the conduct alleged in the DOJ PAP Complaint. On March&#160;10, 2023, Teva moved to dismiss United Healthcare&#x2019;s claims on the grounds that it is time-barred and lacks standing and sufficient particularity to assert RICO claims, and that motion remains pending. &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2021, a city and county in Washington filed claims against Teva in the United States District Court for the Western District of Washington for alleged violations of the Racketeer Influenced and Corrupt Organizations Act, Washington&#x2019;s Consumer Protection Act, and unjust enrichment concerning Teva&#x2019;s sale of COPAXONE. Plaintiffs purport to represent a nationwide class of health plans and a subclass of Washington-based health plans that purchased and/or reimbursed health plan members for COPAXONE. Plaintiffs allege that Teva engaged in several fraudulent schemes that resulted in plaintiffs and the putative class members purchasing and/or reimbursing plan members for additional prescriptions of COPAXONE and/or at inflated COPAXONE prices. Plaintiffs seek treble damages for the excess reimbursements and inflated costs, as well as injunctive relief. On September&#160;28, 2021, plaintiffs filed an amended complaint. On November&#160;17, 2021, Teva moved to dismiss the suit, on the grounds that plaintiffs&#x2019; claims are barred by the applicable statutes of limitations and the direct purchaser rule, suffer from jurisdictional defects, and fail to plausibly allege fraud or other elements of their claims. On March&#160;9, 2023, the court held a hearing on the motion to dismiss, and a decision remains pending. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;29, 2021, Mylan Pharmaceuticals (&#x201c;Mylan&#x201d;) filed claims against Teva in the District Court for the District of New&#160;Jersey. On March&#160;11, 2022 and March&#160;15, 2022, FWK Holdings, LLC, KPH Healthcare Servs., Inc. d/b/a&#160;Kinney Drugs, Inc., Meijer Inc., Meijer Distribution, Inc., Labor-Management Healthcare Fund, the Mayor and City Council of Baltimore, and the New York State Teamsters Council Health and Hospital Fund filed claims against Teva in the District Court for the District of New Jersey on behalf of themselves and other similarly situated direct and indirect purchasers of COPAXONE. On August&#160;22, 2022, Blue Cross Blue Shield of Vermont and the Vermont Health Plan sued Teva in the &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;District Court for the District of Vermont on behalf of themselves and other similarly situated indirect purchasers of COPAXONE. The complaints assert claims for alleged violations of the Lanham Act, state and federal unfair competition and monopolization laws, tortious interference, trade libel, and a violation of the RICO Act. Additionally, plaintiffs claim Teva was involved in an unlawful scheme to delay and hinder generic competition concerning COPAXONE sales. Plaintiffs seek damages for lost profits and expenses, disgorgement, restitution, treble damages, attorneys&#x2019; fees and costs, and injunctive relief. Teva has moved to dismiss the complaints filed by Mylan and the class plaintiffs in the District of New Jersey on the grounds, among others, that none of its challenged conduct, violates the law. Those motions are fully briefed and a decision remains pending. On November&#160;21, 2022, the Vermont court denied Teva&#x2019;s motion to transfer the complaint filed in Vermont. On December&#160;21, 2022, Teva moved to dismiss the Vermont complaint on grounds similar to those asserted in its motions to dismiss the complaints in New Jersey. Those motions are fully briefed, and a decision remains pending.&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;1, 2022, Teva received a civil subpoena from the U.S. Attorney&#x2019;s office in Boston, Massachusetts requesting certain documents related to the sale and marketing of AUSTEDO and risperidone LAI. Teva is cooperating with the request for documents. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Opioids Litigation &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Since May 2014, more than 3,500 complaints have been filed with respect to opioid sales and distribution against various Teva affiliates, along with several other pharmaceutical companies, by a number of cities, counties, states, other governmental agencies, tribes and private plaintiffs (including various putative class actions of individuals) in both state and federal courts. Most of the federal cases have been consolidated into a multidistrict litigation in the Northern District of Ohio (&#x201c;MDL Opioid Proceeding&#x201d;) and many of the cases filed in state court have been removed to federal court and consolidated into the MDL Opioid Proceeding. Two cases that were included in the MDL Opioid Proceeding were transferred back to federal district court for additional discovery, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-trial&lt;/div&gt; proceedings and trial. Those cases are: City of Chicago v. Purdue Pharma L.P. et al., &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;14-cv-04361&lt;/div&gt;&lt;/div&gt; (N.D. Ill.) and City and County of San Francisco v. Purdue Pharma L.P. et al., &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;18-cv-07591-CRB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; (N.D. Cal.). Other cases remain pending in various states. In some jurisdictions, such as Illinois, New York, Pennsylvania, South Carolina, Texas, Utah and West Virginia, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. Complaints asserting claims under similar provisions of different state law generally contend that the defendants allegedly engaged in improper marketing and distribution of opioids, including ACTIQ&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and FENTORA&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;. The complaints also assert claims related to Teva&#x2019;s generic opioid products. In addition, over 950 personal injury plaintiffs, including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding.&#160;Furthermore, approximately 700 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-personal&lt;/div&gt; injury complaints and approximately 100 personal injury complaints have named Anda, Inc. (and other distributors and manufacturers) alleging that Anda failed to develop and implement systems sufficient to identify suspicious orders of opioid products and prevent the abuse and diversion of such products to individuals who used them for other than legitimate medical purposes. Plaintiffs seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages,&#160;attorneys&#x2019; fees and injunctive relief. Certain plaintiffs assert that the measure of damages is the entirety of the costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. The individual personal injury plaintiffs further seek &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-economic&lt;/div&gt; damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;19, 2021, a bench trial in California (The People of the State of California, acting by and through Santa Clara County Counsel James R. Williams, et. al. v. Purdue Pharma L.P., et. al.) commenced against Teva and other defendants focused on the marketing of branded opioids. On December&#160;14, 2021, the court issued its final judgment in favor of the defendants on all claims. Plaintiffs filed a notice of appeal of this judgment in February 2022. On June&#160;29, 2021, a jury trial in New York (&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;In re Opioid Litigation&lt;/div&gt;&lt;/div&gt;, Index No.&#160;400000/2017) commenced against Teva and other defendants, focused on the marketing and distribution of opioids. The case was bifurcated between liability and damages. On December&#160;30, 2021, the jury returned a liability verdict in favor of plaintiffs (the County of Suffolk, the County of Nassau and the State of New York) on the plaintiffs&#x2019; public nuisance claim. On November&#160;3, 2022, Teva reached an agreement with the Attorney General of New York that settled the state&#x2019;s and its subdivisions&#x2019; opioid-related claims, the details of which are included in the table below. &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;21, 2021, it was announced that four other defendants (not including Teva) reached nationwide settlements, subject to certain conditions, which include payment of up to approximately $26&#160;billion spread over up to 18 years. In July 2022, Teva, the working group of States&#x2019; Attorneys General (the &#x201c;Working Group&#x201d;), the Multi-District Litigation Plaintiffs&#x2019; Executive Committee (&#x201c;PEC&#x201d;), and counsel for Native American tribes (&#x201c;Tribes&#x201d;) reached an agreement in principle on the financial terms of nationwide settlements similar in structure to the nationwide settlements of other defendants. During the third quarter of 2022, Teva and Allergan resolved their dispute with respect to Teva&#x2019;s indemnification obligations. In November 2022, Teva, Allergan, the Working Group and PEC, and representatives for the Tribes, finalized the terms of their respective proposed opioids nationwide settlement agreements. Under the financial terms of the proposed nationwide settlement agreement with the states and subdivisions, Teva will pay up to $4.25&#160;billion (including the already settled cases), spread over 13 years. This total includes the supply of up to $1.2&#160;billion of Teva&#x2019;s generic version of Narcan&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; (naloxone hydrochloride nasal spray), valued at wholesale acquisition cost, over 10 years or cash at 20% of the wholesale acquisition cost ($240 million) in lieu of product. In January of 2023,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Teva confirmed participation from all states except Nevada, and decided to move forward with the participation process of the subdivisions, and that process is ongoing. In February 2023, Teva and the Tribes finalized their opioids settlement with participation from 100% of the Tribes, the details of which are included in the table below.&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s proposed nationwide settlement agreement with the states and subdivisions is contingent upon sufficient participation by the subdivisions in Teva&#x2019;s and Allergan&#x2019;s respective nationwide opioids settlement agreements. Currently, more than&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;99&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;% of the litigating subdivisions have chosen to participate in Teva&#x2019;s nationwide settlement, which represents &lt;/div&gt;98&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;% &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the population of the participating states. Teva has until June 8, 2023 to determine whether or not to move forward with its proposed nationwide settlement. If these nationwide settlement agreements are not finalized or if Nevada or subdivisions choose not to participate, additional trials are expected to proceed. Trials in two opioids cases currently are scheduled to commence in the second half of 2023; one brought by the Nevada Attorney General, currently scheduled to commence in August 2023, and the other brought by eight hospitals against Teva, other manufacturers, distributors, and pharmacies, currently scheduled to commence in July 2023.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition to its pending nationwide opioids settlement, Teva previously reached settlements with individual states and subdivisions to settle opioids claims brought by those jurisdictions. The material details of those individual settlements and Teva&#x2019;s settlement with the Tribes appear in the table below, which includes the cash payment to be made by Teva and the wholesale acquisition cost (&#x201c;WAC&#x201d;) of product to be provided by Teva, in each case to such states and subdivisions and the Tribes. If the nationwide settlement reaches sufficient participation by the subdivisions, Teva will finalize opioid settlements with a total of 49 of the 50 states.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 23%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 13%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 13%;"/&gt;
&lt;td style="vertical-align: bottom;"/&gt;
&lt;td style="width: 7%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 18%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 17%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Jurisdiction&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Settlement&lt;br/&gt;Payment&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px"&gt;*&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment&lt;br/&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Settlement Product&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product&#160;WAC&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Value&#160;and&#160;Term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;June 7, 2019&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Oklahoma&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$72.3&#160;million (paid)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;1 year&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;N/A&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;N/A&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;December 27, 2019&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Cuyahoga County, OH&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$12.4&#160;million (paid)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;2.5 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;buprenorphine naloxone&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;(generic Suboxone&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$15.5&#160;million (3 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;December 27, 2019&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Summit County, OH&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$7.6&#160;million (paid)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;2.5 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;buprenorphine naloxone&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;(generic Suboxone&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$9.5&#160;million (3 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;January 18, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Louisiana&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$15&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;18 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;buprenorphine naloxone&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;(generic Suboxone&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$3&#160;million (1 year)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;February 4, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Texas&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$131.5&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;15 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;naloxone hydrochloride (generic Narcan&#xae;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$75&#160;million (10 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;March 21, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Rhode Island&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$21&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;13 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;naloxone hydrochloride (generic Narcan&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;) and&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;buprenorphine naloxone (generic Suboxone&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$78.5&#160;million (10 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;March 30, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Florida&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$177.1&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;15 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;naloxone hydrochloride (generic Narcan&#xae;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$84&#160;million (10 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;July 12, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;San Francisco&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$19.5&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;13 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;naloxone hydrochloride (generic Narcan&#xae;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$20&#160;million (10 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;September 19, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;West Virginia&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$75.4&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;15 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;naloxone hydrochloride (generic Narcan&#xae;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$27&#160;million (10 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;November 3, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;New York&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$313.3 million&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;**&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;18 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;N/A&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;N/A&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;February 24, 2023&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Tribes&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$108.3&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;13 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;naloxone hydrochloride (generic Narcan&#xae;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$25&#160;million (10 years)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;*&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts exclude attorneys&#x2019; fees and costs, except New York. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;**&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Not including cash payment and attorneys&#x2019; fees allocated under the nationwide settlement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"&gt; &lt;/div&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;In light of the agreement on the proposed nationwide settlement between Teva and the States&#x2019; Attorneys General and their subdivisions, Teva&#x2019;s indemnification obligations arising from Teva&#x2019;s acquisition of the Actavis Generics business for opioid-related claims, prior settlements with Louisiana, Texas, Rhode Island, Florida, San Francisco, West Virginia, New York, and the Tribes, as well as an estimate for a number of items including, but not limited to, costs associated with administering injunctive terms, and most favored nations clauses associated with prior settlements, the Company has recorded a provision for the potential settlement. The provision is a reasonable estimate of the ultimate costs in the likely event that the nationwide settlement is finalized under its current proposed terms and conditions, after discounting payments to states to their net present value. However, if the nationwide settlement is not finalized for the entirety of the remaining cases, a reasonable upper end of a range of loss cannot be determined. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-monetary&lt;/div&gt; relief and could have a material and adverse effect on Teva&#x2019;s reputation, business, results of operations and cash flows. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"/&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In September 2019, Teva received subpoenas from the New York State Department of Financial Services (&#x201c;NYDFS&#x201d;) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. This was followed by a Statement of Charges and Notice of Hearing filed by the NYDFS. This matter has been resolved by Teva&#x2019;s November&#160;3, 2022 settlement with the Attorney General of New York that settled the state&#x2019;s and its subdivisions&#x2019; opioid-related claims. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition, Teva, certain of its subsidiaries and other defendants, are defending claims and putative class action lawsuits in Canada related to the manufacture, sale, marketing and distribution of opioid medications. The lawsuits include a claim by the Province of British Columbia on behalf of itself and a putative class of other federal and provincial governments, and claims of municipalities, First Nations, and persons who used opioids on behalf of themselves and putative classes. These cases are in early stages with the preliminary motions brought by the Province of British Columbia expected to be heard in late 2023. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shareholder Litigation &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November&#160;6, 2016 and December&#160;27, 2016, two putative securities class actions were filed in the U.S. District Court for the Central District of California against Teva and certain of its current and former officers and directors. Those lawsuits subsequently were consolidated and transferred to the U.S. District Court for the District of Connecticut (the &#x201c;Ontario Teachers Securities Litigation&#x201d;). On December&#160;13, 2019, the lead plaintiff filed an amended complaint, purportedly on behalf of purchasers of Teva&#x2019;s securities between February&#160;6, 2014 and May&#160;10, 2019, asserting that Teva and certain of its current and former officers and directors violated federal securities and common laws in connection with Teva&#x2019;s alleged failure to disclose pricing strategies for various drugs in its generic drug portfolio and by making allegedly false or misleading statements in certain offering materials. From July 2017&#160;to June 2019, other putative securities class actions were filed in other federal courts based on similar allegations and claims, and were transferred to the U.S. District Court for the District of Connecticut. Between August 2017 and January 2022, twenty-three complaints were filed against Teva and certain of its current and former officers and directors on behalf of plaintiffs in various forums across the country, but many of those plaintiffs &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opted-out&#x201d;&lt;/div&gt; of the Ontario Teachers Securities Litigation. On March&#160;10, 2020, the Court consolidated the Ontario Teachers Securities Litigation with all of the above-referenced putative class actions for all purposes and the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; cases for pretrial purposes. On January&#160;18, 2022, Teva entered into a settlement in the Ontario Teachers Securities Litigation for $420&#160;million, which received final approval from the court on June&#160;2, 2022. The vast majority of the total settlement amount was covered by the Company&#x2019;s insurance carriers, with a small portion contributed by Teva. Additionally, as part of the settlement, Teva admitted no liability and denied all allegations of wrongdoing. On January&#160;22, 2021, the Court dismissed the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; plaintiffs&#x2019; claims arising from statements made prior to the five year statute of repose, but denied Teva&#x2019;s motion to dismiss their claims under Israeli laws. On May&#160;24, 2021, Teva moved to dismiss a majority of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; complaints on various other grounds, and on May&#160;1, 2023, the Court granted in part and denied in part Teva&#x2019;s motions. Teva has settled several &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; claims, but a number of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;opt-out&lt;/div&gt; cases remain outstanding. In addition, Teva reached a settlement agreement of Israeli shareholder motions to certify class action on similar allegations to those raised in the Ontario Teachers Securities Litigation. The settlement agreement is awaiting court approval. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers. On August&#160;10, 2021, the lead plaintiff filed a corrected amended class action complaint, purportedly on behalf of persons who purchased or otherwise acquired Teva securities between October&#160;29, 2015 and August&#160;18, 2020. The corrected amended complaint alleges that Teva and certain of its current and former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had allegedly caused the submission of false claims to Medicare through Teva&#x2019;s donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONE&#x2019;s commercial success and the sustainability of its revenues and resulted in the DOJ PAP Complaint filed by the DOJ. The corrected amended complaint seeks unspecified damages and legal fees. On March&#160;25, 2022, the court granted in part and denied in part Teva&#x2019;s and the individual defendants&#x2019; motion to dismiss the corrected amended complaint, (i)&#160;holding that the plaintiffs&#x2019; complaint failed to plead that certain public statements regarding Teva&#x2019;s compliance with the law were misleading, (ii)&#160;holding that two alleged partial corrective disclosures did not establish loss causation and cannot serve as the basis for plaintiff&#x2019;s claimed loss, (iii)&#160;dismissing all claims against one of the individual defendants, and (iv)&#160;otherwise denying the motion to dismiss. On August&#160;2, 2022, the court stayed all proceedings other than class certification proceedings pending the resolution of the DOJ PAP Complaint filed by the DOJ. On September&#160;13, 2022, the plaintiff moved for class certification, which remains pending. A motion to approve a securities class action was also filed in the Central District Court in Israel, which has been stayed pending the U.S. litigation, with similar allegations to those made in the above complaint filed in the U.S. District Court for the Eastern District of Pennsylvania. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Environmental Matters &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva or its subsidiaries are party to a number of environmental proceedings, or have received claims, including under the federal Superfund law or other federal, provincial or state and local laws, imposing liability for alleged noncompliance, or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third party-owned site, or the party responsible for a release of hazardous substances that impacted a site, to investigate and clean the site or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have received claims, or been made a party to these proceedings, along with others, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Teva&#x2019;s facilities or former facilities. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Although liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;clean-up&lt;/div&gt; and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Teva&#x2019;s potential liability varies greatly at each of the sites; for some sites the costs of the investigation, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;clean-up&lt;/div&gt; and natural resource damages have not yet been determined, and for others Teva&#x2019;s allocable share of liability has not been determined. At other sites, Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;clean-up&lt;/div&gt; costs from insurers, indemnitors, former site owners or operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Teva&#x2019;s facilities may result in the imposition of significant penalties (in amounts not expected to materially adversely affect Teva&#x2019;s results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implemented. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Item&#160;103 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-K&lt;/div&gt; promulgated by the SEC requires disclosure of certain environmental matters when a governmental authority is a party to the proceedings and such proceedings involve potential monetary sanctions, unless the Company reasonably believes that the matter will result in no monetary sanctions, or in monetary sanctions, exclusive of interest and costs, of less &lt;span style="-sec-ix-hidden:hidden78649508"&gt;than&lt;/span&gt; $300,000. The following matter is disclosed in accordance with that requirement. On July&#160;8, 2021, the National Green Tribunal Principal Bench, New Delhi, issued an order against Teva&#x2019;s subsidiary in India, Teva API India Private Limited, finding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compliance&lt;/div&gt; with environmental laws and assessed a penalty of $1.4&#160;million. The Company disputed certain of the findings and the amount of the penalty and filed an appeal before the Supreme Court of India. On August&#160;5, 2021, the Supreme Court of India admitted the appeal for hearing and granted an interim unconditional stay on the National Green Tribunal&#x2019;s order. The Company does not believe that the eventual outcome of such matter will have a material effect on its business. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other Matters &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;1, 2018, former shareholders of Ception Therapeutics, Inc., a company that was acquired by and merged into Cephalon in 2010, prior to Cephalon&#x2019;s acquisition by Teva, filed breach of contract and other related claims against the Company, Teva USA and Cephalon in the Delaware Court of Chancery.&#160;Among other things, the plaintiffs allege that Cephalon breached the terms of the 2010 Ception-Cephalon merger agreement by failing to exercise commercially reasonable efforts to develop and commercialize CINQAIR&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; (reslizumab) for the treatment of eosinophilic esophagitis (&#x201c;EE&#x201d;). The plaintiffs claim damages of at least $200&#160;million, an amount they allege is equivalent to the milestones payable to the former shareholders of Ception in the event Cephalon were to obtain regulatory approval for EE in the United States ($150 million) and Europe ($50 million). On December&#160;28, 2018, following defendants&#x2019; motion to dismiss the complaint, the court granted the motion in part and dismissed all of plaintiffs&#x2019; claims, except for their claim against Cephalon for breach of contract. In November 2021, plaintiffs moved to amend their complaint to, among other things, reassert claims against the Company and Teva USA. However, on July&#160;12, 2022, plaintiffs filed a new amended complaint that includes claims against Teva USA but not the Company, in exchange for Teva USA&#x2019;s agreement to guarantee any judgment entered against Cephalon in the litigation. A bench trial for this matter was held in September 2022, and a ruling is expected in 2023, following closing arguments.&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March 15, 2022, The Scripps Research Institute (&#x201c;Scripps&#x201d;) filed claims against Teva&#x2019;s subsidiary, Teva Pharmaceuticals International GmbH (&#x201c;TPIG&#x201d;) in the United States District Court for the Southern District of California for alleged breach of a sublicense agreement between Scripps and Ivax Corporation (&#x201c;Ivax&#x201d;) dated November 2000 (&#x201c;Sublicense Agreement&#x201d;). After Teva&#x2019;s acquisition of Ivax, TPIG became the successor-in-interest to Ivax under the Sublicense Agreement, pursuant to which Scripps licensed to Ivax certain rights to the drug cladribine. Scripps alleges that TPIG breached the Sublicense Agreement by failing to pay royalties on sales of cladribine in certain countries, and is seeking breach of contract damages for royalties allegedly due but not paid, as well as a declaratory judgment related to royalties due in the future. On November 17, 2022, the Court dismissed Scripps&#x2019; claim for breach of the implied covenant of good faith and fair dealing but denied TPIG&#x2019;s motion to dismiss Scripps&#x2019; breach of contract and declaratory judgment claims. TPIG answered the first amended complaint on December 16, 2022, and discovery is ongoing. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;Gain Contingencies&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;From time to time, Teva may directly or indirectly pursue claims against certain parties, including but not limited to patent infringement lawsuits against other pharmaceutical companies to protect its patent rights, as well as derivative actions brought on behalf of Teva. Teva recognizes gain contingencies from the defendants in such lawsuits when they are realized or when all related contingencies have been resolved. No gain has been recognized regarding the matters disclosed below, unless mentioned otherwise. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In October 2017, Teva filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that Eli Lilly&#160;&amp;amp; Co.&#x2019;s (&#x201c;Lilly&#x201d;) marketing and sale of its galcanezumab product for the treatment of migraine infringes nine Teva patents, including three method of treatment patents and six composition of matter patents. Lilly then submitted inter partes review (&#x201c;IPR&#x201d;) petitions to the Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;), challenging the validity of the nine Teva patents. The PTAB issued decisions upholding the three method of treatment patents but finding the six composition of matter patents invalid, which decisions were affirmed by the Court of Appeals for the Federal Circuit on August&#160;16, 2021. A jury trial regarding the three method of treatment patents began on October&#160;18, 2022, and on November&#160;9, 2022, the jury issued a verdict in Teva&#x2019;s favor, finding the three method of treatment patents valid and infringed by Lilly and awarding Teva $176.5&#160;million in damages. On January&#160;28, 2023, Lilly filed a motion requesting that the District Court overturn the jury&#x2019;s verdict. Once the motion is decided, the losing party may appeal the decision to the Court of Appeals for the Federal Circuit. On June&#160;8, 2021, Teva filed another lawsuit in the U.S. District Court for the District of Massachusetts alleging that Lilly&#x2019;s marketing and sale of galcanezumab product infringes two patents related to the treatment of refractory migraine. Lilly&#x2019;s IPR petitions challenging the patentability of these two patents as well as a third patent also related to the treatment of refractory migraine were instituted by the PTAB. The litigation in the District of Massachusetts was stayed during the pendency of these IPR proceedings. Teva intends to continue to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Motions to approve derivative actions seeking monetary damages against certain past and present directors and officers have been filed in Israeli Courts alleging negligence and recklessness, as well as motions for document disclosure prior to initiating derivative actions. Motions were filed with respect to several U.S. and EU settlement agreements, opioids, allegations related to the DOJ&#x2019;s complaint regarding COPAXONE patient assistance program in the U.S., and with respect to the COPAXONE European Commission&#x2019;s inspection. &lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <teva:DamagesAssessment
      contextRef="PAsOn03_31_2023"
      decimals="-5"
      unitRef="Unit_USD">235500000</teva:DamagesAssessment>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="P08_05_2021To08_05_2021"
      decimals="-5"
      unitRef="Unit_USD">235500000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_EUR">60500000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <teva:AnnualSalesOfEffexor
      contextRef="P08_21_2018To08_21_2022"
      decimals="-8"
      unitRef="Unit_USD">2600000000</teva:AnnualSalesOfEffexor>
    <teva:AnnualSalesOfLamictal
      contextRef="PAsOn02_28_2005"
      decimals="-6"
      unitRef="Unit_USD">950000000</teva:AnnualSalesOfLamictal>
    <teva:AnnualSalesOfLamictal
      contextRef="PAsOn07_31_2008"
      decimals="-5"
      unitRef="Unit_USD">2300000</teva:AnnualSalesOfLamictal>
    <teva:AnnualSalesOfNiaspan
      contextRef="P04_01_2013To04_30_2013"
      decimals="-6"
      unitRef="Unit_USD">416000000</teva:AnnualSalesOfNiaspan>
    <teva:AnnualSalesOfNiaspan
      contextRef="P09_01_2013To09_30_2013"
      decimals="-8"
      unitRef="Unit_USD">1100000000</teva:AnnualSalesOfNiaspan>
    <teva:AnnualSalesOfActos
      contextRef="P12_01_2010To12_31_2010"
      decimals="-8"
      unitRef="Unit_USD">3700000000</teva:AnnualSalesOfActos>
    <teva:AnnualSalesOfActoplus
      contextRef="P12_01_2010To12_31_2010"
      decimals="-6"
      unitRef="Unit_USD">500000000</teva:AnnualSalesOfActoplus>
    <teva:AnnualSalesOfActos
      contextRef="P08_01_2012To08_31_2012"
      decimals="-8"
      unitRef="Unit_USD">2800000000</teva:AnnualSalesOfActos>
    <teva:AnnualSalesOfActoplus
      contextRef="P08_01_2012To08_31_2012"
      decimals="-6"
      unitRef="Unit_USD">430000000</teva:AnnualSalesOfActoplus>
    <teva:AnnualSalesOfSensipar
      contextRef="P01_01_2019To12_31_2019"
      decimals="-8"
      unitRef="Unit_USD">1400000000</teva:AnnualSalesOfSensipar>
    <teva:AnnualSalesAtTimeOfSettlement
      contextRef="PAsOn08_31_2019"
      decimals="-6"
      unitRef="Unit_USD">350000000</teva:AnnualSalesAtTimeOfSettlement>
    <teva:AnnualSalesAtTimeOfSettlement
      contextRef="PAsOn08_31_2019_AndroGelRateAtOnePercentageMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">140000000</teva:AnnualSalesAtTimeOfSettlement>
    <teva:AnnualSalesAtTimeOfSettlement
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">700000000</teva:AnnualSalesAtTimeOfSettlement>
    <teva:AnnualSalesOfTheTimeOfSettlementOfViread
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">582000000</teva:AnnualSalesOfTheTimeOfSettlementOfViread>
    <teva:AnnualSalesOfTheTimeOfSettlementOfTruvada
      contextRef="P01_01_2023To03_31_2023"
      decimals="-8"
      unitRef="Unit_USD">2400000000</teva:AnnualSalesOfTheTimeOfSettlementOfTruvada>
    <teva:AnnualSalesOfTheTimeOfSettlementOfAtripla
      contextRef="P01_01_2023To03_31_2023"
      decimals="-8"
      unitRef="Unit_USD">2900000000</teva:AnnualSalesOfTheTimeOfSettlementOfAtripla>
    <teva:AnnualSalesOfTheTimeOfNewLaunchOfViread
      contextRef="P01_01_2017To12_31_2017"
      decimals="-6"
      unitRef="Unit_USD">728000000</teva:AnnualSalesOfTheTimeOfNewLaunchOfViread>
    <teva:AnnualSalesOfTheTimeOfNewLaunchOfTruvada
      contextRef="P01_01_2020To12_31_2020"
      decimals="-8"
      unitRef="Unit_USD">2100000000</teva:AnnualSalesOfTheTimeOfNewLaunchOfTruvada>
    <teva:AnnualSalesOfTheTimeOfNewLaunchOfAtripla
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">444000000</teva:AnnualSalesOfTheTimeOfNewLaunchOfAtripla>
    <teva:AnnualSalesOfCopaxone
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">373000000</teva:AnnualSalesOfCopaxone>
    <teva:AnnualSalesOfColcrys
      contextRef="P01_01_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">187000000</teva:AnnualSalesOfColcrys>
    <teva:AnnualSalesOfRevlimid
      contextRef="P01_01_2023To03_31_2023"
      decimals="-8"
      unitRef="Unit_USD">3500000000</teva:AnnualSalesOfRevlimid>
    <teva:AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler
      contextRef="P12_31_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">300000000</teva:AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler>
    <teva:AnnualSalesOfEpipen
      contextRef="P12_31_2022To12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">600000000</teva:AnnualSalesOfEpipen>
    <teva:LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation
      contextRef="P12_31_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">1000000</teva:LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation>
    <teva:PercentageOfShareOfTheNationalPopulation
      contextRef="P12_31_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.01</teva:PercentageOfShareOfTheNationalPopulation>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis"
      decimals="-9"
      unitRef="Unit_USD">26000000000</us-gaap:LossContingencyDamagesPaidValue>
    <teva:LitigationSettlementAmountAwardedDistributionPeriod contextRef="P07_21_2021To07_21_2021_FourOtherDefendantsOtherThanTevaMemberTEVADefendantsAxis_NationwideSettlementMembersrtLitigationCaseAxis">P18Y</teva:LitigationSettlementAmountAwardedDistributionPeriod>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="P11_30_2022To11_30_2022"
      decimals="-7"
      unitRef="Unit_USD">4250000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <teva:LitigationSettlementAmountAwardedDistributionPeriod contextRef="P11_30_2022To11_30_2022">P13Y</teva:LitigationSettlementAmountAwardedDistributionPeriod>
    <teva:LitigationSettlementAmountDistributableinKind
      contextRef="PAsOn11_30_2022"
      decimals="-8"
      unitRef="Unit_USD">1200000000</teva:LitigationSettlementAmountDistributableinKind>
    <teva:LitigationSettlementAmountPayableInCashPercentage
      contextRef="PAsOn11_30_2022"
      decimals="2"
      unitRef="Unit_pure">0.20</teva:LitigationSettlementAmountPayableInCashPercentage>
    <teva:LitigationSettlementAmountDistributableInCash
      contextRef="PAsOn11_30_2022"
      decimals="-6"
      unitRef="Unit_USD">240000000</teva:LitigationSettlementAmountDistributableInCash>
    <teva:PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      unitRef="Unit_pure">0.99</teva:PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement>
    <teva:PercentageOfThePopulationOfTheParticipatingStates
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      unitRef="Unit_pure">0.98</teva:PercentageOfThePopulationOfTheParticipatingStates>
    <us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock contextRef="P01_01_2023To03_31_2023">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 23%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 13%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 13%;"/&gt;
&lt;td style="vertical-align: bottom;"/&gt;
&lt;td style="width: 7%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 18%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 17%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Jurisdiction&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Settlement&lt;br/&gt;Payment&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px"&gt;*&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment&lt;br/&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Settlement Product&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product&#160;WAC&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Value&#160;and&#160;Term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;June 7, 2019&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Oklahoma&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$72.3&#160;million (paid)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;1 year&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;N/A&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;N/A&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;December 27, 2019&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Cuyahoga County, OH&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$12.4&#160;million (paid)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;2.5 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;buprenorphine naloxone&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;(generic Suboxone&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$15.5&#160;million (3 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;December 27, 2019&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Summit County, OH&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$7.6&#160;million (paid)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;2.5 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;buprenorphine naloxone&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;(generic Suboxone&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$9.5&#160;million (3 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;January 18, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Louisiana&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$15&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;18 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;buprenorphine naloxone&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;(generic Suboxone&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$3&#160;million (1 year)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;February 4, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Texas&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$131.5&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;15 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;naloxone hydrochloride (generic Narcan&#xae;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$75&#160;million (10 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;March 21, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Rhode Island&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$21&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;13 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;naloxone hydrochloride (generic Narcan&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;) and&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;buprenorphine naloxone (generic Suboxone&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$78.5&#160;million (10 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;March 30, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Florida&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$177.1&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;15 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;naloxone hydrochloride (generic Narcan&#xae;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$84&#160;million (10 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;July 12, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;San Francisco&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$19.5&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;13 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;naloxone hydrochloride (generic Narcan&#xae;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$20&#160;million (10 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;September 19, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;West Virginia&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$75.4&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;15 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;naloxone hydrochloride (generic Narcan&#xae;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$27&#160;million (10 years)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;November 3, 2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;New York&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$313.3 million&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;**&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;18 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;N/A&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;N/A&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;February 24, 2023&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Tribes&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$108.3&#160;million&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;13 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;naloxone hydrochloride (generic Narcan&#xae;)&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;$25&#160;million (10 years)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;*&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts exclude attorneys&#x2019; fees and costs, except New York. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;**&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Not including cash payment and attorneys&#x2019; fees allocated under the nationwide settlement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock>
    <us-gaap:LossContingencySettlementAgreementDate contextRef="P01_01_2023To03_31_2023_OKusgaapStatutoryAccountingPracticesByJurisdictionAxis">June 7, 2019</us-gaap:LossContingencySettlementAgreementDate>
    <us-gaap:LossContingencyDomicileOfLitigation contextRef="P01_01_2023To03_31_2023_OKusgaapStatutoryAccountingPracticesByJurisdictionAxis">Oklahoma</us-gaap:LossContingencyDomicileOfLitigation>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P01_01_2023To03_31_2023_OKusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-5"
      id="Fact_78649399"
      unitRef="Unit_USD">72300000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencySettlementAgreementTerms contextRef="P01_01_2023To03_31_2023_OKusgaapStatutoryAccountingPracticesByJurisdictionAxis">1 year</us-gaap:LossContingencySettlementAgreementTerms>
    <us-gaap:LossContingencySettlementAgreementDate contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">December 27, 2019</us-gaap:LossContingencySettlementAgreementDate>
    <us-gaap:LossContingencyDomicileOfLitigation contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">Cuyahoga County, OH</us-gaap:LossContingencyDomicileOfLitigation>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-5"
      id="Fact_78649400"
      unitRef="Unit_USD">12400000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencySettlementAgreementTerms contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">2.5 years</us-gaap:LossContingencySettlementAgreementTerms>
    <teva:ContingencySettlementProduct contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">buprenorphine naloxone (generic Suboxone&#xae;)</teva:ContingencySettlementProduct>
    <teva:ProductWeightedAverageCost
      contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-5"
      unitRef="Unit_USD">15500000</teva:ProductWeightedAverageCost>
    <teva:ProductWeightedAverageCostTerm contextRef="P01_01_2023To03_31_2023_CuyahogaCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">P3Y</teva:ProductWeightedAverageCostTerm>
    <us-gaap:LossContingencySettlementAgreementDate contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">December 27, 2019</us-gaap:LossContingencySettlementAgreementDate>
    <us-gaap:LossContingencyDomicileOfLitigation contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">Summit County, OH</us-gaap:LossContingencyDomicileOfLitigation>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-5"
      id="Fact_78649401"
      unitRef="Unit_USD">7600000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencySettlementAgreementTerms contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">2.5 years</us-gaap:LossContingencySettlementAgreementTerms>
    <teva:ContingencySettlementProduct contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">buprenorphine naloxone (generic Suboxone&#xae;)</teva:ContingencySettlementProduct>
    <teva:ProductWeightedAverageCost
      contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-5"
      unitRef="Unit_USD">9500000</teva:ProductWeightedAverageCost>
    <teva:ProductWeightedAverageCostTerm contextRef="P01_01_2023To03_31_2023_SummitCountyOhMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">P3Y</teva:ProductWeightedAverageCostTerm>
    <us-gaap:LossContingencySettlementAgreementDate contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis">January 18, 2022</us-gaap:LossContingencySettlementAgreementDate>
    <us-gaap:LossContingencyDomicileOfLitigation contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis">Louisiana</us-gaap:LossContingencyDomicileOfLitigation>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-6"
      id="Fact_78649402"
      unitRef="Unit_USD">15000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencySettlementAgreementTerms contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis">18 years</us-gaap:LossContingencySettlementAgreementTerms>
    <teva:ContingencySettlementProduct contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis">buprenorphine naloxone (generic Suboxone&#xae;)</teva:ContingencySettlementProduct>
    <teva:ProductWeightedAverageCost
      contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</teva:ProductWeightedAverageCost>
    <teva:ProductWeightedAverageCostTerm contextRef="P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis">P1Y</teva:ProductWeightedAverageCostTerm>
    <us-gaap:LossContingencySettlementAgreementDate contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis">February 4, 2022</us-gaap:LossContingencySettlementAgreementDate>
    <us-gaap:LossContingencyDomicileOfLitigation contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis">Texas</us-gaap:LossContingencyDomicileOfLitigation>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-5"
      id="Fact_78649403"
      unitRef="Unit_USD">131500000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencySettlementAgreementTerms contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis">15 years</us-gaap:LossContingencySettlementAgreementTerms>
    <teva:ContingencySettlementProduct contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis">naloxone hydrochloride (generic Narcan&#xae;)</teva:ContingencySettlementProduct>
    <teva:ProductWeightedAverageCost
      contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-6"
      unitRef="Unit_USD">75000000</teva:ProductWeightedAverageCost>
    <teva:ProductWeightedAverageCostTerm contextRef="P01_01_2023To03_31_2023_TXusgaapStatutoryAccountingPracticesByJurisdictionAxis">P10Y</teva:ProductWeightedAverageCostTerm>
    <us-gaap:LossContingencySettlementAgreementDate contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis">March 21, 2022</us-gaap:LossContingencySettlementAgreementDate>
    <us-gaap:LossContingencyDomicileOfLitigation contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis">Rhode Island</us-gaap:LossContingencyDomicileOfLitigation>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-6"
      id="Fact_78649404"
      unitRef="Unit_USD">21000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencySettlementAgreementTerms contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis">13 years</us-gaap:LossContingencySettlementAgreementTerms>
    <teva:ContingencySettlementProduct contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis">naloxone hydrochloride (generic Narcan&#xae;) and buprenorphine naloxone (generic Suboxone&#xae;)</teva:ContingencySettlementProduct>
    <teva:ProductWeightedAverageCost
      contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-5"
      unitRef="Unit_USD">78500000</teva:ProductWeightedAverageCost>
    <teva:ProductWeightedAverageCostTerm contextRef="P01_01_2023To03_31_2023_RIusgaapStatutoryAccountingPracticesByJurisdictionAxis">P10Y</teva:ProductWeightedAverageCostTerm>
    <us-gaap:LossContingencySettlementAgreementDate contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis">March 30, 2022</us-gaap:LossContingencySettlementAgreementDate>
    <us-gaap:LossContingencyDomicileOfLitigation contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis">Florida</us-gaap:LossContingencyDomicileOfLitigation>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-5"
      id="Fact_78649405"
      unitRef="Unit_USD">177100000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencySettlementAgreementTerms contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis">15 years</us-gaap:LossContingencySettlementAgreementTerms>
    <teva:ContingencySettlementProduct contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis">naloxone hydrochloride (generic Narcan&#xae;)</teva:ContingencySettlementProduct>
    <teva:ProductWeightedAverageCost
      contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-6"
      unitRef="Unit_USD">84000000</teva:ProductWeightedAverageCost>
    <teva:ProductWeightedAverageCostTerm contextRef="P01_01_2023To03_31_2023_FLusgaapStatutoryAccountingPracticesByJurisdictionAxis">P10Y</teva:ProductWeightedAverageCostTerm>
    <us-gaap:LossContingencySettlementAgreementDate contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">July 12, 2022</us-gaap:LossContingencySettlementAgreementDate>
    <us-gaap:LossContingencyDomicileOfLitigation contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">San Francisco</us-gaap:LossContingencyDomicileOfLitigation>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-5"
      id="Fact_78649406"
      unitRef="Unit_USD">19500000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencySettlementAgreementTerms contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">13 years</us-gaap:LossContingencySettlementAgreementTerms>
    <teva:ContingencySettlementProduct contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">naloxone hydrochloride (generic Narcan&#xae;)</teva:ContingencySettlementProduct>
    <teva:ProductWeightedAverageCost
      contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</teva:ProductWeightedAverageCost>
    <teva:ProductWeightedAverageCostTerm contextRef="P01_01_2023To03_31_2023_SanFranciscoMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">P10Y</teva:ProductWeightedAverageCostTerm>
    <us-gaap:LossContingencySettlementAgreementDate contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis">September 19, 2022</us-gaap:LossContingencySettlementAgreementDate>
    <us-gaap:LossContingencyDomicileOfLitigation contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis">West Virginia</us-gaap:LossContingencyDomicileOfLitigation>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-5"
      id="Fact_78649407"
      unitRef="Unit_USD">75400000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencySettlementAgreementTerms contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis">15 years</us-gaap:LossContingencySettlementAgreementTerms>
    <teva:ContingencySettlementProduct contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis">naloxone hydrochloride (generic Narcan&#xae;)</teva:ContingencySettlementProduct>
    <teva:ProductWeightedAverageCost
      contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-6"
      unitRef="Unit_USD">27000000</teva:ProductWeightedAverageCost>
    <teva:ProductWeightedAverageCostTerm contextRef="P01_01_2023To03_31_2023_WVusgaapStatutoryAccountingPracticesByJurisdictionAxis">P10Y</teva:ProductWeightedAverageCostTerm>
    <us-gaap:LossContingencySettlementAgreementDate contextRef="P01_01_2023To03_31_2023_NYusgaapStatutoryAccountingPracticesByJurisdictionAxis">November 3, 2022</us-gaap:LossContingencySettlementAgreementDate>
    <us-gaap:LossContingencyDomicileOfLitigation contextRef="P01_01_2023To03_31_2023_NYusgaapStatutoryAccountingPracticesByJurisdictionAxis">New York</us-gaap:LossContingencyDomicileOfLitigation>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P01_01_2023To03_31_2023_NYusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-5"
      id="Fact_78649408"
      unitRef="Unit_USD">313300000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencySettlementAgreementTerms contextRef="P01_01_2023To03_31_2023_NYusgaapStatutoryAccountingPracticesByJurisdictionAxis">18 years</us-gaap:LossContingencySettlementAgreementTerms>
    <teva:ContingencySettlementProduct contextRef="P01_01_2023To03_31_2023_NYusgaapStatutoryAccountingPracticesByJurisdictionAxis">N/A</teva:ContingencySettlementProduct>
    <us-gaap:LossContingencySettlementAgreementDate contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">February 24, 2023</us-gaap:LossContingencySettlementAgreementDate>
    <us-gaap:LossContingencyDomicileOfLitigation contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">Tribes</us-gaap:LossContingencyDomicileOfLitigation>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-5"
      id="Fact_78649409"
      unitRef="Unit_USD">108300000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencySettlementAgreementTerms contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">13 years</us-gaap:LossContingencySettlementAgreementTerms>
    <teva:ContingencySettlementProduct contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">naloxone hydrochloride (generic Narcan&#xae;)</teva:ContingencySettlementProduct>
    <teva:ProductWeightedAverageCost
      contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis"
      decimals="-6"
      unitRef="Unit_USD">25000000</teva:ProductWeightedAverageCost>
    <teva:ProductWeightedAverageCostTerm contextRef="P01_01_2023To03_31_2023_TribesMemberusgaapStatutoryAccountingPracticesByJurisdictionAxis">P10Y</teva:ProductWeightedAverageCostTerm>
    <us-gaap:AccrualForEnvironmentalLossContingencies
      contextRef="PAsOn03_31_2023"
      decimals="0"
      unitRef="Unit_USD">300000</us-gaap:AccrualForEnvironmentalLossContingencies>
    <teva:LossContingenciesOnEnvironmentalLawsPenalty
      contextRef="PAsOn07_08_2021"
      decimals="-5"
      unitRef="Unit_USD">1400000</teva:LossContingenciesOnEnvironmentalLawsPenalty>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="P01_01_2021To09_30_2021_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis"
      decimals="-6"
      unitRef="Unit_USD">200000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="P01_01_2021To09_30_2021_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_USsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">150000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="P01_01_2021To09_30_2021_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">50000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="P11_09_2022To11_09_2022"
      decimals="-5"
      unitRef="Unit_USD">176500000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 11 &#x2013; Income taxes: &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the first quarter of 2023, Teva recognized a tax benefit of $19&#160;million, on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; loss of $258&#160;million. In the first quarter of 2022, Teva recognized a tax expense of $2&#160;million, on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; loss of $971&#160;million. Teva&#x2019;s tax rate for the first quarter of 2023 was mainly affected by legal settlements, impairments, amortization and interest expense disallowances. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The statutory Israeli corporate tax rate is 23%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;in 2023. Teva&#x2019;s tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, interest expense disallowances, tax benefits in Israel and other countries, as well as infrequent or non-recurring items.&#160;&lt;/div&gt; &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="null;text-indent: 0px;;display:inline;"&gt;Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. A trial for this case is currently scheduled to begin in July 2023. A final and binding decision against Teva in this case may lead to a charge of $&lt;/div&gt;128&#160;million. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Israeli tax authorities (&#x201c;ITA&#x201d;) issued tax assessment decrees for 2008-2011, 2012 and 2013-2016, challenging the Company&#x2019;s positions on several issues. Teva has protested the 2008-2011, 2012 and 2013-2016 decrees before the Central District Court in Israel. On April&#160;17, 2023, the ITA issued a tax assessment for 2017-2020, challenging the Company&#x2019;s positions on several issues. The Company intends to challenge the tax assessment for 2017-2020, as well. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In October 2021, the Central District Court in Israel held in favor of the ITA with respect to 2008-2011 decrees. The case with respect to 2012-2016 remains pending with similar legal and other claims. Teva appealed this decision to the Israeli Supreme Court and expects the appeal hearing to begin in the second half of 2023. The tax liability resulting from the October 2021 Central District Court decision, with respect to the decrees for 2008-2011 and with regard to the similar legal claims in the related following years, was approximately $350&#160;million, of which a portion has been and will continue to be paid during 2022 and 2023. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company believes it has adequately provided for all of its uncertain tax positions, including those items currently under dispute, however, adverse results could be material. &lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-19000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-258000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-971000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To03_31_2023_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <teva:ExpectedImpairmentOfIncomeTaxBenefit
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">128000000</teva:ExpectedImpairmentOfIncomeTaxBenefit>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="P10_01_2021To10_31_2021_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_TaxYear2008To2011MemberusgaapTaxPeriodAxis"
      decimals="-6"
      unitRef="Unit_USD">350000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <teva:OtherExpensesTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%; text-indent: -2%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 12 &#x2013; Other assets impairments, restructuring and other items: &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:81%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden78649487"&gt;Impairments&lt;/span&gt; of long-lived tangible assets (1)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Contingent consideration&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restructuring&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Including impairments related to exit and disposal activities. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Impairments of tangible assets for the three months ended March&#160;31, 2023 and 2022 were $10&#160;million and $16&#160;million, respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its network consolidation activities. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the three months ended March&#160;31, 2023, Teva recorded an expense of $20&#160;million for contingent consideration, compared to an expense of $33&#160;million in the three months ended March&#160;31, 2022. The expense in the first three months of 2023 was mainly related to a change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales and a change in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;). The expense in the first three months of 2022 was mainly related to a change in the estimated future royalty payments in connection with lenalidomide (generic equivalent of Revlimid&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;). &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"/&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restructuring &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the three months ended March&#160;31, 2023, Teva recorded $56&#160;million of restructuring expenses, compared to $57&#160;million in the three months ended March&#160;31, 2022. The expenses for the three months ended March&#160;31, 2023 and March&#160;31, 2022 were primarily related to network consolidation activities. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables provide the components of restructuring costs: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:82%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restructuring&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Employee termination&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;   &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides the components of and changes in the Company&#x2019;s restructuring accruals: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:67%"/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee&#160;termination&lt;br/&gt; costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of January&#160;1, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(112&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provision&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Utilization and other*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of March&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:68%"/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee&#160;termination&lt;br/&gt; costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of January&#160;1, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(138&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provision&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Utilization and other*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of March&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(130&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Includes adjustments for foreign currency translation. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:OtherExpensesTextBlock>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="P01_01_2023To03_31_2023">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:81%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden78649487"&gt;Impairments&lt;/span&gt; of long-lived tangible assets (1)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Contingent consideration&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restructuring&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Including impairments related to exit and disposal activities. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      id="Fact_78648932"
      unitRef="Unit_USD">10000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      id="Fact_78648933"
      unitRef="Unit_USD">16000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">20000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">56000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:RestructuringCharges>
    <teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">9000000</teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses>
    <teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">21000000</teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses>
    <teva:ImpairmentAndRestructuring
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">96000000</teva:ImpairmentAndRestructuring>
    <teva:ImpairmentAndRestructuring
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">128000000</teva:ImpairmentAndRestructuring>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">16000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">20000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">56000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:RestructuringCharges>
    <teva:ScheduleOfRestructuringChargesTableTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables provide the components of restructuring costs: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:82%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restructuring&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Employee termination&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:ScheduleOfRestructuringChargesTableTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2022To03_31_2022_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">52000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2022To03_31_2022_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">56000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides the components of and changes in the Company&#x2019;s restructuring accruals: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:67%"/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee&#160;termination&lt;br/&gt; costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of January&#160;1, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(112&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provision&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Utilization and other*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of March&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:68%"/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee&#160;termination&lt;br/&gt; costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of January&#160;1, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(138&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provision&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Utilization and other*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of March&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(130&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Includes adjustments for foreign currency translation. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">112000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">119000000</us-gaap:RestructuringReserve>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2023To03_31_2023_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</teva:RestructuringAccrualProvision>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2023To03_31_2023_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">33000000</teva:RestructuringAccrualProvision>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">56000000</teva:RestructuringAccrualProvision>
    <teva:UtilizationAndOther
      contextRef="P01_01_2023To03_31_2023_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      id="Fact_78648968"
      unitRef="Unit_USD">25000000</teva:UtilizationAndOther>
    <teva:UtilizationAndOther
      contextRef="P01_01_2023To03_31_2023_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      id="Fact_78648969"
      unitRef="Unit_USD">27000000</teva:UtilizationAndOther>
    <teva:UtilizationAndOther
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      id="Fact_78648964"
      unitRef="Unit_USD">52000000</teva:UtilizationAndOther>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn03_31_2023_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">110000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn03_31_2023_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">13000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">123000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2021_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">131000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2021_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">138000000</us-gaap:RestructuringReserve>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2022To03_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">52000000</teva:RestructuringAccrualProvision>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2022To03_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</teva:RestructuringAccrualProvision>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">57000000</teva:RestructuringAccrualProvision>
    <teva:UtilizationAndOther
      contextRef="P01_01_2022To03_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      id="Fact_78648965"
      unitRef="Unit_USD">59000000</teva:UtilizationAndOther>
    <teva:UtilizationAndOther
      contextRef="P01_01_2022To03_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      id="Fact_78648966"
      unitRef="Unit_USD">6000000</teva:UtilizationAndOther>
    <teva:UtilizationAndOther
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      id="Fact_78648967"
      unitRef="Unit_USD">65000000</teva:UtilizationAndOther>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn03_31_2022_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">124000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn03_31_2022_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">130000000</us-gaap:RestructuringReserve>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 13 &#x2013; Earnings (Loss) per share: &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva&#x2019;s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested restricted share units (&#x201c;RSUs&#x201d;) and performance share units (&#x201c;PSUs&#x201d;) during the period, net of treasury shares. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In computing diluted loss per share for the three months ended March&#160;31, 2023 and 2022, no account was taken of the potential dilution that could occur upon the exercise of options and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended March&#160;31, 2023 and 2022 were 1,115&#160;million and 1,107&#160;million shares, respectively. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"/&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted loss per share was $0.18 for the three months ended March&#160;31, 2023, compared to basic and diluted loss per share of $0.86 for the three months ended March&#160;31, 2022. &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To03_31_2022_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To03_31_2023_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_shares">1115000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_shares">1107000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 14 &#x2013; Accumulated other comprehensive income (loss): &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:58%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;Unrealized&#160;Gains&#160;(Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Benefit&#160;Plans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;br/&gt; adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative&lt;br/&gt; financial&lt;br/&gt; instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Actuarial&#160;gains&lt;br/&gt; (losses) and&lt;br/&gt; prior service&lt;br/&gt; (costs) credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of December&#160;31, 2022, net of taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,514&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(295&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,838&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other comprehensive income (loss) before reclassifications&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amounts reclassified to the statements of income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net other comprehensive income (loss) before tax&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corresponding income tax&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net other comprehensive income (loss) after tax*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of March&#160;31, 2023, net of taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,385&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(287&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,701&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Amounts do not include a $9&#160;million loss from foreign currency translation adjustments attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:58%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;Unrealized&#160;Gains&#160;(Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Benefit&#160;Plans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;br/&gt; adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative&lt;br/&gt; financial&lt;br/&gt; instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Actuarial&#160;gains&lt;br/&gt; (losses) and&lt;br/&gt; prior service&lt;br/&gt; (costs)&#160;credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;Balance as of December&#160;31, 2021, net of taxes&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,274&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(324&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,683&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Other comprehensive income (loss) before reclassifications&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;Amounts reclassified to the statements of income&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Net other comprehensive income (loss) before tax&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;Corresponding income tax&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Net other comprehensive income (loss) after tax*&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;Balance as of March&#160;31, 2022, net of taxes&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,285&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,687&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Amounts do not include a $53&#160;million loss from foreign currency translation adjustments attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:58%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;Unrealized&#160;Gains&#160;(Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Benefit&#160;Plans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;br/&gt; adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative&lt;br/&gt; financial&lt;br/&gt; instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Actuarial&#160;gains&lt;br/&gt; (losses) and&lt;br/&gt; prior service&lt;br/&gt; (costs) credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of December&#160;31, 2022, net of taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,514&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(295&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,838&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other comprehensive income (loss) before reclassifications&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amounts reclassified to the statements of income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net other comprehensive income (loss) before tax&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corresponding income tax&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net other comprehensive income (loss) after tax*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of March&#160;31, 2023, net of taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,385&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(287&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,701&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Amounts do not include a $9&#160;million loss from foreign currency translation adjustments attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:58%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;Unrealized&#160;Gains&#160;(Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Benefit&#160;Plans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;br/&gt; adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative&lt;br/&gt; financial&lt;br/&gt; instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Actuarial&#160;gains&lt;br/&gt; (losses) and&lt;br/&gt; prior service&lt;br/&gt; (costs)&#160;credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;Balance as of December&#160;31, 2021, net of taxes&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,274&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(324&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,683&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Other comprehensive income (loss) before reclassifications&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;Amounts reclassified to the statements of income&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Net other comprehensive income (loss) before tax&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;Corresponding income tax&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Net other comprehensive income (loss) after tax*&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;Balance as of March&#160;31, 2022, net of taxes&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,285&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,687&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Amounts do not include a $53&#160;million loss from foreign currency translation adjustments attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2514000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-295000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-28000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2838000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2023To03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">122000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">122000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2023To03_31_2023_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-8000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2023To03_31_2023_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-7000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2023To03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">122000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2023To03_31_2023_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">8000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2023To03_31_2023_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">129000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2023To03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-7000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-7000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2023To03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_78649200"
      unitRef="Unit_USD">129000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2023To03_31_2023_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_78649199"
      unitRef="Unit_USD">8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2023To03_31_2023_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_78649198"
      unitRef="Unit_USD">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2023To03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_78649197"
      unitRef="Unit_USD">136000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2385000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2023_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-287000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2023_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-29000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2701000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2023To03_31_2023_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      decimals="-6"
      unitRef="Unit_USD">9000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2274000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-324000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-85000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2683000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2022To03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2022To03_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-7000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-7000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2022To03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2022To03_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2022To03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2022To03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_78649196"
      unitRef="Unit_USD">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2022To03_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_78649195"
      unitRef="Unit_USD">7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_78649194"
      unitRef="Unit_USD">-4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2285000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2022_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-317000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2022_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-85000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2687000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To03_31_2022_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      decimals="-6"
      unitRef="Unit_USD">53000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 15 &#x2013; Segments: &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva operates its business and reports its financial results in three segments: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;North America segment, which includes the United States and Canada. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Europe segment, which includes the European Union, the United Kingdom and certain other European countries. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(c)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;International Markets segment, which includes all countries other than those in the North America and Europe segments. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div/&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licensing&lt;/div&gt; platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva&#x2019;s Chief Executive Officer (&#x201c;CEO&#x201d;), who is the chief operating decision maker (&#x201c;CODM&#x201d;), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely North America, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Segment profit is comprised of gross profit for the segment less R&amp;amp;D expenses, S&amp;amp;M expenses, G&amp;amp;A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva&#x2019;s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Teva&#x2019;s CEO may review its strategy and organizational structure from time to time. Currently, Teva&#x2019;s newly appointed CEO is reviewing its strategy and organizational structure. Any changes in strategy may lead to a reevaluation of the Company&#x2019;s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 3 and note 6. &lt;/div&gt;&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a. Segment information: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:61%"/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenues&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,766&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;812&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;262&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;156&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;223&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;102&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Segment profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;332&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenues&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,737&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,156&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;890&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;694&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;245&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Segment profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;402&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents a reconciliation of Teva&#x2019;s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended March&#160;31, 2023 and 2022: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:83%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;North America profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;332&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;402&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Europe profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;International Markets profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total reportable segments profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;791&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Profit (loss) of other activities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total segments profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;785&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,013&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amounts not allocated to segments:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other assets impairments, restructuring and other items&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangible assets impairments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;149&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legal settlements and loss contingencies&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;233&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other unallocated amounts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consolidated operating income (loss)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(713&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial expenses, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consolidated income (loss) before income taxes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(971&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b. Segment revenues by major products and activities: &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables present revenues by major products and activities for the three months ended March&#160;31, 2023 and 2022: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;North America&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Generic products&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;899&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;AJOVY&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;AUSTEDO&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;170&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;154&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;BENDEKA&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and TREANDA&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;COPAXONE&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Anda&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;342&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;139&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,766&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,737&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; background-color: rgb(204, 238, 255); font-size: 0px;"&gt;
&lt;td colspan="8" style="vertical-align:bottom"/&gt;
&lt;td style="vertical-align:bottom"/&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;  &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;Europe&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Generic products&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;932&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;AJOVY&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;COPAXONE&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Respiratory products&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,156&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;International markets&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Generic products&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;388&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;AJOVY&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;COPAXONE&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="P01_01_2023To03_31_2023"
      decimals="INF"
      unitRef="Unit_Segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a. Segment information: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:61%"/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenues&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,766&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;812&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;262&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;156&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;223&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;102&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Segment profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;332&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenues&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,737&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,156&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;890&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;694&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;245&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Segment profit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;402&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1766000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">492000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">812000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">655000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">262000000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">156000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">53000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">223000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">187000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">98000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">102000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">70000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">31000000</us-gaap:GeneralAndAdministrativeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:OtherOperatingIncomeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">332000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">345000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">114000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1737000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">492000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">890000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">694000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">286000000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">143000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">58000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">245000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">196000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">97000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">112000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">59000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">29000000</us-gaap:GeneralAndAdministrativeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-11000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-40000000</teva:OtherOperatingIncomeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">402000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">381000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">179000000</us-gaap:OperatingIncomeLoss>
    <teva:ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents a reconciliation of Teva&#x2019;s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended March&#160;31, 2023 and 2022: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:83%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;North America profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;332&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;402&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Europe profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;International Markets profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total reportable segments profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;791&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Profit (loss) of other activities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total segments profit&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;785&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,013&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amounts not allocated to segments:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other assets impairments, restructuring and other items&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangible assets impairments&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;149&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legal settlements and loss contingencies&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;233&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other unallocated amounts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consolidated operating income (loss)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(713&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial expenses, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consolidated income (loss) before income taxes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(971&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">332000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">402000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">345000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">381000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">114000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">179000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023_CorporateMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">791000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022_CorporateMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">962000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-6000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">52000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">785000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1013000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:AdjustmentForAmortization
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">165000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">200000000</us-gaap:AdjustmentForAmortization>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">96000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">128000000</teva:ImpairmentsRestructuringAndOthers>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">178000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">149000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">233000000</teva:LegalSettlementsAndLossContingencies>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1124000000</teva:LegalSettlementsAndLossContingencies>
    <teva:OtherUnallocatedAmounts
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">112000000</teva:OtherUnallocatedAmounts>
    <teva:OtherUnallocatedAmounts
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">127000000</teva:OtherUnallocatedAmounts>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-713000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-260000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-258000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2023To03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">-258000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2022To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-971000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables present revenues by major products and activities for the three months ended March&#160;31, 2023 and 2022: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;North America&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Generic products&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;899&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;AJOVY&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;AUSTEDO&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;170&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;154&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;BENDEKA&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt; and TREANDA&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;COPAXONE&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Anda&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;342&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;139&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,766&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,737&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; background-color: rgb(204, 238, 255); font-size: 0px;"&gt;
&lt;td colspan="8" style="vertical-align:bottom"/&gt;
&lt;td style="vertical-align:bottom"/&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;    &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;Europe&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three months ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Generic products&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;932&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;AJOVY&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;COPAXONE&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Respiratory products&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,156&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;International markets&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&#160;ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Generic products&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;388&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;AJOVY&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;COPAXONE&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">824000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">899000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">82000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">424000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">342000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">139000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1766000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1737000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">932000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">876000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">68000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">107000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">388000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_AjovyMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">88000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To03_31_2023_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">492000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">492000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 16 &#x2013; Fair value measurement: &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial items carried at fair value on a recurring basis as of March&#160;31, 2023 and December&#160;31, 2022 are classified in the tables below in one of the three categories of fair value levels: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money markets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;702&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;702&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash, deposits and other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,441&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,441&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Investment in securities:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Equity securities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted cash&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derivatives:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden78649490"&gt;Asset derivatives&lt;/span&gt;:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options and forward contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cross currency interest rate swaps&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden78649488"&gt;Liability derivatives&lt;/span&gt;:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options and forward contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Bifurcated embedded derivatives&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;span style="-sec-ix-hidden:hidden78648269"&gt;&#xa7;&lt;/span&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Contingent consideration*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(148&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(148&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2,192&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(147&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2,027&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, deposits and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,579&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,579&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in securities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden78649491"&gt;Asset derivatives&lt;/span&gt;&#x2014;options and forward contracts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden78649489"&gt;Liability derivatives&lt;/span&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options and forward contracts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bifurcated embedded derivatives&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden78648268"&gt;&#xa7;&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(153&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(153&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,848&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(152&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva determined the fair value of the liabilities for contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level&#160;3 measurement within the fair value hierarchy. The fair value of contingent consideration is based on several factors, such as cash flows projected from the success of unapproved product candidates; probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; time and resources required to complete the development and approval of product candidates; life of the potential commercialized products and associated risks with obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. A probability of success factor of 100% was used in the fair value calculation to reflect inherent regulatory and commercial risks of the contingent payments and IPR&amp;amp;D. The discount rate applied ranged from 8.5% to 11%. The weighted average discount rate, calculated based on the relative fair value of Teva&#x2019;s contingent consideration liabilities, was 8.95%. Contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in the consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the activity for the financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&lt;br/&gt; ended&#160;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&lt;br/&gt; ended&#160;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the beginning of the period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(152&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bifurcated embedded derivatives&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden78649329"&gt;&#xa7;&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden78649330"&gt;&#xa7;&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments to provisions for contingent consideration:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actavis Generics transaction&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eagle transaction&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Novetide transaction&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Settlement of contingent consideration:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actavis Generics transaction&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eagle transaction&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Novetide transaction&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additional contingent consideration resulting from Novetide acquisition*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the end of the period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In January 2022, Teva acquired 100% ownership of Novetide Ltd. (&#x201c;Novetide&#x201d;), which was previously accounted for as &#x201c;investment in associated companies&#x201d;. This transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under &#x201c;Share in (profits) losses of associated companies, net&#x201d;, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments not measured at fair value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated fair value*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes and sustainability-linked senior notes included under senior notes and loans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,007&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes and convertible senior debentures included under short-term debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,075&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,769&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value was estimated based on quoted market prices.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P01_01_2023To03_31_2023"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial items carried at fair value on a recurring basis as of March&#160;31, 2023 and December&#160;31, 2022 are classified in the tables below in one of the three categories of fair value levels: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money markets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;702&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;702&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash, deposits and other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,441&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,441&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Investment in securities:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Equity securities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted cash&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derivatives:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden78649490"&gt;Asset derivatives&lt;/span&gt;:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options and forward contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cross currency interest rate swaps&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;span style="-sec-ix-hidden:hidden78649488"&gt;Liability derivatives&lt;/span&gt;:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options and forward contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Bifurcated embedded derivatives&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;span style="-sec-ix-hidden:hidden78648269"&gt;&#xa7;&lt;/span&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Contingent consideration*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(148&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(148&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2,192&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(147&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;2,027&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, deposits and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,579&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,579&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in securities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden78649491"&gt;Asset derivatives&lt;/span&gt;&#x2014;options and forward contracts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden78649489"&gt;Liability derivatives&lt;/span&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options and forward contracts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bifurcated embedded derivatives&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden78648268"&gt;&#xa7;&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(153&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(153&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,848&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(152&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">702000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2023_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">702000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2023_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">1441000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2023_DemandDepositsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1441000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2023_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2023_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2023_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:RestrictedCash
      contextRef="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:RestrictedCash>
    <us-gaap:DerivativeAssets
      contextRef="PAsOn03_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">45000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="PAsOn03_31_2023_InterestRateSwapMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">45000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2023_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-6"
      unitRef="Unit_USD">63000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2023_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-6"
      unitRef="Unit_USD">63000000</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn03_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      id="Fact_78648272"
      unitRef="Unit_USD">148000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      id="Fact_78648273"
      unitRef="Unit_USD">148000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn03_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">2192000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn03_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">-18000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn03_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">-147000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">2027000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1222000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1222000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">1579000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_DemandDepositsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1579000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">9000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">9000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_OtherRestrictedCashMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:RestrictedCash>
    <us-gaap:DerivativeAssets
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">29000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="PAsOn12_31_2022_InterestRateSwapMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">29000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-6"
      unitRef="Unit_USD">101000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2022_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-6"
      unitRef="Unit_USD">101000000</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      id="Fact_78648274"
      unitRef="Unit_USD">153000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      id="Fact_78648275"
      unitRef="Unit_USD">153000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">2848000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">-73000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">-152000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2624000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn03_31_2023_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">100</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn03_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="1"
      unitRef="Unit_pure">8.5</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn03_31_2023_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">11</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn03_31_2023_WeightedAverageMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">8.95</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the activity for the financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&lt;br/&gt; ended&#160;March&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;months&lt;br/&gt; ended&#160;March&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the beginning of the period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(152&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bifurcated embedded derivatives&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden78649329"&gt;&#xa7;&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden78649330"&gt;&#xa7;&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments to provisions for contingent consideration:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actavis Generics transaction&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eagle transaction&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Novetide transaction&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Settlement of contingent consideration:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actavis Generics transaction&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eagle transaction&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Novetide transaction&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additional contingent consideration resulting from Novetide acquisition*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the end of the period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(196&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In January 2022, Teva acquired 100% ownership of Novetide Ltd. (&#x201c;Novetide&#x201d;), which was previously accounted for as &#x201c;investment in associated companies&#x201d;. This transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under &#x201c;Share in (profits) losses of associated companies, net&#x201d;, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">152000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">175000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod
      contextRef="P01_01_2023To03_31_2023_ActavisGenericsMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">-9000000</teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod>
    <teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod
      contextRef="P01_01_2022To03_31_2022_ActavisGenericsMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">-31000000</teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod>
    <teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_EagleTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">-11000000</teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease>
    <teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease
      contextRef="P01_01_2022To03_31_2022_EagleTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">-2000000</teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease>
    <teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease
      contextRef="P01_01_2023To03_31_2023_NovetideTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2023To03_31_2023_ActavisGenericsMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2023To03_31_2023_EagleTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">21000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2022To03_31_2022_EagleTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2023To03_31_2023_NovetideTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="P01_01_2022To03_31_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">-11000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">148000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">196000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn01_01_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2023To03_31_2023">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated fair value*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes and sustainability-linked senior notes included under senior notes and loans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,007&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes and convertible senior debentures included under short-term debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,075&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,769&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value was estimated based on quoted market prices.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2023_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">18007000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2022_SeniorNotesAndSustainabilityLinkedSeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">16694000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2023_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1013000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2022_SeniornotesandconvertibleseniordebenturesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">2075000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      unitRef="Unit_USD">19020000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      unitRef="Unit_USD">18769000000</us-gaap:DebtInstrumentFairValue>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_78648272"
          xlink:label="Fact_78648272"
          xlink:type="locator"/>
        <link:footnote id="FN_269435" xlink:label="FN_269435" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648272"
          xlink:to="FN_269435"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648273"
          xlink:label="Fact_78648273"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648273"
          xlink:to="FN_269435"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648274"
          xlink:label="Fact_78648274"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648274"
          xlink:to="FN_269435"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648275"
          xlink:label="Fact_78648275"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648275"
          xlink:to="FN_269435"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648314"
          xlink:label="Fact_78648314"
          xlink:type="locator"/>
        <link:footnote id="FN_269438" xlink:label="FN_269438" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Accumulated goodwill impairment as of March&#160;31, 2023 and December&#160;31, 2022 was approximately $27.6&#160;billion.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648314"
          xlink:to="FN_269438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648315"
          xlink:label="Fact_78648315"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648315"
          xlink:to="FN_269438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648316"
          xlink:label="Fact_78648316"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648316"
          xlink:to="FN_269438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648317"
          xlink:label="Fact_78648317"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648317"
          xlink:to="FN_269438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648318"
          xlink:label="Fact_78648318"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648318"
          xlink:to="FN_269438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648319"
          xlink:label="Fact_78648319"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648319"
          xlink:to="FN_269438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648326"
          xlink:label="Fact_78648326"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648326"
          xlink:to="FN_269438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648327"
          xlink:label="Fact_78648327"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648327"
          xlink:to="FN_269438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648328"
          xlink:label="Fact_78648328"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648328"
          xlink:to="FN_269438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648329"
          xlink:label="Fact_78648329"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648329"
          xlink:to="FN_269438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648330"
          xlink:label="Fact_78648330"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648330"
          xlink:to="FN_269438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648331"
          xlink:label="Fact_78648331"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648331"
          xlink:to="FN_269438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648578"
          xlink:label="Fact_78648578"
          xlink:type="locator"/>
        <link:footnote id="FN_269449" xlink:label="FN_269449" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648578"
          xlink:to="FN_269449"
          xlink:type="arc"/>
        <link:footnote id="FN_269453" xlink:label="FN_269453" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 8c. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648578"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648579"
          xlink:label="Fact_78648579"
          xlink:type="locator"/>
        <link:footnote id="FN_269452" xlink:label="FN_269452" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In March 2023, Teva repaid $646 million of its 1.25% senior notes at maturity. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648579"
          xlink:to="FN_269452"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648580"
          xlink:label="Fact_78648580"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648580"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnote id="FN_269450" xlink:label="FN_269450" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648580"
          xlink:to="FN_269450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648581"
          xlink:label="Fact_78648581"
          xlink:type="locator"/>
        <link:footnote id="FN_269448" xlink:label="FN_269448" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In March 2023, Teva consummated a cash tender offer and extinguished $630 million aggregate principal amount of its 1,000 million euro 6% senior notes due in 2025; $432 million aggregate principal amount of its 900 million euro 4.5% senior notes due in 2025; $573 million aggregate principal amount of its $1,000 million 7.13% senior notes due in 2025; $453 million aggregate principal amount of its $3,000 million 2.8% senior notes due in 2023; $293 million aggregate principal amount of its $1,250 million 6% senior notes due in 2024 and $122 million aggregate principal amount of its $3,500 million 3.15% senior notes due in 2026. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648581"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648582"
          xlink:label="Fact_78648582"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648582"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648583"
          xlink:label="Fact_78648583"
          xlink:type="locator"/>
        <link:footnote id="FN_269444" xlink:label="FN_269444" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 800 million euro bearing 7.38% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648583"
          xlink:to="FN_269444"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648583"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648586"
          xlink:label="Fact_78648586"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648586"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnote id="FN_269445" xlink:label="FN_269445" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 500 million euro bearing 7.88% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648586"
          xlink:to="FN_269445"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648587"
          xlink:label="Fact_78648587"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648587"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648588"
          xlink:label="Fact_78648588"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648588"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648590"
          xlink:label="Fact_78648590"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648590"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648592"
          xlink:label="Fact_78648592"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648592"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648593"
          xlink:label="Fact_78648593"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648593"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648593"
          xlink:to="FN_269450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648594"
          xlink:label="Fact_78648594"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648594"
          xlink:to="FN_269449"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648594"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648596"
          xlink:label="Fact_78648596"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648596"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnote id="FN_269446" xlink:label="FN_269446" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $600 million bearing 7.88% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648596"
          xlink:to="FN_269446"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648597"
          xlink:label="Fact_78648597"
          xlink:type="locator"/>
        <link:footnote id="FN_269447" xlink:label="FN_269447" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $500 million bearing 8.13% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648597"
          xlink:to="FN_269447"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648597"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648654"
          xlink:label="Fact_78648654"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648654"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648654"
          xlink:to="FN_269449"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648656"
          xlink:label="Fact_78648656"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648656"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648656"
          xlink:to="FN_269447"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648657"
          xlink:label="Fact_78648657"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648657"
          xlink:to="FN_269446"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648657"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648659"
          xlink:label="Fact_78648659"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648659"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648659"
          xlink:to="FN_269449"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648660"
          xlink:label="Fact_78648660"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648660"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648660"
          xlink:to="FN_269450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648661"
          xlink:label="Fact_78648661"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648661"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648663"
          xlink:label="Fact_78648663"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648663"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648665"
          xlink:label="Fact_78648665"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648665"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648666"
          xlink:label="Fact_78648666"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648666"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648667"
          xlink:label="Fact_78648667"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648667"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648667"
          xlink:to="FN_269445"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648670"
          xlink:label="Fact_78648670"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648670"
          xlink:to="FN_269444"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648670"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648671"
          xlink:label="Fact_78648671"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648671"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648672"
          xlink:label="Fact_78648672"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648672"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648673"
          xlink:label="Fact_78648673"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648673"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648673"
          xlink:to="FN_269450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648674"
          xlink:label="Fact_78648674"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648674"
          xlink:to="FN_269452"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648791"
          xlink:label="Fact_78648791"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648791"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648791"
          xlink:to="FN_269449"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648792"
          xlink:label="Fact_78648792"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648792"
          xlink:to="FN_269449"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648792"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648793"
          xlink:label="Fact_78648793"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648793"
          xlink:to="FN_269452"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648794"
          xlink:label="Fact_78648794"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648794"
          xlink:to="FN_269452"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648795"
          xlink:label="Fact_78648795"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648795"
          xlink:to="FN_269450"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648795"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648796"
          xlink:label="Fact_78648796"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648796"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648796"
          xlink:to="FN_269450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648797"
          xlink:label="Fact_78648797"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648797"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648798"
          xlink:label="Fact_78648798"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648798"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648799"
          xlink:label="Fact_78648799"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648799"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648800"
          xlink:label="Fact_78648800"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648800"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648801"
          xlink:label="Fact_78648801"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648801"
          xlink:to="FN_269444"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648801"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648802"
          xlink:label="Fact_78648802"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648802"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648802"
          xlink:to="FN_269444"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648807"
          xlink:label="Fact_78648807"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648807"
          xlink:to="FN_269445"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648807"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648808"
          xlink:label="Fact_78648808"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648808"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648808"
          xlink:to="FN_269445"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648809"
          xlink:label="Fact_78648809"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648809"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648810"
          xlink:label="Fact_78648810"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648810"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648811"
          xlink:label="Fact_78648811"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648811"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648812"
          xlink:label="Fact_78648812"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648812"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648815"
          xlink:label="Fact_78648815"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648815"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648816"
          xlink:label="Fact_78648816"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648816"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648819"
          xlink:label="Fact_78648819"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648819"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648820"
          xlink:label="Fact_78648820"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648820"
          xlink:to="FN_269448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648821"
          xlink:label="Fact_78648821"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648821"
          xlink:to="FN_269450"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648821"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648822"
          xlink:label="Fact_78648822"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648822"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648822"
          xlink:to="FN_269450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648823"
          xlink:label="Fact_78648823"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648823"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648823"
          xlink:to="FN_269449"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648824"
          xlink:label="Fact_78648824"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648824"
          xlink:to="FN_269449"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648824"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648827"
          xlink:label="Fact_78648827"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648827"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648827"
          xlink:to="FN_269446"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648828"
          xlink:label="Fact_78648828"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648828"
          xlink:to="FN_269446"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648828"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648829"
          xlink:label="Fact_78648829"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648829"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648829"
          xlink:to="FN_269447"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648830"
          xlink:label="Fact_78648830"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648830"
          xlink:to="FN_269447"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648830"
          xlink:to="FN_269453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648843"
          xlink:label="Fact_78648843"
          xlink:type="locator"/>
        <link:footnote id="FN_269451" xlink:label="FN_269451" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Debt issuance costs as of March 31, 2023 include $26 million in connection with the issuance of the sustainability-linked senior notes in March 2023, partially offset by $6 million acceleration of issuance costs related to the cash tender offer. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648843"
          xlink:to="FN_269451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648844"
          xlink:label="Fact_78648844"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648844"
          xlink:to="FN_269451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648932"
          xlink:label="Fact_78648932"
          xlink:type="locator"/>
        <link:footnote id="FN_269439" xlink:label="FN_269439" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Including impairments related to exit and disposal activities.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648932"
          xlink:to="FN_269439"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648933"
          xlink:label="Fact_78648933"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648933"
          xlink:to="FN_269439"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648964"
          xlink:label="Fact_78648964"
          xlink:type="locator"/>
        <link:footnote id="FN_269440" xlink:label="FN_269440" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes adjustments for foreign currency translation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648964"
          xlink:to="FN_269440"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648965"
          xlink:label="Fact_78648965"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648965"
          xlink:to="FN_269440"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648966"
          xlink:label="Fact_78648966"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648966"
          xlink:to="FN_269440"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648967"
          xlink:label="Fact_78648967"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648967"
          xlink:to="FN_269440"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648968"
          xlink:label="Fact_78648968"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648968"
          xlink:to="FN_269440"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78648969"
          xlink:label="Fact_78648969"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78648969"
          xlink:to="FN_269440"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649125"
          xlink:label="Fact_78649125"
          xlink:type="locator"/>
        <link:footnote id="FN_269442" xlink:label="FN_269442" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649125"
          xlink:to="FN_269442"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649126"
          xlink:label="Fact_78649126"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649126"
          xlink:to="FN_269442"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649127"
          xlink:label="Fact_78649127"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649127"
          xlink:to="FN_269442"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649128"
          xlink:label="Fact_78649128"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649128"
          xlink:to="FN_269442"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649129"
          xlink:label="Fact_78649129"
          xlink:type="locator"/>
        <link:footnote id="FN_269443" xlink:label="FN_269443" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty and several other currencies to protect its projected operating results for 2023. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In the first quarter of 2023, the negative impact from these derivatives recognized under revenues was $6 million. In the first quarter of 2022, the positive impact from these derivatives recognized under revenues was $19 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. Cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649129"
          xlink:to="FN_269443"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649130"
          xlink:label="Fact_78649130"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649130"
          xlink:to="FN_269443"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649131"
          xlink:label="Fact_78649131"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649131"
          xlink:to="FN_269443"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649132"
          xlink:label="Fact_78649132"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649132"
          xlink:to="FN_269443"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649194"
          xlink:label="Fact_78649194"
          xlink:type="locator"/>
        <link:footnote id="FN_269437" xlink:label="FN_269437" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts do not include a $53 million loss from foreign currency translation adjustments attributable to non-controlling interests.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649194"
          xlink:to="FN_269437"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649195"
          xlink:label="Fact_78649195"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649195"
          xlink:to="FN_269437"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649196"
          xlink:label="Fact_78649196"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649196"
          xlink:to="FN_269437"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649197"
          xlink:label="Fact_78649197"
          xlink:type="locator"/>
        <link:footnote id="FN_269436" xlink:label="FN_269436" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts do not include a $9 million loss from foreign currency translation adjustments attributable to non-controlling interests.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649197"
          xlink:to="FN_269436"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649198"
          xlink:label="Fact_78649198"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649198"
          xlink:to="FN_269436"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649199"
          xlink:label="Fact_78649199"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649199"
          xlink:to="FN_269436"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649200"
          xlink:label="Fact_78649200"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649200"
          xlink:to="FN_269436"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649399"
          xlink:label="Fact_78649399"
          xlink:type="locator"/>
        <link:footnote id="FN_269454" xlink:label="FN_269454" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts exclude attorneys&#x2019; fees and costs, except New York.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649399"
          xlink:to="FN_269454"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649400"
          xlink:label="Fact_78649400"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649400"
          xlink:to="FN_269454"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649401"
          xlink:label="Fact_78649401"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649401"
          xlink:to="FN_269454"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649402"
          xlink:label="Fact_78649402"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649402"
          xlink:to="FN_269454"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649403"
          xlink:label="Fact_78649403"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649403"
          xlink:to="FN_269454"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649404"
          xlink:label="Fact_78649404"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649404"
          xlink:to="FN_269454"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649405"
          xlink:label="Fact_78649405"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649405"
          xlink:to="FN_269454"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649406"
          xlink:label="Fact_78649406"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649406"
          xlink:to="FN_269454"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649407"
          xlink:label="Fact_78649407"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649407"
          xlink:to="FN_269454"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649408"
          xlink:label="Fact_78649408"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649408"
          xlink:to="FN_269454"
          xlink:type="arc"/>
        <link:footnote id="FN_269457" xlink:label="FN_269457" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Not including cash payment and attorneys&#x2019; fees allocated under the nationwide settlement.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649408"
          xlink:to="FN_269457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649409"
          xlink:label="Fact_78649409"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649409"
          xlink:to="FN_269454"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649437"
          xlink:label="Fact_78649437"
          xlink:type="locator"/>
        <link:footnote id="FN_269441" xlink:label="FN_269441" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On March 31, 2023, Teva entered into a cross currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649437"
          xlink:to="FN_269441"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649438"
          xlink:label="Fact_78649438"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649438"
          xlink:to="FN_269441"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649441"
          xlink:label="Fact_78649441"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649441"
          xlink:to="FN_269441"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649442"
          xlink:label="Fact_78649442"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649442"
          xlink:to="FN_269441"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649444"
          xlink:label="Fact_78649444"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649444"
          xlink:to="FN_269441"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_78649445"
          xlink:label="Fact_78649445"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_78649445"
          xlink:to="FN_269441"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MM6T5EVT&%'?P>:@C0>224/9E\97,A+=1 %K)@2M!RU6AQQ-R!_4 ?06VQ<4
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M);%#!=L<7-S79S&/#)[=S,%69<V32LX:K;K_"EW;']R3^L,(MA8KP_0K*.@
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M[I/=P'IF1[&- 4Q&<T<A&^##9)8XO+2#E_JWN -$-K+(W3ZN(0PQ>.G8-<$
MG5?D"-RR [?T@ONBK2A>X;LELF[10?"W^! I%D03*8(&/5,%7I!W<B4!8 Y<
ME.E2$BN>\2VXUW,$($J&:XQ)A=%$A- #/J6GMV&;OBM=S?<^;6],.W:O]"BF
MH^&Z8T+AE%M[,J1>_H&@AB+2V)=SL@7VMRX]-CRQA>K.NB2, F;C$$FBX4Y
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ML,8(+7<E9YLF6%2P2?/])_G1=,1) +9Z LPFP)0"S%E/@-4$6%* 9?<$3)N
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MVS!M0Y*3=_Z,WB429W170OE=U!CCJ2MU8J" B3.Z1!8J4(HS>A?E6;()$2M
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MX6Q;O_QXSSAGF_IR34E"BPH@?G]@C#_?5.]3'MXRGO\'4$L#!!0    ( (*
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M$$]_T<*@R.B+1:KL+WHJ9/L=%&^4%EDQ&!!DC.?_Y+F8B+T!H,<] !<#<'W
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M'^WD^ #V%Q8<W2S80/=O@+-_ %!+ P04    " ""@*I6JW[ U7 '  #8$0
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MGW7)70.A$5J+;B711!#?**8PH91"2N(1@FMU_;!U#B51@N2$67Y"8>#3%)V
M*AEYF_IODXR.H8:*G!;IZ BZ\RQC"XJ$DD5$$>R)IUD6CGJ&6^E P,H%&E"K
MMIVE1AI#=HV-HV"6#N[]]]A%?VSL\IPMCV%Y@I 4 2P/X^S=V(441H0@4UR\
MCEV<1+O89;O8Q6G1QVX2(6@+BCAFD+'P<8MSXG>89GAS[(Y D>+YW?&C7X2N
M726@HDQ=2>W!^LXVSZOF!3$JFVV%TC"(#U>**UE65Y'@ A-=B>6$_8J"D[O;
M'T2[.;EPR_#D> JI[4;7!LER5?'@JF_BQ7(4/\NJ+D5=.8G*162EGI YCBL2
MM]%JI47+)5:R>X9EKH5>053YB/K2TFYU9P[XP=*J/N\'FC #FB4J6I6/*.5?
MT4=<ZHZIMI)+_$:KIYIGJ4'O\%(VEC;BA<GV^I%W%+2T%BZ)%:)D+$9G_TW+
M4M9/'$X(Y"YT!2&B>^$/:M75OTE.#8+(X@=MPO(>6<QR#A)'VL?7&>D86JJ7
MC@B-< NW?*H-K%HNX;%KE/Q9&D@1;-I>_HR&K)!5Y+"_:Z('Z1$;L'QQW,A[
M5OR9;;%[%W;=TG(1[64*PX2ON]C4]VIPN[HR .H!;BYVN!GM]F][9+R"P]4^
MSR#P:3XHY#T:OU+7EZ)A51SDOXMNBW,5]4:",O-5EKK*RC+>6BQ"KKC4[[B"
MR]/ O8LP'QV 1,O&11I!]<71BDJR\G*K-4/F10K 2.I:583^$4Z#@#MLA%\%
MY.<Q1:GKR 7WEKSX)N'(EAJDFET[F>1H(I.8^^]D@4=&DY!_)_GP'%UIA-;Z
M#/2@1B&B,X, C29RE%&Q\.L%K&-9J=MULN)I&J3]#R8;W:/_F<:W"P]$Z9K!
M8%1!:/GHB$/W@_/Q83Y>8X;C';MT)"FWNZ3@9^%RD"2<@6SATA '_3N/_G_1
MQ;9GA7,G<U@JTL2M@H)7:<S/,'2.3J/$88X]^WZ 1;2("@H!)L"+YWA!"QY:
M0>'A%?PO\(*D8XJ JL+!PX.&'T4^/-\#F.>8!K$'6![T $O\C]"]/-KB:1('
M/<+"XAL0-HD'0X:=W1=G7=H_WD6=2U/4HX[15P3<$A:I2X@#'%>&J_Z@?V>+
M[QJ_-XVL5MQGWY@5=/'&YI2G#/?6W9QU<ZET8:9&&<,T_8"F(YS&!F4N!=C(
M]AMO-&E']1'ZV@=@?@@(#U2SD>XNV+R@D:]K\/#,V_0. #,WUU=T*;K'*5T/
M!ZP+8U19^U0Q1%77]??*813XT6,DT(MC]&^>=!CODD]K$%YW$ _^:YP!G%UL
MDS]^+[?:5>?OSMYJJW\O="G*NL'R]?$[6++I; B?=%135ZX$EG6'V-9PP5AL
M>-ARH)G259@_:[X1J3[V;/7K"\5%U_&4!CYP(F4C^8(,"_[RCQF]=3>;']Q/
M,997[A;.PQF8\%?5W>[NHG_A[[=[<O\O 7*\PID$,%R"-9CEZ9BTOWG[A54;
M=]M]4!9G /=S+5']F@GP?:D0K7[!"G9_?YS_!U!+ P04    " ""@*I6@OO&
MLW@"   *!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6R=5%UOFS 4
M?>=76*R:-BD*8$I+LR12TP^U#]VB=MV>';@$J\9FME/:?[]K0U@FK7W8"_A>
MWW-\#KZ7>:?TDZD!+'EIA#2+L+:VG461*6IHF)FJ%B3N5$HWS&*HMY%I-;#2
M@QH1T3@^B1K&9;B<^]Q:+^=J9P67L-;$[)J&Z=<5"-4MPB3<)^[YMK8N$2WG
M+=O" ]C'=JTQBD:6DC<@#5>2:*@6X7DR6Z6NWA?\X-"9@S5Q3C9*/;G@MER$
ML1,$ @KK&!B^GN$"A'!$*./7P!F.1SK@X7K/?NV]HY<-,W"AQ$]>VGH1YB$I
MH6([8>]5=P.#G\SQ%4H8_R1=7YND(2EVQJIF *."ALO^S5Z&[W  R.,W '0
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M,L>/%;+,@/=+8_S^P H./W\N_P%02P,$%     @ @H"J5M=_HVVP!@  O \
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M_JK_.GS^)J;U;L$_I=B:O>^,+)DI]84NWN>O^D,") J16=+ \6<C;D11D"+
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M]?^H>"JI"U/R2%SU43-&Z ?1OV9OWWWZC3UGO_[R?#J9O&3_50XN>GS( $C
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ML,I4/,O6((Y"H9RYI6]#KE0&BB2CB4QK&91R)BJM!NSC2AK#$HT@#MB_.%P
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M&"[JZUI/Z3_IP@K+VYF@MED!_0C:G%7UP;]C%92']1OV-UMW7)Z,O#SNFDC
M$7;\M=7<[3_CRJ#N5;#HR6120]SM>?*L>70.[X#U0%-RE[5,<-!4Z')V9\#<
M'N5)GZ^>X"-0G:V';-^/,J/6#U2YT$OW,YSQ]YG^MZKF;?-+WXW_@6NSW/],
M""N6U+,SD6#K>/CLO,^T_^G-/UA5NI^[%LI:E;N/J>!PGA;@^T0!R>&!%#2_
M?U[_!U!+ P04    " ""@*I6ZK9Q(;X"  !*!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6RU55%/VS 0_BNG#.VI:YJD@U+:2A28A@0; K8]N\DU
ML7#L8#M-^?<[.VW(IE'QLI?&9]]]W]W9]W76*/UD"D0+VU)(,P\*:ZMI&)JT
MP)*9H:I0TLE:Z9)9,G4>FDHCRWQ0*<)X-#H.2\9EL)CYO3N]F*G:"B[Q3H.I
MRY+IER4*U<R#*-AOW/.\L&XC7,PJEN,#VA_5G28K[% R7J(T7$G0N)X'Y]%T
MF3A_[_"38V-Z:W"5K)1Z<L9U-@]&+B$4F%J'P.BSP0L4P@%1&L\[S*"C=(']
M]1[]BZ^=:EDQ@Q=*_.*9+>;!)( ,UZP6]EXU7W%7SV>'ERIA_"\TK>^8&-/:
M6%7N@LDNN6R_;+OK0R]@,GHC(-X%Q#[OELAG><DL6\RT:D [;T)S"U^JCZ;D
MN'27\F UG7**LXL;S)D ZKT52+VV!IC,X$89 Q=*6BYSE"E',PLML;F8,-TA
M+UOD^ WD!&X)H#!P)3/,_HP/*<LNU7B?ZC(^"'C+]!"2: #Q*$X.X"5=Z8G'
M&_^'T@\BNT&:FHJE. ]H4@SJ#08+^/;]\0I.X>.'21Q%9]#2F[_HA:-/^_13
MN)9@"X0UU\;"<\VT10UJ[?LP@$?<,!J/5&EJ,^"6QM6@<>='<9+0FQ'"/7\N
M0;R3<4!F63%-<%;!432(XG$?YZUDXB%<[>D/N"70H$9PBB%>*'/!;,N$QO+2
M&Y56&^[GWL"YKX4N/RVZV_>)7V**Y8I@=[MQVPO?WY,STP,A[7IW\:^MK.G=
M:I*-5-?]QKHP1;5IL&R+>QB9?Z(*2Q"<K;C@UB$US,#1>!"?GG;=<\ZT%4V.
M]UL#(C05>G$2+T/XU\,.>_-=HLZ]BKF\:VG;4>]V.Z$\;_7AU;U56>ICSJ6A
M=JPI=#0\^1R ;I6K-:RJO%JLE"7M\<N"Q!ZU<Z#SM5)V;SB"[N]C\1M02P,$
M%     @ @H"J5A?'B_]2*P  )X<  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&ULM3UI<]M&EG\%Y3W*KJ)D2;;C'(ZK9/F($CO66CEV]UL3:)(=@V@.
M#LG,K]]W]@& LF>2K=J=6"30_?KUNR\^N_7MQVYC;5]\VM9-]_V]3=_OOGWX
ML"LW=FNZ8[^S#7RS\NW6]/!GNW[8[5IK*GII6S\\.SGYZN'6N.;>\V?TV57[
M_)D?^MHU]JHMNF&[->W^A:W][??W3N_I!Q_<>M/C!P^?/]N9M;VV_:^[JQ;^
M>AA6J=S6-IWS3=':U??WSD^_??$(GZ<'?G/VMDO^7>!)EMY_Q#\NJ^_OG2!
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MI@+%RR&ZN)/H!-U&+AE,M#6P/9AJ@>X9I,#.X/44Y09NR((J$(:C!X3+68V
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M ,+?*B"*$B_W0#I4\,?D-:#R'! BQD,'Y[7EIG'_&$2D*\"B&)+[HNN,:B2
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ME<$%E>^T%FJYI\WP@N4%BNOL?4NZ>6DWIEY1"G)H=[[M.=Q!0@+#VA)P.K!
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M_N\D\V+#A,DJ#'2DKZ2\)/@1DHB)4V:5!I*2) 3NLVF;PRD5'86:K( E__\
M9NE9!''88I1> ?N%6I/3'$OPAQ%K)AICP:?*/3M-5)*;]<\4A7XN.AQ]-M#7
M4H:G?M2ABNC@2_UN^BY+)1X(.?[_Y"=*7Y<;LBWB  <%^0*^:_?=U+--TZN2
MQHG!ZP4-Y4P*9G\W-3)50\V2>,R?6H_30*^QCY#FUDA7Y9YS^)(<9D4$[[]&
M/[[%!.U[RG\C\K%+V2[ ]3-;5[SUV%^"7O]E<$%_(2R]'AJN(OS1E!\!RS<@
M(*V\7;S'MF/U85_C=,77V!".G[#(G"QW'[!5J]%*%R(:/!P1EWIU=96@(YGJ
M1O-3L\CL7ZA(GH0)8G<R!Q?;G@9G_6QZ<  8PZI'@N5!7T8(_P;*2^-<GT\Q
ML@%K:Z0X' H"UA]_<3^V?$3=C.5QI8S\!+IX >*W]_71.PI$7\,7RR5972AN
MPV2]=]=ZO@=%/N<-RX**#_8&[=G@2>&X#J[0>+_KC]Z#;PGT_L$FSYGM[CN0
M;Z;V^.=5"+N=!PPEHQK.OCW]YJB\.7KZY-'9T:OKHW?G/QSK5N_3J*":Z_]B
MN.I 0>.KG0,Y%7)_.V#SW::E]MY&].\#+O(?;MS:U?HD$(L6%3P(PC3+E_Q+
MY/N3:3HS'K&K=08J\='H5S?*?K+E@&<57\'?-EWP;5_B_9UC)8\DI0)5OXSV
M-(*1'XZ$LZ_33AN);2R2,0I9=22/AI:B-31'!)Q0&7$.6^KXA_!JBOQ%:J;%
MZ'$CX>#H[U*IYXY[#6'-9%[CQB8WP.$?+*29&3\;@D))K#!+&,Q':]AW^0"2
M$NQ36.ZR6=4#EV52/8AO6_!(00B#*>3^%/&03K'\<'GQ'C](! J\IZ')$ >:
ME1YIO=5=*9(\#H()T-C,D 1@J%HT*0[5>M#0K>W%Q]ZALXE/A+GF.IIG\?D"
MR_<:M0CM?"E9'&BE")>H-)$6CDP2A!GI?GGF0EYX@QFEAN3O9>Y#X2D2.?4A
M02M.+N7R*G5:0U; A9'G1+SKN+R;+I_<VLA2MHFB$OX37$E"ZD A]BP"R!(,
M*7G.#ZM;$I)XOUZ?<WU=&G9*ZJJ'Y<[;QG010LZ:8A:A5_WU(W *&@Y*[R_?
M_QCD3)3^+YV8WIH5KGPYQ)^)8%9-8E"3T-X8-WP;$HLS4A9')QK'9H4VMUL@
MZE)N0F9_L<M*W:HTF5XGI0OKQ!E/9T\TA6*"G%B3E*3F9 V<?,XB3L9SD?MW
M1%/C2$^5C%!04^TZ4!8>AT%M*;R$\\Y!*>R+ZPWULY"@B6;)<7%M,;YZ#+ >
ME>W1V<E)\>KHHK5FBTQ^%"0?1Q:SX1OAUHTDZ!/:14$ C@:<-A "W')Q0<_I
MS2[X!R5,;)=41+TV-4BD"PY;GZ-&F2>"]/IEP%HE26L-&U!^Z^2;6/TM6^6@
M)"'0-&R1#/J;!.GF>WX.^R>LI9.(GI:%UUC7&<);5!)_M'*?:--DFOO.@)GD
M:IY/"U[<T,C,5"T:IP#IBC"G0XED..H2K%7)VT\R#F-4H^P,HUQ)@PSQ\>B:
MI[.KR-%=Q/J,1>+,POVLK*-?;Q"F CM#QBHU'#'X6R2/";(G"82(;@33)Q:W
MZ._)_"M2)89\M"@WT?LY5R7&=M[(S!%./**RC7C3:*,GWAXY"ZHX0Q<RWL(M
MK+IG"$859HBCU&<>QR!C1[ 0"#='S)HQT8GA)@VAR)E,U@%M\LNT0P\MIS9T
M_&$HL*J*!DQ0/4PGW4Y9@V(,-^*C*1_B6</K!+3.W9<Z*BJ7/R6K O_W($X?
M?Z,@4$?(U0!H\L4'3/EHUT:6>@*FV"Z=24SZI'-VTM$XB?(E,8IQYVER69(R
MEQY9L9+VDI+ R@7J]KLOC04TK+,&-X/YNIL[J=K9O%6\[H.0QM]8^AQXBQ&]
M! G65#.";MQ-FA3!CZF+SAT"):=Z=HH],A,>/.;T)A; 80"5>JY4U)TV88;
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M[.3%1+ATL4POP;;Q,K>Q 5?#N$2K(AP6P'YEP7[]"SL8;_>KOP%02P,$%
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M=GCP]K=+_-+AAB;@^[G6KAM0@,VWT^Q?4$L#!!0    ( (* JE8XVC/:6P,
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M&Y\<)6"[5Z2;D&ECYUX9XG<@#FM^>-$& ]Y?&ZZY?A(<#$_YXCM02P,$%
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ML?#H RVSA/G?M/T=LR_*\C+J?QW<#]@SDE3)LD0*FK/H-3>%4SJC!_&]D9
MSQ!SZ+,!M/4W80WH9J,4?YU#T^M'3_CB&,5(OY4R$MN)I8(EFB7Q^7G2;=[^
MNM7H??T@C*5(D%:&'"PMS+V*WD(3NPF66#(Z9#**/CH9T]T2FT6?P5/+S(K6
MJO'X@'(\CMX(#5NI!$'<2V-0;_/=4O1Q147*&X)2N^8:W)!1&F7+='S.)\%C
M]%HK P@!):+.-C#)"B#2,HTX,K/F*Q,HDDQGG3[1!\GGLB2+_[@._>F8G3U^
MBU[)1:,)/CDC*.8H 2'G W_LJ?,:0@!TB@OD&0E23JJ\."#L)^<7D.Y_(@<T
M "*-DTL"2S^AC_1[/G,/:3Q*9]%!@OS-R$WB-#V%7??M*?1.9I='T(O5/X3>
M0QZ7+78G 7:G_Q?L=CO3R^#QKV$L&24AR-SKWX>R9T=P-AD[G-%/B[,TO@#J
M@*[9N$79)&U1-DW/HU;:9^':0NW"RGBE&LA#W34HLEAX-AI,MJ@:1"_8*:50
M_CL^9>M)"BRZ@M+Y0<< ($!>MZ/.6EI@-0,J "]R]X!]$0\<SD*%P! !<JKZ
M8<?Q?2"4A.BXR!S5C@:AW/>IE5;S-M(_KMT01&&1)B/+M[A:4,_A-2\W:&70
MID!#6QSMD0Q?.NY&+FOTL(QCO:G5G-HM=3'8NVK@F;:S^=1SF+)%8T+?\2ZW
M0QGDH)8VT**0, \=;D,*[KOGI"L>Z0M9&E!9 ,U*FQBS+AHF-SLG&/+7K\)E
MW$*KRNF 71DA!&*:FJ^PXP&?\9,W&<3!+ID#]N8Z=#;M#@@/=\=P3U8V.8T0
M6IIO-$(8A>&#9#N(-'4FM,7D#FY:+)&+M)=G<,2#=Q2Y=,4W[AE" %P4#!H<
ML 'NO686$[K;!8<K9*>#*("G"6,*KJI6)5#GS,PI$FK5,?:6PEU'U;\&&A<=
M,E?*@HP&)["LA*892OZ^\Y*O*(&!WF)GIIJ3C<X-8MF4'*'9=,([$'VM)='=
M6Q+NN+UM- X_<8LKX5@RGO^*J3R N&^WE"W' 3U@+T^%S<.$5I+1Z#E; RB-
MV0UL ;^,EQEI3H"#6W%RH6,--J*DDSM#PZA'=3YJ_=!Z,0!Q&U5OZ?M/GW_@
MU>KZC4?^8]/@J9+&2,U!V:+V8C!Y3HHDR7-/TF4^IPQ8[O&(.P.PH\L6YU-1
MNNJ]EVU4KEPMGEV;TZD7E*O8>>]B<#F!0B>+*G)5D RGQ_>&:]3#<A,S!*%2
M&)H7A%V0T9I$SDN=-96Q&-D!B1Q]$H1@7Y GS)$P/54G:"COJG=+2CM4Z?">
M,T/<?4S ![FK*@B[#TI@MA-\I!K&C [AY<;GRW'$=0/,7BU"@%13NBS&<=9-
M/E!&NWQKA2+:>Q Z&8RV?JH20BCMW,FC/?<C:8UCY,[CI!ZECO-C=S;B-&)X
M9<..M":PG\@RX_R+XB0KY\S&@NIW$KZM_]Y)5]$7=]:I_&DU?#D^]P4G.;1<
MTG,NEK)VY61;F^ HE>\F@GXRF_Q/XTH[GM!/]-+5%6\*7$W%21HW*CW5B#&.
M 938R7X2-7AG($:>&NX'@?XEJ3.FX>DM7R(&CSXF-&/UH7'T"QJ.!=.][[L1
M++H7UI9BVP?^I#IIQ^Y0FS1A.%(>522%<W(WR+CR?W)@(NA26%R%ZC@%<]"+
M8+XCGQS&5M D?A#5\^VQXG(*JC\WZ+VOV;]XC9*S<4>0V$]D3CGJE:X!J#6<
M9@JY(ATZ S[8?,#ZI'DZNMZNNM?D^@QUKY"8,:CZ09\'J1J#$L"S[?A%Z.%^
M-@:Y?'2&"-HE-6I>(\M:QNV,%H:!1!SPY6S>&$R4=!!5U1PI3'L'_B2U%Z%M
MHH=,_8BR'1-=>?(C21AHK3:\1*7H>I8MM&J6!3PY/D=_A>DHY=UEQHY]ZV4J
MNZBB-"YPMN2N?$*KK5/N"ZH=6.TCZQ8XD)VQ$B=K?PURS$<QJX5M'15OF[$K
M=*YY+A;4E#.J%'8MA"_U=#&YZQ+2#:]A+'9XA0_H<U#G>-? J5-XF[:3E=\<
M@'P07C+5.-XUWF>ULMN"N7]Z.$[0;79COK^$\J=4!_"P#BN#ENFC;5P<D!<2
MT8;,=I;"-PP&5KI&X#_F8@XYD&!8WZ *TV8V._.#G*86YM)K[P)K=W]%9YG]
MFZI^V9[L?;4_P]FX:PF[;2^"FZSP<B!R=VKNAN!H+[C?M\J@9 -.V^-/*>MO
MU,C#;1W />0.'%,JH)4N!B[BT6A&#]-X>GE^*.MI#^Z+*92V/Y*':)-E23Q*
MQG0=,IMTMR;)93Q*1U[T;'J)&K5WZJ&$WW74;FS[WBAZ;P]=*U1Y=/QC-[3#
MX%H:X^C27;Y3G4 %\3?4W6IWO__27VOOMOM_#B!>:+HX"HL%2$>#V:2'R=9=
MN/L7JU;NDGNNK%65>RP$ARMH [XO%)1N7TA ]U^/N_\"4$L#!!0    ( (*
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MT%YW>!Z!;:9&LR%3A4Y=&^*^#\N"!RU:[\#GN3%TV/@ [>B>_@=02P,$%
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M$S#]V[O?.+WU[]V5=OA\]<L*?ZXH0P+X?:WQ@3-LR,'X VCY%U!+ P04
M" ""@*I6N_Z5GG4"   "!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q]5$U/XS 0O>=7C"(.(%7-%X&"VDH4%BT'I(HNNV<WF306CIVU70+_GK&3
M9KL2<(D]]KSG]^(9SSNE7TR-:.&M$=(LPMK:]CJ*3%%CP\Q4M2AIIU*Z899"
MO8M,JY&5'M2(*(WCBZAA7(;+N5];Z^5<[:W@$M<:S+YIF'Y?H5#=(DS"P\(3
MW]76+43+><MVN$'[W*XU1='(4O(&I>%*@L9J$=XDUZO,Y?N$WQP[<S0'YV2K
MU(L+'LI%&#M!*+"PCH'1\(JW*(0C(AE_!\YP/-(!C^<']GOOG;QLF<%;)?[P
MTM:+<!9"B17;"_NDNI\X^,D=7Z&$\5_H^MPT"Z'8&ZN: 4P*&B[[D;T-_^$(
M,(N_ *0#(/6Z^X.\RCMFV7*N50?:91.;FWBK'DWBN'27LK&:=CGA[/)!OJ*T
M2G,T</J+;06:LWEDB=GM1\7 LNI9TB]8,GA4TM8&?L@2R__Q$2D:9:4'6:OT
M6\)'IJ>0)1-(XS3[AB\;;6:>[_P+ODU?<Z J.'+\F='O>8[ $Y#4,T2HT:!^
M=0N%HF(U%DNW;&N$2@FJ>BYWUP$Y*FIOZ0X+;+:H71 X?\YD&IP^3S=3. $N
MZ9Z%H)(U9\$]EYPNMX16JW)?6$,)Z21)8AJ3R=7L,GAB'3!)":QX83LZBJK#
MHN9,&,I(XYR^<7X5K \$Q$]D!1H#%VD,>9Z3M@."-JUFY,(.I._4@ 3R_5.H
MO;20S$APE@8G<$Y"9B0DF\RR3R\I.JK+!O7.=Y\!S].7Z+@Z-OA-7]?_TOO7
M@7X?F3,@L")H/+W,0]!]Q_6!5:VO\JVRU#-^6M,CA=HET'ZEE#T$[H#QV5M^
M %!+ P04    " ""@*I6TP0TA<X"  #O!0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6R55-MNVS ,?<]7$-XPM$ 0V[+C)%T2(&UWZ4.'HI?M6;&9
M6*@L99+2M/OZ47*2MD,;8 ^V2)$\.J1$CC?:W-L:T<%C(Y6=1+5SJY,XMF6-
M#;<]O4)%EH4V#7>DFF5L5P9Y%8(:&;,D*>*&"Q5-QV'ORDS'>NVD4'AEP*Z;
MAING4Y1Z,XG2:+=Q+9:U\QOQ=+SB2[Q!=[>Z,J3%>Y1*-*BLT H,+B;1+#TY
MS;Q_</@I<&-?R. SF6M][Y6+:A(EGA!*+)U'X+0\X!E*Z8&(QN\M9K0_T@>^
ME'?H7T/NE,N<6SS3\I>H7#V)AA%4N.!KZ:[UYCMN\^E[O%)+&_ZP:7US%D&Y
MMDXWVV!BT C5KOQQ6X<7 </DG0"V#6"!=WM08'G.'9^.C=Z \=Z$YH60:H@F
M<D+Y2[EQAJR"XMSTHD+EQ$+PN42X4(ZKI?#BS%IT%HYNO<$>CV-'A_F0N-P"
MG[; [!W@#"ZU<K6%+ZK"ZG5\3"3W3-F.Z2D["'C)30^RM LL8=D!O&R?>1;P
M\G?P;MIG"'H!AXOP5NZ'H5_AB6<\WA:UU/2FK</*G^UJA(66U!Q"+4\ZWXRV
MY,&->2(=>*/7RH&B[B3?65FNF[7D/I0LQHD_/+SM'V3_)Z9#]2KK4+!S++&9
MHPG*?VUW?*U]P1F\(76.[GHW/?A(*=+3E)*8V./.E='5NG1@?#]8LJ;#;C+*
MMT(Q\ +KCK*\%8HL(:'?38MVS;-!Y];P"D'Q!BWTAQGT!P-@>0HL2R'+&7U%
MYT+!RN@2J5H&+0;Z7%74D0\T:58T-QSD!8-\.(!/'X8L99_WZW:_<ZL=EY[&
MJ)MFHYV0>B'KIH-^RW!8I('9J/"4BRX;)&\]O_A%$S9HEF'4^,NFRVC[<;^[
MGV:SMHF?W=M12)>Q%,J"Q 6%)KU!/VK+N5.<7H66GFM' R*(-4UD--Z![ NM
MW4[Q!^QG_/0O4$L#!!0    ( (* JE9I!H!)_ (  "L&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;'U5VV[;, Q]SU<07C&T0!#?<FN6!&BZZT.W
M8FFW9\5F;&&RY$ERW?[]*#EQNZ+M2R1*Y#F'M,@L6Z7_F!+1PGTEI%D%I;7U
M(@Q-5F+%S$C5*.EFKW3%+)FZ"$VMD>4^J!)A$D73L&)<!NNE/[O6ZZ5JK. 2
MKS68IJJ8?MB@4.TJB(/CP4]>E-8=A.MES0K<HKVMKS5988^2\PJEX4J"QOTJ
MN(@7F]3Y>X=?'%OS9 \NDYU2?YSQ+5\%D1.$ C/K$!@M=WB)0C@@DO'W@!GT
ME"[PZ?Z(_MGG3KGLF,%+)7[SW):K8!Y CGO6"/M3M5_QD,_$X65*&/\+;><[
MG020-<:JZA!,"BHNNY7='^KP)& >O1*0' (2K[LC\BH_,LO62ZU:T,Z;T-S&
MI^JC21R7[J-LK:9;3G%V_46IO.5"P.D-VPDT9\O0$JR[#+,#Q*:#2%Z!2.%*
M25L:^"1SS/^/#TE.KRDY:MHD;P)>,3V"-!Y"$B7I&WAIGV/J\<:OX&V[!P=J
M#Y<EDP4:X!)LB7#)M'[@LH"+2C72.H^^(+L'V&)![\^^5)(W&5TG+4S-,EP%
MU"H&]1T&ZV?<V9&;]=S%D9N:S?O4J+G* 5UA@<J2E7U=H$6-P SY"NHLLQA\
M5]J6\*G1U+'P35K4DKF7SP3\(# --\HR,;C!._;^W3R)9Q\,7&'.S>#T=K0=
MP8E35A$]Q9BSP88))C-/0=(^8H;5CD ._ F<QF<4,AV.)Q&M\V$:);3&PS0]
M]VMRGM*:C+TU&T[3='"L0-YHE_ACAHO!C6;2"*\7<K[?4W)$;B"&>0+3&.($
MX@CBZ?29KF=%>105=Z+F8R]F'$6=N&CB1$T.HF;GYP,7<I%E3=40/96Y_PB\
MJAG7[@&\S,5D_D)96O)E=:W5/:>9@>(!3I+9: J[KK C>.E!AT\:N$)=^#%E
M(',/H^OE_K2?A!?= 'AT[\8HB2RX-"!P3Z'1:$:#1W>CJ3.LJOTXV"E+P\5O
M2YKFJ)T#W>^5LD?#$?3_#^M_4$L#!!0    ( (* JE80:$^Z208  *45   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;,U8;6_;-A#^[E]!>,X0%XXL
MB7IMDP!-TJ(!VJUHFNTS;=&V5DGT2#II_OWNJ)=(CNPZPY .2&11NGOXW N/
M)Y[>"_E-K3C7Y'N>%>ILN-)Z_7HZ5?,5SYFRQ)H7\&8A9,XT#.5RJM:2L\0H
MY=G4M>U@FK.T&)Z?FF>?Y?FIV.@L+?AG2=0FSYE\N."9N#\;.L/ZP9=TN=+X
M8'I^NF9+?L/U[?JSA-&T04G2G!<J%061?'$V?.N\OO!0W@C\D?)[U;HG:,E,
MB&\XN$[.AC82XAF?:T1@\'/'+WF6(1#0^+O"'#93HF+[OD9_;VP'6V9,\4N1
M_9DF>G4VC(8DX0NVR?07<?^!5_;XB#<7F3)7<E_*4G](YANE15XI X,\+<I?
M]KWR0TLALG<HN)6":WB7$QF65TRS\U,I[HE$:4##&V.JT09R:8%!N=$2WJ:@
MI\^O^$P3,<O2)4,O*7+\E<TRKL:G4PWP*#2=5U 7)92[ XJ23Z+0*T7>%0E/
MNOI3H-5P<VMN%^Y>P$],6H0Z$^+:+MV#1QM;J<'S=N#=0$8GFXP3L2 W*R'U
MB>8R)^B"/FOW@S&KC9$ QNL!$)ZO#.,K/N?YC$L<#*X+D.%*$\DT)TSA_(^B
M:!P,]4:F^J$<P<4='-]:-Q89D;2 N&<9!F<\N!3%'9<ZA1 1Q8M42)R:%Z#-
M%;$MUR='J!X0A*&#RXV4\!8RQN"GW$R>B6)9\LY2-DNS\H4SL6V;N!,["@9?
MA68945T#@0S( / (I!P[WA,2KPF)=WA(2GM^$QK(L"(A'P4K5%]D]F/.+-"L
M#2P#\YP([ AB;S@JRH6A_.[V"_C'!Q]6 L2Q'%K&PR-!1$D0VH,;6--0*TNW
M/YP ^6\\J6.Y"^@X&!^_&A//HI'!HS8(!-3'JQWTT:!M[7@,5.K4H.377R+7
M<=^0@-+#Z3AMP-#0H598888H$,=X#<,^.G9;VQ^3P(('1M4GGH>*-OIF6S'>
M4O,LOU'S/8?$P<$61&THQ_ /:W>Z,8E"M_;+4QJAWXYI4,4T(I'C(6Z/0B<)
MHJCV4ABX)/2B0SEW4L"M.%=HU $/^/V<;V^N".TFD(_A<IKJ0"<T].#JQ4&?
MZG:X7"NRZ^PI@^E,/)\^574[JI[EE&I>  IQ5%V?JCD3U]^5(!Z)_;"4^)%B
MT"1D5+W9J;9M8=@L54A(D\^V?=!B[8$+J\7:7AVES_X]9ED _(9EW,7<U@ZC
MN.65*NXT@.<4_P\E$;0IT&X" @5\W23@88B=I/0,8E0;A2G=1FSK7GYX3VAG
M&3X6$!I!*D=NO6FUU5Q[$@8.<2$/@F#PNUY!-<\ZFP-QB#/XR)6";NO)7GE<
M.GD,JP^W13(N)8U>JM2&%7-.YD)I$(U *O90-HQ L(<,[FD9[FFXD<:3((C*
M&\>F RA)Y+JH-A]<9Q/RE=\Q,POZ\<?>A8V)P=]R*?D2=[FU3(MYN@82+!<;
ML OVO'81Y!LIR(PS$%N:4G@$^L4&Y--ZMT3"R8;#SKS6Y4Z(8;?(]:(DMV!I
MIH@6T%NO4GX'KH#>!&ANT25K+LWG WI+,[GD6DT(Q.)Q)K,OJQ7+</8Y?%TH
M3F8/T-# MG-T8ENPG1T-H 2^@(_\W3Z*#O01=7Z>C^A+^&C4+@S/]\_/S"'O
M1?SC]_@'Z]S_/W_\?O_,H=_%[W8-[H 14RNB.7SG23!W 5<T@W_78.<FA:_1
M!%($RGGM@OW>2K7:VN[,N@N.NHY'+X'=6/+?D)%'W6? Q]O@T$GNA?>A/3H<
M?M2E'YI([R/O/PN]VY!!,[83G *X&]/G4>^T4#NA/1/CD>,^Q^^C;AN*+>C.
M"0)K &W.BR:^ZYO$#WU(_/ _FIH14? 3G>8<9S 3>(@/_<%53]_0^S$*-+--
MPB&60>,[F!X685&=9MVG>E5:6<,!"HX/JV#M];UF4J?@G =<RHIK],WH<5XV
MG_.,2W,\9,+:Y2]Y9HH"> NG?U(9(*AQ?TF1?,U2+!3>XV1U-8"OU:T\84UC
M]@"0KQ"R\TV?_ 6&Y]"_E7T6(VM0*]"P)AY]YQ73UM%9SB&$>$ (O2 F<7F*
MUCQMSB#?ED=OC^+E 288N$RAN<OX E1M:/^'1):'@N5 B[4YB)L)K45N;E><
M@:=0 -XO!%"N!CA!<S)[_@]02P,$%     @ @H"J5L>V@A*O!   L@T  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULO5?;;MLX$'W75PS4HK"!Q++E
MV$E<VT N&R3 M@V2M/M,RR.+J$1J2=I.]NMW2,FRDBAJT(<^6"8ISH4SYXR&
MTZU4/W6":. Q2X6>^8DQ^20(=)1@QG1/YBCH32Q5Q@Q-U2K0N4*V=$)9&H3]
M_CC(&!?^?.K6;M5\*M<FY0)O%>AUEC'U=(ZIW,[\@;];N..KQ-B%8#[-V0KO
MT7S/;Q7-@DK+DF<H-)<"%,8S_VPP.1_;_6[##XY;71N#/<E"RI]V<K.<^7WK
M$*88&:N!T=\&+S!-K2)RX]]2IU^9M(+U\4[[E3L[G67!-%[(]!^^-,G,/_%A
MB3%;I^9.;J^Q/,_(ZHMDJMT3MN7>O@_16AN9E<+D0<9%\<\>RSB\1R L!4+G
M=V'(>7G)#)M/E=R"LKM)FQVXHSII<HX+FY1[H^@M)SDSOT3%-\Q&!KC01JTI
MX$8#$TM(<+GB8E4$CAN.&CH/;)&B[DX#0[:MAB J[9P7=L(W[ SABQ0FT?"7
M6.+RN7Q /E>.ASO'S\-6A5^8ZL%P< !A/QRVZ!M6@1@Z?4=OZ+LO4 DRAJ_2
M H:E<);)M8T&81^N*1JXA!N#F6XZ?JMV2ZV)SEF$,Y^XHU%MT)_#0X*D.R5B
MV#@;&]N2'?P_BK:AUV+G"ZOYDA2^<.O+ 6P3%& 4$YHYI%/V%!(R-5\)9F@?
MTX4$93*R2LC8Q*/X18D+X"5&F"U0V8EGHVE#&GJ=[[W['GPD6!#NTM0J[GH7
M2FI]&*V50A$]@=ZR' XA8CJ!F(Y1VND,NB0X&)_2\].'DW 0?F[)T%&5H:/W
M9N@B95KSF$>LH#:A]8IQ!3]8NJ; T8X:KF_VN&Y*7*O1WT]<]-K%V+JXV;GH
M7553[_)5LJS>.B$)DPTI?;&KEE27QWIF75+A5QN\.\RELA;6Q%,%32!H7/3.
MM$;KXB[L>N)]HS@H*,!BR&7:8%?S?4"DVC*UA(A*@R+PZCU>GHV.1O0(3TN%
M0HH2@:8)CX=-:/ST83 ^_ERI?/'O_<W9@J?</+4=("TW<?S5*5Z:Z8R'0&$;
M] ?0]4I7*- 63T6Q+=D-5%LM>FCA8[\WVD6W!RWL&57L&;6R9T^( DS/(7==
M@ND77&DUT<*5@B$+VP) KN2&$Y0)/D5/47S>5Q1"1R;:GLH::\K0$*=)Z:%A
MC]X5%TQ$G(HB/E)SHI&*H"#P?:6?P@T*(ICWD"A$R(J/#MJ/S@$TK-4HTSIZ
M#S$(1@*+JFS7MPDG68QCM)@@_QT<B^JL,)**[%M<C_OV.3JA9V=X,!X32&K#
M=J1U0HLKAZX1=%_ANE667! RX]&.)L-7\C FY:>DMP5_XPI_XW=5[V\QW!9Y
MA,Z*FD:J)REQF.(2*YE!':8UB%(X+RRMKRR"=F"]P]3!1"<\;X1KJT=_"JZ-
MQZR5F7I9IV,^KU[6A*H?<_(F^LMB)3.RF]BNV;5T-*?46M/=WZ"$^T@T\>+Y
MBS]#CD%X;'DQ.H;&/D2_T8@,]F4XK%&D"=)!K8_.4*W<;4&#:YJ*EKI:K2XD
M9T4?OM]>W&8H-I0\314])M%^[YA*IRIN",7$R-QUY0MIJ,=WPX0N5:CL!GH?
M2VEV$VN@NJ;-_P=02P,$%     @ @H"J5I@IX,(K!   Z@H  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&ULK59=3^LX$'WG5XQRT=4%H:9)6EJ@K51@
MT04M'Z(L:+7:!S>9-A:.W;4=2O_]CI,TA%6I%G8?VMB.YYPYX_%D!DNEGTV*
M:.$U$](,O=3:Q;'OFSC%C)F66J"D-S.E,V9IJN>^66AD26&4"3]LMP_]C''I
MC0;%VIT>#51N!9=XI\'D6<;TZA2%6@Z]P%LOW/-Y:MV"/QHLV!PG:'];W&F:
M^35*PC.4ABL)&F=#;QP<GW;<_F+#(\>E:8S!*9DJ]>PFE\G0:SN'4&!L'0*C
MQPN>H1 .B-SXJ\+T:DIGV!ROT2\*[:1ER@R>*?'$$YL.O;X'"<Y8+NR]6O[$
M2D_7X<5*F.(?EN7>;M>#.#=6994Q>9!Q63[9:Q6'AD&__8%!6!F$A=\E4>'E
M.;-L--!J"=KM)C0W**06UN0<E^Y0)E;36TYV=G2FLHQ;BK(UP&0"L9*6RSG*
MF*.!'P]L*M#L#7Q+7,["CRO<TQ(W_  W@FM"2@W\(A-,WMO[Y&/M:+AV]#3<
M"GC-= NBX #"=AAMP8MJX5&!%_U+X6?OA)]S$PME<HWPQWAJK*;L^7-3%$J2
MSF82=Z..S8+%./3HRAC4+^B-OG\+#MLG6R1T:@F=;>BC"=W0)!<(MS.X9A8U
M9P+.T3(NC%N[E E_X4E.JW2YK,!"[2856WDVJZ!L0[C*-3<)+R_8&P?LPQU;
M%:/&XIU621Z_/9_&9_#(1(Y%_!]09SM7N43HN3,.CN#V6;!490QV>V$KHN07
MPM'\6#">[$$ *V0:;ORQ^^V<8XS9%#6$:_.S?$7F<T8GFTN[.H#;G[ ;A*W.
M/Y'"5K? ,C#-29]4>I%2!$ RH5X5#7Y05E!P8YCDTW*%CK#7.2&X+MG6<%$)
ML[?!F4GNLNV=*[W6X?_HR=%&1ZZ8S*G40M O[DT(OZJ<&\XD<[[7!D'_J[2-
M8RD/9&_G J>Z(.U4G _XR@SQ14'#QV"MM"9)5XE6<2J4YDF#\H;IF,F2;X^B
MUI 9M-<ZJ3C$*81!Q7B?*H*X-,(EUFX8O+%&GV)=R_QT6'K]UA8_HW;EYT5!
MZ\ZBUVL%_SDV_<XFSJM<4 *$%>6$5%UH1E7.Q(J(FWGSR>C4O&%[$^\$%[:\
M!<%11?Z$QL(CUW,NN;O6W<9E_*KHL+>)_$:]E-Q117U#_<'OU!]0R@91HYKL
M[[]E_[J6U!D<EBD<P8/F4W0YW.XW;+\<KXVYL0_CS)4' _@:BYSLF;5*2UR9
M[]_Z8= [@1GB^BMMK#EP&RG(M;;6#JFY41:X= #T-8.8F10652UVEA]@"J%B
M*N@)Y/2YUF!3E^:NJB^=$%,7\19L^F[YC?XC0STONBQ#7I*<LA6I5^M&;ESV
M+V_;RRZ0;@AEAP&!,S)MMWK4-^FRLRHG5BV*;F:J2$E6#%-J1E&[#?1^II1=
M3QQ!W=Z._@902P,$%     @ @H"J5GVNZ5O; P  X@D  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&ULM5;;;N,V$'W75PS4H+ 7"\NB(CMQ;0-Q-HNF
MP*)!+NTS(]$6NQ2IDE2<].L[)&6MW3I&T:(/DDAJ.'/.&7+(^5;IKZ9BS,)K
M+:19Q)6US2Q)3%&QFIJ1:IC$/VNE:VJQJS>):32CI9]4BX2,QY.DIES&R[D?
MN]/+N6JMX)+=:3!M75/]MF)";1=Q&N\&[OFFLFX@6<X;NF$/S#XU=QI[2>^E
MY#63ABL)FJT7\54Z6^7.WAO\PMG6[+7!,7E6ZJOKW):+>.P ,<$*ZSQ0_+RP
M:R:$<X0P?N]\QGU(-W&_O?/^V7-'+L_4L&LE?N6EK1;Q10PE6]-6V'NU_9%U
M?#S 0@GCW[ -MM,\AJ(U5M7=9$10<QF^]+7386_"Q?B=":2;0#SN$,BC_$0M
M7<ZUVH)VUNC--3Q5/QO!<>F2\F U_N4XSRY_MA730(UAU@"O&\HU2F[-1U3<
M6-T6MM5<;H#*$I2WY9;5!@:/]%DP,YPG%E$X7TG115R%B.2=B!E\4=)6!FYD
MR<K#^0FB[RF0'845.>GP"]4CR-*/0,8D.^$OZR7)O+_S=_P]X,(O6\% K2'(
M<Q7DN=V7Y_YO\@3;6R?/,55.!G5[;V8:6K!%C)O+,/W"XN5CI1F#.LC%G%R
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MM#/ _VNE[*[C O37NN6?4$L#!!0    ( (* JE9)^1'[Q0,  %T*   9
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M.&0?M7(KR]ZI5*3[^P<0KI8PWDEX&Y\D^)&;/AM&/1:'\? $O6&M\=#3&[U
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MPQ2T /,+#:&K#C&H'_FN_P]02P,$%     @ @H"J5E69G73B!@  BE$  !D
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M3A5"X)R@G>,!)4Q7#UO5L:KP;\-,67II?#.C;P'4+H#FYTK93<<M4']=Q'\
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MD:$26FY;"$PU@:F;P(MM+#=J3;'\[,:"V\W@G7U/WKI!:Z93[K^RX9PF#.X
M3]ZZ':#G"M0]5QB.!6HNN&<SW!^BIA$.(LN2@FJ*4_?"W",7J+DFQQ'O+XU
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MN@0  +T7   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;+68;6_J-A2
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M'J@86+7R;<1466Q*_.,2^T;0+@#?SY6R3P/W@:H33?X!4$L#!!0    ( (*
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M,O@&[//'@HWX_@7?P>%1]U?_ U!+ P04    " ""@*I6CU.OKNT/   4U
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MB8^4! DC2!@%P11)@KTD@<GAL=P<'B5;9?G,R1;%>EGW":)EV0J"A)$M+-K
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MY !%4Y40R4$Z\,0]LR7RD4':HV_)^NB!A@I0&D715,U$J)!BG\&70K,$*(U
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MR)T13!;Y##1E?R1!\P4LCL)P'>4"2;D 7.B@*0,61[ X"L-UY DE>:"W1AC
MV:L#32=V.#D%.O:H05C3G:&/I*&WNQ.B41 T!-4L]AG8U7ZPH8L48+B.'K&D
MAS[+@,5! PW9'R3]EU,D;L=^$>,MJ<F6G8%,I(%\\K4+?9/UF4*A@=[;JP--
M'[ X"L-U/@RI]&' 7L&PX\'D@4826!R%X51Y7"F4<,]R'<.NF<&$:* _UGI
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M0T!Q%(93%?&D&,+3QQ &5:YC;WL%T;=B?1A!<02+HS!<1S0IJ_# :Q@\;'H
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M2QM^8=_N'43 :^MTV8(I@U*HYI]];7DX  S3(X"D!22/ :,C@+0%I+\*&+6
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MDI)\!2CFN1):\W;1[RH%@>*-$*;[ R5SRLH5V1<=TLPZI'D^W,@U26#LZ0>
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MR,ERHB\76N1VQGT4FB9F>QDCBU : ;H_%4(O%^: ^KO*Z#]02P,$%     @
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MQH#C-E]GJ6ABD@U4!IA42R6=SC3]DMK?9+G)K'"=(:9T,6Q);-/ID,<RF>=
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M\]S=<X[/@PT7KW(!H- VITP.G852R[[KRG0!.98=O@2F=V9<Y%CIJ9B[<BD
M9Q:44S?PO)Z;8\*<>&#7'D0\X"M%"8,'@>0JS['X.P;*-T/'=W8+CV2^4&;!
MC0=+/(<G4,_+!Z%G;L62D1R8))PA ;.A,_+[TZZQMP8_"&QD;8Q,)B^<OYK)
M;39T/!,04$B58<#Z;PT3H-00Z3#^E)Q.Y=( Z^,=^S>;N\[E!4N8</J39&HQ
M=*X<E,$,KZAZY)OO4.9C TPYE?87;4I;ST'I2BJ>EV =04Y8\8^WI0XU0!!\
M  A*0' H("P!X:& J 1$AP*Z)<"F[A:Y6^$2K' \$'R#A+'6;&9@U;=HK1=A
MYIP\*:%WB<:I^ [FF")]'!0%77XE$689NN-2H@EGBK YL)2 1%_0*,N(*:ZV
MOV7%"36E/D] 84(OT-G)5=B+;A!AZ)Y0JO?D)3JM3P>NTB$;QVY:AC<NP@L^
M""]$]SJ*A413ED&VCW=UJE6^P2[?<=!*>(]%!X7^)0J\($3/3PDZ/[UHB&MR
M.$W00I.TTR20'D0S_0S-]/D1G9?%N&B1+*R.2&C9PX^.R/O#\.M.VZ!;!;G\
MW534@C!J)C177U\N<0I#1]]M$L0:G/CLQ.]Y-TV5."99<DRRZ9'(]JH2556)
MVMC+#U>^^7"IJ55:K]4E@JUN*A*:ZE2XZ%D7IJ.LXR ,!^ZZ+O][&]\/HGVC
MI#76S\IZ)+(]6;N5K-U664=I*E:0(9SS%5-(7W.('JATD\#==^)%P?7U&X5;
M(_KL 6_PZ%_U]CU."R._;M7S.MW*JI#.K;65',3<]G.3M%:FN#ZJU>K),+*=
M\LWZV.]/_(;U1#\QBA?!?_KB?:+OUSEA4FL_TZZ\SE<=L2AZ?C%1?&F;V@M7
MND7:X4(_DT 8 [T_XUSM)L9!]?"*_P%02P,$%     @ @H"J5LA1YN*J%0
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M84Y],1@70,^76N/#Q&W0=-JS/U!+ P04    " ""@*I6SGXDN4<$  !9$@
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MG+I!5#: GF=2FN>!7<#WE]/_ 5!+ P04    " ""@*I66S H[D &  !\(P
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M<FMS:&5E=',O<VAE970W,2YX;6RU6FUOVS80_BN$5PPMT-0B*;]EB8'$;;$
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MQ( -#NPBEB*-B_GP0[7PIY^%6O$A2L* 7:<%"\T,W]'A.^BT+"&Q$H"$9B9
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M2&,;W2];^[* <@[VO);2G P78'JKBG]02P,$%     @ @H"J5HY3(6;*!P
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M^H[:4:]V%-A'_ZS6$9PYAWRT0I?["\$V[K!HK/7U\%FW1MM^8BJ<=/!TS1O
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M?*#+%T8NLYEH)@U.6-ECC#,P*!N [^<23T:QL&-6.54'?P%02P,$%     @
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M)4Q$-:IN?X+T_'![RE.Q6!;3%8TG55?,I[KIJ(:*6EW@L(]<Z,N.8#X&LR.
M87$P!9B/\<+B_$_Y#-!\#(9I&UB1 >HS0'V,EPV9Z \6Q^X3J<N>:10%01AB
M,SJ96!5,L'D+0_BSLV':P .+ Y$>-]?X:N,5<K@.L#4]5"%8IG@E8IGB<PV(
M?=[ (XKLJXW% 0]L%;#:@?CV.%!3=I\@@%7%M&$[&$>B"$.@%NTU&H;([(3P
ML:\/MDN"((KL"&!V!4& (; ;<013 !HP) CT>W#O?>1MWE->_0^*\1]02P,$
M%     @ @H"J5I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M4$L! A0#%     @ @H"J5B)5XG3M    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ @H"J5IE<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " ""@*I6:0F]>U %  !R%0  &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ @H"J5NB")ZT$"   Y2(
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M965T-BYX;6Q02P$"% ,4    " ""@*I6:25/>E(&  !Q+   &
M    @(&J)   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M@H"J5MH%>]-_ @  Z 4  !@              ("!,BL  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( (* JE;XUM<J%0<  %T?   8
M          " @><M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " ""@*I6I6X<*FX&   2$   &0              @($R-0  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( (* JE:K?L#5< <  -@1
M   9              " @=<[  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ @H"J5L9FWCWO!@  "A$  !D              ("!?D,
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " ""@*I6@OO&
MLW@"   *!0  &0              @(&D2@  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( (* JE: 'OXY@@4   H-   9
M  " @5--  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M@H"J5M=_HVVP!@  O \  !D              ("!#%,  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " ""@*I6ILAXE#T*  "+'P  &0
M            @('S60  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( (* JE;RVJ<_) H   L=   9              " @6=D  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ @H"J5NJV<2&^ @
M2@8  !D              ("!PFX  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " ""@*I6%\>+_U(K   GAP  &0              @(&W
M<0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( (* JE8S
M?W+92 4  .D+   9              " @4"=  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ @H"J5@2VDS<!!0  1PT  !D
M     ("!OZ(  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M" ""@*I6.-HSVEL#  #6!P  &0              @('WIP  >&PO=V]R:W-H
M965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( (* JE:*#E3ZMP,  (8*   9
M              " @8FK  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L!
M A0#%     @ @H"J5A8>,-/R!P  I10  !D              ("!=Z\  'AL
M+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " ""@*I6C5T9.4P)
M   !&0  &0              @(&@MP  >&PO=V]R:W-H965T<R]S:&5E=#(U
M+GAM;%!+ 0(4 Q0    ( (* JE:SJ#RJU0,  '0)   9              "
M@2/!  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ @H"J
M5E.9S5?* @  Q@4  !D              ("!+\4  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " ""@*I6OS?.E@X%   ,#0  &0
M        @($PR   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( (* JE:[_I6>=0(   (%   9              " @77-  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ @H"J5M,$-(7. @  [P4
M !D              ("!(=   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " ""@*I6:0: 2?P"   K!@  &0              @($FTP
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( (* JE80:$^Z
M208  *45   9              " @5G6  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ @H"J5L>V@A*O!   L@T  !D
M ("!V=P  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " ""
M@*I6F"G@PBL$  #J"@  &0              @(&_X0  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( (* JE9]KNE;VP,  .()   9
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M970S.2YX;6Q02P$"% ,4    " ""@*I6RL2QFRL#  !I"   &0
M    @(&( @$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M (* JE9' ?4:2P,  %(*   9              " @>H% 0!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ @H"J5NX^+5>I!P  84,  !D
M             ("!; D! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " ""@*I6NI"<R=8'  #2-   &0              @(%,$0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( (* JE8^7E,IMP(
M )0'   9              " @5D9 0!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ @H"J5L$FK.'. P  #!(  !D              ("!
M1QP! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " ""@*I6
M%0+3X <&   .*P  &0              @(%,( $ >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( (* JE;]YYOLN@0  +T7   9
M      " @8HF 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ @H"J5I_/:")) @  1P4  !D              ("!>RL! 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " ""@*I6N'7F\#,"  #G!
M&0              @('[+0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( (* JE:O*CAZ(P,  )4*   9              " @64P 0!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ @H"J5K4L V1_
M#@  ]GX  !D              ("!OS,! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    " ""@*I6CU.OKNT/   4U   &0
M@(%U0@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( (*
MJE:TT?_L,@@  !!/   9              " @9E2 0!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ @H"J5MHU$=!E P  V@@  !D
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M=#4X+GAM;%!+ 0(4 Q0    ( (* JE:T=Y'5[P(  (0)   9
M  " @2!R 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @
M@H"J5LA1YN*J%0  _X$! !D              ("!1G4! 'AL+W=O<FMS:&5E
M=',O<VAE970V,"YX;6Q02P$"% ,4    " ""@*I6]%9@I#0)  #&/0  &0
M            @($GBP$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4
M Q0    ( (* JE90!H*/K0,  (T0   9              " @9*4 0!X;"]W
M;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ @H"J5NO]P ;K P
MU0T  !D              ("!=I@! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX
M;6Q02P$"% ,4    " ""@*I6W(D")2H#  !U"P  &0              @(&8
MG $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( (* JE;.
M?B2Y1P0  %D2   9              " @?F? 0!X;"]W;W)K<VAE971S+W-H
M965T-C4N>&UL4$L! A0#%     @ @H"J5K5#BWWK @  F0<  !D
M     ("!=Z0! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (* JE;9G_A"#@8  #,F   9              "
M@?2Y 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ @H"J
M5M>+2?[7!@  GS<  !D              ("!.< ! 'AL+W=O<FMS:&5E=',O
M<VAE970W,BYX;6Q02P$"% ,4    " ""@*I61 GQ+R@"  "W!   &0
M        @(%'QP$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0
M   ( (* JE:.4R%FR@<  %,]   9              " @:;) 0!X;"]W;W)K
M<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ @H"J5GXS?P,. P  CPP
M !D              ("!I]$! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q0
M2P$"% ,4    " ""@*I6T[F @WT$   2%@  &0              @('LU $
M>&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( (* JE9OW0U*
M= (  '@%   9              " @:#9 0!X;"]W;W)K<VAE971S+W-H965T
M-S<N>&UL4$L! A0#%     @ @H"J5@NJ)'(I P  80L  !D
M ("!2]P! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4    " ""
M@*I6I@$H XP#  "M&   #0              @ &KWP$ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( (* JE:7BKL<P    !,"   +              "  6+C
M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (* JE8=OSY%R@4  )0S   /
M          "  4OD 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " ""@*I6
M>@0#75P"   A+@  &@              @ %"Z@$ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " ""@*I6+B@*V!4"  #\+   $P
M        @ '6[ $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     5@!6 )$7
(   <[P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>476</ContextCount>
  <ElementCount>320</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>153</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss</Role>
      <ShortName>Consolidated Statements of Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Income (Loss) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical</Role>
      <ShortName>Consolidated Statements of Income (Loss) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Basis of presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Certain transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactions</Role>
      <ShortName>Certain transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Revenue from contracts with customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomers</Role>
      <ShortName>Revenue from contracts with customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Identifiable Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IdentifiableIntangibleAssets</Role>
      <ShortName>Identifiable Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Debt obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligations</Role>
      <ShortName>Debt obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Derivative instruments and hedging activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities</Role>
      <ShortName>Derivative instruments and hedging activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Legal Settlements and Loss Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies</Role>
      <ShortName>Legal Settlements and Loss Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Other assets impairments, restructuring and other items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems</Role>
      <ShortName>Other assets impairments, restructuring and other items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Earnings (Loss) per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Accumulated other comprehensive income (loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated other comprehensive income (loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Fair value measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurement</Role>
      <ShortName>Fair value measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Certain transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactionsTables</Role>
      <ShortName>Certain transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/CertainTransactions</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Revenue from contracts with customers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables</Role>
      <ShortName>Revenue from contracts with customers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/RevenueFromContractsWithCustomers</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/Inventories</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Identifiable Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables</Role>
      <ShortName>Identifiable Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/IdentifiableIntangibleAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/Goodwill</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Debt obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsTables</Role>
      <ShortName>Debt obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/DebtObligations</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Derivative instruments and hedging activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables</Role>
      <ShortName>Derivative instruments and hedging activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Commitments and contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Other assets impairments, restructuring and other items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables</Role>
      <ShortName>Other assets impairments, restructuring and other items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Accumulated other comprehensive income (loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated other comprehensive income (loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/Segments</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Certain Transactions - Other Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail</Role>
      <ShortName>Certain Transactions - Other Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail</Role>
      <ShortName>Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail</Role>
      <ShortName>Revenue from Contracts with Customers - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail</Role>
      <ShortName>Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail</Role>
      <ShortName>Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Inventories - Summary of Inventories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail</Role>
      <ShortName>Inventories - Summary of Inventories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail</Role>
      <ShortName>Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Identifiable Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Identifiable Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail</Role>
      <ShortName>Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail</Role>
      <ShortName>Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Goodwill - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail</Role>
      <ShortName>Goodwill - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail</Role>
      <ShortName>Debt Obligations - Schedule of Short-term Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail</Role>
      <ShortName>Debt Obligations - Schedule of Senior Notes and Loans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail</Role>
      <ShortName>Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Debt Obligations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail</Role>
      <ShortName>Debt Obligations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Derivative instruments and hedging activities - Summary of Notional Amounts for Hedged Items (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail</Role>
      <ShortName>Derivative instruments and hedging activities - Summary of Notional Amounts for Hedged Items (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Derivative instruments and hedging activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail</Role>
      <ShortName>Derivative instruments and hedging activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Derivative instruments and hedging activities - Summary Of Pre-tax (gains) losses from Derivatives Designated in Cash Flow Hedging Relationships (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail</Role>
      <ShortName>Derivative instruments and hedging activities - Summary Of Pre-tax (gains) losses from Derivatives Designated in Cash Flow Hedging Relationships (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Derivative instruments and hedging activities - Schedule of Other Derivatives Not Designated As Hedging Instruments Statements of Financial Performance And Financial Position Location (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail</Role>
      <ShortName>Derivative instruments and hedging activities - Schedule of Other Derivatives Not Designated As Hedging Instruments Statements of Financial Performance And Financial Position Location (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Derivative instruments and hedging activities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail</Role>
      <ShortName>Derivative instruments and hedging activities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Legal Settlements and Loss Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail</Role>
      <ShortName>Legal Settlements and Loss Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Commitments and contingencies - Schedule Of Material Details Of Individual Settlements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail</Role>
      <ShortName>Commitments and contingencies - Schedule Of Material Details Of Individual Settlements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail</Role>
      <ShortName>Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail</Role>
      <ShortName>Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail</Role>
      <ShortName>Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Other assets impairments, restructuring and other items - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail</Role>
      <ShortName>Other assets impairments, restructuring and other items - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Earnings (Loss) per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Earnings (Loss) per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/EarningsLossPerShare</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Accumulated Other Comprehensive Income (Loss)  (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss)  (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Segments - Summary of Segment Profit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail</Role>
      <ShortName>Segments - Summary of Segment Profit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail</Role>
      <ShortName>Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Segments - Schedule of Revenues by Major Products and Activities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail</Role>
      <ShortName>Segments - Schedule of Revenues by Major Products and Activities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Segments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail</Role>
      <ShortName>Segments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Fair value measurement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail</Role>
      <ShortName>Fair value measurement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d464631d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockShares in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d464631d10q.htm 919</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2022 used in 4 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d464631d10q.htm 1708, 1936, 2155, 2383</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AccountingStandardsUpdate201601Member in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d464631d10q.htm 7085, 7386</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: teva:BifurcatedEmbeddedDerivatives, us-gaap:DebtInstrumentMaturityDate, us-gaap:DerivativeLiabilities -  d464631d10q.htm 430</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="d464631d10q.htm">d464631d10q.htm</File>
    <File>d464631dex101.htm</File>
    <File>d464631dex311.htm</File>
    <File>d464631dex312.htm</File>
    <File>d464631dex32.htm</File>
    <File>teva-20230331.xsd</File>
    <File>teva-20230331_cal.xml</File>
    <File>teva-20230331_def.xml</File>
    <File>teva-20230331_lab.xml</File>
    <File>teva-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="945">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d464631d10q.htm": {
   "axisCustom": 5,
   "axisStandard": 32,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 945,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 476,
   "dts": {
    "calculationLink": {
     "local": [
      "teva-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "teva-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d464631d10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "teva-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "teva-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "teva-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 683,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 11,
    "http://www.tevapharm.com/20230331": 2,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 19
   },
   "keyCustom": 81,
   "keyStandard": 239,
   "memberCustom": 93,
   "memberStandard": 59,
   "nsprefix": "teva",
   "nsuri": "http://www.tevapharm.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.tevapharm.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Basis of presentation",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.tevapharm.com/role/BasisOfPresentation",
     "shortName": "Basis of presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:CertainTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Certain transactions",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.tevapharm.com/role/CertainTransactions",
     "shortName": "Certain transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:CertainTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Revenue from contracts with customers",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
     "shortName": "Revenue from contracts with customers",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.tevapharm.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Identifiable Intangible Assets",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
     "shortName": "Identifiable Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Goodwill",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.tevapharm.com/role/Goodwill",
     "shortName": "Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Debt obligations",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.tevapharm.com/role/DebtObligations",
     "shortName": "Debt obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Derivative instruments and hedging activities",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
     "shortName": "Derivative instruments and hedging activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Legal Settlements and Loss Contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
     "shortName": "Legal Settlements and Loss Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Commitments and contingencies",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.tevapharm.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Income taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.tevapharm.com/role/IncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:OtherExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Other assets impairments, restructuring and other items",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
     "shortName": "Other assets impairments, restructuring and other items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:OtherExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Earnings (Loss) per Share",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.tevapharm.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Accumulated other comprehensive income (loss)",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss",
     "shortName": "Accumulated other comprehensive income (loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Segments",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.tevapharm.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Fair value measurement",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.tevapharm.com/role/FairValueMeasurement",
     "shortName": "Fair value measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "26",
     "role": "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Certain transactions (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.tevapharm.com/role/CertainTransactionsTables",
     "shortName": "Certain transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Revenue from contracts with customers (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
     "shortName": "Revenue from contracts with customers (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.tevapharm.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Identifiable Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
     "shortName": "Identifiable Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Goodwill (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.tevapharm.com/role/GoodwillTables",
     "shortName": "Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Debt obligations (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.tevapharm.com/role/DebtObligationsTables",
     "shortName": "Debt obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Derivative instruments and hedging activities (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
     "shortName": "Derivative instruments and hedging activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Commitments and contingencies (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.tevapharm.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Other assets impairments, restructuring and other items (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
     "shortName": "Other assets impairments, restructuring and other items (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Accumulated other comprehensive income (loss) (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated other comprehensive income (loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Segments (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.tevapharm.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Fair Value Measurement (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:UpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Certain Transactions - Other Transactions - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
     "shortName": "Certain Transactions - Other Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:UpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Income (Loss)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
     "shortName": "Consolidated Statements of Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail",
     "shortName": "Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023_AccountsReceivableSecuritizationFacilityMemberusgaapDerivativeInstrumentRiskAxis_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022MemberusgaapPledgingPurposeAxis_PncBankMemberTEVAFactoringInstitutionAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableFromSecuritization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
     "shortName": "Revenue from Contracts with Customers - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023_AccountsReceivableSecuritizationFacilityMemberusgaapDerivativeInstrumentRiskAxis_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022MemberusgaapPledgingPurposeAxis_PncBankMemberTEVAFactoringInstitutionAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableFromSecuritization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
     "shortName": "Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_ProductMembersrtProductOrServiceAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SalesReservesAndAllowancesCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
     "shortName": "Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SalesReservesAndAllowancesCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Inventories - Summary of Inventories (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail",
     "shortName": "Inventories - Summary of Inventories (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail",
     "shortName": "Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Identifiable Intangible Assets - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
     "shortName": "Identifiable Intangible Assets - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
     "shortName": "Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail",
     "shortName": "Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn06_30_2022_EuropeReportingUnitMemberusgaapMeasurementInputTypeAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Goodwill - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
     "shortName": "Goodwill - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn06_30_2022_EuropeReportingUnitMemberusgaapMeasurementInputTypeAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_MaximumMembersrtRangeAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Income (Loss) (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical",
     "shortName": "Consolidated Statements of Income (Loss) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_MaximumMembersrtRangeAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Detail)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail",
     "shortName": "Debt Obligations - Schedule of Short-term Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeniorNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Detail)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
     "shortName": "Debt Obligations - Schedule of Senior Notes and Loans (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeniorNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:SeniorNotesRepaidAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
     "shortName": "Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:SeniorNotesRepaidAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:LongTermDebtCurrencyPortionUSD",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Debt Obligations - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
     "shortName": "Debt Obligations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:LongTermDebtCurrencyPortionUSD",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeAssetNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Derivative instruments and hedging activities - Summary of Notional Amounts for Hedged Items (Detail)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail",
     "shortName": "Derivative instruments and hedging activities - Summary of Notional Amounts for Hedged Items (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023_CrossCurrencySwapCashFlowHedgeMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeAssetNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Derivative instruments and hedging activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
     "shortName": "Derivative instruments and hedging activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Derivative instruments and hedging activities - Summary Of Pre-tax (gains) losses from Derivatives Designated in Cash Flow Hedging Relationships (Detail)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail",
     "shortName": "Derivative instruments and hedging activities - Summary Of Pre-tax (gains) losses from Derivatives Designated in Cash Flow Hedging Relationships (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Derivative instruments and hedging activities - Schedule of Other Derivatives Not Designated As Hedging Instruments Statements of Financial Performance And Financial Position Location (Detail)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail",
     "shortName": "Derivative instruments and hedging activities - Schedule of Other Derivatives Not Designated As Hedging Instruments Statements of Financial Performance And Financial Position Location (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:RevenuesOtherThanUsd",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Derivative instruments and hedging activities - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
     "shortName": "Derivative instruments and hedging activities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:RevenuesOtherThanUsd",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LegalMattersAndContingenciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Legal Settlements and Loss Contingencies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
     "shortName": "Legal Settlements and Loss Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LegalMattersAndContingenciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "teva:DamagesAssessment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "teva:DamagesAssessment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencySettlementAgreementDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Commitments and contingencies - Schedule Of Material Details Of Individual Settlements (Detail)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail",
     "shortName": "Commitments and contingencies - Schedule Of Material Details Of Individual Settlements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_LAusgaapStatutoryAccountingPracticesByJurisdictionAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencySettlementAgreementDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:ExpectedImpairmentOfIncomeTaxBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Income Taxes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:ExpectedImpairmentOfIncomeTaxBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail",
     "shortName": "Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
     "shortName": "Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:ScheduleOfRestructuringChargesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail",
     "shortName": "Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Other assets impairments, restructuring and other items - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
     "shortName": "Other assets impairments, restructuring and other items - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Earnings (Loss) per Share - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail",
     "shortName": "Earnings (Loss) per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn12_31_2022_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Accumulated Other Comprehensive Income (Loss)  (Parenthetical) (Detail)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
     "shortName": "Accumulated Other Comprehensive Income (Loss)  (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Consolidated Statements of Changes in Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Segments - Summary of Segment Profit (Detail)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail",
     "shortName": "Segments - Summary of Segment Profit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
     "shortName": "Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Segments - Schedule of Revenues by Major Products and Activities (Detail)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
     "shortName": "Segments - Schedule of Revenues by Major Products and Activities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Segments - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
     "shortName": "Segments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail",
     "shortName": "Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure - Fair value measurement - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
     "shortName": "Fair value measurement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
     "shortName": "Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn01_01_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
     "shortName": "Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn01_01_2022_NoveTideAcquisitionMemberusgaapBusinessAcquisitionAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure - Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
     "shortName": "Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "PAsOn03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
     "shortName": "Consolidated Statements of Changes in Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1009 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d464631d10q.htm",
      "contextRef": "P01_01_2023To03_31_2023",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 153,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan [Member]"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
      "http://www.tevapharm.com/role/CertainTransactions",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsTables",
      "http://www.tevapharm.com/role/CommitmentsAndContingencies",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/DebtObligations",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail",
      "http://www.tevapharm.com/role/DebtObligationsTables",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
      "http://www.tevapharm.com/role/EarningsLossPerShare",
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurement",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementTables",
      "http://www.tevapharm.com/role/Goodwill",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail",
      "http://www.tevapharm.com/role/GoodwillTables",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
      "http://www.tevapharm.com/role/IncomeTaxes",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/Inventories",
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail",
      "http://www.tevapharm.com/role/InventoriesTables",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
      "http://www.tevapharm.com/role/Segments",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail",
      "http://www.tevapharm.com/role/SegmentsTables",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
      "http://www.tevapharm.com/role/CertainTransactions",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsTables",
      "http://www.tevapharm.com/role/CommitmentsAndContingencies",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/DebtObligations",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail",
      "http://www.tevapharm.com/role/DebtObligationsTables",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
      "http://www.tevapharm.com/role/EarningsLossPerShare",
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurement",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementTables",
      "http://www.tevapharm.com/role/Goodwill",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail",
      "http://www.tevapharm.com/role/GoodwillTables",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
      "http://www.tevapharm.com/role/IncomeTaxes",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/Inventories",
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail",
      "http://www.tevapharm.com/role/InventoriesTables",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
      "http://www.tevapharm.com/role/Segments",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail",
      "http://www.tevapharm.com/role/SegmentsTables",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r258",
      "r297",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r319",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r401",
      "r403",
      "r404",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r258",
      "r297",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r319",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r401",
      "r403",
      "r404",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r256",
      "r257",
      "r409",
      "r437",
      "r674",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r387",
      "r388",
      "r391",
      "r392",
      "r471",
      "r606",
      "r640",
      "r666",
      "r667",
      "r693",
      "r706",
      "r716",
      "r778",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r387",
      "r388",
      "r391",
      "r392",
      "r471",
      "r606",
      "r640",
      "r666",
      "r667",
      "r693",
      "r706",
      "r716",
      "r778",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "North America [Member]",
        "terseLabel": "North America [Member]"
       }
      }
     },
     "localname": "NorthAmericaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r321",
      "r607",
      "r694",
      "r714",
      "r773",
      "r774",
      "r779",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r321",
      "r607",
      "r694",
      "r714",
      "r773",
      "r774",
      "r779",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r387",
      "r388",
      "r391",
      "r392",
      "r463",
      "r471",
      "r474",
      "r475",
      "r476",
      "r581",
      "r606",
      "r640",
      "r666",
      "r667",
      "r693",
      "r706",
      "r716",
      "r766",
      "r778",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r387",
      "r388",
      "r391",
      "r392",
      "r463",
      "r471",
      "r474",
      "r475",
      "r476",
      "r581",
      "r606",
      "r640",
      "r666",
      "r667",
      "r693",
      "r706",
      "r716",
      "r766",
      "r778",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r256",
      "r257",
      "r409",
      "r437",
      "r675",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r279",
      "r472",
      "r728",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r322",
      "r323",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r695",
      "r715",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r322",
      "r323",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r695",
      "r715",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r279",
      "r472",
      "r728",
      "r729",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r666",
      "r667",
      "r797",
      "r799",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average [Member]"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_FL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FLORIDA"
       }
      }
     },
     "localname": "FL",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_LA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOUISIANA"
       }
      }
     },
     "localname": "LA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK"
       }
      }
     },
     "localname": "NY",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_OK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OKLAHOMA"
       }
      }
     },
     "localname": "OK",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_RI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RHODE ISLAND"
       }
      }
     },
     "localname": "RI",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TEXAS"
       }
      }
     },
     "localname": "TX",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WV": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEST VIRGINIA"
       }
      }
     },
     "localname": "WV",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AccountsReceivableSecuritizationFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable securitization facility.",
        "label": "Accounts Receivable Securitization Facility [Member]",
        "terseLabel": "Accounts Receivable Securitization Facility [Member]"
       }
      }
     },
     "localname": "AccountsReceivableSecuritizationFacilityMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses.",
        "label": "Accrued Expenses",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedExpenses",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ActavisGenericsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actavis Generics [Member]",
        "label": "Actavis Generics [Member]",
        "terseLabel": "Actavis Generics [Member]"
       }
      }
     },
     "localname": "ActavisGenericsMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AjovyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AJOVY [Member]"
       }
      }
     },
     "localname": "AjovyMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AlvotechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alvotech.",
        "label": "Alvotech [Member]",
        "terseLabel": "Alvotech [Member]"
       }
      }
     },
     "localname": "AlvotechMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AmendedRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended revolving credit facility member.",
        "label": "Amended Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "AmendedRevolvingCreditFacilityMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AmountsAllocatedToSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts allocated to segments.",
        "label": "Amounts Allocated To Segments [Abstract]",
        "terseLabel": "Amounts allocated to segments:"
       }
      }
     },
     "localname": "AmountsAllocatedToSegmentsAbstract",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_AmountsNotAllocatedToSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts not allocated to segments.",
        "label": "Amounts Not Allocated To Segments [Abstract]",
        "terseLabel": "Amounts not allocated to segments:"
       }
      }
     },
     "localname": "AmountsNotAllocatedToSegmentsAbstract",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_AndaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anda [Member]",
        "label": "Anda [Member]",
        "terseLabel": "Anda [Member]"
       }
      }
     },
     "localname": "AndaMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AndroGelRateAtOnePercentageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Andro gel rate at one percentage.",
        "label": "Andro Gel Rate At One Percentage [Member]",
        "terseLabel": "AndroGel Rate at 1% [Member]"
       }
      }
     },
     "localname": "AndroGelRateAtOnePercentageMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales at The time of nuvigil entered into first settlement of with AN ANDA hiler.",
        "label": "Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer",
        "terseLabel": "Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer"
       }
      }
     },
     "localname": "AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesAtTimeOfSettlement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales at time of settlement.",
        "label": "Annual Sales At Time Of Settlement",
        "terseLabel": "Annual sales at the time of settlement"
       }
      }
     },
     "localname": "AnnualSalesAtTimeOfSettlement",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfActoplus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of Acto plus.",
        "label": "Annual Sales Of Actoplus",
        "terseLabel": "Annual sales of Acto plus"
       }
      }
     },
     "localname": "AnnualSalesOfActoplus",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfActos": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of Actos.",
        "label": "Annual Sales Of Actos",
        "terseLabel": "Annual sales of Actos"
       }
      }
     },
     "localname": "AnnualSalesOfActos",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfColcrys": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of colcrys.",
        "label": "Annual sales of Colcrys",
        "terseLabel": "Annual sales of Colcrys"
       }
      }
     },
     "localname": "AnnualSalesOfColcrys",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfCopaxone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Sales Of Copaxone.",
        "label": "Annual Sales Of Copaxone",
        "terseLabel": "Annual sales of Copaxone"
       }
      }
     },
     "localname": "AnnualSalesOfCopaxone",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfEffexor": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of effexor.",
        "label": "Annual Sales Of Effexor",
        "terseLabel": "Annual sales of Effexor"
       }
      }
     },
     "localname": "AnnualSalesOfEffexor",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfEpipen": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of EpiPen.",
        "label": "Annual Sales Of EpiPen",
        "terseLabel": "Annual Sales Of EpiPen"
       }
      }
     },
     "localname": "AnnualSalesOfEpipen",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfLamictal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of Lamictal.",
        "label": "Annual Sales Of Lamictal",
        "terseLabel": "Annual sales of Lamictal"
       }
      }
     },
     "localname": "AnnualSalesOfLamictal",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfNiaspan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of Niaspan.",
        "label": "Annual Sales Of Niaspan",
        "terseLabel": "Annual sales of Niaspan"
       }
      }
     },
     "localname": "AnnualSalesOfNiaspan",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfRevlimid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of revlimid.",
        "label": "Annual Sales Of Revlimid",
        "terseLabel": "Annual Sales Of Revlimid"
       }
      }
     },
     "localname": "AnnualSalesOfRevlimid",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfSensipar": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Annual Sales Of Sensipar.",
        "label": "Annual Sales Of Sensipar",
        "terseLabel": "Annual Sales Of Sensipar"
       }
      }
     },
     "localname": "AnnualSalesOfSensipar",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of the time of new launch of Atripla.",
        "label": "Annual Sales Of The Time Of New Launch Of Atripla",
        "terseLabel": "Annual sales of the time of New launch of Atripla"
       }
      }
     },
     "localname": "AnnualSalesOfTheTimeOfNewLaunchOfAtripla",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of the time of New launch of truvada.",
        "label": "Annual Sales Of The Time Of New Launch Of Truvada",
        "terseLabel": "Annual sales of the time of New launch of Truvada"
       }
      }
     },
     "localname": "AnnualSalesOfTheTimeOfNewLaunchOfTruvada",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfTheTimeOfNewLaunchOfViread": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of the time of new launch of viread.",
        "label": "Annual Sales Of The Time Of New Launch Of Viread",
        "terseLabel": "Annual sales of the time of New launch of viread"
       }
      }
     },
     "localname": "AnnualSalesOfTheTimeOfNewLaunchOfViread",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfTheTimeOfSettlementOfAtripla": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of the time of settlement of atripla.",
        "label": "Annual Sales Of The Time Of Settlement Of Atripla",
        "terseLabel": "Annual sales of the time of settlement of Atripla"
       }
      }
     },
     "localname": "AnnualSalesOfTheTimeOfSettlementOfAtripla",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfTheTimeOfSettlementOfTruvada": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of the time of settlement of truvada.",
        "label": "Annual Sales Of The Time Of Settlement Of Truvada",
        "terseLabel": "Annual sales of the time of settlement of Truvada"
       }
      }
     },
     "localname": "AnnualSalesOfTheTimeOfSettlementOfTruvada",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfTheTimeOfSettlementOfViread": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of the time of settlement of viread.",
        "label": "Annual Sales Of The Time Of Settlement Of Viread",
        "terseLabel": "Annual sales of the time of settlement of viread"
       }
      }
     },
     "localname": "AnnualSalesOfTheTimeOfSettlementOfViread",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AustedoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Austedo [Member]",
        "label": "Austedo [Member]",
        "terseLabel": "AUSTEDO [Member]"
       }
      }
     },
     "localname": "AustedoMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_BasisOfPresentationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation [Abstract]"
       }
      }
     },
     "localname": "BasisOfPresentationAbstract",
     "nsuri": "http://www.tevapharm.com/20230331",
     "xbrltype": "stringItemType"
    },
    "teva_BendekaAndTreandaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BENDEKA and TREANDA.",
        "label": "BENDEKA and TREANDA [Member]",
        "verboseLabel": "BENDEKA\u00ae and TREANDA\u00ae [Member]"
       }
      }
     },
     "localname": "BendekaAndTreandaMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial Interest Obtained in Exchange for Securitized Trade Receivables",
        "label": "Beneficial Interest Obtained in Exchange for Securitized Trade Receivables",
        "terseLabel": "Beneficial interest obtained in exchange for securitized accounts receivables"
       }
      }
     },
     "localname": "BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_BifurcatedEmbeddedDerivatives": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bifurcated embedded derivatives.",
        "label": "Bifurcated Embedded Derivatives",
        "terseLabel": "Bifurcated embedded derivatives"
       }
      }
     },
     "localname": "BifurcatedEmbeddedDerivatives",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_COPAXONEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COPAXONE.",
        "label": "COPAXONE [Member]",
        "terseLabel": "COPAXONE [Member]"
       }
      }
     },
     "localname": "COPAXONEMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_CertainTransactionsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Certain Transactions Disclosure [Text Block]",
        "terseLabel": "Certain transactions"
       }
      }
     },
     "localname": "CertainTransactionsDisclosureTextBlock",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks.",
        "label": "Chargebacks [Member]",
        "terseLabel": "Chargebacks [Member]"
       }
      }
     },
     "localname": "ChargebacksMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_CollaborativeAgreementMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Milestone Payments",
        "label": "Collaborative Agreement Milestone Payments",
        "terseLabel": "Collaborative agreement milestone payments"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestonePayments",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_CommitmentAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment And Contingencies [Line Items]",
        "label": "Commitment And Contingencies [Line Items]",
        "terseLabel": "Commitment And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesLineItems",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_CommitmentAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment And Contingencies [Table]",
        "label": "Commitment And Contingencies [Table]",
        "terseLabel": "Commitment And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesTable",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_ContingencySettlementProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingency Settlement Product",
        "label": "Contingency Settlement Product",
        "verboseLabel": "Settlement Product"
       }
      }
     },
     "localname": "ContingencySettlementProduct",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_CrossCurrencySwapCashFlowHedgeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cross Currency Swap Cash Flow Hedge",
        "label": "Cross Currency Swap Cash Flow Hedge [Member]"
       }
      }
     },
     "localname": "CrossCurrencySwapCashFlowHedgeMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_CuyahogaCountyOhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cuyahoga County, OH",
        "label": "Cuyahoga County, OH [Member]"
       }
      }
     },
     "localname": "CuyahogaCountyOhMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_DamagesAssessment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Damages assessment.",
        "label": "Damages Assessment",
        "terseLabel": "Damages assessment"
       }
      }
     },
     "localname": "DamagesAssessment",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DebtInstrumentMaturityYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Maturity Year",
        "label": "Debt Instrument Maturity Year",
        "terseLabel": "Maturity"
       }
      }
     },
     "localname": "DebtInstrumentMaturityYear",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "teva_DebtInstrumentMonthOfMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument month of maturity.",
        "label": "Debt Instrument Month Of Maturity",
        "terseLabel": "Debt instrument month of maturity"
       }
      }
     },
     "localname": "DebtInstrumentMonthOfMaturity",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "teva_DefendantsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defendants.",
        "label": "Defendants [Axis]"
       }
      }
     },
     "localname": "DefendantsAxis",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_DefendantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defendants.",
        "label": "Defendants [Member]"
       }
      }
     },
     "localname": "DefendantsMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_DeferredIncomeTaxesNetAndUncertainTaxPositions": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred income taxes net and uncertain tax positions.",
        "label": "Deferred Income Taxes Net And Uncertain Tax Positions",
        "verboseLabel": "Deferred income taxes \u2013 net and uncertain tax positions"
       }
      }
     },
     "localname": "DeferredIncomeTaxesNetAndUncertainTaxPositions",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development progress and changes in other key valuation assumptions.",
        "label": "Development Progress And Changes In Other Key Valuation Assumptions [Member]",
        "verboseLabel": "Development Progress And Changes In Other Key Valuation Assumptions [Member]"
       }
      }
     },
     "localname": "DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments",
        "label": "Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments [Line Items]"
       }
      }
     },
     "localname": "DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsLineItems",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments",
        "label": "Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments [Table]"
       }
      }
     },
     "localname": "DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTable",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments",
        "label": "Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments [Table Text Block]",
        "terseLabel": "Summary of Notional Amounts for Hedged Items"
       }
      }
     },
     "localname": "DisclosureInTabularFormOfNotionalAmountOfDerivativesDesignatedAsHedgingInstrumentsTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments",
        "label": "Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Line Items]"
       }
      }
     },
     "localname": "DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsLineItems",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments",
        "label": "Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Table]"
       }
      }
     },
     "localname": "DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTable",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments",
        "label": "Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Table Text Block]",
        "terseLabel": "Summary Of Pre-tax (gains) losses from Derivatives Designated in Cash Flow Hedging Relationships"
       }
      }
     },
     "localname": "DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_DiscontinuationOfBusinessAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinuation Of Business [Axis]"
       }
      }
     },
     "localname": "DiscontinuationOfBusinessAxis",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_DiscontinuationOfBusinessDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinuation Of Business [Domain]"
       }
      }
     },
     "localname": "DiscontinuationOfBusinessDomain",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_EagleTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eagle transaction.",
        "label": "Eagle Transaction [Member]",
        "terseLabel": "Eagle Transaction [Member]"
       }
      }
     },
     "localname": "EagleTransactionMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_EmployeeTerminationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee termination.",
        "label": "Employee Termination [Member]",
        "terseLabel": "Employee termination costs [Member]"
       }
      }
     },
     "localname": "EmployeeTerminationMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_EosinophilicEsophagitisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eosinophilic Esophagitis [Member]",
        "label": "Eosinophilic Esophagitis [Member]",
        "terseLabel": "Eosinophilic Esophagitis [Member]"
       }
      }
     },
     "localname": "EosinophilicEsophagitisMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_EuropeReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Europe reporting unit member.",
        "label": "Europe Reporting Unit [Member]",
        "terseLabel": "Europe Reporting Unit [Member]"
       }
      }
     },
     "localname": "EuropeReportingUnitMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_EuropeSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Europe segment.",
        "label": "Europe Segment [Member]",
        "terseLabel": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeSegmentMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_EventBasisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event basis .",
        "label": "Event Basis [Axis]"
       }
      }
     },
     "localname": "EventBasisAxis",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_EventBasisDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event basis .",
        "label": "Event Basis [Domain]"
       }
      }
     },
     "localname": "EventBasisDomain",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ExitAndDisposalAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit And Disposal [Axis]",
        "label": "Exit And Disposal [Axis]",
        "terseLabel": "Exit And Disposal [Axis]"
       }
      }
     },
     "localname": "ExitAndDisposalAxis",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_ExitAndDisposalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit And Disposal [Domain]",
        "label": "Exit And Disposal [Domain]",
        "terseLabel": "Exit And Disposal [Domain]"
       }
      }
     },
     "localname": "ExitAndDisposalDomain",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ExpectedImpairmentOfIncomeTaxBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected impairment of income tax benefit.",
        "label": "Expected Impairment OF Income Tax Benefit",
        "terseLabel": "Expected impairment of income tax benefit"
       }
      }
     },
     "localname": "ExpectedImpairmentOfIncomeTaxBenefit",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FactoringInstitutionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Factoring institution.",
        "label": "Factoring Institution [Axis]"
       }
      }
     },
     "localname": "FactoringInstitutionAxis",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_FactoringInstitutionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Factoring institution.",
        "label": "Factoring Institution [Domain]"
       }
      }
     },
     "localname": "FactoringInstitutionDomain",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration arising during period.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Arising During Period",
        "terseLabel": "Actavis Generics transaction"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Increase Decrease",
        "terseLabel": "Adjustments to provisions for contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FinancialExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial expenses [Member]",
        "terseLabel": "Financial expenses [Member]"
       }
      }
     },
     "localname": "FinancialExpensesMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_FinancialExpensesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial expenses net.",
        "label": "Financial Expenses Net [Member]"
       }
      }
     },
     "localname": "FinancialExpensesNetMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward starting interest rate swaps and treasury lock agreements losses.",
        "label": "Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses",
        "terseLabel": "Forward starting interest rate swaps and treasury lock agreements losses"
       }
      }
     },
     "localname": "ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FourOtherDefendantsOtherThanTevaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four other defendants other than teva.",
        "label": "Four Other Defendants Other Than Teva [Member]",
        "terseLabel": "Four Other Defendants Other Than Teva [Member]"
       }
      }
     },
     "localname": "FourOtherDefendantsOtherThanTevaMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_FromSeptemberFifteenthTwoThousandAndTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "From September Fifteenth Two Thousand And Twenty Six [Member]"
       }
      }
     },
     "localname": "FromSeptemberFifteenthTwoThousandAndTwentySixMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_GenericPipelineProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Generic Pipeline Products [Member]"
       }
      }
     },
     "localname": "GenericPipelineProductsMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_GenericsMediciansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generics Medicians.",
        "label": "Generics Medicians [Member]",
        "terseLabel": "Generic products [Member]"
       }
      }
     },
     "localname": "GenericsMediciansMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ImpairmentAndRestructuring": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment and restructuring.",
        "label": "Impairment And Restructuring",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ImpairmentAndRestructuring",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Of Intangible Assets Reasons For Impairment.",
        "label": "Impairment Of Intangible Assets Reasons For Impairment [Axis]"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Of Intangible Assets Reasons For Impairment.",
        "label": "Impairment Of Intangible Assets Reasons For Impairment [Domain]"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ImpairmentsRestructuringAndOthers": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 14.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Other assets impairments, restructuring and other items",
        "documentation": "Impairments restructuring and others.",
        "label": "Impairments Restructuring And Others",
        "verboseLabel": "Other asset impairments, restructuring and other items"
       }
      }
     },
     "localname": "ImpairmentsRestructuringAndOthers",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_IntangibleAssetsImpairments": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 12.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets Impairments",
        "label": "Intangible Assets Impairments",
        "terseLabel": "Intangible assets impairments"
       }
      }
     },
     "localname": "IntangibleAssetsImpairments",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_InterestRateIncreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate increase.",
        "label": "Interest Rate Increase [Member]",
        "terseLabel": "Interest Rate Increase [Member]"
       }
      }
     },
     "localname": "InterestRateIncreaseMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_InternationalMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International markets.",
        "label": "International Markets [Member]",
        "terseLabel": "International Markets [Member]"
       }
      }
     },
     "localname": "InternationalMarketsMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_InventoriesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories [Line Items]",
        "label": "Inventories [Line Items]",
        "terseLabel": "Inventories [Line Items]"
       }
      }
     },
     "localname": "InventoriesLineItems",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_InventoriesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories [Table]",
        "label": "Inventories [Table]",
        "terseLabel": "Inventories [Table]"
       }
      }
     },
     "localname": "InventoriesTable",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_LegalSettlementsAndLossContingencies": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 15.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).",
        "label": "Legal Settlements And Loss Contingencies",
        "terseLabel": "Legal settlements and loss contingencies"
       }
      }
     },
     "localname": "LegalSettlementsAndLossContingencies",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": 4.0,
       "parentTag": "teva_ImpairmentAndRestructuring",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal settlements loss contingencies impairments other expenses.",
        "label": "Legal Settlements Loss Contingencies Impairments Other Expenses",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "LegalSettlementsLossContingenciesImpairmentsOtherExpenses",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LenalidomideProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lenalidomide Product [Member]"
       }
      }
     },
     "localname": "LenalidomideProductMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_LeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leverage ratio.",
        "label": "Leverage Ratio",
        "terseLabel": "Leverage Ratio"
       }
      }
     },
     "localname": "LeverageRatio",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement potential aggregate milestone payments amount.",
        "label": "License Agreement Potential Aggregate Milestone Payments Amount",
        "verboseLabel": "License agreement potential aggregate milestone payments amount"
       }
      }
     },
     "localname": "LicenseAgreementPotentialAggregateMilestonePaymentsAmount",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LineOfCreditExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit extension period.",
        "label": "Line Of Credit Extension Period",
        "terseLabel": "Line of credit extension period"
       }
      }
     },
     "localname": "LineOfCreditExtensionPeriod",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_LitigationSettlementAmountAwardedDistributionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount awarded distribution period.",
        "label": "Litigation Settlement Amount Awarded Distribution Period",
        "terseLabel": "Litigation settlement amount awarded distribution period"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedDistributionPeriod",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "teva_LitigationSettlementAmountDistributableInCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount distributable in cash.",
        "label": "Litigation Settlement Amount Distributable in Cash",
        "terseLabel": "Litigation Settlement Amount Distributable in cash"
       }
      }
     },
     "localname": "LitigationSettlementAmountDistributableInCash",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LitigationSettlementAmountDistributableinKind": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount distributableIn kind.",
        "label": "Litigation Settlement Amount DistributableIn Kind",
        "terseLabel": "Litigation Settlement Amount Distributable In Kind"
       }
      }
     },
     "localname": "LitigationSettlementAmountDistributableinKind",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LitigationSettlementAmountPayableInCashPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount payable in cash percentage",
        "label": "Litigation settlement amount payable in cash percentage",
        "terseLabel": "Percentgae of amount in cash settlement"
       }
      }
     },
     "localname": "LitigationSettlementAmountPayableInCashPercentage",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_LongTermDebtCurrencyPortionCHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt currency portion C H F.",
        "label": "Long Term Debt Currency Portion C H F",
        "terseLabel": "Long term debt currency portion CHF"
       }
      }
     },
     "localname": "LongTermDebtCurrencyPortionCHF",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_LongTermDebtCurrencyPortionEUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt currency portion E U R.",
        "label": "Long Term Debt Currency Portion E U R",
        "terseLabel": "Long term debt currency portion EUR"
       }
      }
     },
     "localname": "LongTermDebtCurrencyPortionEUR",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_LongTermDebtCurrencyPortionUSD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt currency portion U S D.",
        "label": "Long Term Debt Currency Portion U S D",
        "terseLabel": "Long term debt currency portion USD"
       }
      }
     },
     "localname": "LongTermDebtCurrencyPortionUSD",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_LongTermDebtExcludingConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule of data and information pertaining to long-debt instruments or arrangements, excluding convertible debt, that includes identification, terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Long Term Debt Excluding Convertible Debt Table [Text Block]",
        "terseLabel": "Schedule of Senior Notes and Loans"
       }
      }
     },
     "localname": "LongTermDebtExcludingConvertibleDebtTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_LossContingenciesOnEnvironmentalLawsPenalty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss contingencies on environmental laws penalty.",
        "label": "Loss Contingencies On Environmental Laws Penalty",
        "terseLabel": "Loss Contingencies On Environmental Laws Penalty"
       }
      }
     },
     "localname": "LossContingenciesOnEnvironmentalLawsPenalty",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss contingency claims dismissed value paid to each state proportional to its share of national population",
        "label": "Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population",
        "terseLabel": "Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_MeasurementInputProbabilityOfSuccessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input probability of success.",
        "label": "Measurement Input Probability Of Success [Member]",
        "terseLabel": "Measurement input probability of success [Member]"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfSuccessMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_MedicaidAndOtherGovernmentalAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid and other governmental allowances.",
        "label": "Medicaid And Other Governmental Allowances [Member]",
        "terseLabel": "Medicaid and other governmental allowances [Member]"
       }
      }
     },
     "localname": "MedicaidAndOtherGovernmentalAllowancesMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_MedincellMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MedinCell [ Member].",
        "label": "MedinCell [Member]"
       }
      }
     },
     "localname": "MedincellMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_MedisReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medis reporting unit.",
        "label": "Medis Reporting Unit [Member]",
        "terseLabel": "Medis Reporting Unit [Member]"
       }
      }
     },
     "localname": "MedisReportingUnitMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ModagMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modag .",
        "label": "Modag [Member]",
        "terseLabel": "MODAG [Member]"
       }
      }
     },
     "localname": "ModagMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NationwideSettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nationwide Settlement [Member]"
       }
      }
     },
     "localname": "NationwideSettlementMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NetRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Revenues [Member]",
        "terseLabel": "Net Revenues [Member]"
       }
      }
     },
     "localname": "NetRevenuesMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NorthAmericaSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "North America segment.",
        "label": "North America Segment [Member]",
        "terseLabel": "North America [Member]"
       }
      }
     },
     "localname": "NorthAmericaSegmentMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NoveTideAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nove tide acquisition.",
        "label": "Nove Tide Acquisition [Member]",
        "terseLabel": "Nove tide Acquisition [Member]"
       }
      }
     },
     "localname": "NoveTideAcquisitionMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NovetideTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novetide transaction.",
        "label": "Novetide Transaction [Member]",
        "terseLabel": "Novetide Transaction [Member]"
       }
      }
     },
     "localname": "NovetideTransactionMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OneTimePremiumPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One time\u00a0premium payment.",
        "label": "One Time Premium Payment [Member]",
        "terseLabel": "One Time Premium Payment [Member]"
       }
      }
     },
     "localname": "OneTimePremiumPaymentMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OptionsAndForwardContractsDerivativeLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and forward contracts derivative liabilities.",
        "label": "Options And Forward Contracts Derivative Liabilities [Member]",
        "terseLabel": "Liabilities Derivatives Options and Forward Contracts [Member]"
       }
      }
     },
     "localname": "OptionsAndForwardContractsDerivativeLiabilitiesMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Activities [Member]",
        "label": "Other Activities [Member]",
        "terseLabel": "Other activities [Member]"
       }
      }
     },
     "localname": "OtherActivitiesMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other countries.",
        "label": "Other Countries [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherDebentures2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other debentures 2026.",
        "label": "Other Debentures 2026 [Member]",
        "terseLabel": "Other Debentures [Member]"
       }
      }
     },
     "localname": "OtherDebentures2026Member",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherExitAndDisposalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other exit and disposal.",
        "label": "Other Exit And Disposal [Member]",
        "terseLabel": "Other Exit and Disposal [Member]"
       }
      }
     },
     "localname": "OtherExitAndDisposalMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Expenses [Text Block]",
        "label": "Other Expenses [Text Block]",
        "terseLabel": "Other assets impairments, restructuring and other items"
       }
      }
     },
     "localname": "OtherExpensesTextBlock",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_OtherOperatingIncomeExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Operating Income (Expense)",
        "label": "Other Operating Income (Expense)",
        "verboseLabel": "Other income"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpense",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products [Member]",
        "label": "Other Products [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherRestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other restricted cash.",
        "label": "Other Restricted Cash [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherRestrictedCashMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherSalesReservesAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other sales reserves and allowances.",
        "label": "Other Sales Reserves And Allowances [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherSalesReservesAndAllowancesMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherUnallocatedAmounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other unallocated amounts.",
        "label": "Other Unallocated Amounts",
        "terseLabel": "Other unallocated amounts"
       }
      }
     },
     "localname": "OtherUnallocatedAmounts",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_OtsukaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Otsuka [Member]",
        "label": "Otsuka [Member]",
        "terseLabel": "Otsuka [Member]"
       }
      }
     },
     "localname": "OtsukaMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from purchase of available for sales securities and other assets.",
        "label": "Payment To Acquire Marketable Securities And Other Assets",
        "negatedLabel": "Purchases of investments and other assets"
       }
      }
     },
     "localname": "PaymentToAcquireMarketableSecuritiesAndOtherAssets",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_PercentageOfShareOfTheNationalPopulation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of share of the national population.",
        "label": "Percentage Of Share Of The National Population",
        "terseLabel": "Percentage Of Share Of The National Population"
       }
      }
     },
     "localname": "PercentageOfShareOfTheNationalPopulation",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the litigating subdivisions have chosen to participate in teva's nationwide settlement.",
        "label": "Percentage Of The Litigating Subdivisions Have Chosen To Participate In Tevas Nationwide Settlement",
        "terseLabel": "Percentage of the litigating subdivisions have chosen to participate in Teva's nationwide settlement"
       }
      }
     },
     "localname": "PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_PercentageOfThePopulationOfTheParticipatingStates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the population of the participating states.",
        "label": "Percentage Of The Population Of The Participating States",
        "terseLabel": "Percentage of the population of the participating states"
       }
      }
     },
     "localname": "PercentageOfThePopulationOfTheParticipatingStates",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_PeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period axsis.",
        "label": "Period [Axis]"
       }
      }
     },
     "localname": "PeriodAxis",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_PeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period domain.",
        "label": "Period [Domain]"
       }
      }
     },
     "localname": "PeriodDomain",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period From Which Interest Rate Increase Could Be Applicable [Axis]"
       }
      }
     },
     "localname": "PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period From Which Interest Rate Increase Could Be Applicable [Domain]"
       }
      }
     },
     "localname": "PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pledged to PNC Bank, national association in connection with the U.S. securitization program entered into in November 2022.",
        "label": "Pledged to PNC Bank, National Association in connection with the U.S. securitization program entered into in November 2022 [Member]"
       }
      }
     },
     "localname": "PledgedToPncBankNationalAssociationInConnectionWithTheU.s.SecuritizationProgramEnteredIntoInNovember2022Member",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_PncBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PNC bank.",
        "label": "PNC Bank [Member]",
        "terseLabel": "PNC Bank [Member]"
       }
      }
     },
     "localname": "PncBankMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_PriceAndVolumeOfProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price and volume of products.",
        "label": "Price And Volume Of Products [Member]",
        "verboseLabel": "Price And Volume Of Products [Member]"
       }
      }
     },
     "localname": "PriceAndVolumeOfProductsMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from beneficial interest in exchange for securitized trade receivables",
        "label": "Proceeds from beneficial interest in exchange for securitized trade receivables",
        "terseLabel": "Beneficial interest collected in exchange for securitized trade receivables"
       }
      }
     },
     "localname": "ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ProductRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Rights [Member]",
        "label": "Product Rights [Member]",
        "terseLabel": "Identifiable product rights [Member]",
        "verboseLabel": "Product rights [Member]"
       }
      }
     },
     "localname": "ProductRightsMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ProductWeightedAverageCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product\u00a0 Weighted Average Cost",
        "label": "Product Weighted Average Cost",
        "verboseLabel": "Product WAC Value"
       }
      }
     },
     "localname": "ProductWeightedAverageCost",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ProductWeightedAverageCostTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Weighted Average Cost term",
        "label": "Product Weighted Average Cost term",
        "terseLabel": "Product WAC Term"
       }
      }
     },
     "localname": "ProductWeightedAverageCostTerm",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "teva_ProfitFromSaleOfLongLivedAssetsAndInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit from sale of long lived assets and investment.",
        "label": "Profit From Sale Of Long Lived Assets And Investment",
        "negatedLabel": "Net loss (gain) from investments and from sale of long lived assets"
       }
      }
     },
     "localname": "ProfitFromSaleOfLongLivedAssetsAndInvestment",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_RebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rebates.",
        "label": "Rebates [Member]",
        "terseLabel": "Rebates [Member]"
       }
      }
     },
     "localname": "RebatesMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued accounting pronouncements not yet adopted.",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements, not yet adopted"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_RegulatoryPriceAndVolumeOfProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory price and volume of products.",
        "label": "Regulatory Price And Volume Of Products [Member]",
        "terseLabel": "Regulatory Price And Volume Of Products [Member]"
       }
      }
     },
     "localname": "RegulatoryPriceAndVolumeOfProductsMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ReservesIncludedInAccountsReceivableNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserves included in accounts receivable net.",
        "label": "Reserves Included In Accounts Receivable Net [Member]",
        "terseLabel": "Reserves Included in Accounts Receivable, net [Member]"
       }
      }
     },
     "localname": "ReservesIncludedInAccountsReceivableNetMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RespiratoryProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Respiratory product.",
        "label": "Respiratory Product [Member]",
        "terseLabel": "Respiratory Product [Member]"
       }
      }
     },
     "localname": "RespiratoryProductMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RestructuringAccrualProvision": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Accrual Provision",
        "label": "Restructuring Accrual Provision",
        "negatedLabel": "Provision"
       }
      }
     },
     "localname": "RestructuringAccrualProvision",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_RestructuringAndImpairmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and impairment.",
        "label": "Restructuring And Impairment [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndImpairmentAbstract",
     "nsuri": "http://www.tevapharm.com/20230331",
     "xbrltype": "stringItemType"
    },
    "teva_RestructuringAndImpairmentCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and impairment costs.",
        "label": "Restructuring And Impairment Costs [Line Items]",
        "terseLabel": "Restructuring and Impairment Costs [Line Items]"
       }
      }
     },
     "localname": "RestructuringAndImpairmentCostsLineItems",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RestructuringAndImpairmentCostsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Impairment Costs [Table]",
        "label": "Restructuring And Impairment Costs [Table]",
        "terseLabel": "Restructuring And Impairment Costs [Table]"
       }
      }
     },
     "localname": "RestructuringAndImpairmentCostsTable",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_ReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Returns.",
        "label": "Returns [Member]",
        "terseLabel": "Returns [Member]"
       }
      }
     },
     "localname": "ReturnsMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RevenueRecognitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition [Line Items]",
        "label": "Revenue Recognition [Line Items]",
        "terseLabel": "Revenue Recognition [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionLineItems",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RevenueRecognitionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition [Table]",
        "label": "Revenue Recognition [Table]",
        "terseLabel": "Revenue Recognition [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionTable",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RevenueTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Type [Axis]"
       }
      }
     },
     "localname": "RevenueTypeAxis",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RevenueTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Type [Domain]"
       }
      }
     },
     "localname": "RevenueTypeDomain",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RevenuesOtherThanUsd": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues other than US Dollar.",
        "label": "Revenues Other Than Usd",
        "terseLabel": "Revenues other than USD"
       }
      }
     },
     "localname": "RevenuesOtherThanUsd",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_SalesReservesAndAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection.",
        "label": "Sales Reserves And Allowances",
        "terseLabel": "Sales reserves and allowances"
       }
      }
     },
     "localname": "SalesReservesAndAllowances",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_SalesReservesAndAllowancesCurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of sales reserves and allowances current.",
        "label": "Sales Reserves And Allowances Current [Table Text Block]",
        "terseLabel": "Summary of Sales Reserves and Allowances"
       }
      }
     },
     "localname": "SalesReservesAndAllowancesCurrentTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_SalesReservesAndAllowancesToCustomersPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales reserves and allowances to customers percentage.",
        "label": "Sales Reserves and Allowances to Customers Percentage",
        "terseLabel": "Percentage sales reserves and allowances to U.S. customers"
       }
      }
     },
     "localname": "SalesReservesAndAllowancesToCustomersPercentage",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_SanFranciscoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Francisco",
        "label": "San Francisco [Member]"
       }
      }
     },
     "localname": "SanFranciscoMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Assets And Liabilities Held For Sale [Table Text Block]",
        "label": "Schedule Of Assets And Liabilities Held For Sale [Table Text Block]",
        "terseLabel": "Summary of Major Classes of Assets and Liabilities Included as Held for Sale"
       }
      }
     },
     "localname": "ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of consolidated income before income tax.",
        "label": "Schedule Of Consolidated Income Before Income Tax [Table Text Block]",
        "terseLabel": "Schedule Of Consolidated Income Before Income Tax"
       }
      }
     },
     "localname": "ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ScheduleOfRestructuringChargesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Restructuring Charges [Table Text Block]",
        "label": "Schedule of Restructuring Charges [Table Text Block]",
        "terseLabel": "Summary of Restructuring Plan Including Costs Related to Exit and Disposal"
       }
      }
     },
     "localname": "ScheduleOfRestructuringChargesTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_SegmentsAndOtherActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segments and other activities.",
        "label": "Segments And Other Activities [Member]",
        "terseLabel": "Segments and Other Activities [Member]"
       }
      }
     },
     "localname": "SegmentsAndOtherActivitiesMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes and sustainability linked senior notes.",
        "label": "Senior Notes And Sustainability Linked Senior Notes [Member]",
        "terseLabel": "Senior Notes And Sustainability Linked Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesAndSustainabilityLinkedSeniorNotesMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SeniorNotesMaturityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes maturity percentage.",
        "label": "Senior Notes Maturity Percentage",
        "verboseLabel": "Senior notes maturity percentage"
       }
      }
     },
     "localname": "SeniorNotesMaturityPercentage",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_SeniorNotesRepaidAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes repaid amount.",
        "label": "Senior Notes Repaid Amount",
        "verboseLabel": "Senior notes repaid amount"
       }
      }
     },
     "localname": "SeniorNotesRepaidAmount",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_SeniornotesandconvertibleseniordebenturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes and convertible senior debentures.",
        "label": "Seniornotesandconvertibleseniordebentures [Member]",
        "terseLabel": "Senior Notes and Convertible Senior Debentures Included Under Short-Term Debt [Member]"
       }
      }
     },
     "localname": "SeniornotesandconvertibleseniordebenturesMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ShortCreditAgreement2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short credit agreement 2026.",
        "label": "Short Credit Agreement 2026 [Member]",
        "terseLabel": "Convertible senior debentures [Member]"
       }
      }
     },
     "localname": "ShortCreditAgreement2026Member",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2022OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2022 one.",
        "label": "Subsidiary Senior Notes Due 2022 One [Member]",
        "terseLabel": "Senior notes EUR 700 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2022OneMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2022ThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2022 Three [Member]",
        "label": "Subsidiary Senior Notes Due 2022 Three [Member]",
        "terseLabel": "Senior notes CHF 350 Million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2022ThreeMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2023OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2023 one.",
        "label": "Subsidiary Senior Notes Due 2023 One [Member]",
        "terseLabel": "Senior notes EUR 1,300 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2023OneMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2023TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2023 two.",
        "label": "Subsidiary Senior Notes Due 2023 Two [Member]",
        "terseLabel": "Senior notes USD 3,000 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2023TwoMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2024.",
        "label": "Subsidiary Senior Notes Due 2024 [Member]",
        "terseLabel": "Senior notes EUR 1,500 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2024Member",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2024OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2024 One [Member]",
        "label": "Subsidiary Senior Notes Due 2024 One [Member]",
        "terseLabel": "Senior notes USD 1,250 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2024OneMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2025 Member",
        "label": "Subsidiary Senior Notes Due 2025 [Member]",
        "terseLabel": "Senior notes EUR 900 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2025Member",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2025OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2025 One [Member]",
        "label": "Subsidiary Senior Notes Due 2025 One [Member]",
        "terseLabel": "Senior notes EUR 1,000 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2025OneMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2025TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2025 two.",
        "label": "Subsidiary Senior Notes Due 2025 Two [Member]",
        "terseLabel": "Senior notes USD 1,000 million [Member]",
        "verboseLabel": "Senior notes USD 1,000 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2025TwoMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2026OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2026 one.",
        "label": "Subsidiary Senior Notes Due 2026 One [Member]",
        "terseLabel": "Senior notes USD 3,500 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2026OneMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2028.",
        "label": "Subsidiary Senior Notes Due 2028 [Member]",
        "terseLabel": "Senior notes EUR 750 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2028Member",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2028OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2028 One [Member]",
        "label": "Subsidiary Senior Notes Due 2028 One [Member]",
        "terseLabel": "Senior notes USD 1,250 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2028OneMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2036.",
        "label": "Subsidiary Senior Notes Due 2036 [Member]",
        "terseLabel": "Senior notes USD 789 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2036Member",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2046.",
        "label": "Subsidiary Senior Notes Due 2046 [Member]",
        "terseLabel": "Senior notes USD 2,000 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2046Member",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SummitCountyOhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summit County, OH",
        "label": "Summit County, OH [Member]"
       }
      }
     },
     "localname": "SummitCountyOhMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SustainabilityLinkedSeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sustainability linked senior notes due 2027.",
        "label": "Sustainability Linked Senior Notes Due 2027 [Member]",
        "terseLabel": "Sustainability-linked senior notes EUR 1,100\u00a0million [Member]"
       }
      }
     },
     "localname": "SustainabilityLinkedSeniorNotesDue2027Member",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SustainabilityLinkedSeniorNotesDue2027TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sustainability linked senior notes due 2027 two.",
        "label": "Sustainability Linked Senior Notes Due 2027 Two [Member]",
        "terseLabel": "Sustainability-linked senior notes USD 1,000\u00a0million [Member]"
       }
      }
     },
     "localname": "SustainabilityLinkedSeniorNotesDue2027TwoMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SustainabilityLinkedSeniorNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sustainability linked senior notes due 2029.",
        "label": "Sustainability Linked Senior Notes Due 2029 [Member]",
        "terseLabel": "Sustainability-linked senior notes USD 1,000\u00a0million [Member]"
       }
      }
     },
     "localname": "SustainabilityLinkedSeniorNotesDue2029Member",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SustainabilityLinkedSeniorNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sustainability linked senior notes due 2030.",
        "label": "Sustainability Linked Senior Notes Due 2030 [Member]",
        "terseLabel": "Sustainability-linked senior notes EUR 1,500\u00a0million [Member]"
       }
      }
     },
     "localname": "SustainabilityLinkedSeniorNotesDue2030Member",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sustainability Senior Linked Loans Due Two Thousand And Thirty One One [Member]",
        "terseLabel": "Sustainability-linked senior notes EUR 500\u00a0million"
       }
      }
     },
     "localname": "SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneOneMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sustainability Senior Linked Loans Due Two Thousand And Thirty One Two [Member]",
        "terseLabel": "Sustainability-linked senior notes USD 500\u00a0million"
       }
      }
     },
     "localname": "SustainabilitySeniorLinkedLoansDueTwoThousandAndThirtyOneTwoMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sustainability Senior Linked Loans Due Two Thousand And Twenty Nine One [Member]",
        "terseLabel": "Sustainability-linked senior notes EUR 800\u00a0million"
       }
      }
     },
     "localname": "SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineOneMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sustainability Senior Linked Loans Due Two Thousand And Twenty Nine Two [Member]",
        "terseLabel": "Sustainability-linked senior notes USD 600\u00a0million"
       }
      }
     },
     "localname": "SustainabilitySeniorLinkedLoansDueTwoThousandAndTwentyNineTwoMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sustainiability Senior Linked Notes Two Thousand Twenty Nine And Two Thousand And Thirty One One And Two [Member]"
       }
      }
     },
     "localname": "SustainiabilitySeniorLinkedNotesTwoThousandTwentyNineAndTwoThousandAndThirtyOneOneAndTwoMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda.",
        "label": "Takeda [Member]"
       }
      }
     },
     "localname": "TakedaMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TaxYear2008To2011Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2008 To 2011 [Member]"
       }
      }
     },
     "localname": "TaxYear2008To2011Member",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TevasApiReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teva's API reporting unit.",
        "label": "Tevas API Reporting Unit [Member]",
        "terseLabel": "Tevas API Reporting Unit [Member]"
       }
      }
     },
     "localname": "TevasApiReportingUnitMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TotalReservesIncludedInSalesReservesAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total reserves included in sales reserves and allowances.",
        "label": "Total Reserves Included In Sales Reserves And Allowances [Member]",
        "terseLabel": "Total reserves included in sales reserves and allowances [Member]"
       }
      }
     },
     "localname": "TotalReservesIncludedInSalesReservesAndAllowancesMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche.",
        "label": "Tranche [Axis]"
       }
      }
     },
     "localname": "TrancheAxis",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_TrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche.",
        "label": "Tranche [Domain]"
       }
      }
     },
     "localname": "TrancheDomain",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TribesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tribes",
        "label": "Tribes [Member]"
       }
      }
     },
     "localname": "TribesMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_UnrealizedGainLossOnDerivativeNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized gain (loss) on derivative net of tax.",
        "label": "Unrealized gain (loss) on derivative net of tax",
        "terseLabel": "Unrealized gain (loss) from derivative financial instruments, net"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivativeNetOfTax",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_UnsecuredSyndicatedRevolvingCrediTfacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured syndicated revolving credit facility member.",
        "label": "Unsecured Syndicated Revolving Credi tFacility [Member]"
       }
      }
     },
     "localname": "UnsecuredSyndicatedRevolvingCrediTfacilityMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_UpdatedMarketAssumptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Updated market assumptions .",
        "label": "Updated Market Assumptions [Member]",
        "terseLabel": "Updated Market Assumptions [Member]"
       }
      }
     },
     "localname": "UpdatedMarketAssumptionsMember",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments",
        "label": "Upfront Payments",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_UtilizationAndOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Utilization and other.",
        "label": "Utilization And Other",
        "terseLabel": "Utilization and other"
       }
      }
     },
     "localname": "UtilizationAndOther",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ValuationAllowancesAndReservesForeignCurrencyTranslation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowances and reserves foreign currency translation.",
        "label": "Valuation Allowances And Reserves Foreign Currency Translation",
        "terseLabel": "Translation differences"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesForeignCurrencyTranslation",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowances and reserves related to current period sales.",
        "label": "Valuation Allowances And Reserves Related To Current Period Sales",
        "terseLabel": "Provisions related to sales made in current year period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesRelatedToCurrentPeriodSales",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowances and reserves related to prior period sales.",
        "label": "Valuation Allowances And Reserves Related To Prior Period Sales",
        "terseLabel": "Provisions related to sales made in prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesRelatedToPriorPeriodSales",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_YearOfSettlementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year of settlement.",
        "label": "Year Of Settlement [Axis]",
        "terseLabel": "Year of settlement"
       }
      }
     },
     "localname": "YearOfSettlementAxis",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_YearOfSettlementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year of settlement.",
        "label": "Year Of Settlement [Domain]"
       }
      }
     },
     "localname": "YearOfSettlementDomain",
     "nsuri": "http://www.tevapharm.com/20230331",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201601Member": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.",
        "label": "Accounting Standards Update 2016-01 [Member]",
        "terseLabel": "Accounting Standards Update 2016-01 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201601Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r4",
      "r24"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "verboseLabel": "Accounts payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableFromSecuritization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount owed to the reporting entity by counterparties in securitized loan transactions.",
        "label": "Accounts Receivable from Securitization",
        "verboseLabel": "Accounts receivable from securitization"
       }
      }
     },
     "localname": "AccountsReceivableFromSecuritization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r327",
      "r328"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivables, net of allowance for credit losses of $88 million and $91 million as of March 31, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccrualForEnvironmentalLossContingencies": {
     "auth_ref": [
      "r390",
      "r683",
      "r726",
      "r727",
      "r767",
      "r769"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies.",
        "label": "Accrual for Environmental Loss Contingencies",
        "terseLabel": "Accrual for Environmental Loss Contingencies"
       }
      }
     },
     "localname": "AccrualForEnvironmentalLossContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedAmortizationDeferredFinanceCosts": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of debt issuance costs.",
        "label": "Accumulated Amortization, Debt Issuance Costs",
        "terseLabel": "Debt instrument accumulated amortization"
       }
      }
     },
     "localname": "AccumulatedAmortizationDeferredFinanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r41",
      "r45",
      "r140",
      "r733",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Benefit Plans [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r234",
      "r241",
      "r242",
      "r510",
      "r677",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivative Financial Instruments [Member]"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r223",
      "r633",
      "r648",
      "r652"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r42",
      "r45",
      "r140",
      "r569",
      "r643",
      "r644",
      "r733",
      "r734",
      "r735",
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r40",
      "r45",
      "r140",
      "r241",
      "r242",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r712"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional\u00a0paid-in\u00a0capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r744",
      "r745",
      "r746",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r62",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r267",
      "r268",
      "r269",
      "r270",
      "r279",
      "r330",
      "r331",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r477",
      "r478",
      "r479",
      "r487",
      "r488",
      "r489",
      "r490",
      "r500",
      "r501",
      "r502",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r555",
      "r556",
      "r558",
      "r559",
      "r560",
      "r561",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r609",
      "r610",
      "r611",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r121",
      "r122",
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r293",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other Segments [Member]"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r224",
      "r329",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r62",
      "r84",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Weighted average shares with anti-dilutive effect on earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r62",
      "r90"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of long-lived assets and assets held for sale"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r181",
      "r194",
      "r221",
      "r253",
      "r305",
      "r311",
      "r317",
      "r334",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r400",
      "r402",
      "r404",
      "r405",
      "r506",
      "r511",
      "r537",
      "r712",
      "r776",
      "r777",
      "r795"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r215",
      "r228",
      "r253",
      "r334",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r400",
      "r402",
      "r404",
      "r405",
      "r506",
      "r511",
      "r537",
      "r712",
      "r776",
      "r777",
      "r795"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.",
        "label": "Assets, Fair Value Adjustment",
        "terseLabel": "Adjustments of assets held for sale to fair value"
       }
      }
     },
     "localname": "AssetsFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r3",
      "r91",
      "r95",
      "r213",
      "r214"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Assets held for sale",
        "verboseLabel": "Total assets of the disposal group classified as held for sale in the consolidated balance sheets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r151",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/BasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r499",
      "r704",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r499",
      "r704",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business acquisition, Percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r504",
      "r740"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": 2.0,
       "parentTag": "teva_ImpairmentAndRestructuring",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Contingent consideration",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "verboseLabel": "Business combination contingent consideration arrangements change in amount of contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r131",
      "r132",
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "negatedLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business combination, contingent consideration, liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r64",
      "r217",
      "r668"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r59",
      "r64",
      "r68"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Balance of cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Balance of cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "verboseLabel": "Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r59",
      "r175"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r187",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies, see note 10"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r384",
      "r385",
      "r656",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r744",
      "r745",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary Shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par or stated value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r712"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Ordinary shares of NIS 0.10 par value per share; March 31, 2023 and December 31, 2022: authorized 2,495 million shares; issued 1,226 million shares and 1,217 million shares, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r47",
      "r237",
      "r239",
      "r246",
      "r629",
      "r637"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Teva"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r136",
      "r137",
      "r143",
      "r237",
      "r239",
      "r245",
      "r628",
      "r636"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to non-controlling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r135",
      "r143",
      "r237",
      "r239",
      "r244",
      "r627",
      "r635"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r71",
      "r72",
      "r172",
      "r173",
      "r325",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r71",
      "r72",
      "r172",
      "r173",
      "r325",
      "r653",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r71",
      "r72",
      "r172",
      "r173",
      "r325",
      "r655",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r71",
      "r72",
      "r172",
      "r173",
      "r325",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r109",
      "r406",
      "r407",
      "r418",
      "r419",
      "r420",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt [Member]"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r435",
      "r436",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateMember": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate Segment [Member]",
        "terseLabel": "Corporate Segment [Member]"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r52",
      "r607"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Short-term debt",
        "totalLabel": "Total short-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r251",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r422",
      "r429",
      "r430",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt obligations"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r182",
      "r183",
      "r192",
      "r258",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r557",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r12",
      "r183",
      "r192",
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal amount currently outstanding on the debt instruments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentCovenantDescription": {
     "auth_ref": [
      "r12",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.",
        "label": "Debt Instrument, Covenant Description"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r177",
      "r179",
      "r406",
      "r557",
      "r689",
      "r690"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r420",
      "r536",
      "r689",
      "r690"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r31",
      "r177",
      "r434",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Weighted average interest rate",
        "verboseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "terseLabel": "Debt Instrument, Interest Rate, Increase (Decrease)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r229",
      "r688",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt Instrument, Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r32",
      "r258",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r557",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r32",
      "r112",
      "r113",
      "r114",
      "r115",
      "r176",
      "r177",
      "r179",
      "r191",
      "r258",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r412",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r557",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs gross"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedLabel": "Less debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r480",
      "r481"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DemandDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits.",
        "label": "Demand Deposits [Member]",
        "terseLabel": "Cash, Deposits and Other [Member]"
       }
      }
     },
     "localname": "DemandDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r62",
      "r92"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r783",
      "r784",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Cross-currency swap - cash flow hedge"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative asset.",
        "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r231",
      "r232",
      "r536",
      "r676"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r38",
      "r153",
      "r180",
      "r230",
      "r676"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Asset derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r38",
      "r153",
      "r180",
      "r230",
      "r676"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "negatedLabel": "Liability derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainOnDerivative": {
     "auth_ref": [
      "r514"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain on Derivative"
       }
      }
     },
     "localname": "DerivativeGainOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain from derivative.",
        "label": "Derivative, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeInstrumentDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Detail [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentDetailAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r152",
      "r154",
      "r159",
      "r160",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r165",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Instruments and Hedging Activities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r149",
      "r152",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r231",
      "r232",
      "r536",
      "r676"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "negatedLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative liability.",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "auth_ref": [
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Loss on Derivative",
        "terseLabel": "Teva other comprehensive loss"
       }
      }
     },
     "localname": "DerivativeLossOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes loss from derivative.",
        "label": "Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r149",
      "r150",
      "r156",
      "r159",
      "r161",
      "r162",
      "r164",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r460",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of disaggregates revenues by major revenue streams"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r3",
      "r91",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r3",
      "r91",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current",
        "terseLabel": "Property, plant and equipment, net and others"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DistributionServiceMember": {
     "auth_ref": [
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distribution assistance, including, but not limited to, marketing and selling fund shares, advertising, printing and mailing of prospectus and sale literature to investor.",
        "label": "Distribution Service [Member]",
        "terseLabel": "Distribution [Member]"
       }
      }
     },
     "localname": "DistributionServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings (loss) per share attributable to ordinary shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r247",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r280",
      "r282",
      "r284",
      "r285",
      "r286",
      "r290",
      "r527",
      "r528",
      "r630",
      "r638",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Earnings per share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r247",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r282",
      "r284",
      "r285",
      "r286",
      "r290",
      "r527",
      "r528",
      "r630",
      "r638",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted",
        "verboseLabel": "Earnings per share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Translation adjustment on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r254",
      "r483",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory tax rate in Israel"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument embedded in host contract.",
        "label": "Embedded Derivative Financial Instruments [Member]",
        "terseLabel": "Bifurcated embedded derivatives [Member]"
       }
      }
     },
     "localname": "EmbeddedDerivativeFinancialInstrumentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee-related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee termination [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes accrual for environmental loss contingency.",
        "label": "Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r111",
      "r209",
      "r240",
      "r241",
      "r242",
      "r264",
      "r265",
      "r266",
      "r268",
      "r276",
      "r278",
      "r292",
      "r338",
      "r450",
      "r477",
      "r478",
      "r479",
      "r489",
      "r490",
      "r526",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r569",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r80",
      "r193",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities [Member]"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Debt instrument principal amount of debt extinguished"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r530",
      "r531",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsParentheticalDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Instrument Measured on a Basis Other Than Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r166",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r420",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r531",
      "r578",
      "r579",
      "r580",
      "r689",
      "r690",
      "r701",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r420",
      "r464",
      "r469",
      "r531",
      "r578",
      "r701",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r420",
      "r464",
      "r469",
      "r531",
      "r579",
      "r689",
      "r690",
      "r701",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r420",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r531",
      "r580",
      "r689",
      "r690",
      "r701",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r168",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "verboseLabel": "Redemption of debt securities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "terseLabel": "Settlement of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "negatedPeriodEndLabel": "Fair value at the end of the period",
        "negatedPeriodStartLabel": "Fair value at the beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r420",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r578",
      "r579",
      "r580",
      "r689",
      "r690",
      "r701",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r332",
      "r333",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r431",
      "r448",
      "r516",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r681",
      "r751",
      "r752",
      "r753",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Amortization of intangible assets useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r219",
      "r369"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r370",
      "r608",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r87",
      "r612"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount net of impairment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r87",
      "r608"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 32.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Identifiable intangible assets, net",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r676",
      "r701",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis": {
     "auth_ref": [
      "r572",
      "r573",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment for effect of reorganization under Chapter 11 of Bankruptcy Code. Includes, but is not limited to, adjustment for reorganization plan effect and adoption of fresh-start reporting.",
        "label": "Fresh-Start Adjustments [Axis]",
        "terseLabel": "Fresh-Start Adjustments [Axis]"
       }
      }
     },
     "localname": "FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 11.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "G&amp;A expenses",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r218",
      "r353",
      "r625",
      "r682",
      "r712",
      "r755",
      "r762"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 33.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "auth_ref": [
      "r362",
      "r364",
      "r366",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill.",
        "label": "Goodwill Disclosure [Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/Goodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedLabel": "Translation differences"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r354",
      "r361",
      "r682"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r51",
      "r253",
      "r305",
      "r310",
      "r316",
      "r319",
      "r334",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r400",
      "r402",
      "r404",
      "r405",
      "r537",
      "r680",
      "r776"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r149",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use.",
        "label": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "verboseLabel": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r62",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets excluding goodwill",
        "verboseLabel": "Intangible asset impairments"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r62",
      "r90",
      "r94"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": 1.0,
       "parentTag": "teva_ImpairmentAndRestructuring",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairments of long-lived tangible assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In process research and development [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r305",
      "r310",
      "r316",
      "r319",
      "r680"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Pre tax income",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r49",
      "r62",
      "r81",
      "r188",
      "r202",
      "r302"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 17.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Share in (profits) losses of associated companies, net",
        "terseLabel": "Income loss from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r373",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r254",
      "r484",
      "r485",
      "r486",
      "r491",
      "r494",
      "r496",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated amount of loss resulting from an adverse tax position.",
        "label": "Income Tax Examination, Estimate of Possible Loss",
        "terseLabel": "Income Tax Examination, Estimate of Possible Loss"
       }
      }
     },
     "localname": "IncomeTaxExaminationEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r255",
      "r277",
      "r278",
      "r303",
      "r482",
      "r492",
      "r495",
      "r639"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 16.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "presentationGuidance": "Tax Expense",
        "terseLabel": "Income taxes (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
        "label": "Increase (Decrease) in Operating Capital",
        "negatedLabel": "Net change in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Identifiable Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Asset Derivatives - Options and Forward Contracts [Member]"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r82",
      "r671"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r225",
      "r669",
      "r712"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r82",
      "r673"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw and packaging materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r82",
      "r672"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Products in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investment in securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Israel.",
        "label": "Israel Tax Authority [Member]",
        "terseLabel": "Israel Tax Authority [Member]"
       }
      }
     },
     "localname": "IsraelTaxAuthorityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Legal Settlements and Loss Contingencies"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r253",
      "r334",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r400",
      "r402",
      "r404",
      "r405",
      "r507",
      "r511",
      "r512",
      "r537",
      "r679",
      "r776",
      "r795",
      "r796"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r185",
      "r198",
      "r712",
      "r743",
      "r754",
      "r790"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r216",
      "r253",
      "r334",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r400",
      "r402",
      "r404",
      "r405",
      "r507",
      "r511",
      "r512",
      "r537",
      "r712",
      "r776",
      "r795",
      "r796"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r12",
      "r13",
      "r253",
      "r334",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r400",
      "r402",
      "r404",
      "r405",
      "r507",
      "r511",
      "r512",
      "r537",
      "r776",
      "r795",
      "r796"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Licensing Arrangements [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r12",
      "r183",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Long Term Debt Payable Under Revolving Credit Facility"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r25",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r25",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement amount"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Legal settlements and loss contingencies, expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less current maturities",
        "terseLabel": "Current maturities of long-term liabilities"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "terseLabel": "Long term debt bearing fixed interest rate percentage"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermNotesAndLoans": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes and Loans, Noncurrent",
        "terseLabel": "Senior notes and loans",
        "verboseLabel": "Total senior notes and loans"
       }
      }
     },
     "localname": "LongTermNotesAndLoans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Category of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.",
        "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]",
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r32",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r106",
      "r107",
      "r386",
      "r387",
      "r388",
      "r770",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r106",
      "r107",
      "r386",
      "r387",
      "r388",
      "r770",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r386",
      "r728"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Accrued amount for legal settlements and loss contingencies",
        "verboseLabel": "Generic modafinil, and imposed fines amount"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r769"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Payment"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "auth_ref": [
      "r769"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.",
        "label": "Loss Contingency Accrual, Provision",
        "terseLabel": "Loss Contingency Accrual, Provision"
       }
      }
     },
     "localname": "LossContingencyAccrualProvision",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r769",
      "r770",
      "r772"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Loss Contingency, Damages Awarded, Value"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "auth_ref": [
      "r769",
      "r770",
      "r772"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages paid to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Paid, Value",
        "terseLabel": "Loss contingency payment"
       }
      }
     },
     "localname": "LossContingencyDamagesPaidValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r769",
      "r770",
      "r772"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damage claimed"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDomicileOfLitigation": {
     "auth_ref": [
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies the domicile or jurisdiction of the court of law, arbitration or mediation proceeding.",
        "label": "Loss Contingency, Domicile of Litigation",
        "terseLabel": "Jurisdiction"
       }
      }
     },
     "localname": "LossContingencyDomicileOfLitigation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r106",
      "r107",
      "r386",
      "r387",
      "r388",
      "r770",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencySettlementAgreementDate": {
     "auth_ref": [
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective date of a duly executed litigation settlement agreement.",
        "label": "Loss Contingency, Settlement Agreement, Date",
        "terseLabel": "Date"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencySettlementAgreementTerms": {
     "auth_ref": [
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the terms of a settlement agreement which resolved the legal matter, including the nature of the consideration, timing of payment, and the nature of rights obtained or lost (for example, but not limited to, patent, trademark, copyright, license and franchise rights).",
        "label": "Loss Contingency, Settlement Agreement, Terms",
        "verboseLabel": "Payment Term"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement input, discount rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r37",
      "r184",
      "r197",
      "r253",
      "r334",
      "r393",
      "r396",
      "r397",
      "r398",
      "r404",
      "r405",
      "r537"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Markets [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r250"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r250"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r59",
      "r60",
      "r63"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r50",
      "r63",
      "r189",
      "r203",
      "r214",
      "r235",
      "r238",
      "r242",
      "r253",
      "r267",
      "r271",
      "r272",
      "r273",
      "r274",
      "r277",
      "r278",
      "r283",
      "r305",
      "r310",
      "r316",
      "r319",
      "r334",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r400",
      "r402",
      "r404",
      "r405",
      "r528",
      "r537",
      "r680",
      "r776"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income (loss) attributable to Teva"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r138",
      "r142",
      "r235",
      "r238",
      "r277",
      "r278",
      "r735"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) attributable to non-controlling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Recently adopted and issued accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncash or Part Noncash Acquisitions [Line Items]",
        "terseLabel": "Noncash or Part Noncash Acquisitions [Line Items]"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionsTable": {
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The process of acquiring assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisitions [Table]",
        "terseLabel": "Noncash or Part Noncash Acquisitions [Table]"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r133",
      "r450",
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interests [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Financial expenses, net",
        "negatedTerseLabel": "Financial expenses, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument, not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP), used as economic hedge for exposure to risk.",
        "label": "Not Designated as Hedging Instrument, Economic Hedge [Member]",
        "terseLabel": "Not Designated as Hedging Instrument, Economic Hedge [Member]"
       }
      }
     },
     "localname": "NotDesignatedAsHedgingInstrumentEconomicHedgeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotDesignatedAsHedgingInstrumentTradingMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument, not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP), used for trading purposes for exposure to risk.",
        "label": "Not Designated as Hedging Instrument, Trading [Member]",
        "terseLabel": "Not Designated as Hedging Instrument, Trading [Member]"
       }
      }
     },
     "localname": "NotDesignatedAsHedgingInstrumentTradingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r305",
      "r310",
      "r316",
      "r319",
      "r680"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "presentationGuidance": "Segments profit",
        "terseLabel": "Segment profit",
        "totalLabel": "Operating income (loss)",
        "verboseLabel": "Consolidated operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r563"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r562"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 34.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r227",
      "r712"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other\u00a0non-current\u00a0assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r135",
      "r136",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent",
        "terseLabel": "Net other comprehensive income (loss) before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax, Parent",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax": {
     "auth_ref": [
      "r43",
      "r46",
      "r120"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax",
        "verboseLabel": "Unrealized loss on defined benefit plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r48",
      "r111",
      "r236",
      "r239",
      "r243",
      "r547",
      "r552",
      "r553",
      "r626",
      "r634",
      "r733",
      "r734"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Total other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r135",
      "r136",
      "r139",
      "r236",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Foreign currency translation attributable to non-controlling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r135",
      "r136",
      "r139",
      "r236",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Net other comprehensive income (loss) after tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r135",
      "r136",
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedLabel": "Corresponding income tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r151",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities [Member]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventoryInTransit": {
     "auth_ref": [
      "r732"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported.",
        "label": "Other Inventory, in Transit, Gross",
        "terseLabel": "Materials in transit and payments on account"
       }
      }
     },
     "localname": "OtherInventoryInTransit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r712"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other taxes and long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Non-current Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other items"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 13.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Other income"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r684",
      "r685",
      "r686",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total Teva Shareholders' Equity [Member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r736",
      "r737"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PledgingPurposeAxis": {
     "auth_ref": [
      "r589",
      "r707",
      "r713",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by pledging purpose of pledged asset owned.",
        "label": "Pledging Purpose [Axis]"
       }
      }
     },
     "localname": "PledgingPurposeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PledgingPurposeDomain": {
     "auth_ref": [
      "r589",
      "r707",
      "r713",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pledging purpose of pledged asset owned.",
        "label": "Pledging Purpose [Domain]"
       }
      }
     },
     "localname": "PledgingPurposeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r226",
      "r351",
      "r352",
      "r670"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from senior notes, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from sale of business and long lived assets"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r738",
      "r739"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]",
        "terseLabel": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Sale of Goods [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r214",
      "r235",
      "r238",
      "r249",
      "r253",
      "r267",
      "r277",
      "r278",
      "r305",
      "r310",
      "r316",
      "r319",
      "r334",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r400",
      "r402",
      "r404",
      "r405",
      "r505",
      "r508",
      "r509",
      "r528",
      "r537",
      "r631",
      "r680",
      "r708",
      "r709",
      "r735",
      "r776"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r93",
      "r199",
      "r632",
      "r712"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 31.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "negatedLabel": "Amounts reclassified to the statements of income"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationTypeAxis": {
     "auth_ref": [
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Type [Axis]"
       }
      }
     },
     "localname": "ReclassificationTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationTypeDomain": {
     "auth_ref": [
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Type [Domain]"
       }
      }
     },
     "localname": "ReclassificationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r75",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r75",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Summary of Segment Profit"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r470",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r470",
      "r570",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of senior notes and loans and other long term liabilities"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r363",
      "r365",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r363",
      "r365",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "verboseLabel": "Reporting unit percentage of fair value in excess of carrying amount"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "R&amp;D expenses",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r731",
      "r741",
      "r803",
      "r804"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r64",
      "r68",
      "r217"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash included in other current assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r62",
      "r379",
      "r381",
      "r768"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": 3.0,
       "parentTag": "teva_ImpairmentAndRestructuring",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "positiveLabel": "Restructuring costs",
        "terseLabel": "Restructuring",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r375",
      "r376",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r376",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r116",
      "r196",
      "r647",
      "r652",
      "r712"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r209",
      "r264",
      "r265",
      "r266",
      "r268",
      "r276",
      "r278",
      "r338",
      "r477",
      "r478",
      "r479",
      "r489",
      "r490",
      "r526",
      "r643",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r296",
      "r297",
      "r309",
      "r314",
      "r315",
      "r321",
      "r322",
      "r325",
      "r459",
      "r460",
      "r607"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "positiveLabel": "Revenues",
        "positiveTerseLabel": "Total revenue",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue from contracts with customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r45",
      "r791",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss) (Net of Tax)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Classification and Fair Values of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Net Sales by Product Line"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Items Carried at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r85",
      "r86",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Identifiable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r682",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Summary of Changes in the Carrying Amount of Goodwill by Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r5",
      "r21",
      "r22",
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock": {
     "auth_ref": [
      "r106",
      "r107",
      "r769",
      "r771",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.",
        "label": "Schedule of Loss Contingencies by Contingency [Table Text Block]",
        "terseLabel": "Schedule Of Material Details Of Individual Settlements"
       }
      }
     },
     "localname": "ScheduleOfLossContingenciesByContingencyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r158",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]",
        "terseLabel": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Restructuring Accruals"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r96",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Other Assets Impairments, Restructuring and Other Items"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r76",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Short-term Debt"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r293",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r325",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r378",
      "r383",
      "r682",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r305",
      "r308",
      "r313",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "S&amp;M expenses",
        "verboseLabel": "Selling and marketing expenses"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotes": {
     "auth_ref": [
      "r186",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.",
        "label": "Senior Notes",
        "verboseLabel": "Total senior notes"
       }
      }
     },
     "localname": "SeniorNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r9",
      "r182",
      "r195",
      "r712"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Convertible senior debentures"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r212",
      "r293",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r325",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r374",
      "r378",
      "r383",
      "r682",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r36",
      "r111",
      "r209",
      "r240",
      "r241",
      "r242",
      "r264",
      "r265",
      "r266",
      "r268",
      "r276",
      "r278",
      "r292",
      "r338",
      "r450",
      "r477",
      "r478",
      "r479",
      "r489",
      "r490",
      "r526",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r569",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
      "http://www.tevapharm.com/role/BasisOfPresentation",
      "http://www.tevapharm.com/role/CertainTransactions",
      "http://www.tevapharm.com/role/CertainTransactionsTables",
      "http://www.tevapharm.com/role/CommitmentsAndContingencies",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical",
      "http://www.tevapharm.com/role/DebtObligations",
      "http://www.tevapharm.com/role/DebtObligationsTables",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
      "http://www.tevapharm.com/role/EarningsLossPerShare",
      "http://www.tevapharm.com/role/FairValueMeasurement",
      "http://www.tevapharm.com/role/FairValueMeasurementTables",
      "http://www.tevapharm.com/role/Goodwill",
      "http://www.tevapharm.com/role/GoodwillTables",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
      "http://www.tevapharm.com/role/IncomeTaxes",
      "http://www.tevapharm.com/role/Inventories",
      "http://www.tevapharm.com/role/InventoriesTables",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
      "http://www.tevapharm.com/role/Segments",
      "http://www.tevapharm.com/role/SegmentsTables",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r292",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
      "http://www.tevapharm.com/role/BasisOfPresentation",
      "http://www.tevapharm.com/role/CertainTransactions",
      "http://www.tevapharm.com/role/CertainTransactionsTables",
      "http://www.tevapharm.com/role/CommitmentsAndContingencies",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical",
      "http://www.tevapharm.com/role/DebtObligations",
      "http://www.tevapharm.com/role/DebtObligationsTables",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
      "http://www.tevapharm.com/role/EarningsLossPerShare",
      "http://www.tevapharm.com/role/FairValueMeasurement",
      "http://www.tevapharm.com/role/FairValueMeasurementTables",
      "http://www.tevapharm.com/role/Goodwill",
      "http://www.tevapharm.com/role/GoodwillTables",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
      "http://www.tevapharm.com/role/IncomeTaxes",
      "http://www.tevapharm.com/role/Inventories",
      "http://www.tevapharm.com/role/InventoriesTables",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
      "http://www.tevapharm.com/role/Segments",
      "http://www.tevapharm.com/role/SegmentsTables",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatutoryAccountingPracticesByJurisdictionAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by jurisdiction.",
        "label": "Jurisdiction [Axis]"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesByJurisdictionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatutoryAccountingPracticesJurisdictionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The state or country of domicile in which statutory financial statements are required. Insurance holding companies generally are required to file reports in jurisdictions in which subsidiaries with significant underwritings are domiciled.",
        "label": "Statutory Accounting Practices, Jurisdiction [Domain]"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesJurisdictionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesScheduleOfMaterialDetailsOfIndividualSettlementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r111",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Shares, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r111",
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Shares, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r111",
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options by employees and vested RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r18",
      "r19",
      "r79",
      "r712",
      "r743",
      "r754",
      "r790"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Stockholders' equity attributable to Teva shareholders"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Teva shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r133",
      "r134",
      "r141",
      "r209",
      "r210",
      "r241",
      "r264",
      "r265",
      "r266",
      "r268",
      "r276",
      "r338",
      "r450",
      "r477",
      "r478",
      "r479",
      "r489",
      "r490",
      "r526",
      "r547",
      "r548",
      "r553",
      "r569",
      "r644",
      "r645",
      "r743",
      "r754",
      "r790"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r119",
      "r252",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r554",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r554",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r554",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Non-cash\u00a0financing and investing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r2",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "verboseLabel": "Impairments of property, plant and equipment"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r332",
      "r333",
      "r431",
      "r448",
      "r516",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r751",
      "r752",
      "r753",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r35",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Shares [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r35",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r35",
      "r117",
      "r118"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury shares as of March 31, 2023 and December 31, 2022: 106 million ordinary shares"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r267",
      "r268",
      "r269",
      "r270",
      "r279",
      "r330",
      "r331",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r477",
      "r478",
      "r479",
      "r487",
      "r488",
      "r489",
      "r490",
      "r500",
      "r501",
      "r502",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r555",
      "r556",
      "r558",
      "r559",
      "r560",
      "r561",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r609",
      "r610",
      "r611",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfFreshStartAdjustmentDomain": {
     "auth_ref": [
      "r572",
      "r573",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment for effect of reorganization under Chapter 11 of Bankruptcy Code. Includes, but is not limited to, adjustment for reorganization plan effect and adoption of fresh-start reporting.",
        "label": "Type of Fresh-Start Adjustment [Domain]",
        "terseLabel": "Type of Fresh-Start Adjustment [Domain]"
       }
      }
     },
     "localname": "TypeOfFreshStartAdjustmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r375",
      "r376",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) related to derivatives designated as cash flow hedging instruments, recorded in results of operations to the extent that the cash flow hedge is determined to be ineffective.",
        "label": "Unrealized Gain (Loss) on Cash Flow Hedging Instruments",
        "terseLabel": "Financial expenses, net"
       }
      }
     },
     "localname": "UnrealizedGainLossOnCashFlowHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r259",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Credits and payments"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "presentationGuidance": "Weighted average number of shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r281",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average number of shares (in millions):"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r280",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL75039408-165497",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.16)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(g)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24746-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24790-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB TOPIC 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q1)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6571209&loc=d3e13703-110860",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r721": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r722": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r723": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r724": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r725": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)(1)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)(3)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0001193125-23-140697-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-140697-xbrl.zip
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M/ISN#&WSOT">(9" HQ-B.1S)Y8Z(&V 7,<@HQ@IF@,6OXNA +.[,PPR>@.P
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M0SFA6'!$%8^IER9WF?DH-KU\TBCS_AW,^Y5\4&!< \:M3+9,8C,7 58%UK>
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MI%J+)'//!(M?.>R&/L_;WC''AH\ZS<>ZL^E,0CAZG5AE0L^5:1-;-XG5>9D
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MI0?E6P^0E 2/&QXM45#< HJY191BZFJF7@,M;$[7,G5#NS^S&,B:21^A?9E
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M$2;-,F+):SSF-?EGY(NY621[K'_M+A3!]-7S+1/71:W&"W$WS*Q4X]JK?_I
M.]Z>F/=TXC#<M?MF!P22>B+R0V8A,K?VED<KKP5</<\M?(Y$R(SC29DPB==
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MN]KD1>..91H:&SY^J%8T_-^/\*J__5 [J7Z:$RWVM8V]O5:R)?JT-G!L]W!
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M8:#N7$T::[[L2>$)C9,1#!'AT/"-@$/F/$.7MB$T0A#S0%5J^]:D6/YP[1L
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ML3,,MH,-*J(R4S"-\$ZIV=OB#02+/*.1.,(KE$7E/L*1I2(()9Q>1 H8*B+
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M=W;:1?Z#J=BVC6@OLF[*5Q S!WZ9;5 %=YG[E/H<?Q\[7K]\_L4<>$QD\G=
MB\&<C3DA^1(I&O6S9*18N*?]6^\R?$G[X<G!Y^K2A>N[&V6CNFJ4]= HZ]N,
M\C40_@*J<+<@/"T&"%<1[M'MVN ,B=S4KWBZ#/J\!/HM4:)^E@R##]]LL3-!
MC=XT.*UR3Y\<ZPGF>X$.5A^,#Q$R^2I6<(_C4,0O[I7_2_O%!)T(W9T<5IN'
MC6HRR8K127-?:'%"K?I):V%";7YKU^H!3!^6,3^K<#^G&0]/(N9WG,G#%7B/
MOQ'+ _["^LFO<<>M$6D8//!E.OOXJPG88/IH*AX7%-F=>&]*JD7>(ZE"/"\4
MJ>)%)1(40QF44CS$"$-(X\SF=>?(K95D>N:X&@?&Q/HEQ+P+F5R]D1KHSN(;
MUXX]O,:H1AN#&K]2RP"#^!NG.]6IK94Z%=:)N0"^,N?;(!EWKA8WU'T!5L5<
MM^=A\VQQ_=N(AZ((A1C*FWB8PG1J:_7COJ838'L'4M9L;25E8DI;BEI*\XK3
MSYNQ*L&\/D9]@OD)L\\_6:;]_9SK(SHF, #M1?SM3B<P<XZG(<">D-])+P6M
MRT.D>+71J!V]< ,]&=D)_@MS@3?NY@&TT='+V H>88XH9" G_OS\?/3RR"PQ
M^7JUVOB(/W_$4P"HT)&JU_,7!UW FK+4RW-#]%$#I^RC>.JCOT\$A/L8#!XZ
M&%LV/Q</K&\>/+KT9'2X\YZW)Y1!!YL2"IJ8MEDN,EGD<5,R01-JE8=".K$V
MI5!P\C-?2/JXH.X^A@(E,B2$_]+F_PZ".(]$_SX46^*',IXC0IV?9G$7TQ:9
MY@?15C%!*&VWH7;9'2XCH4H[!S'OU^0 HD$S[6]_>H[[:2%V)K\,A]NT6C@D
MAX$Q+29&)[[[% YLPS<OGZ*["Q;%?(]#?_M5/J'Y/;Y\FA%T1L]PVZ7(_^M/
MOVVBFPY2WGTAXM&U^B?MJGO3OKGHBCV'V<426CCF&/YW' OK!SN819A=<=4V
MRLNO;K_S50:A:T<A;D4.-Z]C5OKBI?@5?FWB[;SD$M902G+/3+RXO>G=7G<O
MV\BJ+^UK$+J.UONUT\F N"E&A5[[(5R/![=?X:46QK8K>#:23ER9S3PK%_.C
M8E^VV&<3S\#TSX2,";^QODS:EQC2(B&#75S1WRR;[Y5<N]UF^\UW4.>)?W*L
MY]7 0%Y1==&?1%RR7:OYU^3U"?TQU*--DGS>?;=IU'-LO5K.\8U%!E>6,@Q5
MM%Q/HB7O:J_2_14W*F99*U$12ZDN8\SS.2'64I;/]O1Z'[!K/CDU7\?-=>+1
M,2BDY"Q-V%$BCDO=%_2 M4IAC>:.!5/_H2K^B:_-^<Z@P/#39CC8-_4+2_=Z
MBG1/JZKPIZ48W ^Z3NE@D*P*>(A$24S'2$U@K;98$5@[K$7K 6O+*6GK[3QD
MQJ&?#:;9F,UG;<S)=J\'WE/4L,M6*>%2/_^^9>^+"'A_1],_JG&ND)_1YU-!
M?NWM:T PQKQ(Q07ALG"MCA_HGY[Y1"R9%;A;K"<OX_Z7+5J'#1ZQ?86"OS:?
M#0G0M@W\3V<^^[9[01B;@@4BTL76YX"\FCFF<1@GO!,^R6SZGP_,%_?<]L:'
MAN,>^L^"O52I-1O+268[JHF_G2P6C7^A7)<=\J]5K:7'/[7*OZ[/VKHNJS Q
MJE- PZ.%=2VP-#R>++0LYUF<0,&XLG]VTW(XEV>__[(>:>V@]97#+AWOT1UX
M5O"Z^]G;?,-A3QJCU5J"FT2,'TD7JCWE>:4A26?+8K0P+\&Q:&@,#W0U_"KL
M<6>]WF])V[J+S?7B,@=OJ+M?<#8JS<9Q[I>S[/,N#0%L5$[.3O*WE)4B=(-G
M=VRL24_?T4I_![$(YCT%:=B3"FM6:K7E)5:IL&UYE8[*:C52])Z4]?VZ9KIC
M=(+%B;"",E9\+)5Z\B??D7/?KZE5J]2/\Q\YR##3TE!8M4H-+^3-F\(JA8TE
M+WC6([L I=)FRZ?Q]J3*CILIRD1Q%5DB?J6AQ8Z;9_G3845259+IVHA:?O5?
M8%NI5)4DP.W@TN03!V;_"ZQ-DVY0U@F^U67Y#&K,JF?LV3J+J1R@--I>V9J*
M_98B6V,47TB#35[VG"K[YLWN^)QNS4]HDR>0)B]^+AL;/GZH5C3\WX^KM%TD
M&3Q?0TP],2(+D\S!$)67]#XY57T'R[_&^50E-%?V;('4*L=IIB84W0K9LV%1
MKU2/52))CE3;)99Z8*(H+I:6PKK6M(RZ+:##K"RA%)_];=B!GCM5\:.T.9=.
M-+R9YA:&LO/VI@QE[#Q2?B;$,LWGV<;'C0$6AWI0:$SHU-*:D*%@[XUCZWLU
M)9O'*IJ5(LO24*W-IC(F<Z0_[_QKI"IX6Y=_:2">S! W;HIDYA*JO( H=TB2
MMFUT H+LS[8\KIRFZ9455_=MR+M4=BDKIXT<[E,JZW+9N@RJ.(,!23C=O9VY
M\PZ%D!PZ@T./TXCF+J_]&O#P&EEXCVUN!]^X+$2]+SNVKNS8/; N%7NVED-5
M7EZ-W<6QF -3E.TR;9?80U/<3BW47UD-VBLLCTW%U0G=&4WV'2X]KIR=-)4:
MW /WTM"#)Y7ZZ7YS4)11FXZ*_,5QC&?3LDJH!X.I[VN#Z+1R>I:B^5!<E;>&
M4:GL!YU63O9\GDMEV!4ILTMEV&6##ZF8$;7$U6*+:3#(7+IL!)#V6_!'&MG[
M"A(U*LWC%.L@[,E:R B'TMG;K%2K^ZU4450SH0&ZWW \#,UD=GW:T1@S;BB4
ME1,JXK W ^*ZV_[2O>[V\5J;]LVEUOG7MV[_=U7G-*//JUV)M"K\6O-K3%69
MWZP^GY8/698RO[V1P]Q#E[(Q6-F/;EE\Q4N8Z[X+\8B[)I2_N#,NI5.HMU95
M*03OJY& 45BEEU/V!!\PQW56GK<<E7;P9N1S089[GPIMVY@5X]U7A*M1::0I
M"L7;#MN<;>D4.SQ-\QR&<L1W48-\0J:B 'DIU-EB\>([.?D^(\:>BR'6*XV6
MRM-/G77I' )MM4[SI]:*I+TZXXGE3"D]9-0B+C4TYQ$F(<HKE4N1!82XEW2X
MGL>)]JO.F@UUH'U/[$OEY-&)JJ.?34T'RQWS:,FJ50OWQ9^Y7_5X7ZYFO5(_
M27%Q+YXJ2\BKE")DJ@)1EDI0A[:I2J&G(G43WLWVJE6J575,,%6VI>-&5JLI
MWCQ5HIRP<J8L9R\CK)Q\4.[-.Q5G7;(V2F5SO)^Y4:TT:RITG1;+4C$U:I7F
MB<HER)&FNW;LH4R%4JE_.7A>V0!;2,::NL0E6<L#"F!%6]M8=$OW7CWS6%7/
MW#,7T[GS*L5+8=6*GS0V*K292!VTXM;T4NFY=]=LC4HK33NXN+KMW;49<*Z9
MPZ2;4AAP/6J;#H._W9FF(R7+PT%_K0^J_09I *O_-5)@7P&9L\K)B;H /D6N
MI1*3.:O4JCF\2Z)(BFNQ3&]I[;)(O=1@F9_NWSQKIK@A6EPU]A;VI6*C[?F6
M9;6?7:1]5+6?G0T^*%=HS_O9:^)"I;)"WC,P5&]6FFD6\BRN\?&>0:$Z1H54
M7;7L+"0Y&**R.;(Q1!6LV,*TV.:ZH 15IYSQV'3Q[BL9SD5=#J^AMKY@F%0T
M3JF(^\(<,YJ6LG[U"DVU;1L7X8EN;GF\<//<-JV?#USF47CSXKJ4Y0R6?9/R
M%7,@35(J!V??#HYR:^3L]Q9&!;-8W9BS<UZE$C,]KC1JZAA0=NS2' Q1N3#9
M&*)R85(U'O &7G>JDMZS^KRRH_=G1],GHO$1870$OU/&__9#JUX[_22N7%<R
MDMWGU:J0( N'&:9-V%0"G&O.0+OI]K37HPV.W7,=_?L=8;>LYV(!I=^(Y=$[
MRGK8TT86?/>Z]S"A[,%O.;?ENS=7,V.^^HHQG\:05SN(.QER]:@6=]ACX0MM
M0ICVA"/5X(V249^TKX3I(XGV1JVBX1A%O/"2ZG3\2%GDI_JY1CQWY#! CI&<
MN6)RO#UKN1%3):!6D>8UUVR78US-Q>W&6*\TS^*\Q]AP&4BHA1.1K_RDF9Q[
MF_.B*UKM<8ZU2KV^O,D7-R6!OEU-)RU8P71JRYGL<=.I8.GI"84'GJ@U+570
M+,0FH2#W=?)-E?Y*AUFI''!3YT&R:="U#<-$=A K,N(P)S2?%=JF.YD38AHP
M?E\9ZF1BNL0JE6J<4_<.:-&U+R0-]I4H=5HYK:DC=*GR+954J=/*24L="'[O
M6J[>V),%JPTZ,'7S'2\Y2D4"/JP7@7OJ$J",T2',!FW/0P2YE/38G1;C,"[X
M[C5CO%&IMG:<0?AC4?19&MQ\HVY+R,UZI=7:<2'R'Y59F(+Z<V3=6&<\871$
M@6Y/5+,<7K1C=Z](4(@BXH#]19@>75$-YQJ(<D/=VT&?O.Q;.=8KI]4=%WHK
MBV[<GK.I*DK0DXT=&X-[T9-%4H=]H 7WYML>1.Q\;!I37P_#X!VA>&=F NC)
MQI9:4+D:9_6M#<HZT7VJ<BU5$6[M,R3;K-3J::JJ B]"B7B61K A;9ZII,:"
M)].II,9L\"&3_NZ.Q3;306.ANOV<+YD/N:=E][32.E%50-/B6!J++G#L;+\[
MHFK-+9*N5VMN-OB@8B>[SI[>>1+"C6,?HDYGC@7?#'V&FJ#D&>5N&0\Y?C6!
M-[#6=7T:[,M*2?/^O^+:* FXE8J%<I;BH51EGQ1\753V23;XD,F80#$-%UD^
M09[Q*J%1L>Q*=VW=\@PPN>X<A@W:KLO,1\\ECQ;M.UA_;&Z5[=D4:55.:CM.
M/2F',9(:E],P88#+9_N]<EH9,45:/)41DPT^I&+$U%X-LB2@1^[-E5"U)Y&Y
MD@WSY2][7=-"=83:MO%NFSC-1J5YG&)]U#T9)9GG72HY%,U*-39'29D:FZX?
M#5@_#,<#ZS&[:]R.QIAQ8Z.LG)#"!O]&%V;U^&KU5<O_%BM[2 %J.D5W:>.%
MO3UV/"P&.R93K/:J$</0O(EF>%1S'4V$;, 5.]*BB_RF)L[[SK$_HAK1\40"
ML:=X)9!_G1F#KVVQMS-D8-U,"',Q3]>%QP>F36S=A&\YEO(0I4\3$V$%$D-$
M:$W<)7S%=Q=#T@6*+A-TT9 -D5!2\.#SL3:#=>0_\8,0%NC"(/"KD%W]2&')
M [O:>B93?C"CT6BV OEQOS/QSR=?UD @/SV;ACN"653_>O Q.H(0P8Y:#7CA
M?$@: .GHY'3^G1S6_.LP*C0!"Q@4T48,U^\?8.4'6*#$(L.QH"TR^*>/Y',\
M6>;4"?\[&.=2=%,LVS,<:C,@1EK%<"5ZIEK0I75T;$8XB&["IXC+0#S7";YA
M<L+XU>K7!7*T@10N"7 2L?\4\6-0!J*2NV4MZZ6GWS:337>(^YW?VMK=K^W[
MK^V+SK=^]Z)]K75O+K_U^O?=3D^[[G[M]CN7$5VQK#=, \9LVLV3Y@F8E\T#
MQ:4=<^GB]J9W>]V];",O>GWXS]?.3;^GW5X!LRYNOW:T#]>WO=Z/K_!)L66W
M;/GP[:AW!#:891'&03%J_@D,7M'HBTXGKCR!(:(+LW)4FD%<HCBU;T[9Q#-@
M'3,24C[\QOHR[>*-H@4C",UKL2KKU+(F8(O"4$6A,_S;'[KXVW_GE]O[R\[]
MX<7M]77[KM<Y#SYLMCLYMT ^26_AO.JOI^?58"E=X4W[DUCPVN7*W?KK09Q/
M'Q_+\,<0;9+D\^Z[32. VDH</]U5U $L,0",+4].KB/1DAVVUPLY^F"14FT,
MSXVX1D&'&%$Q>XNS_SX,U'QZ:K[<SN7\Z#CB[KPVI80=)6*Y[_W[/=2.JE5<
M8L2&PP]5\<_KL<5W0$7TJ.AFB-B(#Z6'2CWO4,%MA10!LN.."D7W>LX$$W<Q
MWYJ*E;?MS1OJ:HP^4=M[S^/<^]W>NI?SO6+.&$-:^-"_37=TX7'HCK+.BY][
MT^:<PO^,Y>H4U=I#5>Y4]IU4KJ^IG)SD/ZT[MURMA[BZRXMNTN6J.C7SNKJ[
M<+C8N^# L**5KWBM0BUW;P>_.(XA]O0I>S)URGNP9N]9M]4KU5-5/7,O'$Q)
MC]4J9W65 9J=M+X<##'C21GEY(,ZQK*%)?$+<SC7)LP9%*Z$[?IE2$S\3LQ[
MSY9#K7*\Z]*FY; <$K L-5/AM)EB#17E\KRNJ.XIIQ@F%WO%!CC)EC/!/"V-
MODRHS4OF!@74  OZ<DZ+CB3%/$:@_^F9C!I=&Z0&C&R.MO>^_:2&NK\X&PQ.
M23?6Z_N]]%C9=DE59H^*@Y5"8\((OE,7_RJEOO1) =+T-2"$+TM[5H?'S?R?
MXLD%_U+2=L>M_58^47;@HL-*;8KI^ZC4B#$V;9.[C.#%>N74;#X]0#+:$6J\
MCWJKGRGUMC\FIF71I<E$9=%MH?RZMDOLH8DILX1SZG+-'$^(R<;R/$L)U)Y+
MG\CYG QM087NG C[CN6=IG@36_'TW5NYEU98KYGB#JXRYA)<&"\NCUI69>*^
M9)=YNNNQP(.5%TT!)\9ETG1SFMR'*0*6@J#=OO6=,N_VQ\*TE-ZN+_10UMV.
MM.$U'>()=.JZECR"+O0>7J8G$ *8H;9NEL2_%;(C*-*;$P1D!B];NPA38^_[
M&0VE O?(QM1V=&MU%<G+@/%GBBL4"Z;27KG.2\S\=D(QR(.%+Y$"?JCGANY]
M@U9=R;8_'J:U*['GJY)5(FN1$BA5(FLV^*"<IVVLB4 5^Q:%]@$=IQ\+9EB\
MLB9%ER.TL?-M3)3%EDC.M[<;$,GN$S^M[=B]5;>);ZC(KF:U"(-\AHIFTW(E
MY]\XMA-K6N]>G243B[JZ0G,O?$Q;O=6/]QO\5HY2D0QTY2AE@P_*4=HJARCD
M'FFRD&_@,[GDI7#;2Z_8WG.3.RBY8=H>+%>^3>[8_(L@D7RNCP1:O'2Q;1O1
M7N3U E^I.W+@ER=X)*7<I'=:],H2X\T -M(VB,Y.=UP"0?E[;]/'0O5J'QZI
M30>F6[2X52)! P'RW8,OD@KOI3!K.TX++(R^W"D7T\I>S]^N?BGLSA[6]I;4
M-&WM@RPYP7W10&,4NG(&\D_"N:.;Q*6&_%M>YF$6,Q2&G9ZF-*Z<Z9>-[+&]
M65+KU<V>[2<542I2)$-%E++!!^6H)*NQ6^2]]5<6'UEX*)T]]81QG(:*XZ3$
MNM3#+/O.T%-^R9O5FD9"M]3CM8B1:]I"'-)\%FU\V0Z@X!!QZ-]\[^M1TP\9
MEBP #_2?V_7M$.G[SHUCA\@4A%3?2_WN^N!'8;3OGOB;5CESE1"0&9L\!T-4
M[ELVAJC<MYW;.7WZ1$IL>[R;6U?=<0'%PA@6N^!>^IY=FMQ3%D3!5RYE062#
M#RJ$LH5IT2',!@>.!X;%_"KG11,#F&C:A$WESR/' I[R\UT;'6GODI;@^1Q;
MU(U]P?X+X:9>G-L&7[&V B&_HTRD<HC9O]5F?@ 5\2"Z"=M?]9GY54UJ?E6/
M:@78%,DR*U\SH'?(RM:.JXN5U91N@'UD.!ZNN9FUX78TQHP;TV7E1!'-Z;W9
M%9>FY;G4**UEX<]?V19%L"U>8::R+I1UD=TQ*NLB*V,L2G!B;S&Y?XLOJ*$1
MF 401P.-^$B9N#4<U2G7/IBV!MU;>([Q1Q6#R][SRHC.;W#N'1*M HEO2X&_
M$?)^.Q#&$[_U7.X2&R\-?'O@3BJ.MU?<K:5X4V">][GWP->U=O:V?*V>JARZ
M[)A*>1BC,JRS,L:B&-;EB<YE9PGR2;&T$BGCHFR<5>:%,B\R-$9E7F1EC#'"
M!O_&=+#H^"*]MD*K>Z(1!]^M2@Q\_O_LO7U3V\BR./Q5IMC-K>17QNL7,";L
MILH!LLNY!+A ]M1]_DD):XQU(DN^>B&PG_[IGAG)DBW;LJV7D3RI<UA;ED8]
MW3T]_3;=ANZ-X>?VNWE0$4B6G#:DICG5=!1R+*J W\6!/AYEX'!^OKV_N+P_
M/+^]OA[</5Q^##YLZ(!A8']LG7' VJW6NX-T>M>\/.(#'+V;EW6 MNAF@#K2
MJE(CJ9[>7$/;0?F*O)ZP]R]AO'LZA<U%=,LBVL3V+0\><%WBC>'"KSE6%(FI
M,]^_:J_&Q)]\I;B#NHYWKUG/=/!JN.N2SH]3[X6MYJ*.P[E9^'&;)+8"5ZRW
M*/G:G9SI-Z1XM ]UD0@$;*B?G)Q/MJDO'I,=,&*Z -D;T-LCL#J)/R6ZSU))
MF?\25F<PYV#F)?'HEG-\'%.B#7E]HS?L7@ 3A5>QW%F+'0E^QF[G4\WQT'7O
MP>VCL$ X:&4>[ZB5&@E+Y&@$"2A\Y^5Y\G )*)W#Z")"YR5C!(4<@P>?>C,F
MCOTG&0AFY,T!@9<B\I/7./VHF3^U-_<@Q-$XE+7""7[*_IT)$0,;8%0\_Q:'
M((*P9A]MSQE(!!BIV3N97>-@S2Y'N8(PM@"@-#)V4$3\XME#8 NV)P'!L>@D
M;^ZL?4I&RPP[T;\!G NN?J8FAWQ(0D:,/95 E?@I>(:7?O/8L!;VB9A5KOF>
M'5QQ^(3QTO+7!>MH@U6XL(#3+/NSF*L UT!\Y2XLU,V6]<+=V\UDT\("CY=_
M#\C=7X/[KX/SRV^/5^>#:W)U<_'MX?'^ZO*!7%]]O7J\O(C)BD6Y8>@ LV$=
M]8YZL+<='R@J94RE\]N;A]OKJXL!TN+A$?[S]?+F\8'<?B'GMU_O[B__NKQY
MN/K[$D@'WR_)^^O;AX</:ZBFB)0MD=Y_:SXTP0(R3<UQ2314K@A1,"$LS==A
MT])38C[ZQDY:2U(*LW"F;LPL1 [KQU:P;RYQ58E))!F'_?Z[@R2'6;('D3_3
MB3^2YG/VP^81C>BO#480 3$19)^Q2?,XIAJOFWG*@1:' T4-6,SBAY"%&A?S
M<[2;+6 7X>GXI<7^K7<()UHHFZ[&3:T;AXJ:KQ.X>>SRSQ1$E!Y;Q4_.G'Z=
M+UQ?-6<XYK!TVXVX/,F(K(J%&0MWJL["Z-O)D4$R'JA6>.]4;&&VV]OGUJ5P
MVDN57BI1,=""#SBH.J!5/):B2H!*F[E37(M@;-E.T-?NT#$%E+S0N QCW068
MFUU[50GQ\MVO$N)WX/YSWW&H-7PCGJ-9KLGZ5Q%-_X_/HYQ[E<_&),%Y5!!$
M L&V ZBS G0](K;X( -+?YSA;A"B#G2AV]&C]EIPK^UV1_6DW:K;=J'$SUNM
MZ!TIK:)4N?K- F28,*!.GC7L;,1K8(T<>P*D=8P78)B7:-0>T.8Y/@O;U[&=
M4?+B\^B+]G&&JC\!4[C>;JV+$$4EB=$<&T)768CF1L:<RG@7FR.LU,XMQ",*
M1@*LI%,0AO!=]+HD4Q/VU9I)P5UT$-@I &%,S[@=W>'/3/VXL2WQY<Z&'81Z
MAL.2O^X ?7]KIL\>R$^(IFR=67W/E&SV2)[LD(TP'AFO5#_\ASHV8J_?:7?.
MEN2I9DR>/3J]L9]E>>4[N[&?=*BP(5B8>_G1]L"ZL]<YF6NFZ&R_L97F-LO1
M5*BRBK*#REJV$^PX8Y+N:VFW_=S<E)(A!QWJZ&<I6/O8'[UCS6Z5L%$%FQ1\
M,WU,$+NS'1;+D;CG9+NM'"HRTS]OQ:;=:+5.58"O5,EZOERFJE;!LBQJF87X
M49Z)?_LIPV66V<<9I^4H8W2?C"!EC,I!!W5 I#BMJ=S&PP6?1%BQJY6EH/3R
M-#'J>9YD"RKF?\"D8$NQKHK'OI;GDT_UV%=*_*X*MZG";94KW':B"K>IPFVJ
MR)$DA=MZJG!;D87;_AK<_ F4NKHAE__S[>KQ?U6MJJ76PHI:5=UN16M5J6'5
ML+D.FX<_LEJ5I*I?#8V^:+SYXAA^IX[+SDJ<G!'*ZHY7NLJ41-#5?II[+PHJ
M+PEN'9BXYKR)5JQRK_SJ+ PUV?H).S5--4TU33FGN?>*2.6KK/)^?WR&]HB7
M89ZUA^??P\+W-5!3*DJF!XP7Z9P<+YKI4T6*LD@Q@(EC:H5F+A8MSR3C>ZH9
M.LC.:&'TH38U/'BA(GI)1+^GGH8E:S@YJ.98\!*7?WNO#8?^Q#=G*Q3KVPP-
M3W)Y64]*#>:)P<[CBV44S=D2Q(L<C5.$*M09"CJBZSMO49U#T:$$.K!SHRP#
M=T:)N']:2+WJ.ZDK2J+,58P;VSI,"$\7W(1EX5A;.6#,G:53K%VX]"E(ON1R
MHF.MMX)#E%WB\WI?T&YO5! J"%??KV!3L-4/MKWW97>/JJY,+&_96C6M8E^*
M%FU&W\^:J5E#2C2/7- AG44NNNT&F>\75YN:&*O/(3XPQ\F5Z_I4GSMX.'!O
MK78G.'#X_=R>3&SKP;.'/[XRW/DNCO 0'$6Y9/HWGFNT+3RX,'@UW/E3BMQ-
MLVWAQ4:G+47IQ8I2&BDG'#.<5AD4,LJ!1[:OS)EU%4?%'=ERQRST=:<9^I5U
MSL-2)7!*YZ31ZTO1N$-6;EES?+T(=@F"9I<B7)8/GZ2LH]9I]/NJ#).TO!()
MVRVK,UPF^P#WU*'G:EVY)X@EYJBXI*STUFAW%)_(JK_<@?%B>26H*R>-_JD4
MNJWBBD6N2'ZF#"XYS;B5H^*1C'@DPV:#C=YIQA6=BW!&ULGG>$,]<I5G871I
M B=J%C69A=P:_IUCCPP/V\"DJE\HE5^@TSJ655U7]Y=[?[T679ZV3^676KU(
M7:1!DX[TW:ZB? &4SV/1YNKV5+D3.]@QMT4WFI1M@U:S4+/8:Q6QH-:KY07G
M5H=TNSU)W:55OW]/V+JT<)"\G"NW.IP=Z>4SD6K0@:/*PJ B[<55?&>]782Y
MT"Q-W!Z1A\BQ\GU)",=P*,\'O_ =#()2Q[!UC@E (?LII2>I])3QC*5BO<(R
M_T\F7.SXEO#(3=+Y]K23K\1,U?U[?O\>2HT:WE\;*BH?_ ZZ)E.-#I\TE^K,
M$P\VB,9T,OJ*GZERP4L'55VTO]56P$#_C^]ZK,/8H[WDW!8S"1COGD=8]Q[K
ML+@ UP-U7HPAY>;#/1W:SQ8;Y6^L/YG2<2S-@;%NQF=_]GE%J/NENU_)(GF]
M_7*(GAK>KYB^.*]VGDR<8('4M;,TS$;4T9&VG7$V("IJR 2BHH9,("IJR 1B
M[OJ+#).L (B*#G* J.@@!XB*#G* J.@@!X@J#ZJHVII?-6<XYM@6A36[JK#F
M?'$(F;*DVHU.1XJ,X@PH_6OQR7)YU [)F#U43<T:,H8\T='.2>.D79=<RZP9
MI:SZ=I)6S&AW&ZU^QKM-&:<5:L@FTA?1/&EE7/M*,4XFC*/J9\K-(N5S2)FE
M,WLM&303Q1 QAI"G:N9QCO44%7MLQQZ9%LQLJ]R3+-RPW>DKT6T?2"JOJS@C
M&!4]Y()1T4,N&!4]Y()1\ABCHH2BA**$HH2BA**$HL2R;!3XB_9R'+YH5D<G
MD@NR$N"YU^(+<60RI*8I6M+^<= Z8-]%*UWV7;SS\^W]Q>7]X?GM]?7@[N'R
M8_!AP^/;#&D?6V<_#=T;P[76NX-T*3?S-C,?X.C=O#T..(@Z+S ])EUAC^0'
M-\_+V2'E)O)ZPMZ_A'_NZ=2A+GJ]B&81;6+[E@</N"[QQG#AUZUJ^; #0.RW
MVRD^Y5Z^4F=HN N)*AF6]?G^57LU)OZ$/^ ZWKUF/=,TKKSCU+Z>5G.Q0CA?
M":*1<Y/$5F(MU]ULN<V6((?U8XMHOF?/K\+(5/DDDE9?MP.K-ZV,%3#,/9+F
MLQI6#5NQ8?-()>VOS23=J,5\!@,M#C>T4899?QQT>J$$$XJ2&*+=;(% $JF[
MO[38O_4QB"'% ,%<_JE)/;AX*(2FD,"A+%[,1MTL=_61OFB$95"*J,9__=+O
MM$_."&4;631Y-3.$YC+0C"8'$D)7^VGNO2BHO"2X=6#BFO/&I8$K]\JOSL)0
MDZV?L%/35--4TY1SFGNOB'2JKHC<^.@FXS.T1[\_.;]]$CH)>6]8_+MP:@6-
MFBJMIE243,SEJ7-RO*!759&B+%+,3D-Q<D2?3BH*3C8%9ZH9.LA.05OVCB$_
M<:6(7A;1@X--G!Q4'&_BW]YKL^,L_(I.1\;0\"27E_6DU&">&#:>,!++*'K.
M2! OTH%0$:I09Z@XRQ/5.10=2J"##3L+0==TA!)Q_[20>M5W4E>41)FK&#>V
M=1@GY$S7*&Y:D<,:98)AB(,B2OJ4)7T*DB]Y>"O::[T5'*+LCMZL]P7M]D8%
MH8)P]?T*-@5;_6#;>U]V]ZCJRL3[;\V')M%!I=0<EQA6(9[K7+2*?>E+M77M
MOPLZI+/(A2C_UU;E_^:/NK<[(INZ+47YOU9=BG>50>F\RB%DS".J!F!=N4.J
M0H#'/2GJJ<C*+655ZXJPBU35 %N-XT[&FT\9%;OJRBO2EP3L];N*>V3E'E47
ML )\4CZ;E%8<$':?SDG&?*'8(BNVD*9$X&E/BNKXBD<6>"1#4=!N=(Z."BT4
MJ#J.S'D=;ZA'N$X9R__*SF,H3>A$S:(FLY!;Q[]S[)'A7<-26E;8HQ,I[-&1
MRC-P>KQ8S$,2A5W=7^[]]5IT>5H_E5]J4BNXFU):&H,F8Y=97:B=[<+.9:%F
M7,H\ME!5QL0.M@OSCL=/LA!#V3)J%M+=+R=4M=\]EH7/<#^YH=[MZ%%[3:=&
M2!Z3R]B)ILRV?>/O\@TB:5EX7UB@2$LI'4L<JS2#<GDB#YIFG-=8B#55)Z,)
MTZ-9YK@]BITTWY<<\>3RW#QU'%#(?DKI6RH]BUSE"*_@@Z2B]/N*B^U+UF^X
M).1)BY8[(UHV.T?=7ZW[]T6>E)>F*(/XJ.']>\*XE6!$%7S:P8YBO'+XI+E4
M9R$H,+0UQE+T%3]3%7N2#JK]T.8'^G]\U\,=TGVTE^CCS-QEO'L>8=U[+#OD
M EP/U'DQAI1+OWLZM)\M-@H3A%4S!#HY9ACOVXI0]TMWOY)%\AH1<HB>&MZO
MF+XX R1/)DZP0*+U!%\+KB>X^JG=FMC";$39*&G[[&8#HJ*&3" J:L@$HJ*&
M3"#FKK_(,,D*@*CH( >(B@YR@*CH( >(B@YR@%A(T*I.L:FM2\E^U9SAF&-;
MU)'MJ#JR\Z509,H ;#<Z;2D*Y61 Z5^+C_7G42DG8_90)61KR!@214=/&L=]
MQ2ARE7.4M#Q,N]TXZM?@G%8-V43R\ZE8,S;/@S^*<;9E'%4N5FX6*9]#2LN>
M.&UT\ZP.J1AB2X:0IJ32J1RFKV*/*'MD6RFZUU+))QGX8;O35Z+;/M!47E]Q
M1C J>L@%HZ*'7# J>L@%H^1!1D4)10E%"44)10E%"46)9>DH\!<-YCA\T;2.
M3B099"7 <Z_%%^+(9$A-4[1@_N.@=<"^B];1[+MXY^?;^XO+^\/SV^OKP=W#
MY<?@PX;GMQG2/K;.?AJZ-X9KK7<'Z7)NYFUF/L#1NWE['' 0]5Y@?LR2DCVI
M'MP\,6>'G)O(ZPE[_Q+^N:=3A[KH]B*:1;2)[5L>/."ZQ!O#A5^WKT7 ?KN=
MXE/NY2MUAH:[D*F28<VJ[U^U5V/B3_@#KN/=:]8S3>/+.T[M[&DU%^OA\Y4@
M&I<W26PEKEAW4?K'%EX>#)#8VGU]SM6 <8,+D+T!PW@$5C;QIT3W*?%LPDHG
M ,F#.0<S+XG)MYSCXY@2;8BU$33K#6:#$X57:0[%]6# F,^.9I*IYGA8C,Z#
MVT>&I5E# ZZZ 4.ZJ9&P9 >((*$?ZUB_:K@$E,YA=!&A\U(U@D*.P8-/_1D3
M)_TGEFDWNQ0#<J&V!G-^AM@G(?J738VE',Y-#2]%)/H3A;4*$MW\J;VY!R%(
MXU#ZBZH>I^S?F9!\L+U&-XS?ENZ&S7X77C@#B0![-GLGLVL<K-GE**\1QFP
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M*NNV&P2=$ WDS9%AP@TA'@*'ANB.%K@Z<%H3PW419^]Q;IW6V</E.?O4/OO
MB9_YI' &AS #,;'8J0D"I-+(3YB!#OOI"U(-.QNQI99Z 6N,?9=AY\GWN-L
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M<&=CL.,^P8)"8X1M %$V%8R\4LM_HD*N <DUEI8& G4,<\,$>FS5%:ZT #V
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M<@%58SL\CA#C&!9TLMBZ SGT53SBTF?&M6*S:+)GP H!?=Z.,!8K'N:00(S
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MWI*AJ1F3X"0.3'3P]/1BH.C";<6+R"V+&Y!"RPRNA\9)PLZQ;N,@2=(7J;Q
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MZWZ0DX1,>ULHF?;+<$CI:+2&N("NZO2(O[)>8'C;,<KL\+[S$.G;@0>%V"^
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M(O,RKHNV:5S=F+$G?U]&?M(NZ,8XZ] XUXIQ2:9)<DO&=RL2N=D=Q^_F?>6
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M/I.?K-VD9N&$ JHA>K31R# -;&+#W'#-.)Y@MFR6[+<%U&H.#="KPR78,8A
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M;/S_[+UI<QO7DC;X?2+F/]3HWMNOU '"!,#5ZE$$14DV;4EDB[3=/5\<!>"
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MBB)^H4_/%80T7[)/!H)$,PD2O9F,*SWO!YR-@UFG8VIRNCA;9?(8-.O:YOP
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MESQ-P77UDAQ43<,[AYNDC_]F 6YX5W&(G_X[C#/P#1&G=9$FO@@#W)NO(FS
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MV.=FJ8/JKSY:L36WWJWQ-R+/Q8P2@+?AW8@[WR.$$;7KS&+/]WK(".-I@KZ
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MU=I5I4Y/YE7C\QN#G662Q+(.6HKJ#U)R5A$E7W =_E2B\07><I9=1N)*)(@
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MT'W3"=;^Q">P1<#^R'SJ5)PAG2BOC*+0Y;77.71-Q%MC)]'"EPVBGV J/@V
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MFT4N7]='2JW(;:PYPU2!(L7)EFN+/JE,'(#\Z'1Y];')=XRMV77,T<9:2Q8
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MVJ(D.AVGVH$VQ.KG9IX"N@+5KB,\=A1'UDHH!Q)NY3C\JDLHY(\_8ZPSU\D
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MQFBB&;S(8'T?_=%?0L\\^'!/RMSK,0R$8"CNMW?&!Y5FIX.%31'Z@D^R,E2
MNWUX;+L3VD,N'C^#J@7'-_[&%PO'KPY>@H3F4DAHS4#"NLMS<T;I+3N:[K[[
M9X=]_:-S^Z5ST?UV?W71^<RNKB^_W=W?7G7OV.>K+U?WW4LVU3NNP!9!.\*3
M0P]IE?QF4GJ?;!=3$PV'8=R$%%U0Z6V^_N8:8 # WMYDM_%N 1FQ\*#+7#V&
M0W(7#>=, &EN3&928,2O/QIW 68<="UA&&8A/[&J*Q<L1\ #BC\TFHPX',Y
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M&%,RP0UYC3]*+7SC@C%E>[ ?P^SC(N]2,*:4%:OI0P9XRF*CT:I)2X$,>FX
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M]'BU,H88O#R6.BMZ2B%3/)!- I4R<BGBE90$DQNP],%,]BT1XZ4H'+R2! 2
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MH E23::U4YJ[YP-EOTW.ST#VT(+3%,"\MU.A1A 90EB)](-XS_)B*WE4?!9
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MVH]PP_XUW]1XT'C0>-!X*,,")\(.\ \>#F0G*RD/;!_B0F9.Z\9QWF,#ZY(
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MA<<CO2A\Z\ ;P!E(HI%P18A0@F7W."W#8(B<'K"DAWL9^IX5F2'M1P!BV#<
MJB:/R*2G.CS#M<EK XOHL4_Q*J/7LQT;6)A]X;"0PYS8E&J@--=!H8A "O:=
MG@?LHF_S'NO^Y":L^XFS&U@@((2]QBN:]?.+[@U]:IR_0;O>8[9P0TVZ3P3I
M$#Q(:P&2]L#XH=Y^<_DEO1\(Q.;/:M3.=@4MXIU#GP--@+3#@#120RK_'HS
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MCR"*_AMS//P6H<[BXKPMM =T?(;_/61RIH0SJF4![_)G +,Q''IX_F71.^U
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MYHAHY%=%L[:*'5*IG='%%>B-4F"[0\ISRBB"D#\9HK5L4C<HVLJ64VTN-FM
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MAMVCX>H$GL(:8+,!_O %0._H<"5KSMH\8FT#8X2$_01J&;=G@<SC/)"KP"W
M:V!;:+*X 8$[F;WF@#W<!WICU"6!5@SFB"-$)K&_P#JL1#Q.@%XURQ+J?/+P
M/DPK%D:8Y_(0VR"%2,\"\D .^#0?:.;!<'\$ CLY5$3PF" ELA7<1P\?!1?W
M0!"$B6"_C<"<-NC5WW[X('-X#!]\8#!$I%K,MU%P,%1.C]B?(DCP058;<+D?
M#1/C7:%Q0UJ/%\*-D!Y<0#K&1VT:1,,AMKSHPZL/V9WR5^:I^)R\19A>Y%A)
MVUY\>8H_BSO&B(A1T2R((7P8/#ST[8>(OH#?T/CBBB*S@61LHM<@46HR_9NV
M")PNL#OT7/)VL&D'A@GAM4"18"G?<4F@\"HS$DY+IJF0'%27:UW$&D6V$!+-
M.K;B@! YV]A):"":B,2Z2;8U(0 +. 2$ +!DD;E4"8P^B+@V[DD2!U&=N-V)
M)300<"/VIU+!KYI'%+4%+?Q7)-HB@=D#HH>CG,&G8J\<[/$%5XEN3$)[BM=X
M*&L>(^ V#[5P#0@)))])K DB"+X=2>,ML83 ZQ2H 1 $0 $F*=\0Y=DCRCEL
M5T4RS'AF*(5].Z'H&MGQ#K98B8@I2+?30L"-MA]1/1)=]7H!%[-Z!,]*F06P
MS,(019SG ^__ 6()!&\-5]<GI9O('I0;]%#IQ.7C  4?X(X+981R#*4WL5-L
MO9"?9G."CB5L#KQ6ZC(Q22@0EQH.6&/6*)4X")!4?M-ZGFVP31W[!Q?83GA5
M/  4&Q@@N'/!J;VDBX[4"%NP(/Z SP[^O7&WY4Y1$OUT%=)[[]D^N'S2\4=2
MP;R?),___?ABTS>?I)'5J8%6-;"Z(V'5XU>9))&\2UKS Z\T4[1Y,OT9C=QG
MY+QYK2'7!7$P$6&]C<W%F43VC(+VUU;MY*21Z4U:8RA]A"_@B_#@M(<T#\&7
M!KN*? =A+HY$^ZE::K,",:-_)VR7HU<UV*[M@N"PI,P0\BJYG**'<:0I\5BD
MTI_GQ"N.6ZS6%/\Y>5KJNG6^W=UW+V_HB9U_W_SYOQG?F];2<2TC?G\FIA"_
MK*;H BG^8:?"VEQL6U,>B[XD^I7!A$=)Z_W8O;[L_D^'/M_?=CO7EYV9#SR<
M%AXO[/1F^F-6E>@Y9UA'+28%&[#B^+F=/KI;].A.*X;]40PWTT2#D$P44D@D
M%I#HKXW:Z<E)1CN(P+R\2[CR=&6KU<Q>-TOW'++;7.W0?+6HVKG+KL#BRE,:
MIPL_9NYYH3:X-%\MQE?2-)G+4(WVT6(,=71<"$/!;4J(#PPC\''/7HEX6)[=
M5@ #GFG^T_RW:?Z;Z0],8\>CL^9"S-AH'+V(&<G'(G=JC W7Y%ZU"U&@K1/-
MP)J!-\W 65=Y_+QUD5A&LW$V%LDP$L(6E^:KPT8!^E S@F:$ ABAJQX)LX'W
M),?"*4'[7 Y0#U7ZW'JD@S6*P@<Y)[6J&@1Y_VNCV<ZJ-TWTFN@W1_2_4T:0
MM$1FRWDC0!_JN-V<*>BU Z(I>'L4+!Y.M'K4.OS_V_ORYK:19,]/L-\!T6.]
MD#HHFN EJMVO(VA)[M:T;6DDN7MF_]D B2*)-@AP<$A6?_K-HPH7P?NF\6)W
M6B;!0E567I65^4L^@D]1W$E.K5^4&U.?K\K4OXC;\2WJ0L4#'>^@0I>9%7P'
M+.]9%KM4+JE4M-#I 7-XQ,<JF6]H?2LDIY"<M4C.+3"_Y;&3@VE7>,EN]2S:
M?<L)P!<B+#R#6AQ)/U^_:,U_&D\+V!N]?CGW;ZN<]$/]=QJ4-!EZE-T2M?"-
M4QO\J(5O(1J%:*Q%-/ZD!!W<&3/*6J1HU&7F2H;2EOB\C&)"3KZ4J1+G3X4J
MTSA6_!:PZ_13=5IR4C,8.S#,*45ZM1"C0HRV*T8?X?0+C"6"P):':8;3IOZ5
MLN$D93E''"ZC2;7:\E:FI%?GCQ@G)>2R$)!"0+8<?.7D3K .6/ VY#/%FP6N
M\]/,;T3513 BB1E:C M]?FDJSN4%:Z^'M>,&GEGEWJPLK=RKC86<GX*5"U9>
MQT%Y*H.^B'3+Z\#X%M7CD\.>O1FCWK4SZPQ'GCB'H52%8:3-LR) %]4392!_
M>E(B>;RUSN[R0L_,3KE7LEY;+YRL0GRW*[YM8LU/J5Z84G:1$;%_@_2[*J7F
M938C/VU_]%)5S^:MT/!C32-GAHPY-ORF6<^$%%+MASPQ,BQJ5CXT,(X0O.:G
MO+_1+S+#P)Q21:YQ&2P(7K8"<_8=)ZF140@TI%25-]52HY)-3^WW/4'56",8
MK6N-L&AQZ(8.Z4%>3SBB*TZL[QMRC2=\97 Q:B"HI(]*J$L2T,$/^67U;$H>
M-O2>V=D)[U_IY3@0%JAQ7#YQYKLHU%&ACK:KCJY4X;4F85H29[9$TLTLD907
MLAFYR.BKQ2+N3XD:QK%)3IY(5)<M-1LE$7$-CKR6H_IF4D5<T.YZ7^F2S!A9
M >+/8#PTF49A.%%N'3YO=+NH17PJFK2>&6]#2O8C5QFW\]7BI(%&QBN-4@AU
M(=1K$>KK>0QHG G;0Z236,8H'S;K>$2P#R8<)1R\AR/9Y@OFG\9%GQ IYM(M
M)>U-K3H>$^)#"YD]PA1 1"1$>Q5=";H0^1-XZ^&++OHC?*K($]!3KM"GVL$O
M\>.&@@GH>\;PC%1#3L"+8 2$*3,232Q>#RSNQ 7$4DA!"E @OH#Q)[E'M7%-
M2,0B.N%Z(F7DX+NX:&_&KE9G[ZJN7V3.0ZAD(W]P<;TZ43_G;?2QE1W6B[+#
M/4,,W=CVC^,(/,28-G<Q)L+BD *KS8+05T '\Q'DB2"K/A$@D7;CX'5QSCD3
M7;&YGJQN?3FJ%N'6X0X8J!JW/8=T6:2:T9:Q(@CXVD60$=+X,ND*\1[)K"E@
MI2B632!L[-TJZ)+\\D[\%G4\HYLQ=I4F)K(*CHN<, 5_@O!IEG-$LS#R6;=Q
MK8XJZZK+ZDGLLO(T?ZHD=1%YIJH:.N,47C1/?E -"-+?9SP^V6=!N:,_),%Y
MI_^]R,#5XQZ8?(2Y3@K:W)Q )F..^4XY8TQ]?OQ740][O1X=0:0I52.F>CS\
MI)<K:.BXX=H_*O1_V;.(>ND,E.BG,2%76-$=#]R#&;].ZX,<E.FY"7AD.]G<
M^D:B+EYE Y9\?K<KKNX;R^D[9;E-;_8JS+&Q=QV'YICZJVD68I:4G&(%([_O
M#?_'<E('?)__]9;_<\+_<7O\WT>%1(C_4)7*9RM+7>Q&K4_R=(PT9CMS_J/;
M%:+7FW,S%PW )<^OJ-CPC)[TZ<_5APLY]HK,421D'8PU?B4^2>N^6>77BCGI
M (]-RB^:S95FLV;YFO_%XV(5[5\\JTEBL"R]IKY4KU36\,;I[SB9M;)%MVEG
M?%>[*/CNH/EN(^Y99:9A7^HF9C.&(%DHN"-CL/H0&4YKZ=7#E,NU4Z+>+%=6
MFM')<K38+RJT+E<CPO'P0T,OKR8:)UDO>P/*<UD/>X^TJ@)Y5X'Q8]&L>N-
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M\ZG%XAZ.!N $J*%F4PG\=> H)_H%< >XE7A(M0U+VDSX>"8A@60T[Y+V,K!
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M96THSB^T R7:!I%%E9>'B*GD(5K7OO5[>$D B>58EE3M6]PH(RI_B[8GC3W
M+B*H)/>EQ)N25-ZCK+)#4&%)Z/$Y*#(KJ*$8.).LY( -"=J=@"'M<==M@@6R
M C^!;(7P%0D+1-7\*<66@FQQ%9 NWK\A%Z>*Y\C 9[0:_EP6%N*7,WFM5CDG
MG11GT4<8YPATJJ&90\'QYAE,;U7.3>-5C944! F?0>#%$NU"XN,FL\8U$"7\
M3-4XPVLM7\E8#M\>5 9N*TK Q:/%\AFX8+"7R,!MK)H_FSM D2:[3)JLZFYV
MV&FR/(L5<F5WOHPB;W2AO-%-YH'.$UMM^P2+1T@#KXD[ ZI<&H)S;OSMVB*^
ML6OIVK#_MEY17:]JU:@!%GVX*$4BDFPF>DHO^8_KPSKL5=+,-CJ_SRX_?FT$
M1A$.7&<XL%Z$ P\V'%APX R=>2 L^#X=RDMT4V8<(#SKO8B.;P7BV#HHMXK2
M^,,JC?^ AV,'X7D,V;I'01*AEDN4>*._DVA=.W:'4-)\(53H@V"[JN^HSAMH
M2N:7<-4>A(^(MO)[^)? 2P6&M&)$$FZ]_$ YBM=GVHW$I52A$PK$'$"I<QH=
MX%?/]7WL5]NS@AW5.?,41CP%BB N"6* UQUO6GH:E2#;X/KR) -CT+I,]Q[9
MLUZ8*>KPX.0OK(QM!&NO-\N5##D:>KDZJQTHW8-%-$6JYV([4.0:47I<U_2I
MH78, H%A6H=Z#EH2B\8'B8UZB?<8)!K1# AW0 ;2NIZ+* ?N4':O]4-/I,%F
M#">"LL!%1)@9%/\&^12>)*5"2")^0VB%@Y-<J8@B/;0CZ5734#"]J1Z9RPHR
MM:K7&UG(K>3NYHFR7J_MLRA_H"BS&??D)>0U(-$8#:=1IS!G4X3BD9;S:=="
MH::Q?J&H5K,8[#/,6[4^WCUQ;I0>=?EH=2U$EST(*)>,?T,[T=XU0ZAI;$!+
M5F;Y.QD=J2^ VG1PV[U31_9^+A>60/)]OMWM)YT[&X&NLJ:@I&5U24D;8R8"
MBW1>I9\$)M*E#)]$(TEPV.3[R]JCG(A\K>EB-V(WB)-AA@C/_W=\@1OUH>+A
M S'< 8#D?,2=?3ZHU:;+BWZ1$9AZ92&!F>4<LQ.:W/@#$#+9,4UQSF[$ZRD%
M9Z40)RF.ZD>>?BDM%>I4*0],<AV*6Z*X*W<M3H9=<U(*%;IQ]6B LBZKJUS3
M-Y:YIJ\M E*U%P-7]V+&NTQ$6+3,8 X,);V^?1"E64*^,H30\6Q/<^N[@PIV
MPT5G><_O=L75?6,Y?:<LM^G-7H4Y-O:NX] <4W\U3>W/E?;#[WO#_[&<E#LN
M<Y'>\G].^#]N3R8KL:/'_WB0+N)9@16WL<),1>.U5F'N"NI,;ZVM+'Z[9%A]
MB"PM*JN!OIVL37GOC!<::RLP+7BA0(O(O=[=D=)<.X<T&VN#\#EP2C0:Y=K!
M*<[U\\-E84<E)2KE_5>>Q^"&9FY1CD6S-E;3)L<C2/7R:B;F*/1J8VW0E ?.
M#8T#T*J'HSRS%\['HCSUUD4A+TR)1GDUU7$4ZE._+([TDA(7!Z! C\ MS2;N
M'(MF75]+B ,G1*-\6>C5QFHT."9NT/=>JQZ.\KQ+)#<>B^+$ 2\V-*>"&(>I
M/@N>V!@Q<I1H,O?EVYQ)$QM.EU@6XX?RA3$_*8,JD4PWW;=);"<!I:#H,CJP
MH&7!G9ND:!$HF!R"397H_'@$V52U>I$3(!M$7*[Q6'B(R52UUFKK/QY6J%77
M&"\Z?N>VQG;&=$.LE]J5M5MD%OOO0'PW--V[=>S'+ H.W2Q-?R[@([<'WO=C
MDA62WZS3XU\)@&]]M?<Q=_W\_:$TCH<%]W*W'T14GXZX^$,XDDJ8!VK7\J92
MSF"SN)X&GYT0I)6$T8?]/#8HQLL"BO&0H!B7QXM0U6 [ HRX&T=\B#HI(>P#
M?P<+^>(0$$BBT=3OH,A,=YBC@J,?=5&:O5F82!O!0HGH&J&AC"US-FX0EK>E
MM,\8OEKUA-H5O:FV,L\E\5&F0*'<.IKM@O[5NJ&'O:9>8=7>T"_%L'SJ;29"
M 2)T52Z0H)=:[EBO,-RCS(<2!'D7>S.]$TP,2(B;X(B^:OYE 46I)0H00GSK
M@GGH"\TS AC)A@6%LF$5#/3FXC*S'8X@G,6!,/N(C,+-@ORYM^DAWHTI7",E
MQ]3>I%'Y>%.,:"W1-'A%)=FYQ_+C$> ]$KZ.[O3CWC/9MC:(5230/Q):RU1(
M6=TDS!WVEG&ZV 7)Q]9PU'3M /!T(I+#;G\R_@(ANT]R<QM[/7%/KCV&VIF$
MJ@-K&M*:4A)JQ&OZWF%W6O558'?J:^N.,^GO_1UX$U=&WQ7,"H'@2/U-<L=_
MD_ MTHUE?<@YFPLZ99$FECWD+-P *>_0<R\\_!.8=:'SEKZ!J5R1<Y$^4AZ/
M3%6/&;IHW]:]$H#12NO>P1Z?9Q>\D02&G4K.)M[X/<QP[K<<F;+=O@.3TP9N
M)3RG+6Y[@1HUL2XJ$](Y@GRGRUKU,)-<UDF$UL5>55A..&Z.-T;+GAR:)QM-
M6#P<06W_\^Z/_QQ+\4UMKYASEX38J_+-I:54O]BLF!Z!H;VZNV__^^[SS;&(
M<%%JJBJP]\K;6%J$3T&&SPI;*R]YL1VT$;C>ZZX=X[6S:[- +I)RNU>I\,O+
M;7W#8GL$MI?NNH]%@%N%X55HN'L%*K49RWMD=22'7#194/2 *%IXLIQ-Y :&
M?00QW0/N"'#48/A+&[WJQ(#1D5F\PZZA*FAZ4#1-WGC^/%[WMO$,[!DWR..7
MC71['*>UGG*B,F:^WCU=4?IIQW)]"]YFQ$FM9W@%O6#J?2F=\-X\H0:CEV,=
M23>37Z]7%TNPQX4C 5)IO'DI^#O,MI^QU_*^*K/!BV]<AI 7O'&U;'_Z5-_8
M6B6=)S^];>R">UEMC>UEWW-?@@&^9KQ$!3_E/'RBB#8PL#6J>+;<T(<1.D(X
M:A/-[6_B!Q=Q_7JN-Y1UCQTW#.1,1T8@ZR4#T0V(RKX0JGY MK=/]P)6R?7R
MRXFY]JKN %[W+/:.=>.KFM6Y5[4C3G%O(UM&LC:MDWX=:AW)HB/8'VQ,C=2G
M<A8J#,#GL1@:U_#LVB'UKO9#F]JCD[[!F0GZ9Q^[IGL&[+0&?AV6?$3J:?L[
M>.<D:L@RC IS53NHU2O:L/]V^)&Z0?<PA@E+?3;PF H$0E*_=PW/1!*W1S"8
MC7^E"M3N>?"[7@\)"'1Z%*- ##M !MB4"M$Q>'$UK%M RL(0/!\?L88MC^IQ
M''BV5N'*H_0LX*MKT8W&TVF35=E;I$1*VI-X-F!O4.\0']KPLKZ4V3Y^&$2F
M@9C)0=5#A<S)F8W31=(N&!@!SY?9'*=;5K6BAUCIVJ@4E:YKJ'1=V^9OL6AV
MIG[/O]Y;LZZOLZIOI@LX-^1?3G0O3= 8SG2_8C_*\J1CH'V4_BSIU7MK),@\
M[:84KTU%GSEU<25BC;%JV)&:;N0(QH67>K45>_<C^ FH?ZSG0Z.*=7ZN5KT@
MYD#K0-S7J&&UWC"TN?ZTI+U8X&DY;FR:/@G3ZL+[?*W=)QXYE;[9S:>V]+#.
M4B_K"NL9O<S;V"B4^(%O%CB 6 RKE_3J)5+R*UM]4 0#UXM@,1@807H08,Q&
MPJ'3FGH+3KQVD>,&EU)KU2O5]&*KE69JM64-+7SB=5C%JEY&A" C_:F=&I:K
M&OT )*:/A8TXF8I<S Z<E*QS[8D^^!HX5V0?RW& 8E2W.XPV<L*)-V*M/!><
M7(.K9&GN _EPL1?N"^1A&OP:](?MCDB9G<I>76?:C>R*H/QR60*\]UI#2AEW
M<KQG8)?=Z(ID,\DEL0' 0WW3;#0R1P,C,BOX9/,D?=)M7M87.>IN6P)25.'!
M)Y4NSVE98='8V?$D?6;"YGXG,];^-+#B\Q%1.]=B=EV?2OK[K@NJ"63*C$VK
M!\+JH+WU+!_%&)_UU>]!TEEY&>!6H*@Q:,70Z'JNZ+J..R1;(7P_]&;$:_9*
MN%1#/Z4C=B1@V;Z"*<6_' Y'HS95UEH966NT]EG4T-C@_/VN9XW(W,!4D"YC
MA)L>)BWLR[@(J+9L.Q:!;'>X-8B WKJ8*@.-C SHE\U%A&"6SIT,MW(XS*$Z
M2^V8.;(-KM; '!>5+&^D08KT,0UYN28-N5<;O%._\GZZ1XF(/!8Z(>BQ))TM
M@KK+JOZ2EE4A)6V,;R@P[+PJV$-J^L/,I*(6(-/R_8@2M"Y4Q6T:RQE4G>VG
MU^K3_?3+D^R55$M?I^($\PF/IW;<\*7U[\ KZ6*%Z#U3Q1YH?%<OXKM;1S)<
M3=W>XA(<0UY%?.*H3*1 ]A%FJY36BNIT+P^P^>M1.F3]2%OU0P+:NJRN +35
MJBP#M%7;%!Y6];@'/C)@#+V^&VBO:3*^"DS&D6W/]G%+M@@2M3\K7@D>:B-Y
M\SMEN4UO]BK,L;%W'8?FF/JK:6I_+CPC?M\;_H_EI,YH$J'Q+?]'-OQQ>_Q?
MZ;?R/U2BVTIX2#\72$73B[*9QD=0S5*_W"O,@)W6<*X&@'+H#=D*3M@$)Q1U
M?\F+]V,I?*\V"UF1V#NU\FJDV(7:7#\_M/:J%'*7_-!:8U_332G/8W!!,_=I
M1Z-9]PJ%;H>$J)</SQTMN.$0N*%P2;.I!\>B/"\+0#5Y@KLLKT:*H]">EWL%
M2G4L[% XI7,G_AV+7JWM%3[C+A$[RZLA'QV%6JT6J(?RK%]>C1)[X)2JJ>R'
M_KQ+Y+D>O.Z,,27/"GDA><$!+S8TIT/0GS%.<*5@"6:)TY7#I6?3E>B10=@5
M$*,%13><(570LN#.M5"T"!1,#L"F2K5^/((\*ET_4$S@]1^/:VN\ 3[$1"K]
MH@@0J-YJ:XP7';]S6V )%S3=;P?WNZ%F0=-%G-S_DX?PC1AAY[(DN55.E(CF
M5XQB<7VF"BGK<ZNJ9OTDO[94OG@]M:-1Q6BRE#I;K9JI9IW/V\\:*GY!_21K
M!-%?5P85_>\??ODQR0K);];I\2]9#<\S7!\&0\Q=$6]]/QL]'BG>R]U^$%&=
M.H+[#A%AD>$^@@%\4"DW3B9N9CXFP@8*[)= 6\DOIX\@Q&?"KS0V@C,]L\Y?
M"AELAFWGH;Z_",T="0+?8'&C70H&KB\4QFP:0QT%-(U'XB,>B)AW'B#L@E]2
M:R3Q-[LNL"YA=6I^V/$#PPDL!*M&W<!H80A7T+?=#GXZ,+PA'!5"XG4)H<G3
M2*UQ-@Z"4D((KV>_(@9F2% R)6T4PD05)JH$Z2S!W!!)S-=N?<\0=DGK> 85
M5,L'?<V%=SN(13/VDX?0]RTCI>$^(@121%KY"WIB\-KQK)Q!_FD FTU%I-D(
M9/&MHWT0'2]$\$ LWRVIU:C>  R^]&SX<K.^?/5@@:*L,4HM[IU)3-9CA)Y_
M,:0,D!P4!NPQ@H%_<+VAEI+#G$X]O^B5\W^IBG4@BX^$%%BRZO1 4 .BGFGY
M7L@P<Q+(!C96PK2Z3M\%/BLG]T/.-MX!+X&-.Q<?,2X]B,*?P$O&LT D7*!<
MV#.Z04A\[<98=_"AA0CI$=J='[VZK%WSX_.#<Y3H66L(5 HB^D;D<.>8/2'E
M7;SSU2H(FX^T0H3%W[,<P^FB1,+(C,U+N#_6$)%Y/?BB3"!\ED^ [82!B^]%
ML!HP#@F<'\O_BI0!\TB$ ][IXWK!.^A[!F)(@TJB2T$B/2)?PA- *?47#2N^
MC5P$JL1/(PSJR5A"/!]8W4@ 223B&"@26!*HL8$0B$_DDZ!%"-:,3L1)2V7M
M-_<%OO!**(.2GX5CJC\G@!7"2@BJ+'3(18'WPD1!J"('IZ<6PT#\$2U<W^)Y
M2SPE?(=M_3>T@/*O&GP9&DGF9MXA3!=F:D?ST&?G1< LF$0!2!N3$'3L$ W"
MR/ "-0O8@+^ .D!U1P2)QB\N(?_7RMJ]9R%HC$N#^A:2CLC@@PHVDDI:\1X1
M@(2!VH@$QE=<W% 8!#'*Y###+N]HQ&_(8H8_4-M#(C(NJK&@T=@@(U;@1H(#
M1X1G8@FYMBZH"1>T[(3!6./B8#!''$U.$18PP/T;>2!:H*&!I"6<]I"[&XRS
M(C*WGT8CB\F15D4)EB+E&/+J$>$2#6' (*W2WH%PQ\#6B2Y$(Q>ES2)@:PGO
MROI//!NVY!'$8!/_#072\BR[14!J!WWQ#L$+F1;MOQ&P#@G "K"Y<D-;$@A8
M2_1Z(E8LG=!':&B_I,73DE^EY5'1"6W9: 2L"%]:L-[4QA-B+;]R"/M%"H?]
M2>YND=&5VS:##ZEV2/-X%S-1#.N7V1Y/N)$; N+/("(NAWZX*0=CBB*-5D,T
M<T2?@,F!A]CJ\>*FJ'\8Z$U=S] 9U1Q\H90NL[4_=[>;AT0KAJGMH=B+ /?.
M<BS0NM$+>>[I]QE2]X.DI1^C)>AI5ID*TE>2#K[EISP9B9U+664*[E8.P^=H
MB7W[*-"% 3JV3&4ONTF,W=@?\+'7CCP'3.&:_3C%36SYQ%JG#6K^F1VSW>!I
MSH7[-B?$&RQQ2$M,M6DSXB5^YQAPK?H*&' 7C64PX)J;0E3;[L";R&+XKC"_
M")%-ZG(2._Z;9$\IGHZGO9TUSOI@W#9W#Y+-]%P6T[.UJ#7(PV6]!Y\2_@1F
M70@25M_ 5*[(64E'0H]'IJK'C*.W;^M>"4UOI77O8(_/LPO>2$[=3B5G$V_\
M'F8X]UN.3-ENWX&9#4ZX$M;@%KF@0#2<6+D[U@[]X#-RZRNBN.TL#7.=1*BU
M]@H28L+I<_SF+WN0J)UL-*7^< 15]K(_\-K0"&AQGYASEW7U^T2'I87THKY9
M*3T".ZNZGA^-!!<XF/NHRI868;U9&-H$%L.QB.G%7G'G#@EQ).[P:;5R<O:=
M5$4=<@EP0=$#HFCAN\[(5W #PSZ&P-"A-CHX8B(L;0D3E3+';PH/NU2PH.E!
MT31Y;?)S7()WD!UZJT6'WJUWZ%TI-W+&E>3X=167""4RH5?,V(Y2:F7-V-W3
M5?2V4CK1NG:"(^$E*<BO;1L>E3N\J5?2/>L73N"^G#.!NY1IR(WE;?!MDA:J
M""4J,3,PO=JV\;\C(*2(WNQKL( ^IEO#5X8L$L(W>9:/::J<M2_?%!4B8*D8
MIJYRSC]6FEB&;6-)1L\7E)TJB^U<>A!?2.4@<<V1*K[#%8N :X[@#3,KQ. -
MYR,CH#(\Q051#BRL>'8-W4:ZNL_@7WF+P]/%TJJHM&Y\L^;BY61%AEHU_M$.
M^R%P#+")3E4T6.PV=)_Q,5!<+X9G<KG4R#8<8EN>B$83U**Z[*@(@S]?GYC)
MP@@]+2J9AO7-13+AT[( )ZZ7 *58>W;M<"CVCA/B"X%U:S!%VDP=08JR&;I/
M)>W>D:[]Y?'IYOINDA@) RM.D?/Q7U<#RS'B+'C0=0%1$!;7'8 )-[ HT.U:
M5/! (O%;Z 0@)X'K1"63IN6CCN0BR;RA A HK.<P7_VO6"EE&24NRT-E:OMN
M:H)<5HS58"B.+**I@E +I'.,O^6JQY;[WC/^MFP2\JZ+,P<!H'5@8KUD'S_L
M#"W?)Z6+(F%XEAOZ61F?LLVMO2CLR)<)[C-WS\ 3NZGH2+:Z6T_9&&SRFVHS
M6S5F:*9@<XU/9@J]WE1;"RC,[4MUBD@\^)Q%+E-)I2A"-,"N="=I*X*-R4YF
MD.()*R$CTB+QT]9DITX,UXZNKV0LX0+.].UP<4I+=#U7@(9QA^1_L\_GYSM]
M<[J6A'>0G,/!ZB!5]'\C:\EWI(>RS>&X2ID,B[L>KZ*:==@6*63=ML;Y -H%
M5:;?]:R1*EY',HS1:?J)T!="U5222U!]]R2>#8)"B&HE'QA507X/_Q)8MD,"
M= VNG>V.B,2G\M5G$:NH DU9DWF@ J Z:^U8 +(-OM8O )>MS0C /F^N:N^S
MX\W-=AE:_^;6LN7C=)B./:Z+K,=UN2:':Y]WGYN3W%)SDAWM?+(_REIW'=WL
M[)ZG=KB^T$$Y-<]ICR9]3(8+B7PB$02V4%AZ72',P_6*=GHFNU_H--9E6"-"
MD>@G#RJ$:I?U%TI:UM"4M#'M1(7XSJM".$PPK[(35O1^Q&)8%X#B-CVLQ8@\
MARSJ]:E'WEHS<[I[HU\LI(-GG?1D##VU9P0<Q)^G6&.J@!O^7$Y!K:QNJ [R
M?JU6W*]M_7YM-4W.)BJ%@;)5M:P0O5C"?% :"/^%]TPR %["Z &\U9*FT3=X
MK]KWM[Y4FY[)40>"E)1J$&.?B."5 >3SA?=L=2-M/$=()@S.P:2!"H>?1S$9
M4-H]!"YT>ST%8(F ACTX_KDXN2AH@SX)K2R#7DFZP$%Z!P//#?L,G&?T>I:-
MH6?MDS MT-^(]<F_3T"XX-U-PA1$8(4IS,Z2 NQT9VAA7QZ(.XA7U'&?=W U
M@JOTTBA;V37/$XK0+Z?:BFIE_'YV;8A;<=2Q\ZKIER?;)R+( \G&N%#,=3M4
MFQY;KEX0\6"V@S0%48[R:3/GG3697'"+L@(2H?>9()*@IK\2HP.Y*>QJ8PR%
MX(4#T!\F;,20(4'1,$<RA:^]NOOC]OI<OP1J &6'5G<I]WDU)3LQ/+2$MEUM
M)@GLXNU&(N<"3I.G[E*SF3V$;1 ?KWXR*W&"5%(_DVJBM*Y4LR@'T_5L;)LL
MQW&?"<TN'BTV<NIBC[#)\)H]%:*GN;0=T\A':H[2 /+"\+;[,O>R)@P[1<O@
M?-_??+Z^^;U-?S\]W+0_7[>G#LB8<^E8:OI!Q3@E%1=-/RRI/^.IZ3C>ZC<X
MZ?3OLLY1].1N[.1-"NQP"'.0!CR^+)X0L8Z30L:0#_. %;T$8MX;O9H-<<XI
MAVN'$]R,<L[<%^_NHGB.XW"IT9INI^?-%=N/ZUY<5!VO:&=<N"275+\H-Y:_
MO_6 TQW*0UO#56<R&@P3B@%+,=V"E2VOU^@@]/?KW,H[3U&K!*%)>K:DCC2A
MTS.>78_.M/&EL)+[V*?.MQ&YMF_,).U 3!>X0MNV%-\EKA S4)MYYE48L IY
M\Q@=PE1<CSSL4TMV\S4M#V&7<V\XY)#XFF%H2R!I PS<JVR0((*!2[#0BE0E
M5+22%0/AXT"E)"P[S*ECN>*_H?4,)A[1EV,AZ-J60\/Z 1@2:>X3>1!X<'7Z
M/EO14TLM $B:7D+<U8!%#]YIL74&]\9$N%P_4*C8((^> ?]$4%^/)S."$X'K
M.,+>S2EUPBXG'+HA FICRA=-%\CI6S"<X<W/ 1%=3,NG!AF8-,N\C[$0$>U$
M:F=-+^RG68'RWL[Y@ ;F]3SO=TQ3R4B(4:Z(K_(OG@A[FS;/M *"<,?P@T?]
M&R1L/*;.8;3%ZH2< @-S%$ +DY5'%T^*'5>.BSH'1$+&-GP:EU!OO\+0(]L@
M@'DZO;EAP"CIB>G2%4@:=SR2%5ZOCSB/"M?>C\ZL,2UYQ3$5X=P);/DNP;-#
MRS1MD3-2_!O9MT +1R2).(16HS&L,Z;V^*_E4XFF!_$B&'+>T+!1 .VD,8K
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M?3"EY0$IHED2NC<]#U .EF]Z4*TMT_1 /\DMH)=?7NYZR&DC7:Q_<E%#A>/
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M=_M4/U-;G0X616BE>7<XS:6O<-9Z11/=RR3O++.70IE+H_G,>M90\POJ)]E
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MK%6\%^T42&Y;?\OQ;F",U69G]"R[@[E-HX#3M1XMU(+62H/V@6A#.44CR0M
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M$[+[7BE:^%M/+A;),=([USTJI/KC,A<7EVMS/ Z<$I?-O3^N'($+)CL-R2M
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MPG[=/L:RVG+B2=Q0)@A)7*6LMQ:0,C-_*)2Y2KG5G+LY3&W_/;\K3%HB1F%
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M#'[Q\SBXEFTYXEPVH&N5$QA.^9!.U0AW+0+O&'W+('=(&#,] 9=V-!AP]3D
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MFF%U@""2(,/,4WK!YFSF(R=P7N!K1VG;"W42R6J%TT44>BE EU%H2P?MFMX
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M<6^^=)K96X$IAIK\!B$:S8N'_P902P,$%     @ @H"J5J\X1\V2!   NA
M !    !D-#8T-C,Q9&5X,S(N:'1M[5AM3]M($/Z.Q'\8N:("*6].@-*\6')L
MAUCGQJEC*'Q<[ U9G=^Z=H#<K[]9VTE,#LKURL%]N"BRO#NS,\_,/C.[<G_L
M?K&4_MA0=65_K^^:KF4HQE6]T^XWBP'.-DLQ](>V?@W#<\VV;&<@?1N;KB$)
M >SOH9Y&HXQRI:^;ES!SKRUC(-TS/UMTSQHG+)* !.PV&D@!G6?YJOYTK182
M?LNB>A8GW5:2]: <W\19%H?%U#R.LGK*_J!=>3N>DY %JZ[+0IK"A-Z#$X<$
M/:F6>3X92)S=+M!5?Z@8#PMVPS+HM*'?'"K]YE0$]I3_]O$K O#RC.0(-,-Q
MS9&IJ:YI3\ >@3LV0!N;Q@B,*T.[<,U+ Z=1PW! G>BE;&1.U(EFJM9&]@)^
MN?WOX)]>.+,+=>*":X-\!A>-64-KP,S0\GCDSDFK]E[0U!FHNCUU#1VJ*-?8
M/K=.U_F>J<Y0G1BSNGUE&=>@:JZ0M%NM%VGQ*M@5,P(OCB+J92R.X)YE"\@6
M%+XN"<=@@A4X-(EY!O$<7'I'8+H@/"0>76;,(P&8D;],,\[0J,5"EE$?#L7Z
MCQ_DXT\]+0X3$JW$X*QW!.A@%/,0XQG9F)!U02YP63U-T&@WBN\Y221%;M6_
M]IM"2T'X/(>44,YB'VCDHY,OA'N+C]%-FO0Z<@WSU>X 26'. A1NHIA1;\E9
M)M"1R ?CP5N0Z)8"X@I9FHJ(\2\T?9)16%!.,<Y* $7P)?X:W-,:. R-<!_T
M!HPXB3R6UF#*:<I\W/[<C;9@=([.T'G&[BC8\SGS*,<4[N\)TV56:@6F@,%O
MV(;FM7+=B$7"*N9VNPX>+<.YC,WQ)5GR=$G0:Q97"@#1GG[J%?3'E! _3L2V
M5)4+%<'"TO:,\!L2T;1N/P1T!:J7;[A@80WE).O"+A&W)#M%CNUTR[^04E**
MO1)60'1U=6@9:U-#V]$-IXXMW%*G,Z.[?ODA<W=I+D%A9B"U)- ,RYJJNFY.
MSC?CV535UN-OINZ.!Y+<:AU(!1X'TFP54!B E)!;6K_AE/Q>9Y'8UBZYBYE?
M*NKKQ<<'VZ!<?4=X<B#!9=D6,"F;%E$<-(?R475-5?9HE5(YC^!QBN%7*[\'
M.Z!<I$%9Z_-E@(7O(=\"43J;<N+T^Y)Q&B+14\&/M.P:<N>08'5SD$\._:,-
MI[;%MRF\@EC[>_+GSG$OY[]@1)X,?#CB(9A1#?Q_HOT"T=K_4:*Q"+MZ2'+V
MX/&3$19ABV)%+UZSD#!Q_B386P7A:D),@@#AX,$D^B,*$F1@6LM7S3=]$PWZ
M+#>-!-O?0[5E4! VQC,D=YKN--7&RSQ\]9-7QSC\+IYDJV)WY59YCCW?:G/'
M_ZP$=IFYR]PUV9"H58*_:N4HXDY>5(%2ONB/2V2[ UO5-89GR@5^$D/I]CGZ
M__C>+XNIFYC[E&^G'B"- P3RH97_?I(&S;3YQ)WB,1W?+!%/ 7ES$'_K-O4<
MKHJ#BOVQ89Z/7639J?0>:7UO?FTNF>]$JXK_M_>]8<XE\F9[57_VOEWM09MS
M0+SJYB7.EY\4BN[4%)\?<#+_9O$G4$L#!!0    ( (* JE;I?2+S0AX  $!?
M 0 1    =&5V82TR,#(S,#,S,2YX<V3M/6MOVSJ6WQ?8_Z#-ISO IGFUO;?%
M= ;.JS>8M X2]\X=+!8#1J)M3F72)2DGGL7^]^6AWI9H2[1,>];^TL82>=Y\
MG*/#PS_^^742>C/,!6'TT]'9F],C#U.?!82./AU%<GC\R]&?__3O__;'_S@^
M_HPIYDCBP'N>>]>W=U^]WR\?[[T[*B2B/O:NF1]-,)7>L3>6<OKQY.3EY>5-
M,"14L#"2"H%XX[/)B7K_6XS0>[QX<ZI^JK_.3H^_H/GQ^>GYA?=?IV\_7OS\
M\?S#?WO_\_#E?X^/@0#AC_$$>1+Q$99?T02+*?+QIZ,"*HEG:#I&?*+1 *C3
MBXLSQ5"(@:Y;QB?7>(BB4'XZ^A&AD P)#HX\)0$J/D+G1M!T\U++EXLWC(]4
MD].SD]^_W#]I2E.X(:'?2ZU?GWF8MK\X@=?/2."T^6NE?0+][,.'#R?Z;=94
M 2)+0)-$,<7V@<PZ%!N_.XE?YE0L@?O[?8&(2!R/$)IFS8=(/.NFR0L0W'G:
MV&<1E7Q>)D%@_\V(S4Z2E^4.$>?*'$T]DK>E+@$F]:W5BU)#_.J/ZUO"FU)3
MBH@OZMOJ5Z7&@OCU3=6+4D,E(3F?8E$K._VF#%=.N0&P>K,@@RG'/@Q5HQH_
MG"#N<Q9BA=67Q_AU&B**)./S6_4[P\EEE3KUL$P8ER9&LE=E\B1?Z%"B3KT^
M@=?0Y_3X].SX_&S!VHY%-)W&@]IH>-!&8_UQ421T6<_D?=H+9AU$*9,(YB[]
M:SHE=,C@3QB('T%^ T6I!W]\>[Q;,G]H45\Q-=,^H)$:DD2I)O^900RPFBZ)
MQG>FIA,U-Q9F5=W>@PY_/%ELG0*(! [Z]$_Z;V4$0O74Y,.837HE3>IZY ";
MM?=1Z$>A&<%)24QKR V6$!* 15^B$":UIS'&4J1R-+TVR/5<"?-)R05G@LT!
M> D$+P9QD'0LAP>DIEHYQI(H2E:(O=S6H(.+YCKP?BI!_,,>ZR23F.@/[]0^
M;8+OF:@9!H9V!EV\7::+')3'AEX,S/L)P!T4L2C@%:.D22>#BMY9JN@P=FJE
M?\4FBL<QIH+,<-.!9.ID4-G[YBHK03Z,L3K9CQ$=87%';WY$1,Y7*&JAL4%!
M/[=04 S1(]2+81[44B?I%O/?TIX&A?VRAL(.$V&]&I 8WX;L9=74ES4SJ.9#
M"]4H6)X&MF<ZN$2"*%D^%/B)I5[WHE[.9Q NNR;"#YF(.%8_=%\0:U%,>R;8
M*\PE(G3 $17(UY'&Q)QK7A@$>[8HV*2O)PN=]TRNCWB&:81O.9NH\:P$X4OQ
M5R+'5Y&0:H?"$RFO;F:0^?FBS!-(WE"!\OP4EO>B@'E^"FW/E'!'E4PDXP0G
MXBX^, CV8E&PA3[[)KY L4&&!#V':L\NU:Z J+]Z0F3AHZ4M# )^6Q%P 8B7
M0_%B,'LF\\^,!2\D3': V2^#+-\MRC+ML&=2N\;/LO\<DA$JK&"+#PTR?+\H
M0^CGL;SCWLF2DYG" GZZD%Q'T$6/!K_B8$3HJ*>6\YFB&F=2;MK<(/^?J_)/
M(7HD!^DA&GCC&*B',JA[IIQ[/$+A$Y8R_A #@H90!^P=E%PP]3.]-&II4,DO
MBRK1P+P"-*T-@.>5 .Z9-J[89$)D*MX:)2QK8)#]A\IF.H>AI>[OL<#C\-X
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MS68$ 'OG;>W9.]RPEX?:@@Q=K^]U%&Q&>S?#(7YE[J>S F;'&Y@["H'-7=K
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ML%.VL%K!RAHW!*@RTA6'N6O!DW:]8-QA0IETHHR;@6)3SX#8IR-89%8!74E
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MQL$R5*FSX^H^3I%V,+,*JX%:-)Y=P>UMDFFP_J6M_^A@EPK%LSN\GQA0E9E
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MH$G*5)M0/(L\;0C'7 >@O'F3@"[GH)8J@Z]KB1<*B:^MA'+E6Y:TMJZS7F'
M)D"V*X\[!:8Z@I1AP-%/_P=02P,$%     @ @H"J5N2Q%V1PA0  (:H( !4
M  !T979A+3(P,C,P,S,Q7V1E9BYX;6SDO7ESXTBV+_:_(_P=VNV_>UK<R8DW
M?D&II!J]JY(4DFKZWG X&!"0)#%- AHLJM(X_-V="9 $2>3)!<@-NH[G.UU5
MF>#YG9/+R;/^C__Y<[OYY1TE:1A'?_NU]Y>+7W]!D1\'8;3ZVZ]YMOQM^NO_
M_+_^]__M?_P?O_WV%44H\3(4_/+Z\<N7F]O[7_[S\NGNE]LHS;S(1[]\B?U\
MBZ+LE]]^66?9VU]___W'CQ]_"99AE,:;/,,_D/[%C[>_XW__1_F#OSP-_G*!
M_XC_JW?QVS?OX[?^17_PR_]],?SK8/+7_NS_^>7_??SV__WV&R%@$T9_OGHI
M^@43'*5_^_7H)WZ^)IN_Q,GJ]_[%Q>#W_<!?RY%__9F&)Z-_#/9C>[__Y[>[
M9W^-MMYOX0[%81;Y#&U>;S:;_5[\*QZ:AG]-B_EWL>]E!0NY=/T"CB!_^FT_
M[#?R5[_U^K\->G_YF08'NO"8(#O\S/$'1K^7__@K85<2;] 36OY24/K7[.,-
M_>W7--R^;0C"XN_6"5K^[=<,O7L%UR\&Y0_]GU<QD5<8$$E?>AO"E.<U0EGZ
MZR_DH]^?;D] D@^\K;UD6\B6C/B=\87?-='VZ"5XY:U1%OK>ICVA9Y]32/5S
MAO\OV27IP_(6;[0MNHO39JR%/J6=VO;,%OJN)AQ7\?8M06L4I>$[4B@"\+NZ
M<*R]:(72V^CZ7WF8?;2G__Q[9NA6NYC8']>%R$O7-YOXAX(U5'VI):V77AKB
M#SXF*,6?+NXF8>JH<]OR#B69%T8OB1>EGE\H ^+<HLUM2<\3>D=1CFZ2>(N%
MD27XN^D?8;:^RM,,[]Q$G#J!+[6D]3;"OY#%28C$J3J9T_;W _RI<!EZKQM\
ML&$U:17B_YJGJ8Q2P/Y(2PJ_QG'P(]R(GQ_5A):__ 6]9@^OFW#ER:WIVKS6
M="3A._X6N7K2+"D4\70>!7]'P0KK\G.\;=[#3&8%27RQ)>UW:.5MGE&6;=#^
M1\C-2783_B'\')$A6^QCK6^"[3;,]M]O1BCS&ZU/#*)^O'@_I4Z,HSDM?_\!
MW[E)N;=OMV]>F!0PGQ!91WZ6)V3]1$$QZA9??N)$RG^X)9)K+XGP1]-"/T7)
M,R8'"5-+G]R2HKF/G]GYAJ@.!<ZV^JSP]UK2_8Q6A;"$":LFM/SE&[Q._N%M
M<O0->6F>%.>",!7TR6UY$:XB?!?Z7I1A]L=YL?<?L49(=O_^?\49)?8U]1K<
M"[G,6^EQ^R_HUN8D*17^GCK-3I)"RDR-6IXL<0*?4J3Q25)V/DVM]B=)###;
ME"8H3:WD=PWK$))PFG[>S.TM"4;RJXIN<DDBSZ=IN-4E*6)]0OUM64CF^"_F
M01"2__ VM]$R3K;%,? %X7D2AK"VOZ/[YE4!LMV/Z$;XG&^W7O+QL/P2IMYJ
ME:#R/']8[F:FEQ_?O'_&R>Z/SUF"O&VJF@7MJ-#.(W^-@GR#'I;/'MY>^)A%
MR3LBU\=\LXE_$,^+>HY(_*8Z/>X@AZ._DT0F^#6-^E[ULXQ!LJA4_9Y&W"H.
MJ\;?5Z01'WAY\(6\K-&5ER0?1*79DN?APW(_^/)C=RM+@E3S8U81G_B&C,*G
M_K(B7JA8P4+?4OMR.CJKUW&2O:!D2T9($B[W46T(4!3&R7V<H=+XC!4Q93C@
M3QM$TV;GM/X=M3A5;!>93YIZVQ\.)LS0@I;R,$IOXH2,14'QII4&JN77C?/D
M:N.E:6$P)=3AH8=W8(K59]KGM#.J.4G&N?>8$"?15_SH+/P:*"4:>/493%@:
MKB)BBKB-]O$,NZ\]H4VY1];AFWZ>JB;4&*</9V+QDC^B&&^GBNAYNIMY]+GC
M6)*;,,)/G-#;/**D.(?P>X<LK,-?QVEQ3NU#%[7)PRX<4U)3<Y.H^#$#WG@5
M8%O_CCX?OG*L2GY+']YJBW[#&RX)]]I6$9T9X#47Y">B4H>^Z2^KBX]0\N07
M_)QAC\C9R2LQ4Q*_><(,<Y+X4^)H'^>;XG6<IC&^=?"]14R.)Q,?-UZ$%\0F
M)SD4Q>!"FT#!2WS],\SP=[^$Z5N<8JWX<)YKYK<I\DVO[[VF=SK$]Q-\:&A?
MPT(_;I@C*@XSI;^I(?I*!4;I[YKQ^DJBD/RJ&0QMC$-M?D*13_NPK?>VVB1>
MAK)V2+&/J::X_/K!RDQTK2?DQUC/VH0[7^#^G\JA+_%Q'D+)WTN$USXZ4FC:
M0M=+E2H>'A22,V\I)BG IU[A-&QZ6[?[$44(59R:0M_2$-5Q6$N'QWZIU7A)
M$J)@GAWF2.)1\EL:\*J0E?1WM<IM_X]';+T+O5=\!)"EOIL2?$_QG7R']\9F
M<!N]Y=+O3*TTN,B?-G>M.8+,G @'@]F>N(=H7B:R%>%0:R_2?$PT(*"U1><=
M)8_>2CPAX6B&^OBVRQPO!Y2F<_]?>5@:8RLUH+CH"B\'\6CLHB&BX&A1E8_.
MTA"\"6[BA$3MM(^&TTF5/HN<;&0]_TM2M))?2_?E!99>^EK4&,C3WU:>]_8[
M!M'_'6VRE/P-^61*</4+3 @%VSK9M4\45).QOU__S(A^CXF\CO#V28I+Z2Y,
M#WD?7N+OR=[]Y_&7#P40PBC[/0BWO^_&_.Z1Y#X1G)12#/M*"J0&PZB Y1U2
M!1N2@_^;P(RCWP*T]/)-II XRK<5D1IO\6[20^GNTZT(+;[QVQ9M7U&BDLK3
M[[8A<8VI2?S\%?UV@*Z04.K7VY ;Q=E<Z;[9?[ @"J_.,"J==/A3)S^"R"F
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M+@96 ]R$A22  A"368/#P5E1E!UCB.5TX&*@1VD^*@+6TK%"H;>L=?178@1
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M*\X26!K5H$6OYYJM F;_.=DN/'^_)J0I94$8@^%'HQ:S[JSW<[)=>) ^G&Y
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MWDAD4M)G(W>B-K8H$WAZI=1W,'ZK3V?]DF?A=J(6]Z% VN[&N<07$MN=!LS
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MUV6>8DT67U!E$?TBQJO\%U;E!YG/+$:CT<Q. +NA"T $/"!]PW74CI;SE[
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M';"_3'2U>6]X PYK,0< S5W0+H8#-V] 028KM;\H*#%8WH(?8O89D6D$I=4
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M%^]/%'".AN,QNW96L]'$:IYA<R:#8  FFWV</^>O*?I73HP_[R0+'/\4YXT
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M<BIANF@HO=IX:1HN20U6(I@HN/'"Y!_>)D?I\=5T]#D+35#V5+#LHXS1B]Y
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M6AH(]IN,+N<V8%WP6K9/!"+\F;EIV^&)#@;C@A^2M[1>$B_ ?]%Z/YY\I^2
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M["%Y1LE[Z+,,.+2A^)#IX#'(1J.BVE ;69"HTQU1*5,7!L=C'+9..C9K03%
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MNB-\AX49:E4?3M:5E1=R2_X+8%+@; 987]A7GE&6;=!>E2$G/E'1\)9%^&I
MH!Q$YA( 5F+?5 A% J "7S'D!#N<K>D3PA3G?I8G9<A5L6A \7 G$N!6O @J
M9".*S@7/L?,Q0R--[0_MQ Q15%'ES%(8,V0V^5=3S-#HXI/$#)72I2X>$1:X
M4$R[8:#*Z,+QF*&"P8!H*%!<*(/=7!2VG6\Z9,+UR1DN6[W9%*K"'A&_\ %U
M H;6=R&8^V3Q T\\%@ 5+G]-T2ZCODNA6Q0&<TA7X? W$B,WZKM@G>0QFHM
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M*&QOYU-?71Q=#PUU)BD$Y?D2*?63H%W9^DBV8_]8>-(G?BRL3YXNI\."075
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M]V49=W^C#KJ!N<IV-.D%82L%(([M7+?1(5L2&$C[;%GZ<KXP7'? I0WN#JR
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M<*<E%!&_$O4SCI+X\'>8B3^O;"R#^0/-)*)C4$LFH@,0-BBUJF+G4!-C:XP
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M%)%7+"H2PJ7?H'HWAP*ZK:1#T8RIM3GD-![[*ZV])WR==4@YC<HN2D][2+L
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M(A[BE F?N]?C_&GD414E<XEF$PA&EAO+O$#:Z1'&I&UO1U@2N%)1K:=0^0'
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MS*('67[(86EZ]P1:D:ZOE+INZ%9"MR6GQR1!"RZ=5$BITTSFN50ZK2Z6UDK
M!>P!!@)7KX(W"+68[OR/1>K'*8+AG)WAN_?=LO9T\Y>=O8!@N'Z"5Y(M.QC.
M [J>/GX/W(*?B&LA0O*FW\"CY^G8JR>DD[*?E.XCYJMZ;%P1#&=23_Q3]#!Q
ME41;@UHNY=S< ZRN,W0/I"YLS9QDK5SH&CG-VKBH*W!_*1U7X$M3R/YH';X\
MXCF*Z7TFW=:BI*UP YS&J;,0D0\QEIO8)DN'EYB3E1<R!2F1M/@KW$"94AJQ
M."%1G-6N85@AV]HD&YJ/V(E IXO8"3\@#\TA7V-5DIP[FDBVG*X8&PFHS\7*
MM^YW*)H*#(G&KSF*E=I@W5@.85]P7U>+_.8DB.JQN?(F18JWD"1N70#3729N
M=(VIQA"DC/=ZS>>UB)IPN#:Z2<#J)SCYUDM6\M8"*_7VR&5X?8>_F;*_>^Q!
M3*2)CVASRQXBMF5K$9%;U2*/0[;F"G='G[(/G)M?'69T7+> IG:D_'[X%!:L
MUF6CHGW>*?E%=$MDOVBW8W,-QJ'6(::YG@+L;9,^!=)!-+W\JH?'V] 64"=-
MG&HO?DIM64@1=NOPM@%C'=L1B_]IGGU*E @-9&[ ](REZS!.CPEUV>M>U%!;
M F]IM#B%(@=<C9)4I//:V.[HYM%R935*M)U./ZPU-CT(0/,*(QX\,7<[OL!1
M56Z-[(-G<D^)])B)B& 1RL'_+F)+$QK*8(Y#D&3/C6DDFPJ> 3_KD)0O%"$E
M]]*T\;4SXY__M@YB\9G\=OF/M4"S*LPS79'@(:%4G0J_LFS7^+Y,ZY36=B/K
MN"S<4"-<2?ZCH C/$_^2W8@O[-CA5?H-_P[9T'2=L$,1]2):U<53O01[L0+:
M?Z>R_J/<*@31<RV!M_AQ3[-=+.O-TU2\"V7\Z^(8*'KBQZ?4T*WRLH@_\IW'
M(XN/:5ZK?J4JM6^J,&XN-UT1^G1@^0ALY!]4SV+?M@^BB!\]Y?$TR_*IYKTI
MP8KA4L-<CE$QU:LBY:FL0+8Y4A%PS*$A^6M-RK?D8EMBAJ-$'GLC*IKO8S$'
M\@@L?Y0O5OF?CM%&!!;$^[T8_:^<3S$SDB*(@@?%&=?IC*N"["\3>"W_D(^Z
M^&:5I8>/RC$4<U'>P01AF8MP58=K#L+4 )3B$W7 $/I((\)D P%V_K]1W-2%
M>YI]I32J1D$.2PO[09C&Q;?S2>"S(!P3-9R5P19<Z$V1=%%D5>0S3:-4A>S3
M8+U3@"@\$#1((CX(:;%CY41?);>U>6%"2_=T?Z]0$9"')#X>>(L@XR,FWA4'
MS0@N\=F$\N&)VMH@P*Y^#>NQ7AI2^$S)T#+1=XGWC2R=OC5(H<];)<\J5PL^
M@.P@6@CO=RI'/^\WU[?[9RXZ6^_TB+0>HRS&*I0;&?%#G/<OAJ[\G!H]!<X2
M1O*]:UDMOK()J3(*?*05E]^2\Z=@?PC5JUF'E2WQ8H+;J^ ;/F><2JG+_B ^
M*/-?<SU(C_<IV[ @>?X3>77_3?5OICX:%/JGZ'FC]3>*_TJ-13_5D"M%_9/\
MY=7FF]KLPK\ZOQ%*>:3"7WLJ=)8/S5^Y)3L]IEF\IXG'4<&[!U#_J:]4NC]2
M4BJU*VB5<2^H%W+>Z#ESNB>RU[0M 8P^?B?_+I8#1]<&TPN/:*>:J05<Y\3Y
MKG6=TR.[^/N!LJ>BX?B"Q#/OB'?[7.VM/$R]DPJTW)&+>U.V.]FZX0E8A WW
MF :]^$_G'& AR,<^N\EP,>0R4V80H1O>@5*@E[[JQHX'[G%,Y\]QO/G*PE!6
MV<GXZ++[D*K$5+V,:<]^ %6CKX1ME!7T\H!3]5"4QEJ<%1XTHVU\#II.($MM
M8\?/8'M0@]IM'VETP^="X0+,^""A-L+%L&4RJYTF(:Z!]X:<;N>]\09J[OMI
MC9,*P93[ :HTW(M2CF$R+&%!Z0%[#\  5=V[SWIM8VP$H+7V+#SKU9?NL^5M
M/]Q#KM>@<XTW D9\S*&5 @TE+A.BP03=!/;D/;X/V4. %B7@B1,WLK',7\(>
M^<@]THN(:Y:,'!#9A_],-P^-%R$];>2(7D%59(ST.A2+WDBM.WDHS#NLOR5>
MH%D>#04=X:-QL%0M\%L%QG2[;#UPV^2ABK" A0=O)%Z8\GNL;^/A#Y-7*][O
M65:P)RZM.'LT6O==]GKV YDGJZ>$6CQF1:^RV=1[6-Y2-FA"M?Q,0V83!*^7
M]"$(/P69L&AMUGS6)4]Z0'SZ2M3&I:0C.:$!F?@+RCC);LL(3"7=99RF31$Q
MU:P7#MOJU0N$RUD&?/2K;T=+6PB<D?G>*P&ZZDTNZWHIBC<,J8,6.*QPG;S>
M?,]P'0<5Z)6=BWO]JDZT)KSY\C92'O.@WV=U3@(6A/RN?UUDN"!R7_@:481N
MA(>)D05/V!$[W>CQ0/X@ZVEY\BA39IVK=P;.;;ZS-=231BNWYNQG14OL%XL]
MV5:I30G;'P*6Y*_(9++CXSH[)C)W5)G+@V5TC_>(T8V>QJ-% .AX/5*<&D(@
MR\YY_J#JFB:WN\!OS7'0 "XX+L[;(UZT);PQD:T7L-0,$N"5.%)_(]\W2B+,
M1:<3.^T5IQ,X,)#_^Y%ESQ[[\W9#2'"W>=0 (1LL9-MM'E%M]HW#"3+EMQD'
MV2X.-UPO%1N?XXSVVVGWZ ,0*'TD:V.H3OLO)$>4( ?;DGNFO1DCY,F:+]U'
M]>XTS_,>[P\)W?'%5]QS,;6#?Q4*NXJI1+TQVM:OW@"%43WZ('9.-[*$AKA&
MZ[:[=A)(Q;+SK>F1:DK*M@LQRUU#KP&H8]Q1\-+32/M0(Z+(TS!K@%J4CV24
M4*ANDA[@ZE(.;+OZD9_@9=F.BA&?4AEN,D#-Z.!?JP+!FQ/9OJ8+K@H7D+#R
MF8LVGGPF @U(/J:V@PX92BY+9,,2NF$=),BC%&1/ ]%\;ZC0A*T)G:;5"TD@
MNJ"G@O0PJ2XB0"UP\FXX%>D)3A=A2[NGH V?[O$'JL[QM<9)$D?\/]<J%D;R
M]:S^KX]I[=\5:*6.WG+JE2R^-E+L-CI9*40^DU_R_S^G6=[0+8MD!JZ?CVPC
M<GO-*[DH:AYEX3,)-O%!YNH2V:?2]"C^LQJ10Z-SW"H>PU"MU_(8!ND1%Y#%
M6%_(X;5]_7.<_0?-3M1T=*OH9#U#76Q.,@I6&*M>[<HLW(F$]TSRKD&4NOO:
M=-Y!Z=+GE:B@0)[YJ.16 .V6=3H5:=S(+DP_O&YO<2'11D3O1(,6&WB[WM'-
M,:176_5:_R3:7%:5.?Y,P\W'.+D-0GHGDA1T&K[!W4%9N^'R:NZJO"=RM2U2
M4IR(B.:J-R*Z([P_(CKDQT>9YP'7L$TH_W&_#Y)GD4'S4_"?7,C34$2/R)2:
M^7@$K?&X*$KJ!OG8;/.Q0;-O(^'?,&I+P+Z7)5NL#HRQ8[QW46Z<)H]4"'02
MAO%7F8HW+TOM:;_Z=@-FMWK+I\V5Z($47<AYJCHIBG<OQ$B-%[8R3BVY@X;<
M>(9G&%Z;!@<1K'Z&9O0\\@;',$CJ2<M%'G<YI4E]2H,*RGE.:_A4S&<L+3*9
M\T&YVN:)0SLM3T]ZR'?4GA)ISX0;=&+*BBRQV/9EK&0UP[*INI!HE!VD(NWZ
M7NZ'\K^0-$MH@!,I.PB9VK/G/K"$"0$H-S!E4DG?5;Y_%Y#! /YR67=BHL9J
M0;Q:S+(^A825YBTD"VI?&&H1 STQ"*Q;'X7CFUZR1ZHEQ!R@9CUZ0]&X/M*Z
ME$_U\UIV9,B=NCQ%'"5X32<7F\MR!*+M&ML;SL#*6Z0C[*>D!BH4931Q[U*Z
M,N_E\M3+2Y1*C4[K57(H.0V2Y%EFU2E+]I2R\HUF'G.V#.VR0LZN15:\C? $
MU:LRGS\)AR,?O].8K[!))I14_-W/&32D)RA_T" IM9P<HAKW75%LG)3]D%I'
MZB>E5LAO&2>1N6XV;E6Y\L]EN?)+4:X<S2<T'+D-MQ R;+T\0Y-,Y0E):Y.Y
M";) 14M$VSC9*\_#0=6%E.4&8UE]_O5&X)G5DI=Q!' K*\QN?OE*2SU8U_1
MT*U4Z;*R;A[+-SWK0-76DT4'5V1+91$T_E_K.!0O2Y) 5-+[^Y$EM=PW^2O:
M&K<17=,T%2L!9S8@6Q&]5Z^\#._2JDSU[2Y.LF+*^NTJ;*0H6PNK'$Y#(8A>
M9Z6E7-XV8PJQEK&-< /-OI=PHPQ86^0+[BI?H @+.*.B9*MX9G:2YAD#:VD$
M;XORCZD\6ZCJC]<TD<:!C^!)M*G^G->$O(R5W1EP&D?E#T7O<6?$GD=314!5
MK*B[<95*LYYB<WDFYX6/Z#*LW0(,A=VD+L!*C#@(5H\%+J+\'O$CY^-JR\7@
MWPM"=::^VM8D=(OG=VR<_[M0ATR $33<'!87O1<1*:Y_Q5=%C$GQW<(=PO]4
MU_N:SI\LTXIB#6O-P]0:PU0&88DNA;\:-:4/E,(V3LLO2EN]SM;_=%H[48B8
M=5RN$YH%3S\'+!*Y<TZ#=/<QC+].;OZ'?@;=V@\>GWXP49\AXCMY7F#^)2(^
M]0)-^61C5EAN-4"OQ0B]>N#=IM\0D9&$ZX\LO&Q1*#Z4^BC>T%#5EMFQPP*M
M_3AU]#/N"]#%<;9\D3J)Z)XTUF:XB,H#2?T\DA\\RE?%_5PG$WT)Q0DRU2BY
MG(J6$B$<0.5G\C@)]2%2?&E%:N_NL:T[X-C5+G_%"XKR.D%>$E1#DMH'=QFN
MC$E5T.Z4F%3_@*V4M-7UO.0?GJM_>KW\'M 7BJ7QE]1E2_3R$"+JH=;1 NW$
M!))?B2=5_+/".I[Q!9B%J?C;1;1ACVQS;-;16(;R]T2V7;U[PGJ2IX\W]0S'
MI[L@>:">A[U^?< _<O22S*6!C0Y(W@.ZUDTB9;7N-H6\YLWRIXHJ%B;-4G5F
MX@>J+";G3RR3:S/?.A_B-$"I5#P8P98GB\#P[?E.$07&P'N#!HOYHZD/SW?\
MVU=;@<%^NX,>O:'L#_I(ZS^Q>4=BDR"ZDGMJWAFZO9I/?I4J/@\NOZBG[;_1
MTO:KMF@^_@D@;]\V],8[IG:?1)M\/9&+RPC-MO>$K]4.*?4T&&VL%NNM6GT7
MKK\])+7N.D[6ZX3O[)>HF5UP]=3*+JP":V0M[[<TC*?UK-^J](TXBPP(KAK8
M,XK&#AT%UYI4SZBNUIQ&KR2OB917JEB>;D\U)G[C\%T^#J\^4^D8O0N><-/,
M3Z,A=J,P2CV C<1YE+'L^:]LPQDKX[3S!] ?^="=/W%L14%X>DPSSG>2?GB^
M3N(--WDBW\$MWX6PM5^VW!F_B6)8IA\Y?=.@WM?+^\^B.U+V)PX!18]R2U'T
MN4"+,_]@U>VS,#0J*THU1.221:BU@F;7.;M!FDGA0$S5#17CRT*6)V>X.M D
MR-/2;5DF#*D0H<BM?Q>?QE$:AVPCS*^/79KJ X!&:+(Q,63KJW4LC]]%UT3U
M76QJI$TJ/B"<AO5/+,8 S390]?1+>:D*U26FA9E65=KF9%H]F>1:H_X%M:_Z
M0+E]HV5=S[YW'+T[A+_PZ"^SZQ:NH;7YL47U1VKU:;'5&7\(%G #,A#LENL0
M3*3WO!N9<+JYN5[7ISLO?7:OIIN5I8SAWZ&6$1S*T_U)%;/87/%MFDCWIKQ+
MG^,H*?[Y(4B9O^]FFNXQ*IJ,&P][X9-5<:=0=$WXAJ?L7)ZGZMT3V3^Z)9QY
M>&K;FBI\K8I":HQ5D ^)<OS<[8*H%LNUB HL$ZB2M5#+!'H$:U=J*6L-7$LV
MOT3QO;A7$MQ>1(=CUMSR];(SDWX.P^Y,.UXN.U1/)FPV1O)K*U+_'I$?)*T#
MV^+,T[RC6#=7561MPW@9!_=+*D;UDC[R\7BO1A+U6FI.);5:L!DT%#I_7],8
M-[-\VV0:DMEOBN_@Y/R;9(2<V0#U#54[*;[#IBW&8,T^9,:-E0A4D1G0F'C$
MGRUD_S2+@CD2#4ZG72#VY\.1KQY4Q/#N[_E4"D,H3JAL(]UAW"HF091N:<*Y
M]BB=-Z@W0%LR3-HV_(M>2*V;%6ET1&H]+:00WXB9;L-]Q#3#E.[C(Q*DNZOD
M.DBR_!\GZ[\?F7I?HO3- 6-/>L@B?9X2:97Y5%.1-$U0DN+?==I\V4):JS D
M RVXUP>+6I6]/D!<A&J)>VFY$QBA7K4^%J1B=<F&@5'TH+9)"]6U645<DM)I
M*.VK>!I$1]P ?F(A3;,XHM?!L_!+VB[V]'90]W4&#MOP*)N0O W"G5HO-@]F
M-L&NPFRSWKCAFG7*O2ZNAHSI5,4.OQSXF$59_F73BF)N!J46.G_MH<E;%#JA
MN>4 E,*?26R-L$QW0R'FG&LO?>@]G%.E0SH5J8GOXT0^I3]Y2*A\3MQ63ZN2
M>)-#*8^_/.T!;E"2DI1H2Q"&NDTE5E"*M6^;5[P<0#TQV-!<# !Z:30T$,?4
M2F!K&J45D]=Q)A*:!^%)4=A,8UOE<+-9A1$=@E5.&"&S5D!!]56;JK(W4G9G
MF+X\$][DYN21)O=Q5Q6%&>2OC,NAE+^LC6<P."0PR@]7:6$L[IL%%Q8!>K^Z
M"\N9_(F"R-(DJ[F9^+\J%Q/_!S?&_%,T.?!3]_/G8$]/GIAI2V-O"F"6''SJ
M*T35C(AVY!?1$MC],P/#$*K?A8="J;O ,!M8;^B!S],NJ"EHFX^S>!\P3;US
MX7K0 \&ZCT0>T%%M$= .(P>4$O3&65TS>H-L-G7)'V%=)?D3+(=M-S<%4@(+
MGVV<%"_Q:F\5T:S[Y"Q#0=N%B3J*78"8&[#U5X-.>^YH#PM=(\=>8$"SV'-Q
M#@QD.U8,:+8#!>@MJGS4+VZXGF7$1K"6=UL?GNN_6*STD$Y WY3VD$U_-ZJ2
M0,@V*#8=3 S8!YU]\:8_VNP+-G!%LBX0KL9(BF$UL"WDH"P*,S",!7;S0M -
M"!#PJG>'93KFR[R\4X?9=U(!PMG-?1LF^0O8*K%YT1[5R,\K R3H/;#41K\'
MD##5H-.<=]#AJX+59CJ A&KPYY=C 2KA7A*\0 6TM4DIEWC'3RIGXH%9?! ,
MG3\=Q%7")[J_IXE#.;RH03<_/M(8LEU**I5$NJ(C.2'Y19$B[S>\)TK?@'C/
M$@CF+FF04I%$7KP;. :A*!+<L1VQDP"BR\&W=A<GFI):6R(:H^Y"YN(>4@FZ
MD--&?A=LT.#>N>UP$2%#WKI0VV"#NMN84P)LZ+LW&=T0 GV 6(NN[S#V5@J$
MAX0ZU];'@K6FJ(9^%M8Q'C):$&-[K&B!"QK(Q7\FU!XAT(,6&?AM27QPM"(%
M&?(" "@0MI(8$>>C+D:XC8AC/0D?XXRN=]8#I+$55,2IQIV6*#QO8#WXS8O<
MB9@$B]XTSW8C)'/&J?:*L_0>S:F>-EUEZ?'7P(W_9ALH]+<X:P^$^AD3^>,8
M!$.]:88;F)]M>KT0/WP4Q[QTC3?!@QOTC29@[UL;?&GO&\6OF(CO8._J[.1G
M?+P;YK;YE'6FB?5[Q>HQP5.9]D]TP_APA6$'T-O-P,"N\:>-AVAQRELL %7F
MP6PB:\:1]$-7GQ$E^9!.!;>[X%>ZZ=A)--M  :W%67M,U,_X$#,-8 -?LXV>
M%[B\1A$^P_/M\3ZE?S^*BZ)'_G_N^*<ZW'96"LA<@E:N]11W14LBFZH"E?C.
MKXYQUQ+3N0<="RJ=3B\'#2Y<K#XA"V 6X KJ''\/T"!>#-22S*7#4A"F2\DU
MF/9,*I@N-W6@-A4>.0*U>0#!45'V^^<D/A[*.N'\KVM9I_Y(-WGMESBZB 3>
MX^3Y])@DU/AL?I)> 5$X3OHV2(O>B.QN52N[7N^1E%V*%GFG*Y)WB^/FGW8<
MBB:,HF;:G@#:;;6= -<@6JW2ZU;9=C?_>4PS2_8T#QI C71QKKF=9=M5/1]\
MU1Y'D7JQ7_Z8BES1@<JHO:/AAFSCA'"845%L;2ND>\1.%-V)J+:J=,)I:<O;
M=1+S_\R>K_DD92?1YOSO1R9C_29=[KJ_LLSESV-TQB^'Q4?X?XG/R)#2\D,O
M9XD<,%:5Y(=2<EI)'E'UIUC4WWDIBZJO0HU89'VU"2@:7!99%74S'B(5&M!]
M(',1@<9^.WBWU2JNM5[(4:Q["O3P[J[Q'^%]UCNWY59W-X?R2=OY]8( 1J+T
M^?@&<[%WH*3A;8> B)?C??(AGU3-+AUYUKM)\-3MTI%BW#B.EUA)TP$$0%1
M#3\=2C@/> 8JXE1S ..I6*]%OJ64,T29+#ZF"DNOCPGG[A]&T>O'4B]R2/^%
MGSR:+R G(Q5=47:]3@F=8W,JJ9*65*E3*E"_1@_\:2Z.'N ;4P,]"&DJGB$F
MCU0DQ3D)P_AKP*43==>/:1;ON:&^IGSFN:EXL.XN>W<#5N^\MWS:[:+H@11=
MR)-RU8GPH97=D*H?C++FHR6M?I3^0:%9-:&#AM!?OKW]EJR+;O&JF@^#;[.6
M.2)V_2J83X1AQW26,TD.93_PD2W7(=T\L.CA^I@<^,+1$=5B; VX&INYU90J
M;T7R9@L(9'$,<WL5<HPQ!B(Z@U<L[?%08<^DI^%B ?$JSN'NP,9D3Y1DOW1S
M%U]'ZP]!].MG:1R#\"1-XS7+[S]/XRBB,@797UFVN]O1+]^FWS9W1]=)_) $
M^W.1<)5N+J(LOH@^QX\RG$\ S1VX"<T%U(8(?'2-P*<;L>I<?SXE@H<5*;@@
M-38(B\BZ9(1\Y9R0;$?5UJ.YR2<'Q0VABAU.RKOG] 5'1+"$'_"* ^W&;N<%
MX]IKL[1,?$<%OH,9\3U57/O'8"T";**'BRC-6'9T) ;H: ]EU!P<MZ>G;$IJ
M;1$W95XCWM!@D.'VTK5!P\ZJMG,"UKI5[*3 !*UUNVB!+>*>T7/D.Z$[P[ /
M!J_'\,\ WWREZMB/-AN!;1=;O&FK7;[$83[2',TCW/[/--/-[=ELT^RW>_(8
MRGO> *8D49F&\6<JMC^''5OSC9R]=H6C/5 5 !?'[;&L-T$K7S$QPQ":Y(6,
M>L[_3EC,!V#ZT/ZNLXR%HST4@!T<N_& 5K]B<I;!0-R%C@:(NZ#1&\3\B/GM
M0_SXG;QG3)X5CO-_5##.__ W/GHZ9NL_ @"TP8M6_/?SQ=WY&;F].[D[OX5%
MH9NOB(G\^-((I:A;$'TJ"X#I\P@30$\3]BA+N(H]>"*W)S<L_;7CXL=-!AGB
M[N9?BUDOFY.J/6I"PAD% (T;]\"1%@CN 2)@)2@R@GH]TW:3H2B!D7\'AHKV
MR&D(9Q0 1PGL.+(K@1U$8Y(-:C%,31_[QV#-0I8]=R0C[-D+6++"OM+YQ.4U
MNR!%'ZCY#I<@)US*Q$&8;:94Q .L7\K%R2:T%GK9NK#:YGW !Q&=L;2HJ<T9
MN=KF4<D>SZ4Z*6%?3W9(87@16:,0CWZ+>.QE/)_RG!?#@SV?2<&$ENW=E1\9
M/JALCVL<B,)XC04EQ0*4POA&JP^<9O-H?HZ3;'>RY_O&M3WSG:TAD _3R&,;
M%K(1R5LA;:\F9A;*;VG'0-UA:0? ;. \/XHGVTY8-IL  ;+%5WMVU<^(&!S'
M'Q3L3+-;!YQI:F&R[!7W2T7BK=Q7GW:E973306;;ZY! >T^0_XSJO)R8:="\
M@#Z(T7(#^L %!O#JP]VI))OM( '=XM".!537XV@V04%KFG4-I*8I'^%"O! !
MKT7T[*<@^95FJ=M=Z** <@TZN=8SVM4:D[PUIL-O1N[!W'C=N&FX[(! X^6>
M&S'\>]5ZNE(I.YJ<K#/VR#)&._3.TABN>(J95[V\!F]'JH:X]53Z\!QT\PRF
M7DYDM&JMS T+SZ(K$\(#T]EXZ<@^XT^*[W2\="02<;CL+K%RTH"+LP WI(8U
M3U>D!C28M\))O#FN1::^6YH\LC65NMQ9*=U-!OERV,V_(:NC:"X?\^<$*Z+,
M%\Z2-E .-\N@KY\] *0]@O9 #]1RD27L7CY,R5GIA+Z#!G:!L')N,*5EVP+U
MR' ?S/X2(-^)&H/%=T,&TM3[VG8\8]YIO1=AJJU<BKPQ8K_R<QQO<$\=SIFW
M&&4$8%YR?8C2;LO;:@<(S#:'[2G/?T<&IA^7XCWF29+P'VCN)ET 0HT0:"/4
M./\C/#4B#;[<@U>YH?B6I,@9]3%.*'N(5-[J]?,='[$TM&4_'-D?E+]GA,1M
M,)5=U1.[\<ZJI&]Y=Z3HC]0Z1/ ;32A[[5>R8=LM%30XI54F 7+#][0(%'NY
MIV9!<RW%FS@DENG?MCF:UP6:LZI#^'A-M^@?@E#\R;&4>M(#+K&^$FF[K?-3
M<KO>T<TQY$?YM^]>O_EI18S&*:@9IQ4YV8MHW,GMT($F+-[<9D&2=2W70R7.
M?R%!1N[I XLBL:+S_:;Z]$P2G4<; 'FHJ*AADP1R/])+O]K[E%[*M0!S<4;%
MQI__ZG*/^W>Q&*/1D&LJNU%V.IVB_:2$C81'F(Y4,Z?,IPG=L$Q)= B>Y?9_
MN5JFP[*?HNF8G.VL<$-#,74BLZRL<G.M5@&10';88<'9X3)."VZ9^Q\7\O[(
M75R4E2*J2R+[7-R)H9_\UTG\R%(!1KZE5()F<9XQ>A]LJ,QKEXO]3(,$<0V<
M!N\]SA108)_@4#$4]+9310T+Q>RKB5?0F"HFQ5.H:_[E9#K;I7>W,,MED'>4
MW9+]O1"KY2&[C\TZ2)$59I?J .G$]Q!;-2NXI[14O4#N8:?J,S[02LU\GA'/
M\3M>$?AVL)BS3$VF:4XR1/2(^A1A00(OY]#3QFZ_(T\;N M0QL[W#G[DBU%$
M^[.#8:C$?4NQ#%F7HW[N=QI]H#JJ>N*]2'OFCAQO-8*KD-CD32]G=^],V0:P
M 1[+(MBNU3C/K;J&<TVR9R5#KY&<ZI1Z0[-C$G7BOM$(#O=-WO2AD+_CXGX<
MBX"X-\QS"_=S3;(G[KU&<BK<?Z(;M@[8AJ\E,A#VY_B1)I'D,JQ6&K=:].L#
M2FMZ2M8>YX)<.EQ4R'.]A_H^ U'OIA)2;)5B*>1#7<B@6T@PS1V"U(9BH\'4
M2^_!9G*Z%5-M/2^B=7C<B(H[>IJRS]0>\CND$[@5MY]LNI'.3QU%!_P_B"FK
M'N\$=]F>6DYFE'-%(H>@@(O_ ,BV-@=8>/7</$PTGZPVGX$A>2"?SJGLR.DN
M2![X9G[]:\<VP] 0RAZ8>-0"'*HVF"H]%:M@2FF=_X;BS3OY7LK5<V2GTH^[
MF*_?NF+;:PR[M6AP=U"Z-EQ>+51:]$2,:W&K1OA)LT8XHOI.+7UBLNCN8N'H
M%F$DXAMV8PEP][(N^!,_:1*2H>;)DQ@T2<F .5 .@\5:F7%BH1N(7@C3DYLL
M3_G'S0>(5E]$CUR*.&$TM:5/MK2#R^&E<:@G7RJ;X*1$GI!1P,Q<YIEOY>.:
M<=H]LW"-'=5IM./2D>_'T19!2RX=*7 :0W6)E<-G#HXQ]$;#A$UWY@%$7_T9
M.\P@H3\%(\]_C9-?+T3Y=[[:I9]I)K(:J:70H(&]J $#?_RDL4W&\XH(.K'%
MSRE7TK4L,U<I:IP8GV%BY>D@4A7D*TDPPW9Z(*T=M=,#9K!*<Q-\_13P*61!
MV%]G',08*N.2Q:$QG(R4=$O3ESXR"4'4L[KUK\&#>)&[+T@7H3:=6+-J32?0
M0)1&GK)*GBXB^9R?N0H362D U</.M?D46=,,;G;SUBOR<Q+KUA=&&?PE*$$B
M6,]4L\9+4Q*7]UB8*M&!I+8>=, (=L7XR"*6[NA&II;JO62XJ#'6#*<TCD6C
MH%,9MI:V:O22JA3ED&^W%K%8=,/,NEIT8PQ(8S(^S.P^I"=I2C/!R?F3\,'S
ME5FP]I6%H4=QNW[=@.I0+_D,"=!S<J+HE1*]*OL@12??+*00WI )U4':?S9A
M2H/D3RFNMD)],GK)'L6]4Y/;KH)Y?3J!+"K21S;MG4E.+,R[(G\MZ8D&8-SJ
M>LA"@A8TZ8U5K=I);Z""**&#F0_/GX+_C)/3,$B[RE/UZ@50#?M)9]JF.&!Y
M_TQD%T3V@?JH%%].2&4<@-FV-@X ++8Z5EQ]#O:T\X%I[YZ6H986*?M!=M4
MK.@(^<'I@@1>B**ZT-Q#65U0'G&IFE\#W+"'75<-,6-3J"M5,Y^V!.*JV7S1
M/X\TN8\[KE3[<9S,S''W%; ?OQ<;&F5LRV2$^L&/>;#;8 >8&Y?!<R/9ZRYX
M,D2#+-=W2;"APO+8C82]*>"":^#3D-UY0^72@:5OO9F-G,Q"+G0V'+17,AL(
M@+R#^26P\$UR 7<GT>:,/M(P/@BU[$2P)SVH/]!/(MT16 0KD()2WMG4:)%U
M8(1D>=B"C,HL)=MX2 ;KV.R!1=VCV0.(V,>V2X\B?'[DRSB@73HBM+K\>)?8
M%?G@Y5K(<4M#88\SE@9!;)4Z6?.-Y%&FYCO9QTG&_F$K4#*FLV6HFUW6OAZ"
M6D^DWM7B--%?Y+I(@4.DA2AA!VY[J&0':+$55$;N#%/'G'09RE?(T5?5$".7
M!D@C_T[609(\BSOP0)8(D6D3XBUA^T/ $K&M6JA2-;#60X4:0!OA*CQC*1<B
M8]$Q+VS[X9CR!=-Z9>9#!.4^[.+=4).RWIY<;4E!@7@MY#\-#7>7UQS, 0SK
MU8T?&3HXK'<43G@@7D?TF0X_B/2_:!B]W'ZB07I,9/'"B^APS#S2/=M) )=7
M!]]Z)JFR*9%MEY*\N&OLV\M.U\"C :;SUMA%A P:J]FQP68!%Z#=<^ #G058
M&VD)^;;PAA\Y.AW%/L2(8#+*T@FJ%2GHB"!$]@^/EHDIF3:%3(E+)DR5L2.O
M2W7LL!NQJ_N91C1AZVMVH+PQ+=X+NF,$.HB@=G1=O&L'0]6>% 2D?!V)?J?M
M-0V-O9S7'(P QB6-@I!MXCW;%)V[0>$@@ *$BV>MC':M;0$$?!QTCGH# YU#
MWGMM3>GZVX?X\3MI:))GM;3F_ZA6U?P/?_N?UP8PU'\$F/@&+^U)_I\GUR>?
M85<T-S_!(8A04:9/78$H?=[&9/$HW6Q7V[:GZH:O:W$D*CM7K5S.I6%]@64!
M&2:I=M%=-A!N!OU.+N]*E&,GM;;(7JHQT]Q,W($]QWZ)/3#G>K+T4SV%<+OW
MAO:V5/6TGLJ'*BBVGW#<=(]2TAGF>A8UG7C.)RJDER99S;/!_U7MO_@__O:)
M16Q_W%OWY(8V #IGXDP[MJO?D3P.4W (H;S6.2Y4TCK!R+?E7U*Z/8:7;.MZ
MYNI'OHA;\X8\O6[.5T31$D&\M.MSIUCU( QY:UY)%BC3=U22A0;)EG&1KL/0
M_S)=QR"(3M5'75^Y'-K410BH1YTR=$%-6V5Q%&>T')K*8*J)'[+:"N('*YA8
M?\>63LO^X-"4GOU QO[WE-"Q5S5ID3$K"-);@$DEU9<F6@KZD'<"_3)P,DE;
MLM6BUW!3# W11NW5PQ!5!#$V153,:;R_9Y$T?Z<R;.:!,\O_*V4;FL@_7[+@
MGH4L>V[?U3E,T"2] QJF:4:C#>TRD*K6[8I4'9-&SRM2]KTBVE4VCAF;>5S6
M]7%95^.R;HY+6(W+OGT=CFDB)M2AMN&84(% S,D-78L'_6S+UI(KCT@W.PF@
MXCOXUJN=-9NNEA+IUC7V;6QU#3P:8#HCW5Q$R*"Q^E=ML%E I%OW'/A 9[($
M'N<B,>.'(&7.,/QV*ZA+%HV[]D3+!D2VP+ZR-(]DXYYCQF'TNK_P',Y[.9Q3
M70M6'W5?^.GMX%%F-2@-G&'?O-E&U((UK-LR[V&=%F]?#AOQW.]3D/Q*,W[J
M.^X/@LN.R,,N*B@L=G+?'L*<@"@*4B/!S 8$(0:8OODAJJ%]@'#RTL7!\[%7
M\Q'4YF,J1;U.V)J>1)N_Q"$7X&KK%R+<10674:R#>ST5$R>0!085B;CY[XP3
MGMNA""@*8!HO'URU,GJ!@<HSN=>@&1$);![5C,3;,F?\5/IZ0Q_$2_HX>1ZF
MN?[T4#K<0R+]A%F0$AS%[EZ#$:4#T_6^F&QH/0H@O?1_FJD[ !B%6CHISMI#
M(IZ%1YO3'6=)U$B6Y5'^G3[_)0C5TV#O#?D$'8,] )]@#+0GXK4\9$6G4@OS
M;D6%=%44B/=,RJYA]O\^FXJ7-BAP[^NGTICF"_Q%J8N7D9L;(8<"(<("KG.$
ML(C$$B&_<H0\E@BIG6\FBK+MX98O[J)OXC#\&"=?@V3C\,<;6P,ZXLW<:D\B
M\U;D%]&.Y U1/>^.86Z[W!UC#%SQI>#$O[Q+BP*EEDN;:U=-DPHIRRC1,B7O
MD/#NP(R]S(H1,+,]+Q#WZ''(-M+NRFR)EHLG5V.@!P=67MN8:#14"2X1KZ.Z
MA[D>ZN\>8T <6*^'W,W1L&"]U3"B ?'2R&>XW8A 2*QR0P\B2#AZ^!(QVRM>
M1UO0R 2=4_U4GK<AHM$BXE<LPZM''UC&%AX%'J$JAM982' $IS2QL(B@%.LP
M._$P61C*'?\_Z<F!-7IW.XB<)%"N'S??6C4&T9J<7%^0-@;PO,0S2P#F5O%
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MI)!=T:;&UH"[:3.WKDC-RSAZ>,V59T\$+:F(4]RX4PA)(#>T#ARU=ZH.$"%
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M=MAAO2D@B U\MK%0-)'7#*@6>")F(4%KPT$;L#80@(.UT^Z:&B,!UFJ^6BA
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M.!AY+:.33P6VMZ3@_<R]?KJ(T(YJ+=X[#VNE[_,,;<V;40"\,YL)0^Y3FPE
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MY;).K49@+_]:O&DOQXK?L6V4<1";+_9F&T&_IWF^(SDYK-S62FL&#BVKGM7
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M9C^3@SK'\.\A.^6]B^4#S^L@,>YP!O:#'&SEDM S_*IEH;(X?_<LNUE.4-9
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MFA 1]W%F:5P=(6=H=Z3V)V)WF()0D G$'+TH"0U!-GKE (G4EU!ZV<( 5!1
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M2"^2+&NNY057>=:K%A'\>Y_:B]_1QH')V.T,$\L KM4HXA_ 60O !P[@;0?
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MY12K6J OJG72RV^56Z4)+ZZ[Q0+#M#DU@'UQ;<21_/K:""(<"FAO]EC5PJ2
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MQS&JBBXJ782]%NA)V0PPD6/1Z3!2Z,%G[^)?[(^G(*/_^_]02P,$%     @
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M_-G[(78.T&EI,D!6S:HM Q5  B/$%1O9<TR\)(O?E7;PX\*3 ?+M1R6> 1P
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M2>8"<3LD\A&ZFR3)](@M:DR&+BW?(A!N!T ^N,$HL*G>VQ2E)T-;3C$J1$(
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M#M*A6LS9,;^:D #27;&DK"/SL(GPOG_M^^E]_R\2&YIZ(U1FR$?$VF8U7;#
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MT82J</Y;%/]^PQ+#T).(/NEP;2HD3!M_9=9EB-P.491?26^QWH2YY<$7'7Z
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MC5SS4CFF4@S.W2R.E?-P=B^&M#V7-WTI-%/1V((F"360EC/'CY]0CD\*R*$
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M!;C 0''E<>'&!?$R6KWX8<[79>ZCN*!"H#\E/L6S#H3EO?B!G[Z7KQP%P\=
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MS[2.K;=ZQU-- Y&A@Z);CFD=9+U2@1> T&,<AHZ$33Y:,??^J&OKX]KC.:F
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M77/OM%,1I:DTP\U3/S+ ^^A '%;Y,)LB_0@BP+BMYJA.9>VYLU,TW6-6#13
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M@2JA IA7-P5A,[\9TP=1?A3F\D%Y*@NK[,E:LYF#!&!5VSYD8<*KXY!.#[F
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M?OBK;"5DZ*#,#BN28Y-(]L<LP7VW*):5,EE^*"=KO\P.,-*>I4D6V'?<T%6
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M%H5KU?&\%GU;/*8"1UNQL5Y&;R3TZ$&8)-/8ST&IJU''=8N+20N> ==3IP3
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MN%O!6/G W/2VH"R*,W@3;CYNB3UO$B7LR<B78#3DU.M<W!)[;@XE!'&. =I
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MW/:8/A3+^W@ZC3.ZO*677AR_TW_,DWDKSVR@/I.4;;NQ(OT:\$X6]:D92YW
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M1@%D+S._N+I(_NZ]D<ME1+EZCG8HR4W^:C+A!8)0'#2F/K>3LZO6B28$ PQ
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M&^#J[E\05W?_VD%"SCMHEJL2,$/)(QO@ZOH6XNKZ=@<).ZV$4:Y*P QEBFR
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MB]$:2W.&Y2TU6L,*,?;SY<,+5T'T#TY1AMXI>_/Q')) 0S4PJW$FC@;"+<S
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M D0_LKB3@@#?V[]/!K1_0^N>EG 6;'ZW#3DD-1.V.^\^./%*)0J(2%.++VR
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M-C,Q9#$P<2YH=&U02P$"% ,4    " ""@*I6!=<I#3@$  !.#   $0
M        @ &F*0( 9#0V-#8S,61E>#$P,2YH=&U02P$"% ,4    " ""@*I6
M:T34;<P'  ".*   $0              @ $-+@( 9#0V-#8S,61E>#,Q,2YH
M=&U02P$"% ,4    " ""@*I618NE5LH'  !_*   $0              @ $(
M-@( 9#0V-#8S,61E>#,Q,BYH=&U02P$"% ,4    " ""@*I6KSA'S9($  "Z
M$   $               @ $!/@( 9#0V-#8S,61E>#,R+FAT;5!+ 0(4 Q0
M   ( (* JE;I?2+S0AX  $!? 0 1              "  <%" @!T979A+3(P
M,C,P,S,Q+GAS9%!+ 0(4 Q0    ( (* JE8^7-SA_@T   Z[   5
M      "  3)A @!T979A+3(P,C,P,S,Q7V-A;"YX;6Q02P$"% ,4    " ""
M@*I6Y+$79'"%   AJ@@ %0              @ %C;P( =&5V82TR,#(S,#,S
M,5]D968N>&UL4$L! A0#%     @ @H"J5D%$05,GG0  -_(( !4
M     ( !!O4" '1E=F$M,C R,S S,S%?;&%B+GAM;%!+ 0(4 Q0    ( (*
MJE8;1IN668<  )HB"0 5              "  6"2 P!T979A+3(P,C,P,S,Q
>7W!R92YX;6Q02P4&      H "@"# @  [!D$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
